Methoden-Entwicklung für die Analyse von komplexen biologischen Proben mittels nLC-MALDI MS/MS by Arrey, Tabiwang Ndipanquang
 
 
Method establishment for the analysis of complex 




ZUR ERLANGUNG DES DOKTORGRADES 
der Naturwissenschaften 
vorgelegt beim Fachbereich Chemie (14) 
der Johann Wolfgang Goethe – Universität 
in Frankfurt am Main 
von 
Tabiwang Ndipanquang Arrey 







vom Fachbereich Chemie Biochemie, Pharmazie (14) der 
Johann Wolfgang Goethe Universität als Dissertation angenommen. 
 
 
Dekan:       Prof. Dr. Dieter Steinhilber 
Gutachter:      Prof. Dr. Michael. Karas 
        Prof. Dr Rolf Marschalek 
 
 
Datum der Disputation: 
    
 
Contents 
1.  Proteomics .............................................................................................................. 31 
1.1  Tools for proteomics research  .........................................................................  32 
1.1.2  Gel-based separation methods ........................................................................  34 
1.1.2.2  Isoelectric focusing (IEF) ............................................................................ 34 
1.1.2.3  Two dimensional SDS-PAGE (2D-SDS-PAGE) ...................................... 35 
1.1.2.4  Offgel- IEF ................................................................................................... 35 
1.1.3.1  Ion-exchange chromatography (IEC) ......................................................... 37 
1.1.3.2  Size-exclusion chromatography (SEC) ...................................................... 37 
1.2.2.4  Affinity Chromatography ............................................................................ 37 
1.1.3.3  Normal-phase chromatography................................................................... 38 
1.1.3.4  Reversed phase chromatography. ............................................................... 38 
11.3  Two dimensional separation techniques .................................................... 40 
2  Introduction .....................................................................................................  41 
2.1  Mass spectrometry ..........................................................................................  41 
2.1.1  Electrospray ionisation (ESI) ...................................................................... 42 
2.1.2  Matrix assisted Laser Desorption/Ionisation (MALDI) ............................ 42 
2.1.2.1  Mass Analyzers ............................................................................................ 45  
 
2.1.2.2  Time of flight (TOF) Analyzer ................................................................... 45 
2.1.3  Tandem TOF Mass spectrometer................................................................ 49 
2.2  Protein Identification ......................................................................................  51 
2.2.1  Bottom-up approach .................................................................................... 51 
2.2.1.1  Protein identification by peptide mass fingerprinting (PMF) ................... 52 
2.2.1.2  Shotgun protein/ Tandem MS identification  .............................................. 52 
2.2.2  Top-Down protein identification ................................................................ 53 
2.2.3  HPLC; On- and Off-line coupling (ESI, MALDI) .................................... 53 
3  Proteomics application ........................................................................................... 55 
3.1  Lipid particle proteome ...................................................................................  55 
3.2  Interaction of Mixed linage leukemia complexes ...........................................  57 
3.3  Membrane Proteomics ....................................................................................  61 
3.3.1  Quantification of membrane proteins ......................................................... 66 
4  Objectives ............................................................................................................... 73 
5  Methods and Material ............................................................................................. 74 
5.1  Material ...........................................................................................................  74 
5.2  Methods ..........................................................................................................  78  
 
5.2.1  Expression plasmids, cell culture and transfection experiments 
(AF4/ENL/AF4
.MLL) ................................................................................ 78 
5.2.2  Affinity purification (AF4/ENL/AF4
.MLL) .............................................. 78 
5.2.3  Immunoprecipitation experiments (AF4/ENL/AF4
.MLL) ....................... 78 
5.2.4  Yeast strains and culture conditions ........................................................... 78 
5.2.5  Isolation of Lipid particles from the yeast culture ..................................... 78 
5.2.6  Protein quantification .................................................................................. 79 
5.2.7  Delipidation .................................................................................................. 79 
5.2.8  Cell culture (Human Simpson-Golabi-Behmel syndrome) ....................... 79 
5.2.9  Induction of differentiation (Human Simpson-Golabi-Behmel 
syndrome) .................................................................................................... 79 
5.2.10  Protein sample preparation (Human Simpson-Golabi-Behmel 
syndrome) .................................................................................................... 79 
5.2.11  In-solution Proteolytic Digest .........................................................................  80 
5.2.11.1 Digestion of Purple Membrane (Elastase/Trypsin) .................................. 80 
5.2.11.2 Digestion of CB membrane (Elastase/Trypsin) ........................................ 80 
5.2.11.3 Tryptic digest (Lipoprotein. Adipocztes) .................................................. 80 
5.2.11.4 Tryptic digest (AF4, AF4
.MLL and ENL protein complex) .................... 81 
5.2.11.5 Tryptic/elastase digests of standard proteins............................................. 81  
 
5.2.12  Reduction, Alkylation, Digestion and TMT-labelling of yeast plasma 
membrane .................................................................................................... 81 
5.2.13  Construction of frit for pre-column and analytical column ...................... 82 
5.2.14  Pre-column loading ..................................................................................... 82 
5.2.15  Biphasic pre-column loading ...................................................................... 82 
5.2.16  Analytical column  ........................................................................................ 83 
5.2.17  Nano-LC .........................................................................................................  85 
5.2.17.1 Agilent 1100 series ..................................................................................... 85 
5.2.17.2 Proxeon Easy nLC ...................................................................................... 85 
5.2.18  nLC gradient ................................................................................................ 86 
5.2.19  Matrix for manual measurement ................................................................. 87 
5.2.20  Matrix for LC-MALDI spotting ................................................................. 87 
5.2.21  Isoelectric focusing (IEF) fractionation (Offgel-IEF) ............................... 87 
5..2.22  MALDI MS/MS  ........................................................................................... 88 
5.2.23  Database searches ........................................................................................ 88 
5.2.24  Result interpretation and data analysis ....................................................... 90 
5.2.25  Analysis of secreted protein candidates (Human Simpson-Golabi-
Behmel syndrome). ..................................................................................... 90  
 
6  Results and discussion ............................................................................................ 92 
6.1 Method Optimisation .............................................................................................. 92 
6.1.1  Optimisation of spot deposition ......................................................................  92 
6.1.2  Matrix concentration for automatic spotting ..................................................  97 
6.1.3  TOF/TOF method optimization ......................................................................  99 
6.1.4  Influence of mobile phase gradients on peptide identification .....................  102 
6.1.5  Improved mass accuracy ...............................................................................  106 
6.1.6  Effect of temperature on LC Separation .......................................................  109 
6.1.7  Effect of temperature on column back pressure ...........................................  109 
6.1.8  Effect of temperature on proteins and peptides identification ......................  110 
6.1.9  Effect of temperature on repeatability ..........................................................  113 
6.1.10  Conclusion ....................................................................................................  118 
6.2  Proteins from yeast lipid particles and human fat cells ................................  119 
6.2.1  Optimisation of the sample preparation procedure.................................. 119 
6.2.2  Effect of carbon source on lipoprotein composition ............................... 120 
6.2.3  Human fat cells .............................................................................................  125 
6.2.3.1  Protein identification ................................................................................. 125 
6.2.3.2  Validation of the identified secretome ..................................................... 128  
 
6.2.4  Summary .................................................................................................... 132 
6.3  MLL Interaction partners ..............................................................................  135 
6.3.1  AF4/ENL and AF4•MLLcomplex ............................................................ 135 
6.3.3  ENL-complex ............................................................................................. 138 
6.3.4  Summary .................................................................................................... 138 
6.4  Result and Discussion: Membrane proteins  ..................................................  141 
6.4.1  Protein identification ................................................................................. 141 
6.4.2  Transmembrane coverage. ........................................................................ 143 
6.4.3  Fragmentation behaviour of elastase generated peptides ........................ 145 
7  Two Dimensional Separation (Optimisation of the Offgel-IEF for its 
use as a first dimension in a two dimensional separation plateform) .................. 148 
7.1  Proteins and peptides identification.......................................................... 148 
7.2  Peptide Carryover ...................................................................................... 151 
7.3  Standard deviation ..................................................................................... 152 
7.4  pI distribution ............................................................................................. 154 
7.5  Using the pI of peptides to manually validate search results .................. 156 
7.6  Suitability of the Offgel-IEF peptide fractionators for relative 
quantification............................................................................................. 158  
 
7.8  Protein identification ................................................................................. 161 
7.8  Protein quantification ................................................................................ 162 
7.9  Conclusion ................................................................................................. 166 
8  Method establishment for the analysis of post-translational 
modifications  ........................................................................................................ 168 
8.1.1  Results and Discussion .................................................................................  168 
8.1.2  Crystal morphology and analyte stability ................................................ 168 
8.1.3  Analyte sensitivity ..................................................................................... 171 
8.1.4  MALDI MS/MS  ......................................................................................... 175 
8.2.1  Biphasic pre-column .................................................................................. 179 
8.2.2  Evaluation of non-phosphorylated acidic peptides excluders  ................. 180 
8.2.4  ENL protein complex ................................................................................ 188 
8.3  Conclusion ................................................................................................. 193 
9  General Summary ................................................................................................. 194 
9.1 Zusammenfassung ................................................................................................ 197 
10  References ............................................................................................................ 203 
11.1  Papers in jorunals ..........................................................................................  228 
11.3 ..................................................................................... Eidesstattliche Versicherung  230  
 
 




Figure 1  A section through a eukaryotic cell (Patterson & Aebersold, 2003). ..........  32 
Figure 2  Schematic representation of the Offgel-IEF (Hoert et al., 2006). ...............  36 
Figure 3  MALDI spotter (Sunchrom) ........................................................................  40 
Figure 4  A general representation of a mass spectrometer. .......................................  41 
Figure 5  Mechanism of ion formation in ESI (University of Bristol). ......................  42 
Figure 6  Schematic representation of a linear MALDI-TOF instrument...................  46 
Figure 7  Velocity focusing in reflector mode (Training material ABI).  ....................  47 
Figure 8  Schematic representation of a modern 4800 MALDI TOF/TOF™  ...........  48 
Figure 9  Normenclature of Peptide fragmentation…        ……………………….51 
Figure 10  Workflow employed for the analysis of proteome samples. .....................  54 
Figure 11  Schematic representation of a lipoprotein (Kostner, 2002). ......................  56 
Figure 12  Schematic representation of chromosomal translocation  .........................  59 
Figure 13  Schematic diagram of typical membrane proteins   ....................................  61 
Figure 14  Structure of tandem mass tag reagent.. ......................................................  68 
Figure 15  A shows a chromatogram of 4 standard peptides. .....................................  84 
Figure 16  Signal-to-noise plot of 2 peptides (100 fmol).. ..........................................  93  
 
Figure 17  30 sec spotting frequency using the same 50 cm transfer line. .................  94 
Figure 18  Signal-to-noise plots of 2 peptides.. ..........................................................  95 
Figure 19  NanoTight Y-Connector ............................................................................  96 
Figure 20  Extracted ion chromtograpy of 2 peptides witt the y-connector.  ...............  97 
Figure 21  Peak tailing as a result of crystall formation on the needle tip ..................  98 
Figure 22  show the fragment spectra of Angiotensin II. ..........................................  100 
Figure 23  MS/MS method optimisation using the standard peptide . ......................  101 
Figure 24  Gradient profiles used for the separation. ................................................  103 
Figure 25  A comparisons of peptides identified by gradients 1, 2 and 3. ................  104 
Figure 26  Peptide overlap between the 3 gradients. ................................................  105 
Figure 27  Peptide error distribution  observed for the identified peptides. .............  107 
Figure 28  Peptide error tolerance after internal calibration  ....................................  108 
Figure 29  Shows the column back pressure at different temperatures  .....................  110 
Figure 30  Total number of peptides identified using different column temperatures 
proteins…………………. ........................................................................  111 
Figure 31  A summary of the peptide overlap for both tryptic (A) and elastase (B) 
digestion….. .............................................................................................  112 
Figure 32  Run-to-run overlap.  ..................................................................................  116  
 
Figure 33  Assignment to subcellular fractions of LP proteins from wild type cells 
grown on glucose (YPD) or oleate (YPO). ..............................................  121 
Figure 34  Protein overlap from yeast strains grown in glucose (YPD) and those 
grown on oleoic acid (YPO). ...................................................................  123 
Figure 35  Assignment of newly found proteins of lipid particle from wild type 
cells grown on glucose (YPD) or oleate (YPO) to biological processes. 124 
Figure 36  Identified secreted proteins classified accoding to their functions. .........  126 
Figure 37  Overlap of identified secreted proteins. ...................................................  127 
Figure 38  The number of membrane proteins, with one or more TMD identified 
for both PM and CB samples using elastase and trypsin as proteolytic 
enzymes. ...................................................................................................  144 
Figure 39  Membrane proteins identified from PM and CGM. ................................  150 
Figure 40  Total number of peptides identified in each fraction; the light gray bars 
represent peptides from the PM and CGM samples.  ................................  151 
Figure 41  Number of fractions in which each distinct peptide was found.  ..............  152 
Figure 42  Calculated average pI values for all peptides identified in each fraction 
for both samples. ......................................................................................  153 
Figure 43  Peptide pI distribution. Scatter plot of the calculated pI value of every 
peptide against its mass for the PM sample. ............................................  155  
 
Figure 44  A density plot of pI for each peptide identified in fraction 2; 
encirculated peptides indicate false positives (see text).  ..........................  157 
Figure 45  pI values calculated for 12 peptides chosen from the 12 wells using 6 
different formulas. ....................................................................................  158 
Figure 46  (A) Separation  efficiencyof peptides labelled with TMT Offgel-IEF.. ..  160 
Figure 47  Molecular weight distribution of peptides matched to proteins from 
elastase digest of YPO/YPD samples. .....................................................  162 
Figure 48  Fragment spectrum of peptide at m/z = 1238.73 Da. ..............................  164 
Figure 49  Summary of all quantified proteins. Most of the proteins in the yeast 
cell grown in oleic acid were down regulated.  .........................................  165 
Figure 50  Crystal morphology of the FCCA/CHCA 3:1 with 3mM NH4H2PO4.  ....  169 
Figure 51  Signal stability, ion signal intensity of the [M + H]
+ of phosphorylated 
Angiotensin I with an increasing number of laser pulses.. ......................  170 
Figure 52  Mass spectra showing the effect of (NH4)H2PO4 on the phosphopeptide 
signal at m/z 2303.94. ..............................................................................  173 
Figure 53  Summary of the effect of (NH4)H2PO4 on matrices and matrix mixtures 
for  25 fmol of a (A) di-phosphorylated 
(VADPDHDHTGFLpTEpYVATR) and (B) a mono-phosphorylated 
peptide (VRFPpSHFSSDLK). .................................................................  174  
 
Figure 54  Comparison of the analyte ion intensities of different matrices. Pi 
represents the 3 mM NH4H2PO4 ..............................................................  175 
Figure 55  MS/MS spectrum of the peptide with m/z =1126.3 Da. ..........................  177 
Figure 56  Comparison of the fragmentation patterns using Biotools 2.2 (Bruker 
Daltonics, Bremen). Pi represents the 3 mM NH4H2PO4. ........................  178 
Figure 57  Sample loading setup. ..............................................................................  180 
Figure 58  The effect of different concentrations of DHB in the loading solution on 
the crystal morphology for the FCCA/CHCA 3:1 with 3mM NH4H2PO4 
matrix mixture ..........................................................................................  181 
Figure 59  Comparison of the signal intensity of individual phosphopeptides after 
loading with Glycolic acid, DHB and 5 % TFA. .....................................  182 
Figure 60  Plot of the Signal/Noise against spot number of the phosphopeptide 
spiked to a 20-fold excess BSA digest . ...................................................  184 
Figure 61  A new sequence variant of the alpha-S1 casein in the region 104–119 
(YLGEYLIVPNpSAEER, 1832,83 Da). This peptides is not present in 
mascot, thus was identified manually. .....................................................  186 
Figure 62   Fragment spectrum of the peptide with mass 2080.743 
(LSFpSDSESDNSADSSLPSR). ...........................................................  190 
Figure 63  spectrum of the peptide with m/z of 1197.54 (ETKLEpSTSPK). ...........  191 
  
 




Table 1  List of MALDI matrices, the shortcuts and area of application. .................  43 
Table 2   Summary of Solubilisation/Digestion techniques used for the analysis of 
integral membrane proteins (Speers & Wu 2007). ..........................................................  64 
Table 3  Gradient profile used for method optimisation and separation. Gradient 1 
and 2 were used for less complex samples and gradient 3 for complex samples.  ...........  86 
Table 4   Mascot search parameters  ...........................................................................  89 
Table 5  List of phosphopeptides used for method optimisation ...............................  90 
Table 6  The effects of column temperature on run-to-run reproducibility..  ...........  113 
Table 7  Peptide ion score for two peptides identified in triplicate run for all 
experiment performed. ..................................................................................................  117 
Table 8   Number of peptides and proteins identified from lipid particles before 
and after method optimisation.. .....................................................................................  120 
Table 9   Summary of the number of peptides and proteins identified from yeast 
cell lipid particles grown on glucose (YPD) and oleic acid (YPO). .............................  122 
Table 10  Summary of the number of peptides and proteins identified from pre-
adypocytes/adipocytes tissue. ........................................................................................  127  
 
Table 11  Proteins that have never been associated to the adipocye tissues (human 
visceral, human subcutaneous and rodent). ...................................................................  130 
Table 12  Summary of all secreted proteins, which have been identified only for 
rodent proteomic adipocyte studies. ..............................................................................  131 
Table 13  Summary of the relevant interaction partner identified from the AF4-
complex.  136 
Table 14  List of total numbers of unique peptides and  proteins identified. ............  142 
Table 15  An overview of generated fragment ions from all the dataset of elastase 
digestion.  145 
Table 16  OGE fractionation results: ........................................................................  149 
Table 17  Overview of the identified phosphopeptides generated from α/β-casein.  .  187 
Table 18  Phosphopeptides identified. Phosphopeptides sequence, m/z, Mascot 
scores and the position in the ENL protein sequence. ...................................................  192 














This is dedicated to my parents, Perry Wayne Ndip Arrey and Christina Arrah Egbe Arrey, 
who always gave me their loving support and encouragement; to my brothers and sisters, 
Linda Ebanga Arrey, Nchenge N. Arrey, Arrey N. Arrey Ndip N. Arrey, EgbeTakang N. 
Arrey for their love and support throughout the years. 
    
 
Acknowledgements 
First of all I would like to thank my supervisor Prof. Dr. Michael Karas not only for giving 
me the opportunity to do what I was longing for but also for his trust, fruitful discussions 
and the unconditional support. 
I kindly thank Prof. Dr. Rolf Marschalek and members of his group especially for the 
constructive discussion and the successful collaboration. Furthermore, I would like to 
thank Dr. Karlheinz Grillitsch from the group of Prof. Günther Dauma and Anja Rosenow 
for the good co-oporation. 
The support of my colleagues and of newly made friends made my time here pleasurable 
so I would give special thanks to Tobias Beckhaus Dr. Sandra Bornemann, Dr. Markus 
Persike,  Dr.  Benjamin  Rietschel,  Dominic  Bäumlisberger  and  Marion  Rohmer  for  the 
encouragement, constructive criticism, beneficial discussion and for the beautiful time we 
had after working hours. Furthermore, I will thank Dr. Sabrina Baltruschat, Dr. Tri Hoang, 
Dr.Sandra Hofmann, Thorsten Jaskolla, Dr. Björn Meyer, Malte Schürken, Dr. Markus 
Weidlich,  Benjamin  Müller,  Anne  Arnold,  Jan  Gorka  Stavroula  Markoutsa,  Dimitrios 
Papasotiriou Tobias Schorge, Andreas Münch, Dorota Urbanek, Juliane Rietschel, Dragana 
Cubrilovic and Walter Eckhard for the good working atmosphere. 
In  addition, special thanks to  Frau Dr. Ute Bahr not only for the help  in instrumental 
analytic  and  semester  practical  but  also  for  willingness  to  explain  the  functions  and 
application of different analytical instrument. 
Finally I would like to thank my parents, Perry-Wayne Ndip Arrey and Christina Arrah 
Egbe Arrey, my siblings Linda Ebanga Arrey, Nchenge N. Arrey, Arrey N. Arrey Ndip N.  
 
Arrey, EgbeTakang N. Arrey, and my Niece /Nephew,  Linda Arrah Arrey and Renen-
Elken Abunaw Ashu, my brother-in-law, Frederick Ebot Ashu and my friends especially 
Ako Franklin (frankieboy), Francis Njinjo, Chi Willibroad for their unending love, support, 
encouragement, and patience. Each day I give thanks for my good fortune of having such a 
wonderful family and friends. My mother and father’s unending strength and determination 





1-D LC:     One dimensional RPLC technique 
2D-SDS-PAGE:   Two dimensional SDS-PAGE 
3-HPA:     3-hydroxy picolinic acid 
A:       Alanine 
ACN:      Acetonitrile 
ACTH:     Adrenocorticotropin 
AF4:       MLL translocation partner on chromosome 4q21 
AF9:      MLL translocation partner on chromosome 9p22  
 
AML:  Acute  myeloid  leukemia,  a  clonal  malignancy  of  granulocyte 
progenitors 
Bp:       Base pair 
BPC:      Base Peak-Chromatogram 
BSA:      Bovine serum albumin 
C:       Cysteine 
C18:      Reversed phase 
CA:      Carrier ampholytes 
CB:      Corynebacterium glutamicum membranes 
CE:      Capillary electrophoresis 
CGC:      Corynebacterium glutamicum-Cytosol 
CGM:     Corynebacterium glutamicum-Membranene 
CID:      Collision-induced dissociation 
ClCCA:     4-chloro-α-cyanocinnamic acid 
CNBr:     Cyanogen bromide  
C-Trap:    Curved-Trap  
 
D:       Aspartatic acid 
Da:      Dalton 
DB:      Database 
DHB:      2, 5-dihydroxybenzoic acid 
DNA:      Deoxyribonucleic Acid 
DTT:      1,4-Dithiothreitol 
E:      electric field 
E:      Glutamic acid 
ECD:      Electron capture dissociation 
ENL:       ‘Eleven  nineteen  leukemia’,  an  MLL  translocation  partner  on 
19p13.3 
ER:      Endoplasmic Reticulum 
ESI:       Electrospray ionization 
ETD:      Electron transfer dissociation 
FA:      Formic acid 
FFE:      Free flow electrophoresis  
 
FFF:      Field flow fractionation 
FTICR:    Fourier transform ion cyclotron resonance 
Gln:       Glutamine 
Glu:       Glutamic acid 
Gly:       Glycine 
GRAVY:    Grand average of hydropathy 
H:       Histidine 
HABA:    2-(4-hydroxylphenylazo) benzoic acid 
CHCA:    α-cyano-4-hydroxycinnamic acid  
HCD:      Higher Collisional Dissociation 
HILIC:     Hydrophilic Interaction Liquid Chromatography 
His:       Histidine 
hppK:      High-pH-proteinase K 
I:       Isoleucine 
IAA:       N-Iodoacetamide  
 
ICAT:      Isotope Coded Affinity Tag 
ICAT:     Isotope coded affinitt tag 
ICPL:      Isotope Coded Protein Label 
ICPL:      Isotope coded protein label 
ID:      Internal diameter 
IEC:      Ion-exchange chromatography  
IEF:       Isoelectric focusing 
Ile:       Isoleucine 
IMP:      Integral membrane protein 
 IPG      Immobilized pH gel strips 
IT:       Ion Trap 
IT:      Ion trap 
iTRAQ:    Isobaric tag for relative quantification 
K:       Lysine 
kDa:      Kilodalton  
 
L:       Length 
L:      Leucine 
LC:       Liquid chromatography 
Leu:      Leucine 
LIT:      Linear Ion Trap 
LP:      Lipid particles 
Lys:      Lysine 
m/z:       Mass-to-Charge 
m:      Ion mass 
M:      Methionine 
MALDI:     Matrix-assisted laser desorption/ionization 
MCP:      Multichannel plate Detector 
MeOH:    Methanol 
MEP:      Membrane-embedded peptide 
Met:       Methionine  
 
mg:      Milligram 
MGF:      Mascot generic format 
min:      Minute 
mM:      Millimole 
MOWSE:     Molecular Weight Score 
MS/MS:     Tandem mass spectrometry 
MS:       Mass Spectrometry 
MudPIT:    Multidimensional protein identification technology 
N2- laser:    Nitrogen laser 
NA:      Nicotinic acid or 3-pyridincarboxylic acid 
NCBI:     National Center for Biotechnology Information 
Nd:YAG:     Neodymium-doped yttrium aluminium garnet; Nd:Y3Al5O12 
ne:      Charge of the ion 
NHS:      N-hydroxysuccinimide 
nLC:      Nano Liquid chromstography  
 
Offgel-IEF:    Offgel- Isoelectric focusing 
OGE:      Off-gel-Isoelectric focusing 
o-TOF:     orthogonal Time of flight analyser  
PA:      Picolinic acid 
pI:      Isoelectric point 
PM:      Halobacterium salinarium purple membranes 
PMF:      Peptide mass fingerprinting 
ppm:      Parts per million 
PSD:      Post Source Decay 
PTM:      Post-translational modification 
Q:       Glutamine 
Q:      ion charge 
QIT:      Quadrupole ion trap  
R:       Arginine 
RP-HPLC:    Reverse phase high pressure liquid chromatography   
 
S/N:      Signal-to-noise ratio 
SA:      3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid) 
SDS-PAGE:    Sodium dodecyl sulfatepolyacrylamide gelelectrophoresis 
SEC:      Size-exclusion chromatography 
SET:    Domain  histone  methyltransferase  domain  found  in  Sur(var)3-9, 
enhancerof zeste, trithorax and other proteins located at C terminus 
of MLL 
SGBS:     Human Simpson-Golabi-Behmel syndrome 
SILAC:     Stable Isotope Labelling with Amino Acids in Cell Culture 
SILAC:    Stable isotope labelling by amino acids in cell culture 
STE:       steryl esters  
t:       ions flight time 
TAG:      Triacylglycerols 
t-AML:     Acute myeloid leukemia arising as a result of chemotherapy for a 
prior 
TCA:      Trichloroacetic acid  
 
TFA:      Trifluroacetic acid 
THAP:     2,4,6-trihydroxyacetophonon 
TiO2:      Titanium dioxide 
TMD:      Transmembrane domain, specifically a transmembrane 
TMT:      Tandem mass Tag 
TOF:      Time of flight 
TRIS:      2-Amino-2-(Hydoxymethyl)-Propane-1,3-Diol 
UV:      Ultraviolet 
v x B:      vector cross product of the ion velocity and the magnetic field 
V:       Potential 
v:      Velocity of magnitude 
YPD:      Yeast strains grown in Glucose rich media 
YPO:      Yeast strains grown in oleic acid media  
 
1.  Proteomics 
Though individual genes and proteins or small clusters of related components or specific biochemical pathways have widely been 
studied for decades, the term “proteome” was first coined in the early 1990s by Wilkins and colleagues (Wilkins et al., 1995) to describe 
the protein complement of the genome. It was later expanded to include protein identification studies by Patterson and Aebersold who 
defined proteomics, “as a systematic study of the many and diverse properties of proteins in a parallel manner with the aim of providing 
detailed descriptions of the structure, function and control of biological systems in health and disease” (Patterson & Aebersold, 2003). 
Different cellular states result in different gene regulations (Cox & Mann, 2007). This leads to the expression of many different proteins, 
involved in different activities, such as cell-cycle control, signal transduction and transcriptional-factor regulation. While the genome of a 
certain cell is stable, the proteome is subjected to continuous changes. Each gene product does not result in only one protein entity of the 
cell,  due  to  activities  of  the  cell  as  a  result  of  co-translational  and  posttranslational  modifications  such  as  phoyphorylation  or 
glycosylation (Liebler, 2002). The extent to which these proteins are modified depends on the regulatory mechanism within the cell and 
environmental factors. As a consequence, many proteins and their isoforms are generated and the detection and differentiation, even with 
modern  technological  innovations,  are  still  difficult.  Furthermore,  the  wide  dynamic  range  of  protein  concentrations  constitutes 
proteomics studies challenging. Since proteins represent the major part of the cell machinery, the proteome study of sequenced organisms 
delivers information about their occurrence and abundance and is essential for the understanding of protein activities and regulation.   
 
 
Figure 1  A section through a eukaryotic cell (Patterson & Aebersold, 2003). 
1.1  Tools for proteomics research 
Driven by the goal to understand the different biochemical functions of cells and the increasing change in gene expression levels, the 
study of the whole proteome has gained the attention of many research groups all over the globe. The increased innovations in proteomics 
research have been based on the following: 
(i)  The constantly improving separation technology, which provides two advantages: reduced sample complexity and permits the 
differentiation in expression level. 
(ii)  Mass spectrometric instrumentations 
(iii)  A collection of emerging software tools to process MS and MS/MS data   
 
The separation technologies can be classified in two categories: gel-based and gel-free systems. 
    
 
1.1.2  Gel-based separation methods 
1.1.2.1  Sodium dodecyl sulfatepolyacrylamide gelelectrophoresis (SDS-PAGE) 
Traditionally, SDS-PAGE, the most widely used electrophoretic techniques, has been used for protein separation according to 
molecular weight (O´farrel, 1975). The degree of acrylamide/bis-acrylamide cross-linking depends on the characteristic of the protein of 
interest. A lower degree of cross-linking permits an easier passage of large proteins through the gel (Gygi et al., 1997). The proteins are 
initially dissolved in SDS and loaded on gel pockets. Upon application of a voltage, the protein-SDS complexes migrate through the gel 
and are resolved into bands. The separated proteins are then visualised by conventional staining techniques such as fluorescent dyes, 
coomassie and silver stains, which also determine the detection sensitivity. Due to its limited resolution each band can still contain not 
only iso-forms of a particular proteins but also isobaric proteins. This serves as a limitation of this technique; nevertheless it is still an 
important tool for proteomic analysis. 
1.1.2.2  Isoelectric focusing (IEF) 
Another technique, which has widely been implemented for separating proteins, is isoelectric focusing (IEF). In this technique, 
proteins are separated according to their isoelectric point (pI), since the net charge of a protein is determined by the pH gradient of their 
local environment (Righetti et al., 1988; Egen et al., 1988). When subjected to a medium with a linear pH gradient, proteins move 
towards the electrode with the opposite charge. During migration through the pH gradient the protein either picks up or loses protons. As 
it does, its net charge and mobility decrease. The protein slows down and eventually arrive at the point in the pH gradient equalling its pI 
and stop migrating. If a protein at its pI should diffuse to a region of lower pH, it will become protonated and forced towards the cathode 
by the electric field. On the other hand, if it diffuses into a pH higher than its pI, the protein will become negatively charged and will be 
driven towards the anode.  
 
1.1.2.3  Two dimensional SDS-PAGE (2D-SDS-PAGE) 
An  alternative  to  SDS-PAGE  or  IEF  is  the  combination  of  both  methods.  Therefore,  the  separation  is  based  on  two 
physiochemical properties of proteins (2D-SDS-PAGE). In this approach, a protein mixture is separated according to charge (pI) by 
isoelectric focusing (IEF) in the first dimension and according to size (Mr) by SDS-PAGE in the second dimension. Visualisation is also 
achieved by conventional staining techniques as in the SDS-PAGE approach. Compared to conventional IEF, the introduction of the 
immobilized pH (IPG) gel strips significantly improved the reproducibility in the first dimension (Görg et al., 1988; Görg et al., 2000; 
Görg et al., 2004). This method has a unique capacity for the resolution of complex mixtures of proteins, permitting the simultaneous 
analysis of hundreds or even thousands of proteins. Although this method remains a standard tool for proteomic research, it has some 
limitations. The main disadvantage being the limited amount of sample capacity and detection sensitivity, thus, only relatively abundant 
proteins would be identified, especially when analysing samples from a whole cell lysate (Gygi et al., 2000; Pedersen et al., 2003). 
Secondly, despite making it compatible to this class of proteins, the analysis of insoluble and hydrophobic proteins is still a major 
problem (Görg et al., 2004). Last but not least, proteins with extreme pI (below 3 and above 10) or extreme molecular weight are usually 
excluded from separation (Lam, 2007). 
1.1.2.4  Offgel- IEF 
Protein separation according to pI in gels has been proven to be very successful. However, staining, excision, digesting and 
extraction from the gel prior to MS are still tedious. New technological advancements in this field are based on keeping the separated 
sample in solution. Different instruments such as the multi-compartment electrolyzers (Righetti et al., 1989; Herber et al., 2000; Pedersen 
et al., 2003) or the Rotofor system (Wall et al., 2000) are commercially available. The most promising system is the Off-gel-isoelectric 
focusing from Agilent (Ros et al., 2002) (see figure 2). This method exploits the high resolution and separation power of the immobilized 
pH gradient (IPG)-strip (Cargile et al., 2004, Cargile et al., 2005). The separated peptides and proteins are present in solution making 
recovery for LC/MS analysis much easier. Contrary to conventional electrophoretic separation techniques, isoelectric focusing (IEF)  
 
offers the highest resolution, due to the inherent nature of the focusing process: it is a dynamic process resulting from the constant 
equilibrium between diffusion and migration (Lam et al., 2007). Offgel-IEF thus, combines separation and high sample amount, a useful 
feature for preparative or semi-preparative purposes. 
 
Figure 2  Schematic representation of the Offgel-IEF (Hoert et al., 2006). 
1.1.3.   Gel-free methods 
With the improvement of the fast separation techniques, traditional 2-D-SDS-PAGE methods are increasingly being substituted by 
gel-free MS-based strategies. A driving force behind the success of gel-free methods is that they exhibit higher sensitivity, high resolving 
power  and  higher  degree  of  automation.  Most  frequently  reversed  phase  high  pressure  liquid  chromatography  (RP-HPLC),  on  C18 
materials coupled with tandem MS. In these strategies, the proteins are converted to peptides with the use of a proteolytic enzyme or a 
chemical reagent. The advantage of this method over the conventional 1D or 2D- SDS-PAGE method is that peptides are easily subjected 
to MS and easier to keep in solution (Stalder et al., 2008). However, using this approach makes it difficult to monitor the distribution of 
intact protein isoforms and protein fragments (Stalder et al., 2008). Due to the availability of improved stationary phase chemistry,  
 
chromatographic approaches have greatly enhanced the understanding of biological systems. A wide variety of stationary phase materials 
are commercially available. Depending on the mode of separation the can be classified into: 
1.1.3.1  Ion-exchange chromatography (IEC) 
Ion  Exchange  Chromatography  relies  on  charge-charge  interactions  between  the  sample  and  the  stationary  phase.  It  can  be 
subdivided into cation exchange chromatography and anion exchange chromatography. In cation exchange chromatography, positively 
charged molecules are more retained due to the negatively charged stationary phase. On other hand, negatively charged analytes are more 
retained in the anion exchange chromatography due to its positively charged surface. Elution of the loaded samples is achieved by 
steadily increasing the ionic strength of the mobile phase solution (Small, 1989; Weiss & Weiss, 2005). 
1.1.3.2  Size-exclusion chromatography (SEC) 
SEC, also known as gel filtration, discriminates between molecular species on the basis of size, due to differential permeation into 
matrices of controlled porosity. Large molecules, which cannot penetrate into the pores pass un-retained through the column and are 
eluted first. The small molecules, which penetrate the pores are eluted last. 
1.2.2.4  Affinity Chromatography 
Affinity chromatography is based on the bioaffinity of a protein for a specific ligand coupled to a solid support. The immobilised 
ligand interacts only with protein that can selectively bind to it, while the unretained proteins are eluted. Hence, this technique offers high 
selectivity, high resolution and usually high capacity for the protein sample of interest (Voet and Voet, 1995).  
 
1.1.3.3  Normal-phase chromatography 
Normal or adsorption chromatography separates analytes based on adsorption to a stationary phase by polarity. The stationary 
phase is strongly polar in nature (e.g., silica gel). Polar biomolecules are thus retained on the polar surface of the column longer than less 
polar materials. This separation technique has gained less acceptance due to lack of reproducibility of retention times as water or protic 
organic solvents change the hydration state of the silica chromatographic media (Snyder & Dolan, 2006). 
A special case of the normal phase is the Hydrophilic Interaction Liquid Chromatography (HILIC). The stationary phase contains polar 
materials such as cyano, amino or diol. The advantage of this form of chromatography over the normal chromatography is that the solvent 
used is highly organic and miscible with water (Alpert et al., 1990). During separation, the analyte is partitioned between a liquid/liquid 
layer form between the stationary and the mobile phase. Furthermore, hydrogen donor interactions between neutral polar species as well 
as weak electrostatic mechanisms under high organic solvent conditions also contribute to the separation mechanism (Alpert et al., 1990). 
Compared  to  the  conventional  normal  phase  separation,  this  technique  is  increasingly  gaining  acceptance  in  proteomic  workflows, 
especially for the separation of hydrophilic biomolecules such as glycopeptides or phosphopeptides. 
1.1.3.4  Reversed phase chromatography. 
Reverse  phase  high-performance  liquid  chromatography  (RP-HPLC)  involves  the  separation  of  molecules  on  the  basis  of 
hydrophobicity. The separation depends on the hydrophobic binding of the solute molecules from the mobile phase to the hydrophobic 
ligands attached to the stationary phase. The solutes are eluted in order of increasing molecular hydrophobicity. Elution is preceded either 
by isocratic condition, where the concentration of the organic solvent remains constant or by gradient elution, whereby the amount of 
organic solvent is increased over a period of time. RP-HPLC is an established technique for the analysis of peptides because of a number 
of reasons including (i) the excellent resolution that can be achieved under a wide range of chromatographic conditions for closely related 
molecules as well as structurally distinct molecules, (ii) the experimental ease with which chromatographic selectivity can be manipulated 
through  changes  in  mobile  phase  characteristics,  (iii)  the  generally  high  recovery  hence,  high  productivity,  and  (iv)  the  excellent  
 
reproducibility of repetitive separation carried out over a long period of time, which is caused partly by the stability of the sorbent 
material under a wide range of mobile phase condition (reviewed in Aguilar, 2004). 
The stationary phase material is mostly silica based sorbent. The porous nature of these materials enable the use of high linear 
flow velocities, thus rapid analysis time is possible. The silica materials are chemically modified by derivatised silane bearing an n-alkyl 
hydrophobic ligand. The most commonly used are C-18 for peptide separation and C-8 and C-4 for protein separations. Phenyl and 
cyanopropyl  ligands  have  also  been  used  to  modify  silanol  groups.  The  chemical  immobilisation  of  the  silica  surface  results  in 
approximately half of the surface silanol groups being modified. The sorbents are therefore subjected to further silanisation with small 
reactive silane to produce an end-capped packing material. The type of n-alkyl ligands used can signifantly influence the retention of 
peptides and proteins. Although the detailed molecular basis of the effect of ligands structure is not fully understood, a number of factors 
including the relative hydrophobicity, the ligand chain length, flexibility, and the degree of exposure of surface silanol play an important 
role in the retention process. 
1.1.3.5  LC-MALDI Spotting 
The coupling of MALDI to mass spectrometers with MS/MS capability enabled the analyses of complex samples. This resulted in 
the interfacing of MALDI with separation techniques, such as HPLC. Most of these interfaces differ in the method in which the eluate 
gets to the MALDI target. In either way, both the eluate and the matrix are co-mixed on a MicroTee or at the needle tip through a 3 duct 
system and spotted on a MALDI target (see figure 3). Deposition on the MALDI target is achieved through techniques such as blotting 
methods, which involve contact between the eluate droplet and the MALDI plate(Griffin et al., 2001; Bodnar et al., 2003; Parker et al., 
2004; Tegeler et al., 2004), pulse electric field depositors that use a pulsed electric field to eject droplets (Ericson et al., 2003; Young et 
al., 2006), piezoelectric spotting, which dislodge a series of tiny droplets at a high-frequency (Miliotis et al., 2000; Ekstrom et al., 2001; 
Mirgorodskaya  et  al.,  2005)  or  heated  droplet  interfaces,  that  use  thermal  energy  to  evaporate  solvents  in  the  hanging  droplets  to 
concentrate the eluate and produce smaller droplets for deposition (Zhang et al., 2004). In spite the different deposition methods, all share 
a commonality in that the eluate from the HPLC is mixed with a matrix and co-crystallised with a matrix on a metal target.  
 
 
Figure 3  MALDI spotter (Sunchrom) 
11.3  Two dimensional separation techniques 
Despite the high separation power offered by RP-HPLC (Lin et al., 1999; Washburn et al., 2001; Cargile et al., 2004; Cargile et 
al., 2005; Speers & Wu, 2007;) for the separation of peptides or proteins, some samples possess complexity beyond the separation 
capacity of a one-dimensional technique (Opiteck et al., 1997). An effective approach to reduce the complexity of biological samples is 
the combination of orthogonal separation techniques. In multi-dimensional separation strategies, samples are separated in stages using 
different physiochemical properties. Two-dimensional separation methods (2-D), the most common form of multidimensional strategies, 
have been shown to have high resolving power and to improve the number of identified proteins (Peng et al., 2003). Different forms of 
separation techniques such as SCX/RP-HPLC, Offgel-IEF/RP-HPLC or RP/-HPLC have been coupled (Simpson et al., 2000; Hörth. et 
al., 2006).    
 
2  Introduction 
2.1  Mass spectrometry 
A  wide  range  of  new  mass  spectrometry-based  analytical  platforms  and  experimental  strategies  are  available  for  protein 
identification, characterisation and quantification (Domon et al., 2006). Generally, a typical mass spectrometer consists of an ion source, 
which converts samples to ions, a mass analyzer, which sorts the ions according to their mass-to-charge ratio (m/z) and the detector that 
measures the  amount  of  ions  present  (see  figure  4). Two different  types  of  instruments  are  typically  used  for  proteomic  analyses: 
instruments  equipped  with  a  Matrix  assisted  laser  desorption/ionisation  (MALDI)  (Karas  et  al.,  1985)  and  those  equipped  with 
electrospray ionisation (ESI) (Fenn et al., 1989) sources. Both constitute "soft" ionisation techniques that enable the transfer of intact 
proteins, peptides and nucleic acids into the gas phase without fragmentation. 
 
Figure 4  A general representation of a mass spectrometer. 
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2.1.1  Electrospray ionisation (ESI) 
In electrospray ionisation, a spray of highly charged droplets containing the analytes is created at atmospheric pressure in the 
presence of an electric field. The aerosol is sampled into the first vacuum stage of a mass spectrometer through a nozzle or a capillary, 
which can be heated to aids further solvent evaporation from the charged droplets. As the liquid in these droplets evaporates, they shrink, 
until the ionic charge repulsion is sufficiently intense to overcome the surface tension holding the droplet together, thus resulting to an 
explosion into smaller drops (Columbic explosion). This process repeats itself until the solvent is completely evaporated and the droplets 
have split up to the point that each contains a single, charged molecule (see figure 5). 
 
Figure 5  Mechanism of ion formation in ESI (University of Bristol). 
2.1.2  Matrix assisted Laser Desorption/Ionisation (MALDI) 
Laser desorption and ionisation was first applied for the mass determination of small organic compounds (Cotter, 1984). In 1987 
Tanaka et al. reported the use of UV-laser desorption for the analysis of proteins up to 34 kDa after co-deposition with ultra fine metal  
 
powder in liquid glycerol (Tanaka et al., 1987). The extension of the mass range for proteins to 100 kDa and other large biomolecules 
using a large excess of nicotinic acid as matrix by Karas and Hillenkam marked the rebirth of UV-laser for the ionisation/desorption 
(Karas  &  Hillenkamp,  1988;  Karas  et  al,  1989; Karas  et  al.1989;  Hillenkamp  et  al.  1991).  In this technique,  the  analytes  are  co-
crystallised with a matrix and the ionisation is triggered by a laser beam. Laser ion sources used in MALDI differ in specific technical 
details but all are oblige to the same principles of operation. For example, they all use pulse lasers with pulse durations of 1-200 ns. Most 
commonly  used  lasers  are  N2-laser  emitting  at  337  nm  or  
Nd-YAG lasers, whose emission of 1064 nm has been frequency-tripled to 355 nm (Yariv, 1989). MALDI matrices constitute small 
molecular compounds. For a compound to be qualified as a matrix, it must possess certain requirements such as, absorption of laser 
energy, they must be vacuum stable and be able to embed and isolate analytes, promote analyte ionization, finally causing desorption of 
analytes  upon  irradiation  with  a  laser.  The  most  commonly  used  matrices  are  α-cyano-4-hydroxycinnamic  acid  (HCCA),  
2, 5-dihydroxybenzoic acid (DHB) and 3, 5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid). Recently, a new rationally designed 
matrix,  4-chloro-α-cyanocinnamic  acid  (Cl-CCA)  with  enhanced  signal  intensities,  a  much  more  uniform  response  to  peptides 
irrespective of their amino acid composition and a low detection limit for (phospho)-peptides compared to HCCA (Jaskolla et al., 2008) 
has been introduced. Since its introduction, the use of various interfaces, laser and matrices have continuously been exploited. 
Table 1  List of MALDI matrices, their shortcuts and area of application. 
Compound  Shortcuts  Applications 
2,5-dihydroxy benzoic acid (Strupat et al., 1991)  DHB  Peptides,  Proteins,  Nucleotides, 
Oligonucleotides, Oligosaccharide 
3,5-dimethoxy-4-hydroxycinnamic  acid  (Beavis  et  al.,  SA  Peptides, Proteins, Glycopeptides  
 
1989) 
4-hydroxy-3-methoxycinnamic  acid  or  ferulic  acid 
(Beavis et al., 1989) 
FA  Proteins, Peptides 
α-cyano-4-hydroxycinnamic acid (Beavis et al., 1992)  CHCA  Peptides, Lipids, Nucleotides 
Picolinic acid (Tang et al., 1994)  PA  Oligonucleotides 
3-hydroxy picolinic acid (Wu et al., 1993)  3-HPA  Oligonucleotides, Peptides 
4-chloro-α-cyanocinnamic  acid  (Cl-CCA)  (  jaskolla  et 
al., 2008) 
ClCCA  Peptides 
2,4-di-Flouro-α-cyanocinnamic acid (di-FCCA) (jaskolla 
et al., 2010) 
di-FCCA  Peptides 
2,4,6-trihydroxyacetophonon (Pieles et al., 1993)  THAP  Peptides, Oligonucleotides 
  
 
2.1.2.1  Mass Analyzers 
Mass analyzers separate ions according to their mass-to-charge ratio (m/z). Mass analyzers such as quadrupole (Q), ion trap 
(quadrupole ion trap, QIT; linear ion trap, LIT or LTQ), time-of-flight (TOF) mass analyzer, and Fourier-transform ion cyclotron 
resonance (FTICR) mass analyzer have been used for proteomics studies. These analyzers vary in their physical principles and analytical 
performance. Nevertheless, they are characterized by a number of parameters, such as mass accuracy, mass resolution, accessible mass 
range, sensitivity (limit of detection) and the signal-to-noise-ratio. 
2.1.2.2  Time of flight (TOF) Analyzer 
The most commonly used analyzer for MALDI is the TOF. It is particularly suited for MALDI sources because they generate only 
a very short pulse of ions, which then fly down the flight tube and hit the detector. The TOF-analyzers were first described by Stephen 
W.E in 1946. The prototype of modern TOF instruments was built by Wiley and McLaren in 1955. The extent to which the TOF is used 
in modern MS can be attributed to the introduction of MALDI. Theoretically, at the start of the flight tube, all ions have the same kinetic 
energy, since they all experience the same potential difference during acceleration. However, as a result of the MALDI process, they 
exhibit different initial velocities. The ions reach the detector in order of increasing mass (see figure 6). Their arrival time at the detector 
is proportional to their mass. The m/z of the ions relate to the flight times t by the following equations: 
mν
2/2 = zV; ν =√2V/m ..........................(1) 
The m/z of the ions is related to the flight times t by the following equations: 
t=l/ν =l√m/2zV..................... (2) 
Where l is the length of the flight tube, v is the velocity of the ion of mass m and charge z, and V is the acceleration potential.  
 
 
Figure 6  Schematic representation of a linear MALDI-TOF instrument.  
In its early years, MALDI-TOF instruments were operated with low-acceleration-voltage reflectron instruments or in the linear 
mode. Despite the successes in analysing biomolecules, these instruments were faced with insufficient mass resolution resulting from 
flight time variations of ions of the same m/z. The ionisation process adds a certain amount of initial kinetic energy/initial velocity to the 
molecules before acceleration. Finally, the different spatial positions in the source, from where the ions are formed, lead to varying values 
of l (Equation 2) and thus to flight time variations. Delayed extraction was introduced on linear-TOF instruments to compensate for the 
velocity distributions of ions. By delayed extraction, a mass dependent delay time is built between the ionization and the acceleration in 
the flight tube. This is achieved by keeping the electric field between the sample and the first electrode at zero or to a minimum value. 
After this time frame (usually a few 100 nanoseconds), the electric field is switched on to extract the ions to the flight tube. During this 
time,  the  faster  ions  will  move  towards  the  first  electrode  and  upon  switching  on  the  electric  field,  they  experience  less  potential 
difference than the slower ones, thus compensating their higher initial velocity and thereby increasing resolution (reviewed in Hillenkamp 
& Katalinić, 2007).  
 
On the other hand, the reflectrons compensate energy distribution by means of a series of ring electrode with linear voltage gradient to 
decelerate and turn around the ions (see figure 7). Due to different energy distribution, ions of the same m/z will travel different path 
lengths in the reflectron. Ions with greater kinetic energy arrive at the reflectron first but penetrate deeper into the electrode then those of 
low energy, thus increasing their flight time. Both low and high energy-ions are then re-focused to hit the detector at the same time, 
thereby  improving  the  resolution  power  of  the  instrument.  With  these  implementations,  high  resolutions  (>  20000)  and  high  mass 
accuracies (5-20 ppm) can be achieved. Modern TOF instruments commonly employ these two techniques to enhance resolution. 
 
Figure 7  Velocity focusing in reflector mode (Training material ABI). 
A more recent modification of MALDI instrumentation is the introduction of the orthogonal TOF mass analyzer with improved mass 
accuracy (< 10 ppm) and higher resolving power. In this instrument, ions are generated as usual, but by extraction, a voltage pulse is used 
to deflect the ions sideways so that the ion beam path is deflected perpendicular to the original direction of motion. Due to the elimination 
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of the high axial velocity distribution of the plume from the arrival time of the ions, a high resolving and a high mass accuracy are 
achieved (reviewed in Hillenkamp & Katalinić, 2007). 
 
Figure 8  Schematic representation of a modern 4800 MALDI TOF/TOF™ Analyzer (Training material ABI) 
2.1.2.3  Other detectors 
The MALDI-LTQ-Orbitrap constitutes a recently introduced instrumentation in which MALDI is implemented as ion source. In 









































their final position maintained within the centre of the ion trap. These ions are then ejected succeedingly from the linear ion trap, whereby 
ions of interest are detected by conventional secondary electron multipliers. For high mass accuracy measurements, the ions are ejected 
from the linear trap to the C-Trap, where they are captured, cooled by collision with nitrogen gas and are squeezed into a smaller cloud. 
The ion packet is then ejected towards the Orbitrap analyzer, where the voltage on the central electrode increases and forces the ion 
packets into circling around the electrode. As a result the ions start oscillating along the central electrode (forwards and backwards). The 
image current is recorded on the outer split electrode. The signals are amplified and transformed by Fourier transformation into a mass 
spectrum  (Makarov  et  al.,  1999,  2000;  Hardman&  Makarov,  2003;  Hu  et  al.,  2005).  Futhermore,  ‘Hybrid’  instruments  have  been 
designed to combine the capabilities of different mass analyzers and include the MALDI QqTOF (Shevchenko et al., 2000) or MALDI-
FT-ICR (Stoop et al., 2008). 
2.1.3  Tandem TOF Mass spectrometer 
For detailed structural analysis fragment spectra are generated from the peptides precursor masses. Proteins and peptides contain 
C- and N-terminal amino acids. Cleavage of peptides at the peptide bonds yields fragments containing N- and the C- termini. As proposed 
by Roepstorff and Fohlmann (Roepstorff and Fohlmann, 1984), peptide-bond fragments carrying the N-termini from the original peptide 
are termed b-ions and y-ions for those containing the C-termini (see figure 9). Depending on the amino-acid sequence fragment ions of 
the type x-, z-, a-, c-may show up and are promoted by higher energy collisions. In TOF analyzers, fragmentation can be achieved either 
by making use of metastable decay or by externally inducing fragmentation. The decay, which occurs as a result of the induction of 
excess internal energy on a molecule from the MALDI process, can be classified into in-source and post-source decay. In in-source decay, 
c-and z type fragment ions formed during desorption/ionisation processes are detected with low intensities. Fragment ions, which result 
from decays in the field free region of the flight tube, are known as post source decay (PSD) products. They drift along the flight tube 
with the same velocity as the precursor ions, but except for fragment ions with masses close to the precursor are poorly focused on the 
reflector detector, therefore  MALDI PSD  analyses in simple reflectron instruments have never become a widely applied tool. This  
 
problem was solved in today´s TOT/TOF instruments by extending the time for PSD in a low-acceleration voltage first linear TOF and 
than applying post-acceleration to a high final ion energy for fragment-ion analysis in the second reflectron TOF instrument. 
The fragmentation pattern in PSD favors backbone cleavages producing predominantly an, bn bn-17 yn-17 and yn type fragment ions with 
very little (if any) side chain specific cleavages. When introducing a collision gas (N2, Ar) into TOF/TOF systems, collisions are in the 
intermediate energy range and boost the yield of immonium ions [H2N=CH-R]
+ from some individual amino acids in the peptide. These 
ions can be observed in the low mass region of the spectrum and assist in the sequence assignment by confirming the presence of an 
amino acid. 
The MALDI TOF/TOF approach thus differs from conventional MS/MS techniques used for ESI, where mostly induced collisions 
of mass selected precursor ions with air or neutral gas molecules are used to obtain fragmentation in proteomic studies (CID) (Shukla & 
Futrell, 2000). This process yields high intensity an, bn, and yn type fragment ions, however, in contrast to MALDI doubly or more highly 
charged ions are typically used as precursors if available. Furthermore, in ESI, peptides have been fragmented using techniques such as 
Electron transfer dissociation (ETD) or electron capture dissociation (ECD). ETD and ECD produce predominately c and z type ions 
(Zubarev et al., 1998; Zubarev et al., 2003; Syka et al., 2004), but these new fragmentations techniques are restricted to multiply charged 
ions and thus exclusively used for ESI. 
    
 
 
Figure 9  Normenclature of Peptide fragmentation as decribed by Roepstorff and Fohlman (1984). 
2.2  Protein Identification 
Traditionally, protein identification was performed by N-terminal analysis using the Edman degradation (Edman, 1950). During 
this process, the amino-terminal residue was labeled and cleaved from the peptide without disrupting the peptide bonds between other 
amino  acid  residues.  The  major  limitations  of  this  method  were  the  difficulty  to  analyse  samples  with  multiple  posttranslational 
modifications (PTMs), its finite sensitivity as well as the high analysis time, preventing high throughput analyses. Additionally, peptides 
over 50 to 60 amino acids could not be fully sequenced due to incomplete cyclical derivatation (Liu et al., 2007). With the evolution of 
mass spectrometric technologies, protein identification has been achieved using: 
2.2.1  Bottom-up approach 
Bottom up protein identification is the most widely used approach in proteomics. Prior to MS and or MS/MS, proteins are cleaved 
into peptides with a specific protease. Their masses are then measured and compared with generated peptide masses of known protein 
sequences (Pappin et al., 1993) using database search engines such as Mascot (Perkins et al., 1999) and Sequest (Eng et al., 1994). There  
 
are  two  common  approaches  for  protein  identification  using  the  bottom-up  approach,  peptide  mass  fingerprinting  and  tandem  MS 
(MS/MS) or the shotgun method. 
2.2.1.1  Protein identification by peptide mass fingerprinting (PMF) 
In peptide mass fingerprinting, peptide masses obtained from an MS measurement are compared to calculated peptide masses 
generated by "in silico" cleavage of protein in the database. This method is limited to single proteins or simple mixtures of proteins 
(Pappin et al., 1993). Furthermore, a considerable number of peptides with high mass accuracy are required for protein identification. 
This method is advantageous for a fast screening of unknown samples and most of all; it can be performed with the same instrumentation 
used for MS/MS. 
2.2.1.2  Shotgun protein/ Tandem MS identification 
In the shotgun or tandem MS method, protein digestion is performed without any prefractionation/separation and peptides are 
separated either by one dimensional method or by multidimensional chromatography followed by tandem mass spectrometric analysis. 
Tandem mass spectra are collected for as many peptides as possible, and the results are then searched by an algorithmic comparison via 
SEQUEST (Eng et al., 1994) or MASCOT (Perkins et al., 1999) against a database of proteins derived from genomic sequencing to 
identify the peptides. For proteins which are not found in the database, the amino acid sequence or stretches can be deduced from the 
fragment ion spectrum (Mann & Wilm, 1994; Hunt et al., 1986). Though the shotgun approach seems simple, it has some limitations: The 
digestion of complex protein samples results in greatly increased complexity of the generated peptide mixture therefore, highly sensitive 
and efficient separation is a necessity. In addition, not all peptides resulting from the digestion of a protein(s) can be observed or correctly 
identified with MS/MS analysis, especially those with diverse or unexpected modifications (Han et al., 2008). Information is also lost 
upon  the  conversion  of  intact  proteins  into  a  mixture  of  peptides,  which  can  lead  to  incorrect  identifications  (Han  et  al.,  2008). 
Furthermore, the limited dynamic range of mass spectrometric analysis only allows for the peptides present at high relative abundance to  
 
be preferentially sampled, while information regarding the proteins represented as low abundance peptides in the complex mixture is 
commonly not obtained (Han et al., 2008). 
2.2.2  Top-Down protein identification 
In top-down proteomics, intact proteins are directly fragmented without prior digestion. The top-down strategy holds two major 
promises, the potential access to the complete protein sequence and the ability to locate and characterise PTMs. In addition, the time-
consuming protein digestion required for bottom-up methods is eliminated (Wehr et al., 2006). However, the application of the top-down 
approach within proteomics schemes would require efficient and reproducible protein fractionation and clean-up by e.g. HPLC to produce 
pure isolated protein samples. These would then be ionised by ESI and selected multiply charged protein ions would then be subjected to 
ECD or ETD and possibly CID to acquire comprehensive fragmentations data (Wehr et al., 2006). However, these techniques require 
long ion accumulation, activation, and detection time, thus are termed low-efficiency processes and the fragmentation of proteins is not 
well understood (Reid & Scott, 2002) yet. 
2.2.3  HPLC; On- and Off-line coupling (ESI, MALDI) 
With the establishment of electrospray ionisation (ESI) (Whitehouse et al., 1985) and matrix assisted laser desorption/ionization 
(MALDI) (Karas & Hillenkamp, 1988), routine analysis of large biomolecules became possible. Since ESI is a technique that generates 
ions directly from a liquid sample, the benefit of a combination with HPLC was obvious and technically realised almost immediately. 
However, the birth of high-throughput analysis was only possible in early 1989, when Hunt and his colleagues demonstrated that a triple 
quadrupole instrument could be used to fragment the multiply charged molecular ions produced by ESI (Hunt et al., 1989). Shortly 
afterwards, Covey et al. demonstrated the use of tandem MS in combination with online HPLC to obtain peptide sequence information 
from a complex proteins mixture after tryptic digest (Covey et al. 1991). Contrary to ESI, the identification of proteins by MALDI relied 
on the peptide mass fingerprint approach (Yates et al., 1993; James et al., 1993). This was due to the fact that MALDI instruments were 
initially coupled to time-of-flight (TOF) mass analyzer (Zhen et al., 2004). These systems were originally not capable of generating  
 
MS/MS  data  and  even  after  the  discovery  that peptides could  be  sequenced  by post-source  decay  (PSD)  (Kaufmann et  al.,  1993), 
MALDI-TOF MS systems were not as capable of routinely yielding peptide sequence information as ESI-MS/MS systems (Zhen et al., 
2004). Coupling of fast spotting devices with RP-HPLC and the combination of MALDI with Tandem MS mass spectrometers (Fountain 
et al., 1994; Li et al., 1994; Doroshenko & Cotter, 1995; Medzihradszky et al. 2000; Loboda et al., 2000) initiated and established high-
throughput instrumentations using TOF as mass analyzers.  
 
Figure 10  Workflow employed for the analysis of proteome samples.  
 
3  Proteomics application 
For the evaluation of the established proteomics workflow, different biological samples were analyzed. These samples present 
different challenges for the nLC-MALDI-MS/MS workflow. The success of this method was determined by the number of proteins and 
peptides identified. All samples were digested in-solution either with trypsin and or elastase. The samples were analysed using the Agilent 
1100 series and the nLC Easy from Proxeon, using a 150 min gradient. With the exception of the elastase and tryptic digestion of 
Halobacterium salinarium and Corynebacterium glutamicum, all separations were carried out at 40 °C. 
3.1  Lipid particle proteome 
Lipid particles, lipid droplets or oil bodies are the lipid storage organelles of all organisms. In vertebrate animals, the most 
abundant energy reserve is stored as triacylglycerol in the lipid droplets of adipocytes (Brasaemle et al., 2004). Other types of cells 
contain  tiny  lipid  droplets  that  store  primarily  cholesterol  esters,  which  serve  as  a  reservoir  of  cholesterol  for  the  synthesis  and 
maintenance of membranes. Steroidogenic cells of the adrenal cortex, testes, and ovaries use stored cholesterol additionally as a source of 
substrate for steroid hormone synthesis. Little is known about the mechanisms that control the flux of neutral lipids into and out of lipid 
droplets in any type of cell, but it is clear that the processes that control lipid traffic in adipocytes are central to the regulation of whole 
body energy metabolism (Brasaemle et al., 2004). Lipid particles have also been associated with many diseases such as atherosclerosis, 
diabetes or obesity (Beller et al., 2008). Furthermore, due to their dynamism, they participate in several cellular processes and interact 
with various other cellular compartments (Beller et al., 2008). Lipid droplets are composed of a highly hydrophobic core formed from 
neutral lipids, which represent more than 95 % of lipid droplet consisting of the non-polar lipids triacylglycerols (TAG) and steryl esters 
(STE) (Athenstaedt et al., 1999). The surface of the lipid particle consists of a monolayer of phospholipids, which protects the highly 
hydrophobic interior from the cellular environment (Tauchi-Sato et al., 2002). Specific sets of proteins, the lipoproteins, are embedded on 
the membrane monolayer of phospholipids (see figure 11).  
 
 
Figure 11  Schematic representation of a lipoprotein (Kostner, 2002). 
The  protein  composition  of lipid  droplets from  Chinese hamster  ovary  fibroblasts  (Liu et  al.,  2004),  cultured  human HuH7 
hepatoma cells (Fujimoto et al., 2004), cultured human A431 epithelial cells (Umlauf. et al., 2004), and mouse mammary glands (Wu et 
al., 2000) have been studied. These studies revealed that lipid droplet-associated proteins include enzymes involved in many aspects of 
lipid metabolism. In mammals, lipoproteins such as perilipin, adipophilin, hormone-sensitive lipase (HSL), adipose TAG lipase (ATGL), 
TIP47 (Tail-Interacting Protein 47 kDa), PAT-proteins, S3-12 and OXPAT have been identified (Goodman et al., 2008; Olofssonet al., 
2008; Thiele & Spandl, 2008; Farese Jr. &Walther, 2009; Goodman et al.,2009; Bickelet al., 2009; Robeneket al., 2009;Yamaguchi & 
Osumi, 2009; Ohsakiet al., 2009). 
Though the yeast proteome has often been studied, only a limited number of yeast lipoproteins have been identified. Lipid particle 
proteins involved in ergosterol biosynthetic pathway such as serol-∆
24-methyltransferase (Erg6p) (Leber et al., 1994) and Erg7p (Leber 
et al., 1998) reveals a significant contribution to yeast cellular sterol formation (Zweytick et al., 2000). Besides these, enzymes associated 
with activation of fatty acid such as Faa1p (long-chain fatty acid CoA ligase 1), Faa4p (long chain fatty acid CoA ligase 4) and Fat1p  
 
(very long-chain fatty acid activator) have been reported. Faa1p and Faa4p are responsible for 99 % of cellular myristoyl-CoA and 
palmitoyl-CoA synthetase activity (Smid et al., 1995; Watkins et al. 1998) and have also been suggested to stimulate the uptake of 
exogenous  fatty  acids  (Knoll  et  al.,  1994).  Furthermore,  the  identification  of  
1-acyldihydroxyacetonephosphate reductase, Ayr1p (Athenstaedt & Daum, 2000), which catalyses the formation of lysophosphatidic acid 
from 1-acyldihydroxyacetonephosphate through dihydroxyacetonephosphate pathway, associated its involvement in phosphatidic acid 
biosynthesis. Of all the lipoproteins identified, only the gene product of YDL193w is essential for cell growth (Choi & Martin, 1999). 
Through localisation studies, it has been demonstrated that some of these lipoproteins such as Erg1p, Slc1p, Gat1p or Ayr1p are located 
both in the lipid particles and endoplasmic reticulum (Athenstaedt & Daum, 1997; Leber et al., 1998; Athenstaedt et al., 1999; Zweytick 
et al., 2000). 
3.2  Interaction of Mixed linage leukemia complexes 
All informations necessary for the assembly and functions of a cell are present within the DNA but realised only through the 
expression of the RNAs and proteins encoded by the blueprint. The manner in which cells response to extracellular changes or how they 
associate to form multi-cellular organisation and how individual cells work has been a primary interest of many researchers. Protein-
protein interactions are imminent to virtually every cellular process. They control a large number of cellular processes such as the 
interaction of protein kineases, protein phosphatases, glycosyl transferase, acyl transferase, prototeases etc., with their substrate proteins. 
Such  protein-modifying  enzymes  encompasse  a  large  number  of  protein-protein  interactions  in  the  cell  and  regulate  all  sort  of 
fundamental  processes  such  as  cell  growth,  cell  cycle,  metabolic  pathways  and  signal  transduction  (Phizicky  &  Stanley  1995). 
Understanding protein-protein interactions should facilitate the investigation of intracellular signalling pathways, modelling of protein 
complex structures, targeted-drug design and gain insights into various diseases and biochemical processes.  
One of these processes, which have not fully been understood, is the development of cancer. Leukemia, a severe hematological disorder 
originating from the bone marrow, is characterised by abnormal increase of blood cells, usually leukocytes (white blood cells). It results 
from somatic mutation in the DNA. Certain mutations produce leukemia by activating oncogenes or deactivating tumor suppressor genes  
 
and thereby disrupting the regulation of cell death, differentiation or division. These mutations may occur spontaneously or as a result of 
exposure to radiation or carcinogenic substances and are likely to be influenced by genetic factors (Wiernik, 2001; Robinette et al., 2001; 
Stass et al., 2000). Clinically, leukemia can be subdivided in two main groups; acute leukemia, which is characterised by the rapid 
increase of immature blood cells, and chronic leukemia, which is distinguished by the excessive amounts of relatively mature but still 
abnormal white blood cells. Depending on the type of blood cells affected it can be further divided into lymphoblastic or lymphocytic 
leukemias  and  myeloid  or  myelogenous  leukemias.  Acute  lymphoblastic  leukemia  (ALL)  originates  from  progenitor  cells  able  to 
differentiate into the B or T-lineage. Acute myeloid leukemia affects progenitors able to differnetiate into macrophages or granulocytes. 
In both cases, normal red blood cells and platelets are dramatically reduced. When combined, these two groups result in 4 different 
categories; Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) and 
Chronic Lymphocytic Leukemia (CLL). 
Chromosomal  rearrangements  involving  the  MLL  (MLL1,  ALL1,  TRX,  and  HTRX)  gene,  including  balanced  and  unbalanced 
translocations, inversions, insertions, and a partial tandem duplication, have been associated with a heterogeneous group of lymphoid, 
myeloid, and mixed lineage leukemias (MLL) (for review see Meyer et al., 2006; Meyer et al., 2009). MLL is a histone methyltransferase 
considered to be a positive global regulator of gene transcription (Hess et al., 2004). This protein belongs to the group of histone-
modifying enzymes and is involved in the epigenetic maintenance of transcriptional memory (Guenther et al., 2005). The MLL gene is 
located at chromosome 11q23, consists of 37 exons (Nilson et al., 1996; Rasio et al., 1996; Marschalek et al., 1997) and encodes a 
protein of 4.005 amino acid residues with an estimated molecular mass of 435 kDa. Most MLL gene rearrangements map to an 8.3-kb 
breakpoint cluster region (bcr) and result in production of two chimeric oncoproteins (see figure 12; reviewed in Meyer et al., 2006; 
Meyer et al., 2009) by fusion of the amino terminal portion of MLL with the carboxy terminal portion of a partner gene, and vice versa, 
by fusing the N-terminal portion of a partner gene to the C-terminal portion of the MLL protein. Although the molecular basis for the 
oncogenic activity of MLL fusion proteins is incompletely understood, recent reports (Milne et al., 2002; Harper et al., 2008) demonstrate 
that MLL can mediate high levels of homeobox genes HOXC8, HOXA7 and HOXA9 expression through the binding of the MLL fusion 




Figure 12  Schematic representation of chromosomal translocation t(4;11)(q21;q23), fusing the N-terminal region of the MLL 
gene  on  chromosome  11  to  the  C-terminal  region  of  the  AF4  gene  on  chromosome  4,  and  vice  versa  (source 
http://www.erasmusmc.nl/alkg-cs/242905/243025/figure1). 
To date approximately 60 different 11q23 chromosomal partners have been identified (Eguchi et al., 2003; Meyer et al., 2006; 
Meyer et al., 2009). However, about 6 of these fusion genes (ALL1 fused gene from chromosome 4, 6, 9 and 10, (AF4, AF9, AF10, AF6), 
eleven nineteen leukemia (ENL), and eleven nineteen lysin rich leukemia gene (ELL)) are responsible for 85 % of all translocations. The 
AF4 (or FEL) gene is the most common MLL fusion partner. In all, 95 % of t(4;11)-associated leukemia is classified as ALL, but shows 
some lineage infidelity, typically expressing surface markers of the myeloid lienage (CD13
+, CD33
+). Therefore, some of these patients 
are characterised as Mixed Linage Leukemia. Just like the AF4 other homologous family members of these genes such as AF9 or ENL  
 
encode a serine/proline-rich nuclear protein with the ability to activate gene transcription (Nakamura et al., 1993; Domer et al., 1993; 
Prasad et al., 1995).  
Protein or  genes in cells do not act in isolation. Their properties are controlled and modified through their interaction with 
neighboring proteins or peptides and other molecular components. Therefore, the biochemical functions of the proteins encoded by the 
MLL fusion partners are also influenced by the proteins with which they interact. Several interaction proteins of the MLL fusion partners 
have been identified (Bursen et al., 2004). For example, it has been shown that the AF4 protein binds also to the AF9 and ENL (Erfurt et 
al., 2004; Zeisig et al., 2005), two other MLL translocation partners, as well as cyclin-dependent kinase 9 (CDK9) and Cyclin T1, a 
heterodimer that regulates transcriptional elongation (Estable et al., 2002; Benedikt et al., 2010).  
Advances in the understanding of the association of proteins in a cellular system emerged primarily from two types of experiments. The 
first method involves the immunoprecipitation of the protein of interest with any associated proteins. The protein in the resulting immune-
complex is then separated on an SDS-PAGE, transferred to a membrane and probed with antibodies suspected as partners of the target 
protein. The second major approach is the yeast two-hybrid system. In this method, detection of the interaction partner is obtained 
indirectly. Each gene that code for the protein of interest is fused to a transcription factor and the pair of hybrid genes is expressed in 
yeast Saccharomyces cerevisiae (Field & Song, 1989). A positive interaction allows the reconstitution of a functional transcription factor, 
and thus the expression of a selectable marker. One advantage of this system is that the target proteins are immediately identified through 
sequence of the cognate cDNA. Another advantage is that this procedure can be automated so that very large number of proteins can be 
screened for their ability to interact in the yeast two-hybrid assay. Another technological advance in the study of protein interaction was 
the improvement of mass spectrometry. In this approach, the proteins of interest are immuno- or affinity-precipitated, digested and 
analysed on a mass spectrometer. The protein of interest can also be resolved on SDS-PAGE, stained, digested, extracted and measured. 
In a relatively straightforward approach, the proteins resulting from a specific isolation of interaction partners are digested separated on a 
RP-HPLC  and  either  online  or  offline  connected  to  a  mass  spectrometer  for  MS  and  MS/MS  data  acquisition.  In  this  approach, 
identification and quantification can be achieved in a single run. However, it is limited by the fact that peptides do not immediately reveal  
 
whether associated proteins interact directly or indirectly. Other techniques such as cross-linking, affinity blotting, immunoprecipitation, 
Protein Affinity Chromatography or Bait and Reserve bait have also been used in protein-protein interaction studies. 
3.3  Membrane Proteomics 
Protein molecules that are attached to or associated with the membrane of cells or organelle are termed membrane proteins. More 
than half of all proteins interact with the membranes, therefore they play a vital role in numerous cellular functions (Shama et al., 2007) 
such  as  signal  transduction,  cellular  adhersion,  ion  transport and drug  resistance  (Ramus  et  al., 2006). Based  on  the  nature of  the 
membrane-protein, they can be classified into two broad categories-integral (intrinsic) and peripheral (extrinsic) (see figure13). 
 
Figure 13   Schematic diagram of typical membrane proteins in a biological membrane. (Lodish et al., 1999). 
Peripheral membrane proteins or extrinsic proteins are bound to the membrane indirectly by interactions with integral membrane 
proteins or directly by interactions with lipid polar head groups. For example, the regulatory protein subunit of many transmembrane  
 
receptors and ion channels may be described as peripheral membrane proteins (Berk et al., 2000). On the contrary, integral membrane 
proteins (IMPs) or intrinsic proteins are permanently attached to the membrane. Due to their location, they connect a host of cellular 
processes, such as intercellular communication, vesicle trafficking, ion transport, protein translocation/integration, and propagation of 
signalling cascades (Ott et al., 2002, , Torres et al., 2003; Zhou et al., 2004). As a result, they form the major protein class for drug 
targets (Fischer et al., 2006). These proteins have one or more membrane-spanning domains as well as domains, from four to several 
hundred residues long, extending into the aqueous medium on each side of the phospholipid bilayer (Berk et al., 2000). According to their 
structure they can be classified either as α-helical or as β-barrel proteins (Fischer et al., 2006). 
β-Barrel proteins, or porins, exist in the outer membranes of Gram-negative bacteria, chloroplasts, and mitochondria, where they 
regulate membrane integrity and allow for the passive influx/efflux of small molecules (Speers &Wu, 2007). The β-strands possess both 
lipophilic and hydrophilic characters, therefore the overall hydropathy of these IMPs are similar to those of soluble proteins (von Heijne 
et al., 1996; Santoni et al., 2000; Chen et al., 2002). Compared to their α-helical IMPs counterparts, these proteins do not present much 
analytical  challenges  (Eichacker  et  al.,  2004)  in  proteomics  schemes.  Approximately  
20-25 % of all open reading frames (ORFs) in most genomes code for integral membrane proteins (von Heijne et al., 1998; Krogh et al., 
2000). The α-helix bundle can be subdivided into: Bitopic or single-pass IMPs with one transmembrane domain connecting 2 globular 
domains (Hurwitz et al., 2006). These proteins often act as cell surface makers, receptors or adhesion factors with the cytoplasmic 
domains operating in cellular signalling pathways or in contact with the cytoskeleton (Speers & Wu, 2007). In contrast, polytopic IMPs 
have multiple transmembrane domains (TMDs) that span the membrane multiple times such that different regions of the protein are 
exposed on opposite sides of the membrane (Bowie et al., 1997). Bound to the membrane surface via non-covalent interactions with 
phospholipid  head  groups  or  membrane-embedded  proteins  are  the  membrane-associated  proteins.  These  proteins  can  readily  be 
solubilised by treatment with high-pH or high-salt buffers, thus do not generally present the same analytical challenge as IMPs. Last but 
not least, the monotopic or membrane-anchored proteins, which are not transmembrane proteins but are rather bounded to the membrane 
bilayer  by  a  lipid  anchor.  These  proteins  can  be  dissociated  upon  cleavage  of  the  anchor  with  phospholipases  and  they  have  the 
hydrophilic characteristics of soluble proteins.  
 
Since integral membrane proteins are composed of both hydrophilic and hydrophobic regions and behave more like lipids than 
proteins due to their association with lipid bilayer in the membrane, extraction, solubilisation and characterisation by mass spectral 
analysis have been a  major challenge  (Santoni  et al., 2000). Prior to proteolytic digest and  mass spectrometric analysis, gel based 
electrophoretic methods such as two-dimensional polyacrylamide gel electrophoresis have frequently been used to separate membrane 
proteins. Unfortunately, most of the membrane proteins are not solubilised in non-detergent isoelectric focusing sample buffers and those 
solubilised  tend  to  precipitate  at  their  isoelectric  point  (Santoni  et  al.,  2000;  Wu  et  al.,  2003).  Due  to  improved  stationary  phase 
chemistry, the advances in chromatographic methods, and the possibility of coupling either online or offline with high resolution mass 
spectrometry, gel free methods are increasingly been used in most research laboratories. Moreover, in these techniques, the tedious 
process of excision, digestion extraction and gel-to-gel reproducibility, which are associated with gel based electrophoretic methods, are 
avoided.  
Despite some success, the analysis of membrane proteins still presents some major challenges, such as solubilisation in solvents, 
which are mass spectrometry compatible (Santoni et al., 2000) or their low abundance. Therefore, prefractionation and/or enrichment 
steps of the  membrane  fractions are  a necessity (Fischer et al., 2006).  Purification/enrichment  steps such as centrifugation, density 
gradient centrifugation using sucrose, sorbitol, ficoll, or percoll (Goo et al., 2003; Klein et al., 2005) using high-ionic-strength or high-pH 
buffers (sodium chloride, potassium chloride, sodium bromide, and potassium bromide) with subsequent sonication to remove membrane 
associated proteins (Pedersen et al., 2003; Schluesener et al., 2005) etc. are commonly used in most laboratories. For the analysis of a 
more complex plasma membrane of higher eukaryotes, the colloidal silica and aqueous-polymer two-phase partitioning have widely been 
used (Speers & Wu, 2007). Protein precipitation in methanol/chloroform, cold acetone or trichloroacetic acid (TCA) has also been used to 
purify/enrich membrane proteins (Wessel et al., 1984; le Maria et al., 1993; Mastro et al., 1999; Carboni et al., 2002; Borner et al., 2005). 
Furthermore, due to the hydrophobic nature of certain domains of IMPs, exposure to aqueous solvents results in aggregation, adsorption 
and precipitation. This leads to sample loss and interference of enzymatic access during digestion. Therefore, caution is necessary when 
choosing  solvents  for  solubilisation  and  denaturing  of  IMPs  since  this  might  affect  separation,  digestion  and  mass  spectrometric 
efficiencies.   
 
The analysis of integral membrane proteins can be restricted only to the soluble domains of the proteins. In this case the soluble 
domain is cleaved either with a chemical reagent or with proteolytic enzymes. The generated peptides are then separated and analysed 
(Wu et al., 2003). To improve sequence coverage both the soluble and the hydrophobic domains are necessary. In most cases, 2 step 
digestion procedures can be used to analyse both domains. In the first step, the soluble domain is shaved either with a proteolytic enzyme 
such as Lys-C (Nielsen, et al.,2005; Bihan, et al., 2006), Proteinase K (Wu et al., 2003) or trypsin (Rodriguez-Ortega et al.,2006) or a 
chemical cleavage reagent (cyanogen bromide) (Washburn et al.,2001). The intact bilayer with the embedded proteins is solubilised and 
after extraction of the hydrophobic domains, both soluble and hydrophobic domains are either combined, digested and analysed or 
separately digested and analysed (Wu et al., 2003; Goshe et al., 2003; Blonder et al.,2004; Blonder et al., 2004; Wu et al., 2006; Fischer 
et al., 2006). To avoid limitations of the digestion efficiency by only addressing specific cleavages sites in the 2 step approach and to 
improve sequence coverage, less specific enzymes have been employed, also in combination with specific ones or chemical reagents. 
Furthermore, for high solubility, mostly high organic solvent content were used for the solubilisation in the second step. Unfortunately, no 
optimal approach has been developed; therefore there is still a need for simpler and more efficient methods of extraction and analysis of 
membrane proteins. 
Table 2   Summary of Solubilisation/Digestion techniques used for the analysis of integral membrane proteins (Speers & Wu 2007). 
solubilisation/digestiontechniques  comments 
solubledomains(membraneshaving)   
High pH proteinase K (hppK)  Non specific protease, not reliant on specific cleavagesites in solubledomains, 
high-pH opens vesicles all owing access to both sidesof membrane  
 
Lys-C  Requires Lysin soluble domains 
Trypsin  Requires Lys or Arg in soluble domains 
embeddedandsolubledomains   
hppK-CNBr/FA  Combines  benefits  of  non  specific  protease  shaving  withtargeted  TMD 
solubilisation/analysis, gives ca 97% IMPs and ca 68 % TMD peptides 
60 % MeOH/trypsin  Efficient  solubilisationstrategy  for  targeting  both  soluble  and  TM  domains, 
givesca 45 % IMPs 
trypsin/hppK-60 % MeOH/trypsin  Combines benefits of non specific proteases having withgood solubilisationof 
TMD regions, gives ca 40 % IMPs 
trypsin-60% 
MeOH/trypsin/chymotrypsin 
Some  enrichment  afforded  by  shaving,  goodsolubilisation  and  use  of 




3.3.1  Quantification of membrane proteins 
Due to the importance of membrane proteins, not only the identification, but also the quantification of their presence would 
improve the understanding of expression level in cells. Two dimensional SDS-PAGE has been used for the differential comparison of cell 
states (Tonge, et al., 2001). However, this technique has been shown to have poor resolving power with highly hydrophobic proteins 
(Santoni et al., 2000). With the introduction of high resolution mass spectrometers and successful combination with high resolution 
separation techniques, the identification and characterisation were the main goal of most researchers. In the past decade, not only the 
identification and characterisation of proteins but also the determination of the absolute or relative abundance has become a major task in 
proteomics. Several quantification methods have therefore been developed, whereby shotgun-proteomics MS-based techniques are more 
dominant. Shotgun proteomics MS-based quantification techniques can be divided into 2 major groups; label-free and stable isotope 
labelling. Label-free methods are based on quantitation of peak areas/intensities (Scheurer et al. 2005; Foster et al., 2005; Wang et al., 
2007) or the number of MS/MS spectra for a particular peptide. Stable isotope labelling involves the incorporation of heavy atoms into 
proteins/peptides by metabolic means or post-processing chemical modification. At the protein level, labelling commonly involves the 
modification of nucleophilic amino acids (mostly Cys or Lys) with isotopically labelled tags either after protein isolation (but before 
digestion) such as Isotopic Coded Affinity Tag (ICAT) (Gygi et al., 1999) or already on the cellular level, i.e Isotope Coded Protein Label 
(ICPL) or Stable isotope labelling with amino acids in cell culture (SILAC) (Ong et al., 2002). Peptide based relative quantification such 
as Tandem Mass Tag (TMT) (see figure 14) (Thompson et al., 2003), isobaric tag for relative and absolute quantitation (iTRAQ) (Ros et 
al., 2003) focus on lysine site chains and N-terminal amino acids. As a further option, enzyme-mediated incorporation of 
18O (Yao et al., 
2001) enriched water into peptide C-termini may be employed. In any case, during nLC-MS/MS analysis, isotopologic peptides bearing 
heavy and light tags elute simultaneously but seperate in the mass spectrometer and the relative ion peak areas can be quantified, giving 
an indirect value of relative protein abundance (Spears & Wu et al., 2006). Despite the advances in relative quantification studies, 
quantitative studies for membrane proteins may be handicaped by the reduced number of peptides generated from IMPs using standard 
solubilisation/digestion techniques. Therefore, for the quantification of membrane proteins, these protocols have to be optimised.   
 
Absolute quantification on the other hand enables a direct comparison of the absolute protein content of both cellular states. Different 
methods such as Isotope dilution (Barr et al. 1996), absolute quantification using deuterium-labeled peptide (Barnidge et al., 2003), 
Absolute quantification of Proteins (AQUA) (Gerber et al. 2003), QconCAT (Beynon et al., 2005) have been used to quantify the 
absolute protein amount in a sample. Most of the absolute quantitation methods in proteomics rely on the well-established principles of 
stable isotope dilution techniques, using tryptic peptides as surrogate analytes for the proteins of interest. The standard peptides might be 
chemically synthesed or by the design of a DNA construct that is transcribed and translated into a protein concatamer (Beynon et al., 
2005). Therefore, absolute quantification is necessary because it offers a direct comparison of samples analysed at different times, using 




Figure 14  Structure of tandem mass tag reagent. A. TMT0 has no isotopic substitutions and is used for method development. B. A 
six-plex of isobaric mass labels each with five isotopic substitutions per tag is used (Thermo-scientific). 
3.4  Protein phosphorylation 
Covalent  modifications  that  occur  either  during  or  after  ribosomal  assembly  of  proteins  are  termed  post-translational 
modifications. These modifications usually change the properties of a protein and can determine its activity state, localisation, turnover 
and the interaction with other proteins (Mann & Jensen, 2003). Posttranslational modifications such as phosphorylation, acetylation, 
methylation, glycosylation or deamidation have been in the focus of recent research. Reversible phosphorylation of proteins is one of the  
 
most studied post-translation modifications due to its role of controlling protein function and directing the physiological responses of cells 
and their environment (Blackburn & Goshe, 2009). A fundamental understanding of biological processes and signaling networks at the 
molecular level requires the analysis and characterisation of these phosphorylated proteins (Larsen et al., 2005). At least one-third of all 
proteins are thought to contain covalently bound phosphate on serine, threonine and tyrosine residues, with phosphoserine being the most 
abundant, at some time-point (Morandell et al., 2006). Hunter and coworkers determined that the relative abundances of phosphotyrosine 
(pY), phosphothreonine (pT), and phosphoserine (pS) in normally growing cells to be 0.05 %, 10 %, and 90 % respectively (Hunter & 
Sefton, 1980). The low abundance of phosphotyrosine and phosphothreonine was assumed to be that the modification of these residues 
occurs mostly on low abundant proteins. Furthermore, it was presumed that pY is less stable in phosphoamino acid analysis than pS/pT. 
Therefore, pY sites would be underrepresented in the phosphoamino acid analysis (Olsen et al., 2006). 
Despite recent developments in proteomics methodology, especially in MS, there is no ultimate method for the identification of protein 
phosphorylation. This is presumably due to the facts that most signaling proteins are not abundantly expressed and the stoichiometry of 
phosphorylation can be quite low (Morandell et al., 2006). Protein phosphorylations have been characterised mainly using biochemical 
and  mass-spectrometry  based  methods.  The  classical  biochemical  approaches  include  proteins  isolated  from  cells  via 
immunoprecipitation with monoclonal antibodies. In these methods, the phosphoproteins are often monitored by using [
32P] ATP to 
characterise kinase activity and potential substrates. The degree of phosphorylation can be measured by phosphoimaging based on the 
incorporation of a 
32P-radiolabel, immunoblotting using antibodies recognising amino acid residues modified with a phosphate moiety, 
and phosphorylation  specific staining  using  Pro-Q  Diamond. Yet,  these  methods  do  not  provide  detailed  information regarding  the 
phosphorylation or associated phosphorylation site or stoichiometries (Blackburn & Goshe, 2008). Furthermore, the 
32P labelling has been 
combined with Edman degradation (Yan et al., 1998; van der Geer et al., 1999; Haystead et al., 1999). However, this method did not only 
have long analysis time but also exhibited a low dynamic range and low abundance phospho-proteins escape detection, therefore is not 
suited to complex samples (Larsen et al., 2005). 
Mass-spectrometry based strategies are  currently  the  method of choice to detect protein phosphorylation, since they provide 
information on the position and degree of phosphorylation (Mann et al., 2002). In these methods, phosphoproteins are digested with a  
 
specific protease and a subsequent analysis of the peptide pool is carried out by MS and tandem mass spectrometry to detect a mass 
increment of 80 Da per phosphate group. Despite many advances in this field, detection and identification of phosphorylated species is 
challenging  because  of  low  abundances,  therefore  enrichment  techniques  are  typically  employed  prior  to  analysis.  Widely  used  is 





3+ (Hochuli et al., 1987; Posewitz & Tempst, 1999; Nuhse et al., 2003). An alternative to IMAC for the selective 
enrichment of phosphorylated peptides prior to MALDI-MS or liquid chromatography tandem MS is Titanium dioxide (TiO2) (Ikeguchi 
& Nakamura, 1997; Pinkse et al., 2004; Sano & Nakamura, 2004; Larsen et al., 2005). This metal oxide resin show preferential binding 
of phosphopetides to non-phosphorylated acidic peptides at acidic pH. Both techniques are vital for phosphopeptide analysis but have 
their  advantages  and  limitations.  Compared  to  IMAC,  TiO2  is  more  compatible  with  a  number  of  reagents  commonly  used  in  the 
solubilisation and digestion of proteins (Jensen & Larsen, 2007). IMAC is more specific for multi-phosphorylated peptides while TiO2 is 
to mono-phosphorylated peptides (Ficarro et al., 2002; Jensen & Larsen, 2007). Since the metal ions are not covalently bound to the 
substrate, leaching has been reported during the enrichment process on IMAC (Hochuli et al., 1987). The selective enrichment of large 
amounts of acidic non-phosphorylated peptides seems to be a limitation shared by both techniques.  
To minimise the binding of acidic non-phosphorylated peptides on IMAC and TiO2, chemical and non-chemical modification of 
peptides has been reported. One of these methods is based on blocking the acidic residues by O-methyl esterification (Ficarro et al., 2002; 
Moser & White, 2006; Ndassa et al., 2006), but O-methyl esterification often causes partial deamidation and subsequent methylation of 
Asn  and  Gln  residues  (Stewart  et  al.,  2001;  Larsen  et.  al.,  2005).  These  by-products  further  complicate  MS  analysis  and  data 
interpretation. Furthermore, since esterification is a water-free reaction, the aqueous solvents must be completely evaporated. Adsorptive 
losses of the sample to the walls of the reaction tubes can not be completely ruled out, leading to decrease in analyte sensitivity. In 
another method, Adamczyk et al. focused on the conversion of phosphoserine and phosphothreonine residues to S-(2-mercaptoethyl) 
cysteinyl  or  -methyl-S-(2-mercaptoethyl)  cysteinyl  residues  by  -elimination/1,2-ethanedithiol  addition,  followed  by  reversible 
biotinylation of the modified proteins (Adamczyk et. al., 2001). However, this strategy suffers from several drawbacks such as lack of 
reproducibility, sensitivity and introduction of unwanted side reactions (McLachlin & Chait, 2003). A more prominent procedure to  
 
minimise unspecific binding of acidic non-phosphorylated peptides without introducing unwanted side products is the exploitation of the 
concurrent binding with small carbonic acids such as 2,5-DHB, salicylic acid, phosphoric acid, phthalic acid, benzoic acid or glycolic 
acid during loading or washing steps (Larsen et al., 2005). Under specific experimental conditions, these acids interact more strongly with 
TiO2 or IMAC beads than aliphatic carboxylic acids, but show a weaker interaction compared to the phosphate moieties (Larsen et al., 
2005, Seeley et al., 2005). Observation from infrared spectroscopic studies have shown that substituted aromatic carboxylic acids (such as 
salicylic acid and phthalic acid) coordinate strongly to the surface of TiO2, whereas mono-functional carboxylic acids (including benzoic 
acid and acetic acid) only interact very weakly with TiO2 (Dobson et al., 2000). The trapped peptides are released from the TiO2 beads by 
increasing the pH of the eluting solvent, usually ammonium hydroxide or ammonium bicarbonate (pH 9-10.5). 
After enrichment and elution from the TiO2 or IMAC beads, HPLC-ESI- tandem MS has been used as the method of choice for 
the global profiling of phosphopeptides. With the introduction of Electron Transfer dissociation (ETD) and Electron capture dissociation 
(ECD) fragmentation techniques, which occur along the peptide backbone in a sequence independent manner and preserve PTMs, the 
large scale analysis and annotation of the right phosphorylation sites is steadily increasing. Despite the advantages of MALDI over ESI 
such as higher (but still moderate) tolerance to detergents and salts, low sample consumption, high sensitivity and a non-chromatographic 
dependent analysis, it has been used mostly for manual phosphopeptide analysis. This is partially due to the limited choice of matrices for 
automation, given that the matrix affects the signal intensities and signal/ratio of phosphopeptides and fragmentation. DHB remains the 
dominant  matrix  for  phosphopeptides  analysis  since  its  introduction  as  MALDI  matrix  (Strupat  et  al.,  1991)  and  its  subsequent 
optimisation with respect to analyte sensitivity using 1 % phosphoric acid (Kjellström & Jensen, 2004). DHB crystallises into thick long 
needle-like crystals at the edges of the spot. This distinct characteristic of DHB enables the spatial separation of analytes from the salts (in 
the middle of the spot). Intense signals are, in most cases, obtained only at the crystalline rim resulting in the generation of “hot spots”. 
This makes manual measurements superior, but time-consuming and difficult to reproduce (Strupat et al., 1991). In contrast, during 
automatic measurements a number of spectra are acquired from random positions on the spot. Due to the inhomogeneous morphology, 
intense and weak signals are averaged resulting in only moderate signal intensities. Therefore, automatic nLC MALDI MS/MS analysis 
of phosphopeptides using DHB in 1 % phosphoric acid becomes difficult. Furthermore, Also, DHB has a low absorption efficiency at 355  
 
nm (Nd:YAG laser) (ε355nm = 2.100 l mol
-1 cm
-1 (Tang, Allman, RCM), thus, high laser fluences are necessary for measurements. DHB 
has a low fragmentation yield because of its soft matrix characteristics (Glückman et al., 1999). Other matrices and matrix combination 
such as, CHCA, CHCA/diammoniumhydrogen citrate, 2,5-DHB/CHCA, THAP with ammoniumcitrate, THAP/ DHAP (Asara & Alison; 
1999; Yang et al., 2004; Dunn et al., 2006) have been used for the analysis of phosphopetides.  
Recent methods using  MALDI plates coated  with specific  materials (TiO2,  Fe
3+and ZrO2) for the enrichment and detection of low 
picomol amounts of phosphopeptides have been reported (Blacken et al., 2007; Torta et al., 2009; Hoang et al., 2010). For example, 
MALDI plates coated with poly (2-hydroxyethyl methacrylate) (PHEMA) brushes are derivatized with Fe (III)-nitrilotriacetate (NTA) 
complexes  (MS)  (Dunn  et  al.,  2008)  or immobilized  zirconium  on  a  phosphonate-terminated  self-assembled  monolayer  (SAM)  for 
specific phosphopeptide capture and direct analysis by MALDI MS (Hoang et al., 2010). 
    
 
4  Objectives 
Unlike gene products, the proteome is subjected to continuous changes as a result of environmental influences and cell activities. 
This results in the generation of huge numbers of proteins, isoforms and modified proteins. In addition, the large dynamic range of 
proteins makes the study of the whole proteome very challenging. Traditionally, electrophoresis separation using 1D SDS-PAGE or 2D-
SDS-PAGE has been the method of choice for the study of protein biochemistry. With the establishment of electrospray ionisation and 
matrix assisted laser desorption/ionisation including the subsequent combination with gel-free and automation of separation technologies 
the identification, characterisation and quantification of proteins has become feasible. Since only a fraction of the total peptide population 
of a given protein is identified, information such varying types and locations of posttranslational modifications (PTMs) may be lost in 
shotgun proteomics. Other limitations such as sample generation, dynamic range, MS compatible solvents for protein solubilisation, 
required  column/column  material  and  the  perfect  enzymes  for  protein  digestion  still  present  challenges  in  the  field  of  proteomics. 
However, this technique has enhanced our understanding of the proteome. 
The aim of this study was to establish a nLC-MALDI MS/MS based methodology for the analysis of proteomic samples. The first 
section of this study was based on the method establishment. After the optimisation, the potential of this method was demonstrated by 
analysing a membrane protein sample using a less specific enzyme, elastase. Furthermore, the applicability of the established method was 
demonstrated by the analysis of protein-protein interaction, and the influence of the lipoprotein content from yeast cells grown in two 
different  media  was  investigated.  In  the  second  section  of  this  study,  the  method  was  extended  to  characterise  posttranslational 
modifications in proteins using a biphasic pre-column.  Finally, the nLC-MALDI  MS/MS  method was combined with an optimised 
Offgel-IEF separation technique for the analysis and quantification of proteomics samples.This shows that the established method is 
reproducible, very flexible and with small modifications, it can be used to answer many biological questions.    
 
5  Methods and Material 
5.1  Material 
2,5-Dihydroxybenzoic acid (DHB),  Bruker, Germany 
Acetone, Carl Roth GmbH& Co, Germany 
Acetonitrile, Carl Roth GmbH & Co., Germany 
Agilent 1100 series HPLC, Agilent, Germany 
Alcohol dehydrogenase 1-Saccharomyces cerevisiae, Sigma-Aldrich, Germany 
Alpha-amylase, Bacillus amyloliquefaciens, Sigma-Aldrich, Germany 
Alpha-S1-casein - Bos Taurus, Sigma-Aldrich, Germany 
Alpha-S2-casein, Bos Taurus (Bovine), Sigma-Aldrich, Germany. 
Ammonium bicarbonate, Carl Roth GmbH&Co, Germany 
Ammonium hydrogencarbonate (extra pure) 
Angiotensin II, Sigma, Germany 
Auxillary pump, kdScientific 
Beta-casein - Bos Taurus (Bovine), Sigma-Aldrich, Germany  
 
Bradford-based protein assay kit, Bio-Rad, Germany 
Carbonic anhydrase 2 -Bos Taurus (Bovine), Sigma-Aldrich, Germany 
Column Loader, Proxeon, Denmark 
Dichlormethane, Carl Roth GmbH& Co, Germany 
Dithiotreitol, Carl Roth GmbH & Co, Germany  
Easy nLC, Proxeon, Denmark 
Elastase-1, Sus scrofa (Pig), Roche, Germany 
Ethanol, Carl Roth GmbH & Co, Germany 
Formamide, Sigma-Aldrich, Germany 
Formic acid, Sigma- Germany 
Fused silica capillary, Klaus Ziemer, Germany 
Glu1-Fibrinopeptide B, Sigma-Aldrich, Germany 
Hemoglobin subunit alpha - Homo sapiens, Sigma-Aldrich, Germany 
Hemoglobin subunit beta - Homo sapiens, Sigma-Aldrich, Germany 
Iodacetamide, Carl Roth GmbH&Co, Germany  
 
Isopropanol, Carl Roth GmbH& Co, Germany 
Methanol, Carl Roth GmbH&Co, Germany 
MicroTee, Upchurch Scientific, USA 
Ovalbumin-Gallus gallus, Sigma-Aldrich, Germany 
Peptide Mass calibration kit, Bruker Daltonics, Germany 
Phosphoric acid (85%) 
Phosphoric acid, Sigma-Aldrich, Germany 
Pipette, Eppendorf, Germany 
Potassium silicate, PQ Corporation The Netherlands 
Precast immobilized pH gradient Ready Strips™ IPG and the carrier ampholytes Bio-Lyte 3-10 (Bio-Rad Laboratories (Hercules, CA, 
USA). 
Separation column, 75  m × 150 mm column (Zorbax C18 300 Å 3.5 µm) Agilent, LC-Packings and Vydac); 75  m × 150 mm column 
(C18 300 Å 3.5 µm)- LC-Packings ; 75  m × 150 mm column (C18 300 Å 3.5 µm)- Vydac 
Sequazyme™ Mass Standards Kit, Applied Biosystems, Germany 
Sequencing grade trypsin, Sigma-Aldrich, Germany 
Serotransferrin- Homo sapiens, Sigma-Aldrich, Germany  
 
Serum albumin - Homo sapiens, Sigma-Aldrich, Germany 
Serum albumin -Bos Taurus, Sigma-Aldrich, Germany 
Spotter, Sunchrom, Germany 
Titanosphere 5 µm, GL Sciences Inc Japan 
Trifluoroacetic acid, TFA, ≥99.5 % (Carl Roth GmbH & Co., Germany). 
Ubiquitin- Homo sapiens, Sigma-Aldrich, Germany 
Ultrapure water (MilliQ
TM Bedford, MA, USA). 
X-Bridge™ BEH 180 C18 300 Å 3.5 µm, Waters Germany 
α-cyano-4-hydroxycinnamic acid (CHCA ) Bruker, Germany 
 
All solvent were of HPLC quality and primium purity for all chemical except otherwise mention  
    
 
5.2  Methods 
5.2.1  Expression plasmids, cell culture and transfection experiments (AF4/ENL/AF4
.MLL) 
Protein expression, cell culture and transfection experiments were performed in Prof. Rolf Marschalek group by Anne Benedik 
and Sabrina Baltruschat according to (Baltruschat, 2009; Benedik, 2009). 
5.2.2  Affinity purification (AF4/ENL/AF4
.MLL) 
Protein expression, cell culture and transfection experiments were performed in Prof. Rolf Marschalek group by Anne Benedik and Sabrina 
Baltruschat according to (Baltruschat, 2009; Benedik, 2009). 
5.2.3  Immunoprecipitation experiments (AF4/ENL/AF4
.MLL) 
Protein expression, cell culture and transfection experiments were performed in  Prof. Rolf Marschalek group by Anne Benedik 
and Sabrina Baltruschat according to (Baltruschat, 2009; Benedik, 2009). 
5.2.4  Yeast strains and culture conditions 
Yeast strains used in this study are listed in Table 1. Yeast cells were grown at 30 °C in rich media containing 1 % yeast extract, 2 
% peptone, and 2 % glucose (YPD) or 0.3 % yeast extract, 0.5 % peptone, 0.1 % glucose, 0.5 % KH2PO4 and 0.1 % oleic acid (YPO). To 
solubilise fatty acids in YPO, 0.2 % Tween 80 was added to the media (Grillitsch et al., 2010). 
5.2.5  Isolation of Lipid particles from the yeast culture 
The isolation of the plasma membrane samples and the lipoproteins were performed by Karlheinz Grillitsch in the group of Prof. 
Günther Daum according to published procedures (Serrano et al 1988; Leber et al., 1994; Zinser et al., 1995).  
 
5.2.6  Protein quantification 
Proteins from isolated lipid particles (LP) and homogenates were precipitated with 10%. Trichloroacetic acid (TCA). Proteins 
were quantified by the method of Lowry et al. (Lowry et al., 1951) using bovine serum albumin as standard. 
5.2.7  Delipidation 
The isolated lipid particleswere incubated with 2 volumes of diethyl ether with repeated vigorous shaking. After a high speed 
centrifugation step using a table top centrifuge the extracted non-polar lipids were with drawn and the remaining trace of diethyl ether 
was removed under a stream of nitrogen. The proteins were then precipitated with trichloroacetic acid, and the resulting pellets were 
dissolved in 25 mM ammonium bicarbonate. 
5.2.8  Cell culture (Human Simpson-Golabi-Behmel syndrome) 
Human  Simpson-Golabi-Behmel  syndrome  (SGBS)  cells  were  obtained  from  Prof.  Dr.  M.  Wabitsch  (University  of  Ulm, 
Germany) and were cultured according to published reports (Wabitsch et al., 2001). 
5.2.9  Induction of differentiation (Human Simpson-Golabi-Behmel syndrome) 
Differentiation was induced by Anja Rosenow as described by Rosenow et al. (Rosenow et al., 2010). 
5.2.10  Protein sample preparation (Human Simpson-Golabi-Behmel syndrome) 
To discriminate between secreted proteins and cell-leakage proteins a similar BFA blocking strategy was used as previously 
described by Wang et al. (Wang et al., 2004).  
 
5.2.11  In-solution Proteolytic Digest 
5.2.11.1  Digestion of Purple Membrane (Elastase/Trypsin) 
The proteolytic treatment represents a modified version of the specific integral membrane peptide level enrichment (SIMPLE) as 
described in (Fischer et al., 2006). One hundred micrograms of PM were washed using 25 mM NH4HCO3 buffer (pH 8.0). After a  
2 min centrifugation at 10,000 g the supernatant was removed and the pellet was gently re-suspended in methanol. The sample was 
sonicated for 20 min and the methanol was diluted to 60 % using 25 mM NH4HCO3 buffer. The proteolytic digest was started by adding 
either 2 µg of trypsin or 10 µg of elastase. The elastase digest was performed overnight at ambient temperature and the tryptic digestion at 
37 °C. To prevent excessive binding of the membrane slurry to the tubes, the whole digest process was performed without any external 
shaking. 
5.2.11.2  Digestion of CB membrane (Elastase/Trypsin) 
To remove loosely attached cytoplasmic contaminants from the CB membrane, an additional digestive step was performed before 
the actual proteolytic treatment. Two hundred micrograms of washed membranes were digested with elastase in a 1:20 protein/enzyme 
(w/w) ratio in 25 mM NH4HCO3 for 12 hours at 30 °C. Then the supernatant was discarded after centrifugation and the pellete were re-
suspended in methanol. After a 20 min sonication, the methanol was diluted with 25 mM NH4HCO3 buffer to 60 % and the same 
digestion procedure as described above, was performed. 
5.2.11.3  Tryptic digest (Lipoprotein. Adipocztes) 
100 µg of pellates were dissolved in 1 ml 25 mM NH4HCO3 solution in an Eppendorf tube. The disulfide bridges were reduced in 
45 mM DTT for 1 hour at 60 °C and shaking in a Thermomixer (Eppendorf). The solution was allowed to cool to room temperature, and 
cysteines  were  alkylated  in  the  presence  of  100  mM  iodoacetamide  (IAA)  for  45  min  in  the  dark  at  room  temperature.  To  avoid 
subsequent alkylation of the trypsin, the reaction was quenched after 45 min by adding an additional 12.5 µl of 45 mM DTT and  
 
incubating  for  another  45  min  at  room  temperature.  Trypsin  solution  was  added  to  the  reduced  and  alkylated  samples  to  obtain 
anenzyme/proteinratio of 1:50 (w/w) and the solution was incubated overnight at 37 °C. Digestion was stopped by addition of 1 µl of a 10 
% TFA solution. 
5.2.11.4  Tryptic digest (AF4, AF4
.MLL and ENL protein complex) 
For  the  in-solution  digest  60  µl  of  each  elution  the  sample  was  concentrated  using  vivaspin  500  centrifugal  concentrator 
(Sartorius, Germany) and the buffer was replaced with 25 mM NH4HCO3 buffer (pH 8.0). After reducing the samples with DTT and 
alkylation  with  IAA,  the  proteolytic  digest  was  started  by  adding  0.5  µg  trypsin  (Sigma)  and  incubated  for  
24 hours at 37 °C. The activity of the digestive enzyme was stopped by adding 1 µl 10 % TFA. 
5.2.11.5  Tryptic/elastase digests of standard proteins 
1 mg of each protein was dissolved in 1 ml 25 mM NH4HCO3 solution in an Eppendorf tube.100 µg of this solution was reduced 
by adding 45 mM DTT and incubating for 1 hour at 60 °C and shaking in a Thermomixer comfort (Eppendorf). The solution was allowed 
to cool to room temperature, and cysteines were alkylated with 100 mM iodoacetamide for 45 min in the dark at room temperature. 12 µl 
45 mM DTT was then added and incubated for another 45 min at room temperature. Enzyme solutions were added to the reduced and 
alkylated proteins so that the enzyme/protein ratio of 1:50 (w/w) for trypsin and 1:30 (w/w) for elastase by weight was obtained. The 
tryptic sample was incubated overnight at 37 °C and elastase at ambient temperature. Digestion was stopped by addition of 1 µl of a 10 % 
TFA solution. 
5.2.12  Reduction, Alkylation, Digestion and TMT-labelling of yeast plasma membrane 
The depleted plasma membrane samples (YPO and YPD) were dissolved in 60 % methanol/TEAB, 0.5 M, (pH 8.2). Each sample 
was  separated  in  three  equal  portions.  After  reduction  and  alkylation  of  disulfide  bridges  as  described  above,  elastase  digestion 
(Enzyme/protein ratio of 1/20) was performed overnight at room temperature. The peptide pool was then dried down.  
 
The three YPD samples were labeled by TMT with reporters at m/z 126.1, 127.1, and 128.1 and the three YPO samples by TMT 
with reporters at m/z 129.1, 130.1, and 131.1 in 40.2 µL of CH3-CN each. The derivitisation was carried out under gentle agitation. 
During this process the N-termini and lysine residues were labelled. After 60 min of reaction at RT, 8 µL of 5 % hydroxylamine (w/v) 
was added in each tube and mixed for 15 min. The six samples were pooled in a new tube and diluted with 20 % methanol/1 % IPG 
ampholyte buffer to 2 ml. Pre-fractionion on an Offgel-IEF was performed as described above (section 4.2.9). 
5.2.13  Construction of frit for pre-column and analytical column 
88 µl potassium silicate and 16 µl Formamide were mixed in an eppendorf tube and vortexed for 1 min. One end of a fused silica 
capillary (8 cm, 100 µm ID) was immersed into this mixture and placed in an oven for 60 min at 110 °C with the coated end pointing 
downwards. After the polymerisation, the frit end is cut to about 4 mm and excess formamide was washed with isopropanol. 
5.2.14  Pre-column loading 
The column loader with a PTFE adapter was placed on a magnetic stirrer. Slurry of the C18 material was prepared in a 2 ml glass 
bottle using dichloromethane and inserted in the column loader. The capillary (5 cm, 100 µm ID) was then immersed into the column 
loader containing C18 material via a seal with the frit end pointing upwards and screwed. Under pressure of about 65 bar, 4 cm of C18 
material was loaded into the column. The capillary was then removed and further compressed on the nLC with 100 µl solvent A (0.1 % 
TFA in 8 % ACN) at a flow rate of 5 µL/min. 
5.2.15  Biphasic pre-column loading 
For the biphasic pre-column, approximately 3.5 cm long C18 material preloaded column (8 cm, 100 µm ID) was inserted in the 
column loader containing TiO2 slurry (5µm) and the same procedure was repeated. After loading approximately 3.5 cm of the TiO2 
material, the column was removed from the column loader and connected to the nLC and flushed with 50 µl solvent A at a flow rate of 2 
µl/min. After a constant column pressure was obtained, the biphasic pre-column was shaped in other to reduce potential dead volume.  
 
5.2.16  Analytical column 
For the analytical column, fused silica capillary with 100 µm internal diameter and a length of 120 mm were filled with C18 
materials at a pressure of 100-250 bar. To estimate the efficiency of the in-house packed columns, four standard peptides were separated 
with a short gradient and the UV spectrum (figure 15 A) was compared to that obtained from the same peptides using a commercial 
column (75 µm x 150 mm, C18 3.5, 100 Å, LC packings Pepmap
™ 100) (figure 15 B). Apart from a small retention time shift, both 
columns had almost the same peak width, thus it can be concluded that the in-house packed column had the same separation efficiency as 





Figure 15  A shows a chromatogram of 4 standard peptides separated on the in-house packed column. B show a 
chromatogram of the same standards separated using 75 µm x 150 mm, C18 3.5, 100 Å, LC packings 
Dionex Pepmap™ 100 column. 
  
 
5.2.17  Nano-LC 
The RP-HPLC separations were performed using 2 HPLC systems: the 1100 series from Agilent and the Easy-nLC from Proxeon. 
5.2.17.1  Agilent 1100 series 
The 1100 series consist of a capillary pump, nano-pump, a thermostatic autosampler, solvent degasser both on the nano- and 
capillary-pumps, a spotter and a 10-port-Micro valve. The sample was pulled from the autosampler and directly loaded to the pre-column 
using solvent A (0.1 % TFA in 8 % ACN) for on-line desalting via the capillary pump running at a flow rate of 20 µL/min for 5 min. 
After  loading,  the  10-port  valve  is  the  switched  to  the  nano-pump  and  the  sample  is  back-eluted  to  the  analytical  column  for  the 
separation step using a flow rate of 300 nl/min with increasing ACN concentration (solvent B 0.1 % TFA in 95 % ACN). Separation was 
performed on a 75  m × 150 mm column (Agilent, LC-Packings and Vydac). 
5.2.17.2  Proxeon Easy nLC 
The Easy-nLC from Proxeon consists of 2 solvent pumps (A and B) and 1 sample pump, a refrigerated autosampler and a spotter. 
The  sample  was  loaded  to  an  in-house  packed  pre-column  (X-Bridge™  BEH  180  C18  300  Å  3.5  µm,  100  µm  x  30  mm)  or  a  
100 µm x 60 mm biphasic pre-column containing C18 and TiO2 materials (Titansphere 5 µm) and desalted with 2 times the injected 
volume using solvent A (0.1 % TFA in 8 % ACN). Separation was performed on thermostatic (40 
oC ), 75  m × 150 mm column (LC-
Packings) or a custom  made C18 column (X-Bridge™ BEH 180 C18 300 Å 3.5 µm, 100 µm x 120 mm) at flow rates between 300-400 nl 
with increasing ACN concentration (Solvent B 0.1 % TFA in 95 % ACN). 
  
 
5.2.18  nLC gradient 
The following gradients were used (table 3). Though some slight modifications were made to suit certain samples, the gradient 
slopes were maintained. 
Table 3  Gradient profile used for method optimisation and separation. 
Gradient 1    Gradient 2    Gradient 3   
Time(min)  % B  Time (min)  % B  Time (min)  % B 
5  8  5  8  5  8 
65  90  65  45  8  15 
75  90  68  90  125  45 
80  8  75  90  135  90 
    80  8  145  90 
        150  8 
        155  8  
 
5.2.19  Matrix for manual measurement 
6 mg of each matrix, CHCA, DiFCCA and Chloro-CCA were dissolved in 1 ml 70 % acetonitrile/0.1 TFA. The matrices were 
then diluted so that each had a total concentration of 15  mM. The matrices and  matrix mixtures containing ammoniumdihydrogen 
phosphate were prepared so that the final concentration of each matrix and ammoniumdihydrogen phosphate was 15 mM and 3 mM 
respectively. For the DHB matrix, 10 mg was dissolveed in 33 % Acetonitrile/ 1 % H3PO4. 
5.2.20  Matrix for LC-MALDI spotting 
The effluent from the nLC was pre-mixed with a matrix from an auxiliary pump (flow rate, 1.2 µl/min) via a microTee and spotted 
every 20 seconds on a MALDI 123 x 81 mm Opti-TOF
™ metal target. This solution contained 15-20 mM CHCA in 70 % ACN/0.1 % 
TFA, spiked with 20 fmol final amount of [Glu
1]-Fibrinopeptide B per spot for internal calibration. 
5.2.21  Isoelectric focusing (IEF) fractionation (Offgel-IEF) 
Isoelectric focusing (IEF) was carried out on an Agilent Technologies 3100 OFFGEL fractionator device (Böblingen, Germany) 
using the 12-well setup on 13 cm pI 3-10 linear gradient IPG strips. Prior to sample loading, the IPG gelstrips in each well were re-
hydratedwith 20 µl of focusing buffer. The sample was then diluted in a solvent buffer containing 20 % methanol (MeOH) and 1 % IPG 
buffer as final  concentrations. To prevent the  outer chambers  from  running dry through  excessive water transport during focusing, 
additional 100 µl 1 % IPG solution was added to fractions 1 and 12 and 50 µl to fractions 2 and 11. The samplewas focused with a 
maximum current of 50 µA and typical voltages ranging from 500 to 4000 V until 20 kVh was reached. After focusing the fractions were 
removed and the wells were incubated at room temperature with methanol for another 15 min. The incubated and focused fractions were 
then combined and vacuum centrifuged to about 10-12 µl.  
 
5..2.22  MALDI MS/MS 
Mass spectra were acquired using an Applied Biosystems/MDS Sciex 4800 TOF/TOF
™ Analyzer. The instrument is equipped 
with a Nd:YAG laser, emitting at 355 nm with a repetition of 200 Hz. All spectra were acquired in the positive reflector mode between 
700 and 4500 m/z with fixed laser intensity. A total of 750 laser shots per spot were accumulated. External calibration was performed 
using an 8-point plate model with peptides from the Sequazyme
™ Peptide Mass Standards Kit, Applied Biosystems. In order to obtain a 
higher precursor mass accuracy for subsequent MS/MS experiments, the MS spectra were internally recalibrated to the spiked [Glu
1]-
Fibrinopeptide B. Fragmentation was performed with collision energy of 1 kV using air as collision gas at a pressure of approximately 1 x 
10
-6 Torr, a source voltage of 8 kV, a collision cell voltage of 7 kV and an accelerating voltage of 15 kV in the second source. To reduce 
sample consumption during measurement, stop conditions for MS/MS were defined. A minimal number of 15 peaks above 45 S/N with at 
least 12 accumulated sub-spectra, a minimum of 1250 and maximum of 2500 laser shots were recorded. To avoid unnecessary multiple 
selections  of  identical  precursor,  MS/MS  precursor  selection  was  carried  out  via  the  instrument’s  job-wide  interpretation  software. 
Depending on sample, between 6 and 10 precursors per spot with a minimum signal-to-noise-ratio of 100 were selected for fragmentation. 
Potential matrix signals were removed from precursor selection, by excluding all masses in the range from 700 to 1400 m/z obtained from 
measuring spots without analytes. 
5.2.23  Database searches 
Mascot Generic Format (MGF) files were retrieved from each nLC-MALDI MS/MS run using a built-in Peaks2Mascot (software 
4000 explorer) feature, exporting up to 65 peaks per MS/MS spectrum, each requiring a minimum signal-to-noise of 5. The MGF files 
were processed using the Mascot
™ database search engine v2.2.03 (Matrix Science Ltd., UK). The following settings were used: Enzyme, 
trypsin  or  none,  allowed  missed  cleavages  for  trypsin  3  and  9  when  no  enzyme  (None)  definition  was  used;  fixed  modification: 
carboxymethylation of cysteine; variable modification: oxidation of methionin; MS precursor mass tolerance was set to between 30-50 
ppm and MS/MS mass tolerance was 0.5 Da. In addition to the above settings, phosphorylation (STY) was set as a variable setting when  
 
analysing phosphopeptides and amino-terminal pyroglutamate formation was considered as variable modification in all purple membrane 
database  searches.  Depending  on  the  sample,  the  search  was  performed  with  a  custom  Halobacterium  database  generated  from 
SwissProt/TrEMBL containing 2490 entries as at November 30
th 2007, a Corynebacterium glutamicum ATCC 13032 Bielefeld database 
containing 4008 sequences was provided by Jörn Kalinowski (41), DB-Standard containing 24 proteins, Swissprot and NCBI database. 
False positives were estimated by the internal Mascot
™ decoy database search function. 
Table 4  Mascot search parameters 
 
  Yeast Cells  Human fat cells  Standard proteins  Standard proteins  AF4, ENL  CB  PM  Yeast Cells 
Taxonomy filter 
Saccharomyces 
Cerevisiae   Homo sapiens  All entries  All entries  Homo sapiens  All entries  All entries  All entries 
Enzyme  Trypsin  Trypsin  Trypsin  None  Trypsin  None/Trypsin  None/Trypsin  None 
Max missed 



























(M)  Oxidation (M) 
Peptide mass 
tolerance  50 ppm  50 ppm  50 ppm  50 ppm  50 ppm  50 ppm  50 ppm  50ppm 
Fragment mass 
tolerance  0.3 Da  0.3 Da  0.3 Da  0.3 Da  0.3 Da  0.3 Da  0.3 Da  0.3 Da 
Mass values  Monoisotopic  Monoisotopic  Monoisotopic  Monoisotopic  Monoisotopic  Monoisotopic  Monoisotopic  Monoisotopic 
Instrument type  MALDI-TOF-TOF  MALDI-TOF-TOF  MALDI-TOF-TOF  MALDI-TOF-TOF  MALDI-TOF-TOF  MALDI-TOF-TOF  MALDI-TOF-TOF 
MALDI-TOF-
TOF 
Total sequences  6717  466739  24  24  466739  3059  2490  6912 
Total residues  3019518  165389953  7388  7388  165389953  955253  701243  3167490 
Sequences after 
taxonomy filter  6717  20402  24  24  20402  3059  2490  6912 
Database  SGD  SwissProt  DB-standard  DB-standard  SwissProt  Cg-ELA1_PIG  HALSA-ELA1_PIG  Yeast_Swissprot 
Quantifcation  none  none  none  none  none  none  none  yes  
 
5.2.24  Result interpretation and data analysis 
All statistic analyses were based on peptides having Mascot
™ MS/MS ions scores exceeding the “identity or extensive homology 
threshold” (p < 0.05). In the case of multiple fragmentations of identical precursors, due to recurrence in repetitive runs, only data from 
the highest scoring peptide were kept.  
The hydrophobicity of each peptide was calculated using the GRAVY-Scores principles from Kyte and Doolittle (1982). 
For the calculation of the isoelectric points, detail information of each amino acid from Nelson and Cooks Lehninger Principles of 
Biochemistry 3
rd Ed. (2001) were taken into consideration.  
Transmembrane regions of proteins were predicted with the TMHMM 2.0-Algorithmus (Krogh et al., 2001) and displayed with the 
TMRPres2D (Spyropoulos et al., 2004) software. 
5.2.25  Analysis of secreted protein candidates (Human Simpson-Golabi-Behmel syndrome). 
For verification of secreted protein candidates a SwissProt analysis of amino acid sequences with SignalP and SecretomeP was 
performed. SignalP 3.0 predicts the presence and location of signal peptide cleavage sites in amino acid sequences. SecretomeP 2.0 
predicts non-classical, in particular not signal-peptide-triggered protein secretion. In this process the non-classically secreted proteins 
should obtain an NN-score above the threshold of 0.5, but not at the same time be predicted to contain a signal peptide. 
Table 5  List of phosphopeptides used for method optimisation 
Peptide Sequence  Monoisotopic  Mass 
VDNIRpSAT  955.42 
DpSFDDAFKA  1095.39  
 
DRVYIHPF  1126.34 
HYQPpYAPPR  1208.52 
TWTpLCGTPEY  1250.46 
SDLESQLAQpSR  1313.56 
KLLpSFTSNDILR  1485.76 
VRFPSpHFSSDLK  1499.69 
FQpSEEQQQTEDELQDK  2060.82 
VADPDHDHTGFLpTEpYVATR  2303.99 
  
 
6  Results and discussion 
6.1  Method Optimisation 
6.1.1  Optimisation of spot deposition 
The establishment of instruments capable of accurately depositing nano-liter on a target paved the way for the direct analysis of 
complex proteomic samples using MALDI. With the combination of RP-HPLC, the LC separation was then preserved on the MALDI 
target.  Decoupling  the  separation  from  the  MS  and  MS/MS  analysis  consequently  provides  the  opportunity  for  the  researcher  to 
independently optimise the separation and the MS and MS/MS performance, improving the overall quality of the result. During this 
process, the eluent from the LC is mixed with a matrix and spotted on a target. The rate of deposition is independent of the flow rate and 
the chromatographic resolution. Though the deposition on a MALDI target preserves the LC chromatogram, the chromatographic peak 
width is affected. Compared to LC-ESI, where the chromatographic peak widths of most peptides are less than 60 sec, the same peptides 
exhibit peak width of over 60 sec in MALDI experiment. 
In MALDI spotting peak broadening can result from sample mixing with the matrix in the microTee or from longer and large 
transfer capillaries after the analytical column. Furthermore, capillary carry-over from one spot to the next during deposition and spotting 
frequency can also result in peak tailing. To determine the source of the peak broadening in our system, 13 standard peptide and three 
different concentrations were separated and spotted every 15, 20 and 30 sec at three different concentrations (250, 100 and 33 fmol) using 
an 80 min gradient. The flow rate from the LC and the matrix pump were kept constant. After MS acquisition, the distributions of the 
peptides in different fractions were plotted against the signal-to-noise ratio of total number of spots for each gradient (see figure 16). 
Figure 16 shows a graphic representation of 2 standard peptides with 20 sec spotting interval. The peptides were eluted in more than 10 




Figure 16  Signal-to-noise plot of 2 peptides (100 fmol). The spots were deposited every 20 sec on a MALDI target and 
a 50 cm transfer capillary with 100 µm internal diameter after the analytical column. 
Tailing has a general disadvantage that the peptide is distributed in over several spots. Hence, the sample is diluted, thus leading to 
a decrease in sensitivity. For a complex sample, where different dynamic range of peptides concentration exist, this would result in 
possible peptide suppression by more abundant peptides, which might prevent selection of less abundant ones for MS/MS analysis.  
With 30 sec spotting interval, only a minimal change was observed in the number of spots where the peptides were eluted (see figure 17). 


















































Figure 17  30 sec spotting frequency using the same 50 cm transfer line (100 µm) and concentration (100 fmol). 
Since the peptides were still eluted in more than 3 fractions, the transfer capillary with internal diameter (ID) of 100 µm was 
replaced with a 15 cm fused silica capillary with internal diameter of 30 µm. The same peptide mixture was separated and spotted every 
20 sec on a MALDI target. The same interpretation procedues were repeated using the same 2 peptides. These modifications greatly 
reduced the number of spots in which the peptides were detected (figure 18). The peptides appeared in at most 3 fractions, thus the peak 
maxima are exclusively in the second fraction. However, the best scenario would be cases were peptides are present in only 2 spots. 
    
 
 
Figure 18  Signal-to-noise plots of 2 peptides. The spots were deposited every 20 sec on a MALDI target and a 50 cm 
transfer capillary with 30 µm internal diameter after the analytical column. 
In LC-MALDI with automatic deposition dervices, it is assumed that the peak broadening could result from mixing of the matrix 
and the separated sample in the microTee. So the microTee was replaced with a Y connector. This connector is constructed in a way that 
both the matrix and the eluent from the nLC, coming from 2 different capillaries flow into one large capillary that is conneted to the 
needle (see figure 19). Compared to the MicroTee, the Y-connector should improve laminar flow, thus resulting in less turbulence when 
mixing. It was therefore expected that a Y-connector would improve the peak width, tailing and the number of fractions peptides elute. 
    
 
 
Figure 19  NanoTight Y-Connector 
However, experiments using this Y-connector resulted in unexpected tailing and carryover (see figure 20). Also installing the Y-
connector to the spotter was a technical challenge. For this reasons it was not used in further experiments. Experiments without a mixing 
chamber did not further improve the results.  
 
 
Figure 20  Extracted ion chromtograpy of 2 peptides witt the y-connector as mixing chamber. 
The use of a transfer capillary with smaller inner diameter and shorter distance between column and MALDI target reduced the 
number of spots in which peptides are eluted. However, peptides were still eluted in 3 spots. Probably, spotting frequency of 30 sec or 
more would further reduce the number of spots in which peptides are eluted. In general, a compromise has to be made with respect to 
spotting time. Spotting frequency of 30 sec and above would still result to complex spots and thereby higher chances of losing less 
abundant peptides. On the other hand, spotting frequences below 20 sec might lead to diluted samples, thus lower intensities. Therefore, 
for further experiments during this study, a spotting frequency of 20 sec was used. 
6.1.2  Matrix concentration for automatic spotting 
For LC-MALDI-MS/MS experiments it is necessary to have enough matrix material on the target for a considerable amount of 
MS and MS/MS experiments and at the same time to keep the matrix-to-analyte ratio optimal. For high-throughput experiments, usually  
 
more  than  5  precursors  are  chosen  for  fragmentation.  Therefore, it  is  important  that  enough  matrixis  present  on each  spot.  Matrix 
concentrations ranging from 2 mg/ml up to saturated matrix solution have been used for manual crystallization. For automatic deposition 
concentrations above 4 mg/ml result in crystal formation on the needle, especially when the gradient starts approaching high ACN 
concentration. This resulted in extensive carryover and in some case, spots containing no matrix (see figure 21). Concentrations below 2 
mg/ml work well, but due to ablation during MS and MS/MS, the number of accumulated spectra is limited. Matrix concentrations 
between 3 and 4 mg/ml were determined to be optimal for our proteomics analysis and 1:4 (v/v) samples: matrix ratio was used for all 
analysis. 
 
Figure 21  Peak tailing as a result of crystall formation on the needle tip  
 
6.1.3  TOF/TOF method optimization 
Modern MALDI-TOF/TOF instruments are capable of acquiring MS/MS data with significantly improved automation. Owing to 
the large number of spectra, which are generated in shotgun proteomics, manual interpretation of each spectrum is not possible. Therefore 
a high quality of the mass spectra is required to correctly match peptide sequences. However, for optimum spectral quality, operational 
parameters and instrumental settings  must still be determined.  For fragmentation purposes, the 4800 Proteomics Analyzer MALDI-
TOF/TOF is equipped with two default MS/MS acquisition methods, the 1 kV MS/MS and the 2 kV MS/MS method. Both default 
methods have the same settings but differ in their collision energy. To determine the best settings for high throughput analysis, these 
methods were optimised with standard peptides. MS/MS spectra were acquired using air as a collision gas with either a 1 kV or 2 kV 
collision energy settings and fixed number of laser shots (2500). 
The high collision energy used for the 2 kV MS/MS method resulted in the generation of high-intensity internal fragment and 
immonium ions in the lower mass region of the spectrum but low intensity fragment ions in the high mass region as shown in figure 22 A. 
Unlike the 2 kV method, the 1 kV generates a smoother spectrum, with y and b fragment ions ranging from low to the high mass region 
of the spectra. Thes pectra generated by the 1 kVmethod are easy to interpret (figure 22 B). Consequently, the 1 kV MS/MS method was 
adopted for subsequent experiments.  
 
 
Figure 22  Fragment spectra of Angiotensin II obtain using both fragmentation methods. The spectrum below was 
obtained with the 1 kV and that above with the 2 kV MS/MS mode. 
Matrix/analyte consumption during MS and MS/MS acquisition is often a problem in high-throughput analysis. To minimize the 
amount  of  sample  consumption  during  MS/MS,  certain  threshold  conditions  were  introduced.  These  conditions  were  set  so  that 
acquisition would stop when a number of fragment ions (15 fragment ions) having a required minimum signal-to-noise ratio (S/N of at 
least 30) were present in the accumulated MS/MS spectrum, in the region from m/z 100 to 90 % of the precursor mass. With these 
conditions a minimum of 1250 (25 sub-spectra accumulated from 50 laser shots each) and a maximum of 2500 shots were allowed for 
each MS/MS spectrum. The intensities of the fragment ions generated with the fixed-shot method (2500) were compared to those of the 
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stop-condition method using the applied standard peptides. A total of 10 replicates were performed on one spot. The fixed-shot MS/MS 
method resulted in decreased intensity because of increasing number of laser shots. In contrast, the intensities of the same fragments with 
the stop-conditions were relatively constant (figure 23 A and B). On average, fewer laser shots were fired (an average of 1250 per 
spectrum) and, consequently, less sample was consumed. 
 
Figure 23  MS/MS method optimisation using the standard peptide with m/z 1570.677. (A) A plot of the ion intensity 
of  4  fragment  generated  using  the  stop-conditions.  (B)  Shows  the  signal  intensities  of  the  same  four 
















































number of measurments 
 
In shotgun proteomics analysis, identification is obtained by determination of a partial sequence from a series of fragment ions 
whose mass difference matched amino acid residues and given in the form of a peptide score. The peptide score is derived by comparing 
the precursor mass and number of fragment ions, which are matched to theoretical fragment ions. These scores determine how good a 
peptide sequence fits. Owing to the large number of spectra generated in shotgun proteomics, manual interpretation of each spectrum is 
no longer adequate. Therefore, a constant high spectral quality is required to correctly match peptide sequences. The quality of MS/MS 
spectra depends on the instrument, fragmentation principle and the collision energy used for fragmentation. Since a complete fragment 
series is not required for peptide identification and the most prominent fragment ions in most peptides are readily formed, defined 
methods with MS/MS threshold criteria can be introduced. Hence, reducing the rate of sample/analyte consumption would improve signal 
stability and subsequently peptides scores. On the other hand, extreme higher collision energy yields more internal fragments, which are 
disadvantageous  for  peptide  identification.  As  a  result,  the  stop-condition  method  was  adapted  for  further  measurement.  With  this 
method, enough spectra to permit peptide identification were acquired and the matrix/sample consumption due to ablation was minimised. 
6.1.4  Influence of mobile phase gradients on peptide identification 
Given the ion suppression phenomenon associated with MS-based (Cechet al., 2000; Kratzer et al., 1998) analyses of complex 
mixtures, better peptide separation prior to MS and MS/MS analysis is critical for identifying low-abundance proteins. RPLC separation 
can be performed either in isocratic or gradient system. Unlike gas chromatography, where the separation is exclusively dependent on 
temperature,  RPLC  separation  depends  on  the  gradient  system.  Peptides  are  separated  almost  exclusively  using  various  forms  of 
gradients; linear, exponential or step gradients, with the linear gradient being the most widely applied. Regardless of which gradient 
system (see figure 24), the efficiency of separation highly depends on the instrumentation.  
 
 
Figure 24  Gradient profiles used for the separation. 
To establish a suitable gradient for proteomic analysis, a mixture of 21 proteins was digested with elastase and separated with the 
gradients shown above. To estimate the ability of gradient systems to separate abundant from less abundant proteins, the concentration of 
Lipase and Troponin were 10-fold less than the others. While for gradient 1 and 2 the total separation times were kept constant and the 
gradient slopes were varied, the slope and separation time for gradient 3 was varied. Column and pre-column equilibration was performed 
before each run and 3 replicates for each gradient were used for the data analysis. The optimised 1 kV MS/MS method was used for 
MS/MS acquisition and Mascot generic files (MGF) for each run were generated and searched against a standard database containing 24 
proteins. For data analysis only peptides with ion score above the identity threshold (p < 0.05) and present in at least 2 runs were taken 

























A total number of 350, 499 and 734 unique peptides were identified for gradient 1, 2 and 3 respectively (see figure 25). For the 
identified proteins, a gain of at least 10 % and in some cases up to 40 % additional peptides was observed from gradient 1 to 3. Also, the 
individual peptide score, protein score and the sequence coverage were in most cases higher for gradient 3 than for 1 and 2. The change in 
gradient profile leads to a 2-fold increase in peptide identification. Whilst 35.6 % of the identified peptides appeared on all gradients,  
1.5, 3.4 and 59.5 % were found only in gradient 1, 2 and 3 respectively (see figure 26). 
 






























Gradient 3 Gradient 2 Gradient 1 
 
With the exception of lipase and Troponin all other proteins were identified with gradient 1 and 2. This indicates that with a faster 
increase in acetonitrile (ACN) concentration, peptides are not properly separated from each other, thereby inducing a greater possibility of 
loosing less abundant proteins. The difference in identified proteins is a result of the peptide elution profile. The retention times of 
peptides are relatively close to each other. The vast majority of peptides elute between 20-40 % ACN. Due to the fact that proteomic 
samples are complex and the complexity can be exponentially magnified if the whole sample is digested without any pre-fractionations, a 
small change in acetonitrile concentration in this region (20-40 %) result in the elution of many peptides. After elution, interaction 
between peptide and the hydrophobic  groups of the stationary phase is negligible. No  matter how efficient a mass spectrometer is 
(resolution, sensitivity and duty cycle); if the eluted peptides are poorly resolved, only peptides from the most abundant proteins or easily 
ionised peptides would be detected. Reducing the number of eluting peptides by introducing a shallower gradient between 20 and 40 % 
ACN would therefore reduce the amount of co-eluting peptides, thus reducing the degree of ion suppression. Thereby, increasing the 
number of identified peptides, which in turn improves sequence coverage, identification and characterisation of proteins. 
 






This result suggests that for complex samples, shallower gradient separations are generally better than fast gradient separation, 
since they turn to prolong retention time, thus providing better resolution. For a less complex sample or a fast sample screening, a fast 
gradient would be enough, but when dealing with complex samples, shallower gradients are necessary. But it should be noted that at one 
point,  no  matter  how shallow  the  gradient  is,  little  or no additional  information  would  be  acquired.  In  such  cases,  more than  one 
dimension  of  separation  techniques  would  be  required  for  sample  analysis.  The  shallow  gradient  was  adopted  for  subsequent  LC 
experiments of complex samples and faster gradient for screening and less complex samples. 
6.1.5  Improved mass accuracy 
The confidence of peptide identification can be enhanced by accurately measuring the precursor mass. The importance of a 
constant high mass accuracy in characterising peptides has been demonstrated in numerous studies (Haas et al., 2006). Though TOF/TOF 
instruments provide high mass accuracy, they are limited in the fact that the mass accuracy varies over the target. Therefore, poorly 
calibrated  data  might  lead  to  loss  of  potential  positive  identification  and  increase  the  number  of  false  positive  identifications.  To 
investigate mass accuracy, 10 standard peptides were digested separated and analysed. In the first triplicate experiment, only the default 
calibration was used for MS and MS/MS acquisition.  
 
 
Figure 27  Peptide error distribution (±50 ppm) observed for the identified peptides during LC-MALDI experiments 
using the default calibration. 
While the mass accuracy of the MS/MS mode is relatively constant, the precursor mass accuracy all over the target is not constant 
especially using different spot sets. The average mass accuracy observed for the identified peptides during LC-MALDI experiments was 
±50 ppm (see figure 27). This mass accuracy might be sufficient for a tryptic digest of standard protein. However, for less specific 
enzymes, since in most cases the enzyme specificity is left out during database search, a higher mass accuracy is required. Peptides of 
known masses are commonly used to improve the mass accuracy. Glu-fibrinogen peptide, 1570.677 Da is commonly used in MALDI 
analysis as internal standard because of its m/z ratio, which is in the middle of the mass range (700-4000 Da). This peptide is mixed in the 
matrix so that each spot contains an equal amount of this peptide. It is either used directly as an internal standard during measurement or 
in combination with the default calibration. Therefore, to achieve a high mass accuracy Glu-fibrinogen peptide (Glu-fib) was added to the 































internally  to  the  Glu-fib.  Though  more peptides with mass  accuracy  between  ±15  were identified,  only peptides  identified  in  both 
triplicate runs were used for a detailed comparison. Figure 28 shows a plot of the deviation from the calculated mass of the unique 
peptides identified. However, the concentration of the internal standard in each spot is very critical. Higher concentration would lead to a 
saturation of the detector, thus leading to a negative influence of the calibration. On the other hand, at lower concentrations, this peptide 
might not be detected in some spots due to the presence of highly concentrated peptides from the proteins. 
 


































with internal calibration 
 
6.1.6  Effect of temperature on LC Separation 
Unlike Gas Chromatography, temperature effect is not that significant in reversed phase chromatography. However, operating RP-
HPLC at higher than ambient temperatures have been shown to improve peak shapes and enable faster run times (Vanhoenacker & 
Sandra, 2007). Pre-heated columns and mobile phases results in lower solvent viscosity, which in turn influences the flow profile and the 
diffusion characteristics (Vanhoenacker & Sandra, 2007). Different heating systems have been introduced and some have proven to be 
better than others. Independent of the heating system, it is always necessary to determine the temperature at which the HPLC system 
works best. To determine the optimal temperature for our proteomics workflow, 9 standard proteins were digested with Trypsin and 
Elastase. The samples were loaded onto a 150 µm x 35 mm C18 pre-column. The separation was performed on a 75 µm x 150mm C18 
column using an 80 min gradient. The column temperature was set between room temperature and 60 °C (20, 30, 40 and 60 °C). In order 
to obtain the required temperature, the column was left in the column heater for 60 min before the next separation. For each temperature, 
three replicates were used for the data analysis and a total of 100 fmol for each of the standard protein was injected on the pre-column. 
After separation, the eluent was pre-mixed with a matrix and spotted every 20 sec on a metal target. 
6.1.7  Effect of temperature on column back pressure 
The primary gain of elevated column temperature on LC separation was the resultant decrease in backpressure as shown in figure 
29. With the increase in temperature from 20 to 30 °C, a pressure drop of approximately 10 % is observed. From 35 through 60 °C the 
change in pressure is no longer significant, since it becomes more stable. At this point any increase in temperature would probably result 
in little or no change in backpressure. Temperatures above 60 °C would result in a drop of backpressure due to possible column bleeding. 
Therefore,  for  our  proteomics  setup  temperatures  between  35-40  °C  would  be  optimal,  since  there  is  no  significant  change  in 
backpressure.The decrease in backpressure comes as a result of a decrease in solvent viscosity. Reduced backpressure facilitates the use 




Figure 29  Shows the column back pressure at different temperatures at a flow rate of 400nl/min. 
6.1.8  Effect of temperature on proteins and peptides identification 
To determine the optimal temperature for our proteomics workflow, 9 standard proteins were digested with Trypsin and Elastase. 
The samples were loaded onto a 150 µm x 35 mm C18 pre-column. The separation was performed on a 75 µm x 150 mm C18 column 
using an 80 min gradient. The column temperature was set between ambient temperature and 60 °C (20, 30, 40 and 60 °C). In order to 
obtain the required temperature, the column was left in the column heater for 60 min before the next separation. For each temperature, 
three replicates were used for data analysis and a total of 100 fmol for each of the standard proteins was injected onto the pre-column. 
After separation, the eluent was pre-mixed with a matrix and spotted every 20 sec onto a metal target. A Mascot search against the DB-
standard database resulted in the identification of all the standard proteins. Furthermore, an additional protein, Ubiquitin, which was not 
present in the protein list, was identified at elevated temperatures (30, 40 and 60 °C). This protein resulted from a posttranslational 
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proteins  were identified  with  different  number  of  unique peptides.  Figure  30  shows  the total number  of  unique  peptides  that  were 
identified. Between 20 and 40 °C a 33.6 % and 21 % increase in unique peptides was observed for elastase and trypsin respectively. Only 
a minimal increase was observed between 20 and 30 °C. At 60 °C, the number of identified peptides dropped but was still higher than for 
20 °C. According to the manufacturer’s recommendations, the temperature of the column should not exceed 60 °C due to irrevocable 
damage of the column. This could be a possible reason for the drop in unique peptides. For both proteolytic enzymes, the peptide 
separation at a column temperature of 40 °C leads to the identification of highest number of peptides. A complete list of the proteins and 
peptides identified is seen in the supplementary table 1. 
 
 
Figure 30  Total number of peptides that were identified using different column temperatures for tryptic and 

































Furthermore, peptide overlap was determined. In general 34.8 % of peptides were found in all temperatures, 4.6 %, 15.13 %, 2.6 
% and 7.2 % were found only in 60 °C, 40 °C 30 °C and 20 °C (see figure 31 A and B). Moreover, the intensities, signal-to-noise and the 
subsequent Mascot score for most of the shared peptides were higher at elevated temperature. 
 
Figure 31  A summary of the peptide overlap for both tryptic (A) and elastase (B) digestion.  
 
6.1.9  Effect of temperature on repeatability 
Run-to-run  repeatability  is  essential  for  shotgun  proteomics  studies  especially  when  monitoring  dynamic  changes  in  living 
organism. In these studies, identified proteins, which are regulated or not present at all in one state or the other can be consider as 
potential biomarkers candidates. Therefore, repeatability of the analyses is a critical determination of the ability to distinguish true 
differences  between  sample  types.  Table  6  shows  the  run-to-run  repeatability  for  a  tryptic  digest  of  13  standard  proteins.  Higher 
temperature did not only improve run-to-run repeatability, but also more peptides were identified. At higher temperature, reproducible 
triplicate  run  were  easily  obtained,  at  least  5  runs  were  necessary  to  obtain  reproducible  triplicate  runs  at  room  temperature. 
Reproducibility  is  impaired  by  long  inadequate  equilibration  time  between  runs,  fluctuating  column  pressure/flow  rate,  fluctuating 
temperature and irreproducible mixing of both solvent A and B. Flow sensors have been built before and after the mixing chamber to 
monitor the flow rate and LC separations are now being performed at high temperature. Higher temperatures result in decrease solvent 
viscosity, which in turn leads to shorter column re-equilibration time, thus, improvement in run-to-run reproducibility. 
Table 6  The effects of column temperature on run-to-run reproducibility and the number of peptides identified 
from a tryptic digestion of 13 standard proteins  Proteins  identified  with  more  then  1  peptides  is 
represented with protein > 1 and proteins identified with only 1 peptide with “one hit wonders” (OHW). 
All gradient runs were performed on a nLC column from Dionex (75  m × 150 mm column). 
  40 °C_1  40 °C_2  40 °C_3  Average 
Proteins  13  13  13  13 
Peptides  140  143  145  14 2.67  
 
Proteins >1  12  12  12  12 
OHW  1  1  1  0 
false positive rate  2.99  3.19  3.32  3.20 
         
  30 °C_ 1  30 °C_2  30 °C_3  Average 
Proteins  13  13  13  13 
Peptides  110  124  116  116.67 
Proteins >1  9  9  9  9 
OHW  3  3  3  3 
false positive rate  2.70  3.67  2.23  20.87 
         
  RT °C_ 1  RT °C_2  RT  °C_3  Average  
 
Proteins  11  11  11  11 
Peptides  89  107  115  103.67 
Proteins >1  8  7  8  7.60 
OHW  3  4  3  3.30 
false positive rate  2.97  3.17  3.55  3.22 
 
From the number of peptides identified in triplicate runs at elevated temperatures (see table 3), it can be assumed that a higher 
repeatability  is  most  likely  to  be  achieved  at  elevated  temperatures.  However,  assessing  the  run-to-run  overlap  amongst  the  same 
temperature reveals that only about 64 % of the identified peptides appeared in all runs (see figure 32).   
 
 
Figure 32  Run-to-run overlap. 
This shows that no matter how stable a system is running, there are still alterations, which influence peptide signal-to-noise ratios 
and their elution times. This might influence their selection for fragmentation and the fragmentation itself. Poor fragmentation could 
cause misidentification or poor scoring and therefore these peptides can be omited during protein identification. For example, this serum 
albumin  peptides  RRHPEYAV  or  alpha  S1  casein  peptide  YFYPELFRQ  were  identified  by  all  temperature  experiments  but  with  
 
different  ion  scores  (see  table  7).  In  general,  signature  peptides  are  easily  detected  and  their  measurements  are  readily  repeatable. 
Therefore, to improve sequence coverage or the identification of low abundant peptides it is necessary to perform more than 3 replicate 
runs and every run should be included in the data interpretation process. 
Table 7  Peptide ion score for two peptides identified in triplicate run for all experiment performed. 
Though the peptide identification was reproducible, the scores were different. 
  Temperature  peptide score_R1  peptide score_R2  peptide score_R3  average 
RRHPEYAV  60  26  21.85  27.5  25.12 
  40  24  32.65  38.6  31.75 
  30  35.85  28.86  25.3  30.00 
  RT  16.99  33.26  25.4  25.22 
           
YFYPELFRQ  60  31.29  29.49  27.3  29.36 
  40  35.22  30.3  40.2  35.24 
  30  26.46  22.42  25.3  24.73 
  RT  30.2  32.44  29.7  30.78 
  
 
6.1.10  Conclusion 
Compared to gas chromatography, the change in column temperature has a much lower effect on the degree of retention and 
resolution, since the heat transfer of solute between mobile and stationary phase is much smaller (Vanhoenacker & Sandra, 2008). 
Nevertheless, an increase in temperature led to a decrease in backpressure as a result of decrease solvent viscosity. This permits the use of 
longer columns and higher flow rates without compromising efficiency. Furthermore, the effect of a temperature increase was more 
pronounced in the number of peptides identified. A total increase of unique peptides of 33.6 % for elastase and 21 % for trypsin was 
achieved. Speers et al. also reported an increase in the number of identified peptides at elevated temperature (Spears et al., 2008). In 
addition, elevated temperatures resulted in shorter re-equilibration time thus, an improvement in the run-to-run reproducibility. However, 
despite the run-to-run repeatability only about 60 % of the peptides observed in one LC-MALDI TOF/TOF analysis would be identified 
in a second run. In general, while low abundant peptides or poorly detectable peptides are less readily repeatedly identified, signature 
peptides  are  easily  detected  and  their  analyses  are  readily  repeatable.  Since  only  peptides  that  appeared  in  more  than  one  run  are 
considered as true positive, care should be taken during data interpretation of replicate runs. This is due to the fact that, some of these 
peptides (with high ion scores) that appear in only one run can be more informative than those which appear in 2 runs but with very low 
ion score. Due to the advantages of elevated temperature on peptides and protein identification, elevated temperatures were used for our 
proteomics setup, except otherwise mentioned. 
Despite their advantages, elevated temperatures also carries some disadvantages such as: (i) the decomposition of the sample and 
solvent evaporation at elevated temperatures, (ii) a temperature gradient along the column might lead to tailing and (iii) the solubility of 
silica greatly increases at elevated temperature (Meyer, 1999). To avoid a temperature gradient, which might result in peak broadening 
and the loss of hydrophobic peptides most LC separations are carried out at elevated temperatures. 
    
 
6.2  Proteins from yeast lipid particles and human fat cells 
6.2.1  Optimisation of the sample preparation procedure 
After cell culture lipid particles were isolated as described above and proteins were precipitated with trichloroacetic acid. The 
resultant pellets were dissolved in ammonium bicarbonate (AMBIC), digested with trypsin and 5 µg of each sample was loaded on the 
pre-column. The samples were separatred with a 150 min linear gradient at 40 °C. The Mascot search was performed using parameters 
decribed above against a SGD derived database. This resulted in the identification of 111 peptides from 35 proteins (see table 8). The 
most abundant protein, ERG6 with many accessible proteolytic sites was identified with only 5 peptides and sequence coverage of 31 %. 
In general, an average of 3 peptides was matched to each protein. The reasons for these poor results can be attributed to the following: 
Prior to sample loading on the nLC, the digested samples were concentrated. This resulted in a highly viscous solution probably due to 
the high content of lipids and phospholipids. This made sample pick up together with loading onto the pre-column difficult. Furthermore, 
high backpressure, poor resolution and subsequent pre-column clogging were observed during separation on the analytical column. 
To  overcome  these  limitations,  lipids  and  phospholipids  were  extracted  with  diethyl  ether  prior  to  protein  precipitation.  After 
precipitation, proteins were dissolved in AMBIC, digested, concentrated and loaded on the pre-column. Sample picking, loading onto the 
pre-column and separation resulted in a decrease backpressure, thus phospholipids and peptides were successfully extracted from the 
proteins. A database search resulted in the identification of 101 proteins, an increase of more than 200 %. In addition, the number of 
identified  peptides  increased  by  approximately  300  %  (table 8).  For example, 31  peptides  were  matched  to  the  ERG6,  which  was 
identified with only 5 peptides before the optimization. A complete list of the identified proteins and number of peptides matched to each 




Table 8   Number of peptides and proteins identified from lipid particles before and after method optimisation. 
Proteins identified with more then 1 protein are shown with protein>1 peptide and those with just 1 
peptide as “one hit wonders” (OHW). 
  Before  After 
Proteins  35  101 
Peptides  111  437 
Proteins >1 Peptide  17  50 
OHW  18  51 
 
6.2.2  Effect of carbon source on lipoprotein composition 
In order to assess the changes that occur due to different growth media proteins extracted from YPD and YPO grown cells were 
delipidated, precipitated, digested, separated and analysed. A database search of the MALDI MS/MS data against the SGD database 
resulted in the identification of 124 proteins from lipid particles grown in YPD medium, and 117 proteins isolated from yeast cell grown 
on oleic acid (YPO) (see Table 9). However, more than 50 % of the proteins were identified with just one peptide.A summary of the 






























Table 9   Summary of the number of peptides and proteins identified from yeast cell lipid particles grown 
on glucose (YPD) and oleic acid (YPO). 
Proteins identified with more then 1 protein are shown with protein >1 peptide and those with just 1 
peptide as “one hit wonders” (OHW). 
  YPO  YPD 
No. proteins  124  117 
No. Peptides  384  354 
Proteins > 1 Peptide  51  48 
OHW  73  69 
 
Though the peptides used for the verification exhibited ion scores which exceeded the identity threshold and appeared in more 
than one experiment, only proteins, ascertained by more than one peptide, were used for a detailed comparison. Thus, the number of 
identified proteins for both samples, YPD and YPO dropped to 48 and 53 proteins respectively. Of these proteins, 34.67 % appeared in 




Figure 34  Protein overlap from yeast strains grown in glucose (YPD) and those grown on oleoic acid (YPO). 
Among these proteins, 26 have been described to be located in the lipid particles. Nevertheless, it should be mentioned that hardly 
any protein is known to be explicitly localized to a particular lipid particle. For example Erg6p, one of the abundant lipid particle proteins 
(Athenstaedt et al., 1999), is localised in the endoplasmic reticulum (ER) (McCammon et al., 1984) and mitochondria (Sickmann et al., 
2003). Another example is the long chain fatty acyl-CoA synthetase Faa1p, which is localised in the lipid particles (Athenstaedt et al., 
1999), mitochondria (Sickmann et al., 2003) and the plasma membrane (Delom et al., 2006). This characteristic property of lipid particle 
proteins complicates a direct assignment of putative new proteins to this cellular compartment. Therefore, data are to be interpreted with 
caution. However, six proteins, Cpr5p, Gtt1p, Osh4p, Ubx2p, Vps66p, and Ypt7p detected in both samples have never before been 
attributed to Saccharomyces cerevisiae lipid particles. Two of these proteins, Osh4p and Vps66, were previously found to be localised to 
the lipid particles of Yarrowia lipolytica (Athenstaedt et al., 2006). Preliminary results employing GFP-fluorescence microscopy showed 
a formation of distinct punctuate structures in Saccharomyces cerevisiae. Gtt1p, Osh4p, Vps66p and Ypt7p formed distinct punctuate 
structures when grown to stationary phase on glucose containing media. Dye merging and cell fractionation experiments need to be 
performed in order to verify whether or not these structures really overlap with lipid particle.Gene ontology annotations of the novel 
putative lipid-particle proteins revealed that they covered a broad spectrum of biological processes under both growth conditions (see 
figure 35).  
 
 
Figure 35  Assignment of newly found proteins of lipid particle from wild type cells grown on glucose (YPD) 





















































6.2.3  Human fat cells  
This project was done in collaboration with Anja Rosenow, Freek Bouwman, Jean-Paul Noben, Martin Wabitsch, Edwin C.M. 
Mariman and Johan Renes. 
6.2.3.1  Protein identification 
In order to gain an insight into the human-specific secretion profiles during preadipocyte differentiation, proteins from cultured 
preadipocytes  and  adipocytes  human  cell  strain  derived  from  a  Simpson  Golabi  Behmel  syndrome  (SGBS)  patient  were  purified, 
delipidated, buffer changed, digested with trypsin and 10 µg of each sample was loaded on the pre-column. Separation was performed 
with the same conditions as described above and analysed. The search against the Swissprot database containing 20402 sequences after 
taxonomy filter (homo Sapiens), as of 2009-12-16, resulted in the identification of 92 and 97 proteins from preadipocytes and adipocytes, 
respectively (supplemental table S 2D and E). . Of these proteins 42  were detected with preadipocytes  and 68 were  detected  with 
adipocytes, of which 34 proteins were detected with both cell types (figure 37). The motifs of the identified proteins were further 
confirmed using SignalP and/or SecretomeP, commonly used methods for prediction of classically secreted proteins (Bendtsen et al., 
2004) (see figure 36). Based on these software packages, 76 of the identified proteins were predicted to be secreted proteinsProteins with 
a  functional  role  in  the  complement  system  such  as  clusterin,  complement  C1r  subcomponent,  complement  C1s  subcomponent, 
complement C3, complement factor D, and plasma protease C1 inhibitor were found mostly in the adipocytes. The same results were 
reported before (Wang et al., 2004; Zvonicet al., 2007; Chiellini et al., 2008). In addition, adipocyte biomarkers such as PAI-1, PEDF, 
MIF, interleukin-25, adipsin, and RBP-4 as well as other important adipocyte secretion proteins, such as metalloproteinase inhibitors 
(TIMP’s), 72 kDa type IV collagenase (MMP-2) and IBP’s were identified. Furthermore, extracellular matrix proteins, such as collagens, 
basement  membrane-specific  heparan  sulfate  proteoglycan  core  protein  (HSPG),  SPARC,  transforming  growth  factor-beta-induced 
protein ig-h3 (beta-igH3), and thrombospondin 1 and 2 were ascertained. The identification of proteins relevant for adipocytes such as  
 
fatty acid binding proteins, fatty acid synthase, perilipin 4, and enoyl-CoA hyratase, which are correlated with lipid metabolism, indicates 
that proteins with a biological function in the complement systems are mainly secreted by mature adipocytes. 
 






















Table 10  Summary of the number of peptides and proteins identified from pre-adypocytes/adipocytes tissue. 
Proteins identified with more then 1 peptide are shownwith protein > 1 and those identified with only 
1 peptide with “one hit wonders” (OHW). 
  Adipocytes  Pre-adipocytes 
No. proteins  97  92 
No. Peptides  290  374 
Proteins > 1 Peptide  44  47 
OHW  53  45 
 
 




6.2.3.2  Validation of the identified secretome 
The identified secretome was compared to adipocyte proteins from the currently known secretome of human visceral (Alvarez-
Llamas et al., 2007; Roelofsen et al., 2009), subcutaneous (Sell et al., 2006; Zvonic et al., 2007; Chiellini et al., 2008) and rodent adipose 
tissue (Kratchmarova et al., 2002; Wang et al.,2004; Chen. et al., 2005; Aoki et al., 2007; Lim. et al., 2008; Molina et al., 2009) (see 
supplemental  table  2G).  Proteins,  such  as  annexin  5 and cyclophilin  A, which  are  primarily  known  as  cellular  proteins, were  also 
identified as secreted proteins. However, in published reports the function of annexin 5 is usually referred to as unknown. Wang et al. 
(Wang et al., 2009) documented that annexins are related to stress response, whereas others reports assume that annexin 5 may play a role 
in inhibition of blood coagulation by competing for phosphatidylserines (Urso et al., 2001; Rand et al., 2008). Phosphatidylserines are 
part of cell membranes and during stress situations in the cells, phosphatidylserine switches to the outside of the membrane (Fink et al., 
2005). Since annexin 5 is predicted to interact with phosphatidylserine, it may pass the membrane and be detected as a secreted protein. 
Yet, there is evidence that annexin 5 might be a non-classical secreted protein, since the SecretomeP NN-score is 0.503, which is higher 
than the threshold value of 0.5. On the other hand, SignalP and SecretomeP analyses of Cyclophilin A were negative, which explains the 
SwissProt classification as a cytoplasmic protein. However, there are several reports in which cyclophilin A is described as a secreted 
protein by a vesicular pathway (Sherry et al., 1992; Jin et al., 2000; Jin et al., 2004; Suzuki et al., 2006) which complies with our present 
findings. 
Of the 78 secreted proteins, 8(lysyl oxidase homolog 2, alpha-2-HS-glycoprotein, glia-derived nexin, insulin-like growth factor-
binding protein (IBP) 3, and IBP-5, sushi repeat-containing protein, immunoglobulin superfamily containing leucine-rich repeat protein, 
and coiled-coil domain-containing protein 96) have not been reported before. Furthermore, 6 of these 8 proteins have not been reported as 
adipocyte-secreted before and therefore they can be described as novel (pre)adipocytes-secreted proteins (see table 11). Sushi repeat-
containing protein has signal peptide cleavage sites, which allow classification as a secreted protein. Its function is rather unclear, but it 
seems to be involved in cell adhesion and migration (Tanaka et al., 2009). Coiled-coil domain-containing protein 96 and acyl-CoA-
binding protein showed no evidence of a signal peptide cleavage site but reached high NN-scores on SecretomeP analysis. The function  
 
of coiled-coil domain-containing protein 96 with a NN-score of 0.622 is still unknown. Acyl-CoA-binding protein may be an intracellular 
carrier of acyl-CoA esters. It occurs in 3 isoforms, but could not be distinguished. All are ubiquitously expressed. In addition, isoform 2 is 
highly expressed in liver and adipose tissue and isoform 3 is strongly expressed in adipose tissue and heart. The NN-scores are 0.546 
(isoform  1),  0.553  (isoform  2)  and  0.758  (isoform  3),  indicating  secretory  properties.  Further,  Kinseth  et  al.  (Kinseth  et  al.  2007) 
classified acyl-CoA-binding protein as a non-classical secreted protein. Altogether, the provided data indicate that acyl-CoA-binding 
protein is a genuine secreted protein. Correlations between this protein, obesity and diabetes suggest that acyl-CoA-binding protein is an 
adipokine (Zhou et al., 2008; Ejaz et al., 2009). In contrast, IBP-3 is already known as a secreted protein from human subcutaneous 
adipocytes and 3T3-L1 cells (Hossner et al., 1997; Wabitsch et al., 2000). IBP-5 mRNA levels are shown in human subcutaneous adipose 
tissue but the proteinis only described as an adipocyte-secreted protein from pig adipose tissue (Hausman et al., 2006; Baxter et al., 2009; 





Table 11  Proteins that have never been associated to the adipocye tissues (human visceral, human subcutaneous and rodent). 
A complete list of all identified proteins is seen in the supplementary Table S2 
Accession No  protein name  Average no. of peptides 
(pre-adipocyte)  
Average no. of peptides 
(adipocyte ) 
P07093  Glia-derived nexin (GDN) 
(Protease nexin I) (Protease 
inhibitor 7) 
5  1 
P17936  Insulin-like growth factor-
binding protein 3 (IBP-3) 
6  1, 1 
P24593  Insulin-like growth factor-
binding protein 5 (IBP-5) 
not found  2, 2 
O14498  Immunoglobulin superfamily 
containing leucine-rich repeat 
protein  
3  not found 
P78539  Sushi repeat-containing protein 
SRPX  
not found  1 
Q9Y4K0  Lysyl oxidase homolog 2 
(Lysyl oxidase-like protein 2) 
10  not found  
 
Table 12  Summary of all secreted proteins, which have been identified only for rodent proteomic adipocyte studies. 
Accession No  protein name  Average no. of 
peptides 
(preadipocyte) 
Average no. of 
peptides 
(adipocyte ) 
P35555  Fibrillin-1 (FBN1)   11  4 
P09382  Galectin-1 (Lectin galactoside-binding soluble 1)   not found  4, 3 
P28300  Protein-lysine 6-oxidase (Lysyl oxidase)  6  not found 
P05452  Tetranectin (TN) ( Plasminogen kringle 4-binding protein)  not found  1 
Q92626  Peroxidasin homolog (Vascular peroxidase 1)  1  1 
Q9H293  Interleukin-25 (IL-25)  1  not found 
P14174  Macrophage migration inhibitory factor (MIF)  1  1, 1 
P02458  Collagen alpha-1(II) chain   11  2, 1 
P02462  Collagen alpha-1(IV) chain   not found  2, 3 
P05997  Collagen alpha-2(V) chain   12  4, 3 
P29279  Connective tissue growth factor (Hypertrophic chondrocyte-
specific protein 24) 
not found  1 
Q9H293  Interleukin-25 (IL-25)  1  not found  
 
P14174  Macrophage migration inhibitory factor (MIF)  1  1, 1 
P25940  Collagen alpha-3(V) chain   not found  3 
 
 
6.2.4  Summary 
During the past decade, published results suggest that lipid particles in yeast cells as well as other cell types do not only serve as a 
lipid storage compartments, but also play asignificant role in a number of other functions. For example, lipid particles harbour enzymes 
responsible for lipid metabolism, thus contributing actively to the formation of cellular components (Czabany et al., 2008). The majority 
of proteins identified such as Erg-proteins, lipases or fatty acid activating proteins are involved in lipid metabolism. While most of the 
proteins involved in this process were identified in YPD, this number decreases in the YPO sample. On the other hand, remarkable 
increases in proteins involved in the processes of translation were found in lipid particles extracted from yeast cells grown in oleic acid 
medium. Furthermore, other clusters of proteins appeared to be strongly affected by the change of carbon source. For example, proteins 
involved in endoplasmic reticulum (ER) unfolded response were only found in lipid particles from cells grown on glucose, and the large 
portion of proteins involved in protein glycosylation was drastically reduced in cells grown on YPO. In contrast, a large number of 
proteins  involved  in  translation  and  energy  providing  processes  were  found  in  lipid  particles  from  cells  cultivated  on  oleic  acid. 
Furthermore, membrane and membrane-associated proteins and proteins with unknown biological functions were identified.  
In addition, the identification of certain proteins showed a correlation between plant and yeast cells, which has also been reported before 
(Athenstaedt et al., 2006). Also, proteins from other regions of the cell, such as endoplasmic reticulum, Golgi, Nucleus, cysotolic and 
peroxisomal  proteins  were  identified.  However,  it  was  demonstrated  that  lipid  particles  and  some  other  organelles  such  as  the  
 
endoplasmic reticulum share a set of certain proteins. Even though cross-contamination studies demonstrated that the samples were of 
high purity, it cannot be completly ruled out that some of the identified proteins were contaminants from other organelles. Nevertheless, 
six novel proteins were identified and were confirmed by localisation studies in the lipid particles. 
Adipokines play important roles in homeostasis and metabolism. Adipocyte differentiation leads to a change in adipokine secretion 
profile which is probably involved in disruption of homeostasis. The study of human cell stain derived from a Simpson Golabi Behmel 
syndrome (SGBS) patient resulted in the identification of 6 novel (pre)adipocytes-secreted proteins (Dahlman et al., 2004; Lavebratt et 
al., 2005). 
Alpha-2HS-glycoprotein is correlated to adipocytes and obesity. Genetic studies suggest that alpha-2HS-glycoprotein is involved 
in insulin action by adipocytes and in the regulation of body composition and insulin sensitivity. Lysyl oxidase homolog 2, another 
protein that is identified here may play a role in remodeling of adipocyte structure during adipogenesis. Furthermore, lysyl oxidase 
homolog 2 is associated with extracellular matrix remodeling during fibrotic disorders (Decitre et al., 1998). Glia-derived nexin belongs 
to the serine protease inhibitor superfamily and is usually related to neurobiological processes (Silverman et al., 2001; Gettins et al., 
2002). Known adipokines such as plasminogen activator inhibitor 1 (PAI-1) and pigment epithelium-derived factor (PEDF) are also 
members of the serine protease inhibitor superfamily (Wang et al., 2004; Chiellini et al., 2008).  
Immunoglobulin superfamily containing leucine-rich repeat protein (LRR) and an immunoglobulin-like domain (IgC2), which is mostly 
expressed in the nervous systems. However, immunoglobulin superfamily containing leucine-rich repeat protein is not only expressed in 
the nervous system but in various other tissues like heart, skeletal muscle, testis, and retina. Its exact functions in these tissues remain 
unclear (Wu et al., 2006; Nagasawa et al., 1997). Similar to immunoglobulin superfamily containing leucine-rich repeat protein the 
functions and the exact role of sushi repeat-containing protein and coiled-coil domain-containing protein 96 remains unknown. Further 
investigations of these proteins are necessary to distinguish their functional properties.  
Insulin-like growth factor-binding protein 3 (IBP-3) and Insulin-like growth factor-binding protein 5 (IBP-5) are member of the 
insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I 
domain. These proteins form a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like  
 
growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell 
surface receptors. In addition, the identification of relevant adipocyte biomarkers shows that the SGBS cells can be used as a reliable 
model for the study of obesity related dieseses.  
The combination of nLC and MALDI MS/MS proved to be a powerful tool for comprehensive identification of lipoproteins. Since 
these proteins are embedded in a high concentration of natural lipids, their extraction and purification required a number of sample 
preparation steps. Even though delipidation enhanced the identification of more lipoproteins and adipocytes-secreted proteins, it cannot 
be ruled out that some proteins were lost during this additional step, especially proteins which are already under-represented. Poor 
detection of some proteins can also be attributed to the low abundance of these proteins or insufficient number of cleavage sites for the 
proteolytic enzyme used in these experiments.   
 
6.3  MLL Interaction partners 
6.3.1  AF4/ENL and AF4•MLL complex 
For the study of protein-protein interactions within AF4, ENL and AF4•MLL protein complexes, the group of Prof. Marschalek 
purified 10
9 transfected 293T cells by using Strep-tag affinity columns. The analysis of the purified AF4•MLL protein complexes resulted 
in the identification of 1223 unique peptides originating from 411 proteins, majority of these being mitochondrial and cytosolic proteins. 
A more detailed interpretation of the identified proteins revealed that only a handful of these proteins are associated with the AF4 
complex (see table 13). Most of the identified proteins have been reported in numerous publications (e.g. AF9, ENL, AF10, DOT1L, 
CDK9 or CyclinT1). However, the association of the proteins NFkB, BRD4, DDX6, AF5q31 and NPM1 (Nucleophosmin) within the 
AF4 complex has never been reported (see table 13). 
On the other hand, 461 peptides from 80 proteins were identified from the purified AF4•MLL protein complex. Several identified 
proteins (CDK9, Cyclin T1, ASH2L, WDR5, RBBP5, DPY30, HCFC1, HCFC2, CREBBP) were assumed to be associated with the 
AF4•MLL complex. In additon, the presence of CARM1 and DOT1L were confirmed by immunoprecipitation studies. The identification 
of the AF4•MLL complex could not be performed directly since this protein is not present in the database. However, C-terminal peptides 
from the MLL-protein (131) and the N-terminal peptide of the AF4-protein (21) and 23 C-terminal peptides of the AF4 protein indicated 
the presence of the AF4 wild type in the AF4•MLL protein complex. A complete list of all identified proteins is seen in supplementary 
table S4. 
    
 
Table 13  Summary of the relevant interaction partner identified from the AF4-complex. 
Represented is protein accession number (AC), molecular weight in kilodalton MW/k Da), the isoelectric 
points of the proteins (pI) and the number of peptide matched to each protein. All novel proteins are 
underlined. 
  AF4 Complex       
AC  Protein  peptide  MW/k Da)  pI 
P51825  AF4(AFF1)  106  132.14  9.26 
Q03111  ENL  22  62.42  8.75 
P50750  CDK9  12  43.15  8.97 
O60563  CCNT(CyclinT1)  11  81.03  8.9 
P26196  DDX6  9  54.78  8.85 
Q9UHB7  AF5q31(AFF4)  7  127.78  9.33 
P06748  NPM1(Nucleophosmin)  6  32.73  4.64 
Q9C005  DPY-30  1  11.24  4.84 
O60583  Cyclin-T2 (CycT2)  1  81.49  9.04 
  AF4•MLL       
AC  Protein  peptides  MW/k Da)  pI  
 
Q03164  MLL(HRX)  131  436.04  9.22 
P51825  AF4(AFF1)  44  132.14  9.26 
P51610  HCF1  14  210.7  7.49 
Q15291  RbBP5  4  59.72  4.92 
P61964  WDR5  4  37.14  8.54 
P26196  DDX6  4  54.78  8.85 
Q9UBL3  Ash2L  4  69.31  5.45 
O60563  CCNT1(CyclinT1)  3  81.03  8.9 
P50750  CDK9  2  43.15  8.87 
Q9C005  DPY-30  2  11.24  4.84 
Q9Y5Z7  HCF2  2  87.69  8.75 
P06748  NPM1(Nucleophosmin)  1  32.73  4.64 
 
6.3.2  Negative control 
To assess the quality of these results, control experiments were performed. The negative control resulted to the identification of 
128 peptides originating from 20 proteins. The proteins interacting with MLL•AF4 and the AF4 protein complex were compared to those  
 
identified in the negative control. None of these interaction proteins were found in the control experiments, which substantiates the 
reliability of not only the novel interaction proteins but also the other interaction partners. 
6.3.3  ENL-complex 
A structural and functional analysis revealed that the AF4/AF5q31/AF10 binding domain in ENL coincided with the C-terminus 
that  is  essential  for  transformation  by  MLL•ENL  (Zeisig  et  al.,  2005).  Interaction  partners  such  as  AF4,  CDK9,  CCNT1,  RNA-
Polymerase  II,  transcription  factor  NFκB  and  RING1  have  been  identified.  The  analysis  of  an  in-solution  digest  of  the 
MLL•ENLcomplex, resulted in the identification of 339 peptides from 94 proteins. However, 56 % of the identified proteins were “one 
hit  wonders”.Despite  numerous  nLC-MALDI  TOF/TOF  analyses,  only  the  AF4  protein  could  be  truely  identified  within  the  ENL 
complex. A reason for the poor results could be the over-expression of the ENL, which may lead to the suppression of interaction 
partners. Also the additional sample preparation step (buffer exchange) may probably result in the loss of possible interaction partners. 
6.3.4  Summary 
The human t(4;11) translocation is one of the most frequent MLL translocations currently known. As a result of the translocation, 
two chimeric proteins are formed, either fusing the N-terminal part of the AF4 protein with the C-terminal portion of MLL or vice versa 
yielding  the  MLL•AF4  fusion  protein.  The  identification  of  fusion  proteins  and  their  interaction  partners  has  provided  a  deeper 
understanding  of  leukemogenesis.  MALDI-MS  has  long  been  used  for  the  identification  of  interaction  partners  in  protein-protein 
interaction studies.  In this case, the samples are separated on  a  gel and stained; the gel bands  are excised, digested, extracted and 
measured. Coupled with the low resolution power of SDS-PAGE, the process of staining, excision and extraction is tedious and might 
lead  to  sample  loss.  nLC-MALDI-TOF/TOF  provides  a  high-resolution  and  high-throughput  approach  for  the  analyses  of  complex 
samples.  
In total, 17 known interaction partners (see table 13) from the AF4 and AF4•MLL complexes were identified. The functions of the 
known interaction partners identified in this study and the role they play in leukemogenesis have been clearly demonstrated in numerous  
 
studies.  Furthermore,  several  novel  binding  proteins  of  the  AF4  protein  (DDX6,  NPM1,  NFkB,  BRD4,  CARM1,  NSD1)  and  the 
AF4•MLL fusion protein complex (DDX6, NPM1, NFkB, HEXIM1, CARM1, DOT1L) were identified. The association of all novel 
proteins was confirmed by immunoprecipitation studies (Benedikt et al, 2010).  
Lin et al. showed that Nucleophosmin-1 (NPM1) binds to NFkB1/RELA. NFkB1/NPM1 heterodimers modulate the binding of the 
E2F transcription factor 1(E2F1) and proline-rich protein BstNI subfamily (pRB) in order to transcriptionally activate the E2F1 promoter 
(Lin et al., 2006). NPM1 initiates the proteasomal degradation of hexamethylene bis-acetamide inducible 1 (HEXIM1) and thereby may 
influence the positive transcription elongation factor b (P-TEFb) kinase activity (Gurumurthy et al., 2008). Furthermore, NPM1 was 
shown to be frequently mutated in AML patients. These mutations change the expression pattern of specific miRNAs (Cazzaniga et al., 
2005; Garzon et al., 2008) and influence the outcome of leukemia patients (Grummitt et al., 2008; Baldus & Bullinger, 2008) thereby, 
indicating a role of NPM1 for human leukemia. 
Cho et al. showed that in human MLL, Dumpy-30 (DPY-30) binds directly to SET1/ASH2L histone methyltransferase complex 
which is a component of the SET domain-containing Histone methyltransferase (HMTs) (Cho et al., 2007). As part of this complex, it is 
involved in methylation and dimethylation at Lys-4 to trimethylation of histone H3. H3 Lys-4 methylation represents a specific tag for 
epigenetic transcriptional activation. 
DDX6 is found in the processing bodies (P-bodies), which are localised in the cytoplasm. It belongs to the DEAD box proteins, 
which are putative RNA helicases and are characterised by the conserved motif Asp-Glu-Ala-Asp (DEAD). They are involved in a 
number of cellular processes including alteration of RNA secondary structure such as translation initiation, nuclear and mitochondrial 
splicing and ribosome and spliceosome assembly. Recently Chu et al. showed that DDX6 is involved in the processing of miRNA (Chu et 
al., 2006).A role of DDX6 in cell apoptosis, cell growth regulations and leukemogenesis has been suggested (Akao et al., 1998; Navarro 
et al., 2001). As a result of their natural locations, there is some doubt about the interaction of this protein with the AF4 protein complex. 
While the AF4 exerts its effect in the cell nucleus, DDX6 is located in the cytosol. However, the interaction with AF4 was confirmed by 
immunoprecipitation reaction (Benedikt et al., 2009). For a more detailed understanding of the interaction with AF4, more functional 
studies are required.  
 
Though the nLC-MALDI MS/MS approach provides high sensitivity for the analysis of protein-protein interactions, there are still 
some limitations. The real challenge in mapping protein-protein interactions lies on cells cultivation and sample preparation for further 
nLC-MALDI MS/MS analysis. Moreover, the interaction partners are sometimes present in a small amount. Therefore, high starting 
concentration is necessary to increase the chance of identifying less abundant proteins. However, the amount of highly abundant proteins 
will also be increased. Proteolytic digests would result in the generation of large amounts of peptides from the over-expressed or abundant 
proteins. This may result in subsequent precursor suppression during MS measurement by huge amounts of peptides from the abundant 
proteins. Therefore, more than one separation technique would be necessary to deal with this complexity. Furthermore, pre-purification 
on affinity columns, in order to eliminate abundant or unwanted proteins and, sample concentration, may lead to the loss of important 
proteins as a result of excessive binding to the tubes surface.  
Despite  the  use  of  affinity  columns  for  the  purification  of  the  multi-protein  complexes,  high  amounts  of  cytosolic  and 
mitochondrial proteins were still identified. Also, it cannot be ruled out that some of the interaction partners are not in close proximity or 
that they are interacting at different time points. Determining the point in which particular proteins interact with a protein complex is a 
challenging task. The complete interaction network and path ways are not yet known and it cannot be ruled out that some of the proteins 
identified, which could be of interest, were not taken into consideration. However, the proteins identified in this study will hopefully 
provide  valuable  information  to  assist  future  studies  aimed  at  identification  and  characterisation  of  high-molecular-weight  protein 
complexes involved in leukemogenesis. 
 
    
 
6.4  Result and Discussion: Membrane proteins 
This project was done in collaboration with Benjamin Rietschel. Detail results and discussion are present in his Thesis (Rietschel, 
2010). However, a part of this result is presented here to demonstrate the suitability of the established nLC-MALDI-TOF/TOF method. 
6.4.1  Protein identification 
The use of less-specific enzymes in membrane proteomics significantly improves the recovery of integral membrane proteins. 
Elastase, an example of a less-specific protease of the Serine-protease family S1, has been used in phosphoproteomic studies (Schlosser et 
al., 2001). Its use for membrane proteomics has not been reported, probably because little was known about the enzyme specificity. 
However, in phosphoproteomics it has been shown to generate short and often overlapping peptides, which are in the mass range of 
modern mass spectrometers. Due its broad specificity cleaving at small non-charged amino acids, it can be assumed that this enzyme 
would be suitable for the analysis of membrane proteins. To evaluate the suitability of elastase in membrane proteomic, Halobacterium 
salinarium purple and Corynebacterium glutamicum membranes were digested in 60 % methanol, separated using a 150 min linear 
gradient  at  ambient  temperature,  and  analysed  with  the  established  nLC-MALDI-TOF/TOF  method.  Extracted  peak  list  from  the 
Halobacterium  salinarium  purple  membrane  were  searched  against  a  Halobacterium  database,  generated  from  SwissProt/TrEMBL 
containing 2490 entries. A total of 677 peptides were matched to 143 proteins. Of the 143 proteins, 58 % were identified only with one 
matching peptide. A search against the Corynebacterium glutamicum ATCC 13032 Bielefeld database containing 3059 sequences yielded 
a total of 1097 peptides corresponding to 236 proteins. Of these proteins 53 % were identified with only a single peptide. The advantage 
of the established method over others is that solubilisation, extraction and digestion is performed with the same solvent, the same enzyme 
and, most of all, this solvent is compactable with RP-HPLC separation and MS (Washburn et al., 2001; Wu .et al., 2003; Nielsen et al., 
2005; Bihan et al., 2006; Rodriguez-Ortega et al., 2006). The large amount of generated peptides indicates the suitability of the enzyme 
reaction at high organic content.  
 
A tryptic digest of Halobacterium salinarium purple membrane resulted in the identification of 217 peptides originating from 122 
proteins, 21 less than for elastase (see table 14). From the 216 proteins identified using both proteases, only 49 were present in both result 
lists. A total of 94 appeared only in the elastase list and 73 only in the trypsin list. Another major difference between both proteases is the 
number of peptides matched to each protein. More unique peptides from the elastase digest were matched to individual proteins. 
For the tryptic digest of the Corynebacterium glutamicum membrane, 455 peptides were matched to 199 proteins. Again, fewer peptides 
(<  10)  were  matched  to  individual  proteins.  For  example,  while  succinate  dehydrogenase  flavoprotein  subunit  [ATCC  13032]  was 
identified with only 19 tryptic peptides, 57 elastase peptides were matched to the same protein, an increase of about 75 %. Of the 320 
proteins identified, only 25 % were identified using both proteases. In general, a comparable number of proteins were identified using one 
or the other enzyme. The diversity of identified proteins shows the complementary nature of both proteases in protein identification. See 
supplementary table S3 for a complete list of proteins identified. 
Table 14  List of total numbers of unique peptides, proteins, proteins with more than one peptide (proteins > 1), and 
proteins identified with only one peptide, “one hit wonders” (OHW) and the number of transmembrane 
peptides (TM-peptides) identified in both samples analysed 
  PM(Elastase)  PM(Trypsin)  CB(Elastase)  CB(Trypsin) 
Peptides  677  217  1097  455 
Proteins  143  122  236  199 
OHW  83  74  125  107 
Proteins >1 peptide  60  48  111  92 
TM-peptides  174  20  149  - 
  
 
6.4.2  Transmembrane coverage. 
Because IMPs often have a significant portion of their sequence embedded in the membrane, the probability of identifying these proteins 
decreases, if the method is restricted only to soluble domains. A means to determine the success of a membrane proteomic strategy is the 
identification of IMPs, especially from proteins containing multiple TMDs. These TMDs are known for the problems encountered during 
solubilisation and separation. A reliable and common tool for predicting the location of TMD of proteins is by using TMHMM 2.0. The 
analysis of the identified proteins from both samples (143 PM and 236 CB) predicted that 44.06 % of these proteins exhibit at least one 
TMD. Within the 44.06 % of the integral membrane proteins identified, approximately 81.44 % contained at least 2 TM domains. In a 
control study using trypsin, in which 316 proteins were identified, less than 46.52 % of the proteins were predicted to have at least one or 
more TMD domain and 63.94 % of these 46.52 % exhibited more then one TMD. However, most of the identification resulting from the 
tryptic digest was achieved over the hydrophilic region. Elastase, on the other hand, generated higher number of membrane-spanning 
peptides (Rietschel et al., 2009). For example, whereas 89 TMD peptides from bacteriodopsin were identified with the elastese digestion, 
only one TMD peptide was identified when trypsin was used as a proteolytic enzyme (see figure 38). Another example is observed with 
the small membrane protein, porin. In the tryptic digestion, this protein was identified with only one peptide. When using elastase, the 
protein was identified with 8 peptides from a single helix. Furthermore, prominent respiratory chain proteins, such as cytochrome b, ATP 
synthase subunits a, c and cytochrome c oxidase I, were identified with a higher number of TMD peptides than for a typsin digest. The 
first 75 proteins identified from the elastase result list (see supplementary table S3) were membrane proteins. In total, 174 peptides of 
predicted TMD were identified by the elastase approach, in contrast to only 20 peptides in the tryptic digest experiment. Furthermore, the 
increased sequence coverage and transmembrane peptides identified with just one enzyme show the superiority of elastase over other 
methods in which two enzymes were combined for membrane proteomic studies (Washburn et al., 2001; Wu .et al., 2003; Nielsen et al., 
2005; Bihan et al., 2006; Rodriguez-Ortega et al., 2006;). In addition, the good solubilisation of the membrane proteins in 60 % methanol, 
which was first reported by Blonder et al. (Blonder et al., 2006), improved the assessibility of elastase to the TMDs. Zhang et al. also  
 
showed that a higher number of integral membrane proteins were identified when solubilised in 60 % methanol than with SDS (Zhang et 
al., 2007). 
 
Figure 38  The number of membrane proteins, with one or more TMD identified for both PM and CB samples using 






































6.4.3  Fragmentation behaviour of elastase generated peptides 
Fragmentation plays an important role in shotgun proteomics especially when analysing uncharacterised proteins or in search of 
post translational modifications (PTM). Fragmentation methods and the collision energy used for fragmentation are known to largely 
change the characteristics of peptide fragmentation (Arnold et al., 2006). Typically under CID conditions, tryptic peptides generate a 
number of different fragment ion series, wherein N-terminal (b-ions) and C-terminal (y-ions) fragment ions dominate the tandem mass 
spectra (Roepstorff et al., 1984; Johnson et al., 1988; Steen & Mann, 2004). The fragment ions from 7000 precursor masses revealed that 
nearly 29 % of the generated ions belong to the group of the internal fragments and their associated neutral losses. The rest is distributed 
among C-terminal ions (y, y0, y*) and the N-terminal type (b, b0, b*, A) ions (see table 15). A reason for the increase in internal ions and 
a decrease in b and y-ion series is probably due to the lack of charge localisation at the C- and N-terminus of peptides generated by less 
specific enzymes. The increase in internal fragment ions formation led to difficulty in spectral interpretation. However, by modifying the 
peptides with a charge-directing moiety at the N-terminal such as nicotinyl group, TMT or iTRAQ that produces extended b-ions series 
many unwanted internal fragment ions can be suppressed (Bendez et al., 2009). 
Table 15  An overview of generated fragment ions  
Fragment-Ionen-types  Number  % 
b-Ion (N-term sequencing ions)  46.969  5.9 
b
0-Ion (neutral-loss H2O)  11.968  1.5 
b*-Ion (neutral-lossNH3)  13.227  1.7 
a-Ion(neutral-lossCO)  26.818  3,4 
y-Ion (C-term sequencing ions)  38.695  4.9  
 
y
0-Ion (neutral-lossH2O)  12.083  1,5 
y*-Ion (neutral-lossNH3)  13.203  1.7 
i-Ion (Immonium-Ion)  52.575  6.7 
int-Ion (internal fragment-Ion)  95.193  12.0 
int
0-Ion (neutral-lossH2O)  37.297  4,7 
int*-Ion (natural lost NH3)  39.606  5.0 
int
† (natural lost CO)  58.275  7.4 
Unmatched fragment  344.486  43.6 
Sum  790.395  100 
 
6.4.4  Summary 
Until recently less specific enzymes did not play a relvant role for the analysis of membrane proteins. However as shown above, 
they improve the coverage in the hydrophobic domains of these proteins especially when used with a suitable solvent such as methanol, 
which is compatible to mass spectrometry. In this study, elastase was combined with the the solubilisation effect of methanol for the 
analysis  of  membrane  proteins.  The  suitability  of  this  method  was  evaluated  using  Halobacterium  salinarium  purple  and 
Corynebacterium glutamicum membranes. Approximately 85 % of the proteins identified using this method were predicted by the α-
helical transmembrane domain (TMD) prediction algorithms, TMHMM 2.0, to have at least one TMD. Approximately 60 % of these  
 
proteins have at least 2 TMD. In a related study using trypsin as a proteolytic enzyme, only about 18 % of the identified proteins had one 
or more TMD. Compared to the tryptic digest, more transmembrane peptides were identified with the elastase digestion. These results 
confirmed the increased importance of less specific enzymes and the potentials of elastase for membrane protein analysis. The success of 
this enzyme for the analysis of membrane proteins is as a result of the generation of a huge amount of peptides. However, as shown by the 
results presented above, care should be taken when working with elastase or less specific enzymes in general, since common database 
search engines are not optimal for these types of enzymes. Since the enzyme specificity is omitted, a large number of peptides from 
different species can be matched to a precursor. Hence, the rate of false positive discovery will increase. This can be compensated by 
improving  the  mass  accuracy  of  the  precursors  either  by  internal  calibration  and/or  high  resolution  mass  spectrometer  such  as  the 
Orbitrap. Furthermore, elastase and other less specific enzymes leads to the generation of peptides, which lack C- or N-terminal charged 
amino acids. As a result, extended b- and y-ion series are prohibited during fragmentation. Poor fragmentation may influence the search 
result. However, extended b- and y- ion series can be again furthered by derivatisation using tandem mass tag (Bäumlisberger et al., 
2010). 
Despite  their  high  importance  and  a  considerable  effort  in  method  development,  current  approaches  aiming  to  obtain  a 
comprehensive coverage of the membrane proteome are far from being satisfactory. Even though the potential of elastase has been shown 
for phosphopeptides analysis, it has found limited application in proteomics, presumably because of its largely unspecific cleavage. 
However, Rietschel et al. showed that this enzyme cleaves preferentially at 6 amino acids (AVLIST), which render it very suitable for 
complex membrane proteome analysis (Rietschel et al., 2009). The limitations encountered by trypsin, such as lack of tryptic cleavages 
sites, can be overcome by using elastase. Hence, the implementation of this enzyme in database search engines would be of great help not 
only to membrane protein analysis but also for proteins with a low number of tryptic cleavage sites. All in all, elastase proved to be 
superior to trypsin in the analysis of membrane proteins. In conclusion, a combination of both enzymes will further improve the outcome 
of proteomic studies. 
    
 
7  Two Dimensional Separation (Optimisation of the Offgel-IEF for its use as a first dimension in a two dimensional 
separation plateform) 
7.1  Proteins and peptides identification. 
To evaluate the separation efficiency of the Offgel-IEF as a first dimension for a multiple dimensional separation, 200 µg of 
purple membrane (PM) and Corynebacterium glutamicum membrane (CGM) pellates were digested with elastase. The digested samples 
were dissolved with 1 % IPG buffer to a total volume of 1.8 ml. 150 µl of this sample solution was loaded in each well of the 12-well 
setup placed on a 13 cm long IPG-gel strip with a linear pH gradient ranging from 3 to 10 and focused with a maximum current of 50 µA 
for  24  hours.  Prior  to  nLC  separation  and  MALDI  TOF/TOF  analysis,  each  fraction  was  vacuum  concentrated.  During  sample 
concentration, the amount of glycerol, commonly included (10 % Glycerol) to all chambers to prevent electroosmotic peptide-water co-
migration, is increased, thus, resulting in a viscous solution. This highly viscous solution makes sample pickup difficult and loading on 
the  nLC  pre-column  resulted  in  clogging,  which  in  turn  increases  backpressure.  To  circumvent  this  problem,  glycerol  was  totally 
substituted  with  additional  buffer  solution to  wells  1,  2,  11  and  12. After  focusing, each fraction  was  concentrated,  separated  and 
analysed.  The  MS  and  MS/MS  data  were  converted  to  Mascot  generic  files,  combined  and  searched  against  the  Corynebacterium 
database and complete Halobacterium salinarium subset of NCBI containing, 5320 sequences (3
rd of December 2008). In total, 866 
unique peptides originating from 147 proteins from the  PM and 470 unique peptides  from 149 proteins of the CGM sample were 
identified (see table 16). A complete list of all peptides and proteins identified is shown in Table S5 in the Supporting Information. Using 
TMHMM, α-helical TMD prediction algorithms 2.1, 54.4 % (80) of the identified proteins from the purple membrane and 29.5 % of the 
proteins from the CGM sample were predicted to have one or more TMDs (see figure 39). 
  
 
Table 16  OGE fractionation results:  
Overview  of  Off-Gel  IEF  nLC-MALDI-MS/MS  experiments  for  elastase  digest  of  PM  and  CGM  samples 
displaying  the  total  number  of  identified  proteins  and  peptides,  False  discovery  rate,  the  number  of  proteins 
identified with just one peptide (“one hit wonders”) and the peptide number/sequence coverage of the BR Protein. 
  PM  CGM 
peptides  866  470  
proteins  147  149 
protein identified with 1 peptide  64  87 
false positive rate [%]  0.81  0.77 
BR peptides  81  ** 




Figure 39  Membrane proteins identified from PM and CGM digested with elastase. 
In general, most of the peptides were present in the acidic fractions, especially in the PM sample, which contains approx. 90 % BR 
and minor cytosolic proteins (see figure 40). The number of observed peptides dropped to a minimum value at fraction 10. This fraction 
represents peptides with theoretical pI values between 8 and 9. These isoelectric point values can only be generated by unrealistic amino 
acid combinations on the peptide level. The same separation behavior was observed with tryptic peptides analysed with the 12 and 24-
well setup (Heller et al., 2005; Hört et al., 2006; Lam et al., 2007; Chenau et al., 2008). 
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Figure 40  Total number of peptides identified in each fraction; the light gray bars represent peptides from the 
PM and CGM samples. 
7.2  Peptide Carryover 
Since it was not possible to estimate the separation efficiency by comparing samples focused in the presence and absence of 
glycerol, the peptide carryover to an adjacent fraction was used as a criterion. Optimally, for equimolar concentration, all peptides are 
expected to appear in just one or at most 2 fractions. Complex biological samples exhibit a wide dynamic range of protein concentration. 
Highly abundant proteins would result to the generation of large amounts of signature peptides, thus a higher risk to be recovered in 
several wells, and peptides from low abundant proteins in one well (Lam, 2008). Nevertheless, for both samples, approximately 85 % of 


































observed in more fractions (see figure 41). Peptides which were focused in 3 or more fractions originated from the proteolytic enzyme 
through  autolysis and  from  bacteriorhodopsin.  These  peptides  are  well-known  for their high abundance  in  elastase  BR  digests  and 
originate from the highly accessible N-terminus and second loop/helix C regions (Rietschel et al., 2009). 
 
Figure 41  Number of fractions in which each distinct peptide was found. 
7.3  Standard deviation 
The OGE separates peptides according to their pI, so the distribution of peptides in the different fractions can be used to determine 
the separation efficiency.The average pI should increase by 0.58 pH units per fraction, because a 13 cm long IPG gel strip with a linear 
pH gradient ranging from 3 to 10 was used. Slightly lower actual values of 0.53 and 0.56 for both samples respectively were observed: 






























difference is observed (see figure 42). IEF seems to be rather limited for neutral peptides, because most of these peptides do not carry 
more than the two functional charged groups at their termini. Also, increased pI variances in the alkaline fractions are attributed to the 
lower peptide numbers used to determine these statistics (see figure 42). 
 
Figure 42  Calculated average pI values for all peptides identified in each fraction for both samples. 
Generally, pH deviations can also be influenced by the position of the well on the gel strip. In cases where the well is exactly 
between pH gradients, peptides would appear in these 2 fractions. Furthermore, commercially available strips vary slightly in relative 
length  and  position  of  the  immobilised  gradient.  These  variations  can  also  result  in  pH  deviations  or  affect  other  factors  such  as 






















7.4  pI distribution 
Besides the increased separation power, IEF techniques also provide additional physiochemical information about each peptide, 
i.e. its isoelectric point (Cargile et al., 2004; Cargile et al., 2004; Heller et al., 2005; Uwajeet al., 2007). During focusing, peptides 
migrate through the IPG-strip and settle in the well at which their net charge is zero (pI). Detailed information of each amino acid from 
Nelson and Cooks Lehninger Principles of Biochemistry 3
rd Ed. (2001) were used for the pI calculation. The calculated pI distribution of 
each well shows an uneven distribution across the pH scale. 
An overall view of the deviation of the predicted pI values of every identified peptide spectrum from the average pI calculated for each 
fraction is shown in figure 42. The majority of the peptides were found in the pI range from 3.6 to 4.7 (fractions 1-2). These fractions 
display homogeneous clusters within the appropriate areas as shown in the peptide mass vs. calculated pI scatter plots (see figures 43). 
The fractions become more diffuse in the neutral region, followed by a cluster of His-dominated peptides and an obligatory lack of 
peptides having pI values between 8 and 9. In this case, the number of identified peptides dropped to a minimum. The last two fractions, 




Figure 43  Peptide pI distribution. Scatter plot of the calculated pI value of every peptide against its mass for 


























































































7.5  Using the pI of peptides to manually validate search results 
A major advantage of the OGF is its ability to predict the pI values allowing validation of the identified peptides (Cargile et al., 
2005). This can be achieved by calculating the pI of the identified peptides from each fraction, average fraction pH value and the standard 
deviations (Stdev). These values allow setting a tolerance window and eliminating peptides deviating too far from the average value. For 
a 13 cm linear gradient strip, pH 3-10, the pH should increase by a value of 0.58 units per cm. Peptides focused in this fraction, even 
when using a greater standard deviation, corresponding to a pH difference between 2 wells should not be above 1.2 units per cm. For 
example, the first peptide (HSIAAQGGVNSA) in fraction 1, pH region 3.5-4, of the result list of both samples (see table S5C) has a 
calculated pI value of 7.4. This peptide has a total ion score (70.1), which is above the homology and identified score (33/35). Taking the 
standard deviation into account, this peptide should not appear in this fraction, thus it can therefore be considered a false positive 
identification. Also the peptide (FRALLL) identified in fraction 5 (pH range 5.5-6.8) with a pI value of 11.04 should in the case of a pI 
filter be considered as a false positive identification (see figure 44). This is only possible if the focusing efficiency has been validated. 
Figure 4 shows a plot of the pI of peptides identified in fraction 2. The peptides in circle are above the standard deviation and thus, can be 
eliminated from the list. However, pI filtering has not yet been introduced or established in modern search engines. A reason for this 
could be the difficulty in predicting physiochemical properties, especially if the peptides are modified (Heller et al., 2005). For example, 
there are many different formulas (EMBOSS, DTASelect, Solomon, Sillero, Rodwell, Patrickios) for the calculation of the pI values and 
each delivers different results as shown in figure 2 for 12 peptides chosen from each well (see figure 45). The theoretical values were 
obtained by adding the average pH increase, 0.58, to the pH gradient of the strip (3-10).  
 
 
Figure 44  A density plot of pI for each peptide identified in fraction 2; encirculated peptides indicate false 




































Figure 45  pI values calculated for 12 peptides chosen from the 12 wells using 6 different formulas.  
 
7.6  Suitability of the Offgel-IEF peptide fractionators for relative quantification 
One of the major advantages of TMTsixplett is that parallel proteomic analysis of six different samples or technical replicates of 
samples can simultanenously be achieved, therefore reducing the total analysis time. Hence multi-dimensional separation techniques are 
required to reduce sample complexity. To determine the suitability of relative quantative technique, such as TMT with the optimized 
glycerol free offgel-IEF protocol, membrane proteins extracted from yeast cell grown in 2 different media, glucose (YPD) and oleic acid 
(YPO) were analysed. In order to obtain technical replicates, each sample was separated in 3 fractions, digested and labelled with TMT 6-
plex. All the 6 fractions were combined, focused, each of the 12 IEF fractions were separated on a nLC and analyzed with the MALDI 
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Due to modifications of N-terminal amino acids and/or lysines, a more basic moiety is introduced into the peptide sequence. 
Therefore, it would be expected that these peptides may be focused differently from unlabelled peptides, probably with a shift towards the 
basic region. Nevertheless, most of the peptides identified were focused in the acidic regions (1-5). Moving towards the basic region, the 
number of identified peptides decreases. Lengqvist et al. also showed that peptides labeled with iTRAQ experienced only a minimal pH 
shift (0.17-0.22) when the pI-strip covering a smaller acidic range (3.4-4.9) was used (Lengqvist et al., 2007). For a wide pH range (3-10) 
this shift is negligible. If this is true, the separation of unlabeled peptides should show the same behavior as their labeled counterparts. An 
in silico digest of the same proteins identified in this experiment was performed, and the distribution of the calculated pI was estimated. 
Except for fraction 11 and 12, the pI distribution plot of the labeled and the unlabelled in silico digest fits fairly for all fractions (figure 46 
A). However, the general results show that the change in peptide pI through TMT has a negligible influence when focusing on a wide pH 
range IPG-strip. While the fraction containing more peptides had a lower standard deviation, higher standard deviations were observed 
for fractions with a lower number of peptides. Since 84.4 % of all peptides identified were located in a single fraction (see figure 46 B.) 
and 96 % of peptides in one or two, it can be concluded that the separation efficiency was not compromised by the basic (TMT) residue. 
These results are not different from those obtained from labelled and unlabelled peptides (Chenau et al., 2008). Therefore, the glycerol 
free protocol can be used in comparative quantitative proteomics studies without restriction.  
 
 
Figure 46  (A) Most of the peptides were identified in the acidic region. (B) About 85 % of the peptides were focused only in one 
fraction and 96 % in 2 fractions. (C) The average standard deviation is larger for fraction with less number of identified 










































































































7.8  Protein identification 
Because tandem-mass-tag reagents target all peptides for labelling, multiple peptides from the same protein can be detected. 
Protein identification was achieved by peptides for which individual ion scores were above the 95 % confidence threshold (p < 0.05). In 
general, a total of 323 unique proteins were identified from 1756 peptides. A total of 200 proteins (62 %) were identified by two or more 
of the significant peptides. However, only 22.5 % were membrane proteins. Nevertheless 85.9 % of these membrane proteins carry more 
than one transmembrane dormain (see Table S5D in the Supporting Information). 
Most  of  the  peptides  identified  exhibited  mass-to-charge  ratios  between  1000  and  2000  (see  figure  47).  A  reason  for  the 
identification of large number of peptides in the region comes as a result of the basic TMT. This effect is more predominant for smaller 
and medium-sized peptides then for large peptides. An increase in basicity leads to enhanced signal intensities and signal/noise ratio. 
Therefore, these peptides would be more likely chosen for fragmentation (Baeumlisberger et al., 2010). These results show that TMT 
does not only aid in the relative quantification, but also enhances fragmentation and improves identification.  
 
 
Figure 47  Molecular weight distribution of peptides matched to proteins from elastase digest of YPO/YPD samples. 
7.8  Protein quantification 
If cells of the same cell-lines are cultivated in different media or exposed to different environmental conditions, particular genes 
might be prone to regulation. The extent of regulation is dependent on the gene and the conditions. For yeast cells grown in glucose and 
in oleic acid this changes can be monitored by comparing the relative intensities of reporters ions (see figure 48) generated from peptides 
labeled with a tandem mass tag containing 6 tags at m/z = 126.1, 127.1, 128.1, 129.1, 130.1, and 131.1. For the analysis of changes in 
growth media, a threshold value of 2-fold in either direction is considered as a significant regulation. In these studies, a total of 199 
proteins having two or more significant scoring peptides were relatively quantified. The most prominent being the Plasma membrane 
ATPase and the Hexose transporters (HXT). In general 9 (HXT1, HXT2 HXT3 HXT4 HXT5 HXT6 HXT7 HXT9 and HXT11) of the 17 
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two kinetically distinct systems, a glucose-repressible high-affinity system and a constitutive low-affinity system. Since the yeast cell 
primarily uses glucose as the main carbon and energy source, efficient metabolism of glucose can be used as an environmental stimulus 
that regulates the quantity, types, and activity of glucose transporters, both at the transcriptional and post-translational levels (Özcan & 
Mark Johnston, 1999). Hxt2, Hxt6, and Hxt7 are responsible for transporting glucose in cases of low or the absence of fermentable carbon 
source (Liang et al., 1996; Boles et al., 1997; Reifenberger et al., 1997). The results obtained showed that these proteins and others were 
slightly up-regulated. Citrate synthase, a mitochondrial protein was the most up-regulated protein. The presence of this protein in high 
amount is a result of contamination, since it was difficult to isolate membrane proteins from yeast cells grown in oleic acid. A complete 
list of all the quantified proteins is found in the supplementary sheet. 
To determine the distribution of quantification errors, the ratio of the tags was calculated (see figure 49). Since the protein 
expression is not expected to change within the samples after protein harvest, a triplicate comparison should be 1:1:1. The standard 
deviation of the measured ratios was below 20 % for all three experiments. 















Figure 48  Fragment spectrum of peptide at m/z = 1238.73 Da. The zoom of the reporter ion region that facilitates the peptide relative 
quantification through the abundance of the reporter ions at m/z = 126.1, 127.1, 128.1, 129.1, 130.1 and 131.1 
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7.9  Conclusion 
In many published reports using the manufacturer´s separation protocol (20 % Glycerol) approximately 85-90 % of all peptides 
were identified in 1 or 2 fractions (Heller et al., 2005; Hörth et al., 2006; Lam et al., 2007; Chenau et al., 2008). Using the glycerol free 
protocol, approximately 90-95 % of all peptides were identified in one or two fractions, with very little carryover. Therefore, neither the 
absence of glycerol nor the increased volume in the outer chambers interfered with the Offgel-IEF fractionation process. However, the 
modification prevented the wells from running dry, which would normally happen due to the electroosmotic peptide-water co-migration. 
In addition, due to the solubilising effect of methanol, no precipitation was observed during the entire fractionation process. Furthermore, 
each fraction was directly injected onto the pre-column after vacuum concentration without resulting in clogging and high back pressure. 
Compared to conventional 2 D separations methods, Offgel-IEF permits the separation of large amounts of samples. However, in spite of 
the high resolving power, the separation efficiency of Offgel IEF in the neutral and alkaline pI region is still far from being optimal. A 
reduction of the electro-osmotic water flow should overcome this limitation. Strategies such as using a 10 % sorbitol gradient, and adding 
organic solvents or methyl cellulose, have been suggested (Hubner et al., 2008). Unfortunately, sorbitol and methyl cellulose have a 
higher density than glycerol and would lead to the same problems. Even though the use of additional focusing buffer, in place of glycerol, 
prevented the outer chambers from running dry, the focusing quality in the critical pI regions was not significantly improved. The water 
migration is suspected to be a major reason for the lower focusing quality in the 24-well format (Hubner et al., 2008). Furthermore, the 
lower consistency of pI prediction algorithms in the basic pH range implies that the accuracy ofthe pI prediction is not better than in the 
acidic pH range (Cargile et al., 2004). Although there is still much to be done about the focusing efficiency in the neutural and alkaline pI 
regions, an optimised protocol was established using direct sample injection, separation via nLC without column clogging and increased 
backpressure and mass analysis by MALDI-TOF/TOF. 
Detection and quantification of differences in the protein profiles of cells, tissues or body fluids of different origins or states is 
increasingly being recognised as a key objective of proteomics research (Ji et al., 2005). Techniques that are largely based on stable 
isotope protein or peptide labelling and automated tandem mass spectrometry are increasingly being applied in quantitative proteomic  
 
studies. Shotgun proteomics experiments involving TMT reagents have been successful in identifying and quantifying proteins across a 
variety of prokaryotic and eukaryotic samples. One of the major advantages of TMTsixplex is that parallel proteomic analysis of six 
different samples can be achieved, reducing the total analysis time. However, the compatibility with different separation techniques such 
as the Offgel-IEF has not been assessed. The applicability of the Offgel-IEF glycerol free protocol was assessed for relative quantitation 
studies. Generally TMT labelling induces a small pI-shift compared to the native peptide. Nevertheless, the results obtained from in silico 
digest of the same identified proteins shows that, this difference is relatively small and can only be observed when using IPG strips with 
very narrow pH ranges. For a large pH range like the one used in these experiments (3-10), this shift is negligible. The results presented 
here show that the focusing efficiency for peptides is not altered by the TMT derivatisation. Therefore, this method would be suitable for 
the inclusion in quantitative studies using Isobaric Tags. Furthermore, the introduction of TMT to the peptide backbone significantly 
improved signal-to-noise, signal intensity in MS and fragmentation yield and quality. An improved signal-to-noise ratio with increased 
signal intensity in MALDI-TOF/TOF of isobarically tagged peptides resulted in detection of a greater number of small and medium-size 
peptides. This has also been described for experiments using iTRAQ isobaric tags (Aggarwal et al., 2006). However, care should be taken 
when dealing with proteins identified using short and medium size peptides, since they may fit perfectly to many other proteins. 
The inclusion of Offgel electrophoresis into our proteomic workflow offers several advantages: (i) the pI of the peptides which 
can be used to further substantiate the search result, thereby reducing the false positive rate (Tan et al., 2002,), (ii) the peptides are 
recovered in solution and can directly be loaded on the nLC for further purification and (iii) it offers the possibility to start with large 
amounts of samples, thus increasing the probability of identifying low abundant proteins. Unfortunately, the IEF separation takes at least 
24 hours and each fraction has to be further analysed. This increases the total analysis time to over 2 days. 
    
 
8  Method establishment for the analysis of post-translational modifications 
8.1.1  Results and Discussion 
In order to facilitate high-throughput phosphopeptide analysis using MALDI, co- matrices and matrix additives were used to 
improve the analyte sensitivity of existing matrices, such as α-cyano-4-hydroxycinnamic acid (CHCA), 4-chloro-a-cyanocinnamic acid 
(ClCCA (Jaskolla et al., 2008) 2,4-Difluoro-α-cyanocinnamic (Di-FCCA) (Jaskolla et al., 2009; Teuber et al., 2010) as well as matrix 
combinations were used for the optimisation. For this purpose, 5 phosphopeptides were used to assess the analyte sensitivity (see Table 
S7 in the Supporting Information). Their sensitivities were compared to those obtained using the standard matrix, DHB in 1 % H3PO4. 
Furthermore,  additives in  MALDI-MS  analysis  have  been used  to  improve  matrix  characteristics,  such  as  obtaining  a  homogenous 
preparation, clean-up from salts contaminant and reduction of cationisation (Billeci & Stults, 1993; Pieles et al., 1993; Glückmann et al., 
1999).  Nabetani  et  al.  showed  that  the  addition  of  3  mM  NH4H2PO4  as  additive  to  CHCA  enhanced  the  signal  intensities  of 
phosphopeptides in positive- and negative- ion mode (Nabetani et al., 2006); this ammonium salt was used as matrix additive for all other 
matrices and matrix mixtures. 
8.1.2  Crystal morphology and analyte stability 
Despite the advances in matrix development such as optimising its proton affinity, the crystal morphology is hard to predict. 
However, matrix homogenity can be be influenced by additional factors such as co-matrices, solvents or additives. Homogeneous and 
robust crystallisation, as e.g. observed with CHCA is always of advantage. This assures a stable ion signal over an extended period of 
time. Signals of stable ion intensities from random positions on a spot are a necessity for high throughput MS and MS/MS analysis. After 
analyte co-crystallisation with the matrices/matrix mixtures, the crystal morphology of all matrices and matrix mixtures was observed 
using a microscope (see figure 50). With the exception of DHB, the crystal morphology of the matrices and matrix mixtures were similar 
to those of CHCA. The addition of 3 mM NH4H2PO4 showed no negative influence on the crystallisation. The extent to which the  
 
analytes were distributed on the matrix/matrix mixture can only be determined by randomly measuring the intensity of the analytes in 
each matrix (see figure 51). 
 
Figure 50  Crystal morphology of the FCCA/CHCA 3:1 with 3mM NH4H2PO4.  
 
 
Figure 51  Signal stability, ion signal intensity of the [M + H]
+ of phosphorylated Angiotensin I with an increasing 
number of laser pulses. 15 spectra were acquired as a sum of 1000 shot per spectra.  
 
Figure 51 shows the ion stability for phosphorylated Angiotensin I (100 fmol spotted). The intensities were obtained from 15 
spectra using each matrix/ matrix mixture recorded over the course of 15 000 laser pulses (a summation of 1000 single-shots) per spectra. 
The signal intensity of the analytes in the matrix mixtures FCCA/CHCA 5:1- 9:1 and ClCCA rapidly decreases with increasing number of 
spectra acquired. This could be attributed to the high sample/matrix consumption during ablation as a result of the high laser fluence. The 
signal intensity of the analytes in DHB reflects its inhomogeneous crystal morphology. This matrix showed the highest position-to-
position variation of all the matrices and matrix mixtures. Whenever the laser hits a hot spot, the highest signal intensity is registered. 
This explains the superiority of the matrix in manual  measurements, since only spectra from  the hot spots would be  accumulated. 
However,  the irregular  signal intensity  limits  its  use  for  high-throughput measurements.  On  the  other  hand,  the  signal intensity  of 
FCCA/CHCA 3:1 and CHCA showed relatively stable signal intensities. This is particularly important, since more than 5 precursors are 
usually selected for fragmentation. 
8.1.3  Analyte sensitivity 
During MALDI ionisation the matrix transfers its charge to the analyte molecules. Therefore, the reduction of proton affinity of a 
matrix would enhance analyte intensity.The incorporation of chlorine and fluorine into the aromatic system of CHCA, resulted in low 
proton affinities of the resultant matrices, which in turn led to lower detection limits for analytes (Jaskolla et al., 2008, Teuber et al., 
2010). However, the poor absorbance at 355 nm, εClCCA= 140 l/M
-1cm-1, εdiFCCA = 13 l/M
-1cm-1, is a limitation necessitating a high laser 
fluence. CHCA, which possesses good crystal morphology and is structurally related to these molecules, could be added in order to 
improve the absorbance while preserving their sensitivity. It was shown for ClCCA that upon crystallisation in combination with CHCA, 
improved absorbance is observed. However, the matrix compound competes in protonation process, leading to a decrease in analyte 
sensitivity (Jaskolla et al., 2008). On the other hand, depending on the amount of CHCA, the combination with DiFCCA improved the 
overall absorbance and sensitivity. Though the absorbance was not directly measured, the lower laser fluences used for acquisition of the 
mass spectra showed that the absorbance was enhanced. In general, each MS acquisition method was optimised for each matrix or matrix  
 
mixture. The laser fluences varied from 4000 au (CHCA +3 mM NH4H2PO4) to 5500 au (FCCA/CHCA 9:1 + 3 mM NH4H2PO4). The 
frequency-tripled Nd-YAG laser on the 4800 MALDI Analyzer has a maximum laser insity of 7000 au. 
High analyte signal intensities for MS measurement using 3 different analyte concentrations (25, 100 and 250 fmol) were obtained 
with  FCCA/CHCA  5:1-  9:1+3  mM  NH4H2PO4,  ClCCA+3  mM  NH4H2PO4,  FCCA/CHCA  3:1+3  mM  NH4H2PO4  and  
CHCA+ 3 mM NH4H2PO4 respectively (see figure 52 A and B). Compared to the same matrices and matrix mixtures without 3 mM 
NH4H2PO4, the signal quality is substantially increased (see figure 53 A and B). A summary of the analyte intensities for selected 
matrices is represented in the figure 54. The improvement in analyte intensities can be attributed to the lower proton affinity of the 
DiFCCA matrix allowing for a more efficient proton transfer from the [DiFCCA + H]
+ matrix ions to the analyte and the improved 
absorbance from the CHCA matrix. Furthermore, it can be assumed that the poor detection of phosphopeptides in MALDI is a result of 
poor incorporation of the analytes into the matrix because of high phosphate group affinity to metal surface. When phosphopeptides are 
spotted on the metal target, the phosphate groups bind strongly to the target surface, thereby preventing efficient incorporation into the 
matrix.  The  addition  of  phosphate  to  matrix  solutions  probably  saturates  the  metal  surfaces,  therefore  increasing  the  incorporation 
efficiency of subsequently added phosphate analytes into the matrices. For this reason, it can also be assumed that the better sensitivity of 
DHB in 1 % phosphoric acid is due to the saturation of the target surface with phosphoric acid or inorganic phosphate. However, the 




Figure 52  Mass spectra showing the effect of (NH4)H2PO4 on the phosphopeptide signal at m/z 2303.94. 






















































3 mM (NH4)H2PO4 
 
 
Figure 53  Summary  of  the  effect  of  (NH4)H2PO4  on  matrices  and  matrix  mixtures  for  
25 fmol of a (A) di-phosphorylated (VADPDHDHTGFLpTEpYVATR) and (B) a mono-phosphorylated 
peptide (VRFPpSHFSSDLK).  
 
 
Figure 54  Comparison of the analyte ion intensities of different matrices. 25 fmol of each peptide was used DHB was 
dissolve in 1% phosphoric acid. All the other matrices and matrix mixture contained 3 mM NH4H2PO4 
8.1.4  MALDI MS/MS 
To map modifications in a protein, additional information is always needed for the correct identification and localization of these 
modifications, especially if more than one posttranslational modification (PTM) is present. MS/MS is a prerequisite for the identification 
of unknown phosphorylation sites in a protein. Peptide fragmentation in MALDI TOF/TOF is influenced by many factors that determine 
the internal energy of analytes such as matrix starting velocities, the applied acceleration voltages, the collision energy and the laser 
energy/fluence used. To determine the extent to which the matrices and matrix mixtures affect the fragmentation, 100 fmol of each test 



























optimised for each matrix/matrix mixture. Due  to the high laser  fluence (approximately 6000  au) observed during MS/MS  method 
optimisation, the FCCA/CHCA 7:1 with 3mM NH4H2PO4 mixture was omitted. Fragment ion mass spectra obtained using FCCA/CHCA 
5:1 see figure 55 C), ClCCA, DHB in 1 % H3PO4 (see figure 55 A) were of low resolution, low intensity and poor signal-to-noise ratio 
(S/N). Furthermore, there were less intense immonium ion signals in the lower mass region, which aid in the identification of the amino 
acids present in the sequence.  
On the other hand, fragment ions generated using FCCA/CHCA 3:1 (see figure 55 B), were very similar to those generated with 
CHCA. However, in most cases, they exhibited higher intensities and S/N ratios. For some peptides, almost a complete y-ions series 
could be identified. Additionally, lower laser fluence (4900 au) was required for the FCCA/CHCA 3:1 mixture to acquire high quality 
spectra. Higher laser fluences led to increased ablation, and thus poor spectrum quality. Increased ablation is a limitation for high-
throughput MALDI-based proteomic analysis, since it is desirable to acquire a minimum number of MS/MS spectra per spot (typically ≥ 
5). Furthermore, higher laser fluences lead to an increase of unwanted fragmentation during MS and MS/MS, thereby reducing the quality 
of the mass spectra. A summary of the MS/MS scores for 6 phosphopeptides as calculated by the Biotools software is shown in figure 56.  
 
 
Figure 55  MS/MS spectrum of the peptide with m/z =1126.3 Da obtained using 3 matrices. (A) spectrum was 
obtained using DHB, (B) with the matrix mixture FCCA/CHCA 3:1 + 3 mM NH4H2PO4 and (C) was 
obtained with the FCCA/CHCA 5:1 + 3 mM NH4H2PO4. 

















































































































Figure 56  Comparison  of  the  fragmentation  patterns  using  Biotools  2.2  (Bruker  Daltonics,  Bremen).  DHB  was  dissolve  in  1% 
phosphoric acid. All the other matrices and matrix mixture contained 3 mM NH4H2PO4. 
Based on MS results, it can be concluded that FCCA/CHCA 7:1, FCCA/CHCA 5:1, ClCCA, FCCA/CHCA 3:1 with 3 mM 
NH4H2PO4 can be used in the positive ion mode for MS measurements of  phosphopeptides. These matrices have more homogeneous 
morphologies than the standard matrix DHB. Moreover, the signal intensities of these peptides are higher than those obtained using the 
standard matrix. In MS/MS experiments, high intensities fragment ions were obtained with FCCA/CHCA 3:1 + 3 mM NH4H2PO4 at 






































Therefore, for high-throughput nLC-MALDI-TOF/TOF analysis of phophopeptides FCCA/CHCA 3:1 + 3 mM NH4H2PO4 was chosen for 
further analysis. 
8.2.1  Biphasic pre-column 
The establishment of a matrix, with improved sensitivity compared to that of the standard matrix DHB, allowed us to establish a 
high-throughput MALDI method for the analysis of phosphopeptides. This method is based on the online enrichment and separation of 
both the flow through and the enriched phosphopeptides using a biphasic pre-column containing TiO2/C18 material. The enrichment of 
phosphopeptides on TiO2 has shown to improve their signal intensities. Most of these enrichment processes are carried out in offline 
mode. Pinkse et al. introduced an automatic method for the online enrichment and analysis of phosphopeptides via LC-ESI MS/MS. In 
this method, three short columns of C18, TiO2 and C18 material respectively, were combined. This strategy is particularly advantageous 
because column switching is not necessary and it allows a full characterisation of the flow-through (non-phosphorylated peptides) and 
TiO2-eluate (phosphorylated peptides). For our experiments, both C18 and TiO2 were packed in one column (biphasic pre-column) as 
shown in figure 57. This procedure, which is similar to multidimensional protein identification technology (MudPIT), reduced the number 
of connections and possible void volumes in the system. Digested samples are loaded onto the biphasic pre-column, phosphopeptides are 
trapped on the TiO2 beads and the non phosphorylated peptides on the C18 materials. During the first gradient, the peptides trapped on the 
C18 materials are separated on the analytical column (in-house packed 120 cm × 100 µm C18), mixed with CHCA and spotted on a 
MALDI  target.  Prior  to  the  second  gradient,  phosphopeptides  trapped  on  the  TiO2  materials  are  eluted  to  the  C18  material  using 
ammonium bicarbonate (pH 10) injected via the sample loop. The phosphopeptides are subsequently separated in the second gradient 
using  the  same  analytical  column,  mixed  with  the  novel  matrix  mixture  and  spotted  on  a  MALDI  target.  This  online  enrichment 
procedure facilitates high reproducibility, good enrichment efficiency, and the analysis of both flow through. Furthermore, the use of 2 
different matrices for the analysis is possible. In addition, due to the high pH range stability of the C18 materials, it is possible to analyse 
many samples using the same biphasic pre-column.   
 
 
Figure 57  Sample loading setup. 
8.2.2  Evaluation of non-phosphorylated acidic peptides excluders 
A limitation to the efficiency of TiO2 enrichment strategies is given by the non-specific binding of primarily multiply acidic 
residues (i.e., Glu and Asp) in peptides. In an attempt to reduce the rate of nonspecific binding, DHB, glycolic acid and TFA were 
included in the sample and loaded on the biphasic pre-column. Using 4 standard phosphopeptides in BSA digest of 20-fold higher 
concentration as a semi-complex background, the loading and eluting conditions were optimised. Even though, in the case of DHB, the 
biphasic pre-column was washed with four times the injected sample volume, concentrations above 60 mg/ml resulted in extensive tailing 
on  the  first  gradient  (see  figure  58).  This  in  turn  resulted  in  inhomogeneous  crystallisation  of  the  matrix  (figure  50),  leading  to 
irreproducible  measurements  and  an  increase  in  the  required  laser  fluence.  With  concentrations  below  
40 mg DHB/ml, only a few spots (10 spots) were affected. Also, the overall intensities of the eluted phosphopeptides decreased, when  
 
using DHB in the enrichment buffer, an effect, which has also been reported by several groups (Sugiyama et al., 2007; Bodenmiller et al., 
2007). 
 
Figure 58  The effect of different concentrations of DHB in the loading solution on the crystal morphology for 
the FCCA/CHCA 3:1 with 3mM NH4H2PO4 matrix mixture. 
On the other hand, 1 M glycolic acid and 5 % TFA showed little or no effect on the matrix crystallisation. In general, all three acid 
excluders reduced unspecific binding, thus increasing the intensity ratio of the phosphopeptides. 5 % TFA showed no negative influence 
on the crystallisation, less non-phosphorylated peptides were identified (see figure 59 A), yielded the highest intensities and signal-to-
noise ratios of most of the phosphorylated peptides (see figure 59).  
 
 
Figure 59  A shows the number of acidic non-phosphorylated peptides identified. B and C show Comparison of the signal intensity of 
individual phosphopeptides after loading with Glycolic acid, DHB and 5 % TFA.  
 
To assess the affinity and capacity of the titanium beads, between 250 fmol and 50 fmol of standard phosphopeptides in a 20-fold 
excess of BSA digest were loaded on the column. After separation and precursor mass measurement, the intensities of the distribution of 
the phosphopeptides in both flow through (gradient 1 and 2) were plotted against the spots collected during the case of both gradients. 
Figure 60 shows that even at 250 fmol all the phosphopeptides were effectively trapped on the TiO2 biphasic pre-column, indicating the 
high selectivity of TiO2 in trapping phosphopeptides. All phosphopeptides were identified in the second gradient, however with varying 





Figure 60  Plot of the Signal/Noise against spot number of the phosphopeptide loaded on the biphasic pre-column and separated on 
the  EASY-nLC.  (A)  Shows  the  flow  through  during  sample  loading.  (B  and  C)  show  reproducible  base  peak 
chromatogram of the phosphopeptides trappped on the TiO2 beads.  
 
8.2.3  Evaluation of the online enrichment using α/β-casein 
To evaluate the applicability of the matrix mixture and the biphasic pre-column, a tryptic digest of α/β-casein, was analysed. A 
direct analysis of 500 fmol of these proteins, using 5 % TFA as acid excluder resulted in the detection of 14 phosphopeptides representing 
8 different phosphorylation sites. The MGF files were searched against the DB-standard database containing 24 proteins. These peptides 
were considered significant only if they appeared in at least 2 of the triplicate MS and MS/MS experiments and result in Mascot scores 
above the identity threshold (p < 0.5) (see supplementry Table 6). Table 17 shows a summary of all phosphopeptides identified. The 
identification of the phosphopeptide, YLGEYLIVPNpSAEER (1832.83 Da) (see figure 61) was done manually. This peptide represents a 
new sequence variant of the alpha-S1 casein in the region 104–119 and was first described by Larsen and his group (Larsen et al., 2005). 
In addition, a semi-tryptic phosphopeptide RELEELNVPGEIVEpSL (1905.86 Da) from β-casein representing amino acids 16-31 was 
identified. The identification of these peptides was only possible because of their isolation from the non-phosphorylated peptides. Out of 
the  14  phosphopeptides  identified  from  α-S1casein,  only  2  peptides  (YKVPQLEIVPNpSAEER  and  VPQLEIVPNpSAEER)  were 
detected in the first and second gradient. This indicates that, no matter how selective the TiO2 is, some peptides might still escape 
enrichment  while  some  might  not  be  eluted  from  the  beads.  Though  5  %  TFA  significantly  reduced  the  amount  of  acidic  non-
phosphorylated peptides on the TiO2 material, it did not completely prohibit the binding of all acidic non-phosphorylated peptides.  
 
 
Figure 61  A new sequence variant of the alpha-S1 casein in the region 104–119 (YLGEYLIVPNpSAEER, 1832.83 
Da). This peptides is not present in Mascot, thus was identified manually.  
 
Table 17  Overview of the identified phosphopeptides generated from α/β-casein. 
*phosphopeptides found in both the first and the second gradient 
§peptide not identified by mascot search 
Peptides  M+H  Ion score 
DIGSESTEDQAMEDIK (α-S1)  1927.64  36 
YKVPQLEIVPNSAEER (α-S1)  1951.93*  101 
YKVPQLEIVPNSAEERLHSMK (α-S1)  2548.27  74 
VPQLEIVPNSAEER (α-S1)  1660.79*  104 
YKVPQLEIVPNSAEERLHSMK (α-S1)  2564.25  24 
VPQLEIVPNSAEERLHSMK (α-S1)  2273.07  23 
IEKFQSEEQQQTEDELQDK (β)  2431.98  53 
FQSEEQQQTEDELQDK (β)  2061.81  68 
NAVPITPTLNREQLSTSEENSKK (α-S1)  2716.15  25 
RELEELNVPGEIVESLSSSEESSITR (β)  3122.3  63 
IEKFQSEEQQQTEDELQDK (β)  2432.1  42 
YLGEYLIVPNSAEER (α-S1)  1832.83
§  - 
RELEELNVPGEIVESL (α)  1905.86  87  
 
8.2.4  ENL protein complex 
To demonstrate that this method can be used for the study of phosphorylation sites in a real sample, affinity purified ENL complex 
was digested with trypsin. The peptide mixture was then loaded onto the custom-made biphasic pre-column, separation and analyses were 
performed as described above. Three replicate runs were performed; the generated Mascot generic format files were combined and 
searched against a Swissprot database. For data interpretation, only peptides that appeared in at least 2 analyses with Mascot score above 
the homology threshold (p > 0.3) were taken into consideration. A total of 352 peptides were matched to 82 proteins (see supplementary 
excel sheet 1) 
Due to the frequent loss of phosphate groups within the peptide sequence in MS/MS experiments, assigning phosphorylation sites 
is rather difficult. Phosphorylation sites of peptides containing just one possible modifications site can easily be obtained from the Mascot 
search  results.  However,  difficulties  arise  if  the  sequence  contains  more  than  one  possible  modification  site.  Therefore,  the 
phosphorylation sites of the identified peptides were manually verified. For this purpose, the data explorer (AB Sciex) was used to 
generate theoretical fragment ion mass spectra from the sequence with the assumed phosphorylation site. These fragments were then used 
to  label  the  fragment  of  the  spectrum  in  order  to  determine  the  best  possible  fit.  For  example  the  phosphopeptide 
LSFSDSESDNSADSSLPSR with m/z 2080 Da has 8 serine residues. The loss of 98 Da during fragmentation from phosphoserine results 
in an intensive signal and is usually an indicator of these phosphopeptides. However, DeGore and Qin (DeGore & Qin, 1998) showed that 
in some phosphoserine-containing peptides, the 98 Da loss is not dominant, nevertheless still indicates the present of a  phosphate group 
in the peptide backbone (see figure 62). An extended y- ion series is observed, but the series partially disappears after y-15. The lack of b- 
and y-type ions with a deficit of 98 Da in the region between y1-y15 (see figure 62) indicated that the serine residues in this section of the 
sequence were not modified. This section of the sequence contains 6 serine residues (-DSESDNSADSSLPSR). On the other hand the 
presence of the b7-98 was indicative of a phosphorylated serine in this section of the spectrum. A zoom between the regions 1740-1878 
Da revealed a poorly resolved fragment, which represent the y17-ion, with a 98 Da deficit. The loss of H3PO4 from the y17 ion indicated 
that ser2 is most likely carrying the phosphate group. Another example is the phosphopeptide, ETKLESTSPK, with m/z 1198.55. This  
 
peptide was identified as a peptide phosphorylated at serine and it possess 2 serines, ser6 and ser8, which can be modified. The presence 
of y3-98 or b6-98 would give a clear hint of the modified phosphoserine. Considering ser8 as the phosphorylation site, the absence of the 
y3or y4 and the subsequent loss of a phosphate group indicated that that ser8 was not phosphorylated (see figure 63 A). On the other 
hand, assuming that ser6 is phosphorylated, the presence of the b6-98 ions is indicative of a phosphorylated serine (see figure 63 B). 
Therefore it can be concluded that ser6 is phosphorylated 
In general, 352 peptides were uniquely identified, of which 18 were phosphopeptides, covering 15 different phosphorylation sites. 
13 of these phosphopeptides, containing 9 phosphorylations site were matched to the ENL protein. 9 phosphorylations sites have been 
predicted for this protein but never been identified. Six of the 9 predicted and 3 novel phosphorylation sites were identified. All identified 
peptides  were  phosphorylated  at  the  serine  residues  and  amongst  these  only  one  was  a  di-phosphorylated.  A  list  of  all  identified 
phosphopeptides is presented in table 18. 
The function and the role of the phosphoserine modification on ENL have not fully been investigated but it is known that Eleven-
nineteen-leukemia protein (ENL) and 3 other proteins, AF4, AF9, and AF10 are the four most frequent fusion protein partners of Mixed-
Lineage Leukaemia (MLL) gene in pediatric-, adult- and therapy-related acute leukemias (Meyer et al., 2006). In a recent publication, 
Bitoun et al. (Bitoun et al., 2007) demonstrated that AF4 functions as a positive regulator of Pol II transcription elongation factor b (P-
TEFb) kinase and in complex with MLL fusion partners AF9, ENL and AF10, it acts as a mediator of histone H3-K79 methylation by 
recruiting Dot1 to elongating Pol II.  Furthermore, it was mentioned that these pathways are interconnected and tightly regulated by the P-
TEFb-dependent phosphorylation of AF4, AF9 and ENL, which controls their transactivation activity and/or protein stability.  




Figure 62   Fragment spectrum of the peptide with mass 2080.743 (LSFpSDSESDNSADSSLPSR). 
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Figure 63  Fragment spectrum of the peptide with m/z of 1197.54 (ETKLEpSTSPK).  
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Table 18  Phosphopeptides identified. All novel phosphorylation sites are underlined. 





852,35  SAPGTpSPR  37,87  310  317 
1199,52  ETKLESTpSPK  46,52  260  269 
1228,44  pSPESCSKPEK  54,81  475  484 
1384,57  RpSPESCSKPEK  54,01  474  484 
1405,67  RPATADpSPKPSAK  69,02  286  298 
1783,86  VSGRRpSPESCSKPEK  44,04  470  484 
1863,75  ALEVEESNpSEDEASFK  135,56  353  368 
1943,69  ALEVEEpSNpSEDEASFK  74,63  353  368 
1984,96  LESTpSPKGGPPPPPPPPPR  113,45  263  281 
1991,85  KALEVEESNSEDEApSFK  88,48  352  368 
2080,85  LSFpSDSESDNSADSSLPSR  142,7  437  455 
2343,09  ETKLESTpSPKGGPPPPPPPPPR  58,49  260  281 
3571,59  LSFpSDSESDNSADSSLPSREPPPPQKPPPPNSK  66,74  437  469 
  
 
8.3  Conclusion 
Many cellular processes are regulated by reversible phosphorylation of proteins on serine, threonine, and tyrosine residues. A 
better understanding of these biological signalling networks requires global identification of phosphoproteins and their phosphorylation 
sites. Although the analysis of protein phosphorylation has been a rapidly evolving field, the goal of phosphoproteome analysis for cells 
and tissues remains an analytical challenge. MALDI is one of the most commonly used MS-based methods for phosphoproteomics. 
However, its use for high-throughput phosphorproteomics has been limited due to the lack of optimal matrices. DHB has proven to be the 
matrix of choice in this field. Nevertheless, as a result of the inhomogenous morphology of this matrix, automation has been difficult for 
instruments lacking a crystal positioning system. It was shown that crystallisation can be positively affected with co-matrices or matrix 
additives, moreover, the sensitivity of matrices for phosphopeptide analyses can be enhanced, while preserving the crystal morphology. 
Compared to DHB, which is known to exhibit high sensitivities for phosphopeptides, the combination of DiFCCA and CHCA in a 3:1 
ratio in 3 mM NH4H2PO4 led to an increase in the intensities of phosphopeptides. This matrix mixture exhibited higher absorbance and 
more uniform morphology, therefore more reproducible analyte intensities with lower standard deviations and less laser fluences. In 
addition, this matrix mixture showed better fragmentation. 
Based  on  this  novel  matrix  mixture,  a  high-throughput  MALDI-based  method  for  the  analysis  of  phosphorpeptides  was 
established. This method is based on trapping and analysing both the flow through during enrichment and the enriched phosphopeptide 
using a custom-packed biphasic pre-column. The applicability of this method was tested using standard phosphopeptides spiked to a 20-
fold excess of a tryptic BSA digest, a tryptic digest α/β-casein and an affinity-purified ENL protein complex. The advantage of this 
biphasic column is the ability to analyse both flow throughs without column switching and that the pre-column is ready to be used 
immediately  after  each  gradient.  The  use  of  5  %  TFA  greatly  enhances  the exclusion  of acidic  non-phosphorylated peptides.  This 
methodology resulted in a strong increase in the selectivity of purification of phosphorylated peptides from complex mixtures of non-
phosphorylated and phosphorylated peptides. In conclusion, the mass spectrometric identification and characterisation of PTMs is still an 
extremely difficult task since 100 % protein sequence coverage is still not possible.    
 
9  General Summary 
Top-down and bottom-up approaches are the general methods used to analyse proteomic samples today, however, the bottom-up 
approach has been dominant in the last decade. Establishing a bottom-up method involves not only the choice of adequate instruments 
and the optimisation of the experimental parameters, but also choosing the right experimental conditions and sample preparation steps. 
LC-ESI MS/MS has widely been used in this field due to its advanced automation. The primary objective of the present study was to 
establish a sensitive high-throughput nLC-MALDI MS/MS method for the identification and characterisation of proteins in biological 
samples. The method establishment included optimisation and validation of parameters such as the capillaries in the HPLC systems, 
gradient slopes, column temperature, spotting frequencies or the MS and MS/MS acquisition methods. The optimisation was performed 
using two HPLC-systems (Agilent 1100 series and Proxeon Easy nLC system), three spotters and the 4800 MALDI-TOF/TOF analyzer. 
Furthermore, samples preparation protocols were modified to fit to the established nLC-MALDI-TOF/TOF-platform. 
The  potentials  of  this  method  was  demonstrated  by  the  successful  analysis  of  complex  protein  samples  isolated  from  lipid 
particles,  pre-adipocytes/adipocytes  tissues,  membrane  proteins  and  proteins  pulled-down  from  protein-proteins  interaction  studies. 
Despite the small amount of proteins in the lipid particles or oil bodies, and the challenges encountered in studying such proteins, 41(6 
novel + 14 mammal specific + 21 visceral specific) proteins were added to the already existing proteins of the secretome of human 
subcutaneous (pre)adipocytes and 6 novel proteins localised in the yeast lipid particles. Protein-protein interaction studies present another 
area of application. Here the analytical challenges are mostly due to the loss of binding partner upon sample clean-up and to differentiate 
from non-specific background. Novel interaction partners for AF4•MLL and AF4 protein complex were identified.  
Furthermore, a novel sample protocol for the analysis of membrane proteins, based on the less specific protease, elastase, was 
established. Compared to trypsin, a higher sequence coverage and higher coverage of the transmembrane domains were achieved. The use 
of this enzyme in proteomics has been limited because of its non specific cleavage. However, from the results obtained in these studies, 
elastase was found to cleave preferentially at the C-terminal site of the amino acids AVLIST. The advantage of the established protocol 
over conventional protocols is that the same enzyme can be used for shaving of the soluble dormains of intact proteins in membranes and  
 
the digestion of the hydrophobic domain after solubilisation. Furthermore, the solvents used are compatible with the nLC-MALDI method 
setup. In addition, it was also shown that for less specific enzymes, a higher mass accuracy is required to reduce the rate of false positive 
identifications, since current search engines are not perfectly adapted for these types of enzymes. 
A brief statistical analysis of the MS/MS data obtained from the LC-MALDI-TOF/TOF system showed that for less specific 
enzymes, under high-energy collision conditions, approximately 43 % of the fragment ions could not be matched to the known y- b- type 
ions and their resultant internal fragments. This limitation greatly influenced the search results. However, this limitation can be overcome 
by modifying the N-terminal amino acids with basic moieties such as TMT.  
The use of elastase as a digestion enzyme in proteomic workflow further increased the complexity of the sample. Therefore, 
orthogonal multidimensional separation was necessary. Offgel-IEF was used as the separation technique for the first dimension. Here 
peptides are separated according to the pI. However, the acquired samples could not be loaded to the nLC due to the high viscosity of the 
concentrated  samples  when  using  the  standard  protocol.  In  order  to  achieve  compatibility  of  the  Offgel-IEF  to  the  nLC-MALDI-
TOF/TOF-platform, the separation protocol of the Offgel-IEF was modified by omitting the glycerol, which was the cause of the viscous 
solution. The novel glycerol free protocol is advantageous over the conventional method because the samples could directly be picked-up 
and loaded onto the pre-column without resulting in an increase in back pressure or a subsequent pre-column clogging. The glycerol free 
protocol was then assessed using purple membrane and membrane fraction of C. glutamicum. The results obtained were comparable to 
those applied in published reports. Therefore, the absence of glycerol did not affect the separation efficiency of the Offgel-IEF.  
In addition the applicability of elastase and the glycerol free Offgel-IEF for quantitation of membrane proteins was assessed. Most 
of the unique peptides identified were in the acidic region and 85 % were focused only into one fraction and approximately 95 % in only 
two fractions. These results are in accordance with previously published results (Lengqvist et al., 2007). When compared with theoretical 
digests of the proteins identified in this study, it can be concluded that basic moiety (TMT) on the peptide backbone, did not affect the 
separation efficiency of the Offgel-IEF. In an applied study, changes in the protein content of yeast strain grown in two different media 
were relatively quantified. For example, prominent proteins, such as the hexose tranporter proteins responsible for transporting glucose 
accross the membrane, were successfully quantified.  
 
Last but not least, the nLC-MALDI-TOF/TOF platform also served as a basis for the development of a high-throughput method 
for the identification of protein phosphorylation. The establishment of such a method using MALDI has been challenging due to the lack 
of sensitive matrices, such as CHCA for non-modified peptides, which exhibit a homogenous crystallisation and thus yield stable signal 
intensity over a long period of time in an automated setup. The first step of this method was the establishment of a matrix/matrix mixture 
with  better  crystal  morphology  and  higher  analyte  signal  intensity  than  the  matrix  of  choice,  i.e.  DHB.  From  MS  and  MS/MS 
measurements of standard phosphopeptides, a combination of FCCA and CHAC in a 3:1 ratio and 3 mM NH4H2PO4 facilitated high 
analyte  signal  intensities  and  good  fragmentation  behaviour.  Combining  a  custom-packed  biphasic  column  for  the  enrichment  of 
phosphopeptides,  the  applicability  of  the  matrix  mixture  was  assessed  in  anautomated  phosphopeptide  analysis  using  standard 
phosphopeptides spiked to a 20-fold excess BSA digest. These analyses showed that this method is reproducibile and both flow throughs 
can be analysed. Applying the method to the analysis of 2 standard phosphoproteins, α/β-casein, and a leukemia related protein, ENL, 13 
phosphopeptides from both α/β-Casein and 13 phosphopeptides with 6 phosphorylation sites from the ENL were identified. 
As a general conclusion, it can be stated that the nLC-MALDI-TOF/TOF method established here in various modifications for different 
analytical purposes is a robust platform for proteomic analyses.    
 
9.1  Zusammenfassung 
Der Begriff Proteom wurde 1994 vom Australier Marc R. Wilkins in Anlehnung an die Begriffe Genom und Transkriptom beschrieben. 
Später  wurde  das  Gebiet  der  Proteomics  durch  Patterson  &  Aebersold  als  "systematische  Erforschung  der  zahlreichen  und 
unterschiedlichsten Eigenschaften von Proteinen in paralleler Weise mit der Zielsetzung einer detaillierten Beschreibung der Struktur, 
Funktion und Steuerung biologischer Systeme im gesunden und krankhaften Zustand" definiert (Patterson et al., 2003). Somit nimmt 
dieses  Themengebiet  eine  wichtige  Position  in  der  Biologie  ein  und  übt  einen  erheblichen  Einfluss  auf  verwandte  Bereiche  der 
Biowissenschaften  aus.  Mit  Hilfe  der  Massenspektrometrie  und  der  weichen  Ionisierungstechniken  Matrix-unterstützte  Laser-
Desorption/Ionisation (engl Matrix assisted laser desorption/ ionization,MALDI) und Elektrospray ionization (ESI) war die Ausbreitung 
dieses Forschungsgebiets in vielen Laboratorien nicht mehr aufzuhalten. 
Für  die  massenspektrometrische  Bestimmung  von  Proteinen werden  meist zwei  Identifizierungswege –  Top-down  und  Bottom-up  – 
verwendet. Beim Top-down-Verfahren werden die getrennten Proteine direkt gemessen, während beim Bottom-up-Verfahren die Proteine 
zuvor entweder enzymatisch oder chemisch gespalten und die so entstandenen Peptide analysiert werden. Letzteres wird häufiger für 
Proteomics-Experimente angewandt, da mehrere Proteine nebeneinander bestimmt werden können. Trotz dessen ist die “Large-Scale“- 
Proteomanalyse von komplexen biologischen Proben in vielerlei Hinsicht erschwert, da eine hohe Massengenauigkeit, Trennleistung bei 
den LC-Läufen und hochauflösende Massenspektrometrie erforderlich ist. 
Diese Arbeit befasst sich mit der Etablierung einer nLC-MALDI-TOF/TOF Methode, basierend auf reversed phase-Chromatographie, zur 
Identifizierung von Proteinen aus komplexen biologischen Proben. Dabei wurde die Probe an zwei nanoLC-Anlagen, die jeweils mit 
einem automatischen Spotter versehen waren, getrennt. Die anschließende massenspektrometrische Messung fand an einem MALDI-
TOF/TOF Gerät statt.  
Zuerst  wurde  die  Methode  mit  Hilfe  von  Standardpeptiden  und  Standardproteinen  optimiert.  Dabei  wurde  u.a.  untersucht,  welchen 
Einfluss verschiedene Parameter, wie der Fließmittelgradient, die Säulentemperatur oder die verwendete Matrixkonzentration auf die 
Trennung und anschließende Identifizierung haben. Aufgrund der großen Anzahl von Spektren, die bei Bottom-up-Proteomic generiert  
 
werden, ist eine manuelle Interpretation nicht möglich. Aus diesem Grund ist eine hohe Qualität der Spektren notwendig, um die richtige 
Peptidsequenz  zu  identifizieren.  Daher  wurde  neben  der  chromatographischen  Trennung  auch  die  massenspektrometrische  Methode 
optimiert. Es zeigte sich, dass die besten MS/MS-Ergebnisse mit 1 kV Fragmentierungsmethode erzeugt wurden. 
Während der Optimierung wurde außerdem festgestellt, dass Matrixkonzentrationen (α-cyano-4-hydroxyzimtsäure) über 3,5 mg/ml zu 
einer Peak-Verbreiterung führten. Vermutlich kommt es aufgrund der Kristallbildung an der Nadelspitze des Spotter zu Verschleppungen 
des Analyten und dadurch zu der Peak-Verbreiterung. Um die optimale Säulentemperatur zu bestimmen, wurde die Trennung bei 25, 30, 
40 und 60 °C durchgeführt. Die erhöhte Säulentemperatur führte zu einer Druckverminderung während der LC-Trennung. Durch die 
Verringerung des Drucks ist der Einsatz von längeren Trennsäulen oder höheren Flussraten möglich. Ferner zeigte sich, dass bei 40°C 
Säulentemperatur die beste Auftrennung und damit verbunden deutlich mehr Peptide identifiziert werden konnten. Bei 60 °C nahm die 
Menge der identifizierten Peptide als Folge des Abbaus von Säulenmaterial ab. 
Nach der Optimierung wurde die Robustheit der Methode und nLC-Anlage durch Analyse verschiedener biologischer Proben überprüft. 
Dabei  wurden  Proteine  aus  Saccharomyces-Lipidpartikeln  und  aus  humanen  Adipocyten  untersucht.  Die  Herausforderung  für  die 
Analytik dieser Proben war zum einen die niedrige Proteinkonzentration und zum anderen der hohe Lipidanteil der Partikel (> 90 %), der 
nach dem Verdau anfangs zu einem Verstopfen der Vorsäule führte. Um eine Analyse der Proben mittels nLC zu ermöglichen, mussten 
daher die Lipide zuvor mit Diethylether extrahiert werden. Dank der verbesserten Methode konnten neben bereits bekannten jeweils sechs 
neue Proteine identifiziert werden. Insgesamt wurden 41 Proteine aus humanen subkutanen Steatoblasten, bzw. Adipozyten identifiziert, 
davon neben den sechs neuen Proteinen, 14 säugetierspezifische und 21 viszeral-spezifische Proteine. 
Weiterhin wurde die Methode zur Analytik von Proteinkomplexen verwendet. Die Untersuchung von Protein-Protein-Wechselwirkung 
gibt  Aufschlüsse  über  Zellmechanismen  und  über  das  Entstehen  bestimmter  Krankheiten,  wie  etwa  Leukämien,  woraus  sich 
Therapieansätze  und  -maßnahmen  ableiten  lassen.  Das  mixed-lineage  leukemia  (MLL-Gen)  auf  Chromosom  11  Bande  q23  ist  in 
zahlreiche, reziproke chromosomale Translokationen verwickelt. Bei der akuten Leukämie t(4;11), häufig anzutreffen bei Säuglingen und 
Kleinkindern, sind das MLL-Gen auf Chromosom 11 und das AF4-Gen auf Chromosom 4 beteiligt. Durch die Translokation entstehen 
zwei neue Derivatchromosomen – (MLL•AF4) und (AF4•MLL). Chromosomale Translokationen des MLL-Gens werden auf Grund ihrer  
 
sehr schlechten Prognose und Therapierbarkeit als Hochrisiko-Leukämien eingestuft. Bis heute konnten 64 Translokations-Partnergene 
identifiziert werden, wobei das AF4-Gen mit 42 % bei allen untersuchten Leukämien und mit ca. 66 % bei der akuten lymphatischen 
Leukämie (ALL) den größten Prozentsatz ausmacht. 
Dabei war das Ziel dieser Anwendung die Identifizierung neuer Interaktionspartner mit den Fusionsproteinen MLL•AF4 und AF4•MLL. 
Hierfür wurden die Strep-Elutionen von AF4, AF4•MLL, ENL und die Negativkontrolle in Lösung verdaut, getrennt und analysiert. 
Insgesamt wurden 17 bekannte Interaktionspartner, deren Funktion und Rolle in der Leukämogenese eindeutig in zahlreichen Studien 
nachgewiesen  ist,  aus  AF4-  und  AF4•MLL-Komplexen  identifiziert;  daneben  auch  neue  Fusionsproteine  des  AF4-Proteins  (DDX6, 
NPM1,  NFkB,  BRD4,  CARM1,  NSD1)  und  des  AF4•MLL-Fusionsprotein-Komplexes  (DDX6,  NPM1,  NFkB,  HEXIM1,  CARM1, 
DOT1L). Leider konnten bei der ENL keine Fusionsproteine von bekannten Interaktionspartnern nachgewiesen werden. 
Trotz  der  Identifizierung  bekannter  und  neuer  Interaktionspartner  aus  den  AF4-  und  AF4•MLL-  Proteinkomplexen  gibt  es  weitere 
Herausforderungen, wie bei der Zellzucht oder der Probenvorbereitung zu bewältigen. Viele Interaktionen von Proteinen sind leider nicht 
von Dauer, oder die Interaktionspartner sind in zu geringen Mengen vorhanden, sodass die Analyse schwierig ist. 
Als weiterer Anwendungsbereich wurde die nLC-MALDI-TOF/TOF-Methode zur Identifizierung von Membranproteinen verwendet. 
Membranproteine sind aufgrund ihrer hydrophoben Eigenschaften in wässrigen Puffersystemen schlecht löslich und somit im Vergleich 
zu hydrophilen Proteinen analytisch schwer zugänglich. 
Weiterhin  besitzen  sie  weniger  tryptische  Schnittstellen,  weshalb  die  Verwendung  von  Trypsin  zur  Hydrolyse  der  Proteine  nur  zu 
mäßigen Ergebnissen führt. Weniger spezifische Enzyme bilden überlappende Fragmentcluster, da sie Proteine an mehr Aminosäuren als 
Trypsin spalten. Wegen seiner unspezifischen Spaltung ist die Verwendung von Elastase im Bereich Proteomik bisher eingeschränkt. Es 
stellte  sich  allerdings  heraus,  dass  nach  dem  Verdau  von  Membranproteinen  aus  Halobacterium  salinarium  und  Corynebacterium 
glutamicum eine, im Vergleich zu Trypsin, höhere Sequenzabdeckung des gesamten Proteins sowie der Transmembrandomänen erreicht 
wurde.  Insgesamt  konnten  bei  der  Analyse  der  Membranfraktion  379  Proteine  identifiziert  werden.  Davon  waren  44  %  integrale 
Membranproteine. Zum Vergleich wurde mit Trypsinverdau lediglich weniger als 44 % integrale Membranproteine identifiziert Diese 
Ergebnisse zeigen, dass der Einsatz von weniger spezifischen Enzymen bei Membranproteinen zu einer höheren Sequenzabdeckung  
 
führen kann. Ein Problem, das sich nach dem Verdau mit Elastase stellte, war die Auswertung der erzeugten MS/MS-Daten. Etwa 43 % 
der  Fragmentionen  gehörten nicht zu den bekannten  y- oder b-Ionen und konnten daher nicht den internen  Fragmenten zugeordnet 
werden. 
Ein Grund dafür ist vermutlich die fehlende Lokalisierung der positiven Ladung an den C- und N- Termini der entstandenen Peptide. Eine 
Erhöhung der internen Fragmentionenbildung führte zu Schwierigkeiten bei der Interpretation der Spektren. Die Fragmentierung konnte 
wiederum durch Derivatisierung mit einem basischen Rest (z.B. TMT) verbessert werden. 
Durch Verwendung von TMT konnten mehr als 50 % der Fragmentionen wieder zugeordnet werden (Bäumlisberger et al., 2010). 
Selbst die verbesserte Trennleistung der entwickelten nLC-Methode war für sehr komplexe biologische Proben, wie z.B. Zelllysate, nicht 
ausreichend.  Diese  Problematik  wurde  durch  Kombination  mit  der  Offgel-IEF-Trennung  verbessert.  Diese  Technik  trennt  die 
Proteine/Peptide  der  komplexen  Probe  anhand  des  isoelektrischen  Punkt  in  verschiedene  Fraktionen  auf.  Die  erhaltenen  Fraktionen 
wurden anschließend einzeln auf der nLC getrennt. Nach Optimierung des Methodenprotokolls war es möglich die vorfraktionierten 
Proben mittels nLC weiter aufzutrennen und anschließend mittels MALDI-TOF/TOF zu identifizieren. Es zeigte sich, dass durch die 
optimierte Offgel-IEF Methode ca. 90-95 % aller Peptide in einer oder zwei Fraktionen vorlagen. 
Ferner wurde überprüft, ob die optimierte Methode für eine relative Quantifizierungstechnik geeignet ist. Hierfür wurden mit TMT 
markierte Peptide mittels IEF und anschließend nLC getrennt. Bei der Überprüfung der Trennleistung wurde kein negativer Einfluss des 
basischen TMT auf die Trennung festgestellt. Auch mit TMT lagen 95 % der identifizierten Peptide in nur einer oder zwei Fraktionen 
vor. Generell induziert TMT eine geringe Verschiebung des isoelektrischen Punktes, der bei Verwendung von IPG-Streifen mit großen 
pH-Bereich (pH 3-10) aber vernachlässigbar ist. Trotz der effizienten Trennung, ist die Fokussierung im Bereich von neutralen und 
alkalischen  pI´s  bei  Weitem  noch  nicht  optimal.  Dies  ist  durch  die  allgemein  schlechtere  Fokussierung  von  neutralen  Peptiden  zu 
erklären,  da  aliphatische  Peptide  ohne  polare  Seitenketten  im  pH-Intervall  zwischen  2,4  und  9,6  keine  Nettoladung  aufweisen. 
Vorgeschlagene Strategien zur Verbesserung der Trennleistung sind durch die verwendeten Zusätze wie Sorbit oder Methylcellulose 
leider nicht mit der nLC kompatibel.  
 
Der letzte Teil dieser Arbeit befasst sich mit der Etablierung einer automatisierten Methode zur Identifizierung und Charakterisierung von 
Phosphopeptiden. Die Analyse von phosphorylierten Aminosäuren gestaltet sich trotz ständiger instrumenteller Verbesserungen immer 
noch  als  schwierig.  Dies  liegt  vor  allem  daran,  dass  in  der  Regel  nur  ein  geringer  Prozentsatz  eines  potentiellen  Phosphoproteins 
tatsächlich phosphoryliert vorliegt und zudem noch reversibel modifiziert ist. 
Die Identifizierung und Charakterisierung von Phosphopeptiden wird meistens mittels ESI-MS durchgeführt. Der Grund dafür sind unter 
anderem die fortgeschrittenen Fragmentierungstechniken, wie z.B. der Einsatz der Elektronentransferdissoziation (ETD). Des Weiteren 
ermöglicht die direkte Kopplung mit der HPLC eine schnelle Identifizierung von komplexen Proteingemischen. MALDI hingegen wird 
meistens nur für manuelle Messungen von nicht komplexen Proben verwendet. Die üblicherweise für Phosphopeptidanalysen verwendete 
MALDI-Matrix DHB weist eine  geringe Analytensensivität und eine inhomogene  Kristallisation auf. Dies macht  eine  automatische 
Messung nahezu unmöglich. 
Zuerst musste eine für die Phosphopeptidanalysen besser geeignete Matrix gefunden werden. Dazu wurden vier verschiedene Matrizes (4-
Chlor-α-cyano-zimtsäure  [ClCCA],  4-Hydroxy-α-cyano-zimtsäure  [CHCA],  2,5-Dihydroxybenzoesäure  [DHB]  und  Di-2,4-Difluor-α-
cyano-zimtsäure [diFCCA]), sowie Mischungen daraus getestet. Die besten Ergebnisse wurden durch Verwendung eines 3:1-Gemisches 
aus diFCCA und CHCA mit 3 mM NH4H2PO4-Lösung erzielt. Neben der Optimierung der Matrix und Probenpräparation wurde eine 
Anreicherung  und  Trennung  der  Phosphopeptide  mittels  einer  2-phasigen  Vorsäule  (TiO2/C18)  erzielt.  Bei    pH  <  4  bleiben  die 
Phosphopeptide auf dem TiO2 Material und die nicht phosphorylierten Peptide auf dem C18 Material haften. Danach konnten die nicht 
phosphorylierten Peptide mit einem steigenden ACN/0,1 % TFA-Gradient getrennt werden, während die phosphorylierten Peptide auf die 
TiO2-material  haften  blieben.  Durch  Änderung  des  pH-Wertes  mittels  Ammoniumhydrogencarbonat  (pH  10)  wurden  die 
Phosphospeptide in den C18-Teil der Vorsäule eluiert und konnten dann mit einem weiteren LC-Lauf aufgetrennt werden. Mit dieser 
Methode können Phosphopeptide einer Probe separat von den nicht phosphorylierten Peptiden analysiert werden. Dies bewirkt bei der 
anschließenden  massenspektrometrischen  Detektion  eine  deutlich  einfachere  Identifizierung  der  Peptide.  Der  Vorteil  ist,  dass  die 
Reproduzierbarkeit durch die Automatisierung steigt und die Vorsäule mehrmals verwendet werden kann. Die Methode wurde erfolgreich 
sowohl mit Standardphosphoproteinen, als auch mit ENL-Proteinkomplexen validiert.  
 
Abschließend  lässt  sich  sagen,  dass  die  massenspektrometrische  Identifikation  und  Charakterisierung  von  PTMs  immer  noch  eine 
außerordentlich  schwierige  Aufgabe  darstellt,  da  das  standardmäßige  Erreichen  von  100  %  Sequenzabdeckung  bis  jetzt  noch  nicht 
möglich ist. 
Diese Arbeit zeigt, dass durch Verwendung der nLC auch in Kombination mit anderen Trennverfahren, eine erheblichen Verbesserung 
der Identifizierung der Identifizierung von Proteine mittels MALDI-TOF/TOF erreicht werden konnte..    
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Supplementary table 1A (S1A) 
Gradient 1 Proteins identified with their Protein accession number and number of peptides using gradient 1. 
Protein  hit  Protein  Protein  accession  protein description  peptides 
1  P00924  Enolase 1  36 
2  P00925  Enolase 2  24 
3  P01317  Insulin  23 
4  P00698  Lysozyme C  16 
5  P02666  Beta-casein  14 
6  P02662  Alpha-S1-casein  14 
7  P00711  Alpha-lactalbumin 2  12 
8  P02789  Ovotransferrin  15 
9  P00692  Alpha-amylase  16 
10  P68082  Myoglobin  8 
11  P02768  Serum albumin  9 
12  P02769  Serum albumin  11 
13  P01012  Ovalbumin  9 
14  P68871  Hemoglobin subunit beta  5 
15  P00921  Carbonic anhydrase 2  5 
16  P00004  Cytochrome c  3 
17  P61823  Ribonuclease pancreatic  4 
18  P02754  Beta-lactoglobulin  2 





Supplementary table 1B (S1B) 
Gradient 2 Proteins identified with their Protein accession number and number of peptides using gradient 2. 
Protein hit number  Protein  accession number   protein description  peptides 
1  P00924  Enolase 1  76 
2  P00925  Enolase  52 
3  P01317  Insulin  29 
4  P00711  Alpha-lactalbumin  21 
5  P02666  Beta-casein  33 
6  P02789  Ovotransferrin  37 
7  P02662  Alpha-S1-casein  23 
8  P02769  Serum albumin  28 
9  P00692  Alpha-amylase 1  34 
10  P00698  Lysozyme C  22 
11  P68082  Myoglobin  14 
12  P02768  Serum albumin  24 
13  P00921  Carbonic anhydrase 2  20 
14  P02787  Serotransferrin  23 
15  P02754  Beta-lactoglobulin  14 
16  P01012  Ovalbumin  16 
17  P61823  Ribonuclease pancreatic  8 
18  P68871  Hemoglobin subunit beta  11 





Supplementary table 1C (S1C) 
Gradient 3 Proteins identified with their Protein accession number and number of peptides using gradient 3. 
protein_hit_number  Protein  accession  protein description  peptides 
1  P00924  Enolase 1  88 
2  P00925  Enolase 2  62 
3  P02789  Ovotransferrin  63 
4  P01317  Insulin  41 
5  P00711  Alpha-lactalbumin  25 
6  P00692  Alpha-amylase  53 
7  P02666  Beta-casein  36 
8  P02769  Serum albumin  42 
9  P02662  Alpha-S1-casein  36 
10  P02787  Serotransferrin  40 
11  P00698  Lysozyme C  36 
12  P01012  Ovalbumin  36 
13  P00921  Carbonic anhydrase 2  32 
14  P02768  Serum albumin  41 
15  P68082  Myoglobin  20 
16  P02754  Beta-lactoglobulin  17 
17  P61823  Ribonuclease pancreatic SV=1  10 
18  P00004  Cytochrome c  11 
19  P68871  Hemoglobin subunit beta  13 
20  P02588  Troponin C  5 




Supplementary table 2 (S2) Summary, showing the identified proteins, protein hit number, Protein accession number r and number of 
peptides assigned to each protein from YPD (A) and YPO (B) with their respective Protein accession number  number.  





protein description  peptides 
1  YML008C  reverse complement, Verified ORF, ~~Delta(24)-sterol C-
methyltransferase, converts zymosterol to fecosterol in the ergosterol 
biosynthetic pathway by methylating position C-24; localized to both lip 
37 
2  YIL124W  Verified ORF, ~~NADPH-dependent 1-acyl dihydroxyacetone phosphate 
reductase found in lipid particles, ER, and mitochondrial outer membrane; 
involved in phosphatidic acid biosynthesis; required for spo 
15 
3  YOR317W  Verified ORF, ~~Long chain fatty acyl-CoA synthetase with a preference 
for C12:0-C16:0 fatty acids; involved in the activation of imported fatty 
acids; localized to both lipid particles and mitochondr 
20 
4  YBR041W  Verified ORF, ~~Fatty acid transporter and very long-chain fatty acyl-CoA 
synthetase, may form a complex with Faa1p or Faa4p that imports and 
activates exogenous fatty acids~~ 
13 
5  YKR046C  complement, Verified ORF, ~~Protein of unknown function that co-
purifies with lipid particles; expression pattern suggests a role in 
respiratory growth; computational analysis of large-scale  
12 
6  YMR246W  Verified ORF, ~~Long chain fatty acyl-CoA synthetase, regulates protein 
modification during growth in the presence of ethanol, functions to 
incorporate palmitic acid into phospholipids and neutral l 
13 
7  YKL140W  Verified ORF, ~~Steryl ester hydrolase, one of three gene products 
(Yeh1p, Yeh2p, Tgl1p) responsible for steryl ester hydrolase activity and 
involved in sterol homeostasis; localized to lipid particle 
12  
 
8  YBR177C  reverse complement, Verified ORF, ~~Acyl-coenzymeA:ethanol O-
acyltransferase that plays a minor role in medium-chain fatty acid ethyl 
ester biosynthesis; possesses short-chain esterase activity; local 
19 
9  YPL206C  reverse complement, Verified ORF, ~~Phosphatidyl Glycerol 
phospholipase C; regulates the phosphatidylglycerol (PG) content via a 
phospholipase C-type degradation mechanism; contains glycerophosphodie 
9 
10  YJL034W  Verified ORF, ~~ATPase involved in protein import into the ER, also acts 
as a chaperone to mediate protein folding in the ER and may play a role in 
ER export of soluble proteins; regulates the unfolded 
9 
11  YLR100W  Verified ORF, ~~3-keto sterol reductase, catalyzes the last of three steps 
required to remove two C-4 methyl groups from an intermediate in 
ergosterol biosynthesis; mutants are sterol auxotrophs~~ 
9 
12  YCL043C  , reverse complement, Verified ORF, ~~Protein disulfide isomerase, 
multifunctional protein resident in the endoplasmic reticulum lumen, 
essential for the formation of disulfide bonds in secretory and cel 
6 
13  YLR378C  reverse complement, Verified ORF, ~~Essential subunit of Sec61 complex 
(Sec61p, Sbh1p, and Sss1p); forms a channel for SRP-dependent protein 
import and retrograde transport of misfolded proteins out 
5 
14  YMR110C  reverse complement, Verified ORF, ~~Putative fatty aldehyde 
dehydrogenase, located in the mitochondrial outer membrane and also in 
lipid particles; has similarity to human fatty aldehyde dehydrogena 
7 
15  YKR067W  Verified ORF, ~~Glycerol-3-phosphate/dihydroxyacetone phosphate dual 
substrate-specific sn-1 acyltransferase located in lipid particles and the ER; 
involved in the stepwise acylation of glycerol-3-pho 
12 
16  YDR304C  reverse complement, Verified ORF, ~~Peptidyl-prolyl cis-trans isomerase 
(cyclophilin) of the endoplasmic reticulum, catalyzes the cis-trans 
isomerization of peptide bonds N-terminal to proline resid 
7 
17  YDL193W  Verified ORF, ~~Putative prenyltransferase, required for cell viability; 
proposed to be involved in protein trafficking because tet-repressible 
mutant shows accumulation of hypoglycosylated forms of C 
9 
18  YML001W   Verified ORF, ~~GTPase; GTP-binding protein of the rab family; required 
for homotypic fusion event in vacuole inheritance, for endosome-endosome 
fusion, similar to mammalian Rab7~~ 
4  
 
19  YMR148W  Uncharacterized ORF, ~~Putative protein of unknown function; predicted 
to contain a transmembrane domain; YMR148W is not an essential gene~~ 
2 
20  YPR165W  Verified ORF, ~~GTP-binding protein of the rho subfamily of Ras-like 
proteins, involved in establishment of cell polarity; regulates protein kinase 
C (Pkc1p) and the cell wall synthesizing enzyme 1,3 
4 
21  YOR081C  Treverse complement, Verified ORF, ~~Triacylglycerol lipase involved in 
TAG mobilization; localizes to lipid particles; potential Cdc28p 
substrate~~ 
5 
22  YPR139C  reverse complement, Verified ORF, ~~Cytoplasmic protein of unknown 
function involved in vacuolar protein sorting.~~ 
6 
23  YOR254C  reverse complement, Verified ORF, ~~Essential subunit of Sec63 complex 
(Sec63p, Sec62p, Sec66p and Sec72p); with Sec61 complex, Kar2p/BiP 
and Lhs1p forms a channel competent for SRP-dependent and pos 
4 
24  YHR072W  Verified ORF, ~~Lanosterol synthase, an essential enzyme that catalyzes 
the cyclization of squalene 2,3-epoxide, a step in ergosterol biosynthesis~~ 
7 
25  YML013W  Verified ORF, ~~Protein involved in ER-associated protein degradation; 
proposed to coordinate the assembly of proteins involved in ERAD; 
contains a UBX (ubiquitin regulatory X) domain and a ubiquiti 
5 
26  YMR313C  reverse complement, Verified ORF, ~~Triacylglycerol lipase of the lipid 
particle, responsible for all the TAG lipase activity of the lipid particle; 
contains the consensus sequence motif GXSXG, whic 
4 
27  YIL009W  Verified ORF, ~~Long chain fatty acyl-CoA synthetase, has a preference 
for C16 and C18 fatty acids; green fluorescent protein (GFP)-fusion protein 
localizes to the cell periphery~~ 
3 
28  YAL023C  reverse complement, Verified ORF, ~~Protein O-mannosyltransferase, 
transfers mannose residues from dolichyl phosphate-D-mannose to protein 
serine/threonine residues; acts in a complex with Pmt1p, can i 
3 
29  YKR089C  reverse complement, Verified ORF, ~~Triacylglycerol lipase involved in 
triacylglycerol mobilization and degradation; found in lipid particles; 
phosphorylated and activated by Cdc28p; required with Tgl 
3 
30  YDL052C  reverse complement, Verified ORF, ~~1-acyl-sn-gylcerol-3-phosphate 
acyltransferase, catalyzes the acylation of lysophosphatidic acid to form 
phosphatidic acid, a key intermediate in lipid metabolism;  
2  
 
31  YPR183W  Verified ORF, ~~Dolichol phosphate mannose (Dol-P-Man) synthase of 
the ER membrane, catalyzes the formation of Dol-P-Man from Dol-P and 
GDP-Man; required for glycosyl phosphatidylinositol membrane an 
2 
32  YKL094W  Verified ORF, ~~Serine hydrolase with sequence similarity to 
monoglyceride lipase (MGL), localizes to lipid particles~~ 
3 
33  YML128C  reverse complement, Verified ORF, ~~Protein of unknown function; 
mutant is defective in directing meiotic recombination events to 
homologous chromatids; the authentic, non-tagged protein is detected i 
2 
34  YIR038C  reverse complement, Verified ORF, ~~ER associated glutathione S-
transferase capable of homodimerization; expression induced during the 
diauxic shift and throughout stationary phase; functional overlap 
2 
35  YDL204W  Verified ORF, ~~Protein of unknown function; has similarity to 
mammalian reticulon proteins; member of the RTNLA (reticulon-like A) 
subfamily~~ 
3 
36  YGR175C  reverse complement, Verified ORF, ~~Squalene epoxidase, catalyzes the 
epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the 
ergosterol-biosynthesis pathway and is the specific  
5 
37  YKL212W  Verified ORF, ~~Phosphatidylinositol phosphate (PtdInsP) phosphatase 
involved in hydrolysis of PtdIns[4]P; transmembrane protein localizes to 
ER and Golgi; involved in protein trafficking and processing 
1 
38  YCR017C  reverse complement, Verified ORF, ~~Putative sensor/transporter protein 
involved in cell wall biogenesis; contains 14-16 transmembrane segments 
and several putative glycosylation and phosphorylation 
2 
39  YBR196C-B  Yreverse complement, Uncharacterized ORF, ~~Putative protein of 
unknown function; identified by expression profiling and mass 
spectrometry~~ 
1 
40  YDL095W  Verified ORF, ~~Protein O-mannosyltransferase, transfers mannose 
residues from dolichyl phosphate-D-mannose to protein serine/threonine 
residues; acts in a complex with Pmt2p, can instead interact wit 
2 
41  YNL231C  reverse complement, Verified ORF, ~~Phosphatidylinositol transfer protein 
(PITP) controlled by the multiple drug resistance regulator Pdr1p, localizes 
to lipid particles and microsomes, controls lev 
5 
42  YGL228W  Verified ORF, ~~Putative glycosylphosphatidylinositol (GPI)-anchored  4  
 
protein of unknown function; overexpression causes growth arrest~~ 
43  YNL219C  reverse complement, Verified ORF, ~~Mannosyltransferase, involved in 
N-linked glycosylation; catalyzes the transfer of mannose from Dol-P-Man 
to lipid-linked oligosaccharides; mutation of the human o 
2 
44  YOR085W  Verified ORF, ~~Gamma subunit of the oligosaccharyltransferase complex 
of the ER lumen, which catalyzes asparagine-linked glycosylation of newly 
synthesized proteins; Ost3p is important for N-glycosyl 
1 
45  YFL038C  reverse complement, Verified ORF, ~~Ras-like small GTPase, involved in 
the ER-to-Golgi step of the secretory pathway; complex formation with the 
Rab escort protein Mrs6p is required for prenylation of Y 
1 
46  YFL005W  Verified ORF, ~Secretory vesicle-associated Rab GTPase essential for 
exocytosis; associates with the exocyst component Sec15p and may 
regulate polarized delivery of transport vesicles to the exocyst at the 
1 
47  YDR411C  reverse complement, Verified ORF, ~~ER localized derlin-like family 
member involved in ER stress and homeostasis; not involved in ERAD or 
substrate retrotranslocation; interacts with CDC48; contains 
2 
48  YOL048C  reverse complement, Uncharacterized ORF, ~~Putative protein of 
unknown function~~ 
4 
49  YDR086C  reverse complement, Verified ORF, ~~Subunit of the Sec61p translocation 
complex (Sec61p-Sss1p-Sbh1p) that forms a channel for passage of 
secretory proteins through the endoplasmic reticulum membrane,  
1 
50  YKR094C  reverse complement, Verified ORF, ~~Fusion protein, identical to 
Rpl40Ap, that is cleaved to yield ubiquitin and a ribosomal protein of the 
large (60S) ribosomal subunit with similarit 
1 
51  YDL212W  Verified ORF, ~~Endoplasmic reticulum packaging chaperone, required 
for incorporation of amino acid permeases into COPII coated vesicles for 
transport to the cell surface~~ 
1 
52  YER031C  reverse complement, Verified ORF, ~~GTPase of the Ypt/Rab family, very 
similar to Ypt32p; involved in the exocytic pathway; mediates intra-Golgi 
traffic or the budding of post-Golgi vesicles from the  
1 
53  YDR196C  reverse complement, Uncharacterized ORF, ~~Putative dephospho-CoA 
kinase (DPCK) that catalyzes the final step in Coenzyme A biosynthesis; 
essential for viability; the authentic, non-tagged protein  
1  
 
54  YOR175C  reverse complement, Verified ORF, ~~Lysophospholipid acyltransferase, 
partially redundant with Slc1p; part of MBOAT family of membrane-
bound O-acyltransferases; key component of Lands cycle; may have  
1 
55  YOR246C  reverse complement, Uncharacterized ORF, ~~Protein with similarity to 
oxidoreductases, found in lipid particles; required for replication of Brome 
mosaic virus in S. cerevisiae, which is a model sy 
1 
56  YNL302C  reverse complement, Verified ORF, ~~Protein component of the small 
(40S) ribosomal subunit, required for assembly and maturation of pre-40 S 
particles; mutations in human RPS19 are associ 
2 
57  YGR038C-B  reverse complement, transposable_element_gene, ~~Retrotransposon TYA 
Gag and TYB Pol genes; transcribed/translated as one unit; polyprotein is 
processed to make a nucleocapsid-like 
2 
58  YPR114W  Uncharacterized ORF, ~~Putative protein of unknown function~~  1 
59  YBR265W   Verified ORF, ~~3-ketosphinganine reductase, catalyzes the second step 
in phytosphingosine synthesis, essential for growth in the absence of 
exogenous dihydrosphingosine or phytosphingosine, member o 
2 
60  YJL002C  reverse complement, Verified ORF, ~~Alpha subunit of the 
oligosaccharyltransferase complex of the ER lumen, which catalyzes 
asparagine-linked glycosylation of newly synthesized proteins~~ 
1 
61  YDR233C  reverse complement, Verified ORF, ~~ER membrane protein that interacts 
with exocyst subunit Sec6p and with Yip3p; also interacts with Sbh1p; null 
mutant has an altered (mostly cisternal) ER morphology 
1 
62  YDL015C  reverse complement, Verified ORF, ~~Enoyl reductase that catalyzes the 
last step in each cycle of very long chain fatty acid elongation, localizes to 
the ER, highly enriched in a structure marking nu 
1 
63  YLR292C  reverse complement, Verified ORF, ~~Non-essential subunit of Sec63 
complex (Sec63p, Sec62p, Sec66p and Sec72p); with Sec61 complex, 
Kar2p/BiP and Lhs1p forms a channel competent for SRP-dependent an 
1 
64  YAL047C  reverse complement, Verified ORF, ~Component of the cytoplasmic 
Tub4p (gamma-tubulin) complex, binds spindle pole bodies and links them 
to microtubules; has roles in astral microtubule formation and stabiliz 
1 
65  YGR027C   reverse complement, Verified ORF, ~~Protein component of the small 
(40S) ribosomal subunit; nearly identical to Rps25Bp and has similarity to 
1  
 
rat S25 ribosomal protein~~ 
66  YNL059C   reverse complement, Verified ORF, ~~Nuclear actin-related protein 
involved in chromatin remodeling, component of chromatin-remodeling 
enzyme complexes~~ 
1 
67  YEL002C  WBP1 SGDID:S000000728, Chr V from 150013-148721, reverse 
complement, Verified ORF, ~~Beta subunit of the oligosaccharyl 
transferase (OST) glycoprotein complex; required for N-linked 
glycosylation of proteins in the endoplasmic reticulum~~ 
3 
68  YDR294C  reverse complement, Verified ORF, ~~Dihydrosphingosine phosphate 
lyase, regulates intracellular levels of sphingolipid long-chain base 
phosphates (LCBPs), degrades phosphorylated long chain bases, p 
2 
69  YDL075W   Verified ORF, ~~Protein component of the large (60S) ribosomal subunit, 
nearly identical to Rpl31Bp and has similarity to rat L31 ribosomal protein; 
associates with the karyopherin Sxm 
1 
70  YPR147C  reverse complement, Uncharacterized ORF, ~~Putative protein of 
unknown function; green fluorescent protein (GFP)-fusion protein localizes 
to the cytoplasm and is induced in response to the DNA-dam 
1 
71  YDR519W  Verified ORF, ~~Membrane-bound peptidyl-prolyl cis-trans isomerase 
(PPIase), binds to the drugs FK506 and rapamycin; expression pattern 
suggests possible involvement in ER protein trafficking~~ 
1 
72  YBR283C  reverse complement, Verified ORF, ~~Subunit of the Ssh1 translocon 
complex; Sec61p homolog involved in co-translational pathway of protein 
translocation; not essential~~ 
1 
73  YML048W  Verified ORF, ~~ER localized integral membrane protein that may 
promote secretion of certain hexose transporters, including Gal2p; involved 
in glucose-dependent repression~~ 
1 
74  YBR204C  reverse complement, Uncharacterized ORF, ~~Serine hydrolase; 
YBR204C is not an essential gene~~ 
1 
75  YOR270C  reverse complement, Verified ORF, ~~Subunit a of vacuolar-ATPase V0 
domain, one of two isoforms (Vph1p and Stv1p); Vph1p is located in V-
ATPase complexes of the vacuole while Stv1p is located in V-ATP 
1 
76  YGL103W  RPL28 SGDID:S000003071, Chr VII from 310970-311018,311530-
311930, Verified ORF, ~~Ribosomal protein of the large (60S) ribosomal 
1  
 
subunit, has similarity to E. coli L15 and rat L27a ribosomal proteins; may 
have peptidyl transferase activity; can mutat 
77  YML029W  Verified ORF, ~~Protein involved in ER-associated protein degradation 
(ERAD); component of the Hrd1p complex; interacts with the U1 snRNP-
specific protein, Snp1p~~ 
1 
78  YPL095C  reverse complement, Verified ORF, ~~Acyl-coenzymeA:ethanol O-
acyltransferase responsible for the major part of medium-chain fatty acid 
ethyl ester biosynthesis during fermentation; possesses short-ch 
1 
79  YIL043C  reverse complement, Verified ORF, ~~Microsomal cytochrome b 
reductase, not essential for viability; also detected in mitochondria; 
mutation in conserved NADH binding domain of the human ortholog resul 
1 
80  YHR190W  Verified ORF, ~~Farnesyl-diphosphate farnesyl transferase (squalene 
synthase), joins two farnesyl pyrophosphate moieties to form squalene in 
the sterol biosynthesis pathway~~ 
1 
81  YLR065C  reverse complement, Uncharacterized ORF, ~~Putative protein of 
unknown function; YLR065C is not an essential gene~~ 
1 
82  YDR307W  Uncharacterized ORF, ~~Putative protein of unknown function~~  1 
83  YDR518W  Verified ORF, ~~Protein disulfide isomerase of the endoplasmic reticulum 
lumen, function overlaps with that of Pdi1p; may interact with nascent 
polypeptides in the ER~~ 
1 
84  YBR106W  Verified ORF, ~~Probable membrane protein, involved in phosphate 
transport; pho88 pho86 double null mutant exhibits enhanced synthesis of 
repressible acid phosphatase at high inorganic phosphate conc 
1 
85  YMR152W  Verified ORF, ~~Protein of unknown function; null mutant displays 
sensitivity to DNA damaging agents; the authentic, non-tagged protein is 
detected in highly purified mitochondria in high-throughput 
1 
86  YML101C  reverse complement, Verified ORF, ~~Protein of unknown function; has a 
CUE domain that binds ubiquitin, which may facilitate intramolecular 
monoubiquitination~~ 
1 
87  YFR037C  , reverse complement, Verified ORF, ~Component of the RSC chromatin 
remodeling complex; essential for viability and mitotic growth; homolog of 
SWI/SNF subunit Swi3p, but unlike Swi3p, does not activate trans 
1 
88  YHR098C  reverse complement, Verified ORF, ~Member of the Sec24p family; forms  1  
 
a complex, with Sec23p, that is involved in sorting of Pma1p into COPII 
vesicles; peripheral ER membrane protein; potential Cdc28p su 
89  YPR063C  reverse complement, Uncharacterized ORF, ~~ER-localized protein of 
unknown function~~ 
1 
90  YGR130C  reverse complement, Uncharacterized ORF, ~~Putative protein of 
unknown function; green fluorescent protein (GFP)-fusion protein localizes 
to the cytoplasm; specifically phosphorylated in vitro by  
1 
91  YHR042W  Verified ORF, ~~NADP-cytochrome P450 reductase; involved in 
ergosterol biosynthesis; associated and coordinately regulated with 
Erg11p~~ 
1 
92  YGL200C  reverse complement, Verified ORF, ~~Integral membrane component of 
endoplasmic reticulum-derived COPII-coated vesicles, which function in 
ER to Golgi transport~~ 
1 
93  YOR089C  reverse complement, Verified ORF, ~~GTPase required for transport 
during endocytosis and for correct sorting of vacuolar hydrolases; localized 
in endocytic intermediates; detected in mitochondria; ge 
1 
94  YOR216C  reverse complement, Verified ORF, ~Golgi matrix protein involved in the 
structural organization of the cis-Golgi; interacts genetically with COG3 
and USO1~ 
1 
95  YDL102W  PVerified ORF, ~Catalytic subunit of DNA polymerase delta; required for 
chromosomal DNA replication during mitosis and meiosis, intragenic 
recombination, repair of double strand DNA breaks, and DNA replicat 
1 
96  YPL094C  reverse complement, Verified ORF, ~~Essential subunit of Sec63 complex 
(Sec63p, Sec62p, Sec66p and Sec72p); with Sec61 complex, Kar2p/BiP 
and Lhs1p forms a channel competent for SRP-dependent and po 
1 
97  YFR031C  reverse complement, Verified ORF, ~~Subunit of the condensin complex; 
essential SMC chromosomal ATPase family member that forms a complex 
with Smc4p to form the active ATPase; Smc2p/Smc4p complex bind 
1 
98  YJL117W  Verified ORF, ~~Endoplasmic reticulum (ER) resident protein required for 
ER exit of the high-affinity phosphate transporter Pho84p, specifically 
required for packaging of Pho84p into COPII vesicles~~ 
1 
99  YBR171W  Verified ORF, ~~Non-essential subunit of Sec63 complex (Sec63p, 
Sec62p, Sec66p and Sec72p); with Sec61 complex, Kar2p/BiP and Lhs1p 
1  
 
forms a channel competent for SRP-dependent and post-translational  
100  YLR020C  reverse complement, Verified ORF, ~~Steryl ester hydrolase, catalyzes 
steryl ester hydrolysis at the plasma membrane; involved in sterol 
metabolism~~ 
1 
101  YOR165W  Verified ORF, ~~Protein of unknown function, contains two predicted 
GTP-binding motifs GXXXXGKS and DXXG near the N-terminus, 
homolog of the Arabidopsis gene RHD3 (Root Hair Defective)~~ 
1 
102  YGR270W  Verified ORF, ~Protein that localizes to chromatin and has a role in 
regulation of histone gene expression; has a bromodomain-like region that 
interacts with the N-terminal tail of histone H3, and an AT 
1 
103  YAL004W  Dubious ORF, ~~Dubious open reading frame unlikely to encode a protein, 
based on available experimental and comparative sequence data; 
completely overlaps verified gene SSA1/YAL005C~~ 
1 
104  YIL046W  Verified ORF, ~F-box protein containing five copies of the WD40 motif, 
controls cell cycle function, sulfur metabolism, and methionine 
biosynthesis as part of the ubiquitin ligase complex; interacts with  
1 
105  YDR537C  reverse complement, Dubious ORF, ~Dubious open reading frame unlikely 
to encode a protein, almost completely overlaps verified ORF 
PAD1/YDR538W~ 
1 
106  YIL004C  reverse complement, Verified ORF, ~~Type II membrane protein required 
for vesicular transport between the endoplasmic reticulum and Golgi 
complex; v-SNARE with similarity to synaptobrevi 
1 
107  YHR079C  reverse complement, Verified ORF, ~Serine-threonine kinase and 
endoribonuclease; transmembrane protein that mediates the unfolded 
protein response (UPR) by regulating Hac1p synthesis through HAC1 
mRNA sp 
1 
108  YNL139C  reverse complement, Verified ORF, ~Subunit of the THO complex, which 
is required for efficient transcription elongation and involved in 
transcriptional elongation-associated recombination; required for La 
1 
109  YMR243C  reverse complement, Verified ORF, ~~Vacuolar membrane zinc 
transporter, transports zinc from the cytosol into the vacuole for storage; 
also has a role in resistance to zinc shock resulting from a su 
1 
110  YPR080W  Verified ORF, ~~Translational elongation factor EF-1 alpha; also encoded  1  
 
by TEF2; functions in the binding reaction of aminoacyl-tRNA (AA-
tRNA) to ribosomes~~ 
111  Q0250  Verified ORF, ~Subunit II of cytochrome c oxidase, which is the terminal 
member of the mitochondrial inner membrane electron transport chain; one 
of three mitochondrially-encoded subunits~ 
1 
112  YPR010C  reverse complement, Verified ORF, ~~RNA polymerase I subunit A135~~  1 
113  YGL116W  Verified ORF, ~Cell-cycle regulated activator of anaphase-promoting 
complex/cyclosome (APC/C), which is required for metaphase/anaphase 
transition; directs ubiquitination of mitotic cyclins, Pds1p, and o 
1 
114  YIL126W  Verified ORF, ~ATPase component of the RSC chromatin remodeling 
complex; required for expression of early meiotic genes; essential helicase-
related protein homologous to Snf2p~ 
1 
115  YLR206W  Verified ORF, ~Epsin-like protein required for endocytosis and actin patch 
assembly and functionally redundant with Ent1p; contains clathrin-binding 
motif at C-terminus~ 
1 
116  YDL161W  Verified ORF, ~Epsin-like protein involved in endocytosis and actin patch 
assembly and functionally redundant with Ent2p; binds clathrin via a 
clathrin-binding domain motif at C-terminus~ 
1 
117  YIR002C  reverse complement, Verified ORF, ~Member of the DEAH family of 
helicases, functions in an error-free DNA damage bypass pathway that 
involves homologous recombination, binds to flap DNA and stimulates acti 
1 
118  YIL117C  reverse complement, Verified ORF, ~Pheromone-regulated protein, 
predicted to have 1 transmembrane segment; induced during cell integrity 
signaling~ 
1 
119  YHL037C  reverse complement, Dubious ORF, ~~Dubious open reading frame 
unlikely to encode a functional protein, based on available experimental 
and comparative sequence data~~ 
1 
121  YDR481C  reverse complement, Verified ORF, ~~Repressible alkaline phosphatase, a 
glycoprotein localized to the vacuole; regulated by levels of inorganic 
phosphate and by a system consisting of Pho4p, Pho9p,  
1 
122  YBR079C  reverse complement, Verified ORF, ~Subunit of the core complex of 
translation initiation factor 3(eIF3), essential for translation; part of a 
subcomplex (Prt1p-Rpg1p-Nip1p) that stimulates binding of mRNA  
1  
 
123  YGL022W  Verified ORF, ~~Subunit of the oligosaccharyltransferase complex of the 
ER lumen, which catalyzes asparagine-linked glycosylation of newly 




    
 






Protein description  peptides 
1  YML008C  reverse complement, Verified ORF, ~~Delta(24)-sterol C-methyltransferase, 
converts zymosterol to fecosterol in the ergosterol biosynthetic pathway by 
methylating position C-24; localized to both lip 
30 
2  YKR046C  reverse complement, Verified ORF, ~~Protein of unknown function that co-purifies 
with lipid particles; expression pattern suggests a role in respiratory growth; 
computational analysis of large-scale  
24 
3  YMR110C  reverse complement, Verified ORF, ~~Putative fatty aldehyde dehydrogenase, 
located in the mitochondrial outer membrane and also in lipid particles; has 
similarity to human fatty aldehyde dehydrogena 
18 
4  YKL140W  Verified ORF, ~~Steryl ester hydrolase, one of three gene products (Yeh1p, Yeh2p, 
Tgl1p) responsible for steryl ester hydrolase activity and involved in sterol 
homeostasis; localized to lipid particle 
14 
5  YBR177C  reverse complement, Verified ORF, ~~Acyl-coenzymeA:ethanol O-acyltransferase 
that plays a minor role in medium-chain fatty acid ethyl ester biosynthesis; 
possesses short-chain esterase activity; local 
18 
6  YOR317W  Verified ORF, ~~Long chain fatty acyl-CoA synthetase with a preference for 
C12:0-C16:0 fatty acids; involved in the activation of imported fatty acids; 
localized to both lipid particles and mitochondr 
15 
7  YIL124W  Verified ORF, ~~NADPH-dependent 1-acyl dihydroxyacetone phosphate reductase 
found in lipid particles, ER, and mitochondrial outer membrane; involved in 
phosphatidic acid biosynthesis; required for spo 
12 
8  YGR175C  reverse complement, Verified ORF, ~~Squalene epoxidase, catalyzes the 
epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the 
ergosterol-biosynthesis pathway and is the specific  
15 
9  YNL208W  Verified ORF, ~~Protein of unknown function; may interact with ribosomes, based 
on co-purification experiments; authentic, non-tagged protein is detected in purified 
mitochondria in high-throughpu 
3  
 
10  YJR121W  Verified ORF, ~~Beta subunit of the F1 sector of mitochondrial F1F0 ATP 
synthase, which is a large, evolutionarily conserved enzyme complex required for 
ATP synthesis; phosphorylated~~ 
9 
11  YNL231C  reverse complement, Verified ORF, ~~Phosphatidylinositol transfer protein (PITP) 
controlled by the multiple drug resistance regulator Pdr1p, localizes to lipid 
particles and microsomes, controls lev 
9 
12  YIR038C  reverse complement, Verified ORF, ~~ER associated glutathione S-transferase 
capable of homodimerization; expression induced during the diauxic shift and 
throughout stationary phase; functional overlap 
8 
13  YFL014W  Verified ORF, ~~Plasma membrane localized protein that protects membranes 
from desiccation; induced by heat shock, oxidative stress, osmostress, stationary 
phase entry, glucose depletion, oleate and  
6 
14  YOL109W  Verified ORF, ~~Peripheral membrane protein of the plasma membrane that 
interacts with Mid2p; regulates the cell integrity pathway mediated by Pkc1p and 
Slt2p; the authentic protein is detected in a p 
9 
15  YMR246W  Verified ORF, ~~Long chain fatty acyl-CoA synthetase, regulates protein 
modification during growth in the presence of ethanol, functions to incorporate 
palmitic acid into phospholipids and neutral l 
6 
16  YLR100W  Verified ORF, ~~3-keto sterol reductase, catalyzes the last of three steps required 
to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; 
mutants are sterol auxotrophs~~ 
4 
17  YCL043C  reverse complement, Verified ORF, ~~Protein disulfide isomerase, multifunctional 
protein resident in the endoplasmic reticulum lumen, essential for the formation of 
disulfide bonds in secretory and cel 
7 
18  YPR080W  Verified ORF, ~~Translational elongation factor EF-1 alpha; also encoded by 
TEF2; functions in the binding reaction of aminoacyl-tRNA (AA-tRNA) to 
ribosomes~~ 
5 
19  YHL001W  Verified ORF, ~~Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl14Ap and has similarity to rat L14 ribosomal protein~~ 
1 
20  YER004W  Verified ORF, ~~Protein of unknown function, localized to the mitochondrial outer 
membrane; induced by treatment with 8-methoxypsoralen and UVA irradiation~~ 
4 
21  YBR041W  Verified ORF, ~~Fatty acid transporter and very long-chain fatty acyl-CoA 
synthetase, may form a complex with Faa1p or Faa4p that imports and activates 
9  
 
exogenous fatty acids~~ 
22  YBR204C  reverse complement, Uncharacterized ORF, ~~Serine hydrolase; YBR204C is not 
an essential gene~~ 
3 
23  YNL178W  Verified ORF, ~~Protein component of the small (40S) ribosomal subunit, has 
apurinic/apyrimidinic (AP) endonuclease activity; essential for viability; has 
similarity to E. coli S3 and rat S3 ribosoma 
5 
24  YLR167W  Verified ORF, ~~Fusion protein that is cleaved to yield a ribosomal protein of the 
small (40S) subunit and ubiquitin; ubiquitin may facilitate assembly of the 
ribosomal protein into ribosomes; inter 
4 
25  YDL193W  Verified ORF, ~~Putative prenyltransferase, required for cell viability; proposed to 
be involved in protein trafficking because tet-repressible mutant shows 
accumulation of hypoglycosylated forms of C 
4 
26  YGR192C  reverse complement, Verified ORF, ~~Glyceraldehyde-3-phosphate 
dehydrogenase, isozyme 3, involved in glycolysis and gluconeogenesis; tetramer 
that catalyzes the reaction of glyceraldehyde-3-phosphate 
5 
27  YMR148W  Uncharacterized ORF, ~~Putative protein of unknown function; predicted to 
contain a transmembrane domain; YMR148W is not an essential gene~~ 
1 
28  YPL145C  reverse complement, Verified ORF, ~~Member of the oxysterol binding protein 
family, which includes seven yeast homologs; involved in negative regulation of 
Sec14p-dependent Golgi complex secretory fu 
5 
29  YDL052C  reverse complement, Verified ORF, ~~1-acyl-sn-gylcerol-3-phosphate 
acyltransferase, catalyzes the acylation of lysophosphatidic acid to form 
phosphatidic acid, a key intermediate in lipid metabolism;  
3 
30  YDR304C  reverse complement, Verified ORF, ~~Peptidyl-prolyl cis-trans isomerase 
(cyclophilin) of the endoplasmic reticulum, catalyzes the cis-trans isomerization of 
peptide bonds N-terminal to proline resid 
3 
31  YMR313C  reverse complement, Verified ORF, ~~Triacylglycerol lipase of the lipid particle, 
responsible for all the TAG lipase activity of the lipid particle; contains the 
consensus sequence motif GXSXG, whic 
5 
32  YKR089C  reverse complement, Verified ORF, ~~Triacylglycerol lipase involved in 
triacylglycerol mobilization and degradation; found in lipid particles; 
phosphorylated and activated by Cdc28p; required with Tgl 
4 
33  YJL052W  Verified ORF, ~~Glyceraldehyde-3-phosphate dehydrogenase, isozyme 1, involved  4  
 
in glycolysis and gluconeogenesis; tetramer that catalyzes the reaction of 
glyceraldehyde-3-phosphate to 1,3 bis-phosphogly 
34  YMR152W  Verified ORF, ~~Protein of unknown function; null mutant displays sensitivity to 
DNA damaging agents; the authentic, non-tagged protein is detected in highly 
purified mitochondria in high-throughput 
4 
35  YML073C  reverse complement, Verified ORF, ~~N-terminally acetylated protein component 
of the large (60S) ribosomal subunit, has similarity to Rpl6Bp and to rat L6 
ribosomal protein; binds to  
1 
36  YML013W  Verified ORF, ~~Protein involved in ER-associated protein degradation; proposed 
to coordinate the assembly of proteins involved in ERAD; contains a UBX 
(ubiquitin regulatory X) domain and a ubiquiti 
3 
37  YLR378C  reverse complement, Verified ORF, ~~Essential subunit of Sec61 complex 
(Sec61p, Sbh1p, and Sss1p); forms a channel for SRP-dependent protein import 
and retrograde transport of misfolded proteins out 
1 
38  YBL002W  Verified ORF, ~~Histone H2B, core histone protein required for chromatin 
assembly and chromosome function; nearly identical to HTB1; Rad6p-Bre1p-
Lge1p mediated ubiquitination regulates transcriptional 
1 
39  YGL008C  reverse complement, Verified ORF, ~~Plasma membrane H+-ATPase, pumps 
protons out of the cell; major regulator of cytoplasmic pH and plasma membrane 
potential; part of the P2 subgroup of cation-transp 
3 
40  YER065C  reverse complement, Verified ORF, ~~Isocitrate lyase, catalyzes the formation of 
succinate and glyoxylate from isocitrate, a key reaction of the glyoxylate cycle; 
expression of ICL1 is induced by growt 
1 
41  YPR139C  reverse complement, Verified ORF, ~~Cytoplasmic protein of unknown function 
involved in vacuolar protein sorting.~~ 
4 
42  YOL086C  reverse complement, Verified ORF, ~~Alcohol dehydrogenase, fermentative 
isozyme active as homo- or heterotetramers; required for the reduction of 
acetaldehyde to ethanol, the last step in the glycolyt 
2 
43  YKL094W  Verified ORF, ~~Serine hydrolase with sequence similarity to monoglyceride 
lipase (MGL), localizes to lipid particles~~ 
2 
44  YOR245C  reverse complement, Verified ORF, ~~Diacylglycerol acyltransferase, catalyzes the 
terminal step of triacylglycerol (TAG) formation, acylates diacylglycerol using 
acyl-CoA as an acyl donor, localized t 
3  
 
45  YMR173W  Verified ORF, ~~DNA damage-responsive protein, expression is increased in 
response to heat-shock stress or treatments that produce DNA lesions; contains 
multiple repeats of the amino acid sequence  
1 
46  YAL005C  reverse complement, Verified ORF, ~~ATPase involved in protein folding and 
nuclear localization signal (NLS)-directed nuclear transport; member of heat shock 
protein 70 (HSP70) family; forms a chaperon 
2 
47  YGL205W  Verified ORF, ~~Fatty-acyl coenzyme A oxidase, involved in the fatty acid beta-
oxidation pathway; localized to the peroxisomal matrix~~ 
3 
48  YEL060C  reverse complement, Verified ORF, ~~Vacuolar proteinase B (yscB), a serine 
protease of the subtilisin family; involved in protein degradation in the vacuole and 
required for full protein degradation  
1 
49  YHR174W  Verified ORF, ~~Enolase II, a phosphopyruvate hydratase that catalyzes the 
conversion of 2-phosphoglycerate to phosphoenolpyruvate during glycolysis and 
the reverse reaction during gluconeogenesis;  
2 
50  YNL202W  Verified ORF, ~~Peroxisomal 2,4-dienoyl-CoA reductase, auxiliary enzyme of 
fatty acid beta-oxidation; homodimeric enzyme required for growth and sporulation 
on petroselineate medium; expression indu 
1 
51  YPL206C  reverse complement, Verified ORF, ~~Phosphatidyl Glycerol phospholipase C; 
regulates the phosphatidylglycerol (PG) content via a phospholipase C-type 
degradation mechanism; contains glycerophosphodie 
1 
52  YIL041W  Verified ORF, ~~BAR domain-containing protein that localizes to both early and 
late Golgi vesicles; required for adaptation to varying nutrient concentrations, 
fluid-phase endocytosis, polarization  
3 
53  YML063W  Verified ORF, ~~Ribosomal protein 10 (rp10) of the small (40S) subunit; nearly 
identical to Rps1Ap and has similarity to rat S3a ribosomal protein~~ 
2 
54  YLR075W  Verified ORF, ~~Protein component of the large (60S) ribosomal subunit, 
responsible for joining the 40S and 60S subunits; regulates translation initiation; 
has similarity to rat L10 ribosomal protein 
2 
55  YNL055C  reverse complement, Verified ORF, ~~Mitochondrial porin (voltage-dependent 
anion channel), outer membrane protein required for the maintenance of 
mitochondrial osmotic stability and mitochondrial membrane 
2 
56  YDR537C  reverse complement, Dubious ORF, ~~Dubious open reading frame unlikely to 
encode a protein, almost completely overlaps verified ORF PAD1/YDR538W~~ 
1  
 
57  YER031C  reverse complement, Verified ORF, ~~GTPase of the Ypt/Rab family, very similar 
to Ypt32p; involved in the exocytic pathway; mediates intra-Golgi traffic or the 
budding of post-Golgi vesicles  
1 
58  YPL095C   reverse complement, Verified ORF, ~Acyl-coenzymeA:ethanol O-acyltransferase 
responsible for the major part of medium-chain fatty acid ethyl ester biosynthesis 
during fermentation; possesses short-chain  
1 
59  YPR183W  Verified ORF, ~~Dolichol phosphate mannose (Dol-P-Man) synthase of the ER 
membrane, catalyzes the formation of Dol-P-Man from Dol-P and GDP-Man; 
required for glycosyl phosphatidylinositol membrane  
1 
60  YLR044C  reverse complement, Verified ORF, ~~Major of three pyruvate decarboxylase 
isozymes, key enzyme in alcoholic fermentation, decarboxylates pyruvate to 
acetaldehyde; subject to glucose-, ethanol 
1 
61  YBL015W  Verified ORF, ~~Acetyl-coA hydrolase, primarily localized to mitochondria; 
phosphorylated; required for acetate utilization and for diploid pseudohyphal 
growth~~ 
2 
62  YKL103C  reverse complement, Verified ORF, ~~Vacuolar aminopeptidase yscI; zinc 
metalloproteinase that belongs to the peptidase family M18; often used as a marker 
protein in studies of autophagy and cytosol to 
3 
63  YDL082W  Verified ORF, ~~Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl13Bp; not essential for viability; has similarity to rat L13 ribosomal 
protein~~ 
1 
64  YPL131W  Verified ORF, ~~Protein component of the large (60S) ribosomal subunit with 
similarity to E. coli L18 and rat L5 ribosomal proteins; binds 5S rRNA and is 
required for 60S subunit assembly~~ 
3 
65  YML128C  reverse complement, Verified ORF, ~~Protein of unknown function; mutant is 
defective in directing meiotic recombination events to homologous chromatids; the 
authentic, non-tagged protein is detected i 
1 
66  YFL037W  Verified ORF, ~~Beta-tubulin; associates with alpha-tubulin (Tub1p and Tub3p) to 
form tubulin dimer, which polymerizes to form microtubules~~ 
2 
67  YDR519W  Verified ORF, ~~Membrane-bound peptidyl-prolyl cis-trans isomerase (PPIase), 
binds to the drugs FK506 and rapamycin; expression pattern suggests possible 
involvement in ER protein trafficking~~ 
1 
68  YFL038C  reverse complement, Verified ORF, ~~Ras-like small GTPase, involved in the ER- 1  
 
to-Golgi step of the secretory pathway; complex formation with the Rab escort 
protein Mrs6p is required for prenylation of Y 
69  YFL005W  Verified ORF, ~Secretory vesicle-associated Rab GTPase essential for exocytosis; 
associates with the exocyst component Sec15p and may regulate polarized delivery 
of transport vesicles to the exocyst at the 
1 
70  YBL027W  Verified ORF, ~~Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl19Ap and has similarity to rat L19 ribosomal protein; rpl19a and 
rpl19b single null mutat 
1 
71  YJR019C  reverse complement, Verified ORF, ~~Peroxisomal acyl-CoA thioesterase likely to 
be involved in fatty acid oxidation rather than fatty acid synthesis; conserved 
protein also found in human peroxisomes;  
1 
72  YNL059C  reverse complement, Verified ORF, ~~Nuclear actin-related protein involved in 
chromatin remodeling, component of chromatin-remodeling enzyme complexes~~ 
1 
73  YOR081C  reverse complement, Verified ORF, ~~Triacylglycerol lipase involved in TAG 
mobilization; localizes to lipid particles; potential Cdc28p substrate~~ 
3 
74  YEL039C  reverse complement, Verified ORF, ~~Cytochrome c isoform 2, expressed under 
hypoxic conditions; electron carrier of the mitochondrial intermembrane space that 
transfers electrons from ubiquinone-cytochro 
1 
75  YNL134C  reverse complement, Uncharacterized ORF, ~~Putative protein of unknown 
function with similarity to dehydrogenases from other model organisms; green 
fluorescent protein (GFP)-fusion protein localiz 
2 
76  YDR196C  reverse complement, Uncharacterized ORF, ~~Putative dephospho-CoA kinase 
(DPCK) that catalyzes the final step in Coenzyme A biosynthesis; essential for 
viability; the authentic, non-tagged protein  
1 
77  YFR014C  reverse complement, Verified ORF, ~Calmodulin-dependent protein kinase; may 
play a role in stress response, many CA++/calmodulan dependent phosphorylation 




reverse complement, Uncharacterized ORF, ~~Putative protein of unknown 
function; identified by expression profiling and mass spectrometry~~ 
1 
79  YKL085W  Verified ORF, ~~Mitochondrial malate dehydrogenase, catalyzes interconversion 
of malate and oxaloacetate; involved in the tricarboxylic acid (TCA) cycle; 
phosphorylated~~ 
1 
80  YJL082W  Verified ORF, ~~Protein of unknown function; the authentic, non-tagged protein is  1  
 
detected in highly purified mitochondria in high-throughput studies~~ 
81  YBL099W  Verified ORF, ~~Alpha subunit of the F1 sector of mitochondrial F1F0 ATP 
synthase, which is a large, evolutionarily conserved enzyme complex required for 
ATP synthesis; phosphorylated~~ 
1 
82  YHR072W  Verified ORF, ~~Lanosterol synthase, an essential enzyme that catalyzes the 
cyclization of squalene 2,3-epoxide, a step in ergosterol biosynthesis~~ 
2 
83  YML001W  Verified ORF, ~~GTPase; GTP-binding protein of the rab family; required for 
homotypic fusion event in vacuole inheritance, for endosome-endosome fusion, 
similar to mammalian Rab7~~ 
2 
84  Q0050  Verified ORF, ~Reverse transcriptase required for splicing of the COX1 pre-
mRNA, encoded by a mobile group II intron within the mitochondrial COX1 gene~ 
1 
85  YJL034W  Verified ORF, ~~ATPase involved in protein import into the ER, also acts as a 
chaperone to mediate protein folding in the ER and may play a role in ER export of 
soluble proteins; regulates the unfolded 
1 
86  YGR130C  reverse complement, Uncharacterized ORF, ~Putative protein of unknown 
function; green fluorescent protein (GFP)-fusion protein localizes to the cytoplasm; 
specifically phosphorylated in vitro by mammal 
1 
87  YGR270W  Verified ORF, ~Protein that localizes to chromatin and has a role in regulation of 
histone gene expression; has a bromodomain-like region that interacts with the N-
terminal tail of histone H3, and an AT 
1 
88  YJR104C  reverse complement, Verified ORF, ~~Cytosolic superoxide dismutase; some 
mutations are analogous to those that cause ALS (amyotrophic lateral sclerosis) in 
humans~~ 
1 
89  YOL048C  reverse complement, Uncharacterized ORF, ~~Putative protein of unknown 
function~~ 
2 
90  YIL126W  Verified ORF, ~ATPase component of the RSC chromatin remodeling complex; 
required for expression of early meiotic genes; essential helicase-related protein 
homologous to Snf2p~ 
1 
91  YLR340W  Verified ORF, ~~Conserved ribosomal protein P0 similar to rat P0, human P0, and 
E. coli L10e; shown to be phosphorylated on serine 302~~ 
1 
92  Q0250  Verified ORF, ~Subunit II of cytochrome c oxidase, which is the terminal member 




93  YLR206W  Verified ORF, ~Epsin-like protein required for endocytosis and actin patch 
assembly and functionally redundant with Ent1p; contains clathrin-binding motif at 
C-terminus~ 
1 
94  YKR067W  Verified ORF, ~~Glycerol-3-phosphate/dihydroxyacetone phosphate dual 
substrate-specific sn-1 acyltransferase located in lipid particles and the ER; 
involved in the stepwise acylation of glycerol-3-pho 
1 
95  YFL010C  reverse complement, Verified ORF, ~~WW domain containing protein of unknown 
function; binds to Mca1p, a caspase-related protease that regulates H2O2-induced 
apoptosis; overexpression causes Gi phase g 
1 
96  YAL004W  Dubious ORF, ~Dubious open reading frame unlikely to encode a protein, based on 
available experimental and comparative sequence data; completely overlaps 
verified gene SSA1/YAL005C~ 
1 
97  YGR027C  reverse complement, Verified ORF, ~~Protein component of the small (40S) 
ribosomal subunit; nearly identical to Rps25Bp and has similarity to rat S25 
ribosomal protein~~ 
1 
98  YPL154C  reverse complement, Verified ORF, ~~Vacuolar aspartyl protease (proteinase A), 
required for the posttranslational precursor maturation of vacuolar proteinases; 
important for protein turnover after ox 
1 
99  YLR029C   reverse complement, Verified ORF, ~~Protein component of the large (60S) 
ribosomal subunit, nearly identical to Rpl15Bp and has similarity to rat L15 
ribosomal protein; binds to 5.8 S rRNA~~ 
1 
100  YDR171W  Verified ORF, ~~Small heat shock protein (sHSP) with chaperone activity; forms 
barrel-shaped oligomers that suppress unfolded protein aggregation; involved in 
cytoskeleton reorganization after heat s 
1 
101  YER002W  Verified ORF, ~Constituent of 66S pre-ribosomal particles, involved in 60S 
ribosomal subunit biogenesis~ 
1 
102  YOR207C  reverse complement, Verified ORF, ~~Second-largest subunit of RNA polymerase 
III, which is responsible for the transcription of tRNA and 5S RNA genes, and 
other low molecular weight RNAs~~ 
1 
103  YGR263C  reverse complement, Verified ORF, ~~Sterol deacetylase; component of the sterol 
acetylation/deacetylation cycle along with Atf2p; integral membrane protein with 
active site in the ER lumen; green f 
1 
104  YDL091C  reverse complement, Verified ORF, ~~UBX (ubiquitin regulatory X) domain- 1  
 
containing protein that interacts with Cdc48p, green fluorescent protein (GFP)-
fusion protein localizes to the cytoplasm in a pu 
105  YGL121C  reverse complement, Verified ORF, ~~Proposed gamma subunit of the 
heterotrimeric G protein that interacts with the receptor Gpr1p; involved in 
regulation of pseudohyphal growth; requires Gpb1p or Gpb 
1 
106  YGL116W  Verified ORF, ~~Cell-cycle regulated activator of anaphase-promoting 
complex/cyclosome (APC/C), which is required for metaphase/anaphase transition; 
directs ubiquitination of mitotic cyclins, Pds1p, 
1 
107  YLR295C  reverse complement, Verified ORF, ~~Subunit h of the F0 sector of mitochondrial 
F1F0 ATP synthase, which is a large, evolutionarily conserved enzyme complex 
required for ATP synthesis~~ 
1 
108  YOR216C  reverse complement, Verified ORF, ~~Golgi matrix protein involved in the 
structural organization of the cis-Golgi; interacts genetically with COG3 and 
USO1~~ 
1 
109  YOR246C  reverse complement, Uncharacterized ORF, ~~Protein with similarity to 
oxidoreductases, found in lipid particles; required for replication of Brome mosaic 
virus in S. cerevisiae, which is a model sy 
1 
110  YOL127W  Verified ORF, ~~Primary rRNA-binding ribosomal protein component of the large 
(60S) ribosomal subunit, has similarity to E. coli L23 and rat L23a ribosomal 
proteins; binds to 26S rRNA via a 
1 
111  YBL003C  reverse complement, Verified ORF, ~~Histone H2A, core histone protein required 
for chromatin assembly and chromosome function; one of two nearly identical (see 
also HTA1) subtypes; DNA damage-dependen 
1 
112  YAR035W  Verified ORF, ~Outer mitochondrial carnitine acetyltransferase, minor ethanol-
inducible enzyme involved in transport of activated acyl groups from the cytoplasm 
into the mitochondrial matrix; phosphorylated 
1 
113  YNL007C  reverse complement, Verified ORF, ~~Type II HSP40 co-chaperone that interacts 
with the HSP70 protein Ssa1p; not functionally redundant with Ydj1p due to due to 
substrate specificity; shares similarit 
1 
114  YBR265W  Verified ORF, ~~3-ketosphinganine reductase, catalyzes the second step in 
phytosphingosine synthesis, essential for growth in the absence of exogenous 
dihydrosphingosine or phytosphingosine, member o 
1 
115  YDL015C  reverse complement, Verified ORF, ~~Enoyl reductase that catalyzes the last step  1  
 
in each cycle of very long chain fatty acid elongation, localizes to the ER, highly 
enriched in a structure marking nu 
116  YGL082W  Uncharacterized ORF, ~~Putative protein of unknown function; predicted 
prenylation/proteolysis target of Afc1p and Rce1p; green fluorescent protein 
(GFP)-fusion protein localizes to the cytoplasm  
1 
117  YML029W  Verified ORF, ~~Protein involved in ER-associated protein degradation (ERAD); 
component of the Hrd1p complex; interacts with the U1 snRNP-specific protein, 
Snp1p~~ 
1 
118  YGL195W  Verified ORF, ~~Positive regulator of the Gcn2p kinase activity, forms a complex 
with Gcn20p; proposed to stimulate Gcn2p activation by an uncharged tRNA~~ 
1 
119  YMR032W  Verified ORF, ~Bud neck-localized, SH3 domain-containing protein required for 
cytokinesis; regulates actomyosin ring dynamics and septin localization; interacts 
with the formins, Bni1p and Bnr1p, and wit 
1 
120  YDL231C  reverse complement, Verified ORF, ~Zinc finger protein containing five 
transmembrane domains; null mutant exhibits strongly fragmented vacuoles and 
sensitivity to brefeldin A, a drug which is known to affect 
1 
121  YOL117W  Verified ORF, ~~Subunit of the COP9 signalosome (CSN) complex that cleaves 
the ubiquitin-like protein Nedd8 from SCF ubiquitin ligases; plays a role in the 
mating pheromone response~~ 
1 
122  YJL200C  reverse complement, Verified ORF, ~~Putative mitochondrial aconitase isozyme; 
similarity to Aco1p, an aconitase required for the TCA cycle; expression induced 
during growth on glucose, by amino acid star 
1 
123  YLR430W  Verified ORF, ~~Presumed helicase required for RNA polymerase II transcription 
termination and processing of RNAs; homolog of Senataxin which causes Ataxia-
Oculomotor Apraxia 2 and a dominant form o 
1 
124  YML028W  Verified ORF, ~~Thioredoxin peroxidase, acts as both a ribosome-associated and 
free cytoplasmic antioxidant; self-associates to form a high-molecular weight 
chaperone complex under oxidative stress; 
1 
125  YER131W  Verified ORF, ~~Protein component of the small (40S) ribosomal subunit; nearly 
identical to Rps26Ap and has similarity to rat S26 ribosomal protein~~ 
1 
126  YHL037C  reverse complement, Dubious ORF, ~~Dubious open reading frame unlikely to 




127  YOR059C  reverse complement, Uncharacterized ORF, ~~Hypothetical protein~~  1 
128  YGL076C  reverse complement, Verified ORF, ~~Protein component of the large (60S) 
ribosomal subunit, nearly identical to Rpl7Bp and has similarity to E. coli L30 and 
rat L7 riboso 
1 
130  YDR050C  reverse complement, Verified ORF, ~~Triose phosphate isomerase, abundant 
glycolytic enzyme; mRNA half-life is regulated by iron availability; transcription is 
controlled by activators Reb1p, Gcr1p, an 
1 
132  YLR192C  reverse complement, Verified ORF, ~Dual function protein involved in translation 
initiation as a substoichiometric component of eukaryotic translation initiation 
factor 3 (eIF3) and required for processin 
1 
    
 
Supplementary table 2 C (S2 C) Proteome of yeast LP. 
§novel LP protein, found  on glucose as well on oleate grown cells, 
¥ numbers 
indicate  fragments  used  for  identification  of  proteins  from  cells  grown  on  glucose  (D)  or  oleate  (O).  C..cytosol;M..mitochondria; 
PM..plasma  membrane;  ER..endoplasmic  reticulum;  LP..lipid  particle;  End..endosomes;  G..golgi;  Mic..microsomes;  V..vacuole; 
Px..peroxisome;  N..nucleus;  nEnv..nuclear  envelope;  ext..extrinsic  to  membrane;  mem..integral  to  membrane;  bud..cellular  bud; 
rib..ribosomal subunit; CW..cell wall; R..ribosome; Retro..retrotransposon; mTub..microtubule 
Gene name  Systematic 
name 




¥  Localisation 
(SGD) 
Protein description 
ACH1  YBL015W       ￿    2  C / M  CoA transferase activity 
ADH1  YOL086C    ￿    2  C / PM  Alcohol dehydrogenase 
ALG9  YNL219C    ￿  2    ER  Mannosyltransferase 
ATF1  YOR377W      ￿        LP / End  Alcohol acyltransferase 
ATP2  YJR121W        9  M  Subunit of mitochondria ATP synthase 
AYR1  YIL124W      ￿                    ￿  ￿  15  12  C / ER / LP / M  NADPH-dependent 1-acyl dihydroxyacetone 
phosphate reductase 
BSC2  YDR275W      ￿         ￿                   ￿        LP  Unknown 
COY1  YKL179C                  ￿                   ￿        G  Golgi membrane protein 
CPR5
§  YDR304C    ￿  7  3  C / ER  Peptidyl-prolyl cis-trans isomerase 
CSR1  YLR380W      ￿        LP / C / M / Mic  Phosphatidylinositol transfer protein 
CST26  YBR042C  ￿         ￿        ￿       ￿        LP  Required for incorporation of stearic acid 
into phosphatidylinostiol 
CWH43  YCR017C    ￿  2    PM  Putative sensor/transporter protein 
DFM1  YDR411C    ￿  2    ER  ER localized derlin-like family member 
DGA1   YOR245C      ￿  ￿    3  LP  Diacylglycerol acyltransferase 
DPL1  YDR294C    ￿  2    ER  Dihydrosphingosine phosphate lyase 
DPM1  YPR183W    ￿  2    ER / M  Dolichol phosphate mannose synthase 
EHT1  YBR177C  ￿                   ￿       ￿  ￿  19  18  LP / M  Acyl-coenzymeA:ethanol O-acyltransferase 
ENO2  YHR174W    ￿    2  V / PM / M  Enolase II  
 
ERG1  YGR175C  ￿                   ￿       ￿  ￿  5  15  ER / LP  Squalene epoxidase 
ERG6  YML008C  ￿         ￿        ￿       ￿  ￿  37  30  ER / LP / M  Delta(24)-sterol C-methyltransferase 
ERG7  YHR072W  ￿         ￿        ￿       ￿  ￿  7  2  ER /LP / PM  Lanosterol synthase 
ERG27  YLR100W              ￿        ￿       ￿  ￿  9  4  ER / M  3-Keto sterol reductase 
FAA1  YOR317W      ￿  ￿  20  15  LP / PM / M  Long chain fatty acyl-CoA synthetase 
FAA3  YIL009W    ￿  3    unknown  Long chain fatty acyl-CoA synthetase 
FAA4  YMR246W  ￿         ￿        ￿       ￿  ￿  13  6  LP / C  Long chain fatty acyl-CoA synthetase  
FAT1  YBR041W  ￿         ￿        ￿       ￿  ￿  13  9  PM / LP / Mic / 
PX 
Fatty acid transporter 
FMP52  YER004W    ￿    4  ER / M  Unknown 
GPT2   YKR067W    ￿  12    C / ER  sn-1 Acyltransferase 
GTT1
§  YIR038C    ￿  2  8  ER / M / PM  glutathione S-transferase 
GVP36  YIL041W    ￿    3  C / G  BAR domain-containing protein 
HFD1  YMR110C      ￿         ￿                   ￿  ￿  7  18  M / LP / End  Putative fatty aldehyde dehydrogenase 
HSP12  YFL014W    ￿    6  C / PM / N  Heat shock protein 
KAR2  YJL034W    ￿  9    ER  ATPase 
LAP4  YKL103C    ￿    3  V  Vacuolar aminopeptidase 
LDB16  YCL005W      ￿         ￿                   ￿        LP / M  Unknown 
MSC1  YML128C    ￿  2    M / ER / PM  Unknown 
NUS1  YDL193W      ￿                    ￿  ￿  9  4  ER / LP /nEnv  Putative prenyltransferase 
OSH4
§  YPL145C      3  5  C / G / ext  Oxysterol binding protein 
OSW5  YMR148W                  ￿                   ￿  ￿  2    mem  Unknown 
PDI1  YCL043C    ￿  6  7  ER  Disulfide isomerase 
PDR16  YNL231C      ￿         ￿                   ￿  ￿  5  9  LP / Mic / PM / 
C 
Phosphatidylinositol transfer protein 
PET10  YKR046C  ￿         ￿        ￿       ￿  ￿  12  24  LP  Unknown 
PGC1  YPL206C      ￿  ￿  9    LP / M  Phosphatidylglycerol phospholipase C 
PIL1  YGR086C      ￿        C / M / PM   Primary component of eisosomes 
PMA1  YGL008C    ￿    3  PM / M / mem  Plasma membrane H+-ATPase 
PMT1  YDL095W    ￿  2    ER  Protein O-mannosyltransferase 
PMT2  YAL023C    ￿  3    ER  Protein O-mannosyltransferase 
POR1  YNL055C    ￿    2  M  Mitochondrial porin 
  
 
POX1  YGL205W    ￿    3  PX  Fatty-acyl coenzyme A oxidase 
RHO1  YPR165W    ￿  4    mem / PX / PM 
/ M / bud 
GTP-binding protein 
RPL5  YPL131W    ￿    3  rib  Protein component of the large (60S) 
ribosomal subunit 
RPL10  YLR075W    ￿    2  rib  Protein component of the large (60S) 
ribosomal subunit 
RPS1B  YML063W    ￿    2  rib  Ribosomal protein 10 (rp10) of the small 
(40S) subunit 
RPS3  YNL178W    ￿    5  rib  Protein component of the small (40S) 
ribosomal subunit 
RPS19B  YNL302C    ￿  2    rib  Protein component of the small (40S) 
ribosomal subunit 
RPS31  YLR167W    ￿    4  rib / C  Fusion protein that is cleaved to yield a 
ribosomal protein of the small (40S) subunit 
and ubiquitin 
RRT8  YOL048C      ￿         ￿                   ￿  ￿  4  2  LP  Unknown 
RTN2  YDL204W    ￿  3    ER / nEnv  Unknown 
SEC61  YLR378C    ￿  5    ER  Essential subunit of Sec61 complex 
SEC63  YOR254C    ￿  4    ER / M  Essential subunit of Sec63 complex 
SHE10  YGL228W    ￿  4    unknown  Putative glycosylphosphatidylinositol (GPI)-
anchored protein of unknown function 
SLC1  YDL052C  ￿                   ￿        ￿  ￿  2  3  LP  1-Acyl-sn-glycerol-3-phosphate 
acyltransferase 
SNA2  YDR525W-a      ￿         ￿                  ￿        Mem / C  Unknown 
SNX41  YDR425W  ￿                              ￿        End  Sorting nexin 
SRT1  YMR101C      ￿        LP  Cis-prenyltransferase 
SSA1  YAL005C    ￿    2  C / PM / N  ATPase  
SSO1  YPL232W                  ￿                   ￿        PM  Plasma membrane t-snare 














TEF1  YPR080W        5  M / R  Translational elongation factor EF-1 alpha 
TGL1  YKL140W      ￿                              ￿  ￿  12  14  LP / mem  Steryl ester hydrolase 
TGL3  YMR313C      ￿         ￿                  ￿  ￿  4  5  LP  Triacylglycerol lipase  
TGL4  YKR089C      ￿         ￿                  ￿  ￿  3  4  LP  Triacylglycerol lipase  
TGL5  YOR081C      ￿         ￿                  ￿  ￿  5  3  LP  Triacylglycerol lipase  
USE1  YGL098W                  ￿                   ￿        ER  SNARE protein 
TSC10  YBR265W    ￿  2    C / ER / M  3-ketosphinganine reductase 
TUB2  YFL037W    ￿    2  mTub  Beta-tubulin 
UBX2
§  YML013W    ￿  5  3  ER / M  Protein involved in ER-associated protein 
degradation 
VPS66
§  YPR139C    ￿  6  4  C  Cytoplasmic protein of unknown function 
involved in vacuolar protein sorting 
WBP1  YEL002C    ￿  3    ER / nEnv  Beta subunit of the oligosaccharyl transferase 
(OST) glycoprotein complex 
YBR204C  YBR204C    ￿    3  unknown  Serine hydrolase 
YDR018C  YDR018C                             ￿         unknown  Similarity to acyltransferase 
YEH1  YLL012W      ￿         ￿                  ￿        LP / mem  Steryl ester hydrolase 
YIM1  YMR152W      ￿                   ￿          ￿    4  LP / C / M  Unknown 
YGR038C-
B 
YGR038C-B    ￿  2    Retro  Retrotransposon TYA Gag and TYB Pol 
genes 
YJU3  YKL094W  ￿                   ￿        ￿  ￿  3  2  LP / C / M / PM   Serine hydrolase  
YNL134C   YNL134C     ￿    2  C / N  Unknown 
YNL208W   YNL208W     ￿    3  M / R  Unknown 
YOR059C  YOR059C      ￿        LP  Unknown 
YOR246C  YOR246C  ￿                   ￿        ￿        LP  Similarity to oxidoreductase 
YPT7
§  YML001W    ￿  4  2  V / M  GTPase 
ZEO1  YOL109W    ￿    9  M / PM / ext   Peripheral membrane protein 
 
      
 






Protein descrition  peptides 
1  CO1A2  Collagen alpha-2(I) chain   31 
2  CO1A1  Collagen alpha-1(I) chain   20 
3  CO3A1  Collagen alpha-1(III) chain   23 
4  FINC  Fibronectin   26 
5  SPRC  SPARC   9 
6  CO6A1  Collagen alpha-1(VI) chain   11 
7  VIME  Vimentin   8 
8  ACTB  Actin, cytoplasmic 1   6 
9  PRDX6  Peroxiredoxin-6   3 
10  CO4A2  Collagen alpha-2(IV) chain   6 
11  FABP4  Fatty acid-binding protein, adipocyte   3 
12  ACTC  Actin, alpha cardiac muscle 1   4 
13  FSTL1  Follistatin-related protein 1   4 
14  ALDOA  Fructose-bisphosphate aldolase A   4 
15  PEDF  Pigment epithelium-derived factor   4 
16  HSPB6  Heat shock protein beta-6   1 
17  ACBP  Acyl-CoA-binding protein   3 
18  CO5A2  Collagen alpha-2(V) chain   3 
19  FAS  Fatty acid synthase   5 
20  GRP78  78 kDa glucose-regulated protein   4 
21  CO4A1  Collagen alpha-1(IV) chain   3 
22  LEG1  Galectin-1   3 
23  CFAD  Complement factor D   3 
24  FABP5  Fatty acid-binding protein, epidermal   2  
 
25  IBP5  Insulin-like growth factor-binding protein 5   2 
26  MMP2  72 kDa type IV collagenase   2 
27  ALDOC  Fructose-bisphosphate aldolase C   1 
28  SERPH  Serpin H1   1 
29  TIMP1  Metalloproteinase inhibitor 1   3 
30  TBA1B  Tubulin alpha-1B chain   2 
31  PGS2  Decorin   1 
32  HSP7C  Heat shock cognate 71 kDa protein   3 
33  G3P  Glyceraldehyde-3-phosphate dehydrogenase   1 
34  IBP4  Insulin-like growth factor-binding protein 4   3 
35  TKT  Transketolase   1 
36  RTN4  Reticulon-4   1 
37  HSPB1  Heat shock protein beta-1   1 
38  GPDA  Glycerol-3-phosphate dehydrogenase [NAD+], 
cytoplasmic  
1 
39  SAP  Proactivator polypeptide   1 
40  PPIA  Peptidyl-prolyl cis-trans isomerase A   1 
41  ENOB  Beta-enolase   1 
42  ENOA  Alpha-enolase   1 
43  CALU  Calumenin   1 
44  NID1  Nidogen-1   3 
45  CO6A3  Collagen alpha-3(VI) chain   1 
46  AKA12  A-kinase anchor protein 12   2 
47  PDIA1  Protein disulfide-isomerase   1 
48  FLNA  Filamin-A   3 
49  CO5A3  Collagen alpha-3(V) chain   3 
50  TRFE  Serotransferrin   2 
51  ACTN1  Alpha-actinin-1   2 
52  ACTN4  Alpha-actinin-4   2 
53  TSP1  Thrombospondin-1   2  
 
54  SODM  Superoxide dismutase [Mn], mitochondrial   1 
55  SH3L3  SH3 domain-binding glutamic acid-rich-like protein 3   2 
56  LDHA  L-lactate dehydrogenase A chain   1 
57  CH10  10 kDa heat shock protein, mitochondrial   1 
58  PGK1  Phosphoglycerate kinase 1   2 
59  CYB5  Cytochrome b5   1 
60  LEG3  Galectin-3   1 
61  INS  Insulin   1 
62  ADIPO  Adiponectin   1 
63  6PGD  6-phosphogluconate dehydrogenase, decarboxylating   1 
64  TPIS  Triosephosphate isomerase   1 
65  GSTP1  Glutathione S-transferase P   2 
66  RCN3  Reticulocalbin-3   1 
67  CO5A1  Collagen alpha-1(V) chain   1 
68  PPIB  Peptidyl-prolyl cis-trans isomerase B   1 
69  TCPE  T-complex protein 1 subunit epsilon   1 
70  BASP  Brain acid soluble protein 1   1 
71  MIF  Macrophage migration inhibitory factor   1 
72  IBP3  Insulin-like growth factor-binding protein 3   1 
73  CO6A2  Collagen alpha-2(VI) chain   1 
74  VINC  Vinculin   1 
75  LG3BP  Galectin-3-binding protein   2 
76  EF1A1  Elongation factor 1-alpha 1   2 
77  MRLC2  Myosin regulatory light chain MRLC2   1 
78  MOES  Moesin   1 
79  CO2A1  Collagen alpha-1(II) chain   1 
80  AK1C1  Aldo-keto reductase family 1 member C1   1 
81  IC1  Plasma protease C1 inhibitor   2 
82  YBOX1  Nuclease-sensitive element-binding protein 1   1 
83  FKB1A  Peptidyl-prolyl cis-trans isomerase FKBP1A   1  
 
84  UCHL1  Ubiquitin carboxyl-terminal hydrolase isozyme L1   1 
85  K1881  Protein KIAA1881   3 
86  CTGF  Connective tissue growth factor   1 
87  PGAM1  Phosphoglycerate mutase 1   1 
88  RD23B  UV excision repair protein RAD23 homolog B   1 
89  CYTB  Cystatin-B   1 
90  PDIA3  Protein disulfide-isomerase A3   1 
91  CD44  CD44 antigen   1 
92  ECHM  Enoyl-CoA hydratase, mitochondrial   1 
93  NEDD8  NEDD8   1 
94  TIMP2  Metalloproteinase inhibitor 2   1 
95  ZSC29  Zinc finger and SCAN domain-containing protein 29   1 
98  COF1  Cofilin-1   1 
101  CALR  Calreticulin   1 
 
    
 
Supplementary table 2 E (S2 E) Summary, showing the identified proteins and number of peptides assigned to each protein from Pre-






Protein descrition  peptides 
1  FINC  Fibronectin   54 
2  CO1A2  Collagen alpha-2(I) chain   39 
3  CO1A1  Collagen alpha-1(I) chain   36 
4  BGH3  Transforming growth factor-beta-induced protein ig-h3   14 
5  TSP1  Thrombospondin-1   17 
6  TIMP1  Metalloproteinase inhibitor 1   7 
7  PAI1  Plasminogen activator inhibitor 1   14 
8  MMP2  72 kDa type IV collagenase   7 
9  CO3A1  Collagen alpha-1(III) chain   11 
10  SPRC  SPARC   6 
11  CO6A1  Collagen alpha-1(VI) chain   10 
12  PTX3  Pentraxin-related protein PTX3   7 
13  ACTB  Actin, cytoplasmic 1   8 
14  VIME  Vimentin   3 
15  LOXL2  Lysyl oxidase homolog 2   4 
16  SERPH  Serpin H1   5 
17  POSTN  Periostin   3 
18  POTEE  POTE ankyrin domain family member E   4 
19  GDN  Glia-derived nexin   3 
20  ACTC  Actin, alpha cardiac muscle 1   4 
21  QSOX1  Sulfhydryl oxidase 1   5 
22  CO4A2  Collagen alpha-2(IV) chain   7  
 
23  IBP6  Insulin-like growth factor-binding protein 6   2 
24  LEG1  Galectin-1   2 
25  FBLN3  EGF-containing fibulin-like extracellular matrix 
protein 1  
2 
26  LUM  Lumican   4 
27  ALBU  Serum albumin   2 
28  CALU  Calumenin   3 
29  IBP3  Insulin-like growth factor-binding protein 3   3 
30  ACTN1  Alpha-actinin-1   2 
31  FBN1  Fibrillin-1   3 
32  PGS2  Decorin   2 
33  MOES  Moesin   2 
34  IBP7  Insulin-like growth factor-binding protein 7   4 
35  ENOB  Beta-enolase   1 
36  CO5A2  Collagen alpha-2(V) chain   3 
37  PGBM  Basement membrane-specific heparan sulfate 
proteoglycan core protein  
3 
38  TBA1B  Tubulin alpha-1B chain   2 
39  LYOX  Protein-lysine 6-oxidase   3 
40  TRFL  Lactotransferrin   1 
41  1433F  14-3-3 protein eta   1 
42  LDHA  L-lactate dehydrogenase A chain   2 
43  HSPB1  Heat shock protein beta-1   1 
44  TBB2A  Tubulin beta-2A chain   1 
45  GREM1  Gremlin-1   1 
46  LG3BP  Galectin-3-binding protein   2 
47  FABP4  Fatty acid-binding protein, adipocyte   1 
48  TSP2  Thrombospondin-2   3 
49  PCOC1  Procollagen C-endopeptidase enhancer 1   1 
50  COCA1  Collagen alpha-1(XII) chain   2  
 
51  ACTN2  Alpha-actinin-2   1 
52  ARP3B  Actin-related protein 3B   1 
53  GRP78  78 kDa glucose-regulated protein   2 
54  YBOX1  Nuclease-sensitive element-binding protein   1 
55  FSTL1  Follistatin-related protein 1   2 
56  PROF1  Profilin-1   1 
57  ISLR  Immunoglobulin superfamily containing leucine-rich 
repeat protein  
1 
58  TPIS  Triosephosphate isomerase   1 
59  CO2A1  Collagen alpha-1(II) chain   1 
60  INS  Insulin   1 
61  ALDOA  Fructose-bisphosphate aldolase A   2 
62  CO4A4  Collagen alpha-4(IV) chain   1 
63  C2D1A  Coiled-coil and C2 domain-containing protein 1A   1 
64  IBP4  Insulin-like growth factor-binding protein 4   2 
65  MIF  Macrophage migration inhibitory factor   1 
66  CO6A3  Collagen alpha-3(VI) chain   1 
67  CO5A1  Collagen alpha-1(V) chain   1 
68  PDIA3  Protein disulfide-isomerase A3   1 
69  GDIA  Rab GDP dissociation inhibitor alpha   1 
70  SH3L3  SH3 domain-binding glutamic acid-rich-like protein 3   1 
71  LIPA3  Liprin-alpha-3   1 
72  LDHC  L-lactate dehydrogenase C chain   1 
73  VINC  Vinculin   1 
74  FBLN1  Fibulin-1   2 
75  PXDN  Peroxidasin homolog   1 
76  FLNA  Filamin-A   1 
77  NUCB1  Nucleobindin-1   1 
78  FETUA  Alpha-2-HS-glycoprotein   1 
79  PPIA  Peptidyl-prolyl cis-trans isomerase A   1  
 
80  PPIB  Peptidyl-prolyl cis-trans isomerase B   1 
81  CENPJ  Centromere protein J   1 
82  FSCN2  Fascin-2   1 
83  NEBU  Nebulin   1 
84  CO6A2  Collagen alpha-2(VI) chain   1 
85  HRX  Histone-lysine N-methyltransferase HRX   1 
86  HSP72  Heat shock-related 70 kDa protein 2   1 
87  HSP7C  Heat shock cognate 71 kDa protein SV=1  1 
88  PGK1  Phosphoglycerate kinase 1   1 
89  RNF31  RING finger protein 31   1 
90  K1671  Uncharacterized protein KIAA1671   1 
91  DJC21  DnaJ homolog subfamily C member 21   1 
92  ITSN1  Intersectin-1   1 
 
 
    
 
Supplementary table 2 F (S2 F) Protein comparison between adipocytes and pre-adipocytas. 
overlap  Adipocytes  Pre-adipocytes 
Collagen alpha-2(I) chain   Peroxiredoxin-6   Transforming growth factor-beta-
induced protein ig-h3  
Collagen alpha-1(I) chain   Pigment epithelium-derived factor   Plasminogen activator inhibitor 1  
Collagen alpha-1(III) chain   Heat shock protein beta-6   Pentraxin-related protein PTX3  
Fibronectin   Acyl-CoA-binding protein   Lysyl oxidase homolog 2  
SPARC   Fatty acid synthase   Periostin  
Collagen alpha-1(VI) chain   Collagen alpha-1(IV) chain   POTE ankyrin domain family 
member E  
Vimentin   Complement factor D   Glia-derived nexin  
Actin, cytoplasmic 1   Fatty acid-binding protein, 
epidermal  
Sulfhydryl oxidase 1  
Collagen alpha-2(IV) chain   Insulin-like growth factor-binding 
protein 5  
Insulin-like growth factor-binding 
protein 6  
Fatty acid-binding protein, adipocyte   Fructose-bisphosphate aldolase C   EGF-containing fibulin-like 
extracellular matrix protein 1  
Actin, alpha cardiac muscle 1   Glyceraldehyde-3-phosphate 
dehydrogenase  
Lumican  
Follistatin-related protein 1   Transketolase   Serum albumin  
Fructose-bisphosphate aldolase A   Reticulon-4   Fibrillin-1  
Collagen alpha-2(V) chain   Glycerol-3-phosphate 
dehydrogenase [NAD+], 
cytoplasmic  
Insulin-like growth factor-binding 
protein 7  
78 kDa glucose-regulated protein   Proactivator polypeptide   Basement membrane-specific 
heparan sulfate proteoglycan core 
protein  
Galectin-1   Alpha-enolase   Protein-lysine 6-oxidase  
72 kDa type IV collagenase   Nidogen-1   Lactotransferrin  
Serpin H1   A-kinase anchor protein 12   14-3-3 protein eta OS=Homo sapiens 
GN=YWHAH PE=1 SV=4  
 
Metalloproteinase inhibitor 1   Protein disulfide-isomerase   Tubulin beta-2A chain  
Tubulin alpha-1B chain   Collagen alpha-3(V) chain   Gremlin-1  
Decorin =1  Serotransferrin   Thrombospondin-2  
Heat shock cognate 71 kDa protein   Alpha-actinin-4   Procollagen C-endopeptidase 
enhancer 1  
Insulin-like growth factor-binding protein 4   Superoxide dismutase [Mn], 
mitochondrial  
Collagen alpha-1(XII) chain sapiens  
Heat shock protein beta-1   10 kDa heat shock protein, 
mitochondrial  
Alpha-actinin-2  
Peptidyl-prolyl cis-trans isomerase A   Cytochrome b5   Actin-related protein 3B  
Beta-enolase   Galectin-3   Profilin-1  
Calumenin   Adiponectin   Immunoglobulin superfamily 
containing leucine-rich repeat protein  
Collagen alpha-3(VI) chain   6-phosphogluconate 
dehydrogenase, decarboxylating  
Collagen alpha-4(IV) chain  
Filamin-A   Glutathione S-transferase P   Coiled-coil and C2 domain-
containing protein 1A  
Alpha-actinin-1   Reticulocalbin-3   Rab GDP dissociation inhibitor alpha  
Thrombospondin-1   T-complex protein 1 subunit 
epsilon  
Liprin-alpha-3  
SH3 domain-binding glutamic acid-rich-like 
protein 3  
Brain acid soluble protein 1   L-lactate dehydrogenase C chain  
L-lactate dehydrogenase A chain   Elongation factor 1-alpha 1   Fibulin-1  
Phosphoglycerate kinase 1   Myosin regulatory light chain 
MRLC2  
Peroxidasin homolog  
Insulin   Aldo-keto reductase family 1 
member C1  
Nucleobindin-1  
Triosephosphate isomerase   Plasma protease C1 inhibitor   Alpha-2-HS-glycoprotein  
Collagen alpha-1(V) chain   Peptidyl-prolyl cis-trans 
isomerase FKBP1A  
Centromere protein J  
Peptidyl-prolyl cis-trans isomerase B   Ubiquitin carboxyl-terminal 
hydrolase isozyme L1  
Fascin-2  
Macrophage migration inhibitory factor   Protein KIAA1881   Nebulin   
 
Insulin-like growth factor-binding protein 3   Connective tissue growth factor   Histone-lysine N-methyltransferase 
HRX  
Collagen alpha-2(VI) chain   Phosphoglycerate mutase 1   Heat shock-related 70 kDa protein 2  
Vinculin   UV excision repair protein 
RAD23 homolog B  
RING finger protein 31  
Galectin-3-binding protein   Cystatin-B   Uncharacterized protein KIAA1671  
Moesin   CD44 antigen   DnaJ homolog subfamily C member 
21  
Collagen alpha-1(II) chain   Enoyl-CoA hydratase, 
mitochondrial  
Intersectin-1  
Nuclease-sensitive element-binding protein 1   NEDD8  
Protein disulfide-isomerase A3   Metalloproteinase inhibitor  
  Zinc finger and SCAN domain-containing protein 29  
  Cofilin-1  
  Calreticulin  
  
 
Supplementary table 2 G (S2 G) All identified proteins compared to previous adipokine profiling literature. * indicates all secreted 
proteins which are not identified by previous proteomic adipocyte studies. # indicates all secreted proteins which are only identified by 
rodent proteomic adipocyte studies. 1= have been identified before and 0= not been identified before 
 
protein name  known in literature 







Annexin A2   1  1  1 
Basement membrane-specific heparan sulfate proteoglycan core protein (HSPG) 
(perlecan) 
1  1  1 
Collagen alpha-1(I) chain  1  1  1 
Collagen alpha-1(II) chain  #  0  0  1 
Collagen alpha-1(III) chain  1  1 (not pre)  1 
Collagen alpha-1(IV) chain  #  0  0  1 
Collagen alpha-1(V) chain   1  0  1 
Collagen alpha-1(VI) chain   1  1  1 
Collagen alpha-1(XII) chain   1  0  1 
Collagen alpha-2(I) chain   1  1  1 
Collagen alpha-2(IV) chain   1  0  [1 
Collagen alpha-2(V) chain  #  0  0  1 
Collagen alpha-2(VI) chain   1  1  1 
Collagen alpha-3(V) chain #  0  0  1 
Collagen alpha-3(VI) chain   1  1  1 
Connective tissue growth factor ( Hypertrophic chondrocyte-specific protein 24) 
# 
0  0  1 
Decorin (Bone proteoglycan II) (PG-S2) (PG40)  1  1  1  
 
Dermatopontin (tyrosine-rich acidic matrix protein) (tramp)  1  1  0 
EGF-containing fibulin-like extracellular matrix protein 1 (Fibulin-3)  1  0  1 
Fibrillin-1 (FBN1)  #  0  0  1 
Fibronectin (FN) (Cold-insoluble globulin)  1  1  1 
Fibulin-1 (FBLN1)  1  0  1 
Galectin-1 (Lectin galactoside-binding soluble 1) #  0  0  1 
Galectin-3-binding protein ( Lectin galactoside-binding soluble 3-binding 
protein) 
1  1  1 
Laminin subunit beta-1 (laminin B1 chain)  1  0  1 
Laminin subunit gamma-1 (laminin B2 chain)  1  1  1 
Lumican ( Keratan sulfate proteoglycan lumican)  1  1  1 
Nidogen-1 (entactin)   1  1  1 
Periostin (PN) (Osteoblast-specific factor 2)  1  1 (not adi)  1 
SPARC (Osteonectin)   1  1  1 
Thrombospondin-1   1  0  0 
Thrombospondin-2   1  0  1 
Transforming growth factor-beta-induced protein ig-h3 (Beta ig-h3)  1  1  1 
turnover 
72 kDa type IV collagenase (Matrix metalloproteinase-2) (MMP-2)  1  0  1 
Lysyl oxidase homolog 2 (Lysyl oxidase-like protein 2) *
  0  0  0 
Metalloproteinase inhibitor 1 (Tissue inhibitor of metalloproteinases) (TIMP-1)  1  1  1 
Metalloproteinase inhibitor 2 (Tissue inhibitor of metalloproteinases 2) (TIMP-2)  1  1  1 
Procollagen C-endopeptidase enhancer 1 (PCPE-1)  1  1  1 
Protein-lysine 6-oxidase (Lysyl oxidase) #  0  0  1 
regulation/signaling 
Acyl-CoA-binding protein (ACBP) (Diazepam-binding inhibitor)  1  0  0 
Adiponectin   1  1  1  
 
Alpha-2-HS-glycoprotein (Ba-alpha-2-glycoprotein) (Alpha-2-Z-globulin) 
(Fetuin-A) * 
0  0  0 
Apolipoprotein E (Apo-E)  1  0  1 
Calreticulin (CRP55) (calregulin)  1  1  1 
Calumenin (Crocalbin)  0  1  1 
Cystatin-C (Neuroendocrine basic polypeptide)  1  0  1 
Follistatin-related protein 1 (Follistatin-like 1)  1  1  1 
Gelsolin isoform 1 (Actin-depolymerizing factor)  1  0  1 
Glia-derived nexin (GDN) (Protease nexin I) (Protease inhibitor 7) *  0  0  0 
Insulin-like growth factor-binding protein 3 (IBP-3) *  0  0  0 
Insulin-like growth factor-binding protein 4 (IBP-4)   1  0  1 
Insulin-like growth factor-binding protein 5 (IBP-5) *  0  0  0 
Insulin-like growth factor-binding protein 6 (IBP-6)   1  0  0 
Insulin-like growth factor-binding protein 7 (IBP-7)   1  1 (osteo)  0 
Tetranectin (TN) ( Plasminogen kringle 4-binding protein) #  0  0  1 
Latent-transforming growth factor beta-binding protein 2 (LTBP-2)  1  0  1 
Peroxidasin homolog (Vascular peroxidase 1) #  0  0  1 
Pigment epithelium-derived factor (PEDF) ( Serpin-F1) (EPC-1)  1  [1  1 
Plasminogen activator inhibitor 1 (PAI-1)  1  1  1 
Prostaglandin-H2 D-isomerase (PGDS2)  1  0  0 
Retinol-binding protein 4 (PRBP) (RBP)  1  1  1 
Sulfhydryl oxidase 1 (hQSOX)  1  1 (osteo)  1 
Sushi repeat-containing protein SRPX  *  0  0  0 
Vitamin D-binding protein (DBP) (VDB) #  0  0  1 
immune regulation 
Clusterin (Complement cytolysis inhibitor)(CLI)  1  0  1 
Complement C1r subcomponent   1  1  1 
Complement C1s subcomponent  1  1  1  
 
Complement C3   1  0  1 
Complement factor D (C3 convertase activator) (Properdin factor D) (Adipsin)  1  0  1 
Immunoglobulin superfamily containing leucine-rich repeat protein  *  0  0  0 
Interleukin-25 (IL-25) #  0  0  1 
Macrophage migration inhibitory factor (MIF) #  0  0  1 
Pentraxin-related protein PTX3 (Tumor necrosis factor-inducible gene 14 protein)  1  1  0 
Plasma protease C1 inhibitor (C1 Inh)  1  1  0 
other 
Coiled-coil domain-containing protein 96  *  0  0  0 
Transgelin-2 (SM22-alpha homolog)  1  0  1 
not known as secreted proteins 
Annexin A5  1  1  1 
Peptidyl-prolyl cis-trans isomerase A (PPIase A) (Cyclophilin A)  1  1  1 
  
 
Table S3A Complete list of proteins identified from both Halobacterium salinarium purple membrane (PM) and Corynebacterium 
glutamicum membranes (CB) using elastase/trypsin as proteolytic enzymes. 





protein description  peptides 
1  P02945  Bacteriorhodopsin - Halobacterium salinarium   145 
2  P00772  Elastase-1 precursor - Sus scrofa  73 
3  Q9HMW9  Dipeptide ABC transporter dipeptide-binding - Halobacterium 
salinarium  
72 
4  Q9HR99  Halocyanin-like - Halobacterium salinarium   23 
5  Q9HN93  Halocyanin-like - Halobacterium salinarium   28 
6  Q9HMG3  Putative uncharacterized protein - Halobacterium salinarium   17 
7  Q9HMI3  Dipeptide ABC transporter ATP-binding - Halobacterium 
salinarium  
25 
8  Q9HHN1  Na+/H+ antiporter - Halobacterium salinarium   27 
9  Q48302  Precursor proteolipid - Halobacterium salinarium   27 
10  Q9HSA8  Bifunctional short chain isoprenyl diphosphate synthase - 
Halobacterium salinarium  
17 
11  Q9HRQ9  Putative uncharacterized protein - Halobacterium salinarium   15 
12  Q9HND9  H+-transporting ATP synthase subunit K - Halobacterium 
salinarium  
17 
13  Q9HH34  Rhodopsin - Halobacterium salinarium   16 
14  Q9HN95  Cytochrome c oxidase subunit I - Halobacterium salinarium   17 
15  Q9HHP3  Vng6297c - Halobacterium salinarium   8 
16  Q9HRS0  Putative uncharacterized protein - Halobacterium salinarium   13 
17  Q9HN94  Cytochrome c oxidase subunit II - Halobacterium salinarium   7 
18  Q9HM69  Cell surface glycoprotein - Halobacterium salinarium   18 
19  Q9HNQ9  Protein-export membrane protein - Halobacterium salinarium   7 
20  Q9HRR1  Putative uncharacterized protein - Halobacterium salinarium   6  
 
21  Q9HMK0  Putative uncharacterized protein - Halobacterium salinarium   7 
22  Q9HRL1  NADH dehydrogenase/oxidoreductase - Halobacterium 
salinarium  
5 
23  Q9HRR3  Putative uncharacterized protein - Halobacterium salinarium   10 
24  Q9HMW4  Oligopeptide binding protein - Halobacterium salinarium   13 
25  Q9HRL3  F420H2:quinone oxidoreductase chain L - Halobacterium 
salinarium  
9 
26  Q9HSS1  Phosphoglycerate dehydrogenase - Halobacterium salinarium   12 
27  Q9HRR0  Putative uncharacterized protein - Halobacterium salinarium   6 
28  Q9HQA6  Putative uncharacterized protein - Halobacterium salinarium   3 
29  Q9HMX1  Dipeptide ABC transporter permease - Halobacterium salinarium   9 
30  Q9HNB9  Putative uncharacterized protein - Halobacterium salinarium   3 
31  Q9HSQ2  Probable protease htpX homolog - Halobacterium salinarium   4 
32  Q9HS72  Preprotein translocase subunit secE - Halobacterium salinarium   3 
33  Q9HND8  V-type ATP synthase subunit I - Halobacterium salinarium   8 
34  Q9HQF4  Membrane protein - Halobacterium salinarium   4 
35  Q9HSQ7  ABC transport protein - Halobacterium salinarium   7 
36  Q9HRL4  NADH dehydrogenase/oxidoreductase-like protein - 
Halobacterium salinarium  
3 
37  Q9HPB1  Preprotein translocase subunit secY - Halobacterium salinarium   5 
38  Q9HRL8  NADH dehydrogenase/oxidoreductase - Halobacterium 
salinarium  
5 
39  Q9HMT7  Probable thiosulfate sulfurtransferase - Halobacterium salinarium   6 
40  Q9HMF1  Aconitase - Halobacterium salinarium   6 
41  Q9HRJ0  Putative uncharacterized protein - Halobacterium salinarium   2 
42  Q9HN92  Putative uncharacterized protein - Halobacterium salinarium   3 
43  Q9HNL7  Putative uncharacterized protein - Halobacterium salinarium   3 
44  Q9HS26  Na+/H+ antiporter - Halobacterium salinarium   3 
45  Q9HMU9  Nitrite/nitrate reduction protein - Halobacterium salinarium   6 
46  Q9HMH4  Putative uncharacterized protein - Halobacterium salinarium   2 
47  Q9HRU5  Immunogenic protein - Halobacterium salinarium   3  
 
48  Q9HPQ2  Daunorubicin resistance ABC transporter ATP-binding protein - 
Halobacterium salinarium  
1 
49  Q9HMZ3  Heterodisulfide reductase - Halobacterium salinarium   4 
50  Q9HMB7  Probable carboxypeptidase - Halobacterium salinarium   3 
51  Q9HP76  Putative uncharacterized protein - Halobacterium salinarium   7 
52  Q9HNN6  Putative uncharacterized protein - Halobacterium salinarium   3 
53  Q9HRF2  Putative uncharacterized protein - Halobacterium salinarium   2 
54  Q9HRL2  F420H2:quinone oxidoreductase chain M - Halobacterium 
salinarium  
2 
55  Q9HS51  Putative uncharacterized protein - Halobacterium salinarium   2 
56  Q9HMB6  Alcohol dehydrogenase - Halobacterium salinarium   2 
57  Q9HSC3  Putative protease La homolog type - Halobacterium salinarium   3 
58  Q9HR04  Iron-binding protein - Halobacterium salinarium   3 
59  Q9HR22  Ribose ABC transporter permease - Halobacterium salinarium   1 
60  P33518  Cytochrome c oxidase polypeptide 1 - Halobacterium salinarium   2 
61  Q9HPD4  50S ribosomal protein L3P - Halobacterium salinarium   1 
62  Q9HQP2  Transmembrane oligosaccharyl transferase - Halobacterium 
salinarium  
5 
63  Q9HNE6  Brp-like homolog - Halobacterium salinarium   2 
64  Q9HRS4  Putative uncharacterized protein - Halobacterium salinarium   1 
65  Q9HSM4  NADP-specific glutamate dehydrogenase B - Halobacterium 
salinarium  
2 
66  Q9HQV6  Putative uncharacterized protein - Halobacterium salinarium   2 
67  Q9HNS6  Putative uncharacterized protein - Halobacterium salinarium   1 
68  Q9HQ64  Membrane anchor - Halobacterium salinarium   2 
69  Q9HRR2  Cytochrome b6 - Halobacterium salinarium   2 
70  Q9HM89  Elongation factor 1-alpha - Halobacterium salinarium   3 
71  Q9HP88  Phytoene dehydrogenase - Halobacterium salinarium   2 
72  Q9HHS5  Vng6251h - Halobacterium salinarium   1 
73  Q9HS12  Phosphate ABC transporter permease - Halobacterium salinarium   5 
74  Q9HRZ2  Probable oxidoreductase - Halobacterium salinarium   2  
 
75  Q9HMU8  Copper transport ATP-binding protein - Halobacterium 
salinarium  
1 
76  P25964  Sensory rhodopsin-1 - Halobacterium salinarium   4 
77  Q9HRJ9  Cytochrome c oxidase subunit 2 - Halobacterium salinarium   1 
78  Q9HRL9  NADH dehydrogenase/oxidoreductase - Halobacterium 
salinarium  
2 
79  Q9HRM1  NADH dehydrogenase/oxidoreductase-like protein - 
Halobacterium salinarium  
2 
80  Q9HR74  Dimethylsulfoxide reductase - Halobacterium salinarium   1 
81  P57697  Proteasome subunit alpha - Halobacterium salinarium   1 
82  Q9HQ04  Putative uncharacterized protein - Halobacterium salinarium   3 
83  Q9HQU7  Probable oxidoreductase - Halobacterium salinarium   2 
84  Q9HR98  Cystathionine gamma-synthase - Halobacterium salinarium   1 
85  Q9HN07  Acylaminoacyl-peptidase - Halobacterium salinarium   1 
86  Q9HMD1  Preprotein translocase subunit secG - Halobacterium salinarium   1 
87  Q9HMX0  Dipeptide ABC transporter permease - Halobacterium salinarium   4 
88  Q9HN25  Putative uncharacterized protein - Halobacterium salinarium   1 
89  Q9HN22  Putative uncharacterized protein - Halobacterium salinarium   2 
90  Q9HQV3  Putative uncharacterized protein - Halobacterium salinarium   2 
91  Q9HSC9  N-methyltransferase homolog - Halobacterium salinarium   2 
92  Q9HPG8  Ribonucleoside-diphosphate reductase - Halobacterium 
salinarium  
1 
93  Q9HP89  Photolyase/cryptochrome - Halobacterium salinarium   2 
94  Q9HR16  Proline permease - Halobacterium salinarium   1 
95  Q9HHR4  Vng6268c - Halobacterium salinarium   3 
96  Q9HRD0  Anion permease - Halobacterium salinarium   1 
97  Q9HPA6  Htr-like protein - Halobacterium salinarium   2 
98  Q9HN36  Protein export - Halobacterium salinarium   1 
99  Q9HQ52  Thymidylate synthase thyX - Halobacterium salinarium   2 
100  Q9HMB4  Repair helicase - Halobacterium salinarium   1 
101  Q9HQQ9  UDP-glucose dehydrogenase - Halobacterium salinarium   1  
 
102  Q9HP48  NADH oxidase - Halobacterium salinarium   2 
103  Q9HRN3  Proteinase IV homolog - Halobacterium salinarium   1 
104  Q9HRW7  Putative uncharacterized protein - Halobacterium salinarium   1 
105  Q9HNW7  Phosphoribosyl transferase - Halobacterium salinarium   1 
106  Q9HNR0  Protein-export membrane protein - Halobacterium salinarium   3 
107  Q9HSA0  Putative uncharacterized protein - Halobacterium salinarium   1 
108  Q9HT00  Glucosamine--fructose-6-phosphate aminotransferase 
[isomerizing] - Halobacterium salinarium  
2 
109  Q9HRT0  Putative uncharacterized protein - Halobacterium salinarium   3 
110  Q9HPT9  Carboxylesterase - Halobacterium salinarium   1 
111  Q9HRS9  Putative uncharacterized protein - Halobacterium salinarium   1 
112  Q9HM85  Elongation factor 2 - Halobacterium salinarium   2 
113  Q9HT01  Putative uncharacterized protein - Halobacterium salinarium   1 
114  Q9HHK5  Transcription initiation factor IIB 3 - Halobacterium salinarium   1 
115  Q9HSF7  Transcription initiation factor IIB 7 - Halobacterium salinarium   1 
116  Q9HQU8  Acetyl-CoA synthetase - Halobacterium salinarium   1 
117  Q9HNI7  Possible phosphate binding protein - Halobacterium salinarium   1 
118  Q9HMQ2  Argininosuccinate synthase - Halobacterium salinarium   2 
119  Q9HMK7  Glutaryl-CoA dehydrogenase - Halobacterium salinarium   1 
120  Q9HP01  Spermidine/putrescine ABC transporter permease - 
Halobacterium salinarium  
1 
121  Q9HQU3  Putative uncharacterized protein - Halobacterium salinarium   1 
122  Q9HRC9  Putative uncharacterized protein - Halobacterium salinarium   1 
123  Q9HQ43  Putative uncharacterized protein - Halobacterium salinarium   1 
124  Q9HN02  Hemolysin protein - Halobacterium salinarium   1 
125  Q9HN85  Phosphomannomutase - Halobacterium salinarium   1 
126  Q9HPY6  Putative uncharacterized protein - Halobacterium salinarium   1 
127  Q9HRH6  Putative uncharacterized protein - Halobacterium salinarium   1 
128  Q9HRY9  Putative uncharacterized protein - Halobacterium salinarium   1 
129  O59634  Methyl-accepting aerotaxis transducer protein - Halobacterium  2  
 
salinarium  
130  Q9HPQ5  Htr8 transducer - Halobacterium salinarium   2 
131  Q9HNS4  Glycerol-3-phosphate dehydrogenase chain A - Halobacterium 
salinarium  
1 
132  Q9HSF1  Putative uncharacterized protein - Halobacterium salinarium   1 
133  Q9HQ63  Succinate dehydrogenase hydrophobic membrane anchor subunit 
- Halobacterium salinarium  
2 
134  O51960  Putative uncharacterized protein - Halobacterium salinarium   1 
135  Q9HSZ8  Glucose-1-phosphate thymidylyltransferase - Halobacterium 
salinarium  
1 
136  Q9HMS1  Putative uncharacterized protein - Halobacterium salinarium   1 
137  Q9HQH9  Small heat shock protein - Halobacterium salinarium   2 
138  Q9HRK1  Cytochrome c oxidase subunit III - Halobacterium salinarium   1 
139  Q9HMU6  Putative uncharacterized protein - Halobacterium salinarium   1 
140  Q9HNP7  Putative uncharacterized protein - Halobacterium salinarium   1 
141  Q48294  Arginine deiminase - Halobacterium salinarium   1 
142  Q9HNT9  Putative uncharacterized protein - Halobacterium salinarium   1 
143  Q9HT02  Putative uncharacterized protein - Halobacterium salinarium   1 
144  Q9HNU0  Formyltetrahydrofolate deformylase - Halobacterium salinarium   1 
145  Q9HNY9  Quinolinate phosphoribosyltransferase - Halobacterium 
salinarium  
2 
146  Q9HN43  Phosphoenolpyruvate carboxylase - Halobacterium salinarium   1 
147  Q9HN54  Putative uncharacterized protein - Halobacterium salinarium   1 
148  Q9HP72  Glutamyl-tRNA reductase - Halobacterium salinarium   1 
149  Q9HT03  Amino acid ABC transporter, ATP-binding protein - 
Halobacterium salinarium  
1 
150  Q9HRR5  Putative uncharacterized protein - Halobacterium salinarium   1 
151  Q9HR92  Halobacterial transducer protein 6 - Halobacterium salinarium   2 
152  P71415  Transducer HtD protein - Halobacterium salinarium   2 
153  Q9HME2  Putative uncharacterized protein - Halobacterium salinarium   1 
154  Q9HR32  Type II DNA topoisomerase VI subunit A - Halobacterium  1  
 
salinarium  
155  Q9HSL5  Cationic amino acid transporter - Halobacterium salinarium   1 
156  Q9HN08  Thioredoxin reductase - Halobacterium salinarium   1 
157  Q9HR62  Putative uncharacterized protein - Halobacterium salinarium   1 
158  Q9HP98  Htr-like protein - Halobacterium salinarium   1 
159  Q9HS86  Htr14 transducer - Halobacterium salinarium   1 
160  Q9HNB2  DNA repair protein - Halobacterium salinarium   2 
161  Q9HPU7  Bacteriorhodopsin related protein - Halobacterium salinarium   1 
162  Q9HRJ5  Putative uncharacterized protein - Halobacterium salinarium   1 
163  Q9HSJ5  Putative uncharacterized protein - Halobacterium salinarium   1 
164  Q9HS40  Putative uncharacterized protein - Halobacterium salinarium   1 
165  Q9HHJ8  DNA polymerase B2 - Halobacterium salinarium   1 
166  Q9HPX0  Aspartate-semialdehyde dehydrogenase - Halobacterium 
salinarium  
1 
167  Q9HQU6  Putative uncharacterized protein - Halobacterium salinarium   1 
168  Q9HNI3  Putative uncharacterized protein - Halobacterium salinarium   1 
169  Q9HQE2  Putative uncharacterized protein - Halobacterium salinarium   1 
170  Q9HN76  Pyruvate dehydrogenase beta subunit - Halobacterium salinarium   1 
171  Q48290  Cell division protein ftsZ homolog - Halobacterium salinarium   1 
172  Q9HNZ0  L-aspartate oxidase - Halobacterium salinarium   1 
173  Q9HQU4  Inosine monophosphate dehydrogenase - Halobacterium 
salinarium  
1 
174  Q9HPK2  UPF0100 protein VNG1595C - Halobacterium salinarium   1 
175  Q9HNH3  Potassium channel homolog - Halobacterium salinarium   1 
176  Q9HNE5  Geranylgeranyl-diphosphate geranylgeranyltransferase - 
Halobacterium salinarium  
1 
177  Q9HQ46  Deoxyribodipyrimidine photo-lyase - Halobacterium salinarium   1 
178  Q9HP32  CTP synthase - Halobacterium salinarium   1 
179  P16102  Halorhodopsin - Halobacterium salinarium   1 




181  Q9HSL6  DNA mismatch repair protein mutS 2 - Halobacterium 
salinarium  
1 
182  Q9HSW6  Cell division control protein 6 homolog 1 - Halobacterium 
salinarium  
1 
183  Q9HQ03  Putative uncharacterized protein - Halobacterium salinarium   1 
184  Q9HMJ2  Putative uncharacterized protein - Halobacterium salinarium   1 
185  Q9HPW3  Putative uncharacterized protein - Halobacterium salinarium   1 








number  number 
Protein protein description  peptides 
1  Q9HRQ9  Putative uncharacterized protein - Halobacterium salinarium   3 
2  Q9HHP3  Vng6297c - Halobacterium salinarium   3 
3  Q9HSA8  Bifunctional short chain isoprenyl diphosphate synthase - 
Halobacterium salinarium  
5 
4  Q9HMW9  Dipeptide ABC transporter dipeptide-binding - 
Halobacterium salinarium  
8 
5  Q9HS72  Preprotein translocase subunit secE - Halobacterium 
salinarium  
3 
6  Q9HHN1  Na+/H+ antiporter - Halobacterium salinarium   5 
7  Q9HNQ9  Protein-export membrane protein - Halobacterium salinarium   4 
8  Q9HN95  Cytochrome c oxidase subunit I - Halobacterium salinarium   5 
9  Q9HMI3  Dipeptide ABC transporter ATP-binding - Halobacterium 
salinarium  
4 
10  Q9HMW4  Oligopeptide binding protein - Halobacterium salinarium   6 
11  Q9HND9  H+-transporting ATP synthase subunit K - Halobacterium 
salinarium  
1 
12  Q9HRR3  Putative uncharacterized protein - Halobacterium salinarium   4 
13  Q9HRL4  NADH dehydrogenase/oxidoreductase-like protein - 
Halobacterium salinarium  
2 
14  Q9HR99  Halocyanin-like - Halobacterium salinarium   2 
15  Q9HRJ0  Putative uncharacterized protein - Halobacterium salinarium   2 
16  Q9HS26  Na+/H+ antiporter - Halobacterium salinarium   3 
17  Q9HPB1  Preprotein translocase subunit secY - Halobacterium 
salinarium  
4 
18  Q9HRL3  F420H2:quinone oxidoreductase chain L - Halobacterium 
salinarium  
2 
19  P02945  Bacteriorhodopsin - Halobacterium salinarium   4 
20  Q9HRF2  Putative uncharacterized protein - Halobacterium salinarium   3  
 
21  Q9HRR1  Putative uncharacterized protein - Halobacterium salinarium   2 
22  Q9HMZ3  Heterodisulfide reductase - Halobacterium salinarium   6 
23  Q9HN93  Halocyanin-like - Halobacterium salinarium   2 
24  Q9HNE6  Brp-like homolog - Halobacterium salinarium   2 
25  Q9HP76  Putative uncharacterized protein - Halobacterium salinarium   5 
26  Q9HMG3  Putative uncharacterized protein - Halobacterium salinarium   1 
27  Q9HN94  Cytochrome c oxidase subunit II - Halobacterium salinarium   2 
28  Q9HSQ2  Probable protease htpX homolog - Halobacterium salinarium   2 
29  Q9HPD4  50S ribosomal protein L3P - Halobacterium salinarium   1 
30  Q9HR22  Ribose ABC transporter permease - Halobacterium 
salinarium  
1 
31  P33518  Cytochrome c oxidase polypeptide 1 - Halobacterium 
salinarium  
2 
32  Q9HMX1  Dipeptide ABC transporter permease - Halobacterium 
salinarium  
4 
33  Q9HRS0  Putative uncharacterized protein - Halobacterium salinarium   2 
34  Q9HRL8  NADH dehydrogenase/oxidoreductase - Halobacterium 
salinarium  
2 
35  Q9HSC3  Putative protease La homolog type - Halobacterium 
salinarium  
2 
36  Q9HQP2  Transmembrane oligosaccharyl transferase - Halobacterium 
salinarium  
3 
37  Q9HHS5  Vng6251h - Halobacterium salinarium   1 
38  Q9HRL1  NADH dehydrogenase/oxidoreductase - Halobacterium 
salinarium  
1 
39  Q9HRR2  Cytochrome b6 - Halobacterium salinarium   1 
40  Q9HSC9  N-methyltransferase homolog - Halobacterium salinarium   2 
41  Q9HQ64  Membrane anchor - Halobacterium salinarium   1 
42  Q9HHR4  Vng6268c - Halobacterium salinarium   3 
43  Q9HMU9  Nitrite/nitrate reduction protein - Halobacterium salinarium   3 
44  Q9HMD1  Preprotein translocase subunit secG - Halobacterium  1  
 
salinarium  
45  P25964  Sensory rhodopsin-1 - Halobacterium salinarium   2 
46  Q9HQU7  Probable oxidoreductase - Halobacterium salinarium   1 
47  Q9HN07  Acylaminoacyl-peptidase - Halobacterium salinarium   1 
48  Q9HR16  Proline permease - Halobacterium salinarium   2 
49  Q9HP89  Photolyase/cryptochrome - Halobacterium salinarium   3 
50  Q9HN25  Putative uncharacterized protein - Halobacterium salinarium   1 
51  Q9HQ04  Putative uncharacterized protein - Halobacterium salinarium   2 
52  Q9HRM1  NADH dehydrogenase/oxidoreductase-like protein - 
Halobacterium salinarium  
2 
53  Q9HSQ7  ABC transport protein - Halobacterium salinarium   3 
54  Q9HS12  Phosphate ABC transporter permease - Halobacterium 
salinarium  
2 
55  Q9HRZ2  Probable oxidoreductase - Halobacterium salinarium   1 
56  Q9HMX0  Dipeptide ABC transporter permease - Halobacterium 
salinarium  
2 
57  Q9HT01  Putative uncharacterized protein - Halobacterium salinarium   1 
58  Q9HND8  V-type ATP synthase subunit I - Halobacterium salinarium   1 
59  Q9HRC9  Putative uncharacterized protein - Halobacterium salinarium   1 
60  Q9HMK7  Glutaryl-CoA dehydrogenase - Halobacterium salinarium   2 
61  Q9HRT0  Putative uncharacterized protein - Halobacterium salinarium   2 
62  Q9HRR0  Putative uncharacterized protein - Halobacterium salinarium   1 
63  Q9HNN6  Putative uncharacterized protein - Halobacterium salinarium   1 
64  Q9HRN3  Proteinase IV homolog - Halobacterium salinarium   1 
65  Q9HRL2  F420H2:quinone oxidoreductase chain M - Halobacterium 
salinarium  
1 
66  Q9HSF7  Transcription initiation factor IIB 7 - Halobacterium 
salinarium  
1 
67  Q9HPU7  Bacteriorhodopsin related protein - Halobacterium salinarium   2 




69  Q9HPA6  Htr-like protein - Halobacterium salinarium   1 
70  Q9HRQ7  Putative uncharacterized protein - Halobacterium salinarium   1 
71  Q9HQ63  Succinate dehydrogenase hydrophobic membrane anchor 
subunit - Halobacterium salinarium  
1 
72  O51960  Putative uncharacterized protein - Halobacterium salinarium   1 
73  Q9HR80  Putative uncharacterized protein - Halobacterium salinarium   2 
74  Q9HT02  Putative uncharacterized protein - Halobacterium salinarium   1 
75  Q9HQ52  Thymidylate synthase thyX - Halobacterium salinarium   1 
76  Q9HR62  Putative uncharacterized protein - Halobacterium salinarium   1 
77  P33741  Sensory rhodopsin I transducer - Halobacterium salinarium   2 
78  Q9HPQ5  Htr8 transducer - Halobacterium salinarium   1 
79  Q9HSL5  Cationic amino acid transporter - Halobacterium salinarium   1 
80  Q9HQU6  Putative uncharacterized protein - Halobacterium salinarium   1 
81  Q9HQP7  Putative uncharacterized protein - Halobacterium salinarium   1 
82  Q9HN76  Pyruvate dehydrogenase beta subunit - Halobacterium 
salinarium  
1 
83  Q9HPT0  Putative uncharacterized protein - Halobacterium salinarium   1 
84  Q48290  Cell division protein ftsZ homolog - Halobacterium 
salinarium  
1 
85  Q9HN02  Hemolysin protein - Halobacterium salinarium   1 
86  Q9HRM0  NADH dehydrogenase/oxidoreductase - Halobacterium 
salinarium  
1 
87  Q9HNK1  Putative uncharacterized protein - Halobacterium salinarium   1 
88  Q9HQ81  TRK potassium uptake system protein - Halobacterium 
salinarium  
1 
89  Q9HN58  Putative uncharacterized protein - Halobacterium salinarium   1 
90  Q9HQV1  Putative uncharacterized protein - Halobacterium salinarium   1 
91  Q9HQQ6  Glycosyl transferase-like - Halobacterium salinarium   1 
92  Q9HSA3  L-tyrosine decarboxylase - Halobacterium salinarium   1 




94  Q9HNI9  Transport protein - Halobacterium salinarium   1 
95  O52005  Putative uncharacterized protein - Halobacterium salinarium   1 
96  Q9HNG0  Proline dehydrogenase - Halobacterium salinarium   1 
97  Q9HPX5  Htr-like protein - Halobacterium salinarium   1 
98  Q9HR54  Putative uncharacterized protein - Halobacterium salinarium   1 
99  Q9HMH6  Putative uncharacterized protein - Halobacterium salinarium   1 
100  P57699  Potassium-transporting ATPase B chain - Halobacterium 
salinarium  
1 
101  Q9HRC5  Putative uncharacterized protein - Halobacterium salinarium   1 
102  Q9HRS2  Putative uncharacterized protein - Halobacterium salinarium   1 
103  Q9HR04  Iron-binding protein - Halobacterium salinarium   1 
104  Q9HNS2  Glycerol-3-phosphate dehydrogenase chain C - 
Halobacterium salinarium  
1 
105  P16102  Halorhodopsin - Halobacterium salinarium   1 
106  Q9HMW2  Oligopeptide transport permease protein - Halobacterium 
salinarium  
1 
107  Q9HRK2  Putative uncharacterized protein - Halobacterium salinarium   1 
108  Q9HRY6  Probable acetyltransferase - Halobacterium salinarium   1 
109  Q9HP19  Putative uncharacterized protein - Halobacterium salinarium   1 
110  Q9HNB2  DNA repair protein - Halobacterium salinarium   1 
111  Q9HHI4  Vng6379c - Halobacterium salinarium   1 
112  Q9HSJ6  Putative uncharacterized protein - Halobacterium salinarium   1 
113  Q9HQS2  CDP-diacylglycerol-glycerol-3-phosphate 3-
phosphatidyltransferase - Halobacterium salinarium  
1 
114  Q9HQS6  Putative uncharacterized protein - Halobacterium salinarium   1 
115  Q9HHW0  Vng6203h - Halobacterium salinarium   1 










number  number 
Protein descrition  peptides 
1  P00772  Elastase-1   152 
2  Cg2705  MALTOSE-BINDING PROTEIN PRECURSOR ABC-type sugar 
transport system, periplasmic component 
37 
3  Cg2409  CYTOCHROME C OXIDASE CHAIN II   35 
4  Cg1537  GLUCOSE-SPECIFIC ENZYME II BC COMPONENT OF PTS   41 
5  Cg0446  succinate dehydrogenase A   46 
6  Cg3138  Membrane protease subunit, stomatin/prohibitin homolog   18 
7  Cg0587  ELONGATION FACTOR TU   22 
8  Cg2911  ABC-type Mn/Zn transport system, secreted Mn/Zn-binding 
(lipo)protein (surface adhesin)  
10 
9  Cg3009  hypothetical protein predicted by Glimmer/Critica   14 
10  Cg2875   hypothetical protein predicted by Glimmer   14 
11  Cg0447  succinate dehydrogenase B   16 
12  Cg1656  NADH DEHYDROGENASE   13 
13  Cg2195  putative secreted or membrane protein   4 
14  Cg1368  ATP SYNTHASE ALPHA SUBUNIT   12 
15  Cg2780  PROBABLE CYTOCHROME C OXIDASE POLYPEPTIDE 
SUBUNIT  
12 
16  Cg1429  putative membrane protein   6 
17  Cg2196  putative secreted or membrane protein   9 
18  Cg0924  ABC-type cobalamin/Fe3+-siderophores transport sys   5 
19  Cg2403  CYTOCHROME B, MEMBRANE PROTEIN   11 
20  Cg0445  succinate dehydrogenase CD   6 
21  Cg2404  RIESKE IRON-SULFUR PROTEIN   13  
 
22  Cg1685   Sec-independent protein secretion pathway component   8 
23  Cg2444  hypothetical protein predicted by Glimmer/Critica  7 
24  Cg2708  ABC-type sugar transport system, ATPase component   9 
25  Cg2843  ABC-type phosphate transport system, ATPase component   9 
26  Cg1290  Homocysteine methyltransferase  6 
27  Cg1081  ABC-type multidrug transport system, ATPase component   5 
28  Cg0957  FATTY ACID SYNTHASE   10 
29  Cg1791  GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE   6 
30  Cg2181  ABC-type peptide transport system, secreted component   6 
31  Cg3186  Trehalose corynomycolyl transferase   6 
32  Cg1363  ATP SYNTHASE C CHAIN   3 
33  Cg0737  ABC-type transport system, secreted lipoprotein component   5 
34  Cg1880  THREONYL-TRNA SYNTHETASE   7 
35  Cg1121  Permease of the major facilitator superfamily   7 
36  Cg0791  PYRUVATE CARBOXYLASE   6 
37  Cg0766  ISOCITRATE DEHYDROGENASE   5 
38  Cg1362  ATP SYNTHASE F0 SUBUNIT 6   3 
39  Cg2291  PYRUVATE KINASE   1 
40  Cg2137  GLUTAMATE SECRETED BINDING PROTEIN   3 
41  Cg1787  PHOSPHOENOLPYRUVATE CARBOXYLASE   3 
42  Cg2157  TELLURIUM RESISTANCE MEMBRANE PROTEIN   3 
43  Cg2405  CYTOCHROME C1   5 
44  Cg1001  LARGE CONDUCTANCE MECHANOSENSITIVE CHANNEL   4 
45  Cg1169  Na+-dependent transporters of the SNF family   4 
46  Cg1364  ATP synthase B chain   2 
47  Cg2211  putative membrane protein   6 
48  Cg1556  conserved hypothetical protein   2 
49  Cg2499  GLYCYL-TRNA SYNTHETASE (GLYCINE--TRNA LIGASE)   4 
50  Cg1790  PHOSPHOGLYCERATE KINASE   6 
51  Cg0834  Bacterial extracellular solute-binding protein, fa   3  
 
52  Cg2496  putative secreted protein   3 
53  Cg0656  50S RIBOSOMAL PROTEIN L17   1 
54  Cg1813  PUTATIVE CARBAMOYL-PHOSPHATE SYNTHASE SUBUNIT   3 
55  Cg0583  ELONGATION FACTOR G   3 
56  Cg1111  ENOLASE   4 
57  Cg1579  putative secreted protein   1 
58  Cg3227  PUTATIVE L-LACTATE DEHYDROGENASE   5 
59  Cg0647  preprotein translocase subunit SecY   5 
60  Cg3219  L-LACTATE DEHYDROGENASE   3 
61  Cg1737  ACONITASE   3 
62  Cg0935  conserved hypothetical protein   2 
63  Cg0756  PUTATIVE CARBON STARVATION PROTEIN A   6 
64  Cg1365  H+-ATPASE DELTA SUBUNIT   2 
65  Cg3195  Flavin-containing monooxygenase (FMO)   2 
66  Cg1437  KETOL-ACID REDUCTOISOMERASE   3 
67  Cg0528  putative secreted protein   1 
68  Cg1796  putative membrane protein - C. ammoniagenes RibX homolog   1 
69  Cg2613  MALATE DEHYDROGENASE OXIDOREDUCTASE PROTEIN   2 
70  Cg1366  PROBABLE ATP SYNTHASE ALPHA CHAIN PROTEIN   5 
71  Cg2262  Signal recognition particle GTPase   1 
72  Cg0047  conserved hypothetical protein   2 
73  Cg4005  putative secreted protein |  2 
74  Cg2695  ABC-type transport system, ATPase component   2 
75  Cg3008  PORIN   2 
76  Cg0508  iron/thiamine transport system, secreted component   1 
77  Cg2192   MALATE:QUINONE OXIDOREDUCTASE 
OXIDOREDUCTASE  
2 
78  Cg3365  putative ribitol transport membrane protein   2 
79  Cg1280  2-OXOGLUTARATE DEHYDROGENASE   1 
80  Cg2408  putative membrane protein   1  
 
81  Cg2292  PUTATIVE PROLIPOPROTEIN DIACYLGLYCEROL 
TRANSFERASE  
1 
82  Cg1586  ARGININOSUCCINATE SYNTHASE   2 
83  Cg0594  50S RIBOSOMAL PROTEIN L3   1 
84  Cg3244  conserved hypothetical protein   1 
85  Cg3100  Heat shock protein hsp70   1 
86  Cg2325  hypothetical protein predicted by Glimmer/Critica   3 
87  Cg3149  Aminotransferases class-I   3 
88  Cg2466  PYRUVATE DEHYDROGENASE E1 COMPONENT   3 
89  Cg0928  ABC-type cobalamin/Fe3+-siderophores transport system, ATPase 
component  
1 
90  Cg2470  SECRETED ABC TRANSPORTER SUBSTRATE-BINDING 
PROTEIN  
2 
91  Cg0303  2-ISOPROPYLMALATE SYNTHASE   1 
92  Cg2558  related to aldose 1-epimerase   3 
93  Cg2862  PHOSPHORIBOSYLFORMYLGLYCINAMIDINE SYNTHASE   1 
94  Cg2523  4-ALPHA-GLUCANOTRANSFERASE   2 
95  Cg0953  Na+/proline, Na+/panthothenate symporter or related permease   2 
96  Cg2120  SUGAR SPECIFIC PTS SYSTEM, FRUCTOSE/MANNITOL-
SPECIFIC TRANSPORT PROTEIN  
2 
97  Cg1238  putative membrane protein   3 
98  Cg1911  putative secreted protein   2 
99  Cg0952  PUTATIVE INTEGRAL MEMBRANE PROTEIN   3 
100  Cg1227  putative membrane protein   2 
101  Cg3429  Preprotein translocase subunit YidC   1 
102  Cg2845  ABC-type phosphate transport system, permease component   3 
103  Cg0414  cell surface polysaccharide biosynthesis / Chain length determinant 
protein  
2 
104  Cg0523  membrane protein required for cytochrome c biosynthesis   1 
105  Cg2166  PUTATIVE POLYRIBONUCLEOTIDE PHOSPHORYLASE / 
GUANOSINE PENTAPHOSPHATESYNTHETASE  
1  
 
106  Cg0545  PUTATIVE LOW-AFFINITY PHOSPHATE TRANSPORT 
PROTEIN  
2 
107  Cg2437  THREONINE SYNTHASE   1 
108  Cg0914  CELL DIVISION ATP-BINDING PROTEIN   1 
109  Cg2154  CDP-DIACYLGLYCEROL--GLYCEROL-3-PHOSPHATE 3-
PHOSPHATIDYLTRANSFERASE  
1 
110  Cg1128  similar to ribosomal protein S2   1 
111  Cg0949  CITRATE SYNTHASE   2 
112  Cg3182  Trehalose corynomycolyl transferase   3 
113  Cg1418  ABC-type cobalamin/Fe3+-siderophores transport system secreted 
component  
1 
114  Cg1314  PROLINE TRANSPORT SYSTEM   1 
115  Cg0007  DNA GYRASE SUBUNIT B   1 
116  Cg1203  Mg-chelatase subunit ChlI   1 
117  Cg1789  TRIOSEPHOSPHATE ISOMERASE   1 
118  Cg2561  secreted protein potentially involved into thiamin biosynthesis   1 
119  Cg2833  O-Acetylserine (Thiol)-Lyase   2 
120  Cg2467  ABC TRANSPORTER ATP-BINDING PROTEIN   1 
121  Cg1229  ABC-type cobalt transport system, permease component CbiQ   2 
122  Cg0896  membrane protein   3 
123  Cg1432  DIHYDROXY-ACID DEHYDRATASE   1 
124  Cg3257  conserved hypothetical protein   2 
125  Cg0161  putative secreted or membrane protein   1 
126  Cg2644  ATP-DEPENDENT CLP PROTEASE PROTEOLYTIC SUBUNIT 
CLPP2  
1 
127  Cg2799  putative secreted protein   2 
128  Cg2361  Cell division initiation protein - Antigen 84 homolog   1 
129  Cg2300  IMIDAZOLEGLYCEROL-PHOSPHATE SYNTHASE, 
AMIDOTRANSFERASE  
1 
130  Cg2406  CYTOCHROME C OXIDASE SUBUNIT 3   1 
131  Cg3068  fructose-bisphosphate aldolase   1  
 
132  Cg1635  putative membrane protein   1 
133  Cg1811  putative integration host factor cIHF   1 
134  Cg1082  putative membrane protein   1 
135  Cg2704  ABC-type sugar transport system, permease component   2 
136  Cg0489  hypothetical membrane protein   1 
137  Cg0040  PUTATIVE SECRETED PROTEIN   1 
138  Cg1072  Ribosomal protein L25 (general stress protein Ctc)  1 
139  Cg2460  [putative membrane protein  1 
140  Cg1247  putative secreted protein   1 
141  Cg0966  PROBABLE THYMIDYLATE SYNTHASE   1 
142  Cg3079  PROBABLE ATP-DEPENDENT PROTEASE (HEAT SHOCK 
PROTEIN)  
2 
143  Cg1341  RESPIRATORY NITRATE REDUCTASE 2 GAMMA CHAIN   1 
144  Cg2678  ABC-type dipeptide/oligopeptide/nickel transport systems, secreted 
component  
1 
145  Cg1525  DNA POLYMERASE I   1 
146  Cg3096  ALDEHYDE DEHYDROGENASE   1 
147  Cg3323  Myo-inositol-1-phosphate synthase   1 
148  Cg2958  L-2,3-butanediol dehydrogenase/acetoin reductase   2 
149  Cg1629  Similar to preprotein translocase subunit SecA   1 
150  Cg1643  6-PHOSPHOGLUCONATE DEHYDROGENASE   2 
151  Cg1228  ABC-type cobalt transport system, ATPase component   1 
152  Cg1345  PUTATIVE NITRATE/NITRITE TRANSPORTER   1 
153  Cg2924  CYSTEINE TRNA SYNTHETASE   1 
154  Cg2527  PROBABLE PEPTIDYL-DIPEPTIDASE A PROTEIN   1 
155  Cg3139  conserved hypothetical protein   1 
156  Cg0238  L-GULONOLACTONE OXIDASE   1 
157  Cg0683  permease   1 
158  Cg0062  PROTEIN PHOSPHATASE   1 
159  Cg1502  ABC-type polar amino acid transport system, ATPase component   1  
 
160  Cg0674  30S RIBOSOMAL PROTEIN S9   1 
161  Cg3343  putative secreted membrane protein   2 
162  Cg1505  putative secreted protein   1 
163  Cg0326  NADH-QUINONE OXIDOREDUCTASE CHAIN 5   2 
164  Cg1836  secreted solute-binding protein, aminodeoxychorismate lyase-like   1 
165  Cg1463  PUTATIVE GLUTAMYL-TRNA SYNTHETASE   1 
166  Cg1794  Uncharacterised P-loop ATPase protein   1 
167  Cg0291  3,4-dioxygenase beta subunit   1 
168  Cg0652   (Q9RA65) RIBOSOMAL PROTEIN S13   1 
169  Cg1603  CONSERVED MEMBRANE PROTEIN   1 
170  Cg1195  Sulfate permease or related transporter (MFS superfamily)   1 
171  Cg0915  PUTATIVE CELL DIVISION PROTEIN  1 
172  Cg2963  ]: PROBABLE ATP-DEPENDENT PROTEASE (HEAT SHOCK 
PROTEIN)  
1 
173  Cg2174  Exopolyphosphatase-related protein   1 
174  Cg1672  polyprenol-phosphate-mannose synthase domain 1   1 
175  Cg1861  PPGPP SYNTHETASE, PPGPP PYROPHOSPHORYLASE   1 
176  Cg1694  RecB family exonuclease   1 
178  Cg0779  TRYPTOPHAN TRNA SYNTHETASE   1 
179  Cg2811  ABC-type transport system, involved in lipoprotein release, permease 
component  
1 
181  Cg0835  ABC-type sugar transport systems, ATPase component   1 
182  Cg1268  GLYCOSYL TRANSFERASE   1 
183  Cg2703  Sugar permease   1 
184  Cg2052  putative secreted protein   2 
185  Cg1259  similar to tetrahydrodipicolinate N-succinyltransferase   1 
186  Cg3237  MANGANESE SUPEROXIDE DISMUTASE   1 
187  Cg0610  50S RIBOSOMAL PROTEIN L5   1 
188  Cg1829  PUTATIVE CHORISMATE SYNTHASE   1 
189  Cg2841  Predicted TIM-barrel enzyme, possibly dehydrogenase, nifR3 family   1  
 
190  Cg0933  DNA or RNA helicase of superfamily II   1 
191  Cg2033  putative secreted protein   1 
192  Cg2362  putative membrane protein   1 
193  Cg1479  PUTATIVE GLYCOGEN PHOSPHORYLASE   1 
194  Cg2840  BUTYRYL-COA:ACETATE COENZYME A TRANSFERASE   1 
195  Cg0592  PUTATIVE BUTYRYL-COA:ACETATE COENZYME A 
TRANSFERAS  
1 
197  Cg0048  PEPTIDYL-PROLYL CIS-TRANS ISOMERASE B   1 
 








Protein protein description  peptides 
1  gi|19553194  ABC-type transporter, periplasmic component [Corynebacterium 
glutamicum ATCC 13032] 
12 
2  gi|19551617  succinate dehydrogenase flavoprotein subunit [Corynebacterium 
glutamicum ATCC 13032] 
19 
3  gi|19554025  putative membrane protease subunit [Corynebacterium glutamicum ATCC 
13032] 
9 
4  gi|19553141  phosphotransferase system, fructose-specific IIC component 
[Corynebacterium glutamicum ATCC 13032] 
7 
5  gi|19551738  elongation factor G [Corynebacterium glutamicum ATCC 13032]  9 
6  gi|19551746  50S ribosomal protein L3 [Corynebacterium glutamicum ATCC 13032]  5 
7  gi|19552590  hypothetical protein NCgl1320 [Corynebacterium glutamicum ATCC 
13032] 
9 
8  gi|19553391  cytochrome b subunit of the bc complex [Corynebacterium glutamicum 
ATCC 13032] 
7 




10  gi|19553827  ABC-type transporter, periplasmic component [Corynebacterium 
glutamicum ATCC 13032] 
4 
11  gi|19552680  NADH dehydrogenase, FAD-containing subunit [Corynebacterium 
glutamicum ATCC 13032] 
6 
12  gi|19553397  cytochrome C oxidase subunit II [Corynebacterium glutamicum ATCC 
13032] 
6 
13  gi|19551739  elongation factor Tu [Corynebacterium glutamicum ATCC 13032]  5 
14  gi|19553427  hypothetical protein NCgl2145 [Corynebacterium glutamicum ATCC 
13032] 
5 
15  gi|19553197  ABC-type transporter, duplicated ATPase component [Corynebacterium 
glutamicum ATCC 13032] 
8 
16  gi|21325295  Heme/copper-type cytochrome/quinol oxidases, subunit 1 
[Corynebacterium glutamicum ATCC 13032] 
7 
17  gi|19552365  5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase 
[Corynebacterium glutamicum ATCC 13032] 
5 
18  gi|21324774  Hypothetical membrane protein [Corynebacterium glutamicum ATCC 
13032] 
4 
19  gi|19554075  K+ transport flavoprotein [Corynebacterium glutamicum ATCC 13032]  4 
20  gi|19551592  esterase [Corynebacterium glutamicum ATCC 13032]  5 
21  gi|19552574  phosphotransferase system IIC component, glucose/maltose/N-
acetylglucosamine-specific [Corynebacterium glutamicum ATCC 13032] 
3 
22  gi|19551747  50S ribosomal protein L4 [Corynebacterium glutamicum ATCC 13032]  4 
23  gi|19551691  hypothetical protein NCgl0431 [Corynebacterium glutamicum ATCC 
13032] 
4 
24  gi|19552045  hypothetical protein NCgl0784 [Corynebacterium glutamicum ATCC 
13032] 
2 
25  gi|41326199  putative membrane protein [Corynebacterium glutamicum ATCC 13032]  1 
26  gi|19551749  50S ribosomal protein L2 [Corynebacterium glutamicum ATCC 13032]  8 
27  gi|19552104  large-conductance mechanosensitive channel [Corynebacterium 
glutamicum ATCC 13032] 
2 




29  gi|19552797  phosphoenolpyruvate carboxylase [Corynebacterium glutamicum ATCC 
13032] 
6 
30  gi|19551869  ABC-type transporter, periplasmic component [Corynebacterium 
glutamicum ATCC 13032] 
5 
31  gi|19552799  phosphoglycerate kinase [Corynebacterium glutamicum ATCC 13032]  5 
32  gi|19553220  hypothetical protein NCgl1941 [Corynebacterium glutamicum ATCC 
13032] 
2 
33  gi|19553155  glutamate ABC-type transporter, ATPase component [Corynebacterium 
glutamicum ATCC 13032] 
1 
34  gi|19551717  preprotein translocase subunit SecE [Corynebacterium glutamicum ATCC 
13032] 
2 
35  gi|19552314  hypothetical protein NCgl1043 [Corynebacterium glutamicum ATCC 
13032] 
2 
36  gi|19551548  hypothetical protein NCgl0293 [Corynebacterium glutamicum ATCC 
13032] 
1 
37  gi|19554067  putative esterase [Corynebacterium glutamicum ATCC 13032]  5 
38  gi|19552487  hypothetical protein NCgl1218 [Corynebacterium glutamicum ATCC 
13032] 
2 
39  gi|19553166  phage shock protein A (IM30) [Corynebacterium glutamicum ATCC 
13032] 
3 
40  gi|19552493  ketol-acid reductoisomerase [Corynebacterium glutamicum ATCC 13032]  4 
41  gi|19552215  phospho-2-dehydro-3-deoxyheptonate aldolase [Corynebacterium 
glutamicum ATCC 13032] 
3 
42  gi|19551798  30S ribosomal protein S4 [Corynebacterium glutamicum ATCC 13032]  7 
43  gi|19553196  ABC-type transporter, permease component [Corynebacterium 
glutamicum ATCC 13032] 
2 
44  gi|21323302  Ribosomal protein S8 [Corynebacterium glutamicum ATCC 13032]  1 
45  gi|21325344  ABC-type transporter, ATPase component [Corynebacterium glutamicum 
ATCC 13032] 
2 
46  gi|19553765  acetyl-CoA hydrolase [Corynebacterium glutamicum ATCC 13032]  1 
47  gi|19551731  DNA-directed RNA polymerase subunit beta [Corynebacterium 
glutamicum ATCC 13032] 
4  
 
48  gi|19551797  30S ribosomal protein S11 [Corynebacterium glutamicum ATCC 13032]  4 
49  gi|19553032  hypothetical protein NCgl1756 [Corynebacterium glutamicum ATCC 
13032] 
2 
50  gi|19554080  1-acyl-sn-glycerol-3-phosphate acyltransferase [Corynebacterium 
glutamicum ATCC 13032] 
1 
51  gi|19553392  Rieske Fe-S protein [Corynebacterium glutamicum ATCC 13032]  4 
52  gi|21324403  Hypothetical protein [Corynebacterium glutamicum ATCC 13032]  2 
53  gi|21323137  Succinate dehydrogenase/fumarate reductase Fe-S protein 
[Corynebacterium glutamicum ATCC 13032] 
3 
54  gi|19553205  malate:quinone oxidoreductase [Corynebacterium glutamicum ATCC 
13032] 
3 
55  gi|19554065  putative esterase [Corynebacterium glutamicum ATCC 13032]  5 
56  gi|19553828  ABC-type transporter, ATPase component [Corynebacterium glutamicum 
ATCC 13032] 
4 
57  gi|19551529  membrane carboxypeptidase [Corynebacterium glutamicum ATCC 13032]  1 
58  gi|19554105  L-lactate dehydrogenase [Corynebacterium glutamicum ATCC 13032]  4 
59  gi|19551956  ABC-type transporter, periplasmic component [Corynebacterium 
glutamicum ATCC 13032] 
2 
60  gi|21322997  Uncharacterized ACR [Corynebacterium glutamicum ATCC 13032]  1 
61  gi|19552403  arginyl-tRNA synthetase [Corynebacterium glutamicum ATCC 13032]  2 
62  gi|19552219  serine hydroxymethyltransferase [Corynebacterium glutamicum ATCC 
13032] 
2 
63  gi|19552305  ABC-type transporter, duplicated ATPase component [Corynebacterium 
glutamicum ATCC 13032] 
4 
64  gi|19551937  detergent sensitivity rescuer dtsR2 [Corynebacterium glutamicum ATCC 
13032] 
2 
65  gi|19551984  ribosome-associated protein Y [Corynebacterium glutamicum ATCC 
13032] 
3 
66  gi|19554117  hypothetical protein NCgl2831 [Corynebacterium glutamicum ATCC 
13032] 
1 




68  gi|21323598  Uncharacterized membrane protein [Corynebacterium glutamicum ATCC 
13032] 
3 
69  gi|19554227  ascorbate-specific PTS system enzyme IIC [Corynebacterium glutamicum 
ATCC 13032] 
3 
70  gi|19553840  phosphotransferase system IIC component [Corynebacterium glutamicum 
ATCC 13032] 
2 
71  gi|19551616  hypothetical protein NCgl0359 [Corynebacterium glutamicum ATCC 
13032] 
3 
72  gi|19551276  hypothetical protein NCgl0025 [Corynebacterium glutamicum ATCC 
13032] 
3 
73  gi|19552361  hypothetical protein NCgl1090 [Corynebacterium glutamicum ATCC 
13032] 
1 
74  gi|19553738  hypothetical protein NCgl2452 [Corynebacterium glutamicum ATCC 
13032] 
1 
75  gi|19553114  transcriptional regulator [Corynebacterium glutamicum ATCC 13032]  1 
76  gi|19552644  GTP-binding protein EngA [Corynebacterium glutamicum ATCC 13032]  1 
77  gi|19553350  cell division initiation protein [Corynebacterium glutamicum ATCC 
13032] 
1 
78  gi|41325061  FATTY ACID SYNTHASE [Corynebacterium glutamicum ATCC 13032]  3 
79  gi|19552869  preprotein translocase subunit YajC [Corynebacterium glutamicum ATCC 
13032] 
3 
80  gi|19552098  50S ribosomal protein L31 type B [Corynebacterium glutamicum ATCC 
13032] 
1 
81  gi|19552504  D-3-phosphoglycerate dehydrogenase [Corynebacterium glutamicum 
ATCC 13032] 
2 
82  gi|19552746  membrane protease subunit [Corynebacterium glutamicum ATCC 13032]  4 
83  gi|19553156  glutamate ABC-type transporter, periplasmic component 
[Corynebacterium glutamicum ATCC 13032] 
2 
84  gi|41326948  conserved hypothetical protein [Corynebacterium glutamicum ATCC 
13032] 
1 




86  gi|21323688  Hypothetical protein [Corynebacterium glutamicum ATCC 13032]  2 
87  gi|21324968  Hypothetical membrane protein [Corynebacterium glutamicum ATCC 
13032] 
1 
88  gi|19551799  DNA-directed RNA polymerase subunit alpha [Corynebacterium 
glutamicum ATCC 13032] 
2 
89  gi|19551732  DNA-directed RNA polymerase subunit beta~ [Corynebacterium 
glutamicum ATCC 13032] 
3 
90  gi|21324681  DNA-directed RNA polymerase sigma subunits (sigma70/sigma32) 
(SigA) [Corynebacterium glutamicum ATCC 13032] 
1 
91  gi|19552573  30S ribosomal protein S1 [Corynebacterium glutamicum ATCC 13032]  2 
92  gi|21324098  ABC-type transporter, ATPase component [Corynebacterium glutamicum 
ATCC 13032] 
1 
93  gi|21325656  Hypothetical membrane protein [Corynebacterium glutamicum ATCC 
13032] 
3 
94  gi|21322889  Hypothetical membrane protein [Corynebacterium glutamicum ATCC 
13032] 
2 
95  gi|19553476  glycyl-tRNA synthetase [Corynebacterium glutamicum ATCC 13032]  1 
96  gi|21325487  porin [Corynebacterium glutamicum ATCC 13032]  1 
97  gi|19552775  ABC-type transporter, ATPase component [Corynebacterium glutamicum 
ATCC 13032] 
2 
98  gi|19553694  3-oxoacyl-(acyl-carrier-protein) synthase [Corynebacterium glutamicum 
ATCC 13032] 
1 
99  gi|19553123  RNA polymerase sigma factor SigB [Corynebacterium glutamicum ATCC 
13032] 
1 
100  gi|19552143  hypothetical protein NCgl0880 [Corynebacterium glutamicum ATCC 
13032] 
3 
101  gi|19551752  30S ribosomal protein S3 [Corynebacterium glutamicum ATCC 13032]  2 
102  gi|19551290  putative septation inhibitor protein [Corynebacterium glutamicum ATCC 
13032] 
1 
103  gi|19553618  hypothetical protein NCgl2336 [Corynebacterium glutamicum ATCC 
13032] 
2 
104  gi|19552407  homoserine dehydrogenase [Corynebacterium glutamicum ATCC 13032]  3  
 
105  gi|19552617  argininosuccinate synthase [Corynebacterium glutamicum ATCC 13032]  2 
106  gi|19552088  bifunctional phosphoribosylaminoimidazolecarboxamide 
formyltransferase/IMP cyclohydrolase [Corynebacterium glutamicum 
ATCC 13032] 
1 
107  gi|19553751  ABC-type transporter, ATPase component [Corynebacterium glutamicum 
ATCC 13032] 
2 
108  gi|19551541  cAMP-binding domain-containing protein [Corynebacterium glutamicum 
ATCC 13032] 
1 
109  gi|19551759  50S ribosomal protein L24 [Corynebacterium glutamicum ATCC 13032]  2 
110  gi|19552252  hypothetical protein NCgl0987 [Corynebacterium glutamicum ATCC 
13032] 
1 
111  gi|19553333  dehydrogenase [Corynebacterium glutamicum ATCC 13032]  1 
112  gi|19552805  hypothetical protein NCgl1531 [Corynebacterium glutamicum ATCC 
13032] 
1 
113  gi|19553189  translation initiation factor IF-2 [Corynebacterium glutamicum ATCC 
13032] 
2 
114  gi|41325436  ATP SYNTHASE ALPHA SUBUNIT [Corynebacterium glutamicum 
ATCC 13032] 
2 
115  gi|19554063  hypothetical protein NCgl2775 [Corynebacterium glutamicum ATCC 
13032] 
1 
116  gi|19552423  transcription termination factor Rho [Corynebacterium glutamicum ATCC 
13032] 
1 
117  gi|19551816  30S ribosomal protein S9 [Corynebacterium glutamicum ATCC 13032]  2 
118  gi|19551753  50S ribosomal protein L16 [Corynebacterium glutamicum ATCC 13032]  2 
119  gi|19552490  small-conductance mechanosensitive channel [Corynebacterium 
glutamicum ATCC 13032] 
1 
120  gi|19554256  putative proline-betaine transporter [Corynebacterium glutamicum ATCC 
13032] 
1 
121  gi|19552092  30S ribosomal protein S18 [Corynebacterium glutamicum ATCC 13032]  2 
122  gi|19553658  ABC-type transporter, periplasmic component [Corynebacterium 
glutamicum ATCC 13032] 
2 
123  gi|19551720  50S ribosomal protein L1 [Corynebacterium glutamicum ATCC 13032]  1  
 
124  gi|19551777  30S ribosomal protein S5 [Corynebacterium glutamicum ATCC 13032]  1 
125  gi|19552432  F0F1 ATP synthase subunit delta [Corynebacterium glutamicum ATCC 
13032] 
1 
126  gi|21324061  Glutamyl- and glutaminyl-tRNA synthetases [Corynebacterium 
glutamicum ATCC 13032] 
1 
127  gi|19552608  hypothetical protein NCgl1337 [Corynebacterium glutamicum ATCC 
13032] 
2 
128  gi|19553872  ATPase with chaperone activity, ATP-binding subunit [Corynebacterium 
glutamicum ATCC 13032] 
1 
129  gi|19553650  putative ABC transporter ATP-binding protein [Corynebacterium 
glutamicum ATCC 13032] 
2 
130  gi|19552060  Na+/proline, Na+/panthothenate symporter or related permease 
[Corynebacterium glutamicum ATCC 13032] 
1 
131  gi|19552085  metalloendopeptidase-like membrane protein [Corynebacterium 
glutamicum ATCC 13032] 
1 
132  gi|19554026  hypothetical protein NCgl2738 [Corynebacterium glutamicum ATCC 
13032] 
1 
133  gi|19553758  cysteine synthase [Corynebacterium glutamicum ATCC 13032]  1 
134  gi|21324976  Leucyl aminopeptidase [Corynebacterium glutamicum ATCC 13032]  1 
135  gi|19551579  hypothetical protein NCgl0323 [Corynebacterium glutamicum ATCC 
13032] 
1 
136  gi|19552323  hypothetical protein NCgl1052 [Corynebacterium glutamicum ATCC 
13032] 
1 
137  gi|19554184  hypothetical protein NCgl2888 [Corynebacterium glutamicum ATCC 
13032] 
1 
138  gi|19552825  pyrimidine regulatory protein PyrR [Corynebacterium glutamicum ATCC 
13032] 
1 
139  gi|19552029  cell-division ATP-binding protein [Corynebacterium glutamicum ATCC 
13032] 
1 
140  gi|19551957  ABC-type transporter, ATPase component [Corynebacterium glutamicum 
ATCC 13032] 
1 
141  gi|19552093  30S ribosomal protein S14 [Corynebacterium glutamicum ATCC 13032]  1  
 
142  gi|19551647  phosphoglyceromutase [Corynebacterium glutamicum ATCC 13032]  1 
143  gi|19551919  pyruvate carboxylase [Corynebacterium glutamicum ATCC 13032]  1 
144  gi|19551440  short chain dehydrogenase [Corynebacterium glutamicum ATCC 13032]  1 
145  gi|19552095  50S ribosomal protein L28 [Corynebacterium glutamicum ATCC 13032]  1 
146  gi|41326869  putative membrane protein [Corynebacterium glutamicum ATCC 13032]  1 
147  gi|19554069  phosphoribose diphosphate:decaprenyl-phosphate 
phosphoribosyltransferase [Corynebacterium glutamicum ATCC 13032] 
1 
148  gi|19552821  carbamoyl phosphate synthase large subunit [Corynebacterium 
glutamicum ATCC 13032] 
1 
149  gi|19553913  hypothetical protein NCgl2624 [Corynebacterium glutamicum ATCC 
13032] 
1 
150  gi|21324427  Preprotein translocase subunit SecD [Corynebacterium glutamicum ATCC 
13032] 
1 
151  gi|21323174  Hypothetical membrane protein [Corynebacterium glutamicum ATCC 
13032] 
1 
152  gi|41325890  THREONYL-TRNA SYNTHETASE [Corynebacterium glutamicum 
ATCC 13032] 
1 
153  gi|19551295  protein serine/threonine phosphatase [Corynebacterium glutamicum 
ATCC 13032] 
1 
154  gi|21324859  Pyruvate kinase [Corynebacterium glutamicum ATCC 13032]  1 
155  gi|21323977  F0F1-type ATP synthase alpha subunit [Corynebacterium glutamicum 
ATCC 13032] 
1 
156  gi|19552251  SNF family Na(+)-dependent transporter [Corynebacterium glutamicum 
ATCC 13032] 
1 
157  gi|19554257  hypothetical protein NCgl2962 [Corynebacterium glutamicum ATCC 
13032] 
2 
158  gi|19551908  hypothetical protein NCgl0648 [Corynebacterium glutamicum ATCC 
13032] 
1 
159  gi|19552803  hypothetical protein NCgl1529 [Corynebacterium glutamicum ATCC 
13032] 
1 




161  gi|19553838  rRNA methylase [Corynebacterium glutamicum ATCC 13032]  1 
162  gi|21325721  Hypothetical protein [Corynebacterium glutamicum ATCC 13032]  1 
163  gi|19553542  30S ribosomal protein S20 [Corynebacterium glutamicum ATCC 13032]  2 
164  gi|19554029  hypothetical protein NCgl2741 [Corynebacterium glutamicum ATCC 
13032] 
1 
165  gi|19553473  chromosome segregation ATPase [Corynebacterium glutamicum ATCC 
13032] 
1 
166  gi|19551452  ABC-type transporter, permease component [Corynebacterium 
glutamicum ATCC 13032] 
1 
167  gi|19551736  30S ribosomal protein S12 [Corynebacterium glutamicum ATCC 13032]  1 
168  gi|19552431  F0F1 ATP synthase subunit B [Corynebacterium glutamicum ATCC 
13032] 
1 
169  gi|19553687  hypothetical protein NCgl2402 [Corynebacterium glutamicum ATCC 
13032] 
1 
170  gi|19552819  hypothetical protein NCgl1545 [Corynebacterium glutamicum ATCC 
13032] 
1 
171  gi|19551930  acyl-CoA carboxylase [Corynebacterium glutamicum ATCC 13032]  1 
172  gi|21325042  Glucosamine 6-phosphate synthetase, contains amidotransferase and 
phosphosugar isomerase domains [Corynebacterium glutamicum ATCC 
13032] 
1 
173  gi|19551283  hypothetical protein NCgl0032 [Corynebacterium glutamicum ATCC 
13032] 
1 
174  gi|19552037  ABC-type cobalamin/Fe3+-siderophore transport system, periplasmic 
component [Corynebacterium glutamicum ATCC 13032] 
1 
175  gi|19553179  polynucleotide phosphorylase/polyadenylase [Corynebacterium 
glutamicum ATCC 13032] 
1 
176  gi|19553829  ABC-type transporter, permease component [Corynebacterium 
glutamicum ATCC 13032] 
1 
177  gi|19551877  ABC-type Fe3+-siderophores transport system, periplasmic component 
[Corynebacterium glutamicum ATCC 13032] 
1 




179  gi|161486709  alpha-ketoglutarate decarboxylase [Corynebacterium glutamicum ATCC 
13032] 
1 
180  gi|19552172  ABC-type transporter, ATPase component [Corynebacterium glutamicum 
ATCC 13032] 
1 
181  gi|19554061  putative polyketide synthase [Corynebacterium glutamicum ATCC 13032]  1 
182  gi|41326753  ABC-type phosphate transport system, permease component 
[Corynebacterium glutamicum ATCC 13032] 
1 
183  gi|19553415  glutamine synthase [Corynebacterium glutamicum ATCC 13032]  1 
184  gi|19551985  preprotein translocase subunit SecA [Corynebacterium glutamicum ATCC 
13032] 
1 
185  gi|19552595  translation initiation factor IF-3 [Corynebacterium glutamicum ATCC 
13032] 
1 
186  gi|19554128  hypothetical protein NCgl2842 [Corynebacterium glutamicum ATCC 
13032] 
1 
187  gi|19552127  D-lactate dehydrogenase [Corynebacterium glutamicum ATCC 13032]  1 
188  gi|19552705  twin argininte translocase protein A [Corynebacterium glutamicum ATCC 
13032] 
1 
189  gi|19553229  30S ribosomal protein S2 [Corynebacterium glutamicum ATCC 13032]  1 
190  gi|19554208  hypothetical protein NCgl2912 [Corynebacterium glutamicum ATCC 
13032] 
1 
191  gi|19552345  hypothetical protein NCgl1074 [Corynebacterium glutamicum ATCC 
13032] 
1 
192  gi|19553083  integrase [Corynebacterium glutamicum ATCC 13032]  1 
193  gi|19551706  naphthoate synthase [Corynebacterium glutamicum ATCC 13032]  1 
194  gi|19552350  hypothetical protein NCgl1079 [Corynebacterium glutamicum ATCC 
13032] 
1 
195  gi|19554180  penicillin-binding protein [Corynebacterium glutamicum ATCC 13032]  1 
196  gi|19552199  phosphopyruvate hydratase [Corynebacterium glutamicum ATCC 13032]  1 
197  gi|19551758  50S ribosomal protein L14 [Corynebacterium glutamicum ATCC 13032]  1 
198  gi|19553103  hypothetical protein NCgl1824 [Corynebacterium glutamicum ATCC 
13032] 
1 
200  gi|19552283  Mg-chelatase subunit ChlI [Corynebacterium glutamicum ATCC 13032]  1  
 
 
Supplementry table 4 complete list of the proteins identified from atryptic digestion of AF4, AF4•MLL and ENL 






prot_protein description  peptides 
1  AFF1  AF4/FMR2 family member 1 (Protein AF-4) (Proto-oncogene AF4) (Protein FEL) -   106 
2  HSP71  Heat shock 70 kDa protein 1 (HSP70.1) (HSP70-1/HSP70-2) -   49 
3  HSP7C  Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8) -   36 
4  TBB5  Tubulin beta chain (Tubulin beta-5 chain) -   25 
5  HSP76  Heat shock 70 kDa protein 6 (Heat shock 70 kDa protein B~) -   32 
6  GRP78  78 kDa glucose-regulated protein precursor (GRP 78) (Heat shock 70 kDa protein 5) 
(Immunoglobulin heavy chain-binding protein) (BiP) (Endoplasmic reticulum lumenal 
Ca(2+)-binding protein grp78) -  
31 
7  HS70L  Heat shock 70 kDa protein 1L (Heat shock 70 kDa protein 1-like) (Heat shock 70 kDa 
protein 1-Hom) (HSP70-Hom) -  
20 
8  TBAK  Tubulin alpha-ubiquitous chain (Alpha-tubulin ubiquitous) (Tubulin K-alpha-1) -   21 
9  TBA6  Tubulin alpha-6 chain (Alpha-tubulin 6) -   19 
10  TBB2C  Tubulin beta-2C chain (Tubulin beta-2 chain) -   23 
11  TBB2A  Tubulin beta-2A chain -   20 
12  TBA3  Tubulin alpha-3 chain (Alpha-tubulin 3) (Tubulin B-alpha-1) -   20 
13  TBB4  Tubulin beta-4 chain (Tubulin 5 beta) -   18 
14  TBA2  Tubulin alpha-2 chain (Alpha-tubulin 2) -   15 
15  GRP75  Stress-70 protein, mitochondrial precursor (75 kDa glucose-regulated protein) (GRP 
75) (Peptide-binding protein 74) (PBP74) (Mortalin) (MOT) -  
14 
16  K2C1  Keratin, type II cytoskeletal 1 (Cytokeratin-1) (CK-1) (Keratin-1) (K1) (67 kDa 
cytokeratin) (Hair alpha protein) -  
11 
17  HS90A  Heat shock protein HSP 90-alpha (HSP 86) (Renal carcinoma antigen NY-REN-38) -   22 
18  HS90B  Heat shock protein HSP 90-beta (HSP 84) (HSP 90) -   26  
 
19  ACTB  Actin, cytoplasmic 1 (Beta-actin) -   13 
20  ENL  Protein ENL (YEATS domain-containing protein 1) -   22 
21  EF2  Elongation factor 2 (EF-2) -   19 
22  ACTC  Actin, alpha cardiac muscle 1 (Alpha-cardiac actin) -   8 
23  ATX2L  Ataxin-2-like protein (Ataxin-2 domain protein) (Ataxin-2-related protein) -   14 
24  HS105  Heat-shock protein 105 kDa (Heat shock 110 kDa protein) (Antigen NY-CO-25) -   14 
25  PGRC1  Membrane-associated progesterone receptor component 1 (mPR) -   9 
26  ENOA  Alpha-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (Non-neural 
enolase) (NNE) (Enolase 1) (Phosphopyruvate hydratase) (C-myc promoter-binding 
protein) (MBP-1) (MPB-1) (Plasminogen-binding protein) -  
10 
27  FAS  Fatty acid synthase (EC 2.3.1.85) [Includes: [Acyl-carrier-protein] S-acetyltransferase 
(EC 2.3.1.38); [Acyl-carrier-protein] S-malonyltransferase (EC 2.3.1.39); 3-oxoacyl-
[acyl-carrier-protein] synthase (EC 2.3.1.41); 3-oxoacyl-[acyl-carrier-protei 
14 
28  TCPB  T-complex protein 1 subunit beta (TCP-1-beta) (CCT-beta) -   7 
29  CH60  60 kDa heat shock protein, mitochondrial precursor (Hsp60) (60 kDa chaperonin) 
(CPN60) (Heat shock protein 60) (HSP-60) (Mitochondrial matrix protein P1) (P60 
lymphocyte protein) (HuCHA60) -  
8 
30  G3P  Glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) (GAPDH) -   8 
31  ATPB  ATP synthase subunit beta, mitochondrial precursor (EC 3.6.3.14) -   10 
32  CALX  Calnexin precursor (Major histocompatibility complex class I antigen-binding protein 
p88) (p90) (IP90) -  
8 
33  K1C9  Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9) -   6 
34  IMA2  Importin alpha-2 subunit (Karyopherin alpha-2 subunit) (SRP1-alpha) (RAG cohort 
protein 1) -  
7 
35  TPIS  Triosephosphate isomerase (EC 5.3.1.1) (TIM) (Triose-phosphate isomerase) -   8 
36  EF1G  Elongation factor 1-gamma (EF-1-gamma) (eEF-1B gamma) -   10 
37  EF1A1  Elongation factor 1-alpha 1 (EF-1-alpha-1) (Elongation factor 1 A-1) (eEF1A-1) 
(Elongation factor Tu) (EF-Tu) (Leukocyte receptor cluster member 7) -  
8 
38  PYC  Pyruvate carboxylase, mitochondrial precursor (EC 6.4.1.1) (Pyruvic carboxylase) 
(PCB) -  
11 
39  CDK9  Cell division protein kinase 9 (EC 2.7.11.22) (EC 2.7.11.23) (Cyclin-dependent kinase 
9) (Serine/threonine-protein kinase PITALRE) (C-2K) (Cell division cycle 2-like 
12  
 
protein kinase 4) -  
40  ROA1  Heterogeneous nuclear ribonucleoprotein A1 (Helix-destabilizing protein) (Single-
strand RNA-binding protein) (hnRNP core protein A1) -  
5 
41  DDX6  Probable ATP-dependent RNA helicase DDX6 (EC 3.6.1.-) (DEAD box protein 6) 
(ATP-dependent RNA helicase p54) (Oncogene RCK) -  
9 
42  4F2  4F2 cell-surface antigen heavy chain (4F2hc) (Lymphocyte activation antigen 4F2 
large subunit) (4F2 heavy chain antigen) (CD98 antigen) -  
7 
43  RBM25  Probable RNA-binding protein 25 (RNA-binding motif protein 25) (RNA-binding 
region-containing protein 7) (Protein S164) -  
5 
44  PPIA  Peptidyl-prolyl cis-trans isomerase A (EC 5.2.1.8) (PPIase A) (Rotamase A) 
(Cyclophilin A) (Cyclosporin A-binding protein) -  
5 
45  NPM  Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin) (Nucleolar protein 
NO38) -  
6 
46  TCPE  T-complex protein 1 subunit epsilon (TCP-1-epsilon) (CCT-epsilon) -   5 
47  TCPH  T-complex protein 1 subunit eta (TCP-1-eta) (CCT-eta) (HIV-1 Nef-interacting 
protein) -  
6 
48  ATPA  ATP synthase subunit alpha, mitochondrial precursor (EC 3.6.3.14) -   4 
49  PRDX6  Peroxiredoxin-6 (EC 1.11.1.15) (Antioxidant protein 2) (1-Cys peroxiredoxin) (1-Cys 
PRX) (Acidic calcium-independent phospholipase A2) (EC 3.1.1.-) (aiPLA2) (Non-
selenium glutathione peroxidase) (EC 1.11.1.7) (NSGPx) (24 kDa protein) (Liver 2D 
page  
2 
50  TCPA  T-complex protein 1 subunit alpha (TCP-1-alpha) (CCT-alpha) -   7 
51  SF3A1  Splicing factor 3 subunit 1 (Spliceosome-associated protein 114) (SAP 114) (SF3a120) 
-  
4 
52  IMB1  Importin beta-1 subunit (Karyopherin beta-1 subunit) (Nuclear factor P97) (Importin 
90) -  
3 
53  KPYM  Pyruvate kinase isozymes M1/M2 (EC 2.7.1.40) (Pyruvate kinase muscle isozyme) 
(Pyruvate kinase 2/3) (Cytosolic thyroid hormone-binding protein) (CTHBP) (THBP1) 
-  
5 
54  NDKB  Nucleoside diphosphate kinase B (EC 2.7.4.6) (NDK B) (NDP kinase B) (nm23-H2) 
(C-myc purine-binding transcription factor PUF) -  
5 
55  TCPD  T-complex protein 1 subunit delta (TCP-1-delta) (CCT-delta) (Stimulator of TAR 
RNA-binding) -  
3  
 
56  TCPZ  T-complex protein 1 subunit zeta (TCP-1-zeta) (CCT-zeta) (CCT-zeta-1) (Tcp20) 
(HTR3) (Acute morphine dependence-related protein 2) -  
2 
57  KV206  Ig kappa chain V-II region RPMI 6410 precursor -   1 
58  HNRH1  Heterogeneous nuclear ribonucleoprotein H (hnRNP H) -   4 
59  CAH2  Carbonic anhydrase 2 (EC 4.2.1.1) (Carbonic anhydrase II) (Carbonate dehydratase II) 
(CA-II) (Carbonic anhydrase C) -  
3 
60  GDIB  Rab GDP dissociation inhibitor beta (Rab GDI beta) (Guanosine diphosphate 
dissociation inhibitor 2) (GDI-2) -  
4 
61  ACLY  ATP-citrate synthase (EC 2.3.3.8) (ATP-citrate (pro-S-)-lyase) (Citrate cleavage 
enzyme) -  
8 
62  GDIA  Rab GDP dissociation inhibitor alpha (Rab GDI alpha) (Guanosine diphosphate 
dissociation inhibitor 1) (GDI-1) (XAP-4) (Oligophrenin-2) -  
3 
63  CCNT1  Cyclin-T1 (CycT1) (Cyclin-T) -   11 
64  IMA4  Importin alpha-4 subunit (Karyopherin alpha-4 subunit) (Qip1 protein) -   9 
65  YBOX1  Nuclease sensitive element-binding protein 1 (Y-box-binding protein 1) (Y-box 
transcription factor) (YB-1) (CCAAT-binding transcription factor I subunit A) (CBF-
A) (Enhancer factor I subunit A) (EFI-A) (DNA-binding protein B) (DBPB) - ( 
4 
66  CNBP  Cellular nucleic acid-binding protein (CNBP) (Zinc finger protein 9) -   2 
67  HSP74  Heat shock 70 kDa protein 4 (Heat shock 70-related protein APG-2) (HSP70RY) -   5 
68  CH10  10 kDa heat shock protein, mitochondrial (Hsp10) (10 kDa chaperonin) (CPN10) 
(Early-pregnancy factor) (EPF) -  
3 
69  GSTP1  Glutathione S-transferase P (EC 2.5.1.18) (GST class-pi) (GSTP1-1) -   2 
70  DNJA1  DnaJ homolog subfamily A member 1 (Heat shock 40 kDa protein 4) (DnaJ protein 
homolog 2) (HSJ-2) (HSDJ) -  
2 
71  TERA  Transitional endoplasmic reticulum ATPase (TER ATPase) (15S Mg(2+)-ATPase p97 
subunit) (Valosin-containing protein) (VCP) -  
4 
72  ROA2  Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP A2 / hnRNP B1) -   4 
73  KCRB  Creatine kinase B-type (EC 2.7.3.2) (Creatine kinase B chain) (B-CK) -   2 
74  HNRPF  Heterogeneous nuclear ribonucleoprotein F (hnRNP F) (Nucleolin-like protein mcs94-
1) -  
3 
75  RL15  60S ribosomal protein L15 -   5 
76  ALDOA  Fructose-bisphosphate aldolase A (EC 4.1.2.13) (Muscle-type aldolase) (Lung cancer  4  
 
antigen NY-LU-1) -  
77  PRDX2  Peroxiredoxin-2 (EC 1.11.1.15) (Thioredoxin peroxidase 1) (Thioredoxin-dependent 
peroxide reductase 1) (Thiol-specific antioxidant protein) (TSA) (PRP) (Natural killer 
cell-enhancing factor B) (NKEF-B) -  
3 
78  PRP40  Pre-mRNA-processing factor 40 homolog A (Formin-binding protein 3) (Formin-
binding protein 11) (Huntingtin-interacting protein HYPA) (Huntingtin yeast partner 
A) (Fas ligand-associated factor 1) (NY-REN-6 antigen) -  
5 
79  PRDX1  Peroxiredoxin-1 (EC 1.11.1.15) (Thioredoxin peroxidase 2) (Thioredoxin-dependent 
peroxide reductase 2) (Proliferation-associated gene protein) (PAG) (Natural killer cell-
enhancing factor A) (NKEF-A) -  
5 
80  IF5A1  Eukaryotic translation initiation factor 5A-1 (eIF-5A-1) (eIF-5A1) (Eukaryotic 
initiation factor 5A isoform 1) (eIF-5A) (eIF-4D) (Rev-binding factor) -  
2 
81  PGAM1  Phosphoglycerate mutase 1 (EC 5.4.2.1) (EC 5.4.2.4) (EC 3.1.3.13) (Phosphoglycerate 
mutase isozyme B) (PGAM-B) (BPG-dependent PGAM 1) -  
5 
82  RAB10  Ras-related protein Rab-10 -   2 
83  PP2CG  Protein phosphatase 2C isoform gamma (EC 3.1.3.16) (PP2C-gamma) (Protein 
phosphatase magnesium-dependent 1 gamma) (Protein phosphatase 1C) -  
2 
84  ADT2  ADP/ATP translocase 2 (Adenine nucleotide translocator 2) (ANT 2) (ADP,ATP 
carrier protein 2) (Solute carrier family 25 member 5) (ADP,ATP carrier protein, 
fibroblast isoform) -  
4 
85  NDKA  Nucleoside diphosphate kinase A (EC 2.7.4.6) (NDK A) (NDP kinase A) (Tumor 
metastatic process-associated protein) (Metastasis inhibition factor nm23) (nm23-H1) 
(Granzyme A-activated DNase) (GAAD) -  
3 
86  COF1  Cofilin-1 (Cofilin, non-muscle isoform) (18 kDa phosphoprotein) (p18) -   5 
87  AFF4  AF4/FMR2 family member 4 (ALL1-fused gene from chromosome 5q31) (Major 
CDK9 elongation factor-associated protein) -  
7 
88  COA1  Acetyl-CoA carboxylase 1 (EC 6.4.1.2) (ACC-alpha) [Includes: Biotin carboxylase 
(EC 6.3.4.14)] -  
9 
89  ROA3  Heterogeneous nuclear ribonucleoprotein A3 (hnRNP A3) -   1 
90  RL6  60S ribosomal protein L6 (TAX-responsive enhancer element-binding protein 107) 
(TAXREB107) (Neoplasm-related protein C140) -  
2 
91  TCPG  T-complex protein 1 subunit gamma (TCP-1-gamma) (CCT-gamma) (hTRiC5) -   6  
 
92  TCPQ  T-complex protein 1 subunit theta (TCP-1-theta) (CCT-theta) (Renal carcinoma antigen 
NY-REN-15) -  
1 
93  RAP1A  Ras-related protein Rap-1A precursor (GTP-binding protein smg-p21A) (Ras-related 
protein Krev-1) (C21KG) (G-22K) -  
2 
94  VIME  Vimentin -   10 
95  IMA3  Importin alpha-3 subunit (Karyopherin alpha-3 subunit) (SRP1-gamma) -   7 
96  CLH1  Clathrin heavy chain 1 (CLH-17) -   5 
97  SERA  D-3-phosphoglycerate dehydrogenase (EC 1.1.1.95) (3-PGDH) -   1 
98  PIMT  Protein-L-isoaspartate(D-aspartate) O-methyltransferase (EC 2.1.1.77) (Protein-beta-
aspartate methyltransferase) (PIMT) (Protein L-isoaspartyl/D-aspartyl 
methyltransferase) (L-isoaspartyl protein carboxyl methyltransferase) -  
5 
99  SYEP  Bifunctional aminoacyl-tRNA synthetase [Includes: Glutamyl-tRNA synthetase (EC 
6.1.1.17) (Glutamate--tRNA ligase); Prolyl-tRNA synthetase (EC 6.1.1.15) (Proline--
tRNA ligase)] -  
5 
100  VINC  Vinculin (Metavinculin) -   1 
101  NEDD8  NEDD8 precursor (Ubiquitin-like protein Nedd8) (Neddylin) -   1 
102  SF3A3  Splicing factor 3A subunit 3 (Spliceosome-associated protein 61) (SAP 61) (SF3a60) -   2 
103  UBE1  Ubiquitin-activating enzyme E1 (A1S9 protein) -   3 
104  CALM  Calmodulin (CaM) -   2 
105  ANXA5  Annexin A5 (Annexin V) (Lipocortin V) (Endonexin II) (Calphobindin I) (CBP-I) 
(Placental anticoagulant protein I) (PAP-I) (PP4) (Thromboplastin inhibitor) (Vascular 
anticoagulant-alpha) (VAC-alpha) (Anchorin CII) -  
1 
106  HNRPK  Heterogeneous nuclear ribonucleoprotein K (hnRNP K) (Transformation up-regulated 
nuclear protein) (TUNP) -  
4 
107  PSMD1  26S proteasome non-ATPase regulatory subunit 1 (26S proteasome regulatory subunit 
RPN2) (26S proteasome regulatory subunit S1) (26S proteasome subunit p112) -  
1 
108  EF1D  Elongation factor 1-delta (EF-1-delta) (Antigen NY-CO-4) -   5 
109  EFTU  Elongation factor Tu, mitochondrial precursor (EF-Tu) (P43) -   3 
110  IF3A  Eukaryotic translation initiation factor 3 subunit 10 (eIF-3 theta) (eIF3 p167) (eIF3 
p180) (eIF3 p185) (eIF3a) -  
4 
111  KU70  ATP-dependent DNA helicase 2 subunit 1 (ATP-dependent DNA helicase II 70 kDa 
subunit) (Lupus Ku autoantigen protein p70) (Ku70) (70 kDa subunit of Ku antigen) 
2  
 
(Thyroid-lupus autoantigen) (TLAA) (CTC box-binding factor 75 kDa subunit) 
(CTCBF) (CTC75) 
112  K1C10  Keratin, type I cytoskeletal 10 (Cytokeratin-10) (CK-10) (Keratin-10) (K10) -   6 
113  RLA1  60S acidic ribosomal protein P1 -   1 
114  RIB1  Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 67 kDa subunit 
precursor (EC 2.4.1.119) (Ribophorin I) (RPN-I) -  
2 
115  TOM70  Mitochondrial precursor proteins import receptor (Translocase of outer membrane 
TOM70) -  
2 
116  SFPQ  Splicing factor, proline- and glutamine-rich (Polypyrimidine tract-binding protein-
associated-splicing factor) (PTB-associated-splicing factor) (PSF) (DNA-binding 
p52/p100 complex, 100 kDa subunit) (100 kDa DNA-pairing protein) (hPOMp100) - 
Homo sap 
2 
117  RAN  GTP-binding nuclear protein Ran (GTPase Ran) (Ras-like protein TC4) (Androgen 
receptor-associated protein 24) -  
2 
118  KINH  Kinesin heavy chain (Ubiquitous kinesin heavy chain) (UKHC) -   2 
119  SSB  Single-stranded DNA-binding protein, mitochondrial precursor (Mt-SSB) (MtSSB) 
(PWP1-interacting protein 17) -  
1 
120  RS18  40S ribosomal protein S18 (Ke-3) (Ke3) -   2 
121  TRAP1  Heat shock protein 75 kDa, mitochondrial precursor (HSP 75) (Tumor necrosis factor 
type 1 receptor-associated protein) (TRAP-1) (TNFR-associated protein 1) -  
2 
122  HMGB1  High mobility group protein B1 (High mobility group protein 1) (HMG-1) -   2 
123  LDHB  L-lactate dehydrogenase B chain (EC 1.1.1.27) (LDH-B) (LDH heart subunit) (LDH-
H) (Renal carcinoma antigen NY-REN-46) -  
2 
124  CALR  Calreticulin precursor (CRP55) (Calregulin) (HACBP) (ERp60) (grp60) -   3 
125  MOES  Moesin (Membrane-organizing extension spike protein) -   3 
126  MPCP  Phosphate carrier protein, mitochondrial precursor (PTP) (Solute carrier family 25 
member 3) -  
2 
127  C1QBP  Complement component 1 Q subcomponent-binding protein, mitochondrial precursor 
(Glycoprotein gC1qBP) (C1qBP) (GC1q-R protein) (Hyaluronan-binding protein 1) 
(Mitochondrial matrix protein p32) (p33) -  
2 
128  IPO4  Importin-4 (Importin 4b) (Imp4b) (Ran-binding protein 4) (RanBP4) -   1 
129  DDB1  DNA damage-binding protein 1 (Damage-specific DNA-binding protein 1) (UV- 1  
 
damaged DNA-binding factor) (DDB p127 subunit) (DDBa) (UV-damaged DNA-
binding protein 1) (UV-DDB 1) (Xeroderma pigmentosum group E-complementing 
protein) (XPCe) (XPE-binding fa 
130  IF3I  Eukaryotic translation initiation factor 3 subunit 6-interacting protein -   2 
131  PSMD2  26S proteasome non-ATPase regulatory subunit 2 (26S proteasome regulatory subunit 
RPN1) (26S proteasome regulatory subunit S2) (26S proteasome subunit p97) (Tumor 
necrosis factor type 1 receptor-associated protein 2) (55.11 protein) - ( 
1 
132  AAAT  Neutral amino acid transporter B(0) (ATB(0)) (Sodium-dependent neutral amino acid 
transporter type 2) (RD114/simian type D retrovirus receptor) (Baboon M7 virus 
receptor) -  
1 
133  G6PI  Glucose-6-phosphate isomerase (EC 5.3.1.9) (GPI) (Phosphoglucose isomerase) (PGI) 
(Phosphohexose isomerase) (PHI) (Neuroleukin) (NLK) (Sperm antigen 36) (SA-36) -  
1 
134  ARP3  Actin-like protein 3 (Actin-related protein 3) -   1 
135  IPYR  Inorganic pyrophosphatase (EC 3.6.1.1) (Pyrophosphate phospho-hydrolase) (PPase) -   1 
136  U5S1  116 kDa U5 small nuclear ribonucleoprotein component (U5 snRNP-specific protein, 
116 kDa) (U5-116 kDa) (Elongation factor Tu GTP-binding domain protein 2) 
(hSNU114) -  
3 
137  NOLC1  Nucleolar phosphoprotein p130 (Nucleolar 130 kDa protein) (140 kDa nucleolar 
phosphoprotein) (Nopp140) (Nucleolar and coiled-body phosphoprotein 1) -  
1 
138  HMGB2  High mobility group protein B2 (High mobility group protein 2) (HMG-2) -   1 
139  K22E  Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e) (K2e) (CK 2e) -   5 
140  NP1L1  Nucleosome assembly protein 1-like 1 (NAP-1-related protein) (hNRP) -   2 
141  MIF  Macrophage migration inhibitory factor (MIF) (Phenylpyruvate tautomerase) (EC 
5.3.2.1) (Glycosylation-inhibiting factor) (GIF) -  
2 
142  K2C6A  Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK 6A) (K6a keratin) -   3 
143  PYRG1  CTP synthase 1 (EC 6.3.4.2) (UTP--ammonia ligase 1) (CTP synthetase 1) -   1 
144  MDHM  Malate dehydrogenase, mitochondrial precursor (EC 1.1.1.37) -   4 
145  IF4A1  Eukaryotic initiation factor 4A-I (EC 3.6.1.-) (ATP-dependent RNA helicase eIF4A-1) 
(eIF4A-I) (eIF-4A-I) -  
2 
146  K2C5  Keratin, type II cytoskeletal 5 (Cytokeratin-5) (CK-5) (Keratin-5) (K5) (58 kDa 
cytokeratin) -  
4 
147  PHB2  Prohibitin-2 (B-cell receptor-associated protein BAP37) (Repressor of estrogen  2  
 
receptor activity) (D-prohibitin) -  
148  PGK1  Phosphoglycerate kinase 1 (EC 2.7.2.3) (Primer recognition protein 2) (PRP 2) -   3 
149  SERPH  Serpin H1 precursor (Collagen-binding protein) (Colligin) (47 kDa heat shock protein) 
(Rheumatoid arthritis-related antigen RA-A47) (Arsenic-transactivated protein 3) 
(AsTP3) (Proliferation-inducing gene 14 protein) -  
2 
150  PSME2  Proteasome activator complex subunit 2 (Proteasome activator 28-subunit beta) 
(PA28beta) (PA28b) (Activator of multicatalytic protease subunit 2) (11S regulator 
complex subunit beta) (REG-beta) -  
1 
151  PGRC2  Membrane-associated progesterone receptor component 2 (Progesterone membrane-
binding protein) (Steroid receptor protein DG6) -  
1 
152  NP1L4  Nucleosome assembly protein 1-like 4 (Nucleosome assembly protein 2) (NAP2) -   1 
153  RS24  40S ribosomal protein S24 -   1 
154  MLRM  Myosin regulatory light chain 2, nonsarcomeric (Myosin RLC) -   2 
155  FUS  RNA-binding protein FUS (Oncogene FUS) (Oncogene TLS) (Translocated in 
liposarcoma protein) (POMp75) (75 kDa DNA-pairing protein) -  
1 
156  SYRC  Arginyl-tRNA synthetase, cytoplasmic (EC 6.1.1.19) (Arginine--tRNA ligase) (ArgRS) 
-  
2 
157  HORN  Hornerin -   4 
158  PDIA1  Protein disulfide-isomerase precursor (EC 5.3.4.1) (PDI) (Prolyl 4-hydroxylase subunit 
beta) (Cellular thyroid hormone-binding protein) (p55) -  
2 
159  HMOX1  Heme oxygenase 1 (EC 1.14.99.3) (HO-1) -   2 
160  LA  Lupus La protein (Sjoegren syndrome type B antigen) (SS-B) (La ribonucleoprotein) 
(La autoantigen) -  
1 
161  TBCA  Tubulin-specific chaperone A (Tubulin-folding cofactor A) (CFA) (TCP1-chaperonin 
cofactor A) -  
1 
162  IF35  Eukaryotic translation initiation factor 3 subunit 5 (eIF-3 epsilon) (eIF3 p47 subunit) 
(eIF3f) -  
1 
163  PDIA3  Protein disulfide-isomerase A3 precursor (EC 5.3.4.1) (Disulfide isomerase ER-60) 
(ERp60) (58 kDa microsomal protein) (p58) (ERp57) (58 kDa glucose-regulated 
protein) -  
3 
164  RAB7  Ras-related protein Rab-7 -   2 
165  AT1A1  Sodium/potassium-transporting ATPase alpha-1 chain precursor (EC 3.6.3.9) (Sodium  4  
 
pump 1) (Na(+)/K(+) ATPase 1) -  
166  RS19  40S ribosomal protein S19 -   3 
167  TEBP  Prostaglandin E synthase 3 (EC 5.3.99.3) (Cytosolic prostaglandin E2 synthase) 
(cPGES) (Telomerase-binding protein p23) (Hsp90 co-chaperone) (Progesterone 
receptor complex p23) -  
1 
168  API5  Apoptosis inhibitor 5 (API-5) (Fibroblast growth factor 2-interacting factor) (FIF) 
(Protein XAGL) (Antiapoptosis clone 11 protein) (AAC-11) -  
1 
169  AN32A  Acidic leucine-rich nuclear phosphoprotein 32 family member A (Potent heat-stable 
protein phosphatase 2A inhibitor I1PP2A) (Acidic nuclear phosphoprotein pp32) 
(Leucine-rich acidic nuclear protein) (Lanp) (Putative HLA-DR-associated protein I) 
(PHAP 
1 
170  HMGB3  High mobility group protein B3 (High mobility group protein 4) (HMG-4) (High 
mobility group protein 2a) (HMG-2a) -  
1 
171  PUR6  Multifunctional protein ADE2 [Includes: Phosphoribosylaminoimidazole-
succinocarboxamide synthase (EC 6.3.2.6) (SAICAR synthetase); 
Phosphoribosylaminoimidazole carboxylase (EC 4.1.1.21) (AIR carboxylase) (AIRC)] 
-  
3 
172  AKA12  A-kinase anchor protein 12 (A-kinase anchor protein 250 kDa) (AKAP 250) 
(Myasthenia gravis autoantigen gravin) -  
1 
173  K2C4  Keratin, type II cytoskeletal 4 (Cytokeratin-4) (CK-4) (Keratin-4) (K4) -   2 
174  RS4X  40S ribosomal protein S4, X isoform (Single copy abundant mRNA protein) (SCR10) -   4 
175  IMA1  Importin alpha-1 subunit (Karyopherin alpha-1 subunit) (SRP1-beta) (RAG cohort 
protein 2) (Nucleoprotein interactor 1) (NPI-1) -  
4 
176  IF36  Eukaryotic translation initiation factor 3 subunit 6 (eIF-3 p48) (eIF3e) (Viral 
integration site protein INT-6 homolog) -  
1 
177  IPO7  Importin-7 (Imp7) (Ran-binding protein 7) (RanBP7) -   1 
178  RS29  40S ribosomal protein S29 -   1 
179  BASI  Basigin precursor (Leukocyte activation antigen M6) (Collagenase stimulatory factor) 
(Extracellular matrix metalloproteinase inducer) (EMMPRIN) (5F7) (Tumor cell-
derived collagenase stimulatory factor) (TCSF) (OK blood group antigen) (CD147 
antigen) 
1 
180  SEPT2  Septin-2 (Protein NEDD5) -   1  
 
181  DAZP1  DAZ-associated protein 1 (Deleted in azoospermia-associated protein 1) -   1 
182  SSRD  Translocon-associated protein subunit delta precursor (TRAP-delta) (Signal sequence 
receptor subunit delta) (SSR-delta) -  
1 
183  SYAC  Alanyl-tRNA synthetase, cytoplasmic (EC 6.1.1.7) (Alanine--tRNA ligase) (AlaRS) 
(Renal carcinoma antigen NY-REN-42) -  
1 
184  GCN1L  GCN1-like protein 1 (HsGCN1) -   1 
185  SF3A2  Splicing factor 3A subunit 2 (Spliceosome-associated protein 62) (SAP 62) (SF3a66) -   3 
186  THIO  Thioredoxin (Trx) (ATL-derived factor) (ADF) (Surface-associated sulphydryl protein) 
(SASP) -  
1 
187  DHSA  Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial precursor 
(EC 1.3.5.1) (Fp) (Flavoprotein subunit of complex II) -  
1 
188  IMA7  Importin alpha-7 subunit (Karyopherin alpha-6) -   4 
189  TKT  Transketolase (EC 2.2.1.1) (TK) -   2 
190  RAB6B  Ras-related protein Rab-6B -   1 
191  DDX21  Nucleolar RNA helicase 2 (EC 3.6.1.-) (Nucleolar RNA helicase II) (Nucleolar RNA 
helicase Gu) (RH II/Gu) (Gu-alpha) (DEAD box protein 21) -  
1 
192  IF39  Eukaryotic translation initiation factor 3 subunit 9 (eIF-3 eta) (eIF3 p116) (eIF3 p110) 
(eIF3b) (Prt1 homolog) (hPrt1) -  
5 
193  RBBP4  Histone-binding protein RBBP4 (Retinoblastoma-binding protein 4) (RBBP-4) 
(Retinoblastoma-binding protein p48) (Chromatin assembly factor 1 subunit C) (CAF-1 
subunit C) (Chromatin assembly factor I p48 subunit) (CAF-I 48 kDa subunit) (CAF-I 
p48) (Nu 
2 
194  LDHA  L-lactate dehydrogenase A chain (EC 1.1.1.27) (LDH-A) (LDH muscle subunit) (LDH-
M) (Proliferation-inducing gene 19 protein) (Renal carcinoma antigen NY-REN-59) -  
2 
195  GPSN2  Synaptic glycoprotein SC2 -   1 
196  MYH9  Myosin-9 (Myosin heavy chain 9) (Myosin heavy chain, nonmuscle IIa) (Nonmuscle 
myosin heavy chain IIa) (NMMHC II-a) (NMMHC-IIA) (Cellular myosin heavy chain, 
type A) (Nonmuscle myosin heavy chain-A) (NMMHC-A) -  
3 
197  ENPL  Endoplasmin precursor (Heat shock protein 90 kDa beta member 1) (94 kDa glucose-
regulated protein) (GRP94) (gp96 homolog) (Tumor rejection antigen 1) -  
2 
198  APT  Adenine phosphoribosyltransferase (EC 2.4.2.7) (APRT) -   2 
199  RBBP7  Histone-binding protein RBBP7 (Retinoblastoma-binding protein 7) (RBBP-7)  3  
 
(Retinoblastoma-binding protein p46) (Histone acetyltransferase type B subunit 2) 
(Nucleosome remodeling factor subunit RBAP46) -  
200  EWS  RNA-binding protein EWS (EWS oncogene) (Ewing sarcoma breakpoint region 1 
protein) -  
1 
201  KAD2  Adenylate kinase isoenzyme 2, mitochondrial (EC 2.7.4.3) (ATP-AMP 
transphosphorylase) -  
3 
202  RS5  40S ribosomal protein S5 -   1 
203  ACTN1  Alpha-actinin-1 (Alpha-actinin cytoskeletal isoform) (Non-muscle alpha-actinin-1) (F-
actin cross-linking protein) -  
2 
204  SURF4  Surfeit locus protein 4 -   1 
205  SODC  Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) -   2 
206  AT1A3  Sodium/potassium-transporting ATPase alpha-3 chain (EC 3.6.3.9) (Sodium pump 3) 
(Na(+)/K(+) ATPase 3) (Alpha(III)) -  
2 
207  SMC4  Structural maintenance of chromosomes protein 4 (Chromosome-associated 
polypeptide C) (hCAP-C) (XCAP-C homolog) -  
3 
208  PYR1  CAD protein [Includes: Glutamine-dependent carbamoyl-phosphate synthase (EC 
6.3.5.5); Aspartate carbamoyltransferase (EC 2.1.3.2); Dihydroorotase (EC 3.5.2.3)] -  
2 
209  HS74L  Heat shock 70 kDa protein 4L (Osmotic stress protein 94) (Heat shock 70-related 
protein APG-1) -  
3 
210  ECHM  Enoyl-CoA hydratase, mitochondrial precursor (EC 4.2.1.17) (Short chain enoyl-CoA 
hydratase) (SCEH) (Enoyl-CoA hydratase 1) -  
1 
211  RS28  40S ribosomal protein S28 -   1 
212  PRS6B  26S protease regulatory subunit 6B (Proteasome 26S subunit ATPase 4) (MIP224) 
(MB67-interacting protein) (TAT-binding protein 7) (TBP-7) -  
1 
213  SAP  Proactivator polypeptide precursor [Contains: Saposin A (Protein A); Saposin B-Val; 
Saposin B (Sphingolipid activator protein 1) (SAP-1) (Cerebroside sulfate activator) 
(CSAct) (Dispersin) (Sulfatide/GM1 activator); Saposin C (Co-beta-glucosidase) ( 
1 
214  P5CS  Delta 1-pyrroline-5-carboxylate synthetase (P5CS) (Aldehyde dehydrogenase 18 
family member A1) [Includes: Glutamate 5-kinase (EC 2.7.2.11) (Gamma-glutamyl 
kinase) (GK); Gamma-glutamyl phosphate reductase (GPR) (EC 1.2.1.41) (Glutamate-
5-semialdehyde 
1 
215  K2C7  Keratin, type II cytoskeletal 7 (Cytokeratin-7) (CK-7) (Keratin-7) (K7) (Sarcolectin) -   1  
 
216  K0310  Uncharacterized protein KIAA0310 -   1 
217  ERP29  Endoplasmic reticulum protein ERp29 precursor (ERp31) (ERp28) -   1 
218  PCCB  Propionyl-CoA carboxylase beta chain, mitochondrial precursor (EC 6.4.1.3) (PCCase 
subunit beta) (Propanoyl-CoA:carbon dioxide ligase subunit beta) -  
2 
219  TXLNA  Alpha-taxilin -   1 
220  PAIRB  Plasminogen activator inhibitor 1 RNA-binding protein (PAI1 RNA-binding protein 1) 
(PAI-RBP1) (SERPINE1 mRNA-binding protein 1) -  
2 
221  DDX3X  ATP-dependent RNA helicase DDX3X (EC 3.6.1.-) (DEAD box protein 3, X-
chromosomal) (Helicase-like protein 2) (HLP2) (DEAD box, X isoform) -  
1 
222  PYGL  Glycogen phosphorylase, liver form (EC 2.4.1.1) -   1 
223  RANG  Ran-specific GTPase-activating protein (Ran-binding protein 1) (RanBP1) -   1 
224  RENT2  Regulator of nonsense transcripts 2 (Nonsense mRNA reducing factor 2) (Up-
frameshift suppressor 2 homolog) (hUpf2) -  
1 
225  RLA2  60S acidic ribosomal protein P2 (Renal carcinoma antigen NY-REN-44) -   1 
226  ACTZ  Alpha-centractin (Centractin) (Centrosome-associated actin homolog) (Actin-RPV) 
(ARP1) -  
2 
227  PSD7  26S proteasome non-ATPase regulatory subunit 7 (26S proteasome regulatory subunit 
rpn8) (26S proteasome regulatory subunit S12) (Proteasome subunit p40) (Mov34 
protein homolog) -  
1 
228  IF4G1  Eukaryotic translation initiation factor 4 gamma 1 (eIF-4-gamma 1) (eIF-4G1) (eIF-4G 
1) (p220) -  
1 
229  HNRPU  Heterogeneous nuclear ribonucleoprotein U (hnRNP U) (Scaffold attachment factor A) 
(SAF-A) (p120) (pp120) -  
3 
230  PSME3  Proteasome activator complex subunit 3 (Proteasome activator 28-gamma subunit) 
(PA28gamma) (PA28g) (Activator of multicatalytic protease subunit 3) (11S regulator 
complex subunit gamma) (REG-gamma) (Ki nuclear autoantigen) -  
1 
231  ATPO  ATP synthase O subunit, mitochondrial precursor (EC 3.6.3.14) (Oligomycin 
sensitivity conferral protein) (OSCP) -  
1 
232  DYHC  Dynein heavy chain, cytosolic (DYHC) (Cytoplasmic dynein heavy chain 1) (DHC1) 
(Dynein heavy chain 1, cytoplasmic 1) -  
2 
233  TADBP  TAR DNA-binding protein 43 (TDP-43) -   1 
234  MYL6  Myosin light polypeptide 6 (Smooth muscle and nonmuscle myosin light chain alkali  2  
 
6) (Myosin light chain alkali 3) (Myosin light chain 3) (MLC-3) (LC17) -  
235  ASNS  Asparagine synthetase [glutamine-hydrolyzing] (EC 6.3.5.4) (Glutamine-dependent 
asparagine synthetase) (Cell cycle control protein TS11) -  
1 
236  ATP5J  ATP synthase coupling factor 6, mitochondrial precursor (EC 3.6.3.14) (ATPase 
subunit F6) -  
1 
237  RIB2  Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 63 kDa subunit 
precursor (EC 2.4.1.119) (Ribophorin II) (RPN-II) (RIBIIR) -  
1 
238  UBIQ  Ubiquitin -   2 
239  1433Z  14-3-3 protein zeta/delta (Protein kinase C inhibitor protein 1) (KCIP-1) -   1 
240  PRPS1  Ribose-phosphate pyrophosphokinase I (EC 2.7.6.1) (Phosphoribosyl pyrophosphate 
synthetase I) (PRS-I) (PPRibP) -  
2 
241  SET  Protein SET (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor 
I) (TAF-I) (HLA-DR-associated protein II) (PHAPII) (Inhibitor of granzyme A-
activated DNase) (IGAAD) -  
1 
242  RSSA  40S ribosomal protein SA (p40) (34/67 kDa laminin receptor) (Colon carcinoma 
laminin-binding protein) (NEM/1CHD4) (Multidrug resistance-associated protein 
MGr1-Ag) -  
2 
243  IMB3  Importin beta-3 (Karyopherin beta-3) (Ran-binding protein 5) (RanBP5) -   1 
244  1433E  14-3-3 protein epsilon (14-3-3E) -   1 
245  ROAA  Heterogeneous nuclear ribonucleoprotein A/B (hnRNP A/B) (APOBEC-1-binding 
protein 1) (ABBP-1) -  
2 
246  NDUS8  NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial precursor (EC 
1.6.5.3) (EC 1.6.99.3) (NADH-ubiquinone oxidoreductase 23 kDa subunit) (Complex 
I-23kD) (CI-23kD) (TYKY subunit) -  
1 
247  RS10  40S ribosomal protein S10 -   2 
248  CND3  Condensin complex subunit 3 (Non-SMC condensin I complex subunit G) 
(Chromosome-associated protein G) (Condensin subunit CAP-G) (hCAP-G) (XCAP-G 
homolog) (Antigen NY-MEL-3) -  
1 
249  DHCA  Carbonyl reductase [NADPH] 1 (EC 1.1.1.184) (NADPH-dependent carbonyl 
reductase 1) (Prostaglandin-E(2) 9-reductase) (EC 1.1.1.189) (Prostaglandin 9-
ketoreductase) (15-hydroxyprostaglandin dehydrogenase [NADP+]) (EC 1.1.1.197) -  
1 
250  DYL1  Dynein light chain 1, cytoplasmic (Dynein light chain LC8-type 1) (8 kDa dynein light  1  
 
chain) (DLC8) (Protein inhibitor of neuronal nitric oxide synthase) (PIN) -  
251  RL24  60S ribosomal protein L24 (Ribosomal protein L30) -   1 
252  STMN1  Stathmin (Phosphoprotein p19) (pp19) (Oncoprotein 18) (Op18) (Leukemia-associated 
phosphoprotein p18) (pp17) (Prosolin) (Metablastin) (Protein Pr22) -  
1 
253  RUVB1  RuvB-like 1 (EC 3.6.1.-) (49 kDa TATA box-binding protein-interacting protein) (49 
kDa TBP-interacting protein) (TIP49a) (Pontin 52) (Nuclear matrix protein 238) (NMP 
238) (54 kDa erythrocyte cytosolic protein) (ECP-54) (TIP60-associated protein 54- 
1 
254  ATPK  ATP synthase f chain, mitochondrial (EC 3.6.3.14) -   1 
255  HRX  Zinc finger protein HRX (ALL-1) (Trithorax-like protein) -   1 
256  PDIA6  Protein disulfide-isomerase A6 precursor (EC 5.3.4.1) (Protein disulfide isomerase P5) 
(Thioredoxin domain-containing protein 7) -  
1 
257  SYV  Valyl-tRNA synthetase (EC 6.1.1.9) (Valine--tRNA ligase) (ValRS) (Protein G7a) -   1 
258  RCC2  Protein RCC2 (Telophase disk protein of 60 kDa) (RCC1-like protein TD-60) -   1 
259  RM10  39S ribosomal protein L10, mitochondrial precursor (L10mt) (MRP-L10) -   1 
260  PCBP1  Poly(rC)-binding protein 1 (Alpha-CP1) (hnRNP-E1) (Nucleic acid-binding protein 
SUB2.3) -  
2 
261  SPEE  Spermidine synthase (EC 2.5.1.16) (Putrescine aminopropyltransferase) (SPDSY) -   1 
262  SYIC  Isoleucyl-tRNA synthetase, cytoplasmic (EC 6.1.1.5) (Isoleucine--tRNA ligase) 
(IleRS) (IRS) -  
3 
263  MTA2  Metastasis-associated protein MTA2 (Metastasis-associated 1-like 1) (MTA1-L1 
protein) (p53 target protein in deacetylase complex) -  
1 
264  MYH10  Myosin-10 (Myosin heavy chain 10) (Myosin heavy chain, nonmuscle IIb) (Nonmuscle 
myosin heavy chain IIb) (NMMHC II-b) (NMMHC-IIB) (Cellular myosin heavy chain, 
type B) (Nonmuscle myosin heavy chain-B) (NMMHC-B) -  
2 
265  PRS4  26S protease regulatory subunit 4 (P26s4) (Proteasome 26S subunit ATPase 1) -   1 
266  SYTC  Threonyl-tRNA synthetase, cytoplasmic (EC 6.1.1.3) (Threonine--tRNA ligase) 
(ThrRS) -  
1 
267  EF1B  Elongation factor 1-beta (EF-1-beta) -   2 
268  RL38  60S ribosomal protein L38 -   1 
269  PSB2  Proteasome subunit beta type 2 (EC 3.4.25.1) (Proteasome component C7-I) 
(Macropain subunit C7-I) (Multicatalytic endopeptidase complex subunit C7-I) -  
1 
270  OST48  Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit  2  
 
precursor (EC 2.4.1.119) (Oligosaccharyl transferase 48 kDa subunit) (DDOST 48 kDa 
subunit) -  
271  KNG1  Kininogen-1 precursor (Alpha-2-thiol proteinase inhibitor) [Contains: Kininogen-1 
heavy chain; Bradykinin (Kallidin I); Lysyl-bradykinin (Kallidin II); Kininogen-1 light 
chain; Low molecular weight growth-promoting factor] -  
1 
272  APEX1  DNA-(apurinic or apyrimidinic site) lyase (EC 4.2.99.18) (AP endonuclease 1) (APEX 
nuclease) (APEN) (REF-1 protein) -  
2 
273  TFR1  Transferrin receptor protein 1 (TfR1) (TR) (TfR) (Trfr) (CD71 antigen) (T9) (p90) -   1 
274  RL10A  60S ribosomal protein L10a (CSA-19) -   1 
275  H2A1A  Histone H2A type 1-A -   1 
276  DPY30  Dpy-30-like protein -   1 
277  PRDX3  Thioredoxin-dependent peroxide reductase, mitochondrial precursor (EC 1.11.1.15) 
(Peroxiredoxin-3) (PRX III) (Antioxidant protein 1) (AOP-1) (Protein MER5 homolog) 
(HBC189) -  
1 
278  RL12  60S ribosomal protein L12 -   1 
279  KLDC2  Kelch domain-containing protein 2 (Hepatocellular carcinoma-associated antigen 33) 
(Host cell factor homolog LCP) -  
1 
280  DDX46  Probable ATP-dependent RNA helicase DDX46 (EC 3.6.1.-) (DEAD box protein 46) 
(PRP5 homolog) -  
1 
281  RCN2  Reticulocalbin-2 precursor (Calcium-binding protein ERC-55) (E6-binding protein) 
(E6BP) -  
2 
282  SFRS3  Splicing factor, arginine/serine-rich 3 (Pre-mRNA-splicing factor SRP20) -   1 
283  CPNE1  Copine-1 (Copine I) -   1 
284  RS27L  40S ribosomal protein S27-like protein -   1 
285  UBP7  Ubiquitin carboxyl-terminal hydrolase 7 (EC 3.1.2.15) (Ubiquitin thioesterase 7) 
(Ubiquitin-specific-processing protease 7) (Deubiquitinating enzyme 7) (Herpesvirus-
associated ubiquitin-specific protease) -  
1 
286  C1TC  C-1-tetrahydrofolate synthase, cytoplasmic (C1-THF synthase) [Includes: 
Methylenetetrahydrofolate dehydrogenase (EC 1.5.1.5); Methenyltetrahydrofolate 
cyclohydrolase (EC 3.5.4.9); Formyltetrahydrofolate synthetase (EC 6.3.4.3)] - 
(Human 
1 
287  PSMD3  26S proteasome non-ATPase regulatory subunit 3 (26S proteasome regulatory subunit  1  
 
S3) (Proteasome subunit p58) -  
288  RCC1  Regulator of chromosome condensation (Chromosome condensation protein 1) (Cell 
cycle regulatory protein) -  
1 
289  HDGF  Hepatoma-derived growth factor (HDGF) (High-mobility group protein 1-like 2) 
(HMG-1L2) -  
1 
290  RD23B  UV excision repair protein RAD23 homolog B (hHR23B) (XP-C repair-
complementing complex 58 kDa protein) (p58) -  
1 
291  NUP50  Nucleoporin 50 kDa (Nuclear pore-associated protein 60 kDa-like) -   2 
292  FLNA  Filamin-A (Alpha-filamin) (Filamin-1) (Endothelial actin-binding protein) (Actin-
binding protein 280) (ABP-280) (Nonmuscle filamin) -  
2 
293  SYQ  Glutaminyl-tRNA synthetase (EC 6.1.1.18) (Glutamine--tRNA ligase) (GlnRS) -   1 
294  RS15A  40S ribosomal protein S15a -   1 
295  HXK1  Hexokinase-1 (EC 2.7.1.1) (Hexokinase type I) (HK I) (Brain form hexokinase) -   1 
296  FXR1  Fragile X mental retardation syndrome-related protein 1 (hFXR1p) -   1 
297  HINT1  Histidine triad nucleotide-binding protein 1 (Adenosine 5~-monophosphoramidase) 
(Protein kinase C inhibitor 1) (Protein kinase C-interacting protein 1) (PKCI-1) -  
1 
298  JIP4  C-jun-amino-terminal kinase-interacting protein 4 (JNK-interacting protein 4) (JIP-4) 
(JNK-associated leucine-zipper protein) (JLP) (Sperm-associated antigen 9) (Mitogen-
activated protein kinase 8-interacting protein 4) (Human lung cancer protein 6) 
1 
299  RS23  40S ribosomal protein S23 -   1 
300  G3BP2  Ras GTPase-activating protein-binding protein 2 (G3BP-2) (GAP SH3 domain-binding 
protein 2) -  
1 
301  SRP09  Signal recognition particle 9 kDa protein (SRP9) -   1 
302  TIF1B  Transcription intermediary factor 1-beta (TIF1-beta) (Tripartite motif-containing 
protein 28) (Nuclear corepressor KAP-1) (KRAB-associated protein 1) (KAP-1) 
(KRAB-interacting protein 1) (KRIP-1) (RING finger protein 96) -  
1 
303  PERQ2  PERQ amino acid-rich with GYF domain-containing protein 2 (Grb10-interacting GYF 
protein 2) (Trinucleotide repeat-containing protein 15) -  
1 
304  GCSH  Glycine cleavage system H protein, mitochondrial precursor -   2 
305  PSMD6  26S proteasome non-ATPase regulatory subunit 6 (26S proteasome regulatory subunit 
S10) (p42A) (Proteasome regulatory particle subunit p44S10) (Phosphonoformate 
immuno-associated protein 4) (Breast cancer-associated protein SGA-113M) - ( 
1  
 
306  PSA  Puromycin-sensitive aminopeptidase (EC 3.4.11.-) (PSA) -   1 
307  HCDH  Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial precursor (EC 1.1.1.35) 
(Short chain 3-hydroxyacyl-CoA dehydrogenase) (HCDH) (Medium and short chain L-
3-hydroxyacyl-coenzyme A dehydrogenase) -  
1 
308  U520  U5 small nuclear ribonucleoprotein 200 kDa helicase (EC 3.6.1.-) (U5 snRNP-specific 
200 kDa protein) (U5-200KD) (Activating signal cointegrator 1 complex subunit 3-like 
1) (BRR2 homolog) -  
1 
309  RL7A  60S ribosomal protein L7a (Surfeit locus protein 3) (PLA-X polypeptide) -   1 
310  IF34  Eukaryotic translation initiation factor 3 subunit 4 (eIF-3 delta) (eIF3 p44) (eIF-3 
RNA-binding subunit) (eIF3 p42) (eIF3g) -  
2 
311  GBF1  Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 (BFA-
resistant GEF 1) -  
1 
312  AMPL  Cytosol aminopeptidase (EC 3.4.11.1) (Leucine aminopeptidase) (LAP) (Leucyl 
aminopeptidase) (Leucine aminopeptidase 3) (Proline aminopeptidase) (EC 3.4.11.5) 
(Prolyl aminopeptidase) (Peptidase S) -  
1 
313  KAP2  cAMP-dependent protein kinase type II-alpha regulatory subunit -   1 
314  SRP68  Signal recognition particle 68 kDa protein (SRP68) -   2 
315  RL23  60S ribosomal protein L23 (Ribosomal protein L17) -   1 
316  IGHG2  Ig gamma-2 chain C region -   1 
317  HSPB1  Heat-shock protein beta-1 (HspB1) (Heat shock 27 kDa protein) (HSP 27) (Stress-
responsive protein 27) (SRP27) (Estrogen-regulated 24 kDa protein) (28 kDa heat 
shock protein) -  
1 
318  TXND5  Thioredoxin domain-containing protein 5 precursor (Thioredoxin-like protein p46) 
(Endoplasmic reticulum protein ERp46) -  
2 
319  RL18  60S ribosomal protein L18 -   1 
320  RGS3  Regulator of G-protein signaling 3 (RGS3) (RGP3) -   1 
321  LAMP1  Lysosome-associated membrane glycoprotein 1 precursor (LAMP-1) (CD107a antigen) 
-  
1 
322  PHB  Prohibitin -   1 
323  RS20  40S ribosomal protein S20 -   2 
324  COTL1  Coactosin-like protein -   1 
325  RL30  60S ribosomal protein L30 -   1  
 
326  TRY1  Trypsin-1 precursor (EC 3.4.21.4) (Trypsin I) (Cationic trypsinogen) (Serine protease 
1) -  
1 
327  RS7  40S ribosomal protein S7 -   1 
328  RL17  60S ribosomal protein L17 (L23) -   1 
329  SC23A  Protein transport protein Sec23A (SEC23-related protein A) -   1 
330  LRC59  Leucine-rich repeat-containing protein 59 -   1 
331  SAHH  Adenosylhomocysteinase (EC 3.3.1.1) (S-adenosyl-L-homocysteine hydrolase) 
(AdoHcyase) -  
1 
332  RS9  40S ribosomal protein S9 -   1 
333  SGTA  Small glutamine-rich tetratricopeptide repeat-containing protein A (Vpu-binding 
protein) (UBP) -  
1 
334  LAP2A  Lamina-associated polypeptide 2 isoform alpha (Thymopoietin isoform alpha) (TP 
alpha) (Thymopoietin-related peptide isoform alpha) (TPRP isoform alpha) [Contains: 
Thymopoietin (TP) (Splenin); Thymopentin (TP5)] -  
1 
335  GANAB  Neutral alpha-glucosidase AB precursor (EC 3.2.1.84) (Glucosidase II subunit alpha) -   1 
336  OXRP  150 kDa oxygen-regulated protein precursor (Orp150) (Hypoxia up-regulated 1) -   1 
337  RL8  60S ribosomal protein L8 -   1 
338  ENAM  Enamelin precursor -   1 
339  MBB1A  Myb-binding protein 1A -   1 
340  YES  Proto-oncogene tyrosine-protein kinase Yes (EC 2.7.10.2) (p61-Yes) (c-Yes) -   1 
341  CD2L7  Cell division cycle 2-related protein kinase 7 (EC 2.7.11.22) (CDC2-related protein 
kinase 7) (Cdc2-related kinase, arginine/serine-rich) (CrkRS) -  
1 
342  RS14  40S ribosomal protein S14 -   1 
343  SF3B3  Splicing factor 3B subunit 3 (Spliceosome-associated protein 130) (SAP 130) 
(SF3b130) (Pre-mRNA-splicing factor SF3b 130 kDa subunit) (STAF130) -  
1 
345  STT3A  Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3A (EC 
2.4.1.119) (Oligosaccharyl transferase subunit STT3A) (STT3-A) (B5) (Integral 
membrane protein 1) (TMC) -  
1 
346  GP162  Probable G-protein coupled receptor 162 (Gene-rich cluster gene A protein) -   1 
347  AT2A2  Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (EC 3.6.3.8) (Calcium pump 
2) (SERCA2) (SR Ca(2+)-ATPase 2) (Calcium-transporting ATPase sarcoplasmic 




348  PCCA  Propionyl-CoA carboxylase alpha chain, mitochondrial precursor (EC 6.4.1.3) (PCCase 
subunit alpha) (Propanoyl-CoA:carbon dioxide ligase subunit alpha) -  
1 
349  LPPRC  130 kDa leucine-rich protein (LRP 130) (GP130) (Leucine-rich PPR motif-containing 
protein) -  
1 
350  ANM1  Protein arginine N-methyltransferase 1 (EC 2.1.1.-) (Interferon receptor 1-bound 
protein 4) -  
1 
352  CF060  Uncharacterized protein C6orf60 -   1 
353  LAT1  Large neutral amino acids transporter small subunit 1 (L-type amino acid transporter 1) 
(4F2 light chain) (4F2 LC) (4F2LC) (CD98 light chain) (Integral membrane protein 
E16) (hLAT1) -  
1 
354  LAP2B  Lamina-associated polypeptide 2, isoforms beta/gamma (Thymopoietin, isoforms 
beta/gamma) (TP beta/gamma) (Thymopoietin-related peptide isoforms beta/gamma) 
(TPRP isoforms beta/gamma) [Contains: Thymopoietin (TP) (Splenin); Thymopentin 
(TP5)] - Homo  
1 
355  SND1  Staphylococcal nuclease domain-containing protein 1 (p100 co-activator) (100 kDa 
coactivator) (EBNA2 coactivator p100) -  
1 
356  K0146  Uncharacterized protein KIAA0146 -   1 
357  BTNL3  Butyrophilin-like protein 3 precursor (Butyrophilin-like receptor) -   1 
358  LAMP2  Lysosome-associated membrane glycoprotein 2 precursor (LAMP-2) (CD107b antigen) 
-  
1 
359  PROF1  Profilin-1 (Profilin I) -   1 
360  CORT  Cortistatin precursor [Contains: Cortistatin-29; Cortistatin-17] -   1 
361  PUR2  Trifunctional purine biosynthetic protein adenosine-3 [Includes: Phosphoribosylamine-
-glycine ligase (EC 6.3.4.13) (GARS) (Glycinamide ribonucleotide synthetase) 
(Phosphoribosylglycinamide synthetase); Phosphoribosylformylglycinamidine cyclo-
ligase  
1 
362  PTBP1  Polypyrimidine tract-binding protein 1 (PTB) (Heterogeneous nuclear 
ribonucleoprotein I) (hnRNP I) (57 kDa RNA-binding protein PPTB-1) -  
1 
363  XPO5  Exportin-5 (Exp5) (Ran-binding protein 21) -   1 
364  PR285  Peroxisomal proliferator-activated receptor A-interacting complex 285 kDa protein 
(EC 3.6.1.-) (ATP-dependent helicase PRIC285) (PPAR-alpha-interacting complex 
1  
 
protein 285) (PPAR-gamma DBD-interacting protein 1) (PDIP1) -  
365  PFD2  Prefoldin subunit 2 -   1 
366  PIGR  Polymeric-immunoglobulin receptor precursor (Poly-Ig receptor) (PIGR) 
(Hepatocellular carcinoma-associated protein TB6) [Contains: Secretory component] -  
1 
367  MMP15  Matrix metalloproteinase-15 precursor (EC 3.4.24.-) (MMP-15) (Membrane-type 
matrix metalloproteinase 2) (MT-MMP 2) (MTMMP2) (Membrane-type-2 matrix 
metalloproteinase) (MT2-MMP) (MT2MMP) (SMCP-2) -  
1 
368  PUR9  Bifunctional purine biosynthesis protein PURH [Includes: 
Phosphoribosylaminoimidazolecarboxamide formyltransferase (EC 2.1.2.3) (5-
aminoimidazole-4-carboxamide ribonucleotide formyltransferase) (AICAR 
transformylase); IMP cyclohydrolase (EC 3.5.4.10 
1 
369  ROA0  Heterogeneous nuclear ribonucleoprotein A0 (hnRNP A0) -   1 
370  IF4H  Eukaryotic translation initiation factor 4H (eIF-4H) (Williams-Beuren syndrome 
chromosome region 1 protein) -  
1 
371  ENSA  Alpha-endosulfine (ARPP-19e) -   1 
372  H1X  Histone H1x -   1 
373  UAP56  Spliceosome RNA helicase BAT1 (EC 3.6.1.-) (DEAD box protein UAP56) (56 kDa 
U2AF65-associated protein) (ATP-dependent RNA helicase p47) (HLA-B-associated 
transcript-1) -  
1 
374  MCA3  Eukaryotic translation elongation factor 1 epsilon-1 (Multisynthetase complex auxiliary 
component p18) (Elongation factor p18) -  
1 
375  PARP1  Poly [ADP-ribose] polymerase 1 (EC 2.4.2.30) (PARP-1) (ADPRT) (NAD(+) ADP-
ribosyltransferase 1) (Poly[ADP-ribose] synthetase 1) -  
1 
377  RL36  60S ribosomal protein L36 -   1 
378  ANM5  Protein arginine N-methyltransferase 5 (EC 2.1.1.125) (EC 2.1.1.-) (Shk1 kinase-
binding protein 1 homolog) (SKB1Hs) (Jak-binding protein 1) (72 kDa ICln-binding 
protein) -  
1 
379  FLNB  Filamin-B (FLN-B) (Beta-filamin) (Actin-binding-like protein) (Thyroid autoantigen) 
(Truncated actin-binding protein) (Truncated ABP) (ABP-280 homolog) (ABP-278) 
(Filamin 3) (Filamin homolog 1) (Fh1) -  
1 
380  FAK1  Focal adhesion kinase 1 (EC 2.7.10.2) (FADK 1) (pp125FAK) (Protein-tyrosine kinase 
2) -  
1  
 
381  CENPU  Centromere protein U (CENP-U) (CENP-U(50)) (CENP-50) (Interphase centromere 
complex protein 24) (MLF1-interacting protein) (KSHV latent nuclear antigen-
interacting protein 1) -  
1 
382  ZN516  Zinc finger protein 516 -   1 
383  GP175  Integral membrane protein GPR175 -   1 
384  PRKDC  DNA-dependent protein kinase catalytic subunit (EC 2.7.11.1) (DNA-PK catalytic 
subunit) (DNA-PKcs) (DNPK1) (p460) -  
1 
385  IF38  Eukaryotic translation initiation factor 3 subunit 8 (eIF3 p110) (eIF3c) -   1 
386  AF9  Protein AF-9 (ALL1 fused gene from chromosome 9 protein) (Myeloid/lymphoid or 
mixed-lineage leukemia translocated to chromosome 3 protein) (YEATS domain-
containing protein 3) -  
1 
387  GRN  Granulins precursor (Proepithelin) (PEPI) [Contains: Acrogranin; Paragranulin; 
Granulin-1 (Granulin G); Granulin-2 (Granulin F); Granulin-3 (Granulin B); Granulin-
4 (Granulin A); Granulin-5 (Granulin C); Granulin-6 (Granulin D); Granulin-7 
(Granulin 
1 
388  CSK2B  Casein kinase II subunit beta (CK II beta) (Phosvitin) (G5a) -   2 
389  LRMP  Lymphoid-restricted membrane protein (Protein Jaw1) -   1 
390  SEPT7  Septin-7 (CDC10 protein homolog) -   1 
391  TM165  Transmembrane protein 165 (Transmembrane protein TPARL) (Transmembrane 
protein PT27) -  
1 
392  SUHW3  Suppressor of hairy wing homolog 3 -   1 
393  IF37  Eukaryotic translation initiation factor 3 subunit 7 (eIF-3 zeta) (eIF3 p66) (eIF3d) -   1 
394  SYDC  Aspartyl-tRNA synthetase, cytoplasmic (EC 6.1.1.12) (Aspartate--tRNA ligase) 
(AspRS) (Cell proliferation-inducing gene 40 protein) -  
1 
395  RM27  Mitochondrial 39S ribosomal protein L27 (L27mt) (MRP-L27) -   1 
397  NHERF  Ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) (Na(+)/H(+) exchange 
regulatory cofactor NHE-RF) (NHERF-1) (Regulatory cofactor of Na(+)/H(+) 
exchanger) (Sodium-hydrogen exchanger regulatory factor 1) (Solute carrier family 9 
isoform 3 regula 
1 
398  BOLA2  BolA-like protein 2 -   1 
399  CCNT2  Cyclin-T2 (CycT2) -   1 
400  RL3L  60S ribosomal protein L3-like -   1  
 
401  IGF1B  Insulin-like growth factor IB precursor (IGF-IB) (Somatomedin C) (Mechano growth 
factor) (MGF) -  
1 
402  TCOF  Treacle protein (Treacher Collins syndrome protein) -   1 
403  NPA1P  Nucleolar preribosomal-associated protein 1 (Fragment) -   1 
404  RAB2A  Ras-related protein Rab-2A -   1 
405  UN45B  UNC45 homolog B (UNC-45B) -   1 
406  LN28A  Lin-28 homolog A (Zinc finger CCHC domain-containing protein 1) -   1 
407  2AAA  Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform 
(PP2A, subunit A, PR65-alpha isoform) (PP2A, subunit A, R1-alpha isoform) 
(Medium tumor antigen-associated 61 kDa protein) -  
1 
408  GROA  Growth-regulated protein alpha precursor (CXCL1) (Melanoma growth stimulatory 
activity) (MGSA) (Neutrophil-activating protein 3) (NAP-3) (GRO-alpha(1-73)) 
[Contains: GRO-alpha(4-73); GRO-alpha(5-73); GRO-alpha(6-73)] -  
1 
410  RUXE  Small nuclear ribonucleoprotein E (snRNP-E) (Sm protein E) (Sm-E) (SmE) -   1 
411  CG029  Uncharacterized protein C7orf29 -   1 
412  MSH2  DNA mismatch repair protein Msh2 (MutS protein homolog 2) -   1 
414  INOC1  Putative DNA helicase INO80 complex homolog 1 (EC 3.6.1.-) (hINO80) -   1 
416  CKAP4  Cytoskeleton-associated protein 4 (63 kDa membrane protein) (p63) -   1 
417  SFRS2  Splicing factor, arginine/serine-rich 2 (Splicing factor SC35) (SC-35) (Splicing 
component, 35 kDa) (Protein PR264) -  
1 
419  CENA1  Centaurin-alpha 1 (Putative MAPK-activating protein PM25) -   1 
 
    
 





number  number 
Protein protein description  peptides 
1  HRX  Zinc finger protein HRX (ALL-1) (Trithorax-like protein)   131 
2  HSP71  Heat shock 70 kDa protein 1 (HSP70.1) (HSP70-1/HSP70-2)   38 
3  AFF1  AF4/FMR2 family member 1 (Protein AF-4) (Proto-oncogene AF4) (Protein FEL)   44 
4  HSP7C  Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8)   23 
5  GRP78  78 kDa glucose-regulated protein precursor (GRP 78) (Heat shock 70 kDa protein 5) 
(Immunoglobulin heavy chain-binding protein) (BiP) (Endoplasmic reticulum lumenal 
Ca(2+)-binding protein grp78)  
22 
6  HSP76  Heat shock 70 kDa protein 6 (Heat shock 70 kDa protein B~)   13 
7  GRP75  Stress-70 protein, mitochondrial precursor (75 kDa glucose-regulated protein) (GRP 
75) (Peptide-binding protein 74) (PBP74) (Mortalin) (MOT)  
10 
8  TBA6  Tubulin alpha-6 chain (Alpha-tubulin 6)   7 
9  TBB5  Tubulin beta chain (Tubulin beta-5 chain)   11 
10  TBB2C  Tubulin beta-2C chain (Tubulin beta-2 chain)   9 
11  ACTB  Actin, cytoplasmic 1 (Beta-actin)   6 
12  HCFC1  Host cell factor (HCF) (HCF-1) (C1 factor) (VP16 accessory protein) (VCAF) (CFF) 
[Contains: HCF N-terminal chain 1; HCF N-terminal chain 2; HCF N-terminal chain 3; 
HCF N-terminal chain 4; HCF N-terminal chain 5; HCF N-terminal chain 6; HCF C-
termina 
14 
13  PIMT  Protein-L-isoaspartate(D-aspartate) O-methyltransferase (EC 2.1.1.77) (Protein-beta-
aspartate methyltransferase) (PIMT) (Protein L-isoaspartyl/D-aspartyl 
methyltransferase) (L-isoaspartyl protein carboxyl methyltransferase)  
7 
14  RBBP5  Retinoblastoma-binding protein 5 (RBBP-5) (Retinoblastoma-binding protein RBQ-3)   4 
15  CSK2B  Casein kinase II subunit beta (CK II beta) (Phosvitin) (G5a)   2 
16  ATX2L  Ataxin-2-like protein (Ataxin-2 domain protein) (Ataxin-2-related protein)   9 
17  CH60  60 kDa heat shock protein, mitochondrial precursor (Hsp60) (60 kDa chaperonin) 
(CPN60) (Heat shock protein 60) (HSP-60) (Mitochondrial matrix protein P1) (P60 
lymphocyte protein) (HuCHA60)  
4  
 
18  HS105  Heat-shock protein 105 kDa (Heat shock 110 kDa protein) (Antigen NY-CO-25)   6 
19  EF1G  Elongation factor 1-gamma (EF-1-gamma) (eEF-1B gamma)   5 
20  WDR5  WD repeat protein 5 (BMP2-induced 3-kb gene protein)   4 
21  MIF  Macrophage migration inhibitory factor (MIF) (Phenylpyruvate tautomerase) (EC 
5.3.2.1) (Glycosylation-inhibiting factor) (GIF)  
2 
22  DDX6  Probable ATP-dependent RNA helicase DDX6 (EC 3.6.1.-) (DEAD box protein 6) 
(ATP-dependent RNA helicase p54) (Oncogene RCK)  
4 
23  HSP74  Heat shock 70 kDa protein 4 (Heat shock 70-related protein APG-2) (HSP70RY)   2 
24  CSK21  Casein kinase II subunit alpha (EC 2.7.11.1) (CK II)   3 
25  ASH2L  Set1/Ash2 histone methyltransferase complex subunit ASH2 (ASH2-like protein)   4 
26  ADT2  ADP/ATP translocase 2 (Adenine nucleotide translocator 2) (ANT 2) (ADP,ATP 
carrier protein 2) (Solute carrier family 25 member 5) (ADP,ATP carrier protein, 
fibroblast isoform)  
2 
27  HS90B  Heat shock protein HSP 90-beta (HSP 84) (HSP 90)   2 
28  CDK9  Cell division protein kinase 9 (EC 2.7.11.22) (EC 2.7.11.23) (Cyclin-dependent kinase 
9) (Serine/threonine-protein kinase PITALRE) (C-2K) (Cell division cycle 2-like 
protein kinase 4)  
2 
29  DPY30  Dpy-30-like protein   2 
30  HS90A  Heat shock protein HSP 90-alpha (HSP 86) (Renal carcinoma antigen NY-REN-38)   3 
31  EF1A1  Elongation factor 1-alpha 1 (EF-1-alpha-1) (Elongation factor 1 A-1) (eEF1A-1) 
(Elongation factor Tu) (EF-Tu) (Leukocyte receptor cluster member 7)  
3 
32  EF2  Elongation factor 2 (EF-2)   1 
33  COA1  Acetyl-CoA carboxylase 1 (EC 6.4.1.2) (ACC-alpha) [Includes: Biotin carboxylase (EC 
6.3.4.14)]  
1 
34  CCNT1  Cyclin-T1 (CycT1) (Cyclin-T)   3 
35  PRDX1  Peroxiredoxin-1 (EC 1.11.1.15) (Thioredoxin peroxidase 2) (Thioredoxin-dependent 
peroxide reductase 2) (Proliferation-associated gene protein) (PAG) (Natural killer cell-
enhancing factor A) (NKEF-A)  
2 
36  RS29  40S ribosomal protein S29   1 
37  SET  Protein SET (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor 
I) (TAF-I) (HLA-DR-associated protein II) (PHAPII) (Inhibitor of granzyme A-
activated DNase) (IGAAD)  
1  
 
38  PPIA  Peptidyl-prolyl cis-trans isomerase A (EC 5.2.1.8) (PPIase A) (Rotamase A) 
(Cyclophilin A) (Cyclosporin A-binding protein)  
2 
39  UTS2  Urotensin-2 precursor (Urotensin-II) (U-II) (UII)   1 
40  GCSH  Glycine cleavage system H protein, mitochondrial precursor   1 
41  ACTN1  Alpha-actinin-1 (Alpha-actinin cytoskeletal isoform) (Non-muscle alpha-actinin-1) (F-
actin cross-linking protein)  
1 
42  PRDX4  Peroxiredoxin-4 (EC 1.11.1.15) (Prx-IV) (Thioredoxin peroxidase AO372) 
(Thioredoxin-dependent peroxide reductase A0372) (Antioxidant enzyme AOE372) 
(AOE37-2)  
2 
43  MCCC2  Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial precursor (EC 6.4.1.4) (3-
Methylcrotonyl-CoA carboxylase 2) (MCCase subunit beta) (3-methylcrotonyl-
CoA:carbon dioxide ligase subunit beta) (3-Methylcrotonyl-CoA carboxylase non-
biotin-contai 
2 
44  GDE  Glycogen debranching enzyme (Glycogen debrancher) [Includes: 4-alpha-
glucanotransferase (EC 2.4.1.25) (Oligo-1,4-1,4-glucantransferase); Amylo-alpha-1,6-
glucosidase (EC 3.2.1.33) (Amylo-1,6-glucosidase) (Dextrin 6-alpha-D-glucosidase)] - 
Homo sapien 
2 
45  TCPE  T-complex protein 1 subunit epsilon (TCP-1-epsilon) (CCT-epsilon)   1 
46  PSME3  Proteasome activator complex subunit 3 (Proteasome activator 28-gamma subunit) 
(PA28gamma) (PA28g) (Activator of multicatalytic protease subunit 3) (11S regulator 
complex subunit gamma) (REG-gamma) (Ki nuclear autoantigen)  
3 
47  RS9  40S ribosomal protein S9   1 
48  TCPB  T-complex protein 1 subunit beta (TCP-1-beta) (CCT-beta)   2 
49  FAS  Fatty acid synthase (EC 2.3.1.85) [Includes: [Acyl-carrier-protein] S-acetyltransferase 
(EC 2.3.1.38); [Acyl-carrier-protein] S-malonyltransferase (EC 2.3.1.39); 3-oxoacyl-
[acyl-carrier-protein] synthase (EC 2.3.1.41); 3-oxoacyl-[acyl-carrier-protei 
1 
50  HNRPF  Heterogeneous nuclear ribonucleoprotein F (hnRNP F) (Nucleolin-like protein mcs94-
1)  
1 
51  SERA  D-3-phosphoglycerate dehydrogenase (EC 1.1.1.95) (3-PGDH)   1 
52  ROA1  Heterogeneous nuclear ribonucleoprotein A1 (Helix-destabilizing protein) (Single-
strand RNA-binding protein) (hnRNP core protein A1)  
1 
53  SFPQ  Splicing factor, proline- and glutamine-rich (Polypyrimidine tract-binding protein- 1  
 
associated-splicing factor) (PTB-associated-splicing factor) (PSF) (DNA-binding 
p52/p100 complex, 100 kDa subunit) (100 kDa DNA-pairing protein) (hPOMp100) - 
Homo sap 
54  HCFC2  Host cell factor 2 (HCF-2) (C2 factor)   2 
55  PP2AA  Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (EC 3.1.3.16) 
(PP2A-alpha) (Replication protein C) (RP-C)  
1 
56  SF3A1  Splicing factor 3 subunit 1 (Spliceosome-associated protein 114) (SAP 114) (SF3a120)   1 
57  TCPG  T-complex protein 1 subunit gamma (TCP-1-gamma) (CCT-gamma) (hTRiC5)   1 
58  CLH1  Clathrin heavy chain 1 (CLH-17)   1 
59  SYT4  Synaptotagmin-4 (Synaptotagmin IV) (SytIV)   1 
60  PGAM1  Phosphoglycerate mutase 1 (EC 5.4.2.1) (EC 5.4.2.4) (EC 3.1.3.13) (Phosphoglycerate 
mutase isozyme B) (PGAM-B) (BPG-dependent PGAM 1)  
1 
61  CH10  10 kDa heat shock protein, mitochondrial (Hsp10) (10 kDa chaperonin) (CPN10) 
(Early-pregnancy factor) (EPF)  
1 
62  ASPP1  Apoptosis-stimulating of p53 protein 1 (Protein phosphatase 1 regulatory subunit 13B)   1 
63  NPM  Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin) (Nucleolar protein 
NO38)  
1 
64  PGRC1  Membrane-associated progesterone receptor component 1 (mPR)   1 
65  G3P  Glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) (GAPDH)   1 
66  ANK2  Ankyrin-2 (Brain ankyrin) (Ankyrin-B) (Ankyrin, nonerythroid)   1 
67  HS74L  Heat shock 70 kDa protein 4L (Osmotic stress protein 94) (Heat shock 70-related 
protein APG-1)  
1 
68  SUCA  Succinyl-CoA ligase [GDP-forming] subunit alpha, mitochondrial precursor (EC 
6.2.1.4) (Succinyl-CoA synthetase subunit alpha) (SCS-alpha)  
1 
69  COG1  Conserved oligomeric Golgi complex component 1   1 
70  IMB1  Importin beta-1 subunit (Karyopherin beta-1 subunit) (Nuclear factor P97) (Importin 
90)  
1 
71  KCRB  Creatine kinase B-type (EC 2.7.3.2) (Creatine kinase B chain) (B-CK)   1 
72  K2C1  Keratin, type II cytoskeletal 1 (Cytokeratin-1) (CK-1) (Keratin-1) (K1) (67 kDa 
cytokeratin) (Hair alpha protein)  
2 
73  L1CAM  Neural cell adhesion molecule L1 precursor (N-CAM L1) (CD171 antigen)   1 
74  WASF2  Wiskott-Aldrich syndrome protein family member 2 (WASP-family protein member 2)  1  
 
(Protein WAVE-2) (Verprolin homology domain-containing protein 2)  
75  K22E  Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e) (K2e) (CK 2e)   1 
76  HTRA3  Probable serine protease HTRA3 precursor (EC 3.4.21.-) (High-temperature 
requirement factor A3) (Pregnancy-related serine protease)  
1 
78  STMN1  Stathmin (Phosphoprotein p19) (pp19) (Oncoprotein 18) (Op18) (Leukemia-associated 
phosphoprotein p18) (pp17) (Prosolin) (Metablastin) (Protein Pr22)  
1 
81  RAN  GTP-binding nuclear protein Ran (GTPase Ran) (Ras-like protein TC4) (Androgen 
receptor-associated protein 24)  
1 
83  XYLT1  Xylosyltransferase 1 (EC 2.4.2.26) (Xylosyltransferase I) (XylT-I) (XT-I) (Peptide O-
xylosyltransferase 1)  
1 
84  CSK22  Casein kinase II subunit alpha~ (EC 2.7.11.1) (CK II)   1 
85  MAGI1  Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 
(BAI1-associated protein 1) (BAP-1) (Membrane-associated guanylate kinase inverted 
1) (MAGI-1) (Atrophin-1-interacting protein 3) (AIP3) (WW domain-containing 
protein 3)  
1 
87  SNAT  Serotonin N-acetyltransferase (EC 2.3.1.87) (Aralkylamine N-acetyltransferase) (AA-
NAT) (Serotonin acetylase)  
1 
 
    
 





Protein description  peptides 
1  K2C1  Keratin, type II cytoskeletal 1 (Cytokeratin-1) (CK-1) (Keratin-1) (K1) (67 kDa 
cytokeratin) (Hair alpha protein)  
11 
2  HSP71  Heat shock 70 kDa protein 1 (HSP70.1) (HSP70-1/HSP70-2)   14 
3  K1C9  Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)   6 
4  AFF1  AF4/FMR2 family member 1 (Protein AF-4) (Proto-oncogene AF4) (Protein 
FEL)  
21 
5  KV206  Ig kappa chain V-II region RPMI 6410 precursor   1 
6  HSP76  Heat shock 70 kDa protein 6 (Heat shock 70 kDa protein B~)   3 
7  TBAK  Tubulin alpha-ubiquitous chain (Alpha-tubulin ubiquitous) (Tubulin K-alpha-1)   6 
8  TBB5  Tubulin beta chain (Tubulin beta-5 chain)   6 
9  HSP7C  Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8)   5 
10  ACTB  Actin, cytoplasmic 1 (Beta-actin)   5 
11  K1C10  Keratin, type I cytoskeletal 10 (Cytokeratin-10) (CK-10) (Keratin-10) (K10)   5 
12  GRP78  78 kDa glucose-regulated protein precursor (GRP 78) (Heat shock 70 kDa protein 
5) (Immunoglobulin heavy chain-binding protein) (BiP) (Endoplasmic reticulum 
lumenal Ca(2+)-binding protein grp78)  
3 
13  ALBU  Serum albumin precursor   4 
14  K2C4  Keratin, type II cytoskeletal 4 (Cytokeratin-4) (CK-4) (Keratin-4) (K4)   2 
15  K2C6A  Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK 6A) (K6a keratin)   3 
16  K2C5  Keratin, type II cytoskeletal 5 (Cytokeratin-5) (CK-5) (Keratin-5) (K5) (58 kDa 
cytokeratin)  
2 
17  EF1A1  Elongation factor 1-alpha 1 (EF-1-alpha-1) (Elongation factor 1 A-1) (eEF1A-1) 
(Elongation factor Tu) (EF-Tu) (Leukocyte receptor cluster member 7)  
3 
18  PGRC1  Membrane-associated progesterone receptor component 1 (mPR)   2 
19  K22E  Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e) (K2e) (CK 2e)   1 
20  ENL  Protein ENL (YEATS domain-containing protein 1)   3 




22  YBOX1  Nuclease sensitive element-binding protein 1 (Y-box-binding protein 1) (Y-box 
transcription factor) (YB-1) (CCAAT-binding transcription factor I subunit A) 
(CBF-A) (Enhancer factor I subunit A) (EFI-A) (DNA-binding protein B) 
(DBPB) ( 
2 
23  HORN  Hornerin   4 
24  KV401  Ig kappa chain V-IV region precursor (Fragment)   1 
25  CH60  60 kDa heat shock protein, mitochondrial precursor (Hsp60) (60 kDa chaperonin) 
(CPN60) (Heat shock protein 60) (HSP-60) (Mitochondrial matrix protein P1) 
(P60 lymphocyte protein) (HuCHA60)  
2 
26  IGHG2  Ig gamma-2 chain C region   1 
27  TCPD  T-complex protein 1 subunit delta (TCP-1-delta) (CCT-delta) (Stimulator of TAR 
RNA-binding)  
2 
28  CALX  Calnexin precursor (Major histocompatibility complex class I antigen-binding 
protein p88) (p90) (IP90)  
2 
29  RS28  40S ribosomal protein S28   1 
30  EFTU  Elongation factor Tu, mitochondrial precursor (EF-Tu) (P43)   1 
31  TCPA  T-complex protein 1 subunit alpha (TCP-1-alpha) (CCT-alpha)   2 
32  TCPG  T-complex protein 1 subunit gamma (TCP-1-gamma) (CCT-gamma) (hTRiC5)   2 
33  MLRM  Myosin regulatory light chain 2, nonsarcomeric (Myosin RLC)   1 
34  CDK9  Cell division protein kinase 9 (EC 2.7.11.22) (EC 2.7.11.23) (Cyclin-dependent 
kinase 9) (Serine/threonine-protein kinase PITALRE) (C-2K) (Cell division cycle 
2-like protein kinase 4)  
1 
35  CND3  Condensin complex subunit 3 (Non-SMC condensin I complex subunit G) 
(Chromosome-associated protein G) (Condensin subunit CAP-G) (hCAP-G) 
(XCAP-G homolog) (Antigen NY-MEL-3)  
1 
36  IMB1  Importin beta-1 subunit (Karyopherin beta-1 subunit) (Nuclear factor P97) 
(Importin 90)  
1 
37  RL10A  60S ribosomal protein L10a (CSA-19)   1 
38  PYC  Pyruvate carboxylase, mitochondrial precursor (EC 6.4.1.1) (Pyruvic carboxylase) 
(PCB)  
2 




40  UBIQ  Ubiquitin   1 
41  PSMD3  26S proteasome non-ATPase regulatory subunit 3 (26S proteasome regulatory 
subunit S3) (Proteasome subunit p58)  
1 
42  RCN2  Reticulocalbin-2 precursor (Calcium-binding protein ERC-55) (E6-binding 
protein) (E6BP)  
1 
43  PERQ2  PERQ amino acid-rich with GYF domain-containing protein 2 (Grb10-interacting 
GYF protein 2) (Trinucleotide repeat-containing protein 15)  
1 
44  TCPH  T-complex protein 1 subunit eta (TCP-1-eta) (CCT-eta) (HIV-1 Nef-interacting 
protein)  
1 
45  RS10  40S ribosomal protein S10   1 
46  MYH10  Myosin-10 (Myosin heavy chain 10) (Myosin heavy chain, nonmuscle IIb) 
(Nonmuscle myosin heavy chain IIb) (NMMHC II-b) (NMMHC-IIB) (Cellular 
myosin heavy chain, type B) (Nonmuscle myosin heavy chain-B) (NMMHC-B)  
1 
47  SRP68  Signal recognition particle 68 kDa protein (SRP68)   2 
48  WDR7  WD repeat protein 7 (TGF-beta resistance-associated protein TRAG) 
(Rabconnectin-3 beta)  
1 
49  RL30  60S ribosomal protein L30   1 
50  ENAM  Enamelin precursor   1 
51  SMC4  Structural maintenance of chromosomes protein 4 (Chromosome-associated 
polypeptide C) (hCAP-C) (XCAP-C homolog)  
1 
52  ANM1  Protein arginine N-methyltransferase 1 (EC 2.1.1.-) (Interferon receptor 1-bound 
protein 4)  
1 
53  LAT1  Large neutral amino acids transporter small subunit 1 (L-type amino acid 
transporter 1) (4F2 light chain) (4F2 LC) (4F2LC) (CD98 light chain) (Integral 
membrane protein E16) (hLAT1)  
1 
54  RS4X  40S ribosomal protein S4, X isoform (Single copy abundant mRNA protein) 
(SCR10)  
1 
55  LAMP2  Lysosome-associated membrane glycoprotein 2 precursor (LAMP-2) (CD107b 
antigen)  
1 
56  H1X  Histone H1x   1 
57  GRP75  Stress-70 protein, mitochondrial precursor (75 kDa glucose-regulated protein) 
(GRP 75) (Peptide-binding protein 74) (PBP74) (Mortalin) (MOT)  
1  
 
58  RS20  40S ribosomal protein S20   1 
59  ANM5  Protein arginine N-methyltransferase 5 (EC 2.1.1.125) (EC 2.1.1.-) (Shk1 kinase-
binding protein 1 homolog) (SKB1Hs) (Jak-binding protein 1) (72 kDa ICln-
binding protein)  
1 
60  FLNB  Filamin-B (FLN-B) (Beta-filamin) (Actin-binding-like protein) (Thyroid 
autoantigen) (Truncated actin-binding protein) (Truncated ABP) (ABP-280 
homolog) (ABP-278) (Filamin 3) (Filamin homolog 1) (Fh1)  
1 
61  NPM  Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin) (Nucleolar 
protein NO38)  
1 
62  ZN516  Zinc finger protein 516   1 
63  GP175  Integral membrane protein GPR175   1 
64  RBBP4  Histone-binding protein RBBP4 (Retinoblastoma-binding protein 4) (RBBP-4) 
(Retinoblastoma-binding protein p48) (Chromatin assembly factor 1 subunit C) 
(CAF-1 subunit C) (Chromatin assembly factor I p48 subunit) (CAF-I 48 kDa 
subunit) (CAF-I p48) (Nu 
1 
65  SUHW3  Suppressor of hairy wing homolog 3   1 
66  SYDC  Aspartyl-tRNA synthetase, cytoplasmic (EC 6.1.1.12) (Aspartate--tRNA ligase) 
(AspRS) (Cell proliferation-inducing gene 40 protein)  
1 
67  CARD9  Caspase recruitment domain-containing protein 9 (hCARD9)   1 
68  IQEC2  IQ motif and Sec7 domain-containing protein 2   1 
69  ZEP2  Human immunodeficiency virus type I enhancer-binding protein 2 (HIV-EP2) 
(MHC-binding protein 2) (MBP-2)  
1 
71  ESPL1  Separin (EC 3.4.22.49) (Separase) (Caspase-like protein ESPL1) (Extra spindle 
poles-like 1 protein)  
1 
72  INOC1  Putative DNA helicase INO80 complex homolog 1 (EC 3.6.1.-) (hINO80)   1 
73  SO1B3  Solute carrier organic anion transporter family member 1B3 (Solute carrier family 
21 member 8) (Organic anion transporter 8) (Organic anion-transporting 
polypeptide 8) (OATP8) (Liver-specific organic anion transporter 2) (LST-2) 
(Huma 
1 
74  HNRH1  Heterogeneous nuclear ribonucleoprotein H (hnRNP H)   1 
75  TMM33  Transmembrane protein 33 (DB83 protein)   1 
  
 





Protein description  peptides 
1  PCCA  Propionyl-CoA carboxylase alpha chain, mitochondrial precursor (EC 6.4.1.3) 
(PCCase subunit alpha) (Propanoyl-CoA:carbon dioxide ligase subunit alpha)  
24 
2  PYC  Pyruvate carboxylase, mitochondrial precursor (EC 6.4.1.1) (Pyruvic carboxylase) 
(PCB)  
29 
3  PCCB  Propionyl-CoA carboxylase beta chain, mitochondrial precursor (EC 6.4.1.3) 
(PCCase subunit beta) (Propanoyl-CoA:carbon dioxide ligase subunit beta)  
20 
4  MCCC2  Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial precursor (EC 
6.4.1.4) (3-Methylcrotonyl-CoA carboxylase 2) (MCCase subunit beta) (3-
methylcrotonyl-CoA:carbon dioxide ligase subunit beta) (3-Methylcrotonyl-CoA 
carboxylase non-biotin-contai 
11 
5  K2C1  Keratin, type II cytoskeletal 1 (Cytokeratin-1) (CK-1) (Keratin-1) (K1) (67 kDa 
cytokeratin) (Hair alpha protein)  
8 
6  HSP71  Heat shock 70 kDa protein 1 (HSP70.1) (HSP70-1/HSP70-2)   10 
7  GRP78  78 kDa glucose-regulated protein precursor (GRP 78) (Heat shock 70 kDa protein 
5) (Immunoglobulin heavy chain-binding protein) (BiP) (Endoplasmic reticulum 
lumenal Ca(2+)-binding protein grp78)  
7 
8  ATX2L  Ataxin-2-like protein (Ataxin-2 domain protein) (Ataxin-2-related protein)   4 
9  HSP7C  Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8)   3 
10  ACTB  Actin, cytoplasmic 1 (Beta-actin)   5 
11  GRP75  Stress-70 protein, mitochondrial precursor (75 kDa glucose-regulated protein) 
(GRP 75) (Peptide-binding protein 74) (PBP74) (Mortalin) (MOT)  
5 
12  K1C9  Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)   2 
13  MCCA  Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial precursor (EC 
6.4.1.4) (3-methylcrotonyl-CoA carboxylase 1) (MCCase subunit alpha) (3-
methylcrotonyl-CoA:carbon dioxide ligase subunit alpha) (3-methylcrotonyl-CoA 
carboxylase biotin-conta 
4 
14  GCSH  Glycine cleavage system H protein, mitochondrial precursor   1 
15  EF1G  Elongation factor 1-gamma (EF-1-gamma) (eEF-1B gamma)   2  
 
16  PIMT  Protein-L-isoaspartate(D-aspartate) O-methyltransferase (EC 2.1.1.77) (Protein-
beta-aspartate methyltransferase) (PIMT) (Protein L-isoaspartyl/D-aspartyl 
methyltransferase) (L-isoaspartyl protein carboxyl methyltransferase)  
2 
17  KNG1  Kininogen-1 precursor (Alpha-2-thiol proteinase inhibitor) [Contains: Kininogen-
1 heavy chain; Bradykinin (Kallidin I); Lysyl-bradykinin (Kallidin II); Kininogen-
1 light chain; Low molecular weight growth-promoting factor]  
1 
18  UBP35  Ubiquitin carboxyl-terminal hydrolase 35 (EC 3.1.2.15) (Ubiquitin thioesterase 
35) (Ubiquitin-specific-processing protease 35) (Deubiquitinating enzyme 35)  
1 
19  CORT  Cortistatin precursor [Contains: Cortistatin-29; Cortistatin-17]   1 
20  K2C6A  Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK 6A) (K6a keratin)   1 
 
 
    
 
Suplementry table S 5 (S5A) shows the identified proteins and number of peptides assigned to each protein from PM with their respective 
Protein accession number. Membrane proteins are indicated by bold typeface. 
Protein accession number   Protein identifeind   No. of peptide 
gi|10581760  dipeptide ABC transporter dipeptide-binding   101 
gi|50979297  pancreatic elastase I [Sus scrofa]  64 
gi|10580369  halocyanin precursor-like   14 
gi|10580964  bacteriorhodopsin   81 
gi|10581613  halocyanin precursor-like   4 
gi|10584350  Na+/H+ antiporter   10 
gi|10581921  dipeptide ABC transporter ATP-binding   75 
gi|10579949  bifunctional short chain isoprenyl 
diphosphate synthase  
4 
gi|10581945  conserved hypothetical protein   11 
gi|16554513  cytochrome c oxidase subunit I   14 
gi|10580181  conserved hypothetical protein   4 
gi|10580237  NADH dehydrogenase/oxidoreductase   6 
gi|10580777  hypothetical protein   15 
gi|10581558  H+-transporting ATP synthase subunit K   5 
gi|10580180  hypothetical protein   6 
gi|10581468  hypothetical protein   1 
gi|10584336  Vng6297c   12 
gi|10580235  F420H2:quinone oxidoreductase chain L   2 
gi|10580236  F420H2:quinone oxidoreductase chain M   5 
gi|10580721  membrane protein   3 
gi|10581015  daunorubicin resistance ABC transporter 
ATP-binding protein  
3 
gi|10581732  heterodisulfide reductase   3 
gi|10582055  cell surface glycoprotein   16  
 
gi|10580483  iron-binding protein   12 
gi|10581758  dipeptide ABC transporter permease   3 
gi|10579770  ABC transport protein   1 
gi|10580230  NADH dehydrogenase/oxidoreductase   4 
gi|10581182  protein translocase   4 
gi|10580113  hypothetical protein   1 
gi|10580234  NADH dehydrogenase/oxidoreductase-like 
protein  
1 
gi|10581612  cytochrome c oxidase subunit II   6 
gi|10580168  conserved hypothetical protein   40 
gi|10584307  adhesion protein   43 
gi|10580139  immunogenic protein   44 
gi|10579932  lipoate protein ligase   10 
gi|16554486  metallo-beta-lactamase superfamily hydrolase   5 
gi|10581419  protein-export membrane protein   7 
gi|10581255  hypothetical protein   5 
gi|10580177  conserved hypothetical protein   5 
gi|10580062  phosphate ABC transporter periplasmic 
phosphate-binding  
6 
gi|10580210  hypothetical protein   4 
gi|10581692  conserved hypothetical protein   3 
gi|10581371  hypothetical protein   4 
gi|10581882  phosphate ABC transporter binding   6 
gi|10581159  50S ribosomal protein L13P   6 
gi|10581787  hypothetical protein   5 
gi|10580017  hypothetical protein   3 
gi|10580676  50S ribosomal protein L13P   4 
gi|10584333  Vng6296c   4 
gi|10581759  dipeptide ABC transporter permease   3 
gi|10581802  conserved hypothetical protein   3  
 
gi|10581968  hypothetical protein   3 
gi|10580962  bacteriorhodopsin related protein   3 
gi|10581997  probable carboxypeptidase   4 
gi|10580022  conserved hypothetical protein   2 
gi|10580178  cytochrome b6   3 
gi|10580246  cytochrome c oxidase subunit I   3 
gi|10581140  30S ribosomal protein S8E   3 
gi|10581420  protein-export membrane protein   2 
gi|10580517  flagellin B1 precursor   3 
gi|10584332  peroxidase / catalase   2 
gi|10580211  proteinase IV homolog   2 
gi|16554512  hypothetical protein VNG2166Cm   1 
gi|10581401  hypothetical protein   1 
gi|16554520  nicotinate phosphoribosyltransferase   2 
gi|2822317  CydA   2 
gi|10580518  flagellin B2 precursor   2 
gi|10580564  flagellin A1 precursor   2 
gi|10580175  hypothetical protein   2 
gi|10582039  30S ribosomal protein S7P   2 
gi|10579826  50S ribosomal protein L15E   2 
gi|10581923  dipeptide ABC transporter permease   2 
gi|10579829  halorhodopsin   3 
gi|10579959  hypothetical protein   2 
gi|10581502  possible phosphate binding protein   3 
gi|10580541  hypothetical protein   1 
gi|10581366  pyruvate dehydrogenase alpha subunit   1 
gi|10581215  Htr5 transducer   2 
gi|10580278  conserved hypothetical protein   1 
gi|10581131  Htr1 transducer   2 
gi|161349984  putative monovalent cation/H+ antiporter  1  
 
subunit D  
gi|10581818  hypothetical protein   2 
gi|10580251  cytochrome c oxidase subunit II   3 
gi|10580565  flagellin A2 precursor   2 
gi|10580828  succinate dehydrogenase subunit C   3 
gi|10581411  hypothetical protein   1 
gi|10581208  photolyase/cryptochrome   1 
gi|10579815  proteasome, subunit beta   1 
gi|10580617  transmembrane oligosaccharyl transferase   1 
gi|10581350  hypothetical protein   2 
gi|10580166  conserved hypothetical protein   2 
gi|10584311  Vng6268c   3 
gi|10580667  putative 2-ketoglutarate ferredoxin 
oxidoreductase (beta)  
2 
gi|10579748  50S ribosomal protein L10E   3 
gi|10580916  hypothetical protein   1 
gi|10581815  GTP-binding protein homolog   1 
gi|10580374  conserved hypothetical protein   1 
gi|10581307  cation efflux system protein (zinc/cadmium)   1 
gi|10581785  copper transport ATP-binding protein   2 
gi|10581174  30S ribosomal protein S8P   1 
gi|10580182  hypothetical protein   1 
gi|10581298  hypothetical protein   1 
gi|10580755  hypothetical protein   1 
gi|10581693  conserved hypothetical protein   1 
gi|10580262  conserved hypothetical protein   1 
gi|10581447  conserved hypothetical protein   1 
gi|10579799  regulatory protein   1 
gi|10580172  hypothetical protein   1 
gi|10581680  protein export   1  
 
gi|10580137  conserved hypothetical protein   1 
gi|10584298  Vng6251h   1 
gi|10580337  hypothetical protein   1 
gi|10580060  phosphate ABC transporter permease   2 
gi|10580277  conserved hypothetical protein   1 
gi|10580156  conserved hypothetical protein   1 
gi|10581800  probable thiosulfate sulfurtransferase   1 
gi|10580519  flagellin B3 precursor   1 
gi|10579654  glutamine-fructose-6-phosphate transaminase   1 
gi|10580668  putative 2-ketoglutarate ferredoxin 
oxidoreductase (alpha)  
1 
gi|10581224  translation initiation factor eIF-5A   1 
gi|10580553  probable oxidoreductase   1 
gi|10581433  oligopeptidase   1 
gi|10580424  conserved hypothetical protein   2 
gi|10580248  hypothetical protein   1 
gi|10579777  heat shock protein   1 
gi|10580874  conserved hypothetical protein   1 
gi|10582040  30S ribosomal protein S12P   1 
gi|10581312  spermidine/putrescine ABC transporter 
permease  
1 
gi|10581108  halocyanin precursor-like   1 
gi|10584354  transcription regulator   1 
gi|10581486  conserved hypothetical protein   1 
gi|10580917  hypothetical protein   1 
gi|10581181  50S ribosomal protein L15P   1 
gi|10581199  Htr-like protein   1 
gi|10580365  Htr6 transducer   1 
gi|10580990  50S ribosomal protein L37E   1 
gi|10580748  glucose-6-phosphate isomerase   1  
 
gi|10580872  hypothetical protein   1 
gi|10581417  conserved hypothetical protein   1 
gi|10584305  ABC transporter, permease protein   1 
gi|10580459  ribose ABC transporter permease   1 
gi|10579905  conserved hypothetical protein   1 
gi|10580439  possible signaling protein   1 
gi|10581507  hypothetical protein   1 
gi|10580225  NADH dehydrogenase/oxidoreductase-like 
protein  
1 
gi|10581107  cobalamin biosynthesis protein   1 
gi|10580692  small heat shock protein   1 
 
    
 
Suplementry table S 5B (S5B) shows the identified proteins and number of peptides assigned to each protein from CGM with their 






Protein description  No. of 
peptides 
1  Cg0446   succinate dehydrogenase A   38 
2  Cg2181  ABC-type peptide transport system, secreted component   21 
3  Cg2911  ABC-type Mn/Zn transport system, secreted Mn/Zn-binding (lipo)protein   20 
4  P00772  Elastase-1   14 
5  Cg2404  RIESKE IRON-SULFUR PROTEIN  18 
6  Cg2705  MALTOSE-BINDING PROTEIN PRECURSOR   17 
7  Cg2137   GLUTAMATE SECRETED BINDING PROTEIN component/domain  16 
8  Cg2195  putative secreted or membrane protein   10 
9  Cg0737  ABC-type transport system, secreted lipoprotein component   12 
10  Cg1656  NADH DEHYDROGENASE   11 
11  Cg1537  GLUCOSE-SPECIFIC ENZYME II BC COMPONENT OF PTS   7 
12  Cg0935  conserved hypothetical protein   8 
13  Cg0040  PUTATIVE SECRETED PROTEIN   7 
14  Cg3186  Trehalose corynomycolyl transferase   8 
15  Cg0447  succinate dehydrogenase B   9 
16  Cg2409  CYTOCHROME C OXIDASE CHAIN II    11 
17  Cg2403  CYTOCHROME B, MEMBRANE PROTEIN   7 
18  Cg0413  Trehalose corynomycolyl transferase   9 
19  Cg2211  putative membrane protein   4 
20  Cg2708  ABC-type sugar transport system, ATPase component   9 
21  Cg0834  Bacterial extracellular solute-binding protein, fa   5 




23  Cg1787  PHOSPHOENOLPYRUVATE CARBOXYLASE   7 
24  Cg2657  putative membrane protein - fragment   3 
25  Cg3182  Trehalose corynomycolyl transferase    3 
26  Cg2151  Similar to phage shock protein A   6 
27  Cg1085   hypothetical protein predicted by Glimmer/Critica   5 
28  Cg0953  Na+/proline, Na+/panthothenate symporter or related permease   4 
29  Cg2429  GLUTAMINE SYNTHETASE I  5 
30  Cg2925  ENZYME II SUCROSE PROTEIN   5 
31  Cg1081  ABC-type multidrug transport system, ATPase component   6 
32  Cg2843  ABC-type phosphate transport system, ATPase component   2 
33  Cg1790  PHOSPHOGLYCERATE KINASE   2 
34  Cg2949  putative secreted protein   2 
35  Cg1332  PUTATIVE SECRETED HYDROLASE   2 
36  Cg1001  LARGE CONDUCTANCE MECHANOSENSITIVE CHANNEL   2 
37  Cg3138  Membrane protease subunit, stomatin/prohibitin homolog   4 
38  Cg0753  secreted protein   3 
39  Cg2782  Ferritin-like protein   3 
40  Cg3257  conserved hypothetical protein   3 
41  Cg1290  Homocysteine methyltransferase   3 
42  Cg0654  RIBOSOMAL PROTEIN S4   2 
43  Cg2499  GLYCYL-TRNA SYNTHETASE (GLYCINE--TRNA LIGASE)   2 
44  Cg2419  LEUCINE AMINOPEPTIDASE   2 
45  Cg3192  putative secreted or membrane protein   1 
46  Cg0655  DNA-DIRECTED RNA POLYMERASE ALPHA SUBUNIT   2 
47  Cg3195  Flavin-containing monooxygenase (FMO)   2 
48  Cg1111  ENOLASE   2 
49  Cg1363  ATP SYNTHASE C CHAIN   2 
50  Cg2184  ATPase component of peptide ABC-type transport system, contains 
duplicated ATPase domains  
1 
51  Cg2912  ABC-type cobalamin/Fe3+-siderophores transport system, ATPase  1  
 
component  
52  Cg3395  PROLINE/ECTOINE CARRIER   4 
53  Cg1109  Anion-specific porin precursor   2 
54  Cg2325  hypothetical protein predicted by Glimmer/Critica   2 
55  Cg1796  putative membrane protein - C. ammoniagenes RibX homolog   2 
56  Cg0699  INOSITOL-MONOPHOSPHATE DEHYDROGENASE   1 
57  Cg3100  Heat shock protein hsp70  1 
58  Cg0350  TRANSCRIPTIONAL REGULATOR, CRP/FNR FAMILY   1 
59  Cg1836  secreted solute-binding protein, aminodeoxychorismate lyase-like   2 
60  Cg0577  DNA-DIRECTED RNA POLYMERASE BETA~ CHAIN   2 
61  Cg2052  putative secreted protein   1 
62  Cg1227  putative membrane protein   1 
63  Cg1604  putative secreted protein   1 
64  Cg1794  Uncharacterised P-loop ATPase protein   1 
65  Cg1713  DIHYDROOROTATE DEHYDROGENASE  1 
66  Cg2604  putative secreted or membrane protein   1 
67  Cg2492  PROBABLE GLUCOSAMINE--FRUCTOSE-6-PHOSPHATE 
AMINOTRANSFERASE  
1 
68  Cg1108  putative secreted protein  1 
69  Cg1052  corynomycolyl transferase  1 
70  Cg1366  PROBABLE ATP SYNTHASE ALPHA CHAIN PROTEIN   2 
71  Cg2704  ABC-type sugar transport system, permease component   1 
72  Cg0938  Cold shock protein   1 
73  Cg2405  CYTOCHROME C1   1 
74  Cg3343  putative secreted membrane protein  2 
75  Cg3008  PORIN   1 
76  Cg0441  DIHYDROLIPOAMIDE DEHYDROGENASE   1 
77  Cg1654  PHOSPHOMETHYLPYRIMIDINE KINASE / 
HYDROXYMETHYLPYRI 
2 
78  Cg3149  Aminotransferases class-I   2  
 
79  Cg2183  ABC-type peptide transport system, permease component   1 
80  Cg2460  putative membrane protein   1 
81  Cg2275   putative F0F1-type ATP synthase b subunit   1 
82  Cg0811  ACETYL/PROPIONYL COA CARBOXYLASE, BETA SUBUNIT   1 
83  Cg2136  GLUTAMATE UPTAKE SYSTEM ATP-BINDING PROTEIN   1 
84  Cg0336  PENICILLIN-BINDING PROTEIN 1B   1 
85  Cg3252  putative preprotein translocase subunit YidC, SpoIIIJ homolog   1 
86  Cg1286  conserved hypothetical protein   1 
87  Cg2466  PYRUVATE DEHYDROGENASE E1 COMPONENT   1 
88  Cg0464  COPPER-TRANSPORTING ATPASE   1 
89  Cg2963  PROBABLE ATP-DEPENDENT PROTEASE (HEAT SHOCK 
PROTEIN) 
1 
90  Cg0625  secreted protein  1 
91  Cg1368  ATP SYNTHASE ALPHA SUBUNIT   2 
92  Cg0448  conserved hypothetical membrane protein  1 
93  Cg0896  membrane protein   1 
94  Cg0835  ABC-type sugar transport systems, ATPase component   2 
95  Cg0254  AMINO ACID CARRIER PROTEIN (SODIUM/ALANINE 
SYMPORTER)  
1 
96  Cg1367  ATP SYNTHASE GAMMA SUBUNIT   1 
97  Cg1730  secreted protease subunit, stomatin/prohibitin homolog  2 
98  Cg1479  PUTATIVE GLYCOGEN PHOSPHORYLASE   2 
99  Cg0107  secreted protein  1 
100  Cg0451  PUTATIVE MEMBRANE PROTEIN   1 
101  Cg1868   Preprotein translocase subunit YajC homolog   1 
102  Cg0587  ELONGATION FACTOR TU   1 
103  Cg0237  PUTATIVE OXIDOREDUCTASE  1 
104  Cg0161  putative secreted or membrane protein  1 
105  Cg1046  RNA POLYMERASE SIGMA FACTOR, PUTATIVE  1 
106  Cg0410  PUTATIVE PROLYL ENDOPEPTIDASE  1  
 
107  Cg1504  ABC-type amino acid transport system, secreted component   1 
108  Cg3356  Na+/H+-dicarboxylate symporter   1 
109  Cg0756  PUTATIVE CARBON STARVATION PROTEIN A   1 
110  Cg2747  SECRETED PEPTIDASE, M23/M37 FAMILY   1 
111  Cg1813  PUTATIVE CARBAMOYL-PHOSPHATE SYNTHASE SUBUNIT  1 
112  Cg1229  ABC-type cobalt transport system, permease component CbiQ   1 
113  Cg2450  putative pyridoxine biosynthesis enzyme   1 
114  Cg0564  50S RIBOSOMAL PROTEIN L1   1 
115  Cg0603  50S RIBOSOMAL PROTEIN L29  1 
116  Cg3216  GLUCONATE PERMEASE   1 
117  Cg1590  secreted Mg-chelatase subunit  1 
118  Cg0980  secreted protein related to metalloendopeptidases   1 
119  Cg2120  SUGAR SPECIFIC PTS SYSTEM, FRUCTOSE/MANNITOL-
SPECIFIC TRANSPORT PROTEIN  
1 
120  Cg2444  hypothetical protein predicted by Glimmer/Critica   1 
121  Cg4005  putative secreted protein   1 
122  Cg0359  PUTATIVE MEMBRANE PROTEIN   1 
123  Cg2291  PYRUVATE KINASE  1 
124  Cg2467  ABC TRANSPORTER ATP-BINDING PROTEIN  1 
125  Cg1778  GLUCOSE-6-PHOSPHATE 1-DEHYDROGENASE   1 
126  Cg0576  DNA-DIRECTED RNA POLYMERASE BETA CHAIN   1 
127  Cg1133  Serine Hydroxymethyltransferase   1 
128  Cg2160  HYDROLASE OF METALLO-BETA-LACTAMASE SUPERFAMILY   1 
129  Cg3174  exporter of the MMPL family   1 
130  Cg0601  30S RIBOSOMAL PROTEIN S3   1 
131  Cg2235  50S RIBOSOMAL PROTEIN L19   1 
132  Cg2773  Uncharacterized protein with SCP/PR1 domain  1 
133  Cg0791  PYRUVATE CARBOXYLASE   1 
134  Cg1169  Na+-dependent transporters of the SNF family   1 
135  Cg1791  GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE   1  
 
136  Cg0648  ADENYLATE KINASE  1 
137  Cg2132  conserved hypothetical protein   1 
138  Cg3244  conserved hypothetical protein  1 
139  Cg0610  50S RIBOSOMAL PROTEIN L5   1 
140  Cg0508  iron/thiamine transport system, secreted component   1 
141  Cg0524  Cytochrome c assembly membrane protein   1 
143  Cg1238  putative membrane protein   1 
144  Cg0445  succinate dehydrogenase CD  1 
145  Cg0518  GLUTAMATE-1-SEMIALDEHYDE 2,1-AMINOMUTASE   1 
146  Cg1577   putative secreted hydrolase   1 
147  Cg1672  polyprenol-phosphate-mannose synthase domain 1   1 
148  Cg0783  conserved hypothetical protein   1 
149  Cg2213  ABC-type multidrug transport system, ATPase component   1 
150  Cg1277   conserved hypothetical membrane protein  1 
 
    
 
Supplementry table S5 C (S5C) summary of the fractions, peptides sequence, calculated mass (pep_calc_mr ), mass acuuracy (pep_delta), 
peptide score (pep_score), homology (pep_homol), identity threshold (pep_ident), the rank number (pep_Rank), hydrophobicity score 
(GRAVY_score) and isoelectric point (pI_Value) for PM and CGM. 
















1  HSIAAQGGVNSA  1110.5418  0.0024  71.29  33  35  1  0.125  7.84 
1  SVDGWFTLPFTIPNYLGPLLGSERLSEDAPEAQ  3618.7882  -0.0069  94.94  20  39  1  -0.1727  3.5 
1  SFEDELSGRSINQPSAV  1834.8697  -0.0186  45.19  28  35  1  -0.5941  3.82 
1  SDSLQGADVLTYDPERA  1835.8537  -0.0054  57.85  31  35  1  -0.7176  3.5 
1  FSSFEDELSGRSINQPS  1898.8646  -0.0003  55.22  30  34  1  -0.8294  3.82 
1  FSSFEDELSGRSINQPSAV  2068.9702  -0.0162  104.39    35  1  -0.4263  3.82 
1  DDTTFTVELTQPESDFPLRL  2323.122  -0.0092  55.62  23  37  1  -0.555  3.42 
1  NGTEPQNPLVPGNTNEVGGGRIVDSI  2633.3045  -0.0537  41.05  18  37  1  -0.6192  3.82 
1  SDMVESTPEGYRATTL  1755.7985  -0.0108  41.07  28  34  1  -0.6437  3.82 
1  VAPDVDIEAIITGGDIDPH  1945.9633  -0.016  113.08    37  1  0.2421  3.36 
1  DHDVDNEHVWYSTEYV  2006.8283  0.0031  32.16  19  28  1  -1.2375  3.84 
1  NTENFLDAFTKAVDDLTAAT  2156.0273  0.0054  119.41    37  1  -0.155  3.5 
1  NTENFLDAFTKAVDDLTAATN  2270.0703  0.004  39.45  29  36  1  -0.3143  3.5 
1  GGGGYDSWLYGTLEDDDRIIH  2338.0502  -0.0167  109.18  26  33  1  -0.7428  3.76 
1  GGGGYDSWLYGTLEDDDRIIHAL  2522.1714  -0.0002  118.47  32  36  1  -0.4347  3.76 
1  VVHPYWNTDDVAAGYDIA  2004.9218  -0.0273  75.38  26  33  1  -0.05  3.6 
1  KQLTDDIPPLTTEDGEVRGVPF  2426.2329  0.0071  65.18  24  38  1  -0.6272  3.84 
1  TDDIPPLTTEDGEVRGVPFAVEGF  2560.2334  -0.0226  41.47  24  36  1  -0.2208  3.38 
1  NAPIWQEYQDKGVEDTNEIEFS  2611.1714  0.0144  48.86  24  34  1  -1.2181  3.44 
1  KQLTDDIPPLTTEDGEVRGVPFAVEGF  2929.4709  -0.0573  104.04  33  37  1  -0.3296  3.76 
1  YEGDFRVVEMEKDGEPF  2045.9041  -0.0104  41.56  24  32  1  -1.0117  3.82 
1  EYVVNSIADDKGWDHPTIEWRESPS  2929.3519  -0.0127  79.9  25  35  1  -1.068  4.06 
1  EYVVNSIADDKGWDHPTIEWRESPSAQ  3128.4475  -0.0083  99.29  31  35  1  -1.0518  4.06 
1  TGEDIFGEEHERDNENTPA  2158.9039  0.0034  33.32  19  29  1  -1.7842  3.74 
1  GEDWDADQPVTGEDIFGEEH  2244.9084  0.0202  55.64  20  27  1  -1.29  3.24  
 
1  EDIFGEEHERDNENTPAWA  2257.9512  0.0071  33.16  23  29  1  -1.6789  3.74 
1  TGEDIFGEEHERDNENTPAWA  2416.0203  -0.0061  79.32  23  28  1  -1.5714  3.74 
1  DQPVTGEDIFGEEHERDNENTPA  2598.1106  0.0193  38.86  17  31  1  -1.6655  3.62 
1  GEDWDADQPVTGEDIFGEEHERDNENTPA  3271.345  0.012  153.74    26  1  -1.6655  3.42 
1  VGEDWDADQPVTGEDIFGEEHERDNENTPA  3370.4134  -0.0081  141.52  23  26  1  -1.47  3.42 
1  AVGEDWDADQPVTGEDIFGEEHERDNENTPA  3441.4505  -0.0017  114.39  20  27  1  -1.3645  3.42 
1  AAVGEDWDADQPVTGEDIFGEEHERDNENTPA  3512.4876  0.0007  93.92  25  27  1  -1.2656  3.42 
1  DGIDGESVAIPNDPSNQGRAI  2124.0083  0.0117  48.8  33  37  1  -0.6523  3.5 
1  DRPGADLQEILDRLEADQENA  2367.1302  -0.0223  39.35  22  36  1  -1.1761  3.62 
1  SVPVDRPGADLQEILDRLEADQENA  2749.3518  -0.01  60.47  28  38  1  -0.748  3.62 
1  RFQVKDQSIVDQQEIDSDPS  2333.1135  0.0132  84.12  35  37  1  -1.185  3.76 
1  QAPDSYGRIGNQSGSDVSPV  2032.945  0  39.45  24  35  1  -0.81  3.88 
1  NTYPVIDAWTEPEVWQEARPT  2501.1863  -0.0186  153.72    36  1  -0.9047  3.68 
1  DFLRMGWPDGITPE  1632.7606  -0.0266  40.82  28  34  1  -0.5428  3.7 
1  DVSYLEFNRIETLGTTDEIPV  2410.1904  -0.0295  41.67  28  37  1  -0.1857  3.5 
1  VEPDWTYDQATLTGTWGNLTDSQLRSV  3052.4414  -0.0385  144.76    35  1  -0.6666  3.5 
1  GFRPEALEIIPEGESTDLSIPI  2382.2318  -0.0133  70.22    38  1  0.0136  3.58 
1  SESYEDVLTELFERAQVTA  2186.0379  -0.0264  37.96  31  35  1  -0.3894  3.58 
1  TAEQSVEDTKQLHDQALQQADQA  2553.1943  0.0247  55.34  32  37  1  -1.2521  3.84 
1  EFRAPDPSGNPYLGFAA  1807.8529  -0.0122  40.18  29  35  1  -0.4647  4.08 
1  FENPDQKETEDYISGRFG  2130.9494  -0.0097  103.44  27  32  1  -1.5555  3.92 
1  DATVSAPVLESGVENREVGGDTA  2272.0819  -0.0077  78.39  31  36  1  -0.2304  3.5 
1  DATVSAPVLESGVENREVGGDTAEA  2472.1616  -0.0024  77.28  28  36  1  -0.28  3.44 
1  SFSVEDFEEFLHQQ  1740.7631  -0.0172  31.93  23  31  1  -0.6714  3.68 
1  ALGFLDYLDEEQRA  1638.7889  -0.0163  38.14  27  36  1  -0.4214  3.58 
1  FFDQETNERWIPFVIEPA  2237.0793  -0.0275  53.54  33  36  1  -0.3833  3.68 
1  EDFGWRIPFLT  1379.6874  -0.0021  49.73  33  36  1  -0.1090  4.08 
1  GVLEEGQYNRELAEAI  1789.8846  -0.034  55.41    36  1  -0.4812  3.8 
1  AGVLEEGQYNRELAEAI  1860.9217  -0.0331  64.33  31  36  1  -0.3470  3.8 
1  RLELPDFEFVPM  1491.7432  -0.0119  55.51  27  37  1  0.0916  3.82  
 
1  FAEFERTTAEDVANGVPEAI  2165.0277  -0.0112  76.2  25  36  1  -0.16  3.58 
1  DDSLSQEVFGVTFPRPL  1905.9473  -0.0302  78.43    37  1  -0.1647  3.7 
1  AELFDASGQIPSSQEFFRV  2127.0273  -0.0246  56.88  24  36  1  -0.1  3.82 
1  SASDDSDALDWVRELTSYLPS  2326.0601  -0.0039  56.27    34  1  -0.5380  3.36 
1  LRDLLEGTDERIQDLEFFQDAV  2621.2973  -0.0053  41.65  26  38  1  -0.4681  3.62 
1  SLDAVRQEVEEIIGQGSQPT  2155.0757  -0.0322  58.01    37  1  -0.535  3.68 
1  AFQDALGVRDADFIAQLV  1948.0054  -0.0295  56.89  33  37  1  0.6055  3.6 
1  LFDQPEDDQPNDGFDGRT  2064.8661  0.0233  50.21  27  31  1  -1.7388  3.26 
1  INDEVINEIRDGISSF  1819.8952  -0.006  37.43  31  37  1  -0.1562  3.58 
1  DWADDDSMNSYFLANPRMQDYI  2666.1053  -0.0154  37.26    25  1  -0.9409  3.3 
                   
2  KYPYGIDET  1084.5077  0.0031  50.97  33  36  1  -1.3  4.08 
2  GYGPDNKYELN  1268.5673  0.0013  43.39  30  36  1  -1.7363  4.08 
2  SLLETTKQGEHEAF  1588.7733  0.0102  41.29  24  39  1  -0.821  4.54 
2  MAYVINREQFVSDV  1669.8134  -0.0003  42.55  27  38  1  0.2142  4.08 
2  RKDAATNMEEGIWES  1735.7835  0.0025  127.83  36  37  1  -1.2466  4.16 
2  SLLETTKQGEHEAFTL  1802.905  0.0019  101.43  35  39  1  -0.525  4.54 
2  RKDAATNMEEGIWESA  1806.8206  0.0022  124.52    37  1  -1.0562  4.16 
2  RKDAATNMEEGIWESA  1822.8155  -0.0024  41.51  22  36  1  -1.05  4.16 
2  FHLQPPQLFSDGQEGY  1861.8635  -0.0406  102.03  29  36  1  -0.85  4.06 
2  KVMEEAGYGPDNKYELN  1955.8934  0.0059  56.03  26  37  1  -1.3  4.16 
2  RLEQAHIEMTINDANFS  1987.9421  -0.009  72.76  30  38  1  -0.5352  4.42 
2  QTRKDAATNMEEGIWESA  2035.9269  0.0057  48.63  18  38  1  -1.1722  4.16 
2  NSDPGVREFMTEQYERLV  2169.0161  -0.016  40.69  20  38  1  -0.9944  4.16 
2  RKDAATNMEEGIWESAALIPV  2300.147  -0.0261  163.74  34  39  1  -0.2  4.16 
2  EARKVMEEAGYGPDNKYELN  2312.0742  -0.0026  129.93  32  38  1  -1.415  4.36 
2  KVMDLFDAPTNYENGRTEIT  2313.0947  -0.0104  118.67  30  38  1  -0.79  4.06 
2  HLQPPQLFSDGQEGYNNHYQGE  2557.1258  0.0109  49.07  16  36  1  -1.6045  4.4 
2  RLYWKEDANSDPGVREFMTEQ  2570.186  -0.0057  41.02  29  38  1  -1.3619  4.28 
2  KVMDLFDAPTNYENGRTEITNLLIT  2867.4375  -0.0605  39.62  21  39  1  -0.316  4.06  
 
2  GYGPDNKYELNWLQYQSPTWKEMANTI  3245.5128  -0.0188  134.24  31  38  1  -1.1814  4.44 
2  STLGIEHEVDENGAVKRATGVEAVDDYTVRL  3342.6692  0.0308  56.64  19  40  1  -0.3548  4.22 
2  ESMRPEVA  917.4276  0.0063  38.22  31  38  1  -0.75  4.26 
2  RAIFGEAEAPEPS  1372.6623  0.0045  58.85  32  38  1  -0.5153  3.96 
2  RYADWLFTTPL  1381.703  -0.0071  37.85  27  37  1  -0.0909  6.7 
2  RYADWLFTTPLLL  1607.8712  -0.0049  78.48  26  36  1  0.5076  6.7 
2  RYADWLFTTPLLLL  1720.9552  -0.0039  91.58  28  35  1  0.7428  6.7 
2  PFGGEQNPIYWARYA  1767.8369  -0.0039  52.41  23  38  1  -0.7733  6.82 
2  YWARYADWLFTTPL  1801.8828  -0.0097  64.41  30  39  1  -0.1  6.64 
2  RYADWLFTTPLLLLD  1835.9822  -0.0076  73.55  24  37  1  0.46  3.88 
2  RYADWLFTTPLLLLDLA  2020.1033  -0.0051  123.79    36  1  0.7352  3.88 
2  AVEGVSQAQITGRPEWIWL  2139.1113  -0.0153  67.79  29  38  1  0.0315  4.26 
2  AVEGVSQAQITGRPEWIWLA  2210.1484  -0.0317  70.37  30  39  1  0.12  4.26 
2  GGEQNPIYWARYADWLFTTPL  2497.2066  -0.0169  39.11  22  39  1  -0.4666  4.08 
2  GGPFLDRVELA  1172.619  0.0037  69.23    38  1  0.2272  4.08 
2  AILSRDQIESL  1243.6772  -0.0031  57.32    37  1  0.16363  4.08 
2  AAILSRDQIESL  1314.7143  -0.0005  61.86    37  1  0.3  4.08 
2  SVGGPFLDRVELA  1358.7194  0.0029  103.78    38  1  0.4538  4.08 
2  YTPTSVGGPFLDRVELA  1820.9309  -0.0118  55.89  34  38  1  0.0941  4.08 
2  RAQGLINGDAHITDNLDAQ  2020.9926  -0.0125  47.66  22  39  1  -0.6157  4.16 
2  AHDQAPWVYLDYADLIR  2045.0007  -0.0315  78.01  22  39  1  -0.3  4.16 
2  TNQIFDTLIQFKPGTSGEL  2108.079  -0.0236  87.01  26  39  1  -0.2368  4.08 
2  GPFEFDQLDNETQRVRLT  2164.0549  -0.0041  52.78  25  39  1  -1.0833  4.06 
2  AHDQAPWVYLDYADLIRGV  2201.0905  -0.0131  83.58  24  39  1  -0.0684  4.16 
2  TNQIFDTLIQFKPGTSGELT  2209.1267  -0.0407  126.1  35  39  1  -0.26  4.08 
2  TNQIFDTLIQFKPGTSGELTS  2296.1587  -0.0412  133.61  30  39  1  -0.2857  4.08 
2  GTGPFEFDQLDNETQRVRLT  2322.1241  0.0013  89.78  28  39  1  -1.03  4.06 
2  TNQIFDTLIQFKPGTSGELTSGL  2466.2642  -0.01  129.24    39  1  -0.1130  4.08 
2  AHDQAPWVYLDYADLIRGVNEA  2515.2132  -0.0229  136.45  31  39  1  -0.2954  3.96 
2  SQIAHDQAPWVYLDYADLIRGV  2529.2652  -0.0147  99.59  22  39  1  -0.05  4.16  
 
2  SQIAHDQAPWVYLDYADLIRGVNEA  2843.3878  -0.0203  111.99  26  40  1  -0.252  3.96 
















2  VHPYWNTDDV  1244.5462  0.0046  46.2  26  36  1  -0.98  3.88 
















2  KIVVHPYWNTDDVAAGYDIA  2246.1008  0.0047  56.89  20  39  1  -0.015  4.16 





















2  YGDQLGAEIPQSVKDAVSKS  2091.0484  -0.0022  72.49  27  39  1  -0.555  4.3 




















2  TVYGTGGLGDGSFNDQAKQGLERA  2440.1619  0.0007  90.19  23  39  1  -0.7125  4.3 
2  GTVYGTGGLGDGSFNDQAKQGLERA  2497.1834  0.0045  194.94  38  39  1  -0.7  4.3 
2  AYDIEMRPLVV  1304.6798  0.003  65.89  28  37  1  0.54545454
5 
4.08 
2  EWNATWRNFE  1351.5945  0.002  58.02    36  1  -1.64  4.26 




2  IFDRADRDVVQLA  1516.7998  -0.0005  65.28  37  38  1  0.00769230
8 
4.18 

















2  ITKEILDADALIHVGPDFQPWVDRA  2818.4654  -0.0684  125  28  40  1  -0.004  4.12 















3626.8216  0.0246  46.95    40  1  0.08611111
1 
4.3 








2  VKVGPNNQNVFDPAEV  1725.8686  0.0013  58.05    38  1  -0.44375  4.08 








2  QGERQSAIENAQGDKQSNII  2185.0723  0.0015  43.21  24  39  1  -1.26  4.44 
2  FGEYRGLLEPGINVIPPFVS  2203.1677  -0.0178  95.13  29  38  1  0.375  4.26 








2  KGVTLPLARGADTFDQGVIDGIVNAV  2625.4126  -0.0158  158.69  27  38  1  0.42692307
7 
4.18 
2  QFRLVDGLTTIEA  1461.7827  -0.0374  40.46  27  38  1  0.31538461 4.08  
 
5 
2  TNRKADDNTITVELL  1701.8897  -0.0041  80.63  33  38  1  -0.66  4.3 










3838.945  -0.0279  124.14  27  40  1  -0.5  4.24 
2  YWQPGEGMLVEKPFGI  1849.9073  -0.0123  59.78  29  39  1  -0.2375  4.26 




2  VEFEPRSY  1025.4818  -0.0001  43.18  29  36  1  -1.025  4.26 
2  TFIDKFPTEA  1167.5812  0.001  77.9    37  1  -0.2  4.08 
















2  TMSEAFRGGDTGEAHPDVNFNPKST  2664.1875  -0.0116  63.73  20  36  1  -1.016  4.54 
2  HFHGSQTAWEDDGVPT  1782.7598  0.0006  61.81  23  34  1  -1.06875  4.28 




2  SMFENTVEQFKT  1459.6653  0.0001  86.33  30  37  1  -0.7  4.26 
2  SMFENTVEQFKT  1475.6602  0.0007  51.22  23  37  1  -0.7  4.26 





2  NFLLSEFGQEKFV  1556.7875  -0.0098  38.48  32  38  1  0.08461538
5 
4.26 
















2  ASVPFHFWAPEAYEGAPAPV  2142.0211  -0.0432  115.88  29  37  1  0.15  4.24 
2  RVGGGTLADRLEFAADLIEDGGVHAF  2685.3511  -0.0117  48.85  17  40  1  0.18076923
1 
4.2 
2  VWIIDNLVTMVEHFTTA  1988.0078  0.007  54.39  21  39  1  0.89411764
7 
4.06 
2  VWIIDNLVTMVEHFTTA  2004.0027  -0.0097  70.47  29  39  1  0.89411764
7 
4.06 
2  VWIIDNLVTMVEHFTTAA  2075.0398  -0.0056  42.93  23  39  1  0.94444444
4 
4.06 
2  SNRSQFVPSWLVPEAAGDLPLTV  2482.2856  -0.0331  50.87  21  39  1  0.11739130
4 
4.08 




2  GGFWESVDRA  1122.5094  0.0036  55.72    37  1  -0.52  4.08 








2  GTAEIFDTLRVLTVV  1632.9087  -0.0044  40.31  27  35  1  1.02  4.08 
2  SAGTAEIFDTLRVLTVV  1790.9778  -0.0082  68.45  29  36  1  0.95882352 4.08  
 
9 
2  SSAGTAEIFDTLRVLTVV  1878.0099  -0.0095  38.5  23  37  1  0.86111111
1 
4.08 








2  DGFEQWEKRYLPA  1637.7838  -0.0017  64.3    38  1  -1.4  4.44 
2  DFFEFEARKV  1286.6295  0.0033  53.91  32  38  1  -0.45  4.44 
                   




3  NFSSLLETTKQGEHEA  1789.8482  -0.0072  101.49    38  1  -0.9875  4.54 
3  SLLETTKQGEHEAFTL  1802.905  -0.0003  62.55  35  39  1  -0.525  4.54 




3  RKVMEEAGYGPDNKYE  1884.8676  -0.0038  77.11  25  37  1  -1.68125  4.64 




























3  RKVMEEAGYGPDNKYELNWL  2411.1579  -0.0002  81.06  24  39  1  -1.185  4.64 












3  RYADWLFTTPLLL  1607.8712  -0.0085  77.71  28  36  1  0.50769230
8 
6.7 
3  RSRAIFGEAEAPEPS  1615.7954  0.0013  123.56  33  39  1  -0.8  4.56 
3  RYADWLFTTPLLLL  1720.9552  -0.0007  90.62  25  35  1  0.74285714
3 
6.7 




3  YWARYADWLFTTPL  1801.8828  -0.0041  46.43  29  39  1  -0.1  6.64 




3  ILLRSRAIFGEAEAPEPS  1955.0476  -0.0068  82.15  28  38  1  0.00555555
6 
4.56 
3  RYADWLFTTPLLLLDLA  2020.1033  -0.0149  50.09  25  37  1  0.73529411
8 
3.88 
3  GFGLILLRSRAIFGEAEAPEPS  2329.243  0.0007  124.85  32  38  1  0.26818181
8 
4.56 




3  VVGGTEAQRNSWPSQI  1727.8591  -0.0039  50.89    39  1  -0.5875  6.98 
3  SYRFREEAGSYLVGEL  1874.9162  -0.0054  44.94  26  39  1  -0.50625  4.56  
 




3  ASLDRDEEGIGQNRGKDPHFWLDPNRA  3092.4812  -0.0097  54.71  19  39  1  -
1.47037037 
4.7 
3  SAPHEYSHTFEGPTGEYSYV  2256.96  -0.0078  36.24    33  1  -0.99  4.52 




3  TSLVGRYGKHLAGSDVGDGGSDLE  2389.151  -0.0074  40.9  19  39  1  -0.45  4.44 
3  SLVGRYGKHLAGSDVGDGGSDLESM  2506.1758  -0.0166  60.11  20  38  1  -0.36  4.44 








3  RGDELVEVDQPKRDQNGRPFVPV  2649.3623  -0.0251  46.56  22  39  1  -1.2  4.64 
3  VLRGDELVEVDQPKRDQNGRPFVPV  2861.5148  -0.0326  40.53  23  39  1  -0.784  4.64 
3  RGDELVEVDQPKRDQNGRPFVPVQL  2890.505  -0.0019  39.2  19  39  1  -1.092  4.64 








3  SGKVVVIDEAHGNGVGEF  1812.9007  0.0081  100.97  26  38  1  0.13333333
3 
4.42 




3  RLVVLEESDVQPH  1519.7995  0.0047  41.06  24  37  1  -0.3  4.42 
3  NALQHLFSGIDPFAGVPV  1880.9785  0.0099  64.68  23  38  1  0.62222222
2 
4.94 













3  NQFLFGNLSTV  1238.6295  0.0022  39.09  23  37  1  0.45454545
5 
6.02 




4  YHNLAQSFWYDRLDYNPPGA  2426.108  -0.0214  39.28  17  36  1  -1.02  5.1 
4  GFGLILL  731.4582  -0.0019  38.5    28  2  2.55714285
7 
6.02 
4  RYADWLFT  1070.5185  0.0042  49.98  29  37  1  -0.3125  6.7 
4  TGRPEWIWLA  1227.64  0.0016  49.85    37  1  -0.24  6.98 








4  RYADWLFTTPLL  1494.7871  -0.0034  62.87  27  37  1  0.23333333
3 
6.7 
4  TGRPEWIWLALGT  1498.7932  -0.0051  78.74    38  1  0.02307692
3 
6.98 




4  DGIMIGTGLVGALTKV  1543.8644  -0.0013  57.9    35  1  1.14375  6.66 
4  RYADWLFTTPLLL  1607.8712  -0.0023  84.54  31  36  1  0.50769230
8 
6.7 
4  RSRAIFGEAEAPEPS  1615.7954  -0.0044  43.18  24  39  1  -0.8  4.56 
4  GADGIMIGTGLVGALTKV  1671.923  -0.0019  73.16  30  36  1  1.09444444
4 
6.66 
4  RYADWLFTTPLLLL  1720.9552  -0.0035  100.7  25  35  1  0.74285714
3 
6.7 




4  YWARYADWLFTTPL  1801.8828  -0.0042  78.53  35  39  1  -0.1  6.64 
4  GADGIMIGTGLVGALTKVY  1834.9863  -0.0312  38.14  24  38  1  0.96842105
3 
6.6 
4  GFGLILLRSRAIFGEAEAPEPS  2329.243  -0.0135  69.4  26  38  1  0.26818181
8 
4.56 








4  AHDQAPWVYL  1198.5771  -0.0026  82.78  34  37  1  -0.24  4.94 
























4  DLTQQYAPFLRNLAI  1761.9413  -0.003  73.98  28  37  1  0.01333333
3 
6.7 
4  TNQIFDTLIQFKPGTS  1808.9309  -0.0059  70.64  28  38  1  -0.275  6.66 
4  YDDAARQQYYHQASQI  1955.8762  -0.0033  119.53  32  36  1  -1.46875  5.1 




4  DSGGPLHCLV  996.4699  0.0058  49.07  30  36  1  0.44  4.94 
4  SWINNVIASN  1116.5564  0.0048  51.54  35  39  1  0.2  6.02 
4  SAYISWINNVIA  1349.6979  0.0042  87.64  34  37  1  0.875  5.92 
4  SAYISWINNVIASN  1550.7729  0.0042  45.67  23  38  1  0.44285714
3 
5.92 




4  VVGGTEAQRNSWPSQI  1727.8591  -0.0069  86.56    39  1  -0.5875  6.98 




4  QKIVVHPYWNTDDVAA  1837.8999  0.0498  81.35  25  38  1  -0.30625  5.1 
4  QKIVVHPYWNTDDVAA  1854.9265  -0.0008  107.42  34  39  1  -0.30625  5.1 








4  MFNSGADIIYHASAA  1566.7137  -0.0341  62.85  27  35  1  0.49333333
3 
4.94 
4  IHVGPDFQPW  1194.5822  0.0019  40.55  28  37  1  -0.32  4.94 
4  LIHVGPDFQPW  1307.6663  -0.0009  53.39  26  37  1  0.05454545
5 
4.94 








4  GLHGHGWEPNASITKEILDA  2144.065  -0.0035  104.74  26  39  1  -0.465  5.18 




4  AHNAFQYLGTAYDIEMRPLV  2308.131  -0.0121  61.03  21  39  1  -0.03  5.22  
 
4  AHNAFQYLGTAYDIEMRPLVV  2407.1994  -0.005  162.4  32  39  1  0.17142857
1 
5.22 
4  AHNAFQYLGTAYDIEMRPLVV  2423.1944  -0.0092  96.95  35  39  1  0.17142857
1 
5.22 
4  FVVGGWPVGA  987.5178  0.0022  55.25    38  1  1.35  6.02 




4  LIQNDIAYFAKNGTGI  1736.9097  0.0013  38.46  23  37  1  0.1875  6.6 




4  SHNVSAWPDMHDKISIPDGA  2176.0007  -0.0346  145.71  22  36  1  -0.625  5.02 
4  SHNVSAWPDMHDKISIPDGA  2191.9957  0.0003  106.1  25  37  1  -0.625  5.02 




4  WLLYSGPAPT  1103.5651  0.0044  53.68    38  1  0.21  5.92 
4  GYHAADIAPFVPA  1327.6561  -0.0069  58.76    38  1  0.54615384
6 
4.94 
4  AQFPLHTWLPDAM  1525.7388  -0.0027  78.45  29  38  1  0.06923076
9 
4.94 
4  FAGYHAADIAPFVPA  1545.7616  -0.0006  41.03  37  39  1  0.78  4.94 
4  GLHIEFLHTWLAGPEGT  1876.9472  -0.0098  92.95  31  39  1  0.11764705
9 
5.12 
4  TGLHIEFLHTWLAGPEGT  1977.9949  -0.0108  111.52  31  39  1  0.07222222
2 
5.12 
4  QQFRLVDGLTTI  1389.7616  0.0019  49.76  31  36  1  0.19166666
7 
6.78 
4  HILSSGRDGKFGEDTA  1688.8118  -0.0061  41.7  20  39  1  -0.79375  5.28 
4  AHILSSGRDGKFGEDTANSI  2074.0079  -0.0089  63.47  25  39  1  -0.535  5.28 
4  DLWDHVRG  996.4777  0.0032  54.2  33  37  1  -1  5.1 

















4  DWGGHDPIENTGFTHTH  1919.8187  -0.0032  171.33  29  34  1  -1.3  5.02 
4  QRFTGDMTQYGFTSQA  1836.8101  -0.0104  43.75  23  35  1  -0.8875  6.7 




4  FHVTSGDVTHGFELV  1643.7944  -0.0015  53.92  24  38  1  0.37333333
3 
5.04 








4  FFAPHDRDQLPGGPPAALNQ  2147.0548  -0.0108  126.05  33  39  1  -0.69  5.1 
4  NYGDIHRYEPA  1333.6051  0.0006  67.98  25  37  1  -1.5  5.22 
4  ATHAADVLFAG  1071.5349  0.0063  49.93  34  38  1  0.92727272
7 
4.94 
4  GLNPHDWTVY  1200.5564  -0.0044  69.93  31  37  1  -0.71  4.94 




4  TFTQDQTTVSRGGVVPVTL  2005.0481  -0.0088  52.51  21  38  1  0.08947368
4 
6.78 




4  DHHVIAPDLPGFGRSDRPPIEYAA  2629.3037  -0.018  41.69  20  40  1  -0.5625  5.16 
4  SNALQHLFSGIDPF  1544.7623  0.0049  40.85  29  39  1  0.15714285
7 
4.94 
4  SNALQHLFSGIDPFAGVPV  1968.0105  -0.0018  128.71  30  38  1  0.54736842 4.94  
 
1 




4  IYNDPDDLPHHRVGFL  1906.9326  0.002  51.97  35  39  1  -0.66875  5.02 
4  HLGRYNGEFEAPREVV  1871.9278  -0.0075  61.86  25  39  1  -0.81875  5.4 
4  SGALLGFYYSPS  1260.6026  0.0023  57.4  36  38  1  0.4  5.86 
4  NRVGPWGLGTIVVDSV  1667.8995  -0.0058  58.08  30  37  1  0.525  6.78 




4  ALIGGFDGFSHV  1218.6033  0.0037  75.66  31  38  1  0.93333333
3 
4.94 
4  ALIGGFDGFSHVA  1289.6405  -0.0006  63.9  31  38  1  1  4.94 




















4  FGGLLLI  731.4582  -0.0019  42.75    28  1  2.55714285
7 
6.02 
4  ALMPLHSWLPDAM  1480.7207  -0.0004  70.04  31  38  1  0.55384615
4 
4.94 
4  FHAPELGLKMDALPG  1594.8177  -0.0048  55.22  30  38  1  0.10666666
7 
5.22 





4  PTFLTGAF  852.4382  0.0077  43.49  31  35  1  0.975  6.02 
4  SVPTFLTGAF  1038.5386  -0.0001  45.84  29  35  1  1.12  6.02 
4  FGVALLI  731.4582  -0.0019  36.68    28  3  2.92857142
9 
6.02 
4  NSYFDSYGFHTI  1449.6201  0.0011  41.38  28  35  1  -0.45  4.94 




4  AHYVGPEIDVSLH  1435.7096  0.0064  59.85  24  38  1  0.07692307
7 
5.04 
4  NILLDFVRPT  1186.671  0.0032  53.07    35  1  0.53  6.78 
4  NILLDFVRPTTG  1344.7402  -0.0003  40.65  21  36  1  0.35  6.78 
4  SFTLHPLGDSGIIA  1426.7456  -0.0008  64.25  27  38  1  0.7  4.94 




4  APDLPGFGHTDRPSIA  1649.8162  -0.0001  59.99  27  38  1  -0.44375  5.1 
4  VLRERYAAGDIDDEEFTARRR  2537.2735  0.0018  50.66  24  39  1  -1.2  4.78 




4  AVGGHDLPYAFQPA  1441.699  0.0031  42.09  22  38  1  0.05  4.94 
4  FLPFLPQSVVPS  1329.7333  0.001  41.15  27  36  1  0.975  6.02 
4  ALSATPHTDWVTVT  1497.7464  0.0072  40.21  29  38  1  0.21428571
4 
4.94 




                   
5  QSFWYDRL  1113.5243  0.0036  46.32  34  37  1  -0.9875  6.7 









5  MAYVINREQFV  1368.686  0.004  39.81  32  38  1  0.28181818
2 
6.88 
5  MAYVINREQFVS  1455.718  -0.0007  38.21  25  38  1  0.19166666
7 
6.88 
5  KQGEHEAFTLGWVA  1571.7732  -0.0024  90.74  37  39  1  -0.4  5.3 
















5  DGKGRLSGISSTFNSLDPVASGNTASGA  2665.2944  -0.0221  57.81  23  39  1  -0.275  6.8 
















5  GFGLILL  731.4582  -0.0068  46.47    29  3  2.55714285
7 
6.02 
5  RYADWLFT  1070.5185  -0.0059  44.53  27  36  1  -0.3125  6.7 













5  RYADWLFTTP  1268.619  0.0025  58.93  31  37  1  -0.48  6.7 












5  RYADWLFTTPLL  1494.7871  -0.0094  56.2  26  37  1  0.23333333
3 
6.7 
5  TGRPEWIWLALGT  1498.7932  -0.0249  85.84    38  1  0.02307692
3 
6.98 








5  RYADWLFTTPLLL  1607.8712  -0.0065  84.31  30  36  1  0.50769230
8 
6.7 




5  RYADWLFTTPLLLL  1720.9552  -0.0038  96.63  25  35  1  0.74285714
3 
6.7 
5  SQAQITGRPEWIWLA  1754.9104  -0.0057  40.58  34  38  1  -0.26  6.98 




5  YWARYADWLFTTPL  1801.8828  0.0072  82.02    39  1  -0.1  6.64 





5  SDPDAKKFYAITTLVPAIA  2020.0881  -0.0046  97.05  32  37  1  0.28947368
4 
6.68 
5  MGVSDPDAKKFYAITTLVPA  2123.0973  -0.0087  42.71  29  39  1  0.245  6.68 




























5  IDLTQQYAPFLRNLA  1761.9413  -0.0035  44  27  37  1  0.01333333
3 
6.7 
5  TNQIFDTLIQFKPGTS  1808.9309  -0.0044  113  33  38  1  -0.275  6.66 
5  DLTQQYAPFLRNLAIF  1909.0098  -0.0177  43.47  22  38  1  0.1875  6.7 
5  DLTQQYAPFLRNLAIFA  1980.0469  -0.0085  92.87  31  38  1  0.28235294
1 
6.7 




5  DLTQQYAPFLRNLAIFAA  2051.084  -0.0093  89.38    38  1  0.36666666
7 
6.7 





5  IFKTTGSNQTRAQGLINGDAHITDNLDAQ  3098.5381  -0.0007  50.35  22  40  1  -
0.64137931 
5.2 








5  AYISWINNVIA  1262.6659  0.0028  38.61  29  37  1  1.02727272
7 
5.92 




5  AYISWINNVIASN  1463.7408  0.0039  54.01  31  38  1  0.53846153
8 
5.92 












5  VVGGTEAQRNSWPSQI  1727.8591  0.0012  102.85    39  1  -0.5875  6.98 




5  GVQKIVVHPYWNTDDV  1868.9421  -0.0074  111.15  31  39  1  -0.29375  5.1 




5  AQDIGRFAIGV  1145.6193  0.0063  48.32  33  36  1  0.66363636
4 
6.78 
5  RSMFNSGADII  1209.5812  -0.0156  82.84  30  37  1  0.18181818
2 
6.78 





5  TGDGVFRAAQDIGRFA  1679.838  -0.0077  86.51  37  38  1  -0.10625  6.92 
5  TGDGVFRAAQDIGRFAIGV  1949.0119  -0.0004  89.82  29  38  1  0.34736842
1 
6.92 
5  GLHGHGWEPNASITKEILDA  2144.065  -0.0044  133.6  32  39  1  -0.465  5.18 
5  AAHNAFQYLGTAYDIEMRPL  2280.0997  -0.0084  75.05  24  39  1  -0.15  5.22 




5  KQSIDNLTEGFVQLAPSHENTLRT  2697.3722  -0.0316  148.39  26  40  1  -0.7125  5.34 
5  TLYPETITLITRA  1490.8344  -0.0019  44.59    34  1  0.36153846
2 
6.88 




5  LIQNDIAYFAKNGTGI  1736.9097  -0.0039  114.3    38  1  0.1875  6.6 












5  YVSPGDTVKWVWEGSTGHNV  2217.0491  -0.0168  116.4  32  38  1  -0.485  5.22 
5  YTFDMRTQTI  1274.5965  0.0018  45.15  31  38  1  -0.57  6.7 
5  RGLLEPGINVIPPFVS  1706.9719  -0.005  68.65  25  33  1  0.61875  6.98 
5  HAFPHMAEQA  1137.5025  0.0009  61.99  33  36  1  -0.49  6.02 
5  RLVDGLTTI  986.5761  0.0053  64.42    33  1  0.72222222
2 
6.78 




5  QFRLVDGLTTI  1261.703  0.0008  57.75  28  35  1  0.52727272
7 
6.78 












5  SDVQPTVKLLKDVGILS  1811.0404  -0.0072  94.12    34  1  0.34705882
4 
6.72 
5  SLSDVQPTVKLLKDVGILS  2011.1565  -0.0157  81.09    34  1  0.46842105
3 
6.72 








5  SILIQGRGFAEAWQI  1687.9046  -0.0071  41.86  25  37  1  0.41333333
3 
6.98 
















5  MSRLLPKESLQDVLVYHNPDDSNEPKVRTVPA  3646.8777  -0.0823  42.69  18  40  1  -0.721875  5.42 








5  MERYIPQVT  1135.5696  0.0044  37.57  24  37  1  -0.5  6.88 




5  FRGGDTGEAHPDVNFNPKST  2144.9876  -0.0063  72.03  20  37  1  -1.205  5.28 




5  SGKVVVIDEAHGNGVGEFQLRPL  2420.2812  -0.0209  39.82  23  38  1  0.01739130
4 
5.34 








5  ASVPFHFWAPEAY  1520.7088  -0.0031  63.76  31  38  1  0.17692307
7 
5.12 




5  SNRSQFVPSWLVPEAA  1786.9002  -0.0011  74.51  29  39  1  -0.18125  6.98 




5  TIQWIGPDRA  1155.6037  0.0048  55.48    37  1  -0.43  6.78 




5  TFRQSFLDVV  1210.6346  0.0053  54.99  30  36  1  0.48  6.78 
5  TYWANVPESLKDKNAV  1833.9261  -0.0026  68.07  24  39  1  -0.70625  6.8 




5  TYWANVPESLKDKNAV  1833.9261  -0.0026  68.07  24  39  1  -0.70625  6.8 









5  GAFVSLPHVPQSQLPEQV  1932.0105  -0.0211  51.86  23  39  1  0.04444444
4 
5.12 
5  FGGLLLI  731.4582  -0.0068  56.27    29  1  2.55714285
7 
6.02 








5  TIQWIGPDKA  1127.5975  0.006  47.44    37  1  -0.37  6.66 
5  TYWANVPESLKDKNAV  1833.9261  -0.0026  68.07  24  39  1  -0.70625  6.8 
5  FGVALLI  731.4582  -0.0068  49.98    29  2  2.92857142
9 
6.02 
5  FSAGQTRGFAIGGDFTPA  1798.8639  -0.0311  38.63  23  38  1  0.07777777
8 
6.78 
5  FNLLLL  731.4581  -0.0067  39.89    29  4  2.41666666
7 
6.02 
5  FRALLL  731.4694  -0.018  32.38    29  7  1.91666666
7 
11.04 
5  TAYDQRLPFLA  1293.6717  -0.0013  38.72  24  37  1  -0.1  6.7 
5  TIQWIGPDKA  1127.5975  0.006  47.44    37  1  -0.37  6.66 
5  FWRTLLEPV  1159.639  -0.0005  38.95  32  36  1  0.37777777
8 
6.98 
5  NGVSLIELVRGNAEKPV  1793.9999  -0.0038  42.79  23  35  1  0.05294117
6 
7 
5  FARLLL  731.4694  -0.018  34.6    29  6  1.91666666
7 
11.04 




5  NRFSEWTVPV  1233.6142  0.0045  38.71  26  38  1  -0.43  6.98 
5  FRALLL  731.4694  -0.018  32.38    29  7  1.91666666
7 
11.04 
                   




6  RYNYFLNENA  1302.5993  0.0024  45.35  27  37  1  -1.27  6.82 
6  MAYVINREQFV  1368.686  0.0019  70.17  34  37  1  0.28181818
2 
6.88 
6  KYPYGIDETKVA  1382.7082  -0.0017  42.78  30  37  1  -0.8  6.78 




6  RKVMEEAGYGPDNKY  1755.825  0.0012  105.86  26  38  1  -1.56  6.88 












6  WLQYQSPTWKEMANTI  1994.956  -0.0016  48.74  22  38  1  -0.8  6.8 
6  MAYVINREQFVSDVFKG  2001.9982  -0.0016  121.1  32  39  1  0.08823529
4 
6.86 








6  VAGIDGKGRLSGISSTFNSLDPV  2289.1965  0.0005  93.16  29  38  1  0.15652173
9 
6.8 

















6  GFGLILL  731.4582  -0.0008  53.07    28  2  2.55714285
7 
6.02 
6  IAFTMYL  857.4357  -0.0019  39.95  33  37  1  1.82857142
9 
5.92 
6  GLGTLYFLV  981.5535  -0.0009  41.73    33  1  1.73333333
3 
5.92 
6  RYADWLFT  1070.5185  0.0039  46.14  29  37  1  -0.3125  6.7 




6  TGRPEWIWLA  1227.64  0.0088  61.11    37  1  -0.24  6.98 




6  ALMGLGTLYFLV  1296.7152  -0.0008  40.94    35  1  1.925  5.92 
6  DVSAKVGFGLILL  1330.786  -0.0034  68.32    31  1  1.53076923
1 
6.66 
6  ITGRPEWIWLA  1340.7241  0.0018  48.1  33  36  1  0.19090909
1 
6.98 




6  GRPEWIWLALGT  1397.7456  -0.0018  68.79    37  1  0.08333333
3 
6.98 
6  ARYADWLFTTPL  1452.7401  -0.0061  45.58  22  38  1  0.06666666
7 
6.7 




6  RYADWLFTTPLL  1494.7871  0.0028  41.6  26  37  1  0.23333333
3 
6.7 
6  TGRPEWIWLALGT  1498.7932  -0.0005  80.58    38  1  0.02307692
3 
6.98 












6  DGIMIGTGLVGALTKV  1543.8644  -0.0029  60.35  28  35  1  1.14375  6.66 




6  GADGIMIGTGLVGALTKV  1671.923  -0.0026  175.97    36  1  1.09444444
4 
6.66 
6  RYADWLFTTPLLLL  1720.9552  -0.001  43.64  26  35  1  0.74285714
3 
6.7 
6  QITGRPEWIWLALGT  1739.9359  -0.004  43.67  30  37  1  0.08666666
7 
6.98 




6  YWARYADWLFTTPL  1801.8828  0.0041  83.9  37  39  1  -0.1  6.64 
6  GADGIMIGTGLVGALTKVY  1834.9863  -0.0073  150.03    37  1  0.96842105
3 
6.6 




6  LVGADGIMIGTGLVGALTKV  1884.0754  -0.0042  141.11    33  1  1.385  6.66 




6  ALVGADGIMIGTGLVGALTKV  1955.1125  -0.0065  104.57    34  1  1.40476190
5 
6.66 
6  SDPDAKKFYAITTLVPAIA  2020.0881  -0.0107  77.3  26  37  1  0.28947368
4 
6.68 
6  LVGADGIMIGTGLVGALTKVY  2047.1388  -0.0042  90.73  32  35  1  1.25714285
7 
6.6 













6  DLTQQYAPFLRNLAI  1761.9413  -0.0034  89.38  35  37  1  0.01333333
3 
6.7 
6  IDLTQQYAPFLRNLAI  1875.0254  -0.0091  63.48  29  36  1  0.29375  6.7 
6  DLTQQYAPFLRNLAIFA  1980.0469  -0.0059  77.39  34  37  1  0.28235294
1 
6.7 
6  DLTQQYAPFLRNLAIFAA  2051.084  -0.0054  85.29  31  38  1  0.36666666
7 
6.7 








6  AYISWINNVIA  1262.6659  -0.0036  85.49    37  1  1.02727272
7 
5.92 








6  VVGGTEAQRNSWPSQI  1727.8591  0.0196  83.84    39  1  -0.5875  6.98 
6  GLLTQREFSA  1120.5877  0.0039  41.19  26  37  1  -0.12  6.98 
6  AQDIGRFAIGV  1145.6193  0.0024  66.73    37  1  0.66363636
4 
6.78 
6  RSMFNSGADII  1209.5812  0.0026  83.64  29  37  1  0.18181818
2 
6.78 
6  GDGVFRAAQDIGRFAIGV  1847.9642  -0.004  38.27  30  38  1  0.40555555
6 
6.92 
6  GFVGGIETPLIKKFEAGFTA  2081.1197  -0.0127  60.36  19  37  1  0.48  6.92 
6  AQDIGRFAIGVDRDQSVTKS  2162.108  -0.0057  58.71  28  39  1  -0.485  6.9  
 
6  TVGFVGGIETPLIKKFEAGFT  2210.1987  -0.0183  68.42  26  37  1  0.53809523
8 
6.92 
6  GFVGGIETPLIKKFEAGFTAGV  2237.2096  -0.0111  130.62    37  1  0.60909090
9 
6.92 








6  VFETRRPAEQLL  1457.799  -0.0014  58.33  29  37  1  -0.45  7.12 




6  RNINMPTFKLLLGNAAPDDV  2198.1517  -0.0086  147.14  29  38  1  -0.09  6.8 




6  ARNINMPTFKLLLGNAAPDDVGGA  2454.2689  -0.0047  117.2  28  39  1  0.04166666
7 
6.8 
6  LIQNDIAYFAKNGTGI  1736.9097  0.0033  102.23    37  1  0.1875  6.6 








6  GSLAKGNADFALIQNDIAYFAKNGTGI  2768.4133  -0.0143  65.5  17  40  1  0.09259259
3 
6.68 
6  ALAAGYAERGIGS  1234.6306  0.0048  63.68  36  37  1  0.32307692
3 
6.88 
6  ALAAGYAERGIGSA  1305.6677  0.0024  91.94    38  1  0.42857142
9 
6.88 
6  AGYAERGIGSAAVGA  1348.6735  0.005  39.26  31  38  1  0.4  6.88 
6  ALAAGYAERGIGSAAV  1475.7732  0.0006  93.55    38  1  0.75  6.88 
6  ALAAGYAERGIGSAAVG  1532.7947  -0.0002  94.01  32  38  1  0.68235294
1 
6.88 
6  ALAAGYAERGIGSAAVGA  1603.8318  -0.0012  144.17    38  1  0.74444444 6.88  
 
4 
6  AVGLAALAAGYAERGIGS  1645.8787  -0.0036  37.6  33  37  1  0.85555555
6 
6.88 
6  AALAAGYAERGIGSAAVGA  1674.8689  -0.0002  79.74  31  38  1  0.8  6.88 
6  AALAVGLAALAAGYAERGI  1756.9835  -0.0013  106.39    35  1  1.26315789
5 
6.88 
6  LAVGLAALAAGYAERGIGS  1758.9628  -0.0021  117.45    36  1  1.01052631
6 
6.88 
6  LAVGLAALAAGYAERGIGSA  1829.9999  -0.0052  106.28    37  1  1.05  6.88 
6  AALAVGLAALAAGYAERGIGS  1901.037  -0.0032  154.57    37  1  1.08571428
6 
6.88 
6  AALAVGLAALAAGYAERGIGSA  1972.0741  -0.0064  155.29    37  1  1.11818181
8 
6.88 
6  AALAVGLAALAAGYAERGIGSAAV  2142.1797  -0.0128  50.99  29  37  1  1.275  6.88 
6  AALAVGLAALAAGYAERGIGSAAVGA  2270.2382  -0.008  78.78    37  1  1.23076923
1 
6.88 
6  KTVKVGPNNQNVFDPAEV  1955.0112  -0.006  130.83    39  1  -0.65  6.84 
6  DAVVYIRVRDA  1275.6935  0.0033  46.38  31  36  1  0.30909090
9 
6.84 
6  LLEPGINVIPPFVSRT  1750.9982  -0.0026  109.53  28  34  1  0.6  6.98 
6  GLLEPGINVIPPFVSRT  1808.0196  -0.0053  39.93  20  34  1  0.54117647
1 
6.98 
6  FGEYRGLLEPGINVIPPFVSRT  2460.3165  -0.0125  42.9  17  38  1  0.10454545
5 
7.04 




6  AFSALGYEHYHHLLES  1872.8795  -0.0025  129.72  32  38  1  -0.2125  5.74 
6  AFSALGYEHYHHLLESFA  2090.985  0.0004  60.3  19  38  1  0.06666666
7 
5.74 
6  RLVDGLTTI  986.5761  0.0041  47.6    34  1  0.72222222
2 
6.78 








6  IYLGGGEGGRYVALI  1536.83  -0.0003  65.56  32  36  1  0.66666666
7 
6.82 
6  MRQLRGDEATREWLT  1860.9264  -0.0047  57.25  26  39  1  -1.26  7.16 
6  GAILSGVYMGDKQSPL  1634.8338  -0.0044  115.26  35  38  1  0.2125  6.6 




6  AKPLFRGEGAAPFDPV  1670.878  -0.0037  59.47  26  38  1  -0.125  6.92 
6  KPLFRGEGAAPFDPVVG  1755.9308  -0.0016  87.88  34  38  1  -8.48994E-
17 
6.92 
6  AKPLFRGEGAAPFDPVVG  1826.9679  -0.0017  70.43  27  38  1  0.1  6.92 
6  AKPLFRGEGAAPFDPVVGTI  2041.0997  -0.0069  46.58  22  37  1  0.28  6.92 




6  HAGAMLGDVRHDPFQS  1752.8002  -0.0043  46.32  20  37  1  -0.51875  6.02 














3733.7907  -0.0182  81.51  23  40  1  -0.96  6.98 




6  HLPLNPHLSFDLA  1472.7776  0.0012  106.2  29  38  1  0.18461538
5 
6 
6  GNDFFGQFRS  1173.5203  0.0037  36.48  20  36  1  -0.82  6.78 












6  ASFEQTQRGGSTSQIGSAFETRPY  2604.2205  -0.0182  41.39    38  1  -0.925  7.04 
6  SFEQTQRGGSTSQIGSAFETRPYTT  2735.2787  -0.0116  55.06  18  38  1  -1.016  7.04 




6  RVGGGTLADRLEFA  1460.7736  -0.0001  51.17  22  37  1  0.02142857
1 
7.04 
6  RVGGGTLADRLEFAA  1531.8107  0.0017  38.84  27  37  1  0.14  7.04 
6  RLYEDTPYGKKPLTEV  1907.9993  -0.0022  70.37  29  38  1  -1.1625  6.88 
6  RILGTGFPSFETV  1422.7507  0.0009  114.45    37  1  0.42307692
3 
6.98 








6  HWSQGSIGYFPT  1378.6306  0.0027  68.45  25  37  1  -0.525  7.76 
6  LLETLYYRV  1168.6492  0.0013  41.83    35  1  0.47777777
8 
6.82 
6  HLGLVWMQGIAEPH  1586.8028  -0.0014  117.69  30  39  1  0.23571428
6 
6.02 

















6  RLLSKELVIPEGV  1451.8711  0.0006  51.28    30  1  0.46923076
9 
7 




6  GGRQRLPPVDSWPDNV  1791.9016  -0.0033  100.44  35  39  1  -1.13125  6.92 




6  HLALGFEPHGGISPG  1487.7521  -0.0016  106.95  31  39  1  0.08  6.02 












6  FGGLLLI  731.4582  -0.0008  56.31    28  1  2.55714285
7 
6.02 
6  ASVPTFLTGAF  1109.5757  -0.0015  52  28  36  1  1.18181818
2 
6.02 




6  FGVALLI  731.4582  -0.0008  50.01    28  3  2.92857142
9 
6.02 
6  GLRDVVGWSVLAGVA  1497.8304  0.0013  76.65    36  1  1.14  6.78 













6  SRTKTKLEDLGLVDTEKVPI  2241.258  -0.0092  74.65  30  35  1  -0.54  6.94 
6  GLFADLRDSVSRV  1433.7627  -0.0001  69.51    37  1  0.2  6.92 








6  FNLLLL  731.4581  -0.0008  39.9    28  4  2.41666666
7 
6.02 
6  FRALLL  731.4694  -0.012  32.39    28  7  1.91666666
7 
11.04 
6  LLVTQLVGLPGLDIGRAA  1805.0775  -0.0073  49.16    29  1  1.13888888
9 
6.78 








6  LDLTKATIHTYMATL  1690.8964  0.0038  41.41    37  2  0.44666666
7 
7.66 
6  FARLLL  731.4694  -0.012  34.61    28  6  1.91666666
7 
11.04 




6  VVANVFLAATGVDLGRA  1671.9308  -0.0105  39.86    36  2  1.25882352
9 
6.78 
6  GTWLAADLIGQLIRNT  1740.9523  -0.0065  39.67  32  37  1  0.36875  6.78 
6  AGVVGVIAAITEVGLFAIAGGA  1955.1092  -0.0032  38.11    34  2  1.88636363
6 
3.3 
6  VLIFPWTVIYRDA  1591.8763  -0.0017  36.52  31  35  1  1.02307692
3 
6.7 
6  GVVDSIVRFA  1061.587  0.0035  38.73  32  35  1  1.25  6.78 




                   




7  ANGARLYWKEDA  1392.6786  0.0001  72.24  29  38  1  -1.025  6.86 












7  TGRPEWIWLA  1227.64  -0.002  58.1    37  1  -0.24  6.98 
7  DVSAKVGFGLILL  1330.786  -0.0044  63.26    31  1  1.53076923
1 
6.66 








7  TGRPEWIWLALGT  1498.7932  -0.0013  50.44  31  38  1  0.02307692
3 
6.98 








7  GADGIMIGTGLVGALTKV  1671.923  -0.0021  68.91  29  36  1  1.09444444
4 
6.66 
7  YWARYADWLFTTPL  1801.8828  0.0004  73.05  30  39  1  -0.1  6.64 
7  GADGIMIGTGLVGALTKVY  1834.9863  -0.0043  76.35  28  37  1  0.96842105
3 
6.6 
7  LVGADGIMIGTGLVGALTKV  1884.0754  0.0002  50.42  28  33  1  1.385  6.66 
7  LVGADGIMIGTGLVGALTKVY  2047.1388  0.0068  34.18  16  34  1  1.25714285 6.6  
 
7 




7  VVGGTEAQRNSWPSQI  1727.8591  0.0009  90.02    39  1  -0.5875  6.98 
7  GFVGGIETPLIKKFEA  1704.9451  0.0025  49.93  22  35  1  0.38125  6.92 
7  GFVGGIETPLIKKFEAGFT  2010.0826  0.0024  91.75  25  37  1  0.41052631
6 
6.92 
7  GFVGGIETPLIKKFEAGFTA  2081.1197  0.0065  84.66  22  37  1  0.48  6.92 
7  GFVGGIETPLIKKFEAGFTAGV  2237.2096  0.0038  86.16  27  37  1  0.60909090
9 
6.92 








7  GLHGHGWEPNAS  1260.5636  -0.0036  75.93  35  36  1  -1.025  6.02 
7  GLHGHGWEPNASI  1373.6476  -0.0004  40.48    38  1  -0.6  6.02 












7  ALAAGYAERGIGS  1234.6306  -0.004  43.55  35  38  1  0.32307692
3 
6.88 
7  ALAAGYAERGIGSA  1305.6677  0.0008  50.32  33  38  1  0.42857142
9 
6.88 
7  ALAAGYAERGIGSAAVGA  1603.8318  0  119.28    38  1  0.74444444
4 
6.88 
7  LAVGLAALAAGYAERGIGS  1758.9628  0.007  39.41  33  36  1  1.01052631
6 
6.88 




7  AALAVGLAALAAGYAERGIGSA  1972.0741  0.0072  113.8    36  1  1.11818181
8 
6.88 
















7  AKPLFRGEGAAPFDPV  1670.878  0.0008  70.53  28  38  1  -0.125  6.92 
7  AKPLFRGEGAAPFDPVVG  1826.9679  0.0014  55.74  29  38  1  0.1  6.92 












7  PLVDNFLQNYHIGHVL  1877.9788  -0.017  42.22  31  38  1  0.2125  6 
7  PLVDNFLQNYHIGHVLA  1949.0159  0  62.52  22  38  1  0.30588235
3 
6 
7  IGTGEPLARALEKI  1466.8456  -0.0041  43.57  27  33  1  0.12142857
1 
7 
                   














3708.769  0.0302  75.18  19  40  1  -1.12  7.54 




8  TGRPEWIWLA  1227.64  -0.0037  51.45    38  1  -0.24  6.98 




8  TGRPEWIWLALGT  1498.7932  -0.002  52.05  25  38  1  0.02307692
3 
6.98 
8  YWARYADWLFTTPL  1801.8828  0.0022  68.64  29  39  1  -0.1  6.64 




8  TLNSYVQLGVLPRAG  1586.878  -0.0031  38.1  20  36  1  0.32666666
7 
9.84 
8  VVGGTEAQRNSWPSQI  1727.8591  -0.0008  82.57    39  1  -0.5875  6.98 
8  AHNAFQYLGT  1120.5302  -0.0064  59.76  25  38  1  -0.24  7.76 




















8  NFPDDLGMFGHRKS  1619.7515  -0.0118  70.31  24  37  1  -1  7.72 
8  AHRYDAPIVGSPFTI  1642.8467  -0.0024  70.35  26  38  1  0.13333333 7.76  
 
3 




8  LFLGATLPPHLGQPA  1530.8558  -0.0027  45.19  22  35  1  0.57333333
3 
7.84 
8  HVPVEKHVFDDEGHGFSKRA  2290.1243  0.0019  41.48  22  39  1  -0.955  6.32 




8  NAIGFGPIVGPHIA  1361.7456  -0.0027  106.93  33  36  1  0.92857142
9 
7.84 
8  MAGWYRTPEFGHGQLI  1861.8934  -0.0019  63.46  21  39  1  -0.35  7.76 
8  VLHPRLPIDPA  1226.7135  -0.003  40.05  24  34  1  0.19090909
1 
7.84 
                   
9  GAFHLQPPQLF  1253.6557  -0.0064  54.39  27  37  1  0.10909090
9 
7.84 




9  ALIPVYHNLAQS  1324.7139  -0.0054  54.6  24  36  1  0.5  7.76 




9  TGRPEWIWLA  1227.64  -0.0023  54.23    37  1  -0.24  6.98 
9  STFKVLRNVTVV  1361.8031  -0.0023  30.14  22  30  1  0.775  11.24 




9  TGRPEWIWLALGT  1498.7932  -0.0022  76.64    38  1  0.02307692
3 
6.98 
9  YWARYADWLFTTPL  1801.8828  -0.0007  68.1  26  39  1  -0.1  6.64 




9  TLNSYVQLGVLPRAG  1586.878  -0.0016  98.63    36  1  0.32666666 9.84  
 
7 




9  KWVWEGSTGH  1185.5567  -0.0061  59.67  35  36  1  -1.05  7.72 




9  KWVWEGSTGHNVH  1535.727  -0.001  68.39  31  38  1  -1  7.88 




9  GLTNHYYPMLV  1306.638  -0.0058  67.17  33  38  1  0.15454545
5 
7.7 
9  GLTNHYYPMLVF  1453.7064  -0.0029  82.86  26  38  1  0.375  7.7 




9  ANVLYTFYPPLQAHPA  1800.9199  0.0499  72.84    37  1  0.10625  7.7 
9  LFLGATLPPHLGQPA  1530.8558  0.001  75.3  29  35  1  0.57333333
3 
7.84 
9  AFLRFWLEHAT  1389.7193  0  73  36  38  1  0.36363636
4 
7.84 
9  VHDVHPLDSMGGPVKLPRVW  2238.1732  0.0104  43.3  18  38  1  -0.14  7.88 




9  GDSPPRWHAPLLGGLV  1670.8893  0.0003  49.86  28  38  1  -0.09375  7.84 
9  DSPPRWHAPLLGGLVA  1684.9049  0.0006  68.34  25  37  1  0.04375  7.84 
9  GDSPPRWHAPLLGGLVA  1741.9264  0.0021  50.99  25  37  1  0.01764705
9 
7.84 
9  DSPPRWHAPLLGGLVAT  1785.9526  0.0025  49.02  24  37  1  -7.83687E-
17 
7.84 
















9  GFALPPLPHLLA  1244.7281  -0.0048  62.68  30  33  1  1.1  7.84 




                   
10  SAKVGFGLILL  1116.6907  -0.0045  39.11    29  1  1.74545454
5 
9.74 




10  TGRPEWIWLA  1227.64  -0.0023  56.01    37  1  -0.24  6.98 
10  STFKVLRNVTVV  1361.8031  0  60.39  29  30  1  0.775  11.24 




10  YWARYADWLFTTPL  1801.8828  0.0011  59  28  39  1  -0.1  6.64 
10  SYVQLGVLPRAG  1258.7034  -0.0014  68.53  30  36  1  0.44166666
7 
9.84 




10  NSYVQLGVLPRAG  1372.7463  0.0007  37.8  24  37  1  0.13846153
8 
9.84 
10  SYVQLGVLPRAGTI  1472.8351  0.0022  56.02    34  1  0.65  9.84 
10  TLNSYVQLGVLPRAG  1586.878  -0.003  101.22    36  1  0.32666666
7 
9.84 
10  TLNSYVQLGVLPRAGTI  1801.0098  0.0029  108.86  33  34  1  0.51176470
6 
9.84 




10  VVHPYWNTDDVAAGYDIA  2004.9218  -0.0007  126.4  36  38  1  -0.05  3.6 




                   




11  NREQFVSDVFKGRGVG  1793.9173  0.0033  59.79  25  38  1  -0.66875  9.74 
11  DTYYVGFNMTKVPKPV  1857.9335  0.0011  66.06  25  39  1  -0.31875  9.24 








11  SKYDPSLHSSGETLPGGRKL  2128.0913  0.0079  101.26  27  38  1  -1.035  9.34 




11  KVGFGLILL  958.6215  -0.0016  28.26    21  1  2.02222222
2 
9.74 
11  SAKVGFGLILL  1116.6907  -0.0067  61.5    29  1  1.74545454
5 
9.74 




11  TGRPEWIWLA  1227.64  0  40.42    37  1  -0.24  6.98 
11  STFKVLRNVTVV  1361.8031  -0.0005  53.35  24  30  1  0.775  11.24 




11  TGRPEWIWLALGT  1498.7932  -0.0022  67.44  34  38  1  0.02307692
3 
6.98 
11  KGMGVSDPDAKKFYAI  1725.876  0.0057  47.08  30  38  1  -0.3875  9.2 
11  YWARYADWLFTTPL  1801.8828  0.0036  57.73  26  39  1  -0.1  6.64  
 












11  RQNWVMTA  1004.4862  -0.0028  47.15  29  38  1  -0.65  11.04 




11  YVQLGVLPRAG  1171.6713  -0.0037  56.06    35  1  0.55454545
5 
9.84 




11  SYVQLGVLPRAG  1258.7034  -0.0012  97.55    36  1  0.44166666
7 
9.84 
11  NSYVQLGVLPRAG  1372.7463  -0.0013  88.15  33  37  1  0.13846153
8 
9.84 
11  YVQLGVLPRAGTI  1385.8031  -0.0011  44.2    33  1  0.76153846
2 
9.84 
11  TLNSYVQLGVLPR  1458.8195  0.0001  78.84  26  35  1  0.26923076
9 
9.84 
11  SYVQLGVLPRAGTI  1472.8351  -0.0004  83.76    34  1  0.65  9.84 
11  TLNSYVQLGVLPRAG  1586.878  -0.002  109.75    36  1  0.32666666
7 
9.84 
11  TLNSYVQLGVLPRAGTI  1801.0098  0.0018  103.95  30  34  1  0.51176470
6 
9.84 
11  QSVTLNSYVQLGVLPRAG  1901.0371  0.004  92.05  32  36  1  0.26666666
7 
9.84 
11  VVHPYWNTDDVAAGYDIA  2004.9218  0.0003  54.96  21  38  1  -0.05  3.6 
11  SLFGVPYNFERPKLS  1752.9199  0.0032  86.26  35  37  1  -0.3  9.52 

















11  LFRAGGLLL  958.5964  0.0236  23.61    21  2  1.61111111
1 
11.04 
                   
12  GWVADYPRPR  1215.6149  -0.0017  47.15    38  1  -1.23  9.84 




















12  NREQFVSDVFKGRGVG  1793.9173  0.0041  84.21  28  38  1  -0.66875  9.74 
12  DTYYVGFNMTKVPKPV  1857.9335  -0.0021  109.96  30  39  1  -0.31875  9.24 




12  DTYYVGFNMTKVPKPV  1873.9284  0.0049  70.28  25  39  1  -0.31875  9.24 












12  SKYDPSLHSSGETLPGGRKL  2128.0913  0.0055  121.56  33  39  1  -1.035  9.34 












12  MAYVINREQFVSDVFKGRGV  2314.1892  0.0056  48.35  19  39  1  0.04  9.52 
12  GFGLILLR  887.5593  -0.0011  60.17    28  1  1.675  11.04 
12  KVGFGLILL  958.6215  -0.0028  62.67    21  1  2.02222222
2 
9.74 




12  AKVGFGLILL  1029.6586  -0.0062  59.13    25  1  2  9.74 
12  SAKVGFGLILL  1116.6907  -0.0046  79.9    29  1  1.74545454
5 
9.74 
12  GTGLVGALTKVY  1177.6707  -0.0075  52.3    33  1  0.83333333
3 
9.52 
12  TGRPEWIWLA  1227.64  -0.0014  47.53    37  1  -0.24  6.98 
12  STFKVLRNVTVV  1361.8031  -0.0006  56.55  24  30  1  0.775  11.24 




12  MIGTGLVGALTKVY  1421.7952  -0.0044  39.57  21  34  1  1.17142857
1 
9.52 
12  TGRPEWIWLALGT  1498.7932  -0.0026  46.54  36  38  1  0.02307692
3 
6.98 
12  KGMGVSDPDAKKFYAI  1725.876  0.0059  71.61  32  38  1  -0.3875  9.2  
 
12  YWARYADWLFTTPL  1801.8828  0.0024  59.75  25  39  1  -0.1  6.64 
















12  TGWGLTRT  890.461  -0.0019  42.78    37  1  -0.5625  11.04 
12  RQNWVMT  933.4491  -0.0031  43.54    38  1  -1  11.04 
12  RQNWVMTA  1004.4862  -0.0047  59.75    38  1  -0.65  11.04 
12  YVQLGVLPR  1043.6128  -0.0062  38.31    34  1  0.52222222
2 
9.84 




12  QLGVLPRAGTI  1123.6713  -0.0049  31.98    31  1  0.63636363
6 
11.04 
12  SYVQLGVLPR  1130.6448  -0.0009  42.4  25  34  1  0.39  9.84 
12  YVQLGVLPRAG  1171.6713  -0.0032  74.78    35  1  0.55454545
5 
9.84 




12  SYVQLGVLPRAG  1258.7034  0.0011  93.25    36  1  0.44166666
7 
9.84 
12  QKIVVHPYWN  1282.6822  -0.0037  64.04  25  37  1  -0.5  9.52 
12  QLGVLPRAGTILA  1307.7925  -0.0052  36.65    29  1  0.96923076
9 
11.04 
12  NSYVQLGVLPRAG  1372.7463  -0.0026  84.63  31  37  1  0.13846153
8 
9.84 




12  TLNSYVQLGVLPR  1458.8195  -0.0047  106.54  31  35  1  0.26923076
9 
9.84 
12  SYVQLGVLPRAGTI  1472.8351  -0.0023  90.68    34  1  0.65  9.84 
12  TLNSYVQLGVLPRAG  1586.878  0.0083  118.94    35  1  0.32666666
7 
9.84 
12  TLNSYVQLGVLPRAGTI  1801.0098  0.0012  135.77  33  34  1  0.51176470
6 
9.84 
12  QSVTLNSYVQLGVLPRAG  1901.0371  0  109.99  32  36  1  0.26666666
7 
9.84 
12  GFVGGIETPLIKKF  1504.8654  -0.0021  75.39  28  32  1  0.55714285
7 
9.46 








12  SLFGVPYNFERPKLS  1752.9199  0.0035  91.39  31  37  1  -0.3  9.52 








12  GHLRSLLPI  1004.6131  -0.0018  30.59    28  1  0.6  11.04 
12  WYTILPKLA  1103.6379  -0.013  40.26  23  34  1  0.61111111
1 
9.52 












12  QQSIAQQQPMARPQPV  1805.9206  -0.0003  76.01  26  38  1  -1.05625  11.04 
12  GIRVGPGEKHTYTIPA  1694.9104  0.0021  98.18  29  37  1  -0.45  9.52  
 
12  GLKYFLI  852.5109  -0.0061  30.56  27  30  1  1.32857142
9 
9.52 
12  AVRLYEDTPYGKKPL  1748.9461  0.0031  45.32  21  36  1  -0.84  9.24 
12  AAVRLYEDTPYGKKPL  1819.9832  0.003  55.41  20  36  1  -0.675  9.24 
12  LGSDRGPYYPKRPDGI  1789.9111  0.0016  55.48  32  39  1  -1.3125  9.38 




























12  DLVQGAPRLKYLLG  1541.8929  0.0039  79.65    33  1  0.15  9.52 




12  KVVLHPRLPIDPA  1453.8769  -0.0021  51.94  23  30  1  0.18461538
5 
9.74 
12  FLGGLLRA  845.5123  0.0003  35.23    30  1  1.3375  11.04 
12  LIGVGYIIGPRIA  1340.818  -0.0011  60.83    30  1  1.47692307
7 
9.84 
12  GNGLFRYGVFTL  1342.7034  -0.0012  50.94  32  38  1  0.51666666
7 
9.84 




12  LFRAGGLLL  958.5964  0.0224  32.03    21  2  1.61111111
1 
11.04 
12  RLPIVLVVPT  1105.7223  -0.0032  43.43    19  1  1.63  11.04 
12  VTSLLLSVG  887.5328  0.0254  42.1    28  2  1.9  6.02 
12  FMSAVGPRGIIPA  1314.7118  -0.0025  41.38  27  37  1  0.93846153
8 
11.04 
12  SAKRRDYEWQGKTGDN  1909.9031  0.0036  40.21  25  38  1  -2.3125  9.34 
                   
                   
  CGM                 
1  HSIAAQGGVNSA  1110.5418  0.0024  71.29  33  35  1  0.125  7.84 




















1  DDTTFTVELTQPESDFPLRL  2323.122  -0.0092  55.62  23  37  1  -0.555  3.42 




1  SDMVESTPEGYRATTL  1755.7985  -0.0108  41.07  28  34  1  -0.64375  3.82 
1  VAPDVDIEAIITGGDIDPH  1945.9633  -0.016  113.08    37  1  0.24210526
3 
3.36 
1  DHDVDNEHVWYSTEYV  2006.8283  0.0031  32.16  19  28  1  -1.2375  3.84  
 
1  NTENFLDAFTKAVDDLTAAT  2156.0273  0.0054  119.41    37  1  -0.155  3.5 












1  VVHPYWNTDDVAAGYDIA  2004.9218  -0.0273  75.38  26  33  1  -0.05  3.6 












1  KQLTDDIPPLTTEDGEVRGVPFAVEGF  2929.4709  -0.0573  104.04  33  37  1  -
0.32962963 
3.76 




1  EYVVNSIADDKGWDHPTIEWRESPS  2929.3519  -0.0127  79.9  25  35  1  -1.068  4.06 








1  GEDWDADQPVTGEDIFGEEH  2244.9084  0.0202  55.64  20  27  1  -1.29  3.24 

















1  VGEDWDADQPVTGEDIFGEEHERDNENTPA  3370.4134  -0.0081  141.52  23  26  1  -1.47  3.42 




1  AAVGEDWDADQPVTGEDIFGEEHERDNENTPA  3512.4876  0.0007  93.92  25  27  1  -1.265625  3.42 








1  SVPVDRPGADLQEILDRLEADQENA  2749.3518  -0.01  60.47  28  38  1  -0.748  3.62 
1  RFQVKDQSIVDQQEIDSDPS  2333.1135  0.0132  84.12  35  37  1  -1.185  3.76 
1  QAPDSYGRIGNQSGSDVSPV  2032.945  0  39.45  24  35  1  -0.81  3.88 
















1  GFRPEALEIIPEGESTDLSIPI  2382.2318  -0.0133  70.22    38  1  0.01363636
4 
3.58 





















1  DATVSAPVLESGVENREVGGDTAEA  2472.1616  -0.0024  77.28  28  36  1  -0.28  3.44 
















1  GVLEEGQYNRELAEAI  1789.8846  -0.034  55.41    36  1  -0.48125  3.8 




1  RLELPDFEFVPM  1491.7432  -0.0119  55.51  27  37  1  0.09166666
7 
3.82 
1  FAEFERTTAEDVANGVPEAI  2165.0277  -0.0112  76.2  25  36  1  -0.16  3.58 




1  AELFDASGQIPSSQEFFRV  2127.0273  -0.0246  56.88  24  36  1  -0.1  3.82 









1  SLDAVRQEVEEIIGQGSQPT  2155.0757  -0.0322  58.01    37  1  -0.535  3.68 
1  AFQDALGVRDADFIAQLV  1948.0054  -0.0295  56.89  33  37  1  0.60555555
6 
3.6 




1  INDEVINEIRDGISSF  1819.8952  -0.006  37.43  31  37  1  -0.15625  3.58 




                   
2  HAEPLFFESVPL  1384.7027  0.0092  62.75  31  36  1  0.41666666
7 
4.24 




2  SVDGWFTLPFTIPNYLGPLLGSERL  2791.4585  -0.0036  88.21  28  38  1  0.284  4.08 












2  IFEGTRTPATDFTSPVIDGH  2160.0488  -0.009  64.93  26  37  1  -0.26  4.3 
2  NTNEVGGGRIVDSIFSGLVYY  2259.1172  -0.0673  46.76  30  35  1  0.15238095
2 
4.08 





















2  FGPAARALPQLPITVDEEGYLIA  2440.3002  -0.0409  80.48  35  38  1  0.36956521
7 
3.82 
2  DAEKVIEREGQESFHYGDYYAYSKI  2996.3828  -0.072  44.97  22  31  1  -1.12  4.42 




2  ADDKGWDHPTIEWRESPSAQ  2324.0458  -0.0187  100.05  27  33  1  -1.61  4.2 
2  SIADDKGWDHPTIEWRESPS  2325.0662  -0.0171  43.46  22  34  1  -1.34  4.2 












2  TKYDQPGLGLRNPDNSMSGLDVDVA  2661.2704  -0.0687  55.58  21  34  1  -0.696  3.88 




2  NNSFLDRAGIDPNLA  1615.7954  -0.039  37.39  29  35  1  -0.42  3.88 
2  SVIPVDAAQAPTAYQEGRPA  2040.0276  -0.012  57  24  37  1  -0.23  4.08 
2  SVIPVDAAQAPTAYQEGRPAII  2266.1957  -0.0536  78.95  34  37  1  0.2  4.08 





2  SLGEFTRVFEYDSLVV  1859.9305  -0.02  87.27  30  37  1  0.425  3.82 












2  ALDRVMEQGGYVTI  1550.7763  -0.0135  62.5    37  1  0.18571428
6 
4.08 
















2  SVEDLRAIPWVL  1396.7714  -0.0003  52.95    35  1  0.625  4.08 
2  SSVEDLRAIPWVL  1483.8035  -0.0053  47.02  33  36  1  0.51538461
5 
4.08 

















2  AIMNAGEIAVEGTLDELVAREKSII  2641.3996  -0.0336  48.51  31  38  1  0.456  4 
2  SIEAELLTEIRDLLQEQKRLQ  2524.386  -0.0159  56.72  29  36  1  -0.6  4.36 
2  YLQLSYVLDDLGLTGMRDWMKA  2587.2814  0.0055  56.86  27  38  1  0.02727272
7 
4.18 
2  QISRTLFDLLFPSNTDAA  2008.0266  -0.0242  57.86  27  37  1  0.11111111
1 
3.88 
2  AQISRTLFDLLFPSNTDAA  2079.0637  -0.0226  49.45  27  37  1  0.2  3.88 




2  LVELFGLAREL  1258.7285  0.007  60.35    32  1  1.1  4.26 
2  SYNEDTKQWDVTVNRDGAESTLHPT  2862.3056  -0.0019  50.43  21  34  1  -1.368  4.2 
2  AMEDFGWRIPFLT  1581.765  -0.0095  46.86  32  36  1  0.19230769
2 
4.08 
2  VATFRDLENKYMPED  1826.8509  -0.0198  53.85  24  34  1  -1  4.06 
2  SIIDHIVEDVVAGTLTDRPVLV  2360.2952  -0.015  73.88  25  36  1  0.81818181
8 
3.96 








2  GFLTPEEVESFLAGRV  1749.8938  -0.0133  57.77  33  37  1  0.28125  3.96 








2  DLGDGLAQLLKLPERFVIGA  2124.1943  -0.0136  45.71  32  35  1  0.445  4.3 




2  GFVRDVEERLNELEAA  1845.9221  -0.0174  40.06  33  37  1  -0.5  4 




                   












3  FTIPESLEHFSGEEGVLRRQAISLA  2785.4399  -0.0533  44.6  30  38  1  -0.056  4.7 








3  IEREGQESFHYGDYYAYSKI  2454.1128  -0.0158  51.75  23  33  1  -1.155  4.62 












3  TSYQKLKEVAEDMQAKKDELGIEGA  2780.3902  -0.0161  44.97  22  38  1  -0.944  4.44 
3  ATKDFVDWLFTSEAGKEHVVKDLGFIAPF  3266.6652  -0.035  46.99  17  38  1  0.11724137
9 
4.62 
3  RLVELWHDPEVL  1504.8038  -0.0252  56.96  32  37  1  -0.075  4.42 












3  AYPVIKDMVVDRSALDRVMEQGGYVTI  3024.5413  -0.0251  46.38  27  38  1  0.15925925
9 
4.46 
3  AAYPVIKDMVVDRSALDRVMEQGGYVTI  3095.5784  -0.0163  41.02  24  38  1  0.21785714
3 
4.46 












3  TYNGTLYALPQNTNGQLLFRNTEIIPEAPA  3318.6884  -0.0993  75.13  25  37  1  -0.37  4.26 
3  GHDIYNAVIRNGQSTEAEQV  2200.0509  -0.0063  64.5  30  36  1  -0.74  4.42 




3  AVGHDIYNAVIRNGQSTEAEQV  2370.1564  -0.0116  54.82  21  37  1  -0.4  4.42 
3  SAAVGHDIYNAVIRNGQSTEAEQV  2528.2255  -0.0231  68.55  23  37  1  -0.325  4.42 




3  SFVLRGGQVELPVLSGAEII  2083.1677  -0.0302  46.48  33  36  1  0.91  4.26 
3  SIEAELLTEIRDLLQEQKRLQ  2524.386  -0.0127  78.86  34  36  1  -0.6  4.36 




3  ALRVLESLFNEHAYELV  2002.0523  -0.024  88.71  27  37  1  0.36470588
2 
4.54 
3  TALRVLESLFNEHAYELV  2103.1  -0.0165  41.08  26  37  1  0.30555555
6 
4.54 









3  ASLIEREAPAGDFDKVARVI  2156.1589  -0.0029  53.9  27  37  1  0.075  4.56 
3  GAQVAEILRVVAKELES  1811.0152  -0.0119  70.17  33  35  1  0.38235294
1 
4.56 




3  MYKVFEALDDLVQAVQRA  2095.0772  -0.0154  61  33  37  1  0.17222222
2 
4.3 
3  RVIGAVVDVEFPRGELPA  1923.0578  -0.0179  37.53  26  36  1  0.44444444
4 
4.44 
3  AAAPYAEEIQRVLERLASAS  2144.1225  -0.028  52.57  33  37  1  -0.02  4.56 








3  GGLGVLLLKEFLEGGRDFQPV  2243.2314  -0.0309  48.07  33  37  1  0.33333333
3 
4.44 
3  AIQLDRLGILEKYGVELI  2042.1775  -0.0288  38.49  29  34  1  0.56666666
7 
4.44 








3  HLLRDDNWWAPG  1478.7055  0.0003  42.06  24  36  1  -1.05  5.1 




3  GVFADSEKKEAAERYI  1811.9053  -0.009  38.68  28  37  1  -0.74375  4.64 
3  QVDVYGEFLREIGSPILPH  2168.1266  -0.0297  37.88  22  37  1  -2.33731E-
17 
4.42 
3  SGFNVWEEPNDAKRS  1734.7961  -0.0029  36.81  25  35  1  -1.44  4.44  
 
                   
















4  DHMNAIGAPFAREYGGALAT  2060.9738  -0.015  60.19  24  35  1  -0.05  5.22 




4  SYNADGGHQAWVDATANSIRNTLGI  2630.2473  -0.0214  57.42  33  36  1  -0.436  5.1 




4  NDGAEYDPAKDVYEHQMHSVHGPRNA  2936.2896  -0.0105  47.65  16  31  1  -1.45  5.16 




4  SEAGKEHVVKDLGFIAPF  1943.0153  -0.0124  73.42  29  37  1  0.06666666
7 
5.34 
4  LAQDQLDVNLFQHLKFL  2041.0997  -0.008  64.68    37  1  0.14705882
4 
5.1 




4  DVDVTLIDRTNHHLFQPLLYQVA  2706.413  -0.0342  53.42  23  38  1  0.03043478
3 
5.02 
4  EETGYVHPYTRI  1463.7045  -0.001  49.41  22  36  1  -1  5.3 





4  DHRLTGSVLEFVAMT  1674.84  -0.0077  57.91  31  37  1  0.34666666
7 
5.22 








4  NAQALEHIGQAPYAT  1582.7739  -0.0004  59.32  23  36  1  -0.38  5.12 












4  FIEVHQPLGPVDDHGHPIPLPYAGA  2675.3496  -0.0263  55.51  23  38  1  -0.108  5.02 
4  SLLFPQHFPGFYDAA  1708.825  -0.0024  76.36  30  36  1  0.24666666
7 
4.94 
4  HVNAADERVKEMWAYSPS  2088.9687  -0.0114  39.61  25  35  1  -0.85  5.34 




4  GTHSWGWWQDDLRGSWTTFA  2393.0614  -0.0213  50.29  21  31  1  -0.915  5.1 





























4  WYDHLPYIPFPDHWPV  2080.9836  -0.0004  65.85    36  1  -0.55625  4.94 
4  THDVNPLMGLVDRI  1578.8188  -0.0032  73.6  28  36  1  0.10714285
7 
5.1 
4  DFFRPMGI  981.4742  0.0117  36.18  30  34  1  0.25  6.78 
4  DFLHVWGLTVA  1256.6554  0.0025  80.88  32  36  1  1.08181818
2 
4.94 
4  NLRNSAAVGQLDFPLNIA  1912.0166  -0.0094  71.87    37  1  0.19444444
4 
6.78 
4  NDIIAGAFGFRPV  1375.7248  0.0007  50.01  27  36  1  0.65384615
4 
6.78 
4  NALAMFDSRGPQIQAA  1688.8304  -0.0073  51.15  28  37  1  -0.06875  6.78 




4  GHEDHIGAIPWLL  1456.7463  0.0015  42.23  28  37  1  0.13076923
1 
5.04 
4                   








5  RHAEPLFFESVPL  1540.8038  -0.0058  63.32    36  1  0.03846153
8 
5.3 




5  VIDHMNAIGAPFAREYGGA  1987.9574  -0.0287  58.95  30  36  1  0.14736842 5.22  
 
1 




5  VIDHMNAIGAPFAREYGGALAT  2273.1263  -0.0224  40.45  25  37  1  0.35  5.22 












5  VVGGTEAQRNSWPSQI  1727.8591  -0.0369  65.1    36  1  -0.5875  6.98 












5  TSLTSGEDWRWQTHLA  1886.8911  -0.0543  47.55  24  33  1  -0.91875  5.22 
5  KHFNDNWAAEKESNWG  1931.855  -0.0354  94  27  30  1  -1.7875  5.34 





































5  FWVPEFLFKRDA  1553.8031  -0.0045  47.56  31  36  1  0.025  6.92 




5  SLLPWEYLKL  1260.7118  -0.0001  36.95    34  1  0.32  6.8 
5  SLLPWEYLKLTLDRG  1802.993  -0.0095  39.12  25  36  1  -0.14  6.86 




























5  SFVLRGGQVELPV  1399.7824  -0.0011  60.63  30  35  1  0.63846153
8 
6.98 




5  QISRTLFDLLFPSNT  1750.9254  -0.0056  53.11  27  36  1  0.12666666
7 
6.78 
5  QWSVDSFRLA  1207.5986  0.0082  38.42  32  36  1  -0.14  6.78 




5  SLLLPFVGMWSDRV  1618.8541  -0.0042  49.14  36  37  1  0.85714285
7 
6.78 
5  MSLLLPFVGMWSDRV  1749.8946  -0.0026  38.54  31  37  1  0.92666666
7 
6.78 
5  FLPNPFWVPELRPF  1757.9294  -0.0058  54.1  34  37  1  0.1  6.98 
5  KWAGAVADLIGLLG  1382.7922  -0.0012  62.39    34  1  1.14285714
3 
6.66 




5  SGGLTLLVPFVDRV  1471.8399  -0.0021  54.24    34  1  1.06428571
4 
6.78 




5  GWFAEHPDALTDTYRRPTTA  2304.0923  -0.0327  44.22  16  35  1  -0.965  5.28 
5  ADPFRVIPA  984.5393  -0.0291  39.18    35  1  0.43333333
3 
6.78 
5  GWSAYPRHLDFEAFQ  1822.8427  -0.0076  42.43    35  1  -0.68  5.22 
5  SFGIGVERTFPV  1307.6874  -0.0029  41.3  27  36  1  0.55  6.98 




                    
 








6  HGPEYYHRQLGDILYF  2006.9639  -0.0198  64.19  22  36  1  -0.8  6.02 




6  VVGGTEAQRNSWPSQI  1727.8591  -0.0461  80.32    35  1  -0.5875  6.98 
6  GNFIEPLGPAFWERKS  1846.9366  -0.0153  55.49  32  37  1  -0.55625  7 
























6  FWVPEFLFKRDA  1553.8031  -0.0036  44.34  33  36  1  0.025  6.92 




6  SLLPWEYLKLTLDRG  1802.993  -0.0107  40.81  27  36  1  -0.14  6.86 
6  SVLDNMAQVMSKAELRLA  1975.023  -0.022  80.5    37  1  0.27777777
8 
6.92 








6  SNYKKTGPVNTYGLGEIEAGANLL  2508.286  -0.0152  96.58  26  38  1  -0.4  6.84 
6  ILRPELGIMLQ  1281.7478  -0.0078  35.21  29  33  1  0.8  6.98 
6  KTIFWNGPMGVFEFA  1742.8491  -0.005  56.39  26  36  1  0.39333333
3 
6.84 
6  YQNWSNKIVAET  1451.7045  -0.034  44.45  22  35  1  -0.925  6.8 
6  SIGSTEVEGLGFHIRAGNAA  1984.9966  -0.0549  46.04  28  36  1  0.155  5.3 




6  TIGPGLGIGILVGKALEGMARQPEMA  2578.3975  -0.0293  61.22  28  37  1  0.50384615
4 
7 




6  GALDRFAAGREV  1260.6575  -0.02  53.11  33  37  1  -0.05  7.04 
6  FLPNPFWVPELRPF  1757.9294  -0.0043  50.61  34  37  1  0.1  6.98 
6  VYALGGGDGGQGGQNWVTRT  1991.945  -0.0586  72.8  29  33  1  -0.545  6.7 
6  ALNIINTLFNRMNVEGV  1917.0142  -0.0116  47.22  31  37  1  0.49411764
7 
6.98 




6  FNGLGGLDDVEAAYKKLTGK  2095.095  -0.0026  43.64  22  37  1  -0.365  6.8 
6  LAIPELMRLL  1167.7049  0.0053  36.8    30  1  1.38  6.98 




6  NFSHGDHPDHEQNYKWVREA  2465.0897  -0.022  43.16  18  31  1  -1.935  5.76 
6  KLTVRDLLQEFA  1431.8085  0.0011  43.13  29  34  1  0.05  6.92 




                   












7  KMDELHNQIHDLPAVR  1914.9734  -0.0124  45.46  25  37  1  -0.86875  6.02 




















7  TTKMDELHNQIHDLPAVRIA  2301.1899  -0.0251  85.03  28  38  1  -0.45  6.02 
7  GNFIEPLGPAFWERKS  1846.9366  -0.0196  73.72  30  37  1  -0.55625  7 












7  GLTIIAPMGGMIKNPWNPKEGPMDV  2665.343  -0.0158  65.77  29  38  1  -0.096  6.84  
 
7  NFGGPYLLTHQALLV  1641.8879  -0.0108  86  30  36  1  0.62666666
7 
7.76 
7  NAGRSESVNFGGPYLLTHQALLV  2442.2655  -0.034  50.69  23  38  1  0.08260869
6 
7.76 
7  ARIIGAFERAEI  1344.7513  -0.0019  38.74  33  35  1  0.44166666
7 
7.12 


















7  GRGGNAGLYLLDGMRATEYS  2100.0058  -0.0251  59.24  28  36  1  -0.435  6.9 
7  HLSLLPLGKEERGL  1560.8987  -0.0413  60.95  26  35  1  -0.2  7.72 
















7  FELHYPHMI  1185.5641  -0.0162  40.54  28  34  1  0.02222222
2 
6.02 





























7  AGKTLVELFGLAREL  1615.9297  -0.0021  61.67    33  1  0.59333333
3 
7 
7  ATIGPGLGIGILVGKALEGMARQPEMA  2649.4346  -0.0327  51.64  22  37  1  0.55185185
2 
7 




7  GALDRFAAGREV  1260.6575  0.0057  54.5    36  1  -0.05  7.04 
7  ALNIINTLFNRMNVEGV  1917.0142  -0.0072  48.5  27  37  1  0.49411764
7 
6.98 
7  GPQNMPKFSDRQLSADEKKDIIAFI  2847.4589  -0.0563  57.47  22  38  1  -0.7  6.88 




7  NVISHLLSTIPYEKI  1725.9665  -0.013  38.44  26  35  1  0.4  7.66 
                   
8  TTRPEFIHPV  1195.635  0.0068  51.36  31  34  1  -0.43  7.84 
8  FIQFHPTGLPV  1254.6761  0.0048  69.67    35  1  0.64545454
5 
7.84 





8  RVIDHMNAIGAPFAREYGGA  2144.0585  -0.0128  43.3  24  37  1  -0.085  7.76 




8  AVTTKMDELHNQIHDLPAVR  2287.1743  -0.0366  59.62  26  38  1  -0.465  6.02 
















8  VVGGTEAQRNSWPSQI  1727.8591  -0.0102  44.42  31  36  1  -0.5875  6.98 








8  GKEHVVKDLGFIAPF  1655.9035  -0.0116  77.16  31  36  1  0.24666666
7 
7.64 












8  DRTNHHLFQPLLYQVA  1951.0064  -0.0176  43.23  23  37  1  -0.51875  7.9 





8  NYYQEILKLDGMKHFA  1968.9767  -0.0138  44.72  27  37  1  -0.5875  7.58 
8  VHLSLLPLGKEERGL  1659.9672  -0.0103  74.67    32  1  0.09333333
3 
7.72 




8  SLLFPQHFPG  1141.592  0.0014  38.93  28  35  1  0.21  7.84 
8  SLLFPQHFPGFY  1451.7238  -0.0025  39.03  23  36  1  0.3  7.76 
8  FQNYALYPHMTV  1482.6966  -0.0023  45.15  30  35  1  -0.05  7.7 
8  SVFHARIVEGGQHNFS  1783.8754  -0.0097  51.5  26  36  1  -0.21875  8 
8  SVFHARIVEGGQHNFSA  1854.9125  -0.0154  39.33  22  36  1  -0.1  8 
8  MNLGTFSVKDGDATSGHARI  2076.0058  -0.0219  68.52  27  36  1  -0.275  7.72 




























8  LNFHVQRGEVFGLLGT  1785.9526  -0.0082  59.13  35  37  1  0.33125  7.84 








8  WLQVVPENLRILVH  1714.9883  -0.0049  35.16  30  33  1  0.55714285
7 
7.84 
8  WLQVVPENLRILVHQLPERA  2409.3645  -0.0187  59.96  29  35  1  0.015  7.86 
8  SAGLKESHPHHIQQTVEAPNYH  2479.1992  -0.02  82.13  25  37  1  -1.15  6.48 












8  FQNYALYPHMTV  1482.6966  -0.0023  45.15  30  35  1  -0.05  7.7 
8  IIFVHPLFQYV  1374.77  0.0003  48.53  27  34  1  1.56363636
4 
7.76 
8  QHSDVPVLNGFRSLPQSFQPRVDVA  2792.4358  -0.0261  48.11  23  38  1  -0.36  7.84 
8  SHVNDSGFWLVGRLM  1716.8406  0.0096  45.13  24  37  1  0.18  7.84 
8  SYTSGFGARWGTNHNGVDIA  2108.9664  -0.0045  35.19  19  34  1  -0.495  7.76 
                   
9  SALQRQIHLGSVEIFTH  1935.0326  -0.0143  78.23  28  37  1  0.07647058
8 
8 




9  LGELGYDVKAFTYHDAPRRA  2278.1494  -0.0146  78.38  27  37  1  -0.615  7.62 
9  ALGELGYDVKAFTYHDAPRRA  2349.1866  0.0018  87.53  31  38  1  -0.5  7.62 

















9  GKEHVVKDLGFIAPF  1655.9035  -0.0092  59.05  31  36  1  0.24666666
7 
7.64 
9  AATYSINAGRSESVNFGGPYLLTHQ  2652.2932  -0.0229  69.56  18  37  1  -0.256  7.7 








9  LIDRTNHHLFQPLLYQVA  2177.1745  -0.0187  56.04  25  37  1  -3.70074E-
17 
7.9 








9  FELHYPHMIERMR  1757.8494  -0.0055  45.14  23  36  1  -0.8  7.92 








9  MMMAGLDGIKNRIEPH  1811.8844  -0.0096  56.13  33  36  1  -0.2625  7.72 




9  WLQVVPENLRILVH  1714.9883  -0.0029  66.24    33  1  0.55714285
7 
7.84 
9  AADSAGLPLFRYIGGPNAHVLPVPM  2562.3417  -0.0253  44.65  20  38  1  0.472  7.76 
















9  GFGPRWGTFHNGIDIA  1743.8482  -0.0068  49.07  25  36  1  -0.19375  7.84 




9  ARDVIQNHLIQLL  1531.8834  0.0005  43.05    32  1  0.36153846
2 
7.84 








9  AILSEKLGIPHISTGDLFRA  2137.1895  -0.0193  40.84  24  35  1  0.4  7.72 
9  LQSFWFPIHV  1272.6655  0.0026  38.45  24  37  1  0.81  7.84 
9  DIFRFAPFFH  1295.6451  0.0037  37.5  31  35  1  0.47  7.84 




                   
10  NLVPRDVASRAISQQI  1765.9799  -0.0043  50.41  33  35  1  -0.0875  10.88 
10  ALGELGYDVKAFTYHDAPRRA  2349.1866  -0.0129  62.15  27  38  1  -0.5  7.62 




10  GNGPYKLQEWNH  1441.6738  -0.0045  51.23  34  35  1  -1.825  7.66 
10  SYVQLGVLPRAG  1258.7034  0.0056  35.88  23  35  1  0.44166666 9.84  
 
7 
10  NSYVQLGVLPRAG  1372.7463  0.0021  74.56    36  1  0.13846153
8 
9.84 
10  TLNSYVQLGVLPRAG  1586.878  -0.0037  87.05    35  1  0.32666666
7 
9.84 
10  NSYVQLGVLPRAGTILA  1770.9992  -0.0031  46.47  31  35  1  0.65882352
9 
9.84 
10  TLNSYVQLGVLPRAGTI  1801.0098  -0.0081  48.98  25  35  1  0.51176470
6 
9.84 
10  NVLVQAGLVTLKTPGLVTPAPV  2186.3039  -0.0145  124.39    30  1  0.96363636
4 
9.74 
10  NTGAFGLVGRI  1103.6087  0.0051  44.79    35  1  0.65454545
5 
11.04 
10  AGDNGSGMHAHQSLWKDGKPLFH  2489.1659  -0.0161  67.49  23  35  1  -
0.92173913 
7.88 




10  NARPVLVGPLTFL  1395.8238  0.0048  47.15  20  31  1  0.93076923
1 
11.04 
10  AADSAGLPLFRYIGGPNAH  1925.9748  -0.0064  68.46  30  37  1  0.04736842
1 
7.76 
10  NKLLGSFELGGIAPAPR  1738.973  -0.009  80.45  30  35  1  0.1  9.74 
10  NFIIRIPQAPT  1268.7241  0.0043  64.16  31  34  1  0.24545454
5 
11.04 
10  GVQKYFGDFH  1196.5615  -0.0008  60.54  30  34  1  -0.64  7.66 








10  NFKLREGMPI  1203.6434  0.004  38.93  33  36  1  -0.44  9.74 
                   
11  SWTYHGANRL  1203.5785  -0.0044  48.55    36  1  -0.97  9.84 









11  SWTYHGANRLGANSLL  1758.8801  0.0004  45.57  25  37  1  -0.3125  9.84 
11  NLVPRDVASRAISQQI  1765.9799  -0.0063  45.71  26  35  1  -0.0875  10.88 
11  SYVQLGVLPRAG  1258.7034  -0.0014  65.75    35  1  0.44166666
7 
9.84 
11  NSYVQLGVLPRAG  1372.7463  -0.0051  64.07  32  36  1  0.13846153
8 
9.84 
11  TLNSYVQLGVLPR  1458.8195  -0.0103  73.12    35  1  0.26923076
9 
9.84 
11  SYVQLGVLPRAGTI  1472.8351  -0.0074  43.47  31  35  1  0.65  9.84 
11  TLNSYVQLGVLPRAG  1586.878  -0.0007  98.11    35  1  0.32666666
7 
9.84 
11  SYVQLGVLPRAGTILA  1656.9563  -0.0039  39.89  27  34  1  0.91875  9.84 
11  TLNSYVQLGVLPRAGTI  1801.0098  0  68.8  28  35  1  0.51176470
6 
9.84 
11  QSVTLNSYVQLGVLPRAG  1901.0371  0.0538  38.27    33  2  0.26666666
7 
9.84 
11  TLNSYVQLGVLPRAGTILA  1985.131  -0.002  59.76    34  1  0.75263157
9 
9.84 
11  FGPAARALPQLPI  1349.7819  -0.0027  50.96  27  32  1  0.54615384
6 
11.04 
11  FGPAARALPQLPITV  1549.898  -0.0032  38.2  30  32  1  0.70666666
7 
11.04 
11  YNYLVYTGVIKG  1388.734  -0.0072  62.22  28  37  1  0.325  9.28 
11  NVLVQAGLVTLKTPGLVTPAPV  2186.3039  0.0034  65.66    29  1  0.96363636
4 
9.74 
11  HRTLAGEYKNFNTNSA  1821.8758  0.0003  90.43  25  36  1  -1.20625  9.52 
11  FAAGKLGPGIAIQPT  1439.8136  -0.0063  106.27    34  1  0.56666666
7 
9.74 




11  FAAGKLGPGIAIQPTGNTVVAPA  2149.1895  0.0039  79.08  27  35  1  0.62173913  9.74 





11  HLSLLPLGKEERGLRA  1788.037  -0.0062  55.68  22  32  1  -0.34375  9.74 
11  KLVHLSLLPLGKEERGL  1901.1462  -0.0554  74.53    33  1  0.07647058
8 
9.46 








11  NTGAFGLVGRI  1103.6087  -0.0053  44.4  30  35  1  0.65454545
5 
11.04 








11  NNANWFSRAV  1177.5628  -0.0043  43.78  27  36  1  -0.61  11.04 








11  NARPVLVGPLTFL  1395.8238  -0.0003  44.84  25  32  1  0.93076923
1 
11.04 
11  YNTAGEFGYTPKRA  1573.7525  -0.0042  48.91  25  36  1  -1.1  9.38 




11  NFIIRIPQAPT  1268.7241  -0.0079  40.73    34  1  0.24545454
5 
11.04 
11  FLGRVINPLGQPI  1422.8347  -0.0018  41.16    31  1  0.62307692
3 
11.04 





11  HYIKGYVPV  1074.5862  -0.0098  55.73    36  1  0.13333333
3 
9.38 








                   
12  SYVQLGVLPRAG  1258.7034  0.0016  49.08  33  35  1  0.44166666
7 
9.84 
12  TLNSYVQLGVLPR  1458.8195  -0.003  42  24  35  1  0.26923076
9 
9.84 
12  TLNSYVQLGVLPRAG  1586.878  -0.0035  95.17    35  1  0.32666666
7 
9.84 
12  TLNSYVQLGVLPRAGTI  1801.0098  -0.0046  44.24  26  35  1  0.51176470
6 
9.84 
12  FGPAARALPQLPI  1349.7819  -0.0009  42.89  29  32  1  0.54615384
6 
11.04 
12  HRTLAGEYKNFNTN  1663.8066  -0.0025  49.56  24  36  1  -1.45  9.52 
12  HRTLAGEYKNFNTNSA  1821.8758  -0.0026  54.72  24  36  1  -1.20625  9.52 
12  FAAGKLGPGIAIQPT  1439.8136  -0.0086  97.34  34  35  1  0.56666666
7 
9.74 




12  ANRDWLRA  1000.5202  -0.0013  41.49    36  1  -1.1875  10.88 




12  HLSLLPLGKEERGLRA  1788.037  -0.0045  40.53  21  32  1  -0.34375  9.74 

















    
 
Supplementry table S5D Total number of proteins identified from elastade diegest of plama membrane from YEAST cells grown in 





protein description  No. of 
peptides 
1  P05030  Plasma membrane ATPase 1   145 
2  P19657  Plasma membrane ATPase 2   91 
3  P02994  Elongation factor 1-alpha   77 
6  P32324  Elongation factor 2   67 
4  P39004  High-affinity hexose transporter HXT6   55 
5  P39003  High-affinity hexose transporter HXT6   54 
7  P38695  Probable glucose transporter HXT5   41 
8  P32466  Low-affinity glucose transporter HXT3   40 
9  P32467  Low-affinity glucose transporter HXT4   38 
10  P10592  Heat shock protein SSA2   35 
11  P10591  Heat shock protein SSA1   35 
12  P32465  Low-affinity glucose transporter HXT1   28 
13  P22146  1,3-beta-glucanosyltransferase GAS1   26 
14  Q12117  Protein MRH1   23 
15  Q08193  1,3-beta-glucanosyltransferase GAS5   23 
22  P33302  Pleiotropic ABC efflux transporter of multiple drugs   21 
17  P53252  Sphingolipid long chain base-responsive protein PIL1   20 
23  P38079  Protein YRO2   20 
16  P23585  High-affinity glucose transporter HXT2   19 
18  P54862  Hexose transporter HXT11   19 
19  P40885  Hexose transporter HXT9   19 
21  P40441  Putative transporter-like protein YIL170W   17 
20  P09435  Heat shock protein SSA3   16 
24  P40886  Hexose transporter HXT8   16 
25  P22202  Heat shock protein SSA4   15  
 
33  Q04182  ATP-dependent permease   13 
26  Q12230  Sphingolipid long chain base-responsive protein LSP1   12 
27  P11484  Heat shock protein SSB1   12 
34  P16521  Elongation factor 3A   12 
29  P40150  Heat shock protein SSB2   11 
43  Q07824  Polyamine transporter 1   11 
48  P39105  Lysophospholipase 1   11 
49  P00890  Citrate synthase, mitochondrial   11 
31  A6ZL22  Cell wall protein ECM33 (strain YJM789)   10 
32  P38248  Cell wall protein ECM33   10 
35  P36008  Elongation factor 1-gamma 2   10 
36  P00560  Phosphoglycerate kinase   9 
42  P38968  Protein transport protein SEC31   9 
30  P12398  Heat shock protein SSC1, mitochondrial   8 
39  P38216  Uncharacterized protein YBR016W   8 
40  P02365  40S ribosomal protein S6   8 
41  Q03655  Probable 1,3-beta-glucanosyltransferase GAS3   8 
45  P39926  Protein SSO2   8 
46  P36035  Carboxylic acid transporter protein homolog   8 
58  P25349  Flavoprotein-like protein YCP4   8 
62  P47068  Myosin tail region-interacting protein MTI1   8 
28  P25619  30 kDa heat shock protein   7 
44  P39730  Eukaryotic translation initiation factor 5B   7 
47  P15891  Actin-binding protein   7 
60  B3RHV0  40S ribosomal protein S1-A (strain RM11-1a)   7 
63  B3LLJ2  40S ribosomal protein S1-B (strain RM11-1a)   7 
38  Q03482  Uncharacterized protein YDR210W   6 
52  P39987  Heat shock protein SSC3, mitochondrial   6 
53  P60010  Actin   6 
54  P23291  Casein kinase I homolog 1   6  
 
56  P29547  Elongation factor 1-gamma 1   6 
59  Q08972  [NU+] prion formation protein 1   6 
61  P61864  Ubiquitin GN=UBI1 PE=1 SV=1  6 
65  P13181  Galactose transporter   6 
81  P23292  Casein kinase I homolog 2   6 
37  P46992  Uncharacterized protein YJL171C  5 
51  P2529  Protein SIS1   5 
68  P32568  Protein SNQ2   5 
69  P05453  Eukaryotic peptide chain release factor GTP-binding subunit   5 
71  Q08745  40S ribosomal protein S10-A   5 
83  P51533  ATP-dependent permease PDR10   5 
87  P38427  Trehalose synthase complex regulatory subunit TSL1   5 
113  P33892  Translational activator GCN1   5 
121  P52910  Acetyl-coenzyme A synthetase 2   5 
50  Q05931  Heat shock protein SSQ1, mitochondrial   4 
55  P87284  Plasma membrane proteolipid 3   4 
57  Q12256  Polyamine transporter 4   4 
66  P34167  Eukaryotic translation initiation factor 4B   4 
70  P00549  Pyruvate kinase 1   4 
72  P16474  78 kDa glucose-regulated protein homolog   4 
73  P32457  Cell division control protein 3   4 
74  Q07478  ATP-dependent RNA helicase SUB2   4 
76  P46784  40S ribosomal protein S10-B   4 
77  P54003  Protein SUR7   4 
78  P38219  Uncharacterized GTP-binding protein OLA1   4 
92  Q3E795  Uncharacterized protein YLR361C-A GN=YLR361C-A PE=1 SV=1  4 
94  P25491  Mitochondrial protein import protein MAS5 GN=YDJ1 PE=1 SV=1  4 
97  Q3E792  40S ribosomal protein S25-A GN=RPS25A PE=1 SV=1  4 
98  P35271  40S ribosomal protein S18 GN=RPS18A PE=1 SV=4  4 
99  Q02785  ATP-dependent permease PDR12 GN=PDR12 PE=1 SV=1  4  
 
129  P24276  Protein SSD1 GN=SSD1 PE=1 SV=1  4 
131  P00830  ATP synthase subunit beta, mitochondrial   4 
135  P15019  Transaldolase   4 
67  P32867  Protein SSO1   3 
75  P39935  Eukaryotic initiation factor 4F subunit p150   3 
79  P40159  Uncharacterized protein YNL208W   3 
80  P00925  Enolase 2   3 
82  P32329  Aspartic proteinase 3   3 
84  P38788  Ribosome-associated complex subunit SSZ1   3 
88  P01120  Ras-like protein 2   3 
90  P53894  Serine/threonine-protein kinase   3 
91  P33417  Intrastrand cross-link recognition protein   3 
95  Q12489  Uncharacterized protein YDL012C   3 
96  Q06451  Polyamine transporter 3   3 
100  P00330  Alcohol dehydrogenase 1   3 
101  P32356  Neutral trehalase   3 
109  P13587  Sodium transport ATPase 1   3 
110  P07246  Alcohol dehydrogenase 3, mitochondrial   3 
112  P53049  Oligomycin resistance ATP-dependent permease YOR1   3 
114  Q12460  Nucleolar protein 56   3 
115  Q04491  Protein transport protein SEC13   3 
117  P43581  Hexose transporter HXT10   3 
119  P38701  40S ribosomal protein S20   3 
124  P04806  Hexokinase-1   3 
125  P04807  Hexokinase-2   3 
126  Q01896  Sodium transport ATPase 2   3 
132  A6ZP43  Metacaspase-1 (strain YJM789)   3 
134  P04451  60S ribosomal protein L23   3 
137  P49573  Copper transport protein CTR1   3 
138  P40485  Phosphatidylinositol 4,5-bisphosphate-binding protein SLM1   3  
 
147  P08679  Citrate synthase, peroxisomal   3 
153  P25613  Accumulation of dyads protein 2   3 
168  A6ZPE5  Nucleolar protein 58 (strain YJM789)   3 
174  A6ZMG6  Myosin-5 (strain YJM789)   3 
175  Q12122  Homocitrate synthase, mitochondrial   3 
176  P48570  Homocitrate synthase, cytosolic isozyme   3 
180  P00360  Glyceraldehyde-3-phosphate dehydrogenase 1   3 
64  P38249  Eukaryotic translation initiation factor 3 subunit A   2 
85  P35732  Uncharacterized protein YKL054C   2 
86  Q12207  Non-classical export protein 2   2 
89  P06780  GTP-binding protein RHO1   2 
93  P27796  3-ketoacyl-CoA thiolase, peroxisomal   2 
102  P53165  SAGA-associated factor 73   2 
103  P38873  Target of rapamycin complex 1 subunit KOG1   2 
104  Q08887  Nuclear division defective protein 1   2 
105  Q12518  Epsin-1   2 
106  Q00772  Mitogen-activated protein kinase SLT2/MPK1   2 
107  P53968  Transcriptional regulator CRZ1   2 
108  P11746  Pheromone receptor transcription factor   2 
111  A6ZPJ1  Eukaryotic translation initiation factor 3 subunit B (strain YJM789)   2 
116  P52911  Glucan 1,3-beta-glucosidase 2   2 
118  P35997  40S ribosomal protein S27-A   2 
120  P10823  Guanine nucleotide-binding protein alpha-2 subunit   2 
122  P40482  Protein transport protein SEC24   2 
123  Q03516  Uncharacterized protein RSN1   2 
128  Q99271  Na(+)/H(+) antiporter   2 
130  Q05050  Uncharacterized protein YMR031C   2 
133  A6ZQJ1  ATP-dependent RNA helicase eIF4A (strain YJM789)   2 
136  P14126  60S ribosomal protein L3   2 
139  P32527  Zuotin   2  
 
140  Q12213  60S ribosomal protein L7-B   2 
141  P05737  60S ribosomal protein L7-A   2 
143  P38720  6-phosphogluconate dehydrogenase, decarboxylating 1   2 
144  P06367  40S ribosomal protein S14-A   2 
145  P40213  40S ribosomal protein S16   2 
146  P32497  Eukaryotic translation initiation factor 3 subunit C   2 
148  P15108  ATP-dependent molecular chaperone HSC82   2 
149  P01119  Ras-like protein 1   2 
150  P16140  V-type proton ATPase subunit B   2 
151  P05753  40S ribosomal protein S4   2 
152  P38631  1,3-beta-glucan synthase component FKS1   2 
154  P40989  1,3-beta-glucan synthase component GSC2   2 
155  P07278  cAMP-dependent protein kinase regulatory subunit   2 
156  Q07651  SUR7 family protein FMP45   2 
157  P18480  SWI/SNF chromatin-remodeling complex subunit SNF5   2 
158  P46974  Zinc finger protein ZMS1   2 
159  P38856  Clathrin coat assembly protein AP180A   2 
160  P43572  Enhancer of polycomb-like protein 1   2 
161  P48562  Serine/threonine-protein kinase CLA4   2 
162  Q08831  Protein VTS1   2 
163  P39008  Poly(A) ribonuclease POP2   2 
164  P39081  Protein PCF11   2 
165  Q99395  Uncharacterized protein YPL229W   2 
166  P08539  Guanine nucleotide-binding protein alpha-1 subunit   2 
169  P39940  E3 ubiquitin-protein ligase RSP5   2 
170  P46943  GTP-binding protein GUF1   2 
171  P38993  Iron transport multicopper oxidase FET3   2 
172  P32623  Probable glycosidase CRH2   2 
173  P32473  Pyruvate dehydrogenase E1 component subunit beta, mitochondrial   2 
177  P25087  Sterol 24-C-methyltransferase   2  
 
182  P32599  Fimbrin   2 
183  P02405  60S ribosomal protein L42   2 
185  P05317  60S acidic ribosomal protein P0   2 
193  P52917  Vacuolar protein sorting-associated protein 4   2 
196  Q12359  Ammonia transport outward protein 3   2 
199  P26782  40S ribosomal protein S24   2 
201  Q12691  Sodium transport ATPase 5   2 
202  P05755  40S ribosomal protein S9-B   2 
203  O13516  40S ribosomal protein S9-A   2 
205  P32769  Elongation factor 1 alpha-like protein   2 
206  P15303  Protein transport protein SEC23   2 
208  P40440  Putative transporter-like protein YIL171W   2 
209  P38011  Guanine nucleotide-binding protein subunit beta-like protein   2 
211  Q12335  Protoplast secreted protein 2   2 
213  P07342  Acetolactate synthase catalytic subunit, mitochondrial   2 
218  Q08108  Lysophospholipase 3   2 
219  P33322  H/ACA ribonucleoprotein complex subunit 4   2 
220  P02293  Histone H2B.1   2 
223  P05736  60S ribosomal protein L2   2 
224  Q08954  Smr domain-containing protein YPL199C   2 
233  P00359  Glyceraldehyde-3-phosphate dehydrogenase 3   2 
234  Q12449  Hsp90 co-chaperone AHA1   2 
243  P18852  Guanine nucleotide-binding protein subunit gamma   2 
248  P38266  Uncharacterized protein YBR108W   2 
249  P40088  Plasma membrane iron permease   2 
127  P22147  5~-3~ exoribonuclease 1   1 
142  P32471  Elongation factor 1-beta   1 
167  O13577  Uncharacterized protein YLR437C   1 
178  P12385  Eukaryotic peptide chain release factor subunit 1   1 
179  P32907  Ammonia transport outward protein 2   1  
 
181  Q04067  Eukaryotic translation initiation factor 3 subunit G   1 
184  P00924  Enolase 1   1 
186  P36091  Mannan endo-1,6-alpha-mannosidase DCW1   1 
187  P38353  Sec sixty-one protein homolog   1 
188  P26786  40S ribosomal protein S7-A   1 
189  P40053  Uncharacterized protein YER080W   1 
190  P33332  Exocyst complex component SEC3   1 
191  P27692  Transcription elongation factor SPT5   1 
192  P40169  Uncharacterized plasma membrane protein YNL194C   1 
194  P00331  Alcohol dehydrogenase 2   1 
195  P04840  Mitochondrial outer membrane protein porin 1   1 
197  P53879  GTP-binding protein RHO5   1 
198  P0C2H6  60S ribosomal protein L27-A   1 
200  P17079  60S ribosomal protein L12   1 
204  P09547  SWI/SNF chromatin-remodeling complex subunit SWI1   1 
207  P05750  40S ribosomal protein S3   1 
210  P02829  ATP-dependent molecular chaperone HSP82   1 
214  A7A261  LAS seventeen-binding protein 3 (strain YJM789)   1 
215  P00927  Threonine dehydratase, mitochondrial   1 
216  P31539  Heat shock protein 104   1 
217  Q08913  UPF0695 membrane protein YOR390W   1 
221  A6ZP47  ATP-dependent RNA helicase DED1 (strain YJM789)   1 
222  Q12001  Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase   1 
225  Q3E756  Uncharacterized protein YBL029C-A   1 
226  P04147  Polyadenylate-binding protein, cytoplasmic and nuclear   1 
227  P53893  Ribosome assembly protein 1   1 
228  Q06991  Cell membrane protein YLR414C   1 
229  P40075  Vesicle-associated membrane protein-associated protein SCS2   1 
230  P19073  Cell division control protein 42   1 
231  P38085  Valine/tyrosine/tryptophan amino-acid permease   1  
 
232  Q03690  Protein TIF31   1 
235  P40494  Actin-regulating kinase PRK1   1 
236  Q12511  Protein phosphatase 2C homolog 5   1 
237  P07267  Saccharopepsin   1 
238  P31383  Protein phosphatase PP2A regulatory subunit A   1 
239  P34231  Uncharacterized protein YKL187C   1 
240  P39961  Uncharacterized transcriptional regulatory protein YER184C   1 
241  P35691  Translationally-controlled tumor protein homolog   1 
242  P17967  Protein disulfide-isomerase   1 
244  P40552  Cell wall protein TIR3   1 
245  P23254  Transketolase 1   1 
246  A6ZMK5  Eukaryotic translation initiation factor 3 subunit I (strain YJM789)   1 
247  P0C2I0  60S ribosomal protein L20   1 
250  P32589  Heat shock protein homolog SSE1   1 
251  P28274  CTP synthase 1   1 
252  P38627  CTP synthase 2   1 
253  A6ZQ59  CTP synthase 2 (strain YJM789)   1 
254  Q06205  FK506-binding protein 4   1 
255  P38911  FK506-binding nuclear protein   1 
256  P32458  Cell division control protein 11   1 
257  P28321  Serine hydrolase YJU3   1 
258  P53030  60S ribosomal protein L1   1 
259  P42833  Hexose transporter HXT14   1 
260  P53978  Elongation factor 3B   1 
261  P34216  EH domain-containing and endocytosis protein 1   1 
262  Q03718  Non-structural maintenance of chromosome element 5   1 
263  P21373  NAD(+) kinase   1 
264  P53075  Uncharacterized protein YGL228W   1 
265  P40513|  Mitochondrial acidic protein MAM33   1 
266  Q99325  Uncharacterized membrane protein YOR152C   1  
 
267  P32074  Coatomer subunit gamma   1 
268  P12945  N-terminal acetyltransferase A complex subunit NAT1   1 
269  P32901  Peptide transporter PTR2   1 
270  P38682  ADP-ribosylation factor GTPase-activating protein GLO3   1 
271  P47116  Serine/threonine-protein kinase PTK2/STK2   1 
272  Q08299  Siderophore iron transporter ENB1   1 
273  P15992  Heat shock protein 26   1 
274  Q12344  GTPase-activating protein GYP5   1 
275  P23900  Glycerol uptake/efflux facilitator protein   1 
276  Q12252  Phosphate metabolism protein 7   1 
278  Q03390  Vacuolar protein-sorting-associated protein 60   1 
279  Q07950  Sterol esterase 2   1 
280  P40474  Quinidine resistance protein 2   1 
281  P39932  Sugar transporter STL1   1 
282  Q12329  Heat shock protein 42   1 
283  P53121  Putative flavin carrier protein 3   1 
284  Q03361  Uncharacterized protein JIP4   1 
285  P42845  Protein STB1   1 
286  P39078  T-complex protein 1 subunit delta   1 
287  P35192  Metal-binding activator 1   1 
288  A6ZXG9  ATP-dependent RNA helicase DHH1 (strain YJM789)   1 
289  P32912  Vacuolar morphogenesis protein 7   1 
290  P39962  Casein kinase I homolog 3   1 
291  Q12259  BTB/POZ domain-containing protein YLR108C   1 
292  P35127  Ubiquitin carboxyl-terminal hydrolase YUH1   1 
294  P38903  Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta 
isoform  
1 
295  P31412  V-type proton ATPase subunit C   1 
296  Q12355  Cell wall mannoprotein PST1   1 
297  P40576  Uncharacterized protein YIR024C   1  
 
299  P53319  6-phosphogluconate dehydrogenase, decarboxylating 2   1 
300  P07347  N-terminal acetyltransferase A complex catalytic subunit ARD1   1 
301  P07991  Ornithine aminotransferase   1 
302  P28777|  Chorismate synthase   1 
303  P53200  N(6)-adenine-specific DNA methyltransferase-like 1   1 
304  P40204  Small nuclear ribonucleoprotein G   1 
305  P38853  Kelch repeat-containing protein 1   1 
306  P53756  Uncharacterized ABC transporter ATP-binding protein/permease 
YNR070W  
1 
307  Q12087  40S ribosomal protein S30   1 
308  P53145  Large subunit GTPase 1   1 
309  P46971  Dolichyl-phosphate-mannose--protein mannosyltransferase 4   1 
310  P38137  Peroxisomal-coenzyme A synthetase   1 
311  P10363  DNA primase small subunit   1 
312  Q07732  Accumulates dyads protein 3   1 
314  Q00684  Tyrosine-protein phosphatase CDC14   1 
315  A6ZZH2  NADH-cytochrome b5 reductase 2 (strain YJM789)   1 
318  P36006  Myosin-3   1 
319  A6ZZJ1  Myosin-3 (strain YJM789)   1 
320  Q04781  RING finger protein YMR247C   1 
321  P41835  Thiamine biosynthetic bifunctional enzyme   1 
322  Q12059  NEDD8-activating enzyme E1 regulatory subunit   1 
323  P32660  Probable phospholipid-transporting ATPase DNF1   1 
327  P25582  AdoMet-dependent rRNA methyltransferase SPB1   1 
328  P53008  Mannosyl-oligosaccharide glucosidase   1 
329  P43588  26S proteasome regulatory subunit RPN11   1 
330  P36516  54S ribosomal protein L3, mitochondrial   1 
331  P36059  Uncharacterized protein YKL151C   1 
333  P32837  GABA-specific permease   1 
334  P16861  6-phosphofructokinase subunit alpha   1  
 
Supplementry table S5 E (S5E) Protein quantification using TMT6plex. Yeast cell grown in oleic acid were labeled with the tags  of m/z 
126.1, 127.1 and 128.1 and those grown in glucose with 129.1, 130.1 and 131.1. 
 
ACCESION  Protein  131/129  Stdev  126/129  Stdev  127/129  Stdev  0.99  Stdev  No. of 
Peptides 
P05030|PMA1  Plasma membrane ATPase 1   1.02  0.25  0.61  0.29  0.61  0.28  0.58  0.24  145 
P19657|PMA2  Plasma membrane ATPase 2   1.00  0.24  0.62  0.29  0.60  0.27  0.60  0.23  91 
P02994|EF1A  Elongation factor 1-alpha   1.01  0.26  0.60  0.29  0.56  0.20  0.60  0.27  77 
P32324|EF2  Elongation factor 2   0.98  0.22  0.33  0.12  0.32  0.10  0.34  0.12  67 
P39004|HXT7  High-affinity hexose transporter HXT6   1.01  0.29  1.72  0.97  1.57  0.72  1.58  0.81  55 
P39003|HXT6  High-affinity hexose transporter HXT6   1.02  0.29  1.73  0.98  1.59  0.73  1.59  0.82  54 
P38695|HXT5  Probable glucose transporter HXT5   0.99  0.25  1.65  1.08  1.46  0.65  1.55  0.88  40 
P32466|HXT3  Low-affinity glucose transporter HXT3   0.99  0.23  1.10  0.69  1.07  0.63  1.06  0.65  40 
P32467|HXT4  Low-affinity glucose transporter HXT4   0.98  0.23  1.16  0.66  1.13  0.59  1.13  0.61  38 
P10592|HSP72  Heat shock protein SSA2   0.95  0.19  0.45  0.18  0.47  0.19  0.47  0.16  35 
P10591|HSP71  Heat shock protein SSA1   0.93  0.21  0.51  0.21  0.51  0.20  0.50  0.17  35 
P32465|HXT1  Low-affinity glucose transporter HXT1   0.96  0.25  1.42  1.01  1.35  0.72  1.32  0.88  28 
P22146|GAS1  1,3-beta-glucanosyltransferase GAS1   0.98  0.25  0.95  0.28  0.85  0.23  0.94  0.31  26 
Q12117|MRH1  Protein MRH1   0.99  0.26  0.67  0.39  0.71  0.44  0.76  0.57  23 
Q08193|GAS5  1,3-beta-glucanosyltransferase GAS5   1.07  0.29  0.69  0.22  0.69  0.21  0.67  0.17  23 
P33302|PDR5  Pleiotropic ABC efflux transporter of multiple drugs   1.01  0.25  0.46  0.25  0.44  0.30  0.45  0.27  21 
P53252|PIL1  Sphingolipid long chain base-responsive protein PIL1   0.95  0.24  0.28  0.16  0.30  0.17  0.29  0.13  20 
P38079|YRO2  Protein YRO2   0.98  0.21  0.68  0.26  0.65  0.19  0.67  0.20  20 
P23585|HXT2  High-affinity glucose transporter HXT2   0.98  0.23  1.21  0.71  1.06  0.43  1.18  0.63  19 
P54862|HXT11  Hexose transporter HXT11   0.91  0.20  1.22  0.49  1.32  0.57  1.17  0.50  19 
P40885|HXT9  Hexose transporter HXT9   0.91  0.20  1.22  0.49  1.32  0.57  1.17  0.50  19 
P40441|YIR0  Putative transporter-like protein YIL170W   0.93  0.20  1.27  0.49  1.36  0.59  1.22  0.50  17 
P09435|HSP73  Heat shock protein SSA3   0.90  0.17  0.50  0.20  0.47  0.14  0.48  0.17  16 
P40886|HXT8  Hexose transporter HXT8   0.93  0.21  1.31  0.48  1.41  0.57  1.26  0.48  16  
 
P22202|HSP74  Heat shock protein SSA4   0.97  0.21  0.55  0.20  0.52  0.20  0.53  0.18  15 
Q04182|PDR15  ATP-dependent permease PDR15   1.19  0.35  1.71  1.54  1.78  1.93  1.65  1.53  9 
Q12230|LSP1  Sphingolipid long chain base-responsive protein 
LSP1  
1.02  0.23  0.26  0.14  0.25  0.10  0.37  0.14  12 
P11484|HSP75  Heat shock protein SSB1   0.97  0.23  0.44  0.16  0.46  0.15  0.46  0.18  12 
P16521|EF3A  Elongation factor 3A   0.87  0.11  0.24  0.12  0.26  0.08  0.27  0.13  12 
P40150|HSP76  Heat shock protein SSB2   0.97  0.22  0.43  0.16  0.45  0.14  0.45  0.20  11 
Q07824|TPO1  Polyamine transporter 1   1.06  0.23  1.23  0.51  1.08  0.46  1.17  0.49  11 
P39105|PLB1  Lysophospholipase 1   0.98  0.18  0.57  0.18  0.63  0.12  0.61  0.15  11 
P00890|CISY1  Citrate synthase, mitochondrial   0.83  0.09  2.88  1.50  3.22  2.04  2.85  1.26  9 
A6ZL22|ECM33  Cell wall protein ECM33 (strain YJM789)   0.96  0.16  0.79  0.27  0.71  0.10  0.69  0.23  10 
P38248|ECM33  Cell wall protein ECM33   0.96  0.16  0.79  0.27  0.71  0.10  0.69  0.23  10 
P36008|EF1G2  Elongation factor 1-gamma 2   1.03  0.17  0.44  0.11  0.44  0.18  0.42  0.21  10 
P00560|PGK  Phosphoglycerate kinase   0.96  0.21  2.06  0.79  1.68  0.24  1.86  0.68  9 
P38968|SEC31  Protein transport protein SEC31   1.11  0.27  0.47  0.14  0.42  0.09  0.51  0.12  9 
P12398|HSP77  Heat shock protein SSC1, mitochondrial   0.87  0.17  0.41  0.09  0.37  0.08  0.39  0.11  8 
P38216|YBM6  Uncharacterized protein YBR016W   0.99  0.31  0.55  0.27  0.59  0.28  0.51  0.35  8 
P02365|RS6  40S ribosomal protein S6   1.04  0.27  0.61  0.24  0.54  0.12  0.55  0.22  8 
Q03655|GAS3  Probable 1,3-beta-glucanosyltransferase GAS3   0.98  0.24  0.68  0.23  0.64  0.24  0.59  0.16  8 
P39926|SSO2  Protein SSO2   0.98  0.27  0.61  0.26  0.56  0.11  0.61  0.17  8 
P36035|JEN1  Carboxylic acid transporter protein homolog   1.08  0.21  2.16  0.78  2.28  0.87  2.21  0.38  5 
P25349|YCP4  Flavoprotein-like protein YCP4   1.07  0.30  0.76  0.26  0.73  0.23  0.77  0.20  8 
P47068|BBC1  Myosin tail region-interacting protein MTI1   1.08  0.20  0.42  0.11  0.38  0.06  0.41  0.08  8 
P25619|HSP30  30 kDa heat shock protein   1.05  0.19  0.80  0.34  0.89  0.23  0.98  0.44  7 
P39730|IF2P  Eukaryotic translation initiation factor 5B   0.99  0.19  0.34  0.16  0.32  0.22  0.29  0.22  7 
P15891|ABP1  Actin-binding protein   1.01  0.20  0.34  0.14  0.32  0.05  0.33  0.11  7 
B3RHV0|RS3A1  40S ribosomal protein S1-A (strain RM11-1a)   1.08  0.34  0.52  0.19  0.51  0.20  0.51  0.21  7 
B3LLJ2|RS3A2  40S ribosomal protein S1-B (strain RM11-1a)   1.06  0.42  0.48  0.19  0.44  0.09  0.45  0.21  7 
Q03482|YD210  Uncharacterized protein YDR210W   1.13  0.30  0.42  0.27  0.50  0.33  0.56  0.20  6 
P39987|HSP7E  Heat shock protein SSC3, mitochondrial   0.91  0.18  0.38  0.09  0.36  0.18  0.36  0.10  6  
 
P60010|ACT  Actin   0.93  0.16  0.52  0.08  0.47  0.11  0.51  0.17  6 
P23291|KC11  Casein kinase I homolog 1   1.01  0.19  0.49  0.28  0.66  0.16  0.54  0.29  6 
P29547|EF1G1  Elongation factor 1-gamma 1   1.16  0.22  0.52  0.12  0.59  0.15  0.58  0.20  6 
Q08972|NEW1  [NU+] prion formation protein 1   0.87  0.20  0.41  0.14  0.38  0.10  0.35  0.07  6 
P61864|UBIQ  Ubiquitin   1.14  0.25  1.07  0.30  1.03  0.12  1.02  0.15  6 
P13181|GAL2  Galactose transporter   0.83  0.10  0.95  0.43  0.87  0.22  0.95  0.34  6 
P23292|KC12  Casein kinase I homolog 2   1.06  0.31  0.60  0.10  0.71  0.09  0.76  0.21  6 
P46992|YJR1  Uncharacterized protein YJL171C   1.06  0.47  0.45  0.17  0.42  0.04  0.41  0.12  5 
P25294|SIS1  Protein SIS1   1.08  0.20  0.45  0.08  0.37  0.16  0.41  0.12  5 
P32568|SNQ2  Protein SNQ2   0.96  0.19  0.35  0.13  0.24  0.06  0.35  0.11  5 
P05453|ERF3  Eukaryotic peptide chain release factor GTP-binding 
subunit  
0.78  0.08  0.37  0.11  0.42  0.03  0.49  0.14  5 
Q08745|RS10A  40S ribosomal protein S10-A   1.18  0.34  0.35  0.17  0.31  0.21  0.38  0.19  5 
P51533|PDR10  ATP-dependent permease PDR10   1.15  0.19  1.58  2.12  1.96  3.07  1.67  2.22  4 
P38427|TSL1  Trehalose synthase complex regulatory subunit TSL1   0.89  0.11  0.39  0.25  0.26  0.25  0.34  0.19  5 
P33892|GCN1  Translational activator GCN1   0.96  0.15  0.40  0.06  0.46  0.09  0.38  0.10  5 
P52910|ACS2  Acetyl-coenzyme A synthetase 2   1.06  0.43  0.41  0.42  0.40  0.37  0.54  0.35  5 
Q05931|HSP7Q  Heat shock protein SSQ1, mitochondrial   0.84  0.14  0.43  0.12  0.41  0.05  0.41  0.15  4 
P87284|PMP3  Plasma membrane proteolipid 3   1.31  0.62  0.83  0.35  0.80  0.24  0.75  0.38  4 
Q12256|TPO4  Polyamine transporter 4   1.18  0.54  0.86  0.22  1.02  0.31  0.88  0.23  4 
P34167|IF4B  Eukaryotic translation initiation factor 4B   0.84  0.16  0.33  0.10  0.45  0.12  0.53  0.26  4 
P00549|KPYK1  Pyruvate kinase 1   0.92  0.19  0.22  0.06  0.23  0.12  0.26  0.13  4 
P16474|GRP78  78 kDa glucose-regulated protein homolog   0.86  0.10  0.37  0.10  0.46  0.20  0.38  0.13  4 
P32457|CDC3  Cell division control protein 3   1.31  0.16  0.49  0.58  0.99  0.47  0.86  0.60  4 
Q07478|SUB2  ATP-dependent RNA helicase SUB2   0.87  0.12  0.63  0.34  0.49  0.13  0.45  0.23  4 
P46784|RS10B  40S ribosomal protein S10-B   1.15  0.38  0.33  0.19  0.32  0.24  0.37  0.22  4 
P54003|SUR7  Protein SUR7   0.90  0.07  0.69  0.14  0.58  0.10  0.76  0.25  4 
P38219|OLA1  Uncharacterized GTP-binding protein OLA1   1.00  0.16  0.49  0.20  0.35  0.14  0.42  0.14  4 
Q3E795|YL361  Uncharacterized protein YLR361C-A   1.09  0.43  0.90  0.24  0.87  0.25  0.98  0.28  4 
P25491|MAS5  Mitochondrial protein import protein MAS5   0.89  0.06  0.49  0.14  0.51  0.12  0.38  0.05  4  
 
Q3E792|RS25A  40S ribosomal protein S25-A   0.97  0.30  0.46  0.17  0.47  0.09  0.43  0.13  4 
P35271|RS18  40S ribosomal protein S18   1.15  0.24  0.49  0.05  0.48  0.11  0.52  0.16  4 
Q02785|PDR12  ATP-dependent permease PDR12   0.83  0.09  0.21  0.11  0.19  0.09  0.25  0.11  4 
P24276|SSD1  Protein SSD1   0.79  0.17  0.53  0.25  0.46  0.14  0.59  0.30  4 
P00830|ATPB  ATP synthase subunit beta, mitochondrial   1.11  0.28  0.73  0.16  0.62  0.20  0.64  0.23  4 
P15019|TAL1  Transaldolase   0.96  0.22  0.50  0.15  0.44  0.10  0.46  0.10  4 
P32867|SSO1  Protein SSO1   0.85  0.09  0.55  0.16  0.46  0.10  0.53  0.24  3 
P39935|IF4F1  Eukaryotic initiation factor 4F subunit p150   1.04  0.15  0.40  0.07  0.39  0.04  0.40  0.12  3 
P40159|YNU8  Uncharacterized protein YNL208W   0.75  0.08  0.61  0.35  0.44  0.10  0.45  0.23  3 
P00925|ENO2  Enolase 2   1.37  0.07  0.40  0.10  0.36  0.15  0.39  0.11  3 
P32329|YPS1  Aspartic proteinase 3   0.86  0.12  0.50  0.12  0.47  0.08  0.58  0.20  3 
P38788|SSZ1  Ribosome-associated complex subunit SSZ1   0.90  0.08  0.47  0.20  0.41  0.13  0.38  0.14  3 
P01120|RAS2  Ras-like protein 2   1.16  0.30  1.58  1.17  1.33  0.72  1.43  0.93  3 
P53894|CBK1  Serine/threonine-protein kinase CBK1   0.90  0.11  0.37  0.36  0.63  0.20  0.30  0.27  3 
P33417|IXR1  Intrastrand cross-link recognition protein   0.92  0.07  0.40  0.37  0.64  0.19  0.34  0.30  3 
Q12489|YD012  Uncharacterized protein YDL012C   0.75  0.10  0.37  0.15  0.34  0.08  0.34  0.04  3 
Q06451|TPO3  Polyamine transporter 3   1.35  0.37  0.76  0.19  0.71  0.13  0.89  0.14  3 
P00330|ADH1  Alcohol dehydrogenase 1   1.04  0.51  0.80  0.15  0.72  0.35  0.84  0.25  3 
P32356|TREA  Neutral trehalase   0.90  0.14  0.33  0.06  0.41  0.08  0.41  0.03  3 
P13587|ATN1  Sodium transport ATPase 1   1.19  0.06  0.14  0.07  0.12  0.05  0.15  0.04  3 
P07246|ADH3  Alcohol dehydrogenase 3, mitochondrial   1.04  0.51  0.80  0.15  0.72  0.35  0.84  0.25  3 
P53049|YOR1  Oligomycin resistance ATP-dependent permease 
YOR1  
0.73  0.13  0.28  0.06  0.34  0.16  0.35  0.21  3 
Q12460|NOP56  Nucleolar protein 56   1.14  0.24  0.43  0.09  0.50  0.16  0.49  0.07  3 
Q04491|SEC13  Protein transport protein SEC13   1.09  0.23  0.60  0.21  0.62  0.20  0.64  0.07  3 
P43581|HXT10  Hexose transporter HXT10   0.76  0.06  0.86  0.13  0.95  0.06  0.91  0.29  3 
P38701|RS20  40S ribosomal protein S20   1.07  0.45  0.65  0.20  0.58  0.15  0.60  0.20  3 
P04806|HXKA  Hexokinase-1   1.22  0.22  0.82  0.18  0.75  0.13  0.87  0.18  3 
P04807|HXKB  Hexokinase-2   0.76  0.71  0.39  0.41  0.40  0.40  0.44  0.40  3 
Q01896|ATN2  Sodium transport ATPase 2   1.19  0.06  0.14  0.07  0.12  0.05  0.15  0.04  3  
 
A6ZP43|MCA1  Metacaspase-1 (strain YJM789)   1.06  0.21  0.64  0.07  0.52  0.06  0.61  0.09  3 
P04451|RL23  60S ribosomal protein L23   0.90  0.13  0.40  0.16  0.41  0.16  0.38  0.19  3 
P49573|CTR1  Copper transport protein CTR1   1.02  0.15  2.62  1.09  2.68  0.13  2.49  1.11  3 
P40485|SLM1  Phosphatidylinositol 4,5-bisphosphate-binding 
protein SLM1  
0.92  0.07  0.44  0.38  0.63  0.20  0.27  0.26  3 
P08679|CISY2  Citrate synthase, peroxisomal   0.74  0.09  2.25  1.20  1.92  1.46  2.07  1.01  3 
P25613|ADY2  Accumulation of dyads protein 2   1.32  0.72  1.84  0.25  1.97  0.53  1.81  0.02  2 
A6ZPE5|NOP58  Nucleolar protein 58 (strain YJM789)   1.11  0.21  0.44  0.10  0.58  0.22  0.50  0.07  3 
A6ZMG6|MYO5  Myosin-5 (strain YJM789)   1.00  0.15  0.73  0.13  0.59  0.17  0.75  0.11  3 
Q12122|HOSM  Homocitrate synthase, mitochondrial   1.20  0.32  0.56  0.17  0.61  0.19  0.58  0.18  3 
P48570|HOSC  Homocitrate synthase, cytosolic isozyme   1.20  0.32  0.56  0.17  0.61  0.19  0.58  0.18  3 
P00360|G3P1  Glyceraldehyde-3-phosphate dehydrogenase 1   1.19  0.34  0.58  0.38  0.52  0.30  0.47  0.12  3 
P38249|EIF3A  Eukaryotic translation initiation factor 3 subunit A   0.89  0.03  0.21  0.02  0.26  0.12  0.29  0.02  2 
P35732|YKF4  Uncharacterized protein YKL054C   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
Q12207|NCE2  Non-classical export protein 2   0.79  0.15  0.50  0.21  0.81  0.56  0.53  0.34  2 
P06780|RHO1  GTP-binding protein RHO1   0.99  0.24  0.90  0.07  0.78  0.11  0.92  0.12  2 
P53165|SGF73  SAGA-associated factor 73   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
P38873|KOG1  Target of rapamycin complex 1 subunit KOG1   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
Q08887|NDD1  Nuclear division defective protein 1   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
Q12518|ENT1  Epsin-1   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
Q00772|SLT2  Mitogen-activated protein kinase SLT2/MPK1   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
P53968|CRZ1  Transcriptional regulator CRZ1   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
P11746|MCM1  Pheromone receptor transcription factor   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
A6ZPJ1|EIF3B  Eukaryotic translation initiation factor 3 subunit B 
(strain YJM789)  
1.00  0.23  0.46  0.28  0.56  0.28  0.42  0.18  2 
P52911|EXG2  Glucan 1,3-beta-glucosidase 2   1.17  0.57  0.55  0.26  0.47  0.17  0.77  0.46  2 
P35997|RS27A  40S ribosomal protein S27-A   1.10  0.41  0.50  0.12  0.66  0.05  0.67  0.06  2 
P10823|GPA2  Guanine nucleotide-binding protein alpha-2 subunit   0.85  0.12  1.30  0.99  1.50  1.18  1.24  1.01  2 
P40482|SEC24  Protein transport protein SEC24   1.05  0.26  0.57  0.02  0.57  0.10  0.55  0.01  2 
Q03516|RSN1  Uncharacterized protein RSN1   1.10  0.49  0.51  0.03  0.35  0.01  0.45  0.10  2 
Q99271|NAH1  Na(+)/H(+) antiporter   0.87  0.08  0.38  0.03  0.45  0.06  0.39  0.01  2  
 
Q05050|YMS1  Uncharacterized protein YMR031C   1.20  0.04  0.58  0.32  0.46  0.16  0.44  0.01  2 
A6ZQJ1|IF4A  ATP-dependent RNA helicase eIF4A (strain 
YJM789)  
1.22  0.09  0.38  0.09  0.39  0.14  0.48  0.01  2 
P14126|RL3  60S ribosomal protein L3   1.10  0.42  0.63  0.23  0.86  0.51  0.55  0.19  2 
P32527|ZUO1  Zuotin   1.30  0.40  0.47  0.18  0.38  0.06  0.51  0.23  2 
Q12213|RL7B  60S ribosomal protein L7-B   1.00  0.63  0.84  0.25  0.96  0.53  1.02  0.63  2 
P05737|RL7A  60S ribosomal protein L7-A   1.00  0.63  0.84  0.25  0.96  0.53  1.02  0.63  2 
P38720|6PGD1  6-phosphogluconate dehydrogenase, decarboxylating 
1  
1.11  0.43  0.88  0.36  0.81  0.47  0.82  0.37  2 
P06367|RS14A  40S ribosomal protein S14-A   1.27  0.09  0.68  0.07  0.59  0.29  0.56  0.01  2 
P40213|RS16  40S ribosomal protein S16   0.86  0.10  0.30  0.04  0.40  0.09  0.39  0.05  2 
P32497|EIF3C  Eukaryotic translation initiation factor 3 subunit C   1.01  0.37  0.45  0.28  0.61  0.29  0.44  0.24  2 
P15108|HSC82  ATP-dependent molecular chaperone HSC82   0.98  0.43  0.40  0.15  0.33  0.01  0.37  0.09  2 
P01119|RAS1  Ras-like protein 1   1.01  0.47  0.71  0.31  0.59  0.26  0.73  0.28  2 
P16140|VATB  V-type proton ATPase subunit B   1.05  0.15  0.18  0.26  0.22  0.31  0.21  0.29  2 
P05753|RS4  40S ribosomal protein S4   0.92  0.12  0.60  0.14  0.49  0.05  0.59  0.02  2 
P38631|FKS1  1,3-beta-glucan synthase component FKS1   0.93  0.23  0.41  0.15  0.55  0.10  0.63  0.12  2 
P40989|FKS2  1,3-beta-glucan synthase component GSC2   0.94  0.23  0.47  0.23  0.61  0.18  0.72  0.25  2 
P07278|KAPR  cAMP-dependent protein kinase regulatory subunit   0.82  0.07  0.47  0.04  0.55  0.04  0.54  0.21  2 
Q07651|FMP45  SUR7 family protein FMP45   0.90  0.16  1.51  0.33  1.69  0.60  1.42  0.36  2 
P18480|SNF5  SWI/SNF chromatin-remodeling complex subunit 
SNF5  
0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
P46974|ZMS1  Zinc finger protein ZMS1   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
P38856|AP18A  Clathrin coat assembly protein AP180A   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
P43572|EPL1  Enhancer of polycomb-like protein 1   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
P48562|CLA4  Serine/threonine-protein kinase CLA4   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
Q08831|VTS1  Protein VTS1   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
P39008|POP2  Poly(A) ribonuclease POP2   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
P39081|PCF11  Protein PCF11   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
Q99395|YP229  Uncharacterized protein YPL229W   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
P08539|GPA1  Guanine nucleotide-binding protein alpha-1 subunit   0.74  0.02  0.25  0.05  0.31  0.09  0.28  0.01  2  
 
P39940|RSP5  E3 ubiquitin-protein ligase RSP5   0.83  0.04  0.38  0.08  0.50  0.00  0.30  0.01  2 
P46943|GUF1  GTP-binding protein GUF1   1.41  0.07  0.39  0.06  0.48  0.07  0.43  0.02  2 
P38993|FET3  Iron transport multicopper oxidase FET3   1.09  0.54  0.60  0.22  0.60  0.19  0.55  0.23  2 
P32623|CRH2  Probable glycosidase CRH2   0.80  0.15  0.40  0.00  0.25  0.04  0.29  0.06  2 
P32473|ODPB  Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial  
1.14  0.38  0.82  0.18  0.57  0.07  0.60  0.02  2 
P25087|ERG6  Sterol 24-C-methyltransferase   1.11  0.31  0.51  0.12  0.61  0.13  0.78  0.12  2 
P32599|FIMB  Fimbrin   1.08  0.42  0.40  0.08  0.52  0.34  0.42  0.15  2 
P02405|RL44  60S ribosomal protein L42   1.21  0.40  0.62  0.07  0.59  0.10  0.79  0.04  2 
P05317|RLA0  60S acidic ribosomal protein P0   0.81  0.03  0.29  0.08  0.24  0.06  0.24  0.05  2 
P52917|VPS4  Vacuolar protein sorting-associated protein 4   1.25  0.53  0.25  0.03  0.33  0.06  0.25  0.09  2 
Q12359|ATO3  Ammonia transport outward protein 3   1.09  0.09  2.13  0.41  2.23  0.92  1.66  0.58  2 
P26782|RS24  40S ribosomal protein S24   1.24  0.33  0.40  0.00  0.34  0.06  0.40  0.01  2 
Q12691|ATN5  Sodium transport ATPase 5   1.19  0.08  0.18  0.03  0.14  0.05  0.17  0.01  2 
P05755|RS9B  40S ribosomal protein S9-B   0.87  0.07  0.53  0.07  0.58  0.04  0.50  0.07  2 
O13516|RS9A  40S ribosomal protein S9-A   0.87  0.07  0.53  0.07  0.58  0.04  0.50  0.07  2 
P32769|HBS1  Elongation factor 1 alpha-like protein   0.73  0.07  0.56  0.08  0.47  0.06  0.69  0.12  2 
P15303|SEC23  Protein transport protein SEC23   0.78  0.12  0.34  0.00  0.41  0.04  0.37  0.01  2 
P40440|YIR1  Putative transporter-like protein YIL171W   0.79  0.06  0.79  0.05  0.93  0.07  0.74  0.02  2 
P38011|GBLP  Guanine nucleotide-binding protein subunit beta-like 
protein  
0.75  0.01  0.34  0.03  0.55  0.25  0.49  0.18  2 
Q12335|PST2  Protoplast secreted protein 2   1.05  0.29  1.04  0.44  0.89  0.23  0.98  0.37  2 
P07342|ILVB  Acetolactate synthase catalytic subunit, mitochondrial   0.86  0.09  0.26  0.11  0.43  0.23  0.27  0.13  2 
Q08108|PLB3  Lysophospholipase 3   1.03  0.07  0.51  0.03  0.69  0.15  0.70  0.13  2 
P33322|CBF5  H/ACA ribonucleoprotein complex subunit 4   0.88  0.06  0.36  0.04  0.40  0.04  0.53  0.00  2 
P02293|H2B1  Histone H2B.1   1.26  0.06  0.75  0.06  0.72  0.33  0.73  0.10  2 
P05736|RL2  60S ribosomal protein L2   1.21  0.31  0.97  0.27  0.92  0.02  0.90  0.11  2 
Q08954|YP199  Smr domain-containing protein YPL199C   0.88  0.01  0.22  0.31  0.31  0.04  0.43  0.11  2 
P00359|G3P3  Glyceraldehyde-3-phosphate dehydrogenase 3   1.26  0.44  0.68  0.47  0.66  0.26  0.54  0.00  2 
Q12449|AHA1  Hsp90 co-chaperone AHA1   1.21  0.02  0.77  0.02  0.54  0.09  0.81  0.22  2 
P18852|GBG  Guanine nucleotide-binding protein subunit gamma   0.99  0.59  0.36  0.05  0.41  0.07  0.37  0.11  2  
 
P38266|YBV8  Uncharacterized protein YBR108W   0.96  0.01  0.36  0.51  0.74  0.11  0.26  0.36  2 
P40088|FTR1  Plasma membrane iron permease   1.34  0.02  0.95  0.01  1.09  0.42  0.97  0.02  2 
 
 
Supplementry table S5 F (S5F) summary of the fractions, peptides sequence, calculated mass (pep_calc_mr ), mass acuuracy (pep_delta), 
peptide score (pep_score), homology (pep_homol), identity threshold (pep_ident), the rank number (pep_Rank), hydrophobicity score 
(GRAVY_score) and isoelectric point (pI_Value) for yeast cells grown in glucose and oleic acid. 
Fraction  pep_seq  pep_calc_mr  pep_delta  pep_score  pep_homol  pep_ident  GRAVY_Score  pI_Value 
1  AIIDAL  843,5268  -0,0186  42,28    39  2,15  3,1 
1  EGATDAA  862,4235  -0,0059  48,9    40  -0,385714286  3 
1  TATGDNT  907,445  -0,0027  46,71    40  -1,1  3,1 
1  GFVQEF  954,5014  0,0155  46,4    39  0,4  3,3 
1  VEGATDAA  961,4919  0,0127  79,77    42  0,1875  3 
1  SLDIDLI  1016,5957  0,0416  48,1    41  1,257142857  2,92 
1  GLGGGGDMPG  1045,5066  -0,0132  57,62    38  -0,18  3,1 
1  FYYEMS  1067,4837  0,0236  40,53    39  -0,366666667  3,3 
1  ENWTDIV  1104,5654  -0,0222  52,21    40  -0,485714286  3 
1  ATGDNTFVG  1109,5556  -0,0122  54,84  36  40  -0,044444444  3,1 
1  IAYDNAPY  1154,5811  -0,0128  47,97  35  40  -0,3875  3,1 
1  LSDWVDFG  1166,5811  0,0408  59,96  38  41  0,2125  2,92 
1  NEVVPGDIL  1183,6651  -0,0152  53,52  38  41  0,466666667  3 
1  SENWTDIV  1191,5975  -0,0171  54,19    40  -0,525  3 
1  EEDHPIPE  1193,5767  0,0421  53,1  33  41  -1,9875  3,68 
1  TATGDNTFVG  1210,6033  -0,0164  77,53  39  40  -0,11  3,1 
1  GLSDWVDFG  1223,6026  0,0482  67,3  39  41  0,144444444  2,92 
1  DGFAEVFPQ  1237,6182  0,0019  63,69  40  41  -0,1  3 
1  SDWVDFGVI  1265,6495  -0,0014  50,35    41  0,733333333  2,92 
1  LFGWWSEN  1266,6236  -0,0151  49,72    40  -0,425  3,3  
 
1  MTGDGVNDAPS  1291,5917  0,0564  96,08    41  -0,590909091  2,92 
1  SLTENWLIF  1350,7386  -0,0173  50,34  38  42  0,611111111  3,3 
1  GLGGGGDMPGSEL  1374,6652  0,0154  106,24    40  -0,176923077  3 
1  MTGDGVNDAPSL  1404,6758  -0,0215  81,93  34  38  -0,225  2,92 
1  EEDHPIPEDV  1407,6721  -0,0284  58,25  28  38  -1,52  3,5 
1  GLGGGGDMPGSELA  1445,7023  0,0014  107,6  38  40  -0,035714286  3 
1  GLGGGGDMPGSELA  1461,6973  -0,0023  66,45  27  39  -0,035714286  3 
1  ILDNSLDIDLI  1471,8336  -0,0348  94,71    41  0,918181818  2,82 
1  AILDNSLDIDLI  1542,8708  -0,0351  113,86    42  0,991666667  2,82 
1  EEDHPIPEDVH  1544,731  0,0485  61,01  25  41  -1,672727273  3,92 
1  WWSENWTDIV  1563,7561  -0,0251  84,07    39  -0,6  3 
1  GWWSENWTDIV  1620,7776  -0,0365  97,61  36  38  -0,581818182  3 
1  VEEDHPIPEDVH  1643,7994  -0,0193  68,3  26  39  -1,183333333  3,92 
1  FGWWSENWTDIV  1767,846  0,0446  95,48  35  41  -0,3  3 
1  EEDHPIPEDVHEN  1787,8165  0,0712  88,16  30  41  -1,953846154  3,82 
1  GEARPVPEEYLQTD  1831,9155  -0,0337  57,84  28  40  -1,271428571  3,68 
1  LFGWWSENWTDIV  1880,93  -0,0223  50,49  32  40  0,015384615  3 
1  VEEDHPIPEDVHEN  1886,8849  -0,0076  80,97  29  39  -1,514285714  3,82 
1  RDGQLVEIPANEVVPG  1921,0472  0,0578  77,09  32  42  -0,20625  3,82 
1  EEDHPIPEDVHENY  1950,8798  -0,0254  107,56  26  36  -1,907142857  3,82 
1  EARPVPEEYLQTDPS  1958,9788  -0,0399  49,08  27  40  -1,32  3,68 
1  GEARPVPEEYLQTDPS  2016,0003  -0,0252  72,97  35  40  -1,2625  3,68 
1  VEEDHPIPEDVHENY  2049,9482  -0,0545  45,1  16  36  -1,5  3,82 
1  EEDHPIPEDVHENYE  2079,9224  -0,0062  65,26  26  36  -2,013333333  3,74 
1  EEDHPIPEDVHENYEN  2193,9653  0,01  90,43  28  37  -2,10625  3,74 
1  VEEDHPIPEDVHENYEN  2293,0338  -0,0353  37,81  21  36  -1,735294118  3,74 
1  AIIDAL  843,5268  -0,0186  42,28    39  2,15  3,1 
1  EGATDAA  862,4235  -0,0059  48,9    40  -0,385714286  3 
1  TATGDNT  907,445  -0,0027  46,71    40  -1,1  3,1 
1  VEGATDAA  961,4919  0,0127  79,77    42  0,1875  3  
 
1  GLGGGGDMPG  1045,5066  -0,0132  57,62    38  -0,18  3,1 
1  ENWTDIV  1104,5654  -0,0222  52,21    40  -0,485714286  3 
1  ATGDNTFVG  1109,5556  -0,0122  54,84  36  40  -0,044444444  3,1 
1  IAYDNAPY  1154,5811  -0,0128  47,97  35  40  -0,3875  3,1 
1  SENWTDIV  1191,5975  -0,0171  54,19    40  -0,525  3 
1  EEDHPIPE  1193,5767  0,0421  53,1  33  41  -1,9875  3,68 
1  TATGDNTFVG  1210,6033  -0,0164  77,53  39  40  -0,11  3,1 
1  DGFAEVFPQ  1237,6182  0,0019  63,69  40  41  -0,1  3 
1  LFGWWSEN  1266,6236  -0,0151  49,72    40  -0,425  3,3 
1  MTGDGVNDAPS  1291,5917  0,0564  96,08    41  -0,590909091  2,92 
1  SLTENWLIF  1350,7386  -0,0173  50,34  38  42  0,611111111  3,3 
1  GLGGGGDMPGSEL  1374,6652  0,0154  106,24    40  -0,176923077  3 
1  MTGDGVNDAPSL  1404,6758  -0,0215  81,93  34  38  -0,225  2,92 
1  EEDHPIPEDV  1407,6721  -0,0284  58,25  28  38  -1,52  3,5 
1  GLGGGGDMPGSELA  1445,7023  0,0014  107,6  38  40  -0,035714286  3 
1  GLGGGGDMPGSELA  1461,6973  -0,0023  66,45  27  39  -0,035714286  3 
1  EEDHPIPEDVH  1544,731  0,0485  61,01  25  41  -1,672727273  3,92 
1  WWSENWTDIV  1563,7561  -0,0251  84,07    39  -0,6  3 
1  GWWSENWTDIV  1620,7776  -0,0365  97,61  36  38  -0,581818182  3 
1  VEEDHPIPEDVH  1643,7994  -0,0193  68,3  26  39  -1,183333333  3,92 
1  FGWWSENWTDIV  1767,846  0,0446  95,48  35  41  -0,3  3 
1  EEDHPIPEDVHEN  1787,8165  0,0712  88,16  30  41  -1,953846154  3,82 
1  LFGWWSENWTDIV  1880,93  -0,0223  50,49  32  40  0,015384615  3 
1  VEEDHPIPEDVHEN  1886,8849  -0,0076  80,97  29  39  -1,514285714  3,82 
1  EEDHPIPEDVHENY  1950,8798  -0,0254  107,56  26  36  -1,907142857  3,82 
1  VEEDHPIPEDVHENY  2049,9482  -0,0545  45,1  16  36  -1,5  3,82 
1  EEDHPIPEDVHENYE  2079,9224  -0,0062  65,26  26  36  -2,013333333  3,74 
1  EEDHPIPEDVHENYEN  2193,9653  0,01  90,43  28  37  -2,10625  3,74 
1  VEEDHPIPEDVHENYEN  2293,0338  -0,0353  37,81  21  36  -1,735294118  3,74 
1  DAIEQPS  987,5076  0,0228  44,45    41  -0,942857143  3  
 
1  GGVGEFEA  993,497  -0,0192  61,19  38  40  0,075  3,12 
1  GGVGEFEAG  1050,5185  -0,0181  52,66  30  39  0,022222222  3,12 
1  AGGVGEFEA  1064,5341  -0,0044  72,36    41  0,266666667  3,12 
1  AGGVGEFEAG  1121,5556  -0,0236  74,72    39  0,2  3,12 
1  EQGVPGDNV  1142,5771  0,042  44,03  35  41  -0,888888889  3 
1  GGVGEFEAGI  1163,6026  0,0267  63,62  41  42  0,47  3,12 
1  EQLEQGVPG  1184,624  0,0022  69,05  35  40  -0,933333333  3,12 
1  AGGVGEFEAGI  1234,6397  0,0187  95,19  41  42  0,590909091  3,12 
1  GGVGEFEAGIS  1250,6346  0,0195  93,3    41  0,354545455  3,12 
1  LEQGVPGDNV  1255,6611  -0,0307  60,27    40  -0,42  3 
1  AGGVGEFEAGIS  1321,6717  0,0579  104,9  40  42  0,475  3,12 
1  EQGVPGDNVGF  1346,667  -0,0125  55,18  29  40  -0,509090909  3 
1  SGWNGDNMIEA  1421,6448  0,0175  87,67  34  38  -0,754545455  3 
1  GWNGDNMIEAT  1435,6605  0,0171  71,54    39  -0,745454545  3 
1  LEQGVPGDNVGF  1459,751  0,0298  79,99  36  42  -0,15  3 
1  EQLEQGVPGDNV  1512,7623  -0,0316  96,77  35  40  -0,933333333  2,94 
1  SGWNGDNMIEAT  1522,6925  -0,0011  42,09  23  38  -0,75  3 
1  HEQLEQGVPGDNVGF  1853,9111  0,0185  108,38  32  41  -0,8  3,82 
1  VDDPSVL  972,5331  -0,0074  49,88  36  40  0,4  2,92 
1  GDNYFF  990,465  -0,0168  36,33  26  36  -0,516666667  3,1 
1  QQLTGDN  1003,5137  0,0058  42,74    41  -1,614285714  3,1 
1  VFGWDTG  1009,5072  -0,0214  41,07  31  40  0,157142857  3,1 
1  AVDDPSVL  1043,5702  -0,016  49,21  38  40  0,575  2,92 
1  TGDNYFF  1091,5127  -0,0197  47,27  34  37  -0,542857143  3,1 
1  NYDAEEM  1099,4695  0,0193  45,15  35  36  -1,657142857  2,94 
1  NYDAEEM  1115,4644  0,0044  39,83    33  -1,657142857  2,94 
1  FGWDTGTI  1124,5705  -0,011  43,24  29  41  0,0875  3,1 
1  SWGELFSS  1140,5654  -0,0023  48,9    40  -0,075  3,3 
1  GDNYFFY  1153,5283  -0,0172  46,94  32  36  -0,628571429  3,1 
1  FVFGWDTG  1156,5756  0,0259  56,35    40  0,4875  3,1  
 
1  QQLTGDNY  1166,5771  0,0117  68,02    41  -1,575  3,1 
1  GEGEEHEPV  1210,5669  0,007  62,32  33  39  -1,711111111  3,78 
1  FGWDTGTIS  1211,6026  -0,0144  55,83  38  40  -0,011111111  3,1 
1  GFVFGWDTG  1213,5971  0,0554  65,06  38  41  0,388888889  3,1 
1  TGDNYFFY  1254,576  -0,0213  54,53  29  36  -0,6375  3,1 
1  WPNGQDQPS  1256,5989  -0,0081  50,07  27  38  -2,144444444  3,1 
1  GGFVFGWDTG  1270,6186  0,0468  65,53  34  41  0,31  3,1 
1  GFINQTDFI  1282,6761  -0,0063  71,56  30  41  0,333333333  3,1 
1  QQLTGDNYF  1313,6455  0,0324  60,57  33  41  -1,088888889  3,1 
1  GDNYFFYY  1316,5916  0,0003  55,44  23  37  -0,7125  3,1 
1  YGEGEEHEPV  1373,6302  0,0587  63,01  35  40  -1,67  3,78 
1  MWEEGVLPW  1374,6845  -0,0127  54,24  30  40  -0,1  3,12 
1  TGDNYFFYY  1417,6393  -0,0056  53,33    36  -0,711111111  3,1 
1  FGGFVFGWDTG  1417,687  -0,0243  67,53  28  38  0,536363636  3,1 
1  GFVFGWDTGTI  1427,7289  -0,021  75,9  37  40  0,663636364  3,1 
1  AYGEGEEHEPV  1444,6673  0,0184  67,28  29  39  -1,354545455  3,78 
1  FVFGWDTGTIS  1457,7394  -0,0017  71,44  32  41  0,627272727  3,1 
1  GDNYFFYYGT  1474,6608  -0,0311  72,74  28  34  -0,68  3,1 
1  GFVFGWDTGTIS  1514,7609  0,0271  89,13  36  41  0,541666667  3,1 
1  TGDNYFFYYGT  1575,7085  -0,0307  62,71  32  34  -0,681818182  3,1 
1  NTMWEEGVLPW  1589,7751  -0,0109  56,81  31  40  -0,463636364  3,12 
1  QQLTGDNYFFY  1623,7772  -0,0282  78,85  30  38  -0,754545455  3,1 
1  FGGFVFGWDTGTI  1631,8187  0,0545  92,84  29  42  0,746153846  3,1 
1  YGEGEEHEPVVEI  1714,8253  0,0685  95,16    42  -0,884615385  3,66 
1  FGGFVFGWDTGTIS  1718,8508  -0,0156  131,21  37  40  0,635714286  3,1 
1  QQLTGDNYFFYY  1786,8405  0,0037  89,81  31  39  -0,8  3,1 
1  QQLTGDNYFFYYGT  1944,9097  -0,0342  126,24  31  37  -0,764285714  3,1 
1  VDDPSVL  972,5331  -0,0074  49,88  36  40  0,4  2,92 
1  GDNYFF  990,465  -0,0168  36,33  26  36  -0,516666667  3,1 
1  QQLTGDN  1003,5137  0,0058  42,74    41  -1,614285714  3,1  
 
1  VFGWDTG  1009,5072  -0,0214  41,07  31  40  0,157142857  3,1 
1  AVDDPSVL  1043,5702  -0,016  49,21  38  40  0,575  2,92 
1  TGDNYFF  1091,5127  -0,0197  47,27  34  37  -0,542857143  3,1 
1  NYDAEEM  1099,4695  0,0193  45,15  35  36  -1,657142857  2,94 
1  NYDAEEM  1115,4644  0,0044  39,83    33  -1,657142857  2,94 
1  FGWDTGTI  1124,5705  -0,011  43,24  29  41  0,0875  3,1 
1  SWGELFSS  1140,5654  -0,0023  48,9    40  -0,075  3,3 
1  GDNYFFY  1153,5283  -0,0172  46,94  32  36  -0,628571429  3,1 
1  FVFGWDTG  1156,5756  0,0259  56,35    40  0,4875  3,1 
1  QQLTGDNY  1166,5771  0,0117  68,02    41  -1,575  3,1 
1  GEGEEHEPV  1210,5669  0,007  62,32  33  39  -1,711111111  3,78 
1  FGWDTGTIS  1211,6026  -0,0144  55,83  38  40  -0,011111111  3,1 
1  GFVFGWDTG  1213,5971  0,0554  65,06  38  41  0,388888889  3,1 
1  TGDNYFFY  1254,576  -0,0213  54,53  29  36  -0,6375  3,1 
1  WPNGQDQPS  1256,5989  -0,0081  50,07  27  38  -2,144444444  3,1 
1  GGFVFGWDTG  1270,6186  0,0468  65,53  34  41  0,31  3,1 
1  GFINQTDFI  1282,6761  -0,0063  71,56  30  41  0,333333333  3,1 
1  QQLTGDNYF  1313,6455  0,0324  60,57  33  41  -1,088888889  3,1 
1  GDNYFFYY  1316,5916  0,0003  55,44  23  37  -0,7125  3,1 
1  YGEGEEHEPV  1373,6302  0,0587  63,01  35  40  -1,67  3,78 
1  MWEEGVLPW  1374,6845  -0,0127  54,24  30  40  -0,1  3,12 
1  TGDNYFFYY  1417,6393  -0,0056  53,33    36  -0,711111111  3,1 
1  FGGFVFGWDTG  1417,687  -0,0243  67,53  28  38  0,536363636  3,1 
1  GFVFGWDTGTI  1427,7289  -0,021  75,9  37  40  0,663636364  3,1 
1  AYGEGEEHEPV  1444,6673  0,0184  67,28  29  39  -1,354545455  3,78 
1  FVFGWDTGTIS  1457,7394  -0,0017  71,44  32  41  0,627272727  3,1 
1  GDNYFFYYGT  1474,6608  -0,0311  72,74  28  34  -0,68  3,1 
1  GFVFGWDTGTIS  1514,7609  0,0271  89,13  36  41  0,541666667  3,1 
1  TGDNYFFYYGT  1575,7085  -0,0307  62,71  32  34  -0,681818182  3,1 
1  NTMWEEGVLPW  1589,7751  -0,0109  56,81  31  40  -0,463636364  3,12  
 
1  QQLTGDNYFFY  1623,7772  -0,0282  78,85  30  38  -0,754545455  3,1 
1  FGGFVFGWDTGTI  1631,8187  0,0545  92,84  29  42  0,746153846  3,1 
1  YGEGEEHEPVVEI  1714,8253  0,0685  95,16    42  -0,884615385  3,66 
1  FGGFVFGWDTGTIS  1718,8508  -0,0156  131,21  37  40  0,635714286  3,1 
1  QQLTGDNYFFYY  1786,8405  0,0037  89,81  31  39  -0,8  3,1 
1  QQLTGDNYFFYYGT  1944,9097  -0,0342  126,24  31  37  -0,764285714  3,1 
1  EGPADDA  902,4184  -0,0016  35,72    35  -1,271428571  2,88 
1  VESESSQ  993,4818  -0,0117  48,08  38  39  -1,242857143  3,12 
1  DGNSFLI  993,5334  -0,0121  47,03  36  42  0,414285714  3,1 
1  DFSSEVT  1012,4916  -0,0106  52,4  37  38  -0,328571429  3 
1  GIDQFLL  1033,6011  0,015  48,58  39  42  1,071428571  3,1 
1  VESESSQT  1094,5294  -0,0134  59,57    39  -1,175  3,12 
1  EPIDEEVS  1145,5655  -0,0051  47,56    39  -0,9625  2,88 
1  YEGPADDAN  1179,5247  0,0107  46,38  25  37  -1,522222222  2,88 
1  LGDVQVYPA  1189,6546  0,0393  66,36  34  42  0,411111111  3,1 
1  FGPDGNGPNLV  1314,6771  0,0207  64,78    41  -0,372727273  3,1 
1  NESFGFTGEL  1328,6451  -0,0241  85,33    38  -0,34  3,12 
1  FNMFILDPI  1337,7256  0,044  59,07  40  42  1,3  3,1 
1  EQLYEGPADDA  1435,667  -0,0289  70,04  31  36  -1,218181818  2,84 
1  RIMADDYGWDVT  1669,7973  -0,0211  56,82  31  39  -0,491666667  3,6 
1  SEMSDEDVKEI  1738,8701  -0,0203  62,86  36  41  -1,127272727  3,5 
1  GDNYFF  990,465  -0,0168  36,33  26  36  -0,516666667  3,1 
1  GYNDNLA  994,4922  0,0126  52,7  38  41  -0,942857143  3,1 
1  QQLTGDN  1003,5137  0,0058  42,74    41  -1,614285714  3,1 
1  VFGWDTG  1009,5072  -0,0214  41,07  31  40  0,157142857  3,1 
1  TGDNYFF  1091,5127  -0,0197  47,27  34  37  -0,542857143  3,1 
1  FGWDTGTI  1124,5705  -0,011  43,24  29  41  0,0875  3,1 
1  GDNYFFY  1153,5283  -0,0172  46,94  32  36  -0,628571429  3,1 
1  NEMYEEN  1156,4909  0,0296  46,47  30  36  -2,414285714  3,02 
1  FVFGWDTG  1156,5756  0,0259  56,35    40  0,4875  3,1  
 
1  QQLTGDNY  1166,5771  0,0117  68,02    41  -1,575  3,1 
1  FGWDTGTIS  1211,6026  -0,0144  55,83  38  40  -0,011111111  3,1 
1  GFVFGWDTG  1213,5971  0,0554  65,06  38  41  0,388888889  3,1 
1  TGDNYFFY  1254,576  -0,0213  54,53  29  36  -0,6375  3,1 
1  WPNGQDQPS  1256,5989  -0,0081  50,07  27  38  -2,144444444  3,1 
1  GGFVFGWDTG  1270,6186  0,0468  65,53  34  41  0,31  3,1 
1  QQLTGDNYF  1313,6455  0,0324  60,57  33  41  -1,088888889  3,1 
1  GDNYFFYY  1316,5916  0,0003  55,44  23  37  -0,7125  3,1 
1  TGDNYFFYY  1417,6393  -0,0056  53,33    36  -0,711111111  3,1 
1  FGGFVFGWDTG  1417,687  -0,0243  67,53  28  38  0,536363636  3,1 
1  GFVFGWDTGTI  1427,7289  -0,021  75,9  37  40  0,663636364  3,1 
1  FVFGWDTGTIS  1457,7394  -0,0017  71,44  32  41  0,627272727  3,1 
1  GDNYFFYYGT  1474,6608  -0,0311  72,74  28  34  -0,68  3,1 
1  GFVFGWDTGTIS  1514,7609  0,0271  89,13  36  41  0,541666667  3,1 
1  TGDNYFFYYGT  1575,7085  -0,0307  62,71  32  34  -0,681818182  3,1 
1  QQLTGDNYFFY  1623,7772  -0,0282  78,85  30  38  -0,754545455  3,1 
1  FGGFVFGWDTGTI  1631,8187  0,0545  92,84  29  42  0,746153846  3,1 
1  FGGFVFGWDTGTIS  1718,8508  -0,0156  131,21  37  40  0,635714286  3,1 
1  QQLTGDNYFFYY  1786,8405  0,0037  89,81  31  39  -0,8  3,1 
1  QQLTGDNYFFYYGT  1944,9097  -0,0342  126,24  31  37  -0,764285714  3,1 
1  GDNYFF  990,465  -0,0168  36,33  26  36  -0,516666667  3,1 
1  QQLTGDN  1003,5137  0,0058  42,74    41  -1,614285714  3,1 
1  VFGWDTG  1009,5072  -0,0214  41,07  31  40  0,157142857  3,1 
1  TGDNYFF  1091,5127  -0,0197  47,27  34  37  -0,542857143  3,1 
1  FGWDTGTI  1124,5705  -0,011  43,24  29  41  0,0875  3,1 
1  GDNYFFY  1153,5283  -0,0172  46,94  32  36  -0,628571429  3,1 
1  FVFGWDTG  1156,5756  0,0259  56,35    40  0,4875  3,1 
1  QQLTGDNY  1166,5771  0,0117  68,02    41  -1,575  3,1 
1  FGWDTGTIS  1211,6026  -0,0144  55,83  38  40  -0,011111111  3,1 
1  GFVFGWDTG  1213,5971  0,0554  65,06  38  41  0,388888889  3,1  
 
1  TGDNYFFY  1254,576  -0,0213  54,53  29  36  -0,6375  3,1 
1  GGFVFGWDTG  1270,6186  0,0468  65,53  34  41  0,31  3,1 
1  QQLTGDNYF  1313,6455  0,0324  60,57  33  41  -1,088888889  3,1 
1  GDNYFFYY  1316,5916  0,0003  55,44  23  37  -0,7125  3,1 
1  TGDNYFFYY  1417,6393  -0,0056  53,33    36  -0,711111111  3,1 
1  FGGFVFGWDTG  1417,687  -0,0243  67,53  28  38  0,536363636  3,1 
1  GFVFGWDTGTI  1427,7289  -0,021  75,9  37  40  0,663636364  3,1 
1  FVFGWDTGTIS  1457,7394  -0,0017  71,44  32  41  0,627272727  3,1 
1  GDNYFFYYGT  1474,6608  -0,0311  72,74  28  34  -0,68  3,1 
1  GFVFGWDTGTIS  1514,7609  0,0271  89,13  36  41  0,541666667  3,1 
1  NDMYAEGVLPW  1522,7329  0,0348  64,77  26  41  -0,272727273  3 
1  TGDNYFFYYGT  1575,7085  -0,0307  62,71  32  34  -0,681818182  3,1 
1  QQLTGDNYFFY  1623,7772  -0,0282  78,85  30  38  -0,754545455  3,1 
1  FGGFVFGWDTGTI  1631,8187  0,0545  92,84  29  42  0,746153846  3,1 
1  FGGFVFGWDTGTIS  1718,8508  -0,0156  131,21  37  40  0,635714286  3,1 
1  QQLTGDNYFFYY  1786,8405  0,0037  89,81  31  39  -0,8  3,1 
1  QQLTGDNYFFYYGT  1944,9097  -0,0342  126,24  31  37  -0,764285714  3,1 
1  NMPEEKGVQDDFQAEADQV  2607,2528  0,0543  48,34  41  42  -1,273684211  3,38 
1  MNMPEEKGVQDDFQAEADQV  2738,2933  0,0265  67,7  29  41  -1,115  3,38 
1  GDNYFF  990,465  -0,0168  36,33  26  36  -0,516666667  3,1 
1  QQLTGDN  1003,5137  0,0058  42,74    41  -1,614285714  3,1 
1  VFGWDTG  1009,5072  -0,0214  41,07  31  40  0,157142857  3,1 
1  AYQEDTA  1025,4868  0,0027  58,23    39  -1,271428571  3 
1  TGDNYFF  1091,5127  -0,0197  47,27  34  37  -0,542857143  3,1 
1  FGWDTGTI  1124,5705  -0,011  43,24  29  41  0,0875  3,1 
1  GDNYFFY  1153,5283  -0,0172  46,94  32  36  -0,628571429  3,1 
1  FVFGWDTG  1156,5756  0,0259  56,35    40  0,4875  3,1 
1  QQLTGDNY  1166,5771  0,0117  68,02    41  -1,575  3,1 
1  FGWDTGTIS  1211,6026  -0,0144  55,83  38  40  -0,011111111  3,1 
1  GFVFGWDTG  1213,5971  0,0554  65,06  38  41  0,388888889  3,1  
 
1  TGDNYFFY  1254,576  -0,0213  54,53  29  36  -0,6375  3,1 
1  GGFVFGWDTG  1270,6186  0,0468  65,53  34  41  0,31  3,1 
1  QQLTGDNYF  1313,6455  0,0324  60,57  33  41  -1,088888889  3,1 
1  GDNYFFYY  1316,5916  0,0003  55,44  23  37  -0,7125  3,1 
1  LWEEGVLPW  1356,7281  -0,0261  41,02  32  41  0,111111111  3,12 
1  TGDNYFFYY  1417,6393  -0,0056  53,33    36  -0,711111111  3,1 
1  FGGFVFGWDTG  1417,687  -0,0243  67,53  28  38  0,536363636  3,1 
1  GFVFGWDTGTI  1427,7289  -0,021  75,9  37  40  0,663636364  3,1 
1  FVFGWDTGTIS  1457,7394  -0,0017  71,44  32  41  0,627272727  3,1 
1  GDNYFFYYGT  1474,6608  -0,0311  72,74  28  34  -0,68  3,1 
1  GFVFGWDTGTIS  1514,7609  0,0271  89,13  36  41  0,541666667  3,1 
1  TGDNYFFYYGT  1575,7085  -0,0307  62,71  32  34  -0,681818182  3,1 
1  QQLTGDNYFFY  1623,7772  -0,0282  78,85  30  38  -0,754545455  3,1 
1  FGGFVFGWDTGTI  1631,8187  0,0545  92,84  29  42  0,746153846  3,1 
1  FGGFVFGWDTGTIS  1718,8508  -0,0156  131,21  37  40  0,635714286  3,1 
1  QQLTGDNYFFYY  1786,8405  0,0037  89,81  31  39  -0,8  3,1 
1  QQLTGDNYFFYYGT  1944,9097  -0,0342  126,24  31  37  -0,764285714  3,1 
1  GAPEGAAPG  954,4973  -0,0124  76,26  36  39  -0,277777778  3,3 
1  YADNQPG  992,4766  -0,0075  55,32  30  39  -1,714285714  3,1 
1  TYADNQPG  1093,5243  0,0022  43,64  33  40  -1,5875  3,1 
1  YADNQPGVL  1204,6291  -0,0249  62,97  32  40  -0,444444444  3,1 
1  FDLGGGTFDV  1255,6288  0,0098  50,52  36  40  0,47  2,92 
1  FDLGGGTFDVS  1342,6608  -0,0257  83,54    39  0,354545455  2,92 
1  LGGEDFDNRLV  1462,7619  -0,0014  63,66    42  -0,427272727  3,7 
1  GAPPAPEAEGPTVEEVD  1892,9206  -0,0367  98,21  31  39  -0,682352941  2,84 
1  GFPGGAPPAPEAEGPTVEEVD  2251,0848  -0,0135  76,99  26  40  -0,533333333  2,84 
1  YADNQPG  992,4766  -0,0075  55,32  30  39  -1,714285714  3,1 
1  TYADNQPG  1093,5243  0,0022  43,64  33  40  -1,5875  3,1 
1  YADNQPGVL  1204,6291  -0,0249  62,97  32  40  -0,444444444  3,1 
1  FDLGGGTFDV  1255,6288  0,0098  50,52  36  40  0,47  2,92  
 
1  FDLGGGTFDVS  1342,6608  -0,0257  83,54    39  0,354545455  2,92 
1  LGGEDFDNRLV  1462,7619  -0,0014  63,66    42  -0,427272727  3,7 
1  GAPPAPEAEGPTVEEVD  1892,9206  -0,0367  98,21  31  39  -0,682352941  2,84 
1  GFPGGAPPAPEAEGPTVEEVD  2251,0848  -0,0135  76,99  26  40  -0,533333333  2,84 
1  GDNYFF  990,465  -0,0168  36,33  26  36  -0,516666667  3,1 
1  QQLTGDN  1003,5137  0,0058  42,74    41  -1,614285714  3,1 
1  TGDNYFF  1091,5127  -0,0197  47,27  34  37  -0,542857143  3,1 
1  FGWDTGTI  1124,5705  -0,011  43,24  29  41  0,0875  3,1 
1  GDNYFFY  1153,5283  -0,0172  46,94  32  36  -0,628571429  3,1 
1  QQLTGDNY  1166,5771  0,0117  68,02    41  -1,575  3,1 
1  FGWDTGTIS  1211,6026  -0,0144  55,83  38  40  -0,011111111  3,1 
1  TGDNYFFY  1254,576  -0,0213  54,53  29  36  -0,6375  3,1 
1  WPNGQDQPS  1256,5989  -0,0081  50,07  27  38  -2,144444444  3,1 
1  QQLTGDNYF  1313,6455  0,0324  60,57  33  41  -1,088888889  3,1 
1  GDNYFFYY  1316,5916  0,0003  55,44  23  37  -0,7125  3,1 
1  TGDNYFFYY  1417,6393  -0,0056  53,33    36  -0,711111111  3,1 
1  GDNYFFYYGT  1474,6608  -0,0311  72,74  28  34  -0,68  3,1 
1  NDMYAEGVLPW  1522,7329  0,0348  64,77  26  41  -0,272727273  3 
1  TGDNYFFYYGT  1575,7085  -0,0307  62,71  32  34  -0,681818182  3,1 
1  QQLTGDNYFFY  1623,7772  -0,0282  78,85  30  38  -0,754545455  3,1 
1  QQLTGDNYFFYY  1786,8405  0,0037  89,81  31  39  -0,8  3,1 
1  QQLTGDNYFFYYGT  1944,9097  -0,0342  126,24  31  37  -0,764285714  3,1 
1  GYSSND  870,3922  -0,0036  34,67    34  -1,716666667  3,1 
1  LFTEVEA  1036,5644  -0,0237  48,32  39  41  0,7  3,12 
1  LNDADIY  1051,5389  0,0168  49,36    41  -0,242857143  2,92 
1  DVWSGGIV  1060,5756  -0,0224  48,38    41  0,8625  3,1 
1  DDEDTRV  1077,5141  0,0052  40,13    40  -2,142857143  3,5 
1  LFTEVEAL  1149,6484  -0,0211  55,24  41  42  1,0875  3,12 
1  NDADIYVI  1150,6073  0  56,13    42  0,4  2,92 
1  YMYFEET  1210,5419  0,0192  50,53    38  -0,8  3,12  
 
1  LNDADIYVI  1263,6913  -0,0077  72    42  0,777777778  2,92 
1  GYSSNDDEDTRV  1585,7059  0,077  69,87  30  40  -1,816666667  3,5 
1  FFSEYGCNEVTPR  1776,8344  0,0158  85,79  26  40  -0,576923077  4,26 
1  FFSEYGCNEVTPRLF  2036,9869  0,0007  103,26  30  41  -0,06  4,26 
1  NVLQPDSA  1071,5763  -0,0168  45,23  37  40  -0,3875  3,1 
1  FYGIIDLI  1181,6899  0,0372  64,79    39  1,8625  3,1 
1  GIFYGIIDL  1238,7114  0,052  53,87  34  39  1,611111111  3,1 
1  GIFYGIIDLI  1351,7954  -0,0146  68,99  35  42  1,9  3,1 
1  SNPEGNGGY  1122,5144  -0,007  50,76  30  37  -1,711111111  3,3 
1  YQDYSVPV  1198,6073  0,0025  48,23  34  40  -0,45  3,1 
1  YTVDNSQDH  1306,5993  0,0048  65,58  26  38  -1,755555556  3,88 
1  SNPEGNGGYST  1310,5942  -0,0171  76,58    36  -1,536363636  3,3 
1  YTVDNSQDHS  1393,6313  0,0011  79,54  31  38  -1,66  3,88 
1  SNPEGNGGYSTS  1397,6262  -0,0228  77,34    35  -1,475  3,3 
1  VFGWDTG  1009,5072  -0,0214  41,07  31  40  0,157142857  3,1 
1  FGWDTGTI  1124,5705  -0,011  43,24  29  41  0,0875  3,1 
1  FVFGWDTG  1156,5756  0,0259  56,35    40  0,4875  3,1 
1  FGWDTGTIS  1211,6026  -0,0144  55,83  38  40  -0,011111111  3,1 
1  GFVFGWDTG  1213,5971  0,0554  65,06  38  41  0,388888889  3,1 
1  GGFVFGWDTG  1270,6186  0,0468  65,53  34  41  0,31  3,1 
1  FGGFVFGWDTG  1417,687  -0,0243  67,53  28  38  0,536363636  3,1 
1  GFVFGWDTGTI  1427,7289  -0,021  75,9  37  40  0,663636364  3,1 
1  FVFGWDTGTIS  1457,7394  -0,0017  71,44  32  41  0,627272727  3,1 
1  GFVFGWDTGTIS  1514,7609  0,0271  89,13  36  41  0,541666667  3,1 
1  FGGFVFGWDTGTI  1631,8187  0,0545  92,84  29  42  0,746153846  3,1 
1  FGGFVFGWDTGTIS  1718,8508  -0,0156  131,21  37  40  0,635714286  3,1 
1  YDGYEA  945,4283  0,0154  41,21    36  -1,366666667  3 
1  LEQELV  958,5538  0,029  45,32    40  0,216666667  3,12 
1  LNEWTLDSA  1276,6502  -0,0288  56,73    40  -0,388888889  3 
1  ELDDQFIDRY  1541,7565  0,0124  54,68  30  41  -1,22  3,5  
 
1  DDSPVTPGETRPA  1569,7838  0,0753  59,73  32  42  -1,261538462  3,7 
1  SELDDQFIDRY  1628,7885  0,0286  79,26  33  41  -1,181818182  3,5 
1  LDDSPVTPGETRPA  1682,8678  -0,0291  88,47    41  -0,9  3,7 
1  ENDDDVSDITDKL  1935,9679  0,019  87,41    42  -1,338461538  3,26 
1  IEEPEQEEEGAVEEH  1981,8955  -0,0105  110  30  37  -1,746666667  3,44 
1  YEVSELDDQFIDRY  2019,9628  -0,0318  62,72  24  38  -0,971428571  3,42 
1  SIWGLENDDDVSDITDKL  2492,2688  0,0591  140,43    43  -0,622222222  3,26 
1  LSFKQDYEDFEPEEGEEEEEEDGQ  3364,4672  -0,0396  56,62    34  -2,145833333  3,12 
1  GDNYFF  990,465  -0,0168  36,33  26  36  -0,516666667  3,1 
1  QQLTGDN  1003,5137  0,0058  42,74    41  -1,614285714  3,1 
1  TGDNYFF  1091,5127  -0,0197  47,27  34  37  -0,542857143  3,1 
1  FGWDTGTI  1124,5705  -0,011  43,24  29  41  0,0875  3,1 
1  GDNYFFY  1153,5283  -0,0172  46,94  32  36  -0,628571429  3,1 
1  QQLTGDNY  1166,5771  0,0117  68,02    41  -1,575  3,1 
1  FGWDTGTIS  1211,6026  -0,0144  55,83  38  40  -0,011111111  3,1 
1  TGDNYFFY  1254,576  -0,0213  54,53  29  36  -0,6375  3,1 
1  QQLTGDNYF  1313,6455  0,0324  60,57  33  41  -1,088888889  3,1 
1  GDNYFFYY  1316,5916  0,0003  55,44  23  37  -0,7125  3,1 
1  TGDNYFFYY  1417,6393  -0,0056  53,33    36  -0,711111111  3,1 
1  GDNYFFYYGT  1474,6608  -0,0311  72,74  28  34  -0,68  3,1 
1  TGDNYFFYYGT  1575,7085  -0,0307  62,71  32  34  -0,681818182  3,1 
1  QQLTGDNYFFY  1623,7772  -0,0282  78,85  30  38  -0,754545455  3,1 
1  QQLTGDNYFFYY  1786,8405  0,0037  89,81  31  39  -0,8  3,1 
1  QQLTGDNYFFYYGT  1944,9097  -0,0342  126,24  31  37  -0,764285714  3,1 
1  GDNYFF  990,465  -0,0168  36,33  26  36  -0,516666667  3,1 
1  QQLTGDN  1003,5137  0,0058  42,74    41  -1,614285714  3,1 
1  TGDNYFF  1091,5127  -0,0197  47,27  34  37  -0,542857143  3,1 
1  FGWDTGTI  1124,5705  -0,011  43,24  29  41  0,0875  3,1 
1  GDNYFFY  1153,5283  -0,0172  46,94  32  36  -0,628571429  3,1 
1  QQLTGDNY  1166,5771  0,0117  68,02    41  -1,575  3,1  
 
1  FGWDTGTIS  1211,6026  -0,0144  55,83  38  40  -0,011111111  3,1 
1  TGDNYFFY  1254,576  -0,0213  54,53  29  36  -0,6375  3,1 
1  QQLTGDNYF  1313,6455  0,0324  60,57  33  41  -1,088888889  3,1 
1  GDNYFFYY  1316,5916  0,0003  55,44  23  37  -0,7125  3,1 
1  TGDNYFFYY  1417,6393  -0,0056  53,33    36  -0,711111111  3,1 
1  GDNYFFYYGT  1474,6608  -0,0311  72,74  28  34  -0,68  3,1 
1  TGDNYFFYYGT  1575,7085  -0,0307  62,71  32  34  -0,681818182  3,1 
1  QQLTGDNYFFY  1623,7772  -0,0282  78,85  30  38  -0,754545455  3,1 
1  QQLTGDNYFFYY  1786,8405  0,0037  89,81  31  39  -0,8  3,1 
1  QQLTGDNYFFYYGT  1944,9097  -0,0342  126,24  31  37  -0,764285714  3,1 
1  YADNQPG  992,4766  -0,0075  55,32  30  39  -1,714285714  3,1 
1  TYADNQPG  1093,5243  0,0022  43,64  33  40  -1,5875  3,1 
1  YADNQPGVL  1204,6291  -0,0249  62,97  32  40  -0,444444444  3,1 
1  FDLGGGTFDV  1255,6288  0,0098  50,52  36  40  0,47  2,92 
1  FDLGGGTFDVS  1342,6608  -0,0257  83,54    39  0,354545455  2,92 
1  LGGEDFDNRLV  1462,7619  -0,0014  63,66    42  -0,427272727  3,7 
1  GDNYFF  990,465  -0,0168  36,33  26  36  -0,516666667  3,1 
1  QQLTGDN  1003,5137  0,0058  42,74    41  -1,614285714  3,1 
1  TGDNYFF  1091,5127  -0,0197  47,27  34  37  -0,542857143  3,1 
1  GDNYFFY  1153,5283  -0,0172  46,94  32  36  -0,628571429  3,1 
1  QQLTGDNY  1166,5771  0,0117  68,02    41  -1,575  3,1 
1  TGDNYFFY  1254,576  -0,0213  54,53  29  36  -0,6375  3,1 
1  QQLTGDNYF  1313,6455  0,0324  60,57  33  41  -1,088888889  3,1 
1  GDNYFFYY  1316,5916  0,0003  55,44  23  37  -0,7125  3,1 
1  TGDNYFFYY  1417,6393  -0,0056  53,33    36  -0,711111111  3,1 
1  GDNYFFYYGT  1474,6608  -0,0311  72,74  28  34  -0,68  3,1 
1  TGDNYFFYYGT  1575,7085  -0,0307  62,71  32  34  -0,681818182  3,1 
1  QQLTGDNYFFY  1623,7772  -0,0282  78,85  30  38  -0,754545455  3,1 
1  QQLTGDNYFFYY  1786,8405  0,0037  89,81  31  39  -0,8  3,1 
1  QQLTGDNYFFYYGT  1944,9097  -0,0342  126,24  31  37  -0,764285714  3,1  
 
1  NDDEASREA  1234,5628  -0,0078  44,08  35  37  -2,133333333  3,58 
1  QDYVLGDDFIRG  1625,8252  -0,0242  63,82  27  41  -0,441666667  3,6 
1  VPGQDYVLGDDFIRG  1878,9679  -0,0311  71,89    41  -0,206666667  3,6 
1  FSDPEAPGYDPKLDPN  2219,1152  0,055  73,09  33  43  -1,36875  3,5 
1  NVLQPDSA  1071,5763  -0,0168  45,23  37  40  -0,3875  3,1 
1  FYGIIDLL  1181,6899  0,0372  64,79    39  1,775  3,1 
1  GLIFDEEPA  1218,6335  -0,0097  46,55  37  41  0,044444444  2,94 
1  GLIFDEEPAEH  1484,735  0,0188  74,49  29  41  -0,572727273  3,68 
1  KKAQEEEED  1791,9823  0,0357  51,17  32  42  -3  4 
1  GDNYFF  990,465  -0,0168  36,33  26  36  -0,516666667  3,1 
1  QQLTGDN  1003,5137  0,0058  42,74    41  -1,614285714  3,1 
1  TGDNYFF  1091,5127  -0,0197  47,27  34  37  -0,542857143  3,1 
1  GDNYFFY  1153,5283  -0,0172  46,94  32  36  -0,628571429  3,1 
1  QQLTGDNY  1166,5771  0,0117  68,02    41  -1,575  3,1 
1  TGDNYFFY  1254,576  -0,0213  54,53  29  36  -0,6375  3,1 
1  QQLTGDNYF  1313,6455  0,0324  60,57  33  41  -1,088888889  3,1 
1  GDNYFFYY  1316,5916  0,0003  55,44  23  37  -0,7125  3,1 
1  TGDNYFFYY  1417,6393  -0,0056  53,33    36  -0,711111111  3,1 
1  GDNYFFYYGT  1474,6608  -0,0311  72,74  28  34  -0,68  3,1 
1  TGDNYFFYYGT  1575,7085  -0,0307  62,71  32  34  -0,681818182  3,1 
1  QQLTGDNYFFY  1623,7772  -0,0282  78,85  30  38  -0,754545455  3,1 
1  QQLTGDNYFFYY  1786,8405  0,0037  89,81  31  39  -0,8  3,1 
1  QQLTGDNYFFYYGT  1944,9097  -0,0342  126,24  31  37  -0,764285714  3,1 
1  YADNQPG  992,4766  -0,0075  55,32  30  39  -1,714285714  3,1 
1  TYADNQPG  1093,5243  0,0022  43,64  33  40  -1,5875  3,1 
1  YADNQPGVL  1204,6291  -0,0249  62,97  32  40  -0,444444444  3,1 
1  FDLGGGTFDV  1255,6288  0,0098  50,52  36  40  0,47  2,92 
1  FDLGGGTFDVS  1342,6608  -0,0257  83,54    39  0,354545455  2,92 
1  YDGYEA  945,4283  0,0154  41,21    36  -1,366666667  3 
1  LEQELV  958,5538  0,029  45,32    40  0,216666667  3,12  
 
1  TEVPVDDEAH  1339,6459  0,0563  71,76  37  41  -0,93  3,58 
1  ELQDQFIDKY  1755,9449  -0,0089  53,04  39  42  -1,16  3,7 
1  YELGELQDQFIDK  2055,093  -0,0228  78,32  41  42  -0,9  3,58 
1  YELGELQDQFIDKY  2218,1563  0,0462  99,18  31  43  -0,928571429  3,58 
1  LWGADNDDDVSDVTDKL  2335,1586  -0,0187  109,28  33  41  -0,788235294  3,22 
1  SLWGADNDDDVSDVTDKL  2422,1906  -0,0395  131,78  38  40  -0,788888889  3,22 
1  FHQTVDDVYEDEDGEEEEEPEIQ  3009,2726  0,0285  107,88  30  35  -1,760869565  3,1 
1  TLEPVEQV  1142,6386  -0,0243  40,64  37  40  -0,075  3,12 
1  FDLGGGTFDV  1255,6288  0,0098  50,52  36  40  0,47  2,92 
1  FDLGGGTFDVS  1342,6608  -0,0257  83,54    39  0,354545455  2,92 
1  ATDDVEDAAPETKEA  2019,005  -0,0097  69,74  29  41  -1,1  3,38 
1  HATDDVEDAAPETKEA  2156,0639  0,0195  123,13  30  42  -1,23125  3,74 
1  ATDDVEDAAPETKEAVPESPRAS  2842,4238  -0,069  67,83  27  40  -1,013043478  3,68 
1  TLEPVEQV  1142,6386  -0,0243  40,64  37  40  -0,075  3,12 
1  FDLGGGTFDV  1255,6288  0,0098  50,52  36  40  0,47  2,92 
1  FDLGGGTFDVS  1342,6608  -0,0257  83,54    39  0,354545455  2,92 
1  FDNLVWA  1092,5807  0,0446  53,84    42  0,671428571  3,1 
1  SLQEVDSI  1118,6022  0,0121  51,09  41  42  0,05  3 
1  FDNLVWAN  1206,6236  -0,0143  63,38  37  41  0,15  3,1 
1  SFGSLQEVDSI  1409,7241  -0,0204  87,79    41  0,181818182  3 
1  FDNLVWA  1092,5807  0,0446  53,84    42  0,671428571  3,1 
1  SLQEVDSI  1118,6022  0,0121  51,09  41  42  0,05  3 
1  FDNLVWAN  1206,6236  -0,0143  63,38  37  41  0,15  3,1 
1  SFGSLQEVDSI  1409,7241  -0,0204  87,79    41  0,181818182  3 
1  SQDAYDLFDKV  1757,9242  -0,0128  65,37  32  42  -0,672727273  3,6 
1  DLIDERIIDQQ  1585,8514  0,0354  48,35  33  42  -0,745454545  3,5 
1  IGADLIDERIIDQQ  1826,9941  -0,0363  65,85  35  42  -0,164285714  3,5 
1  LENTEIGDSIFDKA  2009,0723  -0,0209  88,32  34  42  -0,421428571  3,58 
1  GVVFDSSGNVV  1307,6925  0,0394  88,38  35  42  0,927272727  3,1 
1  FQGIEDLGTGI  1377,7343  -0,0132  74,79    42  0,290909091  3  
 
1  IGQEVDGEAVGDEFKG  2107,0839  0,0809  112,23  33  43  -0,5625  3,5 
1  YEYTEEA  1132,5127  0,008  42,63  24  37  -1,714285714  3,02 
1  SATNSESDNEVFFV  1773,826  -0,0332  115,92  27  37  -0,342857143  2,94 
1  GFFSGNEVINDQSDYA  1990,9111  -0,01  104,56  26  38  -0,5375  2,88 
1  SIEQNPSQGA  1258,6356  0,0068  81,36    40  -1,13  3,3 
1  DEQETETKQQ  1692,8572  -0,0283  48,57  31  41  -2,98  3,68 
1  NTLDEQETETKQ  1892,9733  0,075  100,06    42  -2,225  3,68 
1  NTLDEQETETKQQ  2021,0319  0,0892  98,75  34  43  -2,323076923  3,68 
1  EGYGFTENGELPY  1703,7882  0,0224  59,82  28  39  -1,038461538  3,02 
1  TFDGPNDPLHPFNWPM  2112,9931  -0,02  43,43  27  38  -0,89375  3,88 
1  ATPTPNPESSAGADDTSREA  2202,0239  0,0446  80,75  33  41  -1,225  3,58 
1  SHENEDQNQGEEEEEGEEEEEEEEERA  3476,3569  0,0222  126,37    29  -3  3,36 
1  SHENEDQNQGEEEEEGEEEEEEEEERAH  3613,4158  -0,0012  35,2  26  30  -3,007142857  3,56 
1  QDVEQG  903,4501  -0,0111  44,75  34  39  -1,7  3 
1  NQIDAQ  916,4817  -0,0138  40,86    39  -1,283333333  3,1 
1  QLFNDMEEL  1366,6641  0,0204  69,64    41  -0,577777778  2,94 
1  QLFNDMEELVIEQ  1835,9178  -0,0348  128,13    40  -0,269230769  2,88 
1  SGEQQQPA  1072,5352  0,0009  49,46  25  39  -1,875  3,3 
1  NQVEEYEADGL  1494,7041  -0,0134  79,91  29  38  -1,172727273  2,88 
1  STFAEPPLVDGEGNPI  1870,9516  -0,026  82,44  31  41  -0,25  2,94 
1  YSQDQGVEYEEDEEDKPNLS  2831,3027  -0,0727  65,87  19  35  -2,03  3,28 
1  ARDEDDLDENELLM  1905,8828  0,0137  78,99  37  39  -1,242857143  3,28 
1  QKEEPEQEEIAPSLPS  2268,1891  -0,0378  106,44  33  42  -1,54375  3,68 
1  EFVDDDWWLGELEKDGSKG  2911,4848  -0,0488  81,79  34  42  -1,131578947  3,62 
1  EAPKPEVPEDEPEGEPDVKDL  3005,5689  0,0889  55,54  26  43  -1,604761905  3,58 
1  LFEFNPF  1141,6011  -0,0036  42,91  38  40  0,514285714  3,3 
1  LFEFNPFEMG  1458,7056  0,0243  46,3  26  40  0,16  3,12 
1  TDFLEDLSDNSDDIAIYAPNPFKEA  3257,6021  -0,08  74,96  37  40  -0,584  3,22 
1  NQEVLEWL  1258,676  0,0324  57,94    41  -0,3875  3,12 
1  QEQQLQEQ  1258,6356  -0,0187  63,15    39  -2,5875  3,12  
 
1  SGTILDIFDVDQV  1649,8715  -0,031  101,88  40  42  0,623076923  2,82 
1  SYGGGQES  1012,4664  -0,0071  62,11    37  -1,3875  3,3 
1  LLEYDAF  1098,58  0,0373  45,36  36  40  0,557142857  3 
1  SYGGGQESTV  1212,5826  0,0353  74,78  39  40  -0,76  3,3 
1  DIYRVEETLPDEV  1805,925  -0,0266  72,85  34  41  -0,684615385  3,5 
1  QDKEGIPPDQQ  1711,9147  0,0719  62,32  29  41  -2,181818182  3,7 
1  SKEVSEEENTEPEVQ  2191,0898  0,0552  99,46  34  42  -1,826666667  3,58 
1  FGWDTGTI  1124,5705  -0,011  43,24  29  41  0,0875  3,1 
1  FGWDTGTIS  1211,6026  -0,0144  55,83  38  40  -0,011111111  3,1 
1  LWEEGVLPW  1356,7281  -0,0261  41,02  32  41  0,111111111  3,12 
1  RTEDDDEDEEAEKQ  2165,9966  -0,0248  85,2    37  -3,021428571  3,52 
1  QAWVEDGLVKPEAVEEV  2355,2728  -0,0435  80,16  40  43  -0,211764706  3,58 
1  RTEDDDEDEEAEKQNGDAKEN  3123,4684  0,0128  47,62  25  40  -2,8  3,64 
1  QLFNDMEEL  1366,6641  0,0204  69,64    41  -0,577777778  2,94 
1  QLFNDMEELVIEQ  1835,9178  -0,0348  128,13    40  -0,269230769  2,88 
1  DSSENPA  947,4399  -0,0031  54,13  29  37  -1,7  3 
1  NDQEEEEGQGEGH  1685,6968  -0,0089  87,85  27  31  -2,761538462  3,5 
1  ANDQEEEEGQGEGH  1756,7339  -0,0077  45,78  22  32  -2,435714286  3,5 
1  NDQEEEEGQGEGHENQ  2056,8409  -0,0192  57,31  23  30  -2,9  3,44 
1  NEADQY  967,445  0,0024  40,67    38  -2,25  3 
1  GDDQQESQQQRGY  1766,8023  -0,018  49,22  29  36  -2,723076923  3,7 
1  GDDQQESQQQRGYT  1867,8499  -0,0267  97,87    36  -2,578571429  3,7 
1  GIPNAGDET  1101,5505  0,041  43,78  29  41  -0,811111111  3 
1  ATGPEDMQQ  1204,5597  0,0141  58,96  32  39  -1,444444444  3 
1  KDYVVEDGDII  1722,9446  -0,0194  73,35  32  42  -0,2  3,5 
1  EFGGPGGQGFGGPNPQ  1730,8216  -0,0469  54,45  18  37  -1  3,3 
1  ANDEQNA  989,4617  0,0064  42,62    38  -1,985714286  3 
1  YDEEREAS  1226,5618  -0,0096  39,74  28  37  -2,35  3,68 
1  AYGIFTDSLYGVFA  1751,8973  0,0016  118,8  33  42  0,95  3,1 
1  QQQQQDPT  1200,5938  -0,0006  48,52    39  -2,9125  3,1  
 
1  QQNPSDQEQQPPASPT  1979,9388  -0,0349  80,15  34  38  -2,18125  3 
1  NIDNSTGQAGQA  1403,6844  -0,0053  100,84    40  -0,975  3,1 
1  RFFPTDELENVPDSPA  2062,021  -0,0393  43,07  23  40  -0,80625  3,58 
1  SDPEKRDIYDQFGEDGL  2441,2116  -0,0521  40,92  25  40  -1,547058824  3,68 
1  FKRDGDDLVYEAEIDLL  2468,3204  0,0336  65,65  27  43  -0,376470588  3,68 
1  GELTQEELERIV  1643,8933  -0,0276  73,14  31  42  -0,566666667  3,8 
1  EAEYGNQGA  1166,5406  -0,0003  76,7  36  38  -1,388888889  3,12 
1  NSDDFDTEFREPDMPT  2143,9207  0,0908  73,63  28  39  -1,68125  3,32 
1  NSEKEDEEQEAV  1863,9103  0,0844  64,23  32  43  -2,225  3,5 
1  SQNSEKEDEEQEAV  2079,0009  0,0856  84,01  36  42  -2,214285714  3,5 
1  SSRNEFSEEDGDHNGEFS  2270,9515  -0,0145  32,77  19  31  -1,894444444  3,82 
1  ALLDQLDKDINTF  1963,1032  -0,0071  78,76  33  43  -0,123076923  3,6 
1  FGWDTGTI  1124,5705  -0,011  43,24  29  41  0,0875  3,1 
1  FGWDTGTIS  1211,6026  -0,0144  55,83  38  40  -0,011111111  3,1 
1  DQSDPNDPKS  1559,7833  -0,0224  74,47    40  -2,62  3,6 
1  NMMDIADLEEPFLPRPN  2230,0965  -0,0148  74,71  32  41  -0,576470588  3,58 
1  GLVDPDERVNDFDIS  1918,9475  0,0105  43,37  32  41  -0,586666667  3,36 
1  RIEDDPFENLEDTDDIFQKDFG  3115,5028  -0,0799  41,57  23  38  -1,290909091  3,44 
1  RIEEDPFENLEDTDDLFQNEFGI  3013,4032  -0,0679  42,19  29  37  -1,052173913  3,2 
1  EYFRDEEGQDVL  1727,8205  0,0352  50,27  25  41  -1,366666667  3,5 
1  QGTDQPY  1036,5028  0,0116  48,65  37  41  -2,071428571  3,1 
1  GQQYEQQ  1108,5352  -0,0184  56,3  31  39  -2,742857143  3,3 
1  YSDLPQQERDTI  1692,8522  -0,0263  74,63  31  40  -1,508333333  3,7 
1  YFEDNA  986,4548  -0,0159  35,64    35  -1,2  3 
1  YFEDNAGVI  1255,6288  0,0016  62,64    40  0,122222222  3 
1  YFEDNAGVIA  1326,6659  0,0177  80,15  39  41  0,29  3 
1  KGDDEANGA  1333,6879  -0,006  53,9  33  41  -1,677777778  3,7 
1  DYFGDADKA  1458,7397  -0,016  41,64  28  40  -1,077777778  3,6 
1  SIDDLIHEII  1395,7812  -0,0207  70,11  33  42  0,73  3,7 
1  SIDDLIHEII  1395,7812  -0,0207  70,11  33  42  0,73  3,7  
 
1  SLDDLQQSIEEDEDHVQST  2416,1081  -0,014  83,83  31  38  -1,315789474  3,28 
1  DFIEDEPKEDSDGV  2051,9941  0,0228  56,45  39  41  -1,407142857  3,28 
1  NQEVLEWL  1258,676  0,0324  57,94    41  -0,3875  3,12 
1  RDDADEDEEDPDTRSS  2079,8668  -0,0434  50,51  23  29  -2,6625  3,44 
1  YLDEEPPLTEGEEPRIY  2278,1208  -0,0276  58,04  26  40  -1,288235294  3,5 
1  YTGGDNNEY  1260,5461  0,0579  41,08  32  39  -2,011111111  3 
1  YLDEEPPLNEGEEPRIY  2291,116  -0,0223  63,2  36  40  -1,452941176  3,5 
1  REGDQGENFY  1442,6629  -0,0124  37,24  26  37  -2,13  3,82 
1  QYESPSVDTG  1310,6193  0,0623  41,11  30  41  -1,19  3 
1  KDLNQEGDDQMFV  1995,9977  0,0577  67,5  35  42  -1,238461538  3,5 
1  EILPEEIEERV  1583,8609  -0,0303  50,08  28  42  -0,6  3,68 
1  FSADDERFGEVV  1598,778  -0,0067  46,41  31  40  -0,325  3,58 
1  NEVDENEERQV  1588,7532  0,0382  42,7  36  41  -2,190909091  3,58 
1  LNEVDENEERQV  1701,8372  -0,0266  76,09  36  39  -1,691666667  3,58 
1  DSTLREGEQFA  1480,7361  -0,026  50,62  35  40  -1,090909091  3,82 
1  RALDDFGVDYI  1511,7823  0,0572  53,2  30  42  0,036363636  3,6 
1  DSTLREGEQFA  1480,7361  -0,026  50,62  35  40  -1,090909091  3,82 
1  RALDDFGVDYI  1511,7823  0,0572  53,2  30  42  0,036363636  3,6 
1  LFDDLKDGLI  1605,9384  -0,018  65,12  40  42  0,39  3,6 
1  QVYDNG  923,4552  -0,0016  41,5    40  -1,333333333  3,1 
1  TAENGGSSVGDGA  1349,6262  -0,0097  71,86    38  -0,507692308  3 
1  KVGEDDQTEAQ  1676,8623  0,0161  75,04  32  42  -1,818181818  3,58 
1  LDRGDGEEGN  1289,6051  -0,0023  42,28  28  38  -1,94  3,58 
1  GYQDDPQYA  1284,5825  0,0541  53,02  32  40  -1,866666667  2,92 
1  FGWDTGTI  1124,5705  -0,011  43,24  29  41  0,0875  3,1 
1  FGWDTGTIS  1211,6026  -0,0144  55,83  38  40  -0,011111111  3,1 
1  YLVDDLRPEFA  1565,8292  0,0397  42,01  37  42  -0,136363636  3,7 
1  KENAGDVDTQ  1533,804  0,01  62,94    42  -1,65  3,7 
1  EKQDEVSGQ  1476,7826  -0,008  59,72  40  42  -2,044444444  3,82 
1  DRFGDHNLGDDDDADFEKQV  2765,2935  -0,0455  52,36  23  38  -1,6  3,68  
 
1  LQQPQEQQQQQQ  1738,8801  -0,0068  52,49  39  41  -2,733333333  3,3 
1  EVGQYEIV  1164,6229  0,0406  47,08  34  42  0,0875  3,12 
1  LDNGWDIF  1207,6076  -0,0105  42,53  35  41  -0,0875  2,92 
1  IFGDAFDVDRA  1453,7404  0,0515  52,32  36  42  0,227272727  3,6 
1  LTRELV  958,6014  -0,0186  50,48    40  0,516666667  6,98 
1  ITRELV  958,6014  -0,0186  50,48    40  0,633333333  6,98 
1  ITRELV  958,6014  -0,0186  50,48    40  0,633333333  6,98 
1  LTRELV  958,6014  -0,0186  50,48    40  0,516666667  6,98 
1  QDMQDEMLDLIEQ  1835,8484  0,0346  47,86    40  -0,930769231  2,76 
1  AKNDDDSGNNLDNN  1962,9285  -0,0214  47,81  38  39  -2,214285714  3,42 
1  FYGILNAR  1181,676  0,0512  43,46    39  0,4  9,84 
1  LEQELV  958,5538  0,029  45,32    40  0,216666667  3,12 
1  IEQELV  958,5538  0,029  45,32    40  0,333333333  3,12 
1  KMNDDPDQQ  1547,7655  0,0326  44,66  30  42  -2,733333333  3,6 
1  INDWFII  1148,6433  0,0488  43,92    41  1,2  3,1 
1  ALLDAL  843,5268  -0,0186  42,28    39  1,916666667  3,1 
1  AILDAL  843,5268  -0,0186  42,28    39  2,033333333  3,1 
1  ALLDAL  843,5268  -0,0186  42,28    39  1,916666667  3,1 
1  EQEEKGESS  1479,7458  -0,0194  41,67  33  40  -2,6  3,8 
1  VMGGGLGGGP  1045,543  -0,0496  41,47    38  0,59  6,02 
                 
2  AITGESL  918,5225  -0,0125  47,97    43  0,671428571  3,3 
2  LAGVEIL  942,5953  -0,001  45,54    39  2,028571429  3,3 
2  GFVQEF  954,5014  0,0467  46,29    39  0,4  3,3 
2  AITGESLA  989,5596  0,0007  66,69    42  0,8125  3,3 
2  QFVMEAA  1023,5262  -0,0135  53,56    41  0,785714286  3,3 
2  GFVQEFQ  1082,56  0,0078  53,99  37  41  -0,157142857  3,3 
2  SLTENWL  1090,5862  -0,0137  44,31    42  -0,257142857  3,3 
2  LTENWLI  1116,6382  0,0461  51,27    41  0,5  3,3 
2  GEGHWEIL  1168,608  -0,006  55,09  33  41  -0,45  4,24  
 
2  SLTENWLI  1203,6702  0,0332  64,62    42  0,3375  3,3 
2  EFHPFDPV  1215,6127  0,035  53,63  37  41  -0,45  4,06 
2  ESPEGERIV  1243,6611  0,0454  46,93  34  41  -1,011111111  3,96 
2  LFGWWSEN  1266,6236  0,0119  47,03  37  41  -0,425  3,3 
2  RDGQLVEIPA  1325,7506  -0,0024  58,39  36  41  -0,27  4,08 
2  LEFHPFDPV  1328,6968  0,0006  50,73  32  41  0,022222222  4,06 
2  VESPEGERIV  1342,7295  0,0103  44,81  34  41  -0,49  3,96 
2  GEARPVPEEY  1374,6982  0,0374  47,24  30  42  -1,39  3,96 
2  AVVESPEGERI  1413,7666  0,0215  68,25  40  41  -0,281818182  3,96 
2  ENYENKVA  1423,7713  0,0167  46,23  33  42  -1,65  4,26 
2  IRDGQLVEIPA  1438,8347  0,0278  41,65  33  40  0,163636364  4,08 
2  ADEKESLVV  1446,8335  -0,0201  65,2    42  -0,133333333  3,82 
2  GEARPVPEEYL  1487,7823  -0,0211  48,38  30  41  -0,918181818  3,96 
2  AVVESPEGERIV  1512,8351  -0,0183  70,52  38  42  0,091666667  3,96 
2  FLAPGLSAIIDAL  1528,9068  -0,0217  41,11  30  41  1,715384615  3,1 
2  GDGVNDAPSLK  1529,8455  0,0458  59,76  37  41  -0,709090909  3,88 
2  VIRDGQLVEIPA  1537,9031  0,0457  53,5  30  39  0,5  4,08 
2  GEARPVPEEYLQ  1615,8409  0,0005  61,38    42  -1,133333333  3,96 
2  VVIRDGQLVEIPA  1636,9715  0,0343  63,33  28  40  0,784615385  4,08 
2  EEDHPIPEDVHE  1673,7736  -0,0014  52,93  23  38  -1,825  3,82 
2  GEARPVPEEYLQT  1716,8885  -0,0169  56,37  26  41  -1,1  3,96 
2  MTGDGVNDAPSLK  1761,9337  -0,0245  69,6  32  42  -0,507692308  3,88 
2  EEDHPIPEDVHEN  1787,8165  -0,0179  64,93  27  37  -1,953846154  3,82 
2  RDGQLVEIPANEVVPG  1921,0472  0,0069  84,95  31  43  -0,20625  3,82 
2  KTVEEDHPIPEDVH  2102,105  0,0614  64,11  29  43  -1,342857143  4,28 
2  KTVEEDHPIPEDVHEN  2345,1905  0,0656  45,97  25  43  -1,6125  4,12 
2  KTVEEDHPIPEDVHENY  2508,2538  0,0622  105,31  27  43  -1,594117647  4,12 
2  EEDHPIPEDVHENYENK  2551,2232  0,0653  100,11  34  42  -2,211764706  4,02 
2  EEDHPIPEDVHENYENKV  2650,2916  0,0185  75,34  31  42  -1,855555556  4,02 
2  EEDHPIPEDVHENYENKVA  2721,3288  0,0605  96,94  29  43  -1,663157895  4,02  
 
2  VEEDHPIPEDVHENYENKV  2749,3601  -0,0233  84,36  26  41  -1,536842105  4,02 
2  KTVEEDHPIPEDVHENYEN  2751,3393  0,1033  57,58  32  43  -1,794736842  4,02 
2  VEEDHPIPEDVHENYENKVA  2820,3972  -0,0136  106,11  36  42  -1,37  4,02 
2  KTVEEDHPIPEDVHENYENKV  3207,6656  -0,0168  57,58  33  43  -1,60952381  4,26 
2  KTVEEDHPIPEDVHENYENKVA  3278,7027  -0,0004  65,78  26  43  -1,454545455  4,26 
2  AITGESL  918,5225  -0,0125  47,97    43  0,671428571  3,3 
2  LAGVEIL  942,5953  -0,001  45,54    39  2,028571429  3,3 
2  AITGESLA  989,5596  0,0007  66,69    42  0,8125  3,3 
2  QFVMEAA  1023,5262  -0,0135  53,56    41  0,785714286  3,3 
2  SLTENWL  1090,5862  -0,0137  44,31    42  -0,257142857  3,3 
2  LTENWLI  1116,6382  0,0461  51,27    41  0,5  3,3 
2  GEGHWEIL  1168,608  -0,006  55,09  33  41  -0,45  4,24 
2  SLTENWLI  1203,6702  0,0332  64,62    42  0,3375  3,3 
2  EFHPFDPV  1215,6127  0,035  53,63  37  41  -0,45  4,06 
2  ESPEGERIV  1243,6611  0,0454  46,93  34  41  -1,011111111  3,96 
2  LFGWWSEN  1266,6236  0,0119  47,03  37  41  -0,425  3,3 
2  LEFHPFDPV  1328,6968  0,0006  50,73  32  41  0,022222222  4,06 
2  VESPEGERIV  1342,7295  0,0103  44,81  34  41  -0,49  3,96 
2  AVVESPEGERI  1413,7666  0,0215  68,25  40  41  -0,281818182  3,96 
2  ENYENKVA  1423,7713  0,0167  46,23  33  42  -1,65  4,26 
2  AVVESPEGERIV  1512,8351  -0,0183  70,52  38  42  0,091666667  3,96 
2  FLAPGLSAIIDAL  1528,9068  -0,0217  41,11  30  41  1,715384615  3,1 
2  GDGVNDAPSLK  1529,8455  0,0458  59,76  37  41  -0,709090909  3,88 
2  EEDHPIPEDVHE  1673,7736  -0,0014  52,93  23  38  -1,825  3,82 
2  MTGDGVNDAPSLK  1761,9337  -0,0245  69,6  32  42  -0,507692308  3,88 
2  EEDHPIPEDVHEN  1787,8165  -0,0179  64,93  27  37  -1,953846154  3,82 
2  KTVEEDHPIPEDVH  2102,105  0,0614  64,11  29  43  -1,342857143  4,28 
2  KTVEEDHPIPEDVHEN  2345,1905  0,0656  45,97  25  43  -1,6125  4,12 
2  KTVEEDHPIPEDVHENY  2508,2538  0,0622  105,31  27  43  -1,594117647  4,12 
2  EEDHPIPEDVHENYENK  2551,2232  0,0653  100,11  34  42  -2,211764706  4,02  
 
2  EEDHPIPEDVHENYENKV  2650,2916  0,0185  75,34  31  42  -1,855555556  4,02 
2  EEDHPIPEDVHENYENKVA  2721,3288  0,0605  96,94  29  43  -1,663157895  4,02 
2  VEEDHPIPEDVHENYENKV  2749,3601  -0,0233  84,36  26  41  -1,536842105  4,02 
2  KTVEEDHPIPEDVHENYEN  2751,3393  0,1033  57,58  32  43  -1,794736842  4,02 
2  VEEDHPIPEDVHENYENKVA  2820,3972  -0,0136  106,11  36  42  -1,37  4,02 
2  KTVEEDHPIPEDVHENYENKV  3207,6656  -0,0168  57,58  33  43  -1,60952381  4,26 
2  KTVEEDHPIPEDVHENYENKVA  3278,7027  -0,0004  65,78  26  43  -1,454545455  4,26 
2  HEQLEQ  1011,5188  -0,0123  41,12  29  40  -2,233333333  4,24 
2  AGGVGEFEA  1064,5341  0,0025  67,31  40  41  0,266666667  3,12 
2  HEQLEQGVPG  1321,6829  -0,0077  67,13  32  41  -1,16  4,24 
2  AGGVGEFEAGIS  1321,6717  0,028  95,76  41  42  0,475  3,12 
2  EMHHEQLEQ  1408,6608  -0,0266  69,78  32  37  -2,022222222  4,52 
2  IDAIEQPSRPT  1454,7932  0,0193  57,37  34  41  -0,809090909  4,08 
2  KTLLEAIDAI  1543,9591  -0,0222  75,37    40  0,86  4,08 
2  HEQLEQGVPGDNV  1649,8212  0,037  101,04  33  42  -1,107692308  3,82 
2  EAFSEYPPLGRFA  1711,8772  -0,025  65,11  28  41  -0,323076923  4,26 
2  EMHHEQLEQGVPG  1718,8249  0,0064  109,24    40  -1,261538462  4,52 
2  CRFDELLEKN  1723,9333  0,0601  43,51  26  42  -0,95  4,44 
2  RFDELLEKND  1735,951  0,0615  51,59  30  42  -1,55  4,06 
2  HEQLEQGVPGDNVGF  1853,9111  -0,0313  95,89  28  40  -0,8  3,82 
2  DAIEQPSRPTDKPL  2024,1308  0,0029  61,13    42  -1,328571429  4,3 
2  EMHHEQLEQGVPGDNV  2046,9632  0,0795  135,54  36  42  -1,2  4,14 
2  EMHHEQLEQGVPGDNVG  2103,9847  0,047  73,51  26  41  -1,152941176  4,14 
2  IDAIEQPSRPTDKPL  2137,2148  0,0103  53,89  33  42  -0,94  4,3 
2  EMHHEQLEQGVPGDNVGF  2251,0531  -0,0292  146,19  33  38  -0,933333333  4,14 
2  EAIDAIEQPSRPTDKPL  2337,2945  0,0121  83,42  30  43  -0,929411765  4,06 
2  NYDAEEM  1099,4695  -0,0074  44,92  27  33  -1,657142857  2,94 
2  GFINQTDFI  1282,6761  -0,0232  74,63  33  41  0,333333333  3,1 
2  YGEGEEHEPV  1373,6302  -0,0015  79,81    37  -1,67  3,78 
2  FGGFVFGWDTG  1417,687  -0,0158  68,88  29  39  0,536363636  3,1  
 
2  NYDAEEM  1099,4695  -0,0074  44,92  27  33  -1,657142857  2,94 
2  GFINQTDFI  1282,6761  -0,0232  74,63  33  41  0,333333333  3,1 
2  YGEGEEHEPV  1373,6302  -0,0015  79,81    37  -1,67  3,78 
2  FGGFVFGWDTG  1417,687  -0,0158  68,88  29  39  0,536363636  3,1 
2  QDLEHDHA  1192,5676  -0,0164  53,94  32  38  -1,85  4,28 
2  LQDLEHDHA  1305,6516  -0,0085  49,96  33  40  -1,222222222  4,28 
2  YRETVESES  1327,6458  -0,0201  39,41  36  39  -1,6  3,96 
2  FNMFILDPI  1337,7256  0,0127  55,31    42  1,3  3,1 
2  SEEQRPGTPL  1341,7091  0,0246  47,71  26  41  -1,63  4,26 
2  FNMFILDPI  1353,7206  0,0168  47,55  28  42  1,3  3,1 
2  AYRETVESES  1398,683  -0,0206  39,78  33  39  -1,26  3,96 
2  YRETVESESS  1414,6779  -0,0179  38,71    38  -1,52  3,96 
2  SKEDLYQT  1440,7866  0,0555  48,38  34  41  -1,675  4,08 
2  ADPKIQEPV  1453,8546  0,0068  49,75  36  40  -0,788888889  4,08 
2  WQEYYDKL  1601,8495  -0,0216  49,53  39  41  -1,7625  4,08 
2  YRETVESESSQT  1643,7841  -0,0293  55,51  25  38  -1,616666667  3,96 
2  QVSKEDLYQT  1667,9136  0,0081  77,12  32  42  -1,27  4,08 
2  LQDLEHDHAGVPL  1671,8783  -0,0094  81,57  36  42  -0,384615385  4,28 
2  NESFGFTGELRQA  1683,8419  0,0145  90,34  34  41  -0,738461538  4,26 
2  TKEGPIFGEEM  1694,8955  0,041  70,75  38  42  -0,754545455  3,96 
2  AYRETVESESSQT  1714,8212  -0,0277  64,31  33  38  -1,353846154  3,96 
2  FLLADPKIQEPV  1827,0912  0,0009  82,2  30  40  0,275  4,08 
2  GFLLADPKIQEPV  1884,1126  -0,0202  84,35  27  41  0,223076923  4,08 
2  FGGFVFGWDTG  1417,687  -0,0158  68,88  29  39  0,536363636  3,1 
2  NKTTEDSPLVT  1661,9242  0,0301  81,86  28  42  -0,990909091  4,08 
2  FGGFVFGWDTG  1417,687  -0,0158  68,88  29  39  0,536363636  3,1 
2  FGGFVFGWDTG  1417,687  -0,0158  68,88  29  39  0,536363636  3,1 
2  LWEEGVLPWKSPS  1985,1028  0,0364  42,62    42  -0,469230769  4,26 
2  IQVFEGERA  1276,6978  -0,0067  45,19  40  42  -0,233333333  4,26 
2  LGGEDFDNRLV  1462,7619  0,0509  75,42    42  -0,427272727  3,7  
 
2  IGRNFNDPEVQ  1516,7837  0,0145  45,04  34  42  -1,136363636  4,08 
2  DVDGKPQIQV  1555,8976  -0,0324  53,11  36  42  -0,7  3,88 
2  HLGGEDFDNRLV  1599,8208  0,0138  49,71  35  41  -0,658333333  4,3 
2  IDVDGKPQIQV  1668,9816  0,0379  58,16  33  39  -0,227272727  3,88 
2  GDTHLGGEDFDNRLV  1872,9169  -0,0094  74,82  30  40  -0,833333333  3,96 
2  AGDTHLGGEDFDNRLV  1943,954  -0,0134  85,14  31  40  -0,66875  3,96 
2  KEEFDDQLKEL  2080,166  0,0555  42,52  31  42  -1,672727273  3,92 
2  ATKEEFDDQLKEL  2252,2508  0,0131  60,2  32  42  -1,330769231  3,92 
2  AFTDTERL  1180,6291  -0,0153  43,28  31  41  -0,5625  4,08 
2  IQVFEGERA  1276,6978  -0,0067  45,19  40  42  -0,233333333  4,26 
2  LGGEDFDNRLV  1462,7619  0,0509  75,42    42  -0,427272727  3,7 
2  IGRNFNDPEVQ  1516,7837  0,0145  45,04  34  42  -1,136363636  4,08 
2  DVDGKPQIQV  1555,8976  -0,0324  53,11  36  42  -0,7  3,88 
2  IGRNFNDPEVQA  1587,8208  -0,0078  43,93  31  41  -0,891666667  4,08 
2  HLGGEDFDNRLV  1599,8208  0,0138  49,71  35  41  -0,658333333  4,3 
2  IDVDGKPQIQV  1668,9816  0,0379  58,16  33  39  -0,227272727  3,88 
2  GDTHLGGEDFDNRLV  1872,9169  -0,0094  74,82  30  40  -0,833333333  3,96 
2  AGDTHLGGEDFDNRLV  1943,954  -0,0134  85,14  31  40  -0,66875  3,96 
2  GFFAGNEV  1068,5443  0,0345  48,48  34  40  0,475  3,3 
2  DDEDTRVK  1434,772  -0,0237  57,99  35  42  -2,3625  3,96 
2  TSINRDDPTWT  1533,7626  0,0215  62,4  35  41  -1,445454545  3,88 
2  TSINRDDPTWTV  1632,8311  -0,0071  47,39  30  41  -0,975  3,88 
2  SNDDEDTRVK  1635,847  -0,0286  51,78  31  41  -2,32  3,96 
2  SSNDDEDTRVK  1722,879  -0,0226  79,6    41  -2,181818182  3,96 
2  YFEETNKYGLV  1819,9762  -0,0114  78,37  28  42  -0,663636364  4,26 
2  SNDDEDTRVKMT  1867,9351  0,0154  46,68    42  -1,833333333  3,96 
2  GYSSNDDEDTRVK  1942,9638  -0,0257  95,47  30  40  -1,976923077  3,96 
2  SSNDDEDTRVKMT  1954,9672  -0,0063  80,06    41  -1,753846154  3,96 
2  GYSSNDDEDTRVKMT  2175,052  0,0366  85,2  29  41  -1,633333333  3,96 
2  FYGIIDL  1068,6058  -0,0023  48,58  36  40  1,485714286  3,1  
 
2  FYGIIDLI  1181,6899  0,0355  64,83    39  1,8625  3,1 
2  GIFYGIIDL  1238,7114  0,0019  54,65  34  41  1,611111111  3,1 
2  IFYGIIDLI  1294,774  -0,0183  70,72    41  2,155555556  3,1 
2  GIFYGIIDLI  1351,7954  -0,0079  74,18  39  41  1,9  3,1 
2  YHFGPSDAEAV  1420,6826  -0,0231  68,95  24  39  -0,336363636  4,06 
2  GYHFGPSDAEAV  1477,7041  -0,0261  78,26  29  38  -0,341666667  4,06 
2  GFFAGNEV  1068,5443  0,0345  48,48  34  40  0,475  3,3 
2  FFAGNEVI  1124,6069  -0,02  56,14    41  1,0875  3,3 
2  NSESGERFYI  1429,704  0,0006  47,77  36  40  -1,1  4,26 
2  FFNSESGERF  1447,6935  0,049  65,58  30  41  -0,86  4,26 
2  AFFNSESGERF  1518,7306  0,0605  71,25  29  42  -0,618181818  4,26 
2  FFNSESGERFY  1610,7568  0,0017  69,66  32  39  -0,9  4,26 
2  DFENLKNEYS  1715,8772  -0,0139  61,88  39  41  -1,69  3,82 
2  FFNSESGERFYI  1723,8409  0,0116  72,95  31  41  -0,45  4,26 
2  AFFNSESGERFYI  1794,878  0,0044  45,48  23  41  -0,276923077  4,26 
2  TDFENLKNEYS  1816,9249  0,004  60,01  30  42  -1,6  3,82 
2  FGGFVFGWDTG  1417,687  -0,0158  68,88  29  39  0,536363636  3,1 
2  FDSIIEH  1088,5705  0,0081  45,11    41  0,114285714  4,06 
2  RDIEGSVQPS  1315,6935  -0,0147  66,1  35  41  -0,99  4,08 
2  IRDIEGSVQPS  1428,7775  0,0135  64,56  36  41  -0,490909091  4,08 
2  FNYQFDSIIEH  1640,8038  -0,0243  83,37  29  39  -0,427272727  4,06 
2  AFTDTERL  1180,6291  -0,0153  43,28  31  41  -0,5625  4,08 
2  LGGEDFDNRLV  1462,7619  0,0509  75,42    42  -0,427272727  3,7 
2  HLGGEDFDNRLV  1599,8208  0,0138  49,71  35  41  -0,658333333  4,3 
2  GDTHLGGEDFDNRLV  1872,9169  -0,0094  74,82  30  40  -0,833333333  3,96 
2  AGDTHLGGEDFDNRLV  1943,954  -0,0134  85,14  31  40  -0,66875  3,96 
2  AYLFESL  1070,5851  0,0164  53,47    40  0,942857143  3,3 
2  NYNGFDEH  1223,541  -0,0023  51,01  29  36  -2,0125  4,06 
2  GEGLNVEQR  1229,6567  -0,0097  44,55  36  41  -1,255555556  4,26 
2  LMQEFDRL  1279,6797  0,0139  55  27  42  -0,3375  4,08  
 
2  AGEGLNVEQR  1300,6938  -0,0029  70,18    41  -0,95  4,26 
2  FSSGVEGVNPI  1333,7081  0,0177  64,34  35  42  0,427272727  3,3 
2  ANDPENVGERS  1415,6844  -0,0206  41,28  28  38  -1,709090909  3,82 
2  SQDAYDLFNKV  1756,9401  -0,0317  60,85  38  41  -0,672727273  3,88 
2  SIEEKNRYVEEVI  2065,1461  0,0538  42,02  33  42  -0,815384615  4,26 
2  FYGIIDL  1068,6058  -0,0023  48,58  36  40  1,485714286  3,1 
2  FYGIIDLL  1181,6899  0,0355  64,83    39  1,775  3,1 
2  IFYGIIDLL  1294,774  -0,0183  70,72    41  2,077777778  3,1 
2  TIFYGIIDLL  1395,8216  -0,0233  78,77    41  1,8  3,1 
2  KKAQEEEEDVATDSE  2394,237  0,0183  45,26  28  43  -1,966666667  3,74 
2  AFTDTERL  1180,6291  -0,0153  43,28  31  41  -0,5625  4,08 
2  GNFGPELA  1032,5443  -0,0154  60,35  35  41  -0,125  3,3 
2  LLGEFDLK  1391,843  0,0175  43,35  34  40  0,3625  4,08 
2  HEPEPEAEQA  1364,6411  -0,0223  45,81  25  37  -2,03  3,78 
2  IHEPEPEAEQA  1477,7251  -0,0058  75,85  27  40  -1,436363636  3,78 
2  HATDDVEDAAPETKEA  2156,0639  0,0095  110,34  29  41  -1,23125  3,74 
2  HATDDVEDAAPETKEAVPESPRAS  2979,4827  0,0944  90,51  27  43  -1,104166667  3,96 
2  LLGEFDLK  1391,843  0,0175  43,35  34  40  0,3625  4,08 
2  RVQGGEEVNAEEL  1657,8474  0,0472  66,81  32  42  -0,946153846  3,8 
2  SNDELSKA  1320,7291  0,0064  42,75    42  -1,3  4,08 
2  SNDELSKA  1320,7291  0,0064  42,75    42  -1,3  4,08 
2  AYLFESL  1070,5851  0,0164  53,47    40  0,942857143  3,3 
2  GEGLNVEQR  1229,6567  -0,0097  44,55  36  41  -1,255555556  4,26 
2  AGEGLNVEQR  1300,6938  -0,0029  70,18    41  -0,95  4,26 
2  SQDAYDLFDKV  1757,9242  -0,019  46,3  25  42  -0,672727273  3,6 
2  SIEEKNRYVEEVI  2065,1461  0,0538  42,02  33  42  -0,815384615  4,26 
2  EELDWMEKNLPGRS  2161,1243  -0,0193  55,94  28  42  -1,435714286  4,16 
2  VQEELDWMEKNLPGRS  2388,2513  0,0147  78,98  34  43  -1,2125  4,16 
2  DNKDIERFIPS  1790,9932  0,0352  42,78  31  42  -1,181818182  4,3 
2  GYKYNDELTLT  1773,9554  -0,0093  61,67  30  42  -1,018181818  4,08  
 
2  NGEDKEIVDGKV  1989,1351  -0,039  47,67  35  43  -1,1  4,06 
2  ALPWFWEHYNPEEY  2108,9835  0,0213  107,08  33  40  -1,171428571  3,96 
2  ALPWFWEHYNPEEYS  2196,0155  0,054  59,1  36  41  -1,146666667  3,96 
2  QLIDNLLDKV  1627,9914  -0,0243  70,49  40  41  0,22  3,88 
2  FHTFQGIEDLGTGI  1762,9093  -0,0058  108,15  31  42  0,15  4,06 
2  GLSKEDDVRDFV  1836,9987  0,0491  45,75  27  42  -0,716666667  3,96 
2  GLSKEDDVRDFVI  1950,0828  -0,0285  52,91  26  43  -0,315384615  3,96 
2  FFDKRIGQEVDGEAVGDEFKG  3029,6067  -0,0162  58,22  28  43  -0,728571429  4,06 
2  GFFSGNEVI  1197,6233  -0,0175  58,48  39  40  0,633333333  3,3 
2  NYGESLNRADPS  1550,7528  -0,0037  72,13  35  40  -1,483333333  4,08 
2  NSGNYGESLNRADPS  1808,8492  -0,0243  84,68  32  38  -1,5  4,08 
2  SATNSESDNEVFFVKGV  2287,1738  0,0275  46,26  36  42  -0,288235294  3,82 
2  KFNDLDWS  1481,792  0,0401  48,05  37  42  -1,1875  3,88 
2  KFAPEAPDLFA  1662,9387  -0,0312  50,98  28  42  0,063636364  4,08 
2  SKREVDDLVENLDVS  2175,1789  -0,0193  44,12  34  43  -0,72  3,84 
2  KVIDDVNEEDWNLLEKL  2758,5361  0,0128  82,53  34  43  -0,729411765  3,76 
2  DMFDTNVRG  1282,6179  -0,0127  49,94  26  39  -0,8  3,88 
2  AFADMFDTNVRG  1571,7605  -0,021  62,67  30  39  -0,066666667  3,88 
2  FDVKVDKEAEQY  2157,1926  0,0323  56,86  24  42  -1,133333333  4,06 
2  DSNYKEESKEQA  2114,11  -0,0158  69,62  28  42  -2,491666667  4,16 
2  QSIQDTRDDELLERV  2045,0592  -0,0016  51,53  31  42  -1,246666667  3,84 
2  NYEPEVYNPDHEKL  2204,1155  -0,0317  75,34  28  41  -1,85  4,16 
2  LFEFNPF  1141,6011  -0,014  45,81    40  0,514285714  3,3 
2  DVFKNGEMPFPI  1851,0006  0,0642  66,79  29  42  -0,15  4,08 
2  IYEVAPG  976,5432  -0,0199  48,03  28  42  0,528571429  3,3 
2  GYENKDFIDLM  1801,9326  -0,0194  56,7  27  41  -0,6  3,7 
2  RELPKAEGSTEPLPEAL  2294,2887  0,0362  55,86  24  42  -0,829411765  4,26 
2  TIPEIQRELPKAEGSTEPLPEAL  2975,6584  -0,0174  49,06  27  43  -0,626086957  4,08 
2  GFAGDDAPRAV  1303,6724  0,0396  44,99  33  42  -0,136363636  3,88 
2  SKQEYDESGPS  1683,8357  -0,0341  71,04  27  40  -2,145454545  3,82  
 
2  GMGQKDSYVGDEA  1813,8922  0,0638  68,28  30  42  -1,023076923  3,7 
2  SKQEYDESGPSIV  1895,9882  -0,0308  103,32  33  42  -1,146153846  3,82 
2  YYFGQEG  1091,5127  -0,0177  45,36  31  37  -1,085714286  3,3 
2  NDGRGWDLN  1274,6207  0,019  43,81  38  40  -1,822222222  3,88 
2  ALPWFWEHYNPEEY  2108,9835  0,0213  107,08  33  40  -1,171428571  3,96 
2  ALPWFWEHYNPEEYS  2196,0155  0,054  59,1  36  41  -1,146666667  3,96 
2  RDAETGELLPVVPEKF  2257,2724  -0,0321  85,05  34  43  -0,38125  4,16 
2  SYGGGQES  1012,4664  0,0147  43,37  27  38  -1,3875  3,3 
2  NAPQKPEDIPVAT  1837,0351  0,0015  47,15  28  42  -0,853846154  4,08 
2  VFGGSDSQREFV  1555,7834  0,0356  59,6  32  42  -0,283333333  4,08 
2  LEEGRDFLLDHL  1684,8987  0,0501  50,68  30  42  -0,341666667  4,06 
2  DSNVNDWKRLEDFL  2208,1581  0,0512  45,63  34  43  -1,178571429  3,96 
2  FYQEKERADEDEGIEIV  2527,2848  0,0201  48,33  24  42  -1,194117647  3,74 
2  LFYQEKERADEDEGIEIV  2640,3688  -0,0261  79,98  25  42  -0,916666667  3,74 
2  QDKEGIPPDQQRLI  2094,1839  -0,0371  56,73  29  43  -1,442857143  4,3 
2  EFNAQERWWI  1606,8095  0,0231  45,87  29  42  -1,12  4,26 
2  SYKPEEGIEQL  1749,9554  -0,0157  43,25  39  42  -1,245454545  3,96 
2  SEFKDEVIQPI  1761,9918  0,0387  56,25  29  42  -0,390909091  3,82 
2  QGSEVGKEAESSPNTG  2034,0271  -0,048  54,12    40  -1,33125  3,96 
2  SREADEGTNDIEKEQ  2178,0806  -0,0344  53,44  31  40  -2,133333333  3,82 
2  TAPPLPRAPPVPPATFEFDSEPT  2662,3846  -0,0077  44,27  23  43  -0,508695652  3,82 
2  LFEEFDRL  1296,6917  0,0277  42,33  39  41  -0,225  3,82 
2  KGVEEEDISPG  1616,8663  0,0359  82,71  40  42  -1,127272727  3,68 
2  QTEEKTEEKS  1895,0456  -0,031  63,25  36  42  -2,75  4,26 
2  RGDLGIEIPAPEVL  1706,977  -0,0141  87,68  37  42  0,257142857  3,82 
2  KQDPEQEERQ  1743,9157  -0,033  41,67  29  41  -3,45  4,16 
2  ATEGDNNNNTAAGDKKG  2363,2285  -0,0376  81,2  35  42  -1,735294118  4,3 
2  SATEGDNNNNTAAGDKKG  2450,2606  -0,0394  85,22  33  42  -1,683333333  4,3 
2  DKYSPGDLIIPF  1822,0282  0,0321  45,77  32  42  -0,083333333  3,88 
2  MQKGKDYVVEDGDII  2396,323  0,0763  65,82  24  42  -0,54  3,96  
 
2  QYGADNGNPNGERG  1676,7706  -0,0261  65,57  27  36  -2,014285714  4,08 
2  EFGGPGGQGFGGPNPQEFGGQGR  2462,1567  -0,0297  61,14  25  39  -1,126086957  4,26 
2  NLDVKDQKAVDDFLLS  2506,4251  -0,0127  73,69  30  43  -0,325  3,88 
2  YYFGQEG  1091,5127  -0,0177  45,36  31  37  -1,085714286  3,3 
2  HYDEEREA  1276,5887  -0,0089  37,92  29  37  -2,65  4,16 
2  GEGLNVEQR  1229,6567  -0,0097  44,55  36  41  -1,255555556  4,26 
2  LMQEFDRL  1279,6797  0,0139  55  27  42  -0,3375  4,08 
2  EQFPFEKDVNVV  1908,0399  -0,0221  55,86  35  42  -0,4  3,82 
2  AEQFPFEKDVNVV  1979,077  -0,0261  75,98  34  43  -0,230769231  3,82 
2  NFIEPLAWPL  1427,8016  -0,0173  58,22  31  41  0,56  3,3 
2  EQLRQEGQQPV  1539,8208  -0,0018  53,56  26  42  -1,772727273  4,26 
2  VFENYVADVEVDGRRV  2095,0901  -0,0175  80,36  27  42  -0,1625  4,06 
2  ARFPVEDTAGGLL  1573,8667  -0,02  49,96  28  42  0,276923077  4,08 
2  QSDEGPRPNVT  1427,7208  -0,0278  47,87  22  40  -1,763636364  4,08 
2  KNEGLFEDEILPI  1974,1079  0,0678  86,43  32  41  -0,307692308  3,68 
2  DNNEKGKEGDSS  1966,0212  -0,0365  54,3  30  41  -2,6  4,06 
2  GELTQEELERI  1544,8249  0,0104  50,16  33  42  -1  3,8 
2  NDITDGKDYH  1634,8306  -0,002  45,35  37  41  -1,9  4,16 
2  LFEQFDRL  1295,7077  0,0498  49,01    41  -0,225  4,08 
2  NILSNEEGIERL  1614,8779  0,0552  62,19    41  -0,55  3,96 
2  RQLEQGIEPGDSGI  1726,9053  -0,0242  59,57  30  41  -0,914285714  3,82 
2  FGKEEETSVGDRL  1924,0307  -0,0107  44,83  26  42  -1,069230769  4,16 
2  FTKDQVNDDQLKNIT  2465,3734  0,0217  47,77  33  43  -1,226666667  4,18 
2  HNPENDLESNNKRDPFEA  2583,2719  -0,0401  70,58  29  40  -2,15  4,28 
2  EEIVEEVLEETKEKVE  2618,451  0  56,96  28  43  -0,975  3,78 
2  GIVENDFENRS  1507,747  0,02  43,52    41  -1,063636364  3,82 
2  KFLVDDGGLVDREPI  2130,2091  -0,0317  53,08  27  42  -0,1  3,96 
2  TIEEDGEHNGTKES  2002,9849  -0,0291  70,14  28  40  -1,9  4 
2  DWTQDYRDRV  1581,7739  -0,0251  48,63  32  39  -2,17  4,18 
2  KEKVEEQEQQQQ  2217,2209  -0,017  81,05  36  43  -2,925  4,26  
 
2  ASSEKNGSTPDTQ  1778,9052  -0,0263  54,5  28  41  -1,684615385  4,08 
2  VDEQSPRPG  1212,6302  -0,0177  55,75    40  -1,688888889  4,08 
2  KYDITIDEESPRPG  2077,1097  -0,0361  67,93  25  42  -1,414285714  4,06 
2  TKYDITIDEESPRPG  2178,1574  -0,0389  50,38  29  42  -1,366666667  4,06 
2  FGKEEETSVGDRL  1924,0307  -0,0107  44,83  26  42  -1,069230769  4,16 
2  FTKDQVNDDQLKNIT  2465,3734  0,0217  47,77  33  43  -1,226666667  4,18 
2  HNPENDLESNNKRDPFEA  2583,2719  -0,0401  70,58  29  40  -2,15  4,28 
2  SGDEGEAEEGGGRKG  1891,9277  -0,0228  68,63    40  -1,82  4 
2  LSGDEGEAEEGGGRKG  2005,0118  -0,02  80,91  37  41  -1,46875  4 
2  VFIQELI  1089,6637  -0,0071  48,78    42  1,828571429  3,3 
2  KDAQPNDS  1331,7087  -0,0132  61,4  34  41  -2,3125  3,88 
2  MNSTEPFPRVLDPV  1829,9549  -0,0283  42,29  23  41  -0,314285714  4,08 
2  NIERDILENS  1430,7568  0,0091  42,95  33  42  -1  3,82 
2  SLDQDGFFKII  1739,9864  0,0296  71,99  37  41  0,254545455  3,88 
2  VKDREQFVDDLEQA  2149,1421  0,0438  53,02  27  43  -1,15  3,84 
2  KADRDESSPY  1624,8462  -0,0087  42,62  28  42  -2,16  4,3 
2  IYEVAPG  976,5432  -0,0199  48,03  28  42  0,528571429  3,3 
2  RNPSDITQEEYNA  1764,8481  0,0065  40,24  27  40  -1,815384615  3,82 
2  ILDEFYDRA  1369,7081  -0,016  48,49    40  -0,377777778  3,7 
2  DATNENFRLV  1406,7357  -0,0148  61,1    41  -0,66  4,08 
2  PWFGILEA  1160,6433  -0,0217  41,03  30  41  0,8125  3,3 
2  IYNNLFDWI  1425,7495  0,0418  43,87    41  0,322222222  3,1 
2  KSPNDYDDRQV  1793,9314  -0,009  46,42  27  42  -2,309090909  4,18 
2  TYQERDPA  1207,6036  -0,0165  41,56  25  40  -2,1  4,08 
2  ATYQERDPA  1278,6407  -0,016  43,73  27  40  -1,666666667  4,08 
2  SLREELLFPFAPI  1760,0075  -0,0077  85,54    42  0,6  4,26 
2  NIDVKDQKAVDDFLIS  2506,4251  -0,0127  73,69  30  43  -0,2375  3,88 
2  YHYPEIEDLVDRI  1889,9726  0,0649  69,62  31  43  -0,684615385  4,06 
2  DLKEDITDFDKL  2138,2079  0,0134  64,36  32  42  -0,925  3,76 
2  KSEPQQPEDNAETA  2001,0056  -0,0418  74,57  27  40  -2,107142857  3,68  
 
2  SQEEGEDNGGEDNKKLRGA  2719,3981  0,0076  51,93  33  43  -2,136842105  4,12 
2  DISRNINDLLNKDFY  2297,2421  0,0517  71,73  31  43  -0,806666667  4,18 
2  ETFEQPSQREEA  1678,8001  -0,0075  66,61    39  -2  3,8 
2  FGKEEETSVGDRL  1924,0307  -0,0107  44,83  26  42  -1,069230769  4,16 
2  FTKDQVNDDQLKNIT  2465,3734  0,0217  47,77  33  43  -1,226666667  4,18 
2  TIIEPKEEEPI  1755,0071  -0,0001  65,58  40  41  -0,754545455  3,8 
2  RVVPNEKADDDSVTII  2228,2418  0,0336  43,2  25  42  -0,35  3,96 
2  RNPSDITQEEYNA  1764,8481  0,0065  40,24  27  40  -1,815384615  3,82 
2  EDQVAEEERRA  1559,7742  -0,0282  50,6  34  39  -2,018181818  4 
2  FVNDIFERI  1380,7604  0,0146  47,12  32  42  0,422222222  4,08 
2  RDYNHSTDEEYQ  1784,7804  -0,0337  38,55  21  33  -2,733333333  4,06 
2  NAPIEEKPLI  1580,9543  0,051  54,68  31  37  -0,3  4,26 
2  GNYEGKGGDEA  1553,7727  -0,0302  53,28  26  40  -1,727272727  3,82 
2  TYQERDPA  1207,6036  -0,0165  41,56  25  40  -2,1  4,08 
2  ATYQERDPA  1278,6407  -0,016  43,73  27  40  -1,666666667  4,08 
2  VITGESR  989,5708  -0,0106  58,88    42  -0,171428571  6,98 
2  DVSEDKEAQRPA  1801,9576  -0,0321  58,67  36  42  -1,708333333  4,06 
2  KEILSILDR  1543,9703  -0,0335  56,29    40  0,044444444  6,92 
2  IGSFKDWEFF  1732,9231  -0,0347  55,14  28  42  -0,01  4,08 
2  VLREGLEAV  1213,7233  0,0521  43,29  28  38  0,655555556  4,26 
2  REELEELVKPL  1812,0762  -0,0183  57,69    41  -0,763636364  4,26 
2  KEEPEEQEQLRES  2088,074  -0,0192  46,27  31  42  -2,692307692  3,96 
2  VAQDVNGERQQ  1471,7582  -0,0246  50,09  32  40  -1,427272727  4,08 
2  GPWYNEPL  1203,6127  0,0325  45,96  33  42  -1,125  3,3 
2  RQNDYDSQ  1253,5839  0,0109  41,15  30  39  -3,0125  3,88 
2  RNDNLDDKSTV  1733,9314  0,0171  44,23  32  42  -1,763636364  4,18 
2  NMESNESPRNVPI  1714,8511  0,0243  48,43  25  41  -1,246153846  4,26 
2  KDIQTIPEEERTEPVPEGY  2687,4059  -0,0387  48,41  34  42  -1,452631579  3,88 
2  VIERKFDIDEELV  2062,1716  -0,0202  47,33  30  43  -0,146153846  3,92 
2  IFFFYPETA  1362,7063  -0,0188  47,07  29  41  0,844444444  3,3  
 
2  EDGGEDSNSRRYPS  1796,8128  -0,0247  47,02  27  36  -2,328571429  4,06 
2  FIWQEFA  1168,612  0,0022  46,83  38  41  0,571428571  3,3 
2  FYGILNAR  1181,676  0,0494  41,17    39  0,4  9,84 
2  YYFGQEG  1091,5127  -0,0177  45,36  31  37  -1,085714286  3,3 
2  GNSIISLEALDAI  1543,866  0,0708  44,14    40  0,938461538  3 
2  LFEQFDRL  1295,7077  0,0498  49,01    41  -0,225  4,08 
2  EYDIYSPEDNYKRV  2248,1417  -0,0091  42,21  22  42  -1,678571429  4,06 
2  KREREDDDEPA  1816,9321  -0,0402  43,35  33  41  -3,063636364  4,06 
2  IYNNLFDWI  1425,7495  0,0418  43,87    41  0,322222222  3,1 
2  IYNNLFDWI  1425,7495  0,0418  43,87    41  0,322222222  3,1 
2  IAREIL  942,6065  -0,0122  41,86    39  1,1  6,98 
2  IAREII  942,6065  -0,0122  41,86    39  1,216666667  6,98 
                 
3  LAGVEIL  942,5953  -0,0091  49,59    39  2,028571429  3,3 
3  GFVQEFQ  1082,56  0,0075  52,69  34  41  -0,157142857  3,3 
3  SLTENWLI  1203,6702  0,018  53,7    42  0,3375  3,3 
3  EFHPFDPV  1215,6127  0,001  42,04  33  40  -0,45  4,06 
3  RDGQLVEIPA  1325,7506  -0,0154  65,9  29  41  -0,27  4,08 
3  GEARPVPEEY  1374,6982  0,0318  45,81  27  42  -1,39  3,96 
3  DVHENYENKVA  1774,9255  0,0438  73,02  36  42  -1,427272727  4,42 
3  ADEKESLVVKFV  2050,2283  -0,0295  53,79  35  42  0,158333333  4,44 
3  EEDHPIPEDVHENYENKVA  2721,3288  -0,0281  57,7  23  40  -1,663157895  4,02 
3  LAGVEIL  942,5953  -0,0091  49,59    39  2,028571429  3,3 
3  SLTENWLI  1203,6702  0,018  53,7    42  0,3375  3,3 
3  EFHPFDPV  1215,6127  0,001  42,04  33  40  -0,45  4,06 
3  DVHENYENKVA  1774,9255  0,0438  73,02  36  42  -1,427272727  4,42 
3  EEDHPIPEDVHENYENKVA  2721,3288  -0,0281  57,7  23  40  -1,663157895  4,02 
3  GGIGTVPV  927,5593  -0,0222  41,3  27  39  1,175  6,02 
3  GGVGEFEA  993,497  -0,0133  54,76  33  40  0,075  3,12 
3  AGGVGEFEA  1064,5341  -0,0208  69,68    40  0,266666667  3,12  
 
3  AGGVGEFEAGIS  1321,6717  -0,0117  58,78  28  41  0,475  3,12 
3  DAIEQPSRPT  1341,7091  -0,0141  51,93    41  -1,34  4,08 
3  EMHHEQLEQ  1408,6608  -0,0225  61,16  28  37  -2,022222222  4,52 
3  IDAIEQPSRPT  1454,7932  -0,0149  50,4  35  42  -0,809090909  4,08 
3  ELLEKNDR  1473,8557  -0,0289  43,23    42  -1,85  4,44 
3  RFDELLEK  1506,8811  -0,0071  42,3  37  42  -1,0625  4,44 
3  KTLLEAIDAI  1543,9591  -0,0187  61,98    40  0,86  4,08 
3  RFDELLEKN  1620,9241  0,0319  44,88  35  41  -1,333333333  4,44 
3  RFDELLEKNDR  1892,0521  0,0119  53,36  40  42  -1,818181818  4,56 
3  DAIEQPSRPTDKPL  2024,1308  -0,0488  52,2  35  43  -1,328571429  4,3 
3  EMHHEQLEQGVPGDNV  2046,9632  0,0346  45,99  29  41  -1,2  4,14 
3  FFYYGT  1025,5061  -0,0184  39,64  29  39  0,316666667  5,86 
3  AFGGFVFG  1029,5487  0,0233  42,67  27  41  1,65  6,02 
3  FVFGWDTG  1156,5756  0,0271  47,92    40  0,4875  3,1 
3  GFVFGWDTG  1213,5971  0,0113  59,07  34  40  0,388888889  3,1 
3  MWEEGVLPW  1374,6845  -0,0214  53,89  35  39  -0,1  3,12 
3  LAGVEAEKL  1386,8488  0,0295  64,33    39  0,455555556  4,26 
3  YGEGEEHEPVVEIPKRPA  2493,3269  -0,0451  115,92  32  43  -1,183333333  4,42 
3  FFYYGT  1025,5061  -0,0184  39,64  29  39  0,316666667  5,86 
3  AFGGFVFG  1029,5487  0,0233  42,67  27  41  1,65  6,02 
3  FVFGWDTG  1156,5756  0,0271  47,92    40  0,4875  3,1 
3  GFVFGWDTG  1213,5971  0,0113  59,07  34  40  0,388888889  3,1 
3  MWEEGVLPW  1374,6845  -0,0214  53,89  35  39  -0,1  3,12 
3  LAGVEAEKL  1386,8488  0,0295  64,33    39  0,455555556  4,26 
3  YGEGEEHEPVVEIPKRPA  2493,3269  -0,0451  115,92  32  43  -1,183333333  4,42 
3  TGGQAFPQ  1033,5396  0,0113  53,7    42  -0,6875  6,02 
3  LLEKLEIV  1413,9212  0,0073  38,44    37  1,15  4,26 
3  DTRKDEQERGI  1803,9845  0,0097  50,1  37  42  -2,454545455  4,56 
3  TKEGPIFGEEMR  1850,9966  -0,0085  68,43  36  42  -1,066666667  4,56 
3  NKDTDAEGKPL  1874,0718  -0,0089  58,42  31  42  -1,718181818  4,3  
 
3  KEGPIFGEEMRSV  1936,0494  0,0405  47,26  29  42  -0,669230769  4,56 
3  TKEGPIFGEEMRS  1938,0286  -0,0133  60,07  31  42  -1,046153846  4,56 
3  TNKDTDAEGKPL  1975,1194  -0,0123  50,93  27  42  -1,633333333  4,3 
3  TKEGPIFGEEMRSV  2037,097  0,0433  58,8  29  43  -0,671428571  4,56 
3  HGMKEEVPGWQEY  2047,0239  0,0094  86,25  27  42  -1,507692308  4,54 
3  KGDEKDLEGKA  2105,2503  -0,0021  46,46  29  41  -1,9  4,56 
3  KDTDAEGKPLERA  2116,2096  0,0305  49,02  28  42  -1,661538462  4,56 
3  LKGDEKDLEGK  2147,2973  -0,0465  48,98  30  42  -1,718181818  4,56 
3  LKGDEKDLEGKA  2218,3344  -0,0437  64,79  33  42  -1,425  4,56 
3  NKDTDAEGKPLERA  2230,2526  0,0859  62,79  29  41  -1,792857143  4,56 
3  TNKDTDAEGKPLERA  2331,3002  0,0714  49,75  26  42  -1,72  4,56 
3  HGMKEEVPGWQEYYDKL  2795,4561  -0,0356  47,97  31  43  -1,441176471  4,62 
3  FFYYGT  1025,5061  -0,0184  39,64  29  39  0,316666667  5,86 
3  AFGGFVFG  1029,5487  0,0233  42,67  27  41  1,65  6,02 
3  FVFGWDTG  1156,5756  0,0271  47,92    40  0,4875  3,1 
3  GFVFGWDTG  1213,5971  0,0113  59,07  34  40  0,388888889  3,1 
3  FFYYGT  1025,5061  -0,0184  39,64  29  39  0,316666667  5,86 
3  AFGGFVFG  1029,5487  0,0233  42,67  27  41  1,65  6,02 
3  FVFGWDTG  1156,5756  0,0271  47,92    40  0,4875  3,1 
3  GFVFGWDTG  1213,5971  0,0113  59,07  34  40  0,388888889  3,1 
3  FFYYGT  1025,5061  -0,0184  39,64  29  39  0,316666667  5,86 
3  AFGGFVFG  1029,5487  0,0233  42,67  27  41  1,65  6,02 
3  FVFGWDTG  1156,5756  0,0271  47,92    40  0,4875  3,1 
3  GFVFGWDTG  1213,5971  0,0113  59,07  34  40  0,388888889  3,1 
3  IQVFEGERA  1276,6978  -0,0078  56,01  40  42  -0,233333333  4,26 
3  KEEDEKESQRIA  2148,1994  0,0528  47,14  41  42  -2,316666667  4,36 
3  EFKGETKNFTPEQI  2354,309  0,0353  61,69  27  42  -1,328571429  4,56 
3  EFKGETKNFTPEQIS  2441,3411  -0,0077  68,2  26  43  -1,293333333  4,56 
3  EKFKEEDEKESQRIA  2781,5683  -0,0577  64,34  32  43  -2,16  4,5 
3  IQVFEGERA  1276,6978  -0,0078  56,01  40  42  -0,233333333  4,26  
 
3  KEEDEKESQRIA  2148,1994  0,0528  47,14  41  42  -2,316666667  4,36 
3  EFKGETKNFTPEQI  2354,309  0,0353  61,69  27  42  -1,328571429  4,56 
3  EFKGETKNFTPEQIS  2441,3411  -0,0077  68,2  26  43  -1,293333333  4,56 
3  EKFKEEDEKESQRIA  2781,5683  -0,0577  64,34  32  43  -2,16  4,5 
3  FFYYGT  1025,5061  -0,0184  39,64  29  39  0,316666667  5,86 
3  FFSEYGCNEVTPR  1776,8344  -0,044  70,06  27  37  -0,576923077  4,26 
3  GYSSNDDEDTRVKMT  2175,052  0,0646  51,3  25  42  -1,633333333  3,96 
3  FYGIIDLI  1181,6899  0,0234  60,05    39  1,8625  3,1 
3  GIFYGIIDLI  1351,7954  -0,0259  73,69  36  42  1,9  3,1 
3  FFAGNEVI  1124,6069  -0,0136  52,71    41  1,0875  3,3 
3  SRPFTEIEAI  1390,7659  0,0237  52,41  34  42  -0,1  4,26 
3  DFENLKNEYSKV  2172,2035  0,0615  58,1  25  42  -1,383333333  4,44 
3  TDFENLKNEYSKV  2273,2512  0,044  63,31  29  42  -1,330769231  4,44 
3  FFYYGT  1025,5061  -0,0184  39,64  29  39  0,316666667  5,86 
3  AFGGFVFG  1029,5487  0,0233  42,67  27  41  1,65  6,02 
3  FVFGWDTG  1156,5756  0,0271  47,92    40  0,4875  3,1 
3  GFVFGWDTG  1213,5971  0,0113  59,07  34  40  0,388888889  3,1 
3  KQIIIDAESA  1544,9179  0,0072  67,15    41  0,19  4,08 
3  FFYYGT  1025,5061  -0,0184  39,64  29  39  0,316666667  5,86 
3  FFYYGT  1025,5061  -0,0184  39,64  29  39  0,316666667  5,86 
3  FFYYGT  1025,5061  -0,0184  39,64  29  39  0,316666667  5,86 
3  ELDWMERELPKKG  2317,3072  -0,0088  50,49  29  43  -1,515384615  4,64 
3  QSELDWMERELPKKG  2532,3978  -0,0143  49,01  29  43  -1,6  4,64 
3  FYGIIDLL  1181,6899  0,0234  60,05    39  1,775  3,1 
3  FFYYGT  1025,5061  -0,0184  39,64  29  39  0,316666667  5,86 
3  KIPVLEQELV  1625,0169  -0,0277  46,22  30  39  0,45  4,26 
3  LSDFFDGKQLEKS  2200,2348  -0,0488  64,05  28  43  -0,815384615  4,3 
3  HHHATDDVEDAAPETKEA  2430,1817  0,013  106,46  34  41  -1,45  4,36 
3  LSDFFDGKQLEKS  2200,2348  -0,0488  64,05  28  43  -0,815384615  4,3 
3  GRRFEDAEVQ  1434,7418  0,0089  48,78  31  42  -1,46  4,44  
 
3  IGRRFEDAEVQ  1547,8259  -0,0213  49,28  27  42  -0,918181818  4,44 
3  SFGSLQ  866,4701  -0,0117  41,34    41  0,183333333  6,02 
3  NNIIVSDTTLESVEGFSTLKKV  3080,7578  0,0763  124,06  38  41  0,081818182  4,44 
3  SFGSLQ  866,4701  -0,0117  41,34    41  0,183333333  6,02 
3  NNIIVSDTTLESVEGFSTLKKV  3080,7578  0,0763  124,06  38  41  0,081818182  4,44 
3  KVLEELF  1334,8215  0,0286  43,41    38  0,528571429  4,26 
3  LKEFEGGVI  1448,8645  -0,0335  51,85    42  0,4  4,26 
3  KVLEELFQ  1462,8801  0,0209  50,14    40  0,025  4,26 
3  KDILDEFR  1492,8655  -0,0008  48,63  34  42  -0,975  4,3 
3  LKEFEGGVIII  1675,0326  0,0448  87,62    38  1,145454545  4,26 
3  NELLKDETVAPR  1842,0616  -0,0427  81,35    42  -0,925  4,44 
3  NQVADEKERA  1616,8887  -0,0185  59,61  33  42  -1,81  4,44 
3  ALPWFWEHYNPE  1816,8776  0,0451  59,84  30  41  -0,966666667  4,24 
3  NGEDKEIVDGKVLK  2459,4771  -0,0128  56,17  34  41  -0,95  4,56 
3  RYHIEEEGS  1347,6622  -0,0028  45,14  24  40  -1,8  4,54 
3  AGFLLEKEL  1476,8957  0,0037  53,21  39  41  0,522222222  4,26 
3  VWNGPPGVFEFEK  1963,0609  -0,0083  82,28  32  43  -0,407692308  4,26 
3  WNGPPGVFEFEKF  2011,0609  0,0424  52,4  30  42  -0,515384615  4,26 
3  VWNGPPGVFEFEKF  2110,1294  -0,002  89,92  35  43  -0,178571429  4,26 
3  VWNGPPGVFEFEKFA  2181,1665  -0,0131  78,17  41  43  -0,046666667  4,26 
3  KKGEQELEGL  1817,0867  -0,025  47,55  37  42  -1,5  4,56 
3  VKKGEQELEGL  1916,1551  0,0035  61,48  33  40  -0,981818182  4,56 
3  VIVKKGEQELEGL  2128,3076  -0,0499  57,62  29  41  -0,161538462  4,56 
3  ALDSNNERLKESV  1932,0682  -0,0413  46,58  32  42  -1,069230769  4,44 
3  NYKEESKEQA  1912,051  0,0195  62,39  27  42  -2,56  4,56 
3  SPNAKKEYEPEST  2166,1777  0,0443  59,97  24  42  -2,061538462  4,56 
3  EEAEQPKTDYKKI  2494,4454  -0,0531  49,18  26  43  -2,038461538  4,64 
3  LQKERELDVI  1700,0238  0,0351  43,12  32  39  -0,61  4,44 
3  READVFKNGEMPFPI  2207,1814  -0,0037  46,56  30  43  -0,533333333  4,44 
3  RANQEVLEWL  1485,8142  -0,0113  53,49  38  41  -0,58  4,26  
 
3  GRRFEDAEVQ  1434,7418  0,0089  48,78  31  42  -1,46  4,44 
3  IGRRFEDAEVQ  1547,8259  -0,0213  49,28  27  42  -0,918181818  4,44 
3  LFLPPVAV  1083,6895  -0,0241  40,16  34  38  2,175  6,02 
3  ALPWFWEHYNPE  1816,8776  0,0451  59,84  30  41  -0,966666667  4,24 
3  LHGEGSGEEKG  1556,82  -0,0103  69,78    41  -1,472727273  4,54 
3  KIQDKEGIPPDQQ  2182,2566  -0,0156  58,6  27  42  -1,8  4,3 
3  LHGEGSGEEKG  1556,82  -0,0103  69,78    41  -1,472727273  4,54 
3  LHAEQDAEVRQQ  1651,8481  -0,0185  82,95  36  41  -1,425  4,42 
3  FFYYGT  1025,5061  -0,0184  39,64  29  39  0,316666667  5,86 
3  LGGGSSDRREEYPVPDAPPYRA  2617,3087  -0,038  55,77  26  41  -1,259090909  4,56 
3  NYKEENKEQA  1939,0619  0,0025  62,77  33  42  -2,83  4,56 
3  ELPKVEDLKI  1870,1748  -0,0447  51,47  39  40  -0,36  4,44 
3  AETKEPTKEPT  1917,1027  0,0055  59,23  31  42  -1,981818182  4,56 
3  WVMDTNKEERNDGKTI  2622,4044  0,0421  63,96  30  43  -1,5875  4,56 
3  REVLGEQGKDV  1686,967  -0,0148  57,19  28  42  -1  4,44 
3  VFPFVFEKEPV  1795,0326  -0,0368  65,5  26  42  0,627272727  4,26 
3  KHEEIDT  1328,7342  -0,0095  45,27  34  41  -1,971428571  4,42 
3  KELNPDITDETNEGKTGPKLV  3213,8268  0,0754  45,2  21  41  -1,238095238  4,28 
3  KHEEIDT  1328,7342  -0,0095  45,27  34  41  -1,971428571  4,42 
3  SHMSPEDAEEELKKL  2429,308  0,0055  56,79  28  43  -1,36  4,36 
3  EAPQLKDEYRTY  1970,0515  -0,0519  42,26  28  42  -1,808333333  4,44 
3  HAEQFPFEKDVNVV  2116,1359  -0,0163  78,72  31  42  -0,442857143  4,42 
3  KFHTENAEDQDRV  2046,0536  0,0261  45,94  27  42  -1,884615385  4,54 
3  VGNKSDLENEKQV  2146,2202  -0,0374  46,68  30  43  -1,369230769  4,44 
3  KEVEEKLGENPKIT  2529,5189  -0,0151  56,69    41  -1,385714286  4,72 
3  KKDYSIDSIE  1884,0813  -0,0405  45,87  28  42  -1,22  4,3 
3  ILDQEKYDRI  1750,0031  0,0274  43,35  27  41  -1,09  4,3 
3  VILDQEKYDRI  1849,0715  0,039  42,76  27  41  -0,609090909  4,3 
3  LYKYEIDIA  1584,9169  -0,0421  63,65  37  42  0,122222222  4,08 
3  MEEHFNPSTGEKT  1963,9715  -0,0072  49,64  29  41  -1,584615385  4,54  
 
3  LDNQEEGKKS  1834,0405  0,0237  44,93  29  42  -2,27  4,44 
3  KWEPAGEV  1372,7756  -0,0252  46,97  33  41  -0,975  4,26 
3  LLKEEKFPDVL  2017,2432  0,0112  61,98  35  39  -0,136363636  4,44 
3  FFYYGT  1025,5061  -0,0184  39,64  29  39  0,316666667  5,86 
3  RYVFDIHPEDVL  1730,9195  -0,0315  41,44  25  41  -0,133333333  4,3 
3  KALQEDHENSSPF  1959,0103  -0,0386  93,6  28  41  -1,492307692  4,42 
3  SFDVFIPEFGIEKRV  2240,2611  0,0211  42,36  37  42  0,273333333  4,44 
3  LVKKDELTLEGI  2044,2752  -0,0437  49,77  31  41  0,058333333  4,44 
3  KLFEQEGV  1406,8175  0,0137  49,95    42  -0,5  4,26 
3  LVEFGKEIL  1504,927  0,0328  52,03    39  0,866666667  4,26 
3  STGKDYKGEADPG  2011,0831  0,0124  55,26  37  42  -1,7  4,3 
3  KFDDVDGKPLVEKI  2518,5182  -0,0394  44,73  24  42  -0,585714286  4,46 
3  TLKDEHDLERA  1783,9834  -0,0009  47,67  25  42  -1,536363636  4,54 
3  RANQEVLEWL  1485,8142  -0,0113  53,49  38  41  -0,58  4,26 
3  LKDILGDQVEKV  2043,2548  -0,045  55,53  30  41  -0,141666667  4,3 
3  FFDTEKKIEIA  2027,1911  -0,0393  43,95  35  42  -0,236363636  4,44 
3  FFDTEKKIEIA  2027,1911  -0,0393  43,95  35  42  -0,236363636  4,44 
3  DKYDENNPEHR  1873,9324  -0,0353  46,6  24  40  -3,227272727  4,54 
3  VHDKILEDLVFPT  1983,1447  0,0337  75,42  30  41  0,261538462  4,3 
3  NVSKDELREKLAEV  2316,3621  0,0122  55,7  31  41  -0,914285714  4,64 
3  LKVEDFLER  1605,9496  -0,0343  50,18  28  42  -0,477777778  4,44 
3  LKVEDFLER  1605,9496  -0,0343  50,18  28  42  -0,477777778  4,44 
3  EAEKKGIEA  1660,9968  0,0119  51,01  34  41  -1,177777778  4,56 
3  EAEKKGIEAA  1732,0339  0,009  46,76  34  41  -0,88  4,56 
3  KKQEELDA  1646,9811  0,0483  50,45    39  -2,025  4,44 
3  FAGEESGDLPFRKG  1967,0518  0,0203  59,22  30  42  -0,807142857  4,44 
3  SNVEEKPGDRG  1644,8837  -0,0299  41,55  31  41  -1,945454545  4,44 
3  SNVEEKPGDRGALA  1900,042  0,0436  54,06  39  42  -1  4,44 
3  DLRDDKVIIEKL  2143,3185  -0,0449  47,76  32  41  -0,458333333  4,46 
3  KWTGIPVGEEDRV  1943,0882  0,0266  43,6  29  42  -0,769230769  4,44  
 
3  IQQDLLDEKRFA  1933,1038  0,0055  53,49  35  42  -0,766666667  4,3 
3  KEILSILDR  1543,9703  -0,0299  41,36    40  0,044444444  6,92 
3  GSRTPGHPEFELPGVEVT  2137,1007  0,043  52,8  25  43  -0,633333333  4,54 
3  YFDFKYDVEKA  2111,1548  -0,0484  55,55  25  43  -0,845454545  4,3 
3  GHGLKEIDVEFI  1814,0344  -0,0368  46,37  27  42  0,116666667  4,42 
3  FFYYGT  1025,5061  -0,0184  39,64  29  39  0,316666667  5,86 
3  FNQKSETTLDTTPEAESVPEKRA  3264,7446  -0,0537  50,4  33  43  -1,304347826  4,36 
3  TLNEESKDKV  1849,0765  -0,03  43,6  30  42  -1,53  4,44 
3  FYGILNAR  1181,676  0,0373  39,72    39  0,4  9,84 
3  TKLPNFNEVSPEERIPL  2440,3731  -0,0499  44,97  25  43  -0,770588235  4,56 
3  SFGSLQ  866,4701  -0,0117  41,34    41  0,183333333  6,02 
3  KFDDVDGKPLVEKI  2518,5182  -0,0394  44,73  24  42  -0,585714286  4,46 
3  ELLEKNDR  1473,8557  -0,0289  43,23    42  -1,85  4,44 
                 
4  LHLEIF  999,5956  0,0022  41,29    39  1,366666667  5,12 
4  MFFVGPI  1038,5775  0,0058  42,51  26  41  2,028571429  6,02 
4  NFGAMNGI  1051,5323  0,0019  51,6  37  41  0,4  6,02 
4  FHPFDPV  1086,5701  0,0088  43,34  29  40  -0,014285714  4,94 
4  LHLEIFLG  1169,7011  0,0365  42,76  23  38  1,45  5,12 
4  QNFGAMNGI  1179,5909  -0,0125  42,57  36  40  -0,033333333  6,02 
4  RDGQLVEIPA  1325,7506  -0,0123  41,31  29  41  -0,27  4,08 
4  DKHYGDQT  1420,7352  -0,0157  45,36  31  41  -2,5  5,1 
4  VDKHYGDQTF  1666,8721  0,0154  50,47  27  42  -1,3  5,1 
4  YDNAPYSPKPV  1707,9238  0,0122  69,95  25  42  -1,190909091  6,56 
4  AYDNAPYSPKPV  1778,9609  0,0012  68,44  30  42  -0,941666667  6,56 
4  MTGDGVNDAPSLKKA  2190,2287  0,0052  48,25  35  43  -0,58  6,72 
4  LHLEIF  999,5956  0,0022  41,29    39  1,366666667  5,12 
4  MFFVGPI  1038,5775  0,0058  42,51  26  41  2,028571429  6,02 
4  FHPFDPV  1086,5701  0,0088  43,34  29  40  -0,014285714  4,94 
4  LHLEIFLG  1169,7011  0,0365  42,76  23  38  1,45  5,12  
 
4  MTGDGVNDAPSLKKA  2190,2287  0,0052  48,25  35  43  -0,58  6,72 
4  GHVDSG  799,4027  -0,0063  41,95  27  37  -0,683333333  4,94 
4  GGIGTVPV  927,5593  -0,0226  46,17  31  40  1,175  6,02 
4  DAPGHRDF  1142,5672  -0,0001  39,7  31  39  -1,5125  5,1 
4  EMHHEQL  1151,5596  0,0031  47,69  29  40  -1,6  5,12 
4  DAPGHRDFI  1255,6512  0,0308  45,14  33  41  -0,844444444  5,1 
4  IDAPGHRDFI  1368,7353  0,0012  46,86  34  41  -0,31  5,1 
4  HHEQLEQGVPG  1458,7418  -0,016  59,73  33  40  -1,345454545  5,12 
4  VIDAPGHRDFI  1467,8037  0,0315  45,29    41  0,1  5,1 
4  RFDELLEKN  1620,9241  0,0438  42,23  38  41  -1,333333333  4,44 
4  RFDELLEKNDR  1892,0521  0,0365  46,98  34  42  -1,818181818  4,56 
4  FGGFVFG  958,5116  0,0189  42,77  37  41  1,628571429  6,02 
4  FGGFVFGW  1144,5909  0,0055  45,87  26  40  1,3125  6,02 
4  NWLWGFL  1163,6331  0,0319  42,29  33  42  0,671428571  6,02 
4  YGEGEEHEPVVEIPKRPA  2493,3269  0,0066  62,36  27  43  -1,183333333  4,42 
4  FGGFVFG  958,5116  0,0189  42,77  37  41  1,628571429  6,02 
4  FGGFVFGW  1144,5909  0,0055  45,87  26  40  1,3125  6,02 
4  NWLWGFL  1163,6331  0,0319  42,29  33  42  0,671428571  6,02 
4  YGEGEEHEPVVEIPKRPA  2493,3269  0,0066  62,36  27  43  -1,183333333  4,42 
4  TGGQAFPQ  1033,5396  0  46,74    42  -0,6875  6,02 
4  QGPNYVPG  1059,5552  -0,0046  50,1  37  41  -1,0125  5,92 
4  HEIKDSVVA  1454,8499  0,0369  55,73  38  39  -0,022222222  5,22 
4  DTRKDEQERGI  1803,9845  0,0199  42,22  33  42  -2,454545455  4,56 
4  DTRKDEQERGITI  2018,1162  0,0347  47,95    42  -1,784615385  4,56 
4  TKEGPIFGEEMRSV  2037,097  0,0786  65,21  30  42  -0,671428571  4,56 
4  LKGDEKDLEGKA  2218,3344  0,0087  45,01  29  40  -1,425  4,56 
4  NKDTDAEGKPLERA  2230,2526  0,0918  44,94  23  41  -1,792857143  4,56 
4  FGGFVFG  958,5116  0,0189  42,77  37  41  1,628571429  6,02 
4  HQGPLEGS  1052,5454  -0,0242  52,03  26  40  -1,2  5,12 
4  FGGFVFGW  1144,5909  0,0055  45,87  26  40  1,3125  6,02  
 
4  NWIWGFL  1163,6331  0,0319  42,29  33  42  0,771428571  6,02 
4  FGGFVFG  958,5116  0,0189  42,77  37  41  1,628571429  6,02 
4  FGGFVFGW  1144,5909  0,0055  45,87  26  40  1,3125  6,02 
4  NWLWGFL  1163,6331  0,0319  42,29  33  42  0,671428571  6,02 
4  APDHPFIQQ  1280,6716  0,0432  44,99  32  42  -0,866666667  4,94 
4  FGGFVFG  958,5116  0,0189  42,77  37  41  1,628571429  6,02 
4  FGGFVFGW  1144,5909  0,0055  45,87  26  40  1,3125  6,02 
4  NWIWGFL  1163,6331  0,0319  42,29  33  42  0,771428571  6,02 
4  YFNDSQRQ  1285,6254  0,0178  52,88  26  40  -2,225  6,7 
4  AGGAPGGFPG  1015,529  0,0178  45,63  27  40  0,12  6,02 
4  YFNDSQRQ  1285,6254  0,0178  52,88  26  40  -2,225  6,7 
4  HFANDRVDII  1427,7724  0,0153  59,36  35  41  -0,04  5,1 
4  NWIWGFL  1163,6331  0,0319  42,29  33  42  0,771428571  6,02 
4  DLFNSYKTV  1543,8652  0,0663  55,48  30  40  -0,322222222  6,6 
4  SNLGWIPV  1113,6385  -0,01  44,96    40  0,6625  6,02 
4  GYHFGPSDA  1178,5559  0,0127  52,52  31  40  -0,733333333  4,94 
4  FIPTLLVPI  1240,7998  0,0278  36,69  30  34  2,188888889  6,02 
4  MLAGTPFWQ  1278,6634  0,005  72,19  35  42  0,355555556  6,02 
4  GIFYGIIDLI  1351,7954  0,0074  53,81  34  41  1,9  3,1 
4  LKDLGINTV  1429,891  0,0294  53,05    39  0,477777778  6,66 
4  YTVDNSQDHSH  1530,6902  -0,0098  36,26  26  36  -1,8  4,94 
4  KLYQDYSVPV  1668,9492  0,0495  80,22  34  40  -0,37  6,56 
4  DNSQDHSHCMKLL  1984,9865  0,0185  60,73  28  42  -1,069230769  6 
4  FGGFVFG  958,5116  0,0189  42,77  37  41  1,628571429  6,02 
4  FGGFVFGW  1144,5909  0,0055  45,87  26  40  1,3125  6,02 
4  NWIWGFL  1163,6331  0,0319  42,29  33  42  0,771428571  6,02 
4  GHQQSESLPQ  1338,6731  -0,022  70,8  36  40  -1,7  5,12 
4  YFNDSQRQ  1285,6254  0,0178  52,88  26  40  -2,225  6,7 
4  NHLAEVA  981,5446  0,0047  54,98    40  0,2  5,12 
4  SHANQDYY  1225,5566  -0,0154  45,54  28  36  -1,9125  4,94  
 
4  GYCQQQDLHLKTA  1962,0399  0,0249  69,43  31  43  -0,892307692  7,14 
4  SNLGWIPV  1113,6385  -0,01  44,96    40  0,6625  6,02 
4  IAPNLFMSI  1233,6994  0,0005  48,82  32  42  1,488888889  6,02 
4  AIAPNLFMSI  1304,7365  0,0203  57,49  35  42  1,52  6,02 
4  YFNDSQRQ  1285,6254  0,0178  52,88  26  40  -2,225  6,7 
4  DMFGIVVPR  1261,7056  -0,0105  45,11  26  42  0,844444444  6,78 
4  LSDFFDGKQLEKS  2200,2348  0,0143  42,14  23  42  -0,815384615  4,3 
4  DIFGIVVPR  1243,7492  -0,0027  45,84  28  41  1,133333333  6,78 
4  LSDFFDGKQLEKS  2200,2348  0,0143  42,14  23  42  -0,815384615  4,3 
4  YFNDSQRQ  1285,6254  0,0178  52,88  26  40  -2,225  6,7 
4  SFGSLQTV  1066,5862  -0,0086  65,01  34  41  0,575  6,02 
4  SFGSLQTV  1066,5862  -0,0086  65,01  34  41  0,575  6,02 
4  HKCPPDANPA  1506,8019  -0,0116  44,73  19  42  -1,28  7,14 
4  AHKCPPDANPA  1577,839  -0,0102  55,86  30  42  -1  7,14 
4  GYCQQQDLHLKTA  1962,0399  0,0249  69,43  31  43  -0,892307692  7,14 
4  NELLKDETVAPR  1842,0616  -0,0051  46,15  32  42  -0,925  4,44 
4  SGPQSYQ  994,4923  -0,0157  48,42  26  40  -1,7  5,92 
4  YYGYGGTT  1109,5232  0,0247  58,83  32  40  -0,8125  5,82 
4  QQGPPQQG  1067,5563  0,006  42,14  34  41  -2,25  6,02 
4  YQQGPPQQG  1230,6196  -0,0244  49,43  25  39  -2,144444444  5,92 
4  YYQQGPPQQG  1393,6829  -0,0106  54,93  29  40  -2,06  5,86 
4  GYYQQGPPQQG  1450,7044  -0,0136  42,13  27  40  -1,909090909  5,86 
4  YYQQGPPQQGYPQ  1781,8576  0,0539  58,15  28  42  -2,076923077  5,82 
4  YYQQGPPQQGYPQQQPV  2234,0959  0,1088  64,16  22  43  -1,847058824  5,82 
4  NQQGYNQQ  1207,5784  0,0117  50,2  34  40  -2,8375  5,92 
4  QQYYQQQ  1213,593  -0,02  44,59  32  39  -2,871428571  5,86 
4  FFEETHHPT  1372,6615  -0,0096  47  28  39  -1,2  5,12 
4  LFFEETHHPT  1485,7455  0,0417  51,73  23  41  -0,7  5,12 
4  YHLFDSFT  1257,6233  -0,0064  50,34    39  -0,0125  4,94 
4  DAQHKDLLTQV  1724,9827  -0,0048  93,7  36  42  -0,745454545  5,1  
 
4  NYKEESKEQA  1912,051  0,0277  47,48  27  42  -2,56  4,56 
4  HLAELAPA  1049,6072  -0,023  49,23  26  42  0,5875  5,12 
4  HIHEFSWENVNPIPELR  2345,2119  0,0121  48,27  26  43  -0,794117647  5,22 
4  IYAPNPF  1049,5749  -0,0021  46,08  31  42  0,157142857  5,92 
4  SHSILTPDGI  1267,6975  0,0036  51,66  29  41  0,18  4,94 
4  NEHGLGGLLQGA  1393,7517  0,0242  81,43  29  42  -0,175  5,12 
4  YFNDSQRQ  1285,6254  0,0178  52,88  26  40  -2,225  6,7 
4  GGGAGMGGMPG  1076,4946  0,008  79,29  30  38  0,109090909  6,02 
4  QFFGGSSPF  1201,5971  -0,0099  43,98  31  39  0,1  6,02 
4  LAWFPG  918,5166  -0,0043  42,82    42  0,916666667  6,02 
4  LFLPPVAV  1083,6895  -0,0001  42,48  34  36  2,175  6,02 
4  LSLFLPPVAV  1283,8056  -0,0056  58  30  38  2,04  6,02 
4  AGGLILPF  1015,6269  0,0199  40,93    40  1,7875  6,02 
4  YGHIDVL  1044,5807  0,0106  48  39  41  0,585714286  4,94 
4  NFHGMDFT  1196,5488  -0,0019  47,82  26  38  -0,475  4,94 
4  NFHGMDFT  1196,5488  -0,0019  47,82  26  38  -0,475  4,94 
4  NLPEHIVPG  1203,6815  -0,0186  70,7  39  42  -0,144444444  5,12 
4  NLPEHIVPG  1203,6815  -0,0186  70,7  39  42  -0,144444444  5,12 
4  DNFNTHI  1088,5454  0,0045  42,32  30  40  -1,014285714  4,94 
4  FDFGGFHI  1167,5916  0,0319  44,46  29  41  0,675  4,94 
4  VFDFGGFHI  1266,66  0,021  64,42  41  42  1,066666667  4,94 
4  HKCPPDANPA  1506,8019  -0,0116  44,73  19  42  -1,28  7,14 
4  AHKCPPDANPA  1577,839  -0,0102  55,86  30  42  -1  7,14 
4  GYCQQQDLHLKTA  1962,0399  0,0249  69,43  31  43  -0,892307692  7,14 
4  QNIKEVEEKLGENPKIT  2884,7045  0,1331  62,6  21  36  -1,288235294  4,72 
4  YVQQQPA  1061,5708  -0,027  41,37  34  41  -1,057142857  5,92 
4  YYQQQQPQ  1310,6458  -0,0233  59,7    39  -2,7125  5,86 
4  GYTHDGSFQ  1239,5723  0,002  67,99    38  -1,222222222  4,94 
4  WHGDWPLPV  1334,6975  0,0183  47,56  26  42  -0,455555556  4,94 
4  AWHGDWPLPV  1405,7346  0,0147  53,17  23  42  -0,23  4,94  
 
4  GYTHDGSFQ  1239,5723  0,002  67,99    38  -1,222222222  4,94 
4  WHGDWPLPV  1334,6975  0,0183  47,56  26  42  -0,455555556  4,94 
4  AWHGDWPLPV  1405,7346  0,0147  53,17  23  42  -0,23  4,94 
4  LIEHQPRVDPL  1544,8878  0,0255  45,4  25  41  -0,463636364  5,22 
4  GHWNLELNPT  1408,7302  0,0272  93,78    42  -0,97  5,12 
4  LVQDLLHPT  1263,739  -0,0232  46,46  31  42  0,344444444  4,94 
4  VLVQDLLHPT  1362,8074  -0,0115  53,66  26  42  0,73  4,94 
4  HYFTGDGAGRDHDGY  1895,839  0,0758  47,19  27  40  -1,446666667  5,02 
4  HWQPGVDSA  1224,609  0,0335  42,3  30  41  -0,877777778  4,94 
4  QHLGENTV  1125,5981  -0,004  42,57  35  41  -0,85  5,12 
4  HIKDSLDNT  1499,8349  0,0538  43,47  28  41  -1,2  5,1 
4  FGGTLNPG  990,5338  -0,0174  61,35    41  -0,05  6,02 
4  APVVGQPQPT  1221,692  0,0059  56,9  26  42  -0,27  6,02 
4  SHEMFNPF  1236,58  0,0232  44,03  29  40  -0,6375  5,12 
4  QHSQDFSPW  1359,6411  -0,0083  41,28  22  38  -1,666666667  4,94 
4  QHSQDFSPWYG  1579,7259  0,0037  66,36  29  38  -1,518181818  4,94 
4  FGGTLNPG  990,5338  -0,0174  61,35    41  -0,05  6,02 
4  SHDDKHIIIDGV  1806,0042  0,0012  55,09  40  42  -0,358333333  5,02 
4  HFLLDVL  1084,6484  0,0316  46,1  37  38  1,671428571  4,94 
4  KHFNDPDAPPILL  1934,1031  0,0054  74,95  36  42  -0,438461538  5,1 
4  THFKDVSTEDDETRKL  2607,4113  0,0171  47,75  37  43  -1,56875  4,62 
4  GYTHDGSFQ  1239,5723  0,002  67,99    38  -1,222222222  4,94 
4  DAPGHRDF  1142,5672  -0,0001  39,7  31  39  -1,5125  5,1 
4  YHGEQIA  1045,5395  -0,0036  42,65  32  41  -0,8  5,12 
4  HQLNPDFI  1211,6502  0,0109  51,83  38  41  -0,525  4,94 
4  NIPPFDHPYVIA  1610,866  0,006  67,12  35  42  0,125  4,94 
4  KETEEEPKKA  2104,2551  0,0547  46,97  31  39  -2,62  4,72 
4  GWGNSGGSNNS  1264,5635  -0,0131  44,41  26  35  -1,4  6,02 
4  SWINNVAL  1144,6443  -0,0136  44,05  33  41  0,7  6,02 
4  HLYDIFSPI  1332,7281  0,0251  48,36  26  42  0,577777778  4,94  
 
4  NHFIEGL  1057,5759  0,009  40,94  33  40  0,071428571  5,12 
4  HVGPEQVV  1092,6131  0,0255  53,17    41  0,05  5,12 
4  HVGPEQVV  1092,6131  0,0255  53,17    41  0,05  5,12 
4  HVGPEQVV  1092,6131  0,0255  53,17    41  0,05  5,12 
4  HGFGEYT  1038,4974  0,0239  52,38  29  40  -0,957142857  5,12 
4  FHNDVYAQ  1221,5981  0,0373  44,45  27  42  -0,775  4,94 
4  FHLDFGPM  1191,595  0,0071  41,42    41  0,325  4,94 
                 
5  FLAPGLS  932,5534  0,0034  46,42  39  41  1,342857143  6,02 
5  EILQNRG  1057,6083  -0,001  44,1  37  40  -1,014285714  6,98 
5  SIPSWQLA  1129,6334  0,0206  52,71    41  0,3125  6,02 
5  NIYNAERL  1220,6716  -0,0055  44,33  41  42  -0,775  6,88 
5  RGEGHWEIL  1324,7091  0,0115  49,58  27  41  -0,9  5,3 
5  IIQNFGAMNGI  1405,759  -0,0239  69,37  36  42  0,790909091  6,02 
5  STQHEKET  1416,7614  -0,0004  63,21  33  42  -2,475  5,3 
5  DKHYGDQT  1420,7352  -0,0147  42,84  29  41  -2,5  5,1 
5  VDKHYGDQT  1519,8037  -0,0221  51,57  31  42  -1,755555556  5,1 
5  HENYENKVA  1560,8302  -0,0138  57,87  30  42  -1,822222222  5,3 
5  DKHYGDQTF  1567,8037  0,026  47,98  28  42  -1,911111111  5,1 
5  AVDKHYGDQT  1590,8408  -0,0301  61,35  29  41  -1,4  5,1 
5  LAVDKHYGDQT  1703,9248  0,0335  58,05  32  42  -0,927272727  5,1 
5  YDNAPYSPKPV  1707,9238  -0,0052  55,01  26  42  -1,190909091  6,56 
5  DGFAEVFPQHK  1731,935  -0,0066  76,32  37  42  -0,727272727  5,22 
5  AYDNAPYSPKPV  1778,9609  -0,0041  62,01  28  42  -0,941666667  6,56 
5  KVLEFHPFDPV  1785,0231  -0,0278  45,52  29  42  0,045454545  5,22 
5  IAYDNAPYSPKPV  1892,0449  -0,0289  70,82  31  42  -0,523076923  6,56 
5  DGFAEVFPQHKY  1894,9983  0,0281  70,95  33  42  -0,775  5,22 
5  GDGVNDAPSLKKA  1958,1405  0,028  69,74  38  41  -0,761538462  6,72 
5  AIAYDNAPYSPKPV  1963,082  -0,0358  43,47  25  42  -0,357142857  6,56 
5  FLAPGLSAIIDALKT  1987,2123  0,0386  101,04  35  39  1,18  6,66  
 
5  MTGDGVNDAPSLKKA  2190,2287  -0,0288  93,71  34  43  -0,58  6,72 
5  MTGDGVNDAPSLKKA  2206,2236  -0,0302  54,47  27  43  -0,58  6,72 
5  ENADGFAEVFPQHKYRVV  2563,3589  0,0427  57,31  32  43  -0,588888889  5,34 
5  FLAPGLS  932,5534  0,0034  46,42  39  41  1,342857143  6,02 
5  EILQNRG  1057,6083  -0,001  44,1  37  40  -1,014285714  6,98 
5  SIPSWQLA  1129,6334  0,0206  52,71    41  0,3125  6,02 
5  NIYNAERL  1220,6716  -0,0055  44,33  41  42  -0,775  6,88 
5  RGEGHWEIL  1324,7091  0,0115  49,58  27  41  -0,9  5,3 
5  HENYENKVA  1560,8302  -0,0138  57,87  30  42  -1,822222222  5,3 
5  DGFAEVFPQHK  1731,935  -0,0066  76,32  37  42  -0,727272727  5,22 
5  KVLEFHPFDPV  1785,0231  -0,0278  45,52  29  42  0,045454545  5,22 
5  DGFAEVFPQHKY  1894,9983  0,0281  70,95  33  42  -0,775  5,22 
5  GDGVNDAPSLKKA  1958,1405  0,028  69,74  38  41  -0,761538462  6,72 
5  FLAPGLSAIIDALKT  1987,2123  0,0386  101,04  35  39  1,18  6,66 
5  MTGDGVNDAPSLKKA  2190,2287  -0,0288  93,71  34  43  -0,58  6,72 
5  MTGDGVNDAPSLKKA  2206,2236  -0,0302  54,47  27  43  -0,58  6,72 
5  ENADGFAEVFPQHKYRVV  2563,3589  0,0427  57,31  32  43  -0,588888889  5,34 
5  GGIGTVPV  927,5593  -0,02  61,5  34  39  1,175  6,02 
5  DAPGHRDFI  1255,6512  0,0356  44,97  32  41  -0,844444444  5,1 
5  ETGVIKPG  1257,7698  0,0108  49,83  39  40  -0,225  6,84 
5  EYPPLGRFA  1277,6971  0,0082  49,17  38  42  -0,5  6,88 
5  VIDAPGHRDF  1354,7197  -0,0048  59,84    41  -0,34  5,1 
5  VIDAPGHRDFI  1467,8037  0,0179  64,08    42  0,1  5,1 
5  FSEYPPLGRFA  1511,7975  -0,0169  51,08  31  41  -0,227272727  6,88 
5  TVIDAPGHRDFI  1568,8514  -0,0166  50,18  28  42  0,033333333  5,1 
5  FGGFVFG  958,5116  0,0136  42,76  35  40  1,628571429  6,02 
5  FGGFVFGW  1144,5909  -0,0067  52,99  36  40  1,3125  6,02 
5  NWLWGFL  1163,6331  0,0175  44,09  41  42  0,671428571  6,02 
5  RLWPNGQDQPS  1525,784  0,0309  51,95  32  42  -1,818181818  6,78 
5  SWGELFSSKT  1598,871  -0,0296  48,47  31  42  -0,52  6,84  
 
5  TRLWPNGQDQPS  1626,8317  0,015  60,19  27  42  -1,725  6,78 
5  FGGFVFG  958,5116  0,0136  42,76  35  40  1,628571429  6,02 
5  FGGFVFGW  1144,5909  -0,0067  52,99  36  40  1,3125  6,02 
5  NWLWGFL  1163,6331  0,0175  44,09  41  42  0,671428571  6,02 
5  AHDDKPLY  1415,7814  0,0318  45,67  28  42  -1,425  5,1 
5  RLWPNGQDQPS  1525,784  0,0309  51,95  32  42  -1,818181818  6,78 
5  SWGELFSSKT  1598,871  -0,0296  48,47  31  42  -0,52  6,84 
5  TRLWPNGQDQPS  1626,8317  0,015  60,19  27  42  -1,725  6,78 
5  TGGQAFPQ  1033,5396  -0,0076  52,53    42  -0,6875  6,02 
5  NLIDSPGHV  1179,6451  -0,0082  55,84  32  42  -0,055555556  4,94 
5  HGMKEEVPG  1440,7801  0,0013  59,71  22  42  -1,155555556  5,3 
5  WGDSFFNPKT  1655,8714  -0,0117  43,11  32  42  -0,97  6,66 
5  QYLHEIKDSV  1688,9503  -0,0031  54,55  34  42  -0,72  5,22 
5  QYLHEIKDSVV  1788,0187  0,0374  76,53  31  41  -0,272727273  5,22 
5  QYLHEIKDSVVA  1859,0558  0,0235  89,95  37  42  -0,1  5,22 
5  FGGFVFG  958,5116  0,0136  42,76  35  40  1,628571429  6,02 
5  FGGFVFGW  1144,5909  -0,0067  52,99  36  40  1,3125  6,02 
5  NWIWGFL  1163,6331  0,0175  44,09  41  42  0,771428571  6,02 
5  RLWPNGQDQPS  1525,784  0,0309  51,95  32  42  -1,818181818  6,78 
5  TRLWPNGQDQPS  1626,8317  0,015  60,19  27  42  -1,725  6,78 
5  FFFVPETKGL  1641,9536  0,0399  44,58  26  40  0,63  6,84 
5  FGGFVFG  958,5116  0,0136  42,76  35  40  1,628571429  6,02 
5  FGGFVFGW  1144,5909  -0,0067  52,99  36  40  1,3125  6,02 
5  NWLWGFL  1163,6331  0,0175  44,09  41  42  0,671428571  6,02 
5  MHDDQPFYK  1637,8278  -0,0207  53,44  26  41  -1,755555556  5,1 
5  FFFVPETKGL  1641,9536  0,0399  44,58  26  40  0,63  6,84 
5  FGGFVFG  958,5116  0,0136  42,76  35  40  1,628571429  6,02 
5  FGGFVFGW  1144,5909  -0,0067  52,99  36  40  1,3125  6,02 
5  NWIWGFL  1163,6331  0,0175  44,09  41  42  0,771428571  6,02 
5  MHDDQPFYK  1637,8278  -0,0207  53,44  26  41  -1,755555556  5,1  
 
5  FFFVPETKGL  1641,9536  0,0399  44,58  26  40  0,63  6,84 
5  NHFIQEF  1162,5974  -0,008  49,11  32  41  -0,514285714  5,12 
5  YFNDSQRQ  1285,6254  -0,0103  41,27  29  39  -2,225  6,7 
5  YFNDSQRQA  1356,6625  -0,0147  44,41  29  39  -1,777777778  6,7 
5  YFNDSQRQAT  1457,7102  -0,0055  42,94  31  39  -1,67  6,7 
5  YFNDSQRQATKDA  2001,0321  0,03  60,65  30  42  -1,715384615  6,76 
5  YFNDSQRQATKDAGTIA  2343,2225  -0,0231  46,1  24  42  -1,005882353  6,76 
5  IGRNFNDPEVQGDMKHFPF  2705,379  -0,0473  44,35  23  42  -0,926315789  5,28 
5  NHFIQEF  1162,5974  -0,008  49,11  32  41  -0,514285714  5,12 
5  YFNDSQRQ  1285,6254  -0,0103  41,27  29  39  -2,225  6,7 
5  YFNDSQRQA  1356,6625  -0,0147  44,41  29  39  -1,777777778  6,7 
5  YFNDSQRQAT  1457,7102  -0,0055  42,94  31  39  -1,67  6,7 
5  YFNDSQRQATKDA  2001,0321  0,03  60,65  30  42  -1,715384615  6,76 
5  YFNDSQRQATKDAGTIA  2343,2225  -0,0231  46,1  24  42  -1,005882353  6,76 
5  NWIWGFL  1163,6331  0,0175  44,09  41  42  0,771428571  6,02 
5  RLWPNGQDQPS  1525,784  0,0309  51,95  32  42  -1,818181818  6,78 
5  TRLWPNGQDQPS  1626,8317  0,015  60,19  27  42  -1,725  6,78 
5  MHDDQPFYK  1637,8278  -0,0207  53,44  26  41  -1,755555556  5,1 
5  FFFVPETKGL  1641,9536  0,0399  44,58  26  40  0,63  6,84 
5  DLFNSYKTV  1543,8652  0,0331  49,84  27  41  -0,322222222  6,6 
5  NLGWIPV  1026,6065  0,011  40,32    39  0,871428571  6,02 
5  FIPTLLVPI  1240,7998  0,0128  47,74  32  35  2,188888889  6,02 
5  MLAGTPFWQ  1278,6634  -0,0191  75,14    41  0,355555556  6,02 
5  MLAGTPFWQMA  1480,741  0,0367  47,8  32  42  0,627272727  6,02 
5  LKDLGINTV  1429,891  0,0312  50,86    39  0,477777778  6,66 
5  KLYQDYSVPV  1668,9492  0,0017  48,32  28  41  -0,37  6,56 
5  FGGFVFG  958,5116  0,0136  42,76  35  40  1,628571429  6,02 
5  FGGFVFGW  1144,5909  -0,0067  52,99  36  40  1,3125  6,02 
5  NWIWGFL  1163,6331  0,0175  44,09  41  42  0,771428571  6,02 
5  GMLMVPESPRFL  1604,8621  0,0015  66,91    42  0,5  6,98  
 
5  FFFVPETKGL  1641,9536  0,0399  44,58  26  40  0,63  6,84 
5  FFFVPETKGL  1641,9536  0,0399  44,58  26  40  0,63  6,84 
5  YFNDSQRQ  1285,6254  -0,0103  41,27  29  39  -2,225  6,7 
5  YFNDSQRQA  1356,6625  -0,0147  44,41  29  39  -1,777777778  6,7 
5  YFNDSQRQAT  1457,7102  -0,0055  42,94  31  39  -1,67  6,7 
5  YFNDSQRQATKDA  2001,0321  0,03  60,65  30  42  -1,715384615  6,76 
5  YFNDSQRQATKDAGTIA  2343,2225  -0,0231  46,1  24  42  -1,005882353  6,76 
5  FFFVPETKGL  1641,9536  0,0399  44,58  26  40  0,63  6,84 
5  SHANQDYYEVWRN  1909,891  -0,0088  80,81  31  39  -1,807692308  5,22 
5  NLGWIPV  1026,6065  0,011  40,32    39  0,871428571  6,02 
5  AIAPNLFMSI  1304,7365  0,027  43,43  30  42  1,52  6,02 
5  LLGGTPLWQI  1325,791  -0,0029  66,57  39  40  0,84  6,02 
5  LLGGTPLWQIA  1396,8281  0,0191  57,48    39  0,927272727  6,02 
5  FFFVPETKGL  1641,9536  0,0399  44,58  26  40  0,63  6,84 
5  YFNDSQRQ  1285,6254  -0,0103  41,27  29  39  -2,225  6,7 
5  YFNDSQRQA  1356,6625  -0,0147  44,41  29  39  -1,777777778  6,7 
5  YFNDSQRQAT  1457,7102  -0,0055  42,94  31  39  -1,67  6,7 
5  YFNDSQRQATKDA  2001,0321  0,03  60,65  30  42  -1,715384615  6,76 
5  YFNDSQRQATKDAGTIA  2343,2225  -0,0231  46,1  24  42  -1,005882353  6,76 
5  DMFGIVVPR  1261,7056  -0,0137  57,1  25  42  0,844444444  6,78 
5  YFNDAQRQ  1269,6305  -0,0047  42,45  24  40  -1,9  6,7 
5  GDMFGIVVPR  1318,7271  -0,0169  53,11  24  42  0,72  6,78 
5  DIFGIVVPR  1243,7492  -0,0205  53,67  32  41  1,133333333  6,78 
5  YFNDAQRQ  1269,6305  -0,0047  42,45  24  40  -1,9  6,7 
5  YFNDSQRQ  1285,6254  -0,0103  41,27  29  39  -2,225  6,7 
5  YFNDSQRQA  1356,6625  -0,0147  44,41  29  39  -1,777777778  6,7 
5  YFNDSQRQAT  1457,7102  -0,0055  42,94  31  39  -1,67  6,7 
5  KHSNGDAWVEA  1670,8782  0,0271  99,34    42  -1,081818182  5,22 
5  YFNDSQRQATKDA  2001,0321  0,03  60,65  30  42  -1,715384615  6,76 
5  SFGSLQTV  1066,5862  -0,0119  70,38  34  41  0,575  6,02  
 
5  DGFNKVQTV  1464,8342  -0,0217  61,63  34  42  -0,477777778  6,66 
5  SFGSLQTV  1066,5862  -0,0119  70,38  34  41  0,575  6,02 
5  DGFNKVQTV  1464,8342  -0,0217  61,63  34  42  -0,477777778  6,66 
5  QEKHRPGDIENN  1894,0062  -0,0343  52,24  26  42  -2,508333333  5,34 
5  TADNRHEIA  1254,6519  -0,0226  44,68  27  40  -1,2  5,22 
5  HLDKTPSEYI  1659,9238  -0,0321  42,47  36  42  -1,02  5,22 
5  ALPWFWEH  1313,676  0,0218  49,93  35  41  -0,2125  5,12 
5  YYGYGGTT  1109,5232  0,0136  57,04  30  40  -0,8125  5,82 
5  YYQQGPPQQG  1393,6829  -0,0264  60,83  27  39  -2,06  5,86 
5  YYQQGPPQQGYPQQQPV  2234,0959  0,0387  51,74  24  42  -1,847058824  5,82 
5  SGGNDKQGFPM  1594,8179  -0,0274  61,4  34  41  -1,209090909  6,66 
5  FIGFGLMGI  1182,6674  0,0027  59,79    41  2,122222222  6,02 
5  APMGGDRPYPPSLPS  1769,8973  -0,0224  43,36  26  41  -0,813333333  6,7 
5  LFNQFLL  1122,664  -0,0045  43,2    41  1,428571429  6,02 
5  STLFNQFLL  1310,7437  0,0057  58,28    41  0,944444444  6,02 
5  ARSEIPEHVI  1378,7771  -0,0008  47,3  29  42  -0,21  5,3 
5  DSLPKDLHPM  1609,8903  -0,0306  44,33    42  -0,86  5,1 
5  KHFPDYELF  1652,8968  -0,0283  52,12  38  42  -0,844444444  5,22 
5  LKHFPDYELF  1765,9809  -0,0333  53,82  29  42  -0,38  5,22 
5  QLLDSLPKDLHPM  1964,1171  -0,0395  45,61  28  43  -0,346153846  5,1 
5  YFNDSQRQ  1285,6254  -0,0103  41,27  29  39  -2,225  6,7 
5  YFNDSQRQA  1356,6625  -0,0147  44,41  29  39  -1,777777778  6,7 
5  YFNDSQRQAT  1457,7102  -0,0055  42,94  31  39  -1,67  6,7 
5  YFNDSQRQATKDA  2001,0321  0,03  60,65  30  42  -1,715384615  6,76 
5  TYKNQGDYNPQ  1784,9099  -0,0314  52,43  26  41  -2,427272727  6,56 
5  YFNDAQRQ  1269,6305  -0,0047  42,45  24  40  -1,9  6,7 
5  KHSNGDAWVEA  1670,8782  0,0271  99,34    42  -1,081818182  5,22 
5  RVAPEEHPV  1261,6982  -0,024  46,56  25  42  -0,855555556  5,3 
5  LFLPPVAV  1083,6895  0,0274  44,31    35  2,175  6,02 
5  SLFLPPVAV  1170,7215  0,0196  42,02  30  38  1,844444444  6,02  
 
5  LSLFLPPVAV  1283,8056  -0,0172  60,6  30  39  2,04  6,02 
5  ALPWFWEH  1313,676  0,0218  49,93  35  41  -0,2125  5,12 
5  AGGLILPF  1015,6269  0,0228  48,28  39  40  1,7875  6,02 
5  DLQGSEDHSFRKI  1989,0685  -0,0141  81,67  29  42  -1,269230769  5,28 
5  LADLQGSEDHSFRKI  2173,1897  -0,007  83,26  29  43  -0,726666667  5,28 
5  ALPKHNEVEEHV  1859,0307  0,0228  66,97  29  42  -0,991666667  5,22 
5  DLQGSEDHSFRKV  1975,0529  0,0274  45,75  31  42  -1,292307692  5,28 
5  LADLQGSEDHSFRKV  2159,1741  -0,0322  93,68  33  42  -0,746666667  5,28 
5  FFFVPETKGL  1641,9536  0,0399  44,58  26  40  0,63  6,84 
5  KEDWHEKWLN  2071,1459  -0,0228  45,07  34  42  -2,3  5,34 
5  NLPEHIVPG  1203,6815  -0,0255  52,18  28  42  -0,144444444  5,12 
5  REYLNLPEHIVPG  1764,9725  0,0196  57,94  22  42  -0,523076923  5,3 
5  KHEEIDTKNL  1913,119  0,0133  51,3  30  41  -1,74  5,34 
5  YFNDAQRQ  1269,6305  -0,0047  42,45  24  40  -1,9  6,7 
5  NEADQYLHRVG  1529,7789  0,0277  54,83  33  41  -1,236363636  5,22 
5  NLPEHIVPG  1203,6815  -0,0255  52,18  28  42  -0,144444444  5,12 
5  REYLNLPEHIVPG  1764,9725  0,0196  57,94  22  42  -0,523076923  5,3 
5  KHEEIDTKNL  1913,119  0,0133  51,3  30  41  -1,74  5,34 
5  VYAGENFH  1164,5767  0,0205  51,91  37  41  -0,3875  5,12 
5  FDFGGFHI  1167,5916  0,0233  51,79  29  41  0,675  4,94 
5  VFDFGGFHI  1266,66  0,0263  62,37  34  42  1,066666667  4,94 
5  YKYDNFPI  1516,8331  0,0002  43,06  26  42  -0,975  6,56 
5  FEDHSWKFY  1715,8713  -0,0077  41,55  28  41  -1,277777778  5,22 
5  HDEELKYNGRVV  1916,0521  0,0211  48,16  22  42  -1,258333333  5,34 
5  GGHRPQISDEEVSK  1996,0743  -0,0228  48,4  25  42  -1,492857143  5,34 
5  ALKYHPDKNPSEEA  2285,2624  0,0461  47,82  41  42  -1,635714286  5,34 
5  YYQQQQPQ  1310,6458  -0,0259  50,39  38  39  -2,7125  5,86 
5  QQQYQQQPQ  1403,6996  -0,0069  42,34    40  -3,044444444  5,92 
5  KAPVPDVNAPQ  1592,9292  0,0166  41,45  19  41  -0,654545455  6,66 
5  NTNVDGNIKIV  1643,9612  -0,0331  48,7  36  42  -0,145454545  6,66  
 
5  LSDVFGYVKPG  1638,9387  -0,0328  47,15  28  42  0,281818182  6,6 
5  WHFPELA  1127,5967  -0,0184  48,26  33  40  -0,114285714  5,12 
5  KEWYGWHFPELA  2020,0612  0,0063  49,9  32  42  -0,9  5,3 
5  VLVQDLLHPT  1362,8074  -0,0247  61,08  29  42  0,73  4,94 
5  KHQEELWS  1513,8295  -0,008  48,72  30  42  -1,9375  5,3 
5  THGNDDDVTKRL  1827,9845  0,0176  61,19  27  42  -1,616666667  5,2 
5  GKVDPDQYGHY  1735,8935  0,0243  43,97  25  42  -1,672727273  5,1 
5  KTDEHGNLNQF  1759,9259  0,0261  57,79  29  42  -1,736363636  5,22 
5  SAVEDRDIHNIGKT  2012,1056  0,015  65,9  24  42  -0,892857143  5,28 
5  KYDNIPEHA  1543,84  0,0137  44,5  29  42  -1,577777778  5,22 
5  HYGEIKNDFI  1692,9241  0,0197  51,18  27  42  -0,75  5,22 
5  NNFLWPF  1165,6123  -0,0102  48,76  37  41  -0,014285714  6,02 
5  NNFLWPF  1165,6123  -0,0102  48,76  37  41  -0,014285714  6,02 
5  SFNDTFVH  1194,5873  -0,0192  59,34  34  39  -0,2375  4,94 
5  YHQKYVDEQ  1666,8721  -0,0157  63,39  29  42  -2,166666667  5,22 
5  LGDGKSDNQNHA  1712,8847  -0,0422  61,4  31  41  -1,716666667  5,1 
5  FGGTLNPG  990,5338  -0,0103  50,59    41  -0,05  6,02 
5  LGDGKSDNQNHA  1712,8847  -0,0422  61,4  31  41  -1,716666667  5,1 
5  NKLKDHDYFGEVA  2222,2304  -0,0329  62,92  26  43  -1,084615385  5,28 
5  WHFPELA  1127,5967  -0,0184  48,26  33  40  -0,114285714  5,12 
5  KEWYGWHFPELA  2020,0612  0,0063  49,9  32  42  -0,9  5,3 
5  DKYDENNPEHRKI  2344,2744  0,0175  55,68  37  43  -2,684615385  5,38 
5  FGGTLNPG  990,5338  -0,0103  50,59    41  -0,05  6,02 
5  SQGFPNIQ  1118,5923  -0,0066  43,6  35  41  -0,75  6,02 
5  RVDFKNPHDIIEGI  2110,1941  0,0288  67,87  23  42  -0,507142857  5,28 
5  RLDSEKHIDFAPT  1986,094  -0,0467  43,29  26  42  -0,946153846  5,28 
5  RLDSEKHIDFAPT  1986,094  -0,0467  43,29  26  42  -0,946153846  5,28 
5  IVDAPGHRDF  1354,7197  -0,0048  44,63    41  -0,34  5,1 
5  LFNQFLL  1122,664  -0,0045  43,2    41  1,428571429  6,02 
5  STLFNQFLL  1310,7437  0,0057  58,28    41  0,944444444  6,02  
 
5  SWINNVAL  1144,6443  -0,0102  44,28  34  41  0,7  6,02 
5  VPHENEKQTS  1625,8779  -0,0402  60,02    42  -2  5,3 
5  SLFDLKIT  1393,8586  -0,0284  45,99  32  41  0,75  6,66 
5  KLDHTENDVRGV  1840,0209  0,015  46,8  24  42  -1,208333333  5,28 
5  NQINEAHPT  1251,641  -0,0288  55,26  28  40  -1,466666667  5,12 
5  HLDKTPSEYI  1659,9238  -0,0321  42,47  36  42  -1,02  5,22 
5  AHTGGDTQKEA  1571,8309  -0,0203  44,08  29  41  -1,472727273  5,22 
5  SKDFIQEHVPGPKES  2384,3308  -0,0387  43,01  25  43  -1,246666667  5,34 
5  DLFRHEWPS  1414,7196  0,0052  41,23  32  41  -1,266666667  5,22 
                 
6  STQHEKET  1416,7614  0,0211  52,74  32  42  -2,475  5,3 
6  EILQNRGYLVA  1503,8612  0,0023  49,77    42  0,127272727  6,88 
6  YDNAPYSPKPV  1707,9238  0,0316  47,73  26  42  -1,190909091  6,56 
6  AYDNAPYSPKPV  1778,9609  0,0229  54,72  24  42  -0,941666667  6,56 
6  GDGVNDAPSLKKA  1958,1405  0,0435  52,69  36  40  -0,761538462  6,72 
6  FLAPGLSAIIDALKT  1987,2123  -0,0058  103,8  36  40  1,18  6,66 
6  MTGDGVNDAPSLKKA  2190,2287  0,0265  85,74  32  42  -0,58  6,72 
6  EILQNRGYLVA  1503,8612  0,0023  49,77    42  0,127272727  6,88 
6  GDGVNDAPSLKKA  1958,1405  0,0435  52,69  36  40  -0,761538462  6,72 
6  FLAPGLSAIIDALKT  1987,2123  -0,0058  103,8  36  40  1,18  6,66 
6  MTGDGVNDAPSLKKA  2190,2287  0,0265  85,74  32  42  -0,58  6,72 
6  GGIGTVPV  927,5593  0,0079  45,9  32  39  1,175  6,02 
6  ETGVIKPG  1257,7698  0,0366  39,72  37  39  -0,225  6,84 
6  FSEYPPLGRFA  1511,7975  -0,0053  51,51  28  42  -0,227272727  6,88 
6  RFQEIVKET  1606,9448  0,0384  59,11    40  -0,9  7 
6  EQPSRPTDKPL  1724,9827  0,0227  47,62  34  41  -1,945454545  6,92 
6  DAIEQPSRPTDKPLRLPL  2503,4528  -0,0275  48,6  25  43  -0,95  6,98 
6  GQDQPSSKGA  1431,7724  0,0049  62,31  33  42  -1,66  6,66 
6  RLWPNGQDQPS  1525,784  0,0414  50,3  26  42  -1,818181818  6,78 
6  GQDQPSSKGA  1431,7724  0,0049  62,31  33  42  -1,66  6,66  
 
6  RLWPNGQDQPS  1525,784  0,0414  50,3  26  42  -1,818181818  6,78 
6  TGGQAFPQ  1033,5396  0,0155  51,42    42  -0,6875  6,02 
6  GQDQPSSKGA  1431,7724  0,0049  62,31  33  42  -1,66  6,66 
6  RLWPNGQDQPS  1525,784  0,0414  50,3  26  42  -1,818181818  6,78 
6  SWGELFTGKPA  1649,9183  -0,0138  45,94  28  42  -0,345454545  6,84 
6  YFNDSQRQ  1285,6254  0,0201  43,21  27  40  -2,225  6,7 
6  YFNDSQRQA  1356,6625  0,0243  43,94  30  40  -1,777777778  6,7 
6  YFNDSQRQATKDA  2001,0321  0,0216  61,05  27  42  -1,715384615  6,76 
6  YFNDSQRQ  1285,6254  0,0201  43,21  27  40  -2,225  6,7 
6  YFNDSQRQA  1356,6625  0,0243  43,94  30  40  -1,777777778  6,7 
6  YFNDSQRQATKDA  2001,0321  0,0216  61,05  27  42  -1,715384615  6,76 
6  GQDQPSSKGA  1431,7724  0,0049  62,31  33  42  -1,66  6,66 
6  RLWPNGQDQPS  1525,784  0,0414  50,3  26  42  -1,818181818  6,78 
6  SWGELFTGKPA  1649,9183  -0,0138  45,94  28  42  -0,345454545  6,84 
6  LKDLGINTV  1429,891  -0,0078  44,43  38  40  0,477777778  6,66 
6  KLYQDYSVPV  1668,9492  -0,0116  68,98  33  42  -0,37  6,56 
6  QNPPPPPSTT  1263,6662  -0,0134  54,29    41  -1,72  6,02 
6  YFNDSQRQ  1285,6254  0,0201  43,21  27  40  -2,225  6,7 
6  YFNDSQRQA  1356,6625  0,0243  43,94  30  40  -1,777777778  6,7 
6  YFNDSQRQATKDA  2001,0321  0,0216  61,05  27  42  -1,715384615  6,76 
6  YFNDSQRQ  1285,6254  0,0201  43,21  27  40  -2,225  6,7 
6  YFNDSQRQA  1356,6625  0,0243  43,94  30  40  -1,777777778  6,7 
6  YFNDSQRQATKDA  2001,0321  0,0216  61,05  27  42  -1,715384615  6,76 
6  YFNDAQRQ  1269,6305  0,0247  49,21  31  41  -1,9  6,7 
6  NEQGNRVTPS  1329,684  -0,0013  45,58    41  -1,78  6,98 
6  ANEQGNRVTPS  1400,7211  0,0469  55,19  38  41  -1,454545455  6,98 
6  YFNDAQRQ  1269,6305  0,0247  49,21  31  41  -1,9  6,7 
6  NEQGNRVTPS  1329,684  -0,0013  45,58    41  -1,78  6,98 
6  ANEQGNRVTPS  1400,7211  0,0469  55,19  38  41  -1,454545455  6,98 
6  YFNDSQRQ  1285,6254  0,0201  43,21  27  40  -2,225  6,7  
 
6  YFNDSQRQA  1356,6625  0,0243  43,94  30  40  -1,777777778  6,7 
6  YFNDSQRQATKDA  2001,0321  0,0216  61,05  27  42  -1,715384615  6,76 
6  KKITGDLNMQELII  2302,3902  -0,0213  42,12  32  41  0,007142857  6,84 
6  KKITGDLNMQELII  2302,3902  -0,0213  42,12  32  41  0,007142857  6,84 
6  ALPWFWEH  1313,676  0,002  51,12  31  41  -0,2125  5,12 
6  SGPQSYQ  994,4923  0,0237  53,1  27  41  -1,7  5,92 
6  YQQGPPQQG  1230,6196  0,0001  45,43  27  40  -2,144444444  5,92 
6  YYQQGPPQQG  1393,6829  -0,0023  67,71  39  40  -2,06  5,86 
6  NQQGYNQQ  1207,5784  -0,0166  54,95  33  38  -2,8375  5,92 
6  QQYYQQQ  1213,593  -0,01  50,45  37  39  -2,871428571  5,86 
6  QQYYQQQQ  1341,6516  -0,0131  55,27    39  -2,95  5,86 
6  NQQGYNQQGY  1427,6632  -0,0113  58,32  34  37  -2,44  5,86 
6  GYNQQGYNQQ  1427,6632  -0,0063  69,45  29  38  -2,44  5,86 
6  NQQGYNQQGYNQQ  1797,8233  0,0169  103,6  35  39  -2,684615385  5,86 
6  FIGFGLMGI  1182,6674  0,0205  56,84  36  40  2,122222222  6,02 
6  AFADMFDTNVRGK  1929,0184  -0,0076  46,07  29  42  -0,361538462  6,8 
6  KQNSGNAET  1405,7567  0,0021  53,79  35  42  -2  6,84 
6  YFNDSQRQ  1285,6254  0,0201  43,21  27  40  -2,225  6,7 
6  YFNDSQRQA  1356,6625  0,0243  43,94  30  40  -1,777777778  6,7 
6  YFNDSQRQATKDA  2001,0321  0,0216  61,05  27  42  -1,715384615  6,76 
6  YFNDAQRQ  1269,6305  0,0247  49,21  31  41  -1,9  6,7 
6  QLQQQQQQQ  1384,7262  -0,0207  86,35    41  -2,688888889  6,02 
6  QQQQQQQQYA  1505,7426  -0,0151  86,44    40  -2,75  5,92 
6  QLQQQQQQQQ  1512,7848  -0,0308  77,56    41  -2,77  6,02 
6  LFLPPVAV  1083,6895  0,0119  46,72    36  2,175  6,02 
6  LSLFLPPVAV  1283,8056  0,0223  45,2  21  36  2,04  6,02 
6  ALPWFWEH  1313,676  0,002  51,12  31  41  -0,2125  5,12 
6  KYSNEDTRPV  1665,9092  0,0108  51,05  31  42  -1,91  6,86 
6  AEIQGKT  1203,7229  0,011  44,27    41  -0,814285714  6,84 
6  SSSQEQLRQT  1391,7207  0,0263  72,91  38  42  -1,78  6,98  
 
6  YFNDAQRQ  1269,6305  0,0247  49,21  31  41  -1,9  6,7 
6  AATENQPKGI  1485,8557  0,0137  52,85  34  41  -0,9  6,84 
6  QLQQQQQQQ  1384,7262  -0,0207  86,35    41  -2,688888889  6,02 
6  QLQQQQQQQQ  1512,7848  -0,0308  77,56    41  -2,77  6,02 
6  QIQQQQQQQ  1384,7262  -0,0207  86,35    41  -2,611111111  6,02 
6  QIQQQQQQQQ  1512,7848  -0,0308  77,56    41  -2,7  6,02 
6  LQQQQQQQQ  1384,7262  -0,0207  66,37    41  -2,688888889  6,02 
6  QQQQQQQQYA  1505,7426  -0,0151  86,44    40  -2,75  5,92 
6  LQQQQQQQQQ  1512,7848  -0,0308  61,3    41  -2,77  6,02 
6  QQQYQQQPQ  1403,6996  -0,0012  63    41  -3,044444444  5,92 
6  KAPVPDVNAPQ  1592,9292  0,0391  41,1  24  40  -0,654545455  6,66 
6  QIQQQQQQQ  1384,7262  -0,0207  86,35    41  -2,611111111  6,02 
6  QIQQQQQQQQ  1512,7848  -0,0308  77,56    41  -2,7  6,02 
6  QLQQQQQQQ  1384,7262  -0,0207  86,35    41  -2,688888889  6,02 
6  QLQQQQQQQQ  1512,7848  -0,0308  77,56    41  -2,77  6,02 
6  QIQQQQQQQ  1384,7262  -0,0207  86,35    41  -2,611111111  6,02 
6  QIQQQQQQQQ  1512,7848  -0,0308  77,56    41  -2,7  6,02 
6  QLQQQQQQQ  1384,7262  -0,0207  86,35    41  -2,688888889  6,02 
6  QLQQQQQQQQ  1512,7848  -0,0308  77,56    41  -2,77  6,02 
6  QLQQQQQQQ  1384,7262  -0,0207  86,35    41  -2,688888889  6,02 
6  QLQQQQQQQQ  1512,7848  -0,0308  77,56    41  -2,77  6,02 
6  QLQQQQQQQ  1384,7262  -0,0207  86,35    41  -2,688888889  6,02 
6  QLQQQQQQQQ  1512,7848  -0,0308  77,56    41  -2,77  6,02 
6  QLQQQQQQQ  1384,7262  -0,0207  86,35    41  -2,688888889  6,02 
6  QLQQQQQQQQ  1512,7848  -0,0308  77,56    41  -2,77  6,02 
6  ATDSGKNQA  1348,7352  0,0378  51,84  34  42  -1,411111111  6,66 
6  LQQQQQQQQ  1384,7262  -0,0207  66,37    41  -2,688888889  6,02 
6  LQQQQQQQQQ  1512,7848  -0,0308  61,3    41  -2,77  6,02 
6  SKQSAEPQ  1331,7451  -0,0021  42,91  34  42  -1,975  6,84 
6  NQNNNNEGNTKYS  1953,9546  -0,024  74,43  34  40  -2,7  6,8  
 
6  LQQQQQQQQ  1384,7262  -0,0207  66,37    41  -2,688888889  6,02 
6  LQQQQQQQQQ  1512,7848  -0,0308  61,3    41  -2,77  6,02 
6  PSGQQQQQQQ  1384,6898  0,0157  66,37    41  -2,73  6,02 
6  PSGQQQQQQQQ  1512,7484  0,0056  61,3    41  -2,8  6,02 
6  LQQQQQQQQ  1384,7262  -0,0207  66,37    41  -2,688888889  6,02 
6  LQQQQQQQQQ  1512,7848  -0,0308  61,3    41  -2,77  6,02 
6  LQQQQQQQQ  1384,7262  -0,0207  66,37    41  -2,688888889  6,02 
6  LQQQQQQQQQ  1512,7848  -0,0308  61,3    41  -2,77  6,02 
6  LQQQQQQQQ  1384,7262  -0,0207  66,37    41  -2,688888889  6,02 
6  LQQQQQQQQQ  1512,7848  -0,0308  61,3    41  -2,77  6,02 
6  LQQQQQQQQ  1384,7262  -0,0207  66,37    41  -2,688888889  6,02 
6  LQQQQQQQQQ  1512,7848  -0,0308  61,3    41  -2,77  6,02 
6  LQQQQQQQQ  1384,7262  -0,0207  66,37    41  -2,688888889  6,02 
6  LQQQQQQQQQ  1512,7848  -0,0308  61,3    41  -2,77  6,02 
6  LQQQQQQQQ  1384,7262  -0,0207  66,37    41  -2,688888889  6,02 
6  LQQQQQQQQQ  1512,7848  -0,0308  61,3    41  -2,77  6,02 
6  LQQQQQQQQ  1384,7262  -0,0207  66,37    41  -2,688888889  6,02 
6  LQQQQQQQQQ  1512,7848  -0,0308  61,3    41  -2,77  6,02 
6  QLQQQQQQQ  1384,7262  -0,0207  86,35    41  -2,688888889  6,02 
6  LQQQQQQQQ  1384,7262  -0,0207  66,37    41  -2,688888889  6,02 
6  YNNNGGQPQGQ  1404,6585  0,0264  45,84  26  40  -2,281818182  5,92 
6  QLQQGVMPQQ  1384,7336  -0,0281  49,53    41  -0,96  6,02 
6  QLQQGVMPQQQ  1512,7922  -0,0382  46,64    41  -1,190909091  6,02 
6  ELIQNRLNME  1503,7918  0,0717  43,75    42  -0,8  4,26 
6  QQGYPPQQEH  1439,6996  0,0227  46,29  21  41  -2,56  5,12 
6  VYLSGDV  980,5382  0,0209  42  39  41  0,885714286  3,1 
6  LADALL  843,5268  0,0269  40,71    38  1,916666667  3,1 
6  LADAIL  843,5268  0,0269  40,71    38  2,033333333  3,1 
                 
7  TIIGVPV  926,6004  -0,0176  38,04    36  2,1  6,02  
 
7  EILQNRG  1057,6083  0,0048  42,19  38  40  -1,014285714  6,98 
7  NIYNAER  1107,5875  0,0002  46,78    42  -1,428571429  6,88 
7  QNFGAMNGI  1179,5909  -0,0182  56,96  37  40  -0,033333333  6,02 
7  EILQNRGYL  1333,7557  -0,0017  50,44    42  -0,511111111  6,88 
7  QPTQEKPA  1355,7814  -0,0152  46,63  35  41  -2,0625  6,84 
7  EILQNRGYLVA  1503,8612  0,0053  52,65    42  0,127272727  6,88 
7  DNAPYSPKPV  1544,8604  0,0162  44,93  31  42  -1,18  6,6 
7  YDNAPYSPKPV  1707,9238  -0,0063  48,26  26  42  -1,190909091  6,56 
7  SIVDELKKT  1719,0751  0,0024  48,1    39  -0,422222222  6,84 
7  AYDNAPYSPKPV  1778,9609  -0,0095  50,13  26  42  -0,941666667  6,56 
7  IAYDNAPYSPKPV  1892,0449  -0,0304  59,25  36  43  -0,523076923  6,56 
7  GDGVNDAPSLKKA  1958,1405  0,0138  51,08  34  41  -0,761538462  6,72 
7  AIAYDNAPYSPKPV  1963,082  -0,0346  45,47  28  42  -0,357142857  6,56 
7  FLAPGLSAIIDALKT  1987,2123  0,0272  99,97  37  39  1,18  6,66 
7  MTGDGVNDAPSLKKA  2190,2287  -0,0185  92,97  34  43  -0,58  6,72 
7  MTGDGVNDAPSLKKA  2206,2236  -0,0247  44,73  25  43  -0,58  6,72 
7  TIIGVPV  926,6004  -0,0176  38,04    36  2,1  6,02 
7  EILQNRG  1057,6083  0,0048  42,19  38  40  -1,014285714  6,98 
7  NIYNAER  1107,5875  0,0002  46,78    42  -1,428571429  6,88 
7  EILQNRGYL  1333,7557  -0,0017  50,44    42  -0,511111111  6,88 
7  EILQNRGYLVA  1503,8612  0,0053  52,65    42  0,127272727  6,88 
7  SIVDELKKT  1719,0751  0,0024  48,1    39  -0,422222222  6,84 
7  GDGVNDAPSLKKA  1958,1405  0,0138  51,08  34  41  -0,761538462  6,72 
7  FLAPGLSAIIDALKT  1987,2123  0,0272  99,97  37  39  1,18  6,66 
7  MTGDGVNDAPSLKKA  2190,2287  -0,0185  92,97  34  43  -0,58  6,72 
7  MTGDGVNDAPSLKKA  2206,2236  -0,0247  44,73  25  43  -0,58  6,72 
7  ASFNAT  838,4388  0,0028  41,06  40  41  0,233333333  6,02 
7  GGIGTVPV  927,5593  -0,0143  45,37  28  39  1,175  6,02 
7  KTLLEAI  1244,8109  -0,0174  41,23    39  0,828571429  6,84 
7  ETGVIKPG  1257,7698  0,0077  46,34    39  -0,225  6,84  
 
7  EYPPLGRFA  1277,6971  0,0141  43,64  30  42  -0,5  6,88 
7  LRLPLQDVY  1344,7968  -0,0168  43,11  32  42  0,133333333  6,7 
7  SEYPPLGRFA  1364,7291  0,0042  43,44  37  42  -0,53  6,88 
7  FSEYPPLGRF  1440,7604  -0,0142  46,29  36  41  -0,43  6,88 
7  FSEYPPLGRFA  1511,7975  -0,0099  68,52  32  42  -0,227272727  6,88 
7  RFQEIVKET  1606,9448  0,0133  57,21    41  -0,9  7 
7  RFQEIVKETS  1693,9769  -0,0145  52,64  29  42  -0,89  7 
7  NAPWYKGWEKET  2195,1983  0,018  52,88  28  43  -1,858333333  6,88 
7  TNAPWYKGWEKET  2296,246  0,0315  63,5  33  43  -1,769230769  6,88 
7  FGGFVFG  958,5116  0,0066  50,03    40  1,628571429  6,02 
7  FGGFVFGW  1144,5909  -0,0002  43,12  35  40  1,3125  6,02 
7  RLWPNGQDQPS  1525,784  0,0233  46,46  28  42  -1,818181818  6,78 
7  FGGFVFG  958,5116  0,0066  50,03    40  1,628571429  6,02 
7  FGGFVFGW  1144,5909  -0,0002  43,12  35  40  1,3125  6,02 
7  RLWPNGQDQPS  1525,784  0,0233  46,46  28  42  -1,818181818  6,78 
7  TGGQAFPQ  1033,5396  -0,0006  51,58    42  -0,6875  6,02 
7  IENGIINPR  1253,7294  -0,0067  49,51  35  40  -0,388888889  6,98 
7  RFTDTRKDEQERGI  2208,2017  0,0203  43,59  22  43  -2,1  7,08 
7  FGGFVFG  958,5116  0,0066  50,03    40  1,628571429  6,02 
7  FGGFVFGW  1144,5909  -0,0002  43,12  35  40  1,3125  6,02 
7  RLWPNGQDQPS  1525,784  0,0233  46,46  28  42  -1,818181818  6,78 
7  FGGFVFG  958,5116  0,0066  50,03    40  1,628571429  6,02 
7  FGGFVFGW  1144,5909  -0,0002  43,12  35  40  1,3125  6,02 
7  SWGELFTGKPA  1649,9183  -0,0253  51,99  30  42  -0,345454545  6,84 
7  FGGFVFG  958,5116  0,0066  50,03    40  1,628571429  6,02 
7  FGGFVFGW  1144,5909  -0,0002  43,12  35  40  1,3125  6,02 
7  YFNDSQRQ  1285,6254  0,0039  45,33  25  39  -2,225  6,7 
7  YFNDSQRQA  1356,6625  0,0047  45,03  27  40  -1,777777778  6,7 
7  YFNDSQRQAT  1457,7102  -0,0032  59,83  32  40  -1,67  6,7 
7  VTDYFNGKEPNRS  1984,042  -0,0132  47,45  36  42  -1,553846154  6,86  
 
7  YFNDSQRQ  1285,6254  0,0039  45,33  25  39  -2,225  6,7 
7  YFNDSQRQA  1356,6625  0,0047  45,03  27  40  -1,777777778  6,7 
7  YFNDSQRQAT  1457,7102  -0,0032  59,83  32  40  -1,67  6,7 
7  VTDYFNGKEPNRS  1984,042  -0,0132  47,45  36  42  -1,553846154  6,86 
7  RLWPNGQDQPS  1525,784  0,0233  46,46  28  42  -1,818181818  6,78 
7  SWGELFTGKPA  1649,9183  -0,0253  51,99  30  42  -0,345454545  6,84 
7  MNLYYEKS  1504,8001  -0,0204  51,51  32  42  -1,075  6,76 
7  SNLGWIPV  1113,6385  -0,0152  40,33  37  40  0,6625  6,02 
7  FIPTLLVPI  1240,7998  0,0021  51,69  32  36  2,188888889  6,02 
7  MLAGTPFWQ  1278,6634  -0,0053  61,73  34  41  0,355555556  6,02 
7  LKDLGINTV  1429,891  0,0058  46,41    39  0,477777778  6,66 
7  FGGFVFG  958,5116  0,0066  50,03    40  1,628571429  6,02 
7  FGGFVFGW  1144,5909  -0,0002  43,12  35  40  1,3125  6,02 
7  SWGELFSNKG  1581,8557  -0,0144  45,69  31  42  -0,76  6,84 
7  QLQNPPPPPSTT  1504,8089  -0,0214  48,12  33  42  -1,408333333  6,02 
7  YFNDSQRQ  1285,6254  0,0039  45,33  25  39  -2,225  6,7 
7  YFNDSQRQA  1356,6625  0,0047  45,03  27  40  -1,777777778  6,7 
7  YFNDSQRQAT  1457,7102  -0,0032  59,83  32  40  -1,67  6,7 
7  KGVDRESYA  1481,8244  -0,0047  47,4  31  42  -1,322222222  6,86 
7  AGEGLNVEQRK  1657,9517  0,0073  61,13  35  42  -1,218181818  7 
7  SNLGWIPV  1113,6385  -0,0152  40,33  37  40  0,6625  6,02 
7  LLGGTPLWQIA  1396,8281  -0,0032  40,14  30  40  0,927272727  6,02 
7  YFNDSQRQ  1285,6254  0,0039  45,33  25  39  -2,225  6,7 
7  YFNDSQRQA  1356,6625  0,0047  45,03  27  40  -1,777777778  6,7 
7  YFNDSQRQAT  1457,7102  -0,0032  59,83  32  40  -1,67  6,7 
7  YFNDAQRQ  1269,6305  0,0019  53,36  28  40  -1,9  6,7 
7  YFNDAQRQA  1340,6676  0,0135  45,05  25  41  -1,488888889  6,7 
7  ANEQGNRVTPS  1400,7211  0,002  49,83  32  41  -1,454545455  6,98 
7  YFNDAQRQATKDA  1985,0372  0,028  43,63  27  42  -1,515384615  6,76 
7  YFNDAQRQ  1269,6305  0,0019  53,36  28  40  -1,9  6,7  
 
7  YFNDAQRQA  1340,6676  0,0135  45,05  25  41  -1,488888889  6,7 
7  ANEQGNRVTPS  1400,7211  0,002  49,83  32  41  -1,454545455  6,98 
7  YFNDAQRQATKDA  1985,0372  0,028  43,63  27  42  -1,515384615  6,76 
7  YFNDSQRQ  1285,6254  0,0039  45,33  25  39  -2,225  6,7 
7  YFNDSQRQA  1356,6625  0,0047  45,03  27  40  -1,777777778  6,7 
7  YFNDSQRQAT  1457,7102  -0,0032  59,83  32  40  -1,67  6,7 
7  SFGSLQ  866,4701  0,0108  42,6    40  0,183333333  6,02 
7  KKITGDLNMQELII  2302,3902  -0,0176  59,89  31  41  0,007142857  6,84 
7  SFGSLQ  866,4701  0,0108  42,6    40  0,183333333  6,02 
7  KKITGDLNMQELII  2302,3902  -0,0176  59,89  31  41  0,007142857  6,84 
7  AGEGLNVEQRK  1657,9517  0,0073  61,13  35  42  -1,218181818  7 
7  KVLEELFQKL  1933,222  -0,0209  71,09  32  39  0,01  6,92 
7  YQQGPPQQG  1230,6196  -0,0091  54,94  26  40  -2,144444444  5,92 
7  YYQQGPPQQG  1393,6829  -0,0196  65,74  27  40  -2,06  5,86 
7  NQQGYNQQGY  1427,6632  -0,0197  37,51  28  37  -2,44  5,86 
7  QERGYPPQQQ  1458,7418  -0,0036  50,94  28  41  -2,69  6,88 
7  DAFKNYPNVL  1637,9183  0,0072  52,84  31  42  -0,47  6,6 
7  YFNDSQRQ  1285,6254  0,0039  45,33  25  39  -2,225  6,7 
7  YFNDSQRQA  1356,6625  0,0047  45,03  27  40  -1,777777778  6,7 
7  YFNDSQRQAT  1457,7102  -0,0032  59,83  32  40  -1,67  6,7 
7  YKNQGDYNPQ  1683,8622  -0,0155  56,73  30  41  -2,6  6,56 
7  ANEQELKKG  1703,0186  -0,0049  54,3  35  41  -1,844444444  6,92 
7  TYKNQGDYNPQ  1784,9099  -0,017  71,93  28  41  -2,427272727  6,56 
7  YFNDAQRQ  1269,6305  0,0019  53,36  28  40  -1,9  6,7 
7  YFNDAQRQA  1340,6676  0,0135  45,05  25  41  -1,488888889  6,7 
7  YFNDAQRQATKDA  1985,0372  0,028  43,63  27  42  -1,515384615  6,76 
7  LFLPPVAV  1083,6895  -0,0022  36,41  31  36  2,175  6,02 
7  SLFLPPVAV  1170,7215  0,0082  41,13  36  38  1,844444444  6,02 
7  LSLFLPPVAV  1283,8056  -0,0152  56,16  28  39  2,04  6,02 
7  KMNAPQKPEDIPVAT  2325,3335  -0,0314  44,88  32  42  -0,873333333  6,84  
 
7  SKLIPEVI  1355,8794  -0,0242  41,88    38  0,9  6,84 
7  GKQLEDGRT  1460,8353  -0,0168  46,5  34  42  -1,844444444  6,92 
7  FAGKQLEDGRT  1678,9408  0,015  68,74    42  -1,090909091  6,92 
7  FAGKQLEDGRTL  1792,0249  -0,0175  61,38  41  42  -0,683333333  6,92 
7  SKLIPEVI  1355,8794  -0,0242  41,88    38  0,9  6,84 
7  VFIWKDV  1363,827  0,0087  42,33  37  40  1,057142857  6,66 
7  YFNDAQRQ  1269,6305  0,0019  53,36  28  40  -1,9  6,7 
7  YFNDAQRQA  1340,6676  0,0135  45,05  25  41  -1,488888889  6,7 
7  YFNDAQRQATKDA  1985,0372  0,028  43,63  27  42  -1,515384615  6,76 
7  AATENQPKGI  1485,8557  0,0017  51,21  39  41  -0,9  6,84 
7  VYAGENFHHGDKL  1944,0259  -0,0229  62,19  25  42  -0,792307692  6,02 
7  YKYDNFPI  1516,8331  -0,0044  46,3  28  42  -0,975  6,56 
7  TATDVEIKKA  1762,0809  0,0059  54,32  31  40  -0,39  6,84 
7  KQATDEGVKT  1763,0397  -0,0203  48,87  33  42  -1,41  6,84 
7  KQLENVS  1274,76  -0,0046  48,59    42  -1,028571429  6,84 
7  DNKQNALEKFI  2006,1769  -0,0227  47,77  30  42  -1,127272727  6,84 
7  FGGTLNPG  990,5338  -0,0072  42,05  39  42  -0,05  6,02 
7  KFAEPEAKDKS  2165,2867  0,0172  41,28  28  41  -1,654545455  6,9 
7  FGGTLNPG  990,5338  -0,0072  42,05  39  42  -0,05  6,02 
7  NVSKDELREKL  2017,214  -0,0227  44,02  28  41  -1,390909091  6,96 
7  VRLILPGELA  1308,8332  -0,0153  49,84  34  39  1,19  6,98 
7  SWINNVAL  1144,6443  -0,0141  41,77  40  41  0,7  6,02 
7  KTLLEAI  1244,8109  -0,0174  41,23    39  0,828571429  6,84 
7  KTLLEAI  1244,8109  -0,0174  41,23    39  0,828571429  6,84 
7  LQTQNELLT  1287,7237  0,0541  46,18    41  -0,444444444  3,3 
7  SIGKIIEIL  1442,9478  0,001  44,95    36  1,466666667  6,84 
7  SFGSLQ  866,4701  0,0108  42,6    40  0,183333333  6,02 
7  LADALL  843,5268  0,0079  42,22    39  1,916666667  3,1 
7  LADAIL  843,5268  0,0079  42,22    39  2,033333333  3,1 
7  TRLILLDAI  1255,8066  -0,0065  43,58    37  1,5  6,78  
 
7  KIPGLNPGDEPRAL  1934,1355  -0,0027  42,22  34  42  -0,757142857  6,92 
                 
8  EILQNRG  1057,6083  0,0093  44,42  38  40  -1,014285714  6,98 
8  NIYNAER  1107,5875  0  51,72    42  -1,428571429  6,88 
8  QNFGAMNGI  1179,5909  -0,0118  49,87  31  40  -0,033333333  6,02 
8  QNFGAMNGI  1195,5858  -0,0183  45,17  37  39  -0,033333333  6,02 
8  NIYNAERL  1220,6716  0,0039  42    42  -0,775  6,88 
8  EILQNRGYL  1333,7557  0,0093  46,88    42  -0,511111111  6,88 
8  EILQNRGYLVA  1503,8612  0,012  42,43  41  42  0,127272727  6,88 
8  YDNAPYSPKPV  1707,9238  -0,0095  47,28  26  42  -1,190909091  6,56 
8  SIVDELKKT  1719,0751  0,0073  48    39  -0,422222222  6,84 
8  AYDNAPYSPKPV  1778,9609  -0,0131  58,81  33  42  -0,941666667  6,56 
8  MTGDGVNDAPSLKKA  2190,2287  -0,0315  62,09  30  43  -0,58  6,72 
8  MTGDGVNDAPSLKKA  2206,2236  -0,0362  49,92  25  43  -0,58  6,72 
8  DGFAEVFPQHKYRVV  2249,2363  0,0168  59,17  26  43  -0,36  7,66 
8  EILQNRG  1057,6083  0,0093  44,42  38  40  -1,014285714  6,98 
8  NIYNAER  1107,5875  0  51,72    42  -1,428571429  6,88 
8  NIYNAERL  1220,6716  0,0039  42    42  -0,775  6,88 
8  EILQNRGYL  1333,7557  0,0093  46,88    42  -0,511111111  6,88 
8  EILQNRGYLVA  1503,8612  0,012  42,43  41  42  0,127272727  6,88 
8  SIVDELKKT  1719,0751  0,0073  48    39  -0,422222222  6,84 
8  MTGDGVNDAPSLKKA  2190,2287  -0,0315  62,09  30  43  -0,58  6,72 
8  MTGDGVNDAPSLKKA  2206,2236  -0,0362  49,92  25  43  -0,58  6,72 
8  DGFAEVFPQHKYRVV  2249,2363  0,0168  59,17  26  43  -0,36  7,66 
8  KTLLEAI  1244,8109  -0,0113  44,69    39  0,828571429  6,84 
8  ETGVIKPG  1257,7698  0,0102  50,46  37  40  -0,225  6,84 
8  EYPPLGRFA  1277,6971  0,0247  43,59  33  42  -0,5  6,88 
8  FSEYPPLGRFA  1511,7975  -0,0094  58,99  30  42  -0,227272727  6,88 
8  RFQEIVKET  1606,9448  -0,0038  54,11    42  -0,9  7 
8  EQPSRPTDKPL  1724,9827  0,014  45,99  38  42  -1,945454545  6,92  
 
8  NAPWYKGWEKET  2195,1983  0,011  58,88  28  43  -1,858333333  6,88 
8  TNAPWYKGWEKET  2296,246  0,049  57,26  29  42  -1,769230769  6,88 
8  FGGFVFG  958,5116  0,0146  40,77  31  40  1,628571429  6,02 
8  FGGFVFGW  1144,5909  0,0014  46,8  38  40  1,3125  6,02 
8  RLWPNGQDQPS  1525,784  0,0134  76,28  30  42  -1,818181818  6,78 
8  FGGFVFG  958,5116  0,0146  40,77  31  40  1,628571429  6,02 
8  FGGFVFGW  1144,5909  0,0014  46,8  38  40  1,3125  6,02 
8  RLWPNGQDQPS  1525,784  0,0134  76,28  30  42  -1,818181818  6,78 
8  TGGQAFPQ  1033,5396  0,0027  45,43    42  -0,6875  6,02 
8  QGPNYVPG  1059,5552  -0,007  43,21  26  40  -1,0125  5,92 
8  FGGFVFG  958,5116  0,0146  40,77  31  40  1,628571429  6,02 
8  FGGFVFGW  1144,5909  0,0014  46,8  38  40  1,3125  6,02 
8  RLWPNGQDQPS  1525,784  0,0134  76,28  30  42  -1,818181818  6,78 
8  FGGFVFG  958,5116  0,0146  40,77  31  40  1,628571429  6,02 
8  FGGFVFGW  1144,5909  0,0014  46,8  38  40  1,3125  6,02 
8  FGGFVFG  958,5116  0,0146  40,77  31  40  1,628571429  6,02 
8  FGGFVFGW  1144,5909  0,0014  46,8  38  40  1,3125  6,02 
8  YFNDSQRQA  1356,6625  0,0099  51,83  35  40  -1,777777778  6,7 
8  QATKDAGTIA  1432,8291  0,0122  43,98  39  42  -0,28  6,66 
8  YFNDSQRQAT  1457,7102  -0,0001  65,4  33  40  -1,67  6,7 
8  YFNDSQRQA  1356,6625  0,0099  51,83  35  40  -1,777777778  6,7 
8  QATKDAGTIA  1432,8291  0,0122  43,98  39  42  -0,28  6,66 
8  YFNDSQRQAT  1457,7102  -0,0001  65,4  33  40  -1,67  6,7 
8  RLWPNGQDQPS  1525,784  0,0134  76,28  30  42  -1,818181818  6,78 
8  DLFNSYKT  1444,7968  0,0089  44,39  28  42  -0,8875  6,6 
8  MLAGTPFWQ  1278,6634  0,0062  55,34  38  42  0,355555556  6,02 
8  FGGFVFG  958,5116  0,0146  40,77  31  40  1,628571429  6,02 
8  FGGFVFGW  1144,5909  0,0014  46,8  38  40  1,3125  6,02 
8  QLQNPPPPPSTT  1504,8089  -0,0211  49,47  34  42  -1,408333333  6,02 
8  YFNDSQRQA  1356,6625  0,0099  51,83  35  40  -1,777777778  6,7  
 
8  QATKDAGTIA  1432,8291  0,0122  43,98  39  42  -0,28  6,66 
8  YFNDSQRQAT  1457,7102  -0,0001  65,4  33  40  -1,67  6,7 
8  YFNDSQRQA  1356,6625  0,0099  51,83  35  40  -1,777777778  6,7 
8  QATKDAGTIA  1432,8291  0,0122  43,98  39  42  -0,28  6,66 
8  YFNDSQRQAT  1457,7102  -0,0001  65,4  33  40  -1,67  6,7 
8  YFNDAQRQ  1269,6305  0,0086  40,46  22  40  -1,9  6,7 
8  ANEQGNRVTPS  1400,7211  -0,0109  54,99  32  41  -1,454545455  6,98 
8  YFNDAQRQ  1269,6305  0,0086  40,46  22  40  -1,9  6,7 
8  ANEQGNRVTPS  1400,7211  -0,0109  54,99  32  41  -1,454545455  6,98 
8  YFNDSQRQA  1356,6625  0,0099  51,83  35  40  -1,777777778  6,7 
8  YFNDSQRQAT  1457,7102  -0,0001  65,4  33  40  -1,67  6,7 
8  SFGSLQTV  1066,5862  -0,0049  58,69    41  0,575  6,02 
8  SFGSLQTV  1066,5862  -0,0049  58,69    41  0,575  6,02 
8  YYGYGGTT  1109,5232  0,0123  53,3  25  39  -0,8125  5,82 
8  YYQQGPPQQG  1393,6829  -0,0208  63,29  37  40  -2,06  5,86 
8  NQQGYNQQGY  1427,6632  -0,0266  70,16  33  36  -2,44  5,86 
8  LFLKYGESI  1526,9114  0,0007  48,36  33  40  0,555555556  6,8 
8  YFNDSQRQA  1356,6625  0,0099  51,83  35  40  -1,777777778  6,7 
8  YFNDSQRQAT  1457,7102  -0,0001  65,4  33  40  -1,67  6,7 
8  ANEQELKKG  1703,0186  0,0001  45,86  33  41  -1,844444444  6,92 
8  YFNDAQRQ  1269,6305  0,0086  40,46  22  40  -1,9  6,7 
8  LFLPPVAV  1083,6895  0,0016  38,59  35  36  2,175  6,02 
8  SLFLPPVAV  1170,7215  0,009  41,37  31  38  1,844444444  6,02 
8  LSLFLPPVAV  1283,8056  -0,0183  47,44  29  39  2,04  6,02 
8  YFNDAQRQ  1269,6305  0,0086  40,46  22  40  -1,9  6,7 
8  QATKDAGTIA  1432,8291  0,0122  43,98  39  42  -0,28  6,66 
8  QQQYQQQPQ  1403,6996  0,0013  50,22    41  -3,044444444  5,92 
8  KQLENVS  1274,76  -0,0058  44,56    42  -1,028571429  6,84 
8  WDIQREIQKA  1744,0037  0,0071  55,3  27  42  -1,25  6,92 
8  KTLLEAI  1244,8109  -0,0113  44,69    39  0,828571429  6,84  
 
8  KTLLEAI  1244,8109  -0,0113  44,69    39  0,828571429  6,84 
                 
9  EILQNRGYLVA  1503,8612  -0,0096  44,8  38  42  0,127272727  6,88 
9  DGFAEVFPQHKYRVV  2249,2363  0,0091  87,37  30  43  -0,36  7,66 
9  EILQNRGYLVA  1503,8612  -0,0096  44,8  38  42  0,127272727  6,88 
9  DGFAEVFPQHKYRVV  2249,2363  0,0091  87,37  30  43  -0,36  7,66 
9  NHPGQIS  980,5242  -0,0034  48,72  33  41  -1,214285714  7,84 
9  VLNHPGQI  1105,6447  -0,0006  47,27  33  42  0,0375  7,84 
9  VLNHPGQIS  1192,6767  -0,0015  59,94  40  42  -0,055555556  7,84 
9  GHVDSGKST  1344,7403  -0,0127  42,49  31  41  -1,055555556  7,72 
9  RLWPNGQDQPS  1525,784  -0,0039  57,92  34  41  -1,818181818  6,78 
9  RLWPNGQDQPS  1525,784  -0,0039  57,92  34  41  -1,818181818  6,78 
9  FGSGLHGWA  1159,5977  0,0119  50,86  38  41  0,255555556  7,84 
9  RLWPNGQDQPS  1525,784  -0,0039  57,92  34  41  -1,818181818  6,78 
9  MHDDQPFYKKM  2126,1261  -0,049  47,02  22  42  -1,618181818  7,6 
9  MHDDQPFYKKM  2126,1261  -0,049  47,02  22  42  -1,618181818  7,6 
9  RLWPNGQDQPS  1525,784  -0,0039  57,92  34  41  -1,818181818  6,78 
9  ANHFGA  844,4394  0,0007  39,1    39  -0,116666667  7,84 
9  MLAGTPF  964,5255  -0,0074  44,11  38  42  1,085714286  6,02 
9  ANHFGADKL  1429,8083  -0,0033  44,35  27  41  -0,477777778  7,72 
9  YQQQQQHPG  1341,6629  -0,0206  45,79  25  39  -2,666666667  7,76 
9  LFLPPVAV  1083,6895  0,0058  42,5    36  2,175  6,02 
9  AATENQPKGI  1485,8557  -0,022  49,92  30  41  -0,9  6,84 
9  HFYVAPT  1062,5701  -0,0042  45,01  31  42  0,285714286  7,76 
9  HFYNSQPG  1177,5719  -0,0142  45,23  25  39  -1,4375  7,76 
9  GHSGTLDPKVT  1568,8928  -0,0274  43,89  27  42  -0,654545455  7,72 
9  ELIQNRLNME  1503,7918  0,0598  44,8  38  42  -0,8  4,26 
9  VYLSGDV  980,5382  0,0178  41,83  39  41  0,885714286  3,1 
9  VYISSIA  980,5745  -0,0186  41,83  39  41  1,728571429  5,92 
9  AYISEAV  980,5381  0,0178  41,83  39  41  0,957142857  3,3  
 
                 
10  NHPGQIS  980,5242  -0,0017  46,29  33  41  -1,214285714  7,84 
10  LNHPGQIS  1093,6083  0,0018  49,91  34  42  -0,5875  7,84 
10  VLNHPGQI  1105,6447  0,0028  48,63  34  42  0,0375  7,84 
10  GHVDSGKST  1344,7403  0,0005  43,09  29  41  -1,055555556  7,72 
10  GISKDGQTREH  1684,9262  0,0015  54,89  22  42  -1,809090909  7,72 
10  AHVDHGKS  1307,7352  -0,0022  45,6  23  42  -1,125  7,88 
10  AHVDHGKST  1408,7829  -0,0004  44,38  27  42  -1,077777778  7,88 
10  ANHFGADKL  1429,8083  0,0002  45,43  31  41  -0,477777778  7,72 
10  KNAEQH  1183,6715  0,0126  40,83    40  -2,633333333  7,72 
10  AHVDHGKS  1307,7352  -0,0022  45,6  23  42  -1,125  7,88 
10  AHVDHGKST  1408,7829  -0,0004  44,38  27  42  -1,077777778  7,88 
                 
11  MFLPKGGIIQ  1560,9467  -0,0419  46,18  36  42  0,77  9,74 
11  NDAPSLKKA  1630,0022  -0,0142  46,83  29  41  -1,088888889  9,46 
11  KFVMFFVGPI  1641,9723  -0,0221  50,56  27  41  1,73  9,74 
11  KFVMFFVGPI  1657,9672  -0,0573  53,34  26  42  1,73  9,74 
11  FLPKGGIIQNF  1691,0176  -0,0029  49,32  27  41  0,463636364  9,74 
11  FLPKGGIIQNFGA  1819,0762  -0,0432  54,39  32  42  0,5  9,74 
11  MFLPKGGIIQNF  1822,0581  0,0029  63,94  29  42  0,583333333  9,74 
11  MFLPKGGIIQNFGAM  2081,1572  -0,0377  47,49  30  43  0,686666667  9,74 
11  MTGDGVNDAPSLKKA  2190,2287  -0,0302  80,8  28  43  -0,58  6,72 
11  LKQYPKAKDALT  2291,4388  -0,029  41,52  26  40  -0,925  9,64 
11  NDAPSLKKA  1630,0022  -0,0142  46,83  29  41  -1,088888889  9,46 
11  MTGDGVNDAPSLKKA  2190,2287  -0,0302  80,8  28  43  -0,58  6,72 
11  KIGGIGTVPV  1397,9012  -0,0229  62,28  34  38  1  9,74 
11  SGKKLEDHPK  2054,2659  0,0123  45,86  32  39  -2,09  9,3 
11  SFKYAWVLDKL  2056,233  -0,0586  49,75  33  42  0,190909091  9,34 
11  GKKLEDHPKFL  2227,3864  0,0312  38,61  26  37  -1,227272727  9,3 
11  SGKKLEDHPKFL  2314,4184  0,0454  45,77  32  38  -1,191666667  9,3  
 
11  DKPLRLPLQDVYKI  2384,4764  -0,0505  44,58  26  41  -0,514285714  9,34 
11  SINKWYQYFIG  1876,0289  -0,0301  80,77    42  -0,345454545  9,38 
11  THDDKPLYKR  1959,151  -0,0049  58,09  26  42  -2,23  9,34 
11  THDDKPLYKRM  2090,1915  -0,0473  45,06  25  43  -1,854545455  9,34 
11  SWGELFSSKTKVL  2168,2814  0,0333  67,25  37  40  -0,084615385  9,46 
11  SINKWYQYFIG  1876,0289  -0,0301  80,77    42  -0,345454545  9,38 
11  SWGELFSSKTKVL  2168,2814  0,0333  67,25  37  40  -0,084615385  9,46 
11  KISPPVV  1196,7898  0,016  40,05    32  0,714285714  9,74 
11  KISPPVVA  1267,8269  -0,0111  47,34  31  35  0,85  9,74 
11  AHVDHGKST  1408,7829  0,0089  46,23  28  42  -1,077777778  7,88 
11  KNANDLPKLV  1798,1285  0,0242  54,48  34  37  -0,63  9,46 
11  SINKWYQYFIG  1876,0289  -0,0301  80,77    42  -0,345454545  9,38 
11  SINKWYQYFIG  1876,0289  -0,0301  80,77    42  -0,345454545  9,38 
11  AVEKGTGKS  1562,96  0,0218  41,55  26  39  -0,844444444  9,46 
11  SAVEKGTGKS  1649,9921  0,0384  52,74  33  39  -0,84  9,46 
11  KTKDNNLLG  1689,0393  -0,0496  45,46  33  42  -1,311111111  9,46 
11  SAVEKGTGKSN  1764,035  0,0053  53,1  30  41  -1,081818182  9,46 
11  AVEKGTGKS  1562,96  0,0218  41,55  26  39  -0,844444444  9,46 
11  SAVEKGTGKS  1649,9921  0,0384  52,74  33  39  -0,84  9,46 
11  KTKDNNLLG  1689,0393  -0,0496  45,46  33  42  -1,311111111  9,46 
11  SAVEKGTGKSN  1764,035  0,0053  53,1  30  41  -1,081818182  9,46 
11  SINKWYQYFIG  1876,0289  -0,0301  80,77    42  -0,345454545  9,38 
11  KYNHVQT  1346,7712  -0,0061  47,55  32  42  -1,7  9,52 
11  IKINPPTGA  1367,8542  -0,0219  41,12    39  -0,1  9,74 
11  KYNHVQTS  1433,8033  0,0068  56,62  25  42  -1,5875  9,52 
11  STQKEHPGYRQI  1901,0525  0,0548  52,59  33  42  -1,866666667  9,52 
11  SINKWYQYFIG  1876,0289  -0,0301  80,77    42  -0,345454545  9,38 
11  SINKWYQYFIG  1876,0289  -0,0301  80,77    42  -0,345454545  9,38 
11  SINKWYQYFIG  1876,0289  -0,0301  80,77    42  -0,345454545  9,38 
11  KYNHVQT  1346,7712  -0,0061  47,55  32  42  -1,7  9,52  
 
11  IKINPPTGA  1367,8542  -0,0219  41,12    39  -0,1  9,74 
11  KYNHVQTS  1433,8033  0,0068  56,62  25  42  -1,5875  9,52 
11  STQKEHPGYRQI  1901,0525  0,0548  52,59  33  42  -1,866666667  9,52 
11  AVEKGTGKS  1562,96  0,0218  41,55  26  39  -0,844444444  9,46 
11  SAVEKGTGKS  1649,9921  0,0384  52,74  33  39  -0,84  9,46 
11  SAVEKGTGKSN  1764,035  0,0053  53,1  30  41  -1,081818182  9,46 
11  AHLKYKDPQ  1786,071  -0,0132  42,82  23  41  -1,7  9,34 
11  LFLQKGGQTV  1547,9441  -0,024  48,75  30  41  0,22  9,74 
11  EKPKAEKS  1832,1542  0,0497  45,23  34  36  -2,4125  9,3 
11  KAEKPKAEKS  2260,4492  0,0524  34,9  24  33  -2,14  9,6 
11  IKDIVQKT  1631,059  -0,0081  38,96    38  -0,2875  9,46 
11  QKSKGESDKPSAS  2264,3147  -0,0007  59,5  28  42  -1,969230769  9,3 
11  QKEKNKELNKQ  2531,5773  0,0626  40,39  26  35  -2,981818182  9,6 
11  QRDGLHDSNKQAQ  1954,0386  -0,001  43,34  25  42  -2,169230769  7,72 
11  EAPMNPKSNREK  2087,1765  0,0417  49,66  32  42  -2,216666667  9,46 
11  ASKKKEEAKPA  2331,4863  0,0407  37,19  28  35  -1,781818182  9,6 
11  KFGSVALPI  1388,8797  -0,0244  43,49  36  41  1,155555556  9,74 
11  KQPKFDVG  1604,9859  -0,0447  43,84    42  -1,225  9,46 
11  LQKIKPGDILVI  2023,3378  0,008  52,74    32  0,708333333  9,46 
11  KQPKFDVG  1604,9859  -0,0447  43,84    42  -1,225  9,46 
11  SINKWYQYFIG  1876,0289  -0,0301  80,77    42  -0,345454545  9,38 
11  RKSEELYPGRPL  1902,1092  -0,0438  44,6  27  42  -1,5  9,52 
11  MLMPKEDRNKI  2061,2047  0,04  47,65  30  41  -1,118181818  9,46 
11  RKQQAAPGGNTSEA  1872,0219  -0,0228  56,26  29  42  -1,492857143  9,74 
11  LRHLEKEGIIKPI  2232,429  -0,0466  39,24  25  39  -0,261538462  9,46 
11  ALRHLEKEGIIKPI  2303,4661  -0,0642  54,97  26  40  -0,114285714  9,46 
11  VQKFFLPL  1448,9161  -0,053  43,58  30  41  1,05  9,74 
11  YHQKYVDEQSKNELKKA  3252,8844  0,0776  42,92  19  40  -1,964705882  9,06 
11  KWFKDTPFI  1868,1169  0,0159  41,71  30  40  -0,488888889  9,46 
11  AHVDHGKST  1408,7829  0,0089  46,23  28  42  -1,077777778  7,88  
 
11  KYQYPQTPS  1568,8604  0,02  56,1  30  42  -2,022222222  9,38 
11  TQKYQYPQTPS  1797,9667  0,0238  50,07  27  42  -2,036363636  9,38 
11  KHFELGGEKKQKG  2630,6246  -0,0356  47,58  27  40  -1,838461538  9,6 
11  KHFELGGEKKQKGQ  2758,6832  -0,0303  56,05  27  41  -1,957142857  9,6 
11  THKRNEYIYDRS  2039,0954  0,0496  42,98  26  42  -2,183333333  9,38 
11  KKGQKDKIHEQS  2570,5882  0,0838  50,9  25  34  -2,458333333  9,6 
11  AHVDHGKTS  1408,7829  0,0089  46,23  28  42  -1,077777778  7,88 
11  KQALPGIPA  1351,8593  -0,0095  48,52  29  39  0,1  9,74 
11  KQALPGIPA  1351,8593  -0,0095  48,52  29  39  0,1  9,74 
                 
12  MFLPKGGII  1533,9359  -0,0422  49,9  39  42  1,244444444  9,74 
12  TMFLPKGGII  1533,9851  -0,0744  56,79  37  42  1,05  9,74 
12  LKQYPKA  1679,9799  -0,0776  44,9  35  42  -1,228571429  9,82 
12  TVKRGEGFMVV  1767,0119  -0,0756  44,12  30  42  0,354545455  9,74 
12  STVKRGEGFMVV  1930,1194  -0,0314  44,03  27  42  0,258333333  9,74 
12  AEVFPQHKYRVV  2102,371  -0,0449  46,91  25  42  -0,358333333  9,52 
12  ASRKKKGLDAI  1930,1194  -0,0314  39,91  27  38  -0,818181818  10,24 
12  AEVFPQHKYRVV  2102,371  -0,0449  46,91  25  42  -0,358333333  9,52 
12  ASRKKKGLDAI  1569,9608  -0,0348  39,91  27  38  -0,818181818  10,24 
12  GRVETGVIKPG  2098,1325  -0,0989  54,31  33  41  -0,227272727  9,74 
12  RLWPNGQDQPSSKGA  2168,2814  -0,0623  42,52  24  41  -1,553333333  9,74 
12  SWGELFSSKTKVL  2098,1325  -0,0989  59,77  29  42  -0,084615385  9,46 
12  RLWPNGQDQPSSKGA  2168,2814  -0,0623  42,52  24  41  -1,553333333  9,74 
12  SWGELFSSKTKVL  2098,1325  -0,0989  59,77  29  42  -0,084615385  9,46 
12  RLWPNGQDQPSSKGA  2098,1325  -0,0989  42,52  24  41  -1,553333333  9,74 
12  RLWPNGQDQPSSKGA  1750,0329  -0,0397  42,52  24  41  -1,553333333  9,74 
12  MAPKAPVASPRPA  1814,0204  -0,0584  46,15  22  42  -0,176923077  11,24 
12  TQKEHPGYRQI  1901,0525  -0,0553  49,33  35  42  -1,963636364  9,52 
12  STQKEHPGYRQI  1814,0204  -0,0584  61,2  37  42  -1,866666667  9,52 
12  TQKEHPGYRQI  1901,0525  -0,0553  49,33  35  42  -1,963636364  9,52  
 
12  STQKEHPGYRQI  2201,1707  -0,095  61,2  37  42  -1,866666667  9,52 
12  SHLGRPNGERNEKYS  1622,9146  -0,0553  79,86  37  41  -2,106666667  9,52 
12  TFENRNVGKT  1622,9146  -0,0553  44,21  25  42  -1,37  9,74 
12  TFENRNVGKT  2613,5363  -0,1198  44,21  25  42  -1,37  9,74 
12  GFHLIKPGYENKVPRTA  2076,1718  -0,0928  44,41  25  43  -0,670588235  9,82 
12  QQQQKQMQQKS  2446,2831  -0,0548  77,21    42  -2,836363636  10,06 
12  NQQEKQQQRQQQPSPH  1615,9452  -0,0769  53,11  23  42  -3,1625  9,74 
12  RGEIGPFASPK  2501,3756  -0,0725  49,31  41  42  -0,690909091  9,74 
12  SGNNNIPTPPQNRDVPKPV  2081,1747  -0,0766  46,4  26  43  -1,389473684  9,74 
12  IQEQQNLRQKQPN  1301,7984  -0,0088  49,43  27  42  -2,284615385  9,74 
12  FLPILLNML  1301,7798  0,0098  58,5    41  2,144444444  6,02 
12  FIPLLAEGTL  1806,9643  -0,0721  50,67    41  1,43  3,3 
12  NHQNPHFRDKG  1308,7427  0,0075  49,57  39  41  -2,545454545  9,74 
12  GLIRISFMQ  2061,2969  -0,0736  43,2  40  42  0,922222222  11,04 















Supplementry table S6 B (S6B) summary of all proteins, peptides sequence, calculated mass (pep_calc_mr ), mass acuuracy (pep_delta), 
peptide score (pep_score), homology (pep_homol), identity threshold (pep_ident), and the type of modifications on the peptides from a 
tryptic digestion of  purified ENL fraction. 
prot_desc  pep_calc_mr  pep_delta  pep_score  pep_homol  pep_ident  pep_seq  pep_var_mod 
Protein ENL  723,4028  0,0232  45,47    28  LELGHR   
Protein ENL  760,3967  0,0044  52,04    34  LESTSPK   
Protein ENL  771,3875  0,012  37,75    31  NKEEPR   
Protein ENL  771,3875  0,0128  55,46    31  SAPGTSPR   
Protein ENL  789,4385  0,0224  44,43    32  AAFKEPK   
Protein ENL  840,4454  -0,0064  49,21  29  31  TKPSHGSK   
Protein ENL  851,3538  -0,0164  37,87    28  SAPGTSPR  Phospho  (S) 
Protein ENL  914,4821  -0,0009  60,85    33  VKAESEPR   
Protein ENL  1001,5141  -0,0442  48,55    32  ELEREQAK   
Protein ENL  1019,511  -0,0359  36,97    33  VCKEPPYK   
Protein ENL  1031,4407  -0,047  73,19    28  TSSSSSFSDK   
Protein ENL  1118,5139  -0,0242  66,75    32  DNQCTVQVR   
Protein ENL  1118,5819  -0,0049  39,31    34  ETKLESTSPK   
Protein ENL  1147,5179  0,0397  62,94    33  SPESCSKPEK   
Protein ENL  1161,6295  -0,0522  95,28    34  GGPPPPPPPPPR   
Protein ENL  1198,5482  -0,0359  46,52  31  32  ETKLESTSPK  Phospho  (S) 
Protein ENL  1227,4842  -0,0497  54,81  22  26  SPESCSKPEK  Phospho  (S)  
 
Protein ENL  1303,619  -0,0649  63,89    31  RSPESCSKPEK   
Protein ENL  1324,7099  -0,043  96,06    34  RPATADSPKPSAK   
Protein ENL  1338,6568  -0,0568  91,13    33  LTFNNPTTEFR   
Protein ENL  1344,6674  0,05  96,13    34  AYTDELVELHR   
Protein ENL  1383,5853  -0,0253  54,01    31  RSPESCSKPEK  Phospho  (S) 
Protein ENL  1404,6762  -0,0091  69,02    34  RPATADSPKPSAK  Phospho  (S) 
Protein ENL  1455,7205  -0,0386  87,38    34  TSSSSSFSDKKPAK   
Protein ENL  1500,7685  0,0253  97,11    34  AYTDELVELHRR   
Protein ENL  1508,7987  0,0029  81,88  31  34  EPPPPQKPPPPNSK   
Protein ENL  1585,7195  0,0489  106,15    35  GPEQCDIQHFVEK   
Protein ENL  1782,7795  0,0159  54,81  32  34  ALEVEESNSEDEASFK   
Protein ENL  1782,8084  0,0479  44,04  31  35  VSGRRSPESCSKPEK  Phospho  (S) 
Protein ENL  1862,7459  -0,0065  135,56    31  ALEVEESNSEDEASFK  Phospho  (S) 
Protein ENL  1942,7122  -0,0203  74,63    28  ALEVEESNSEDEASFK  2 Phospho  (S) 
Protein ENL  1983,9819  -0,0283  113,45    35  LESTSPKGGPPPPPPPPPR  Phospho  (S) 
Protein ENL  1990,8408  0,001  88,48  28  33  KALEVEESNSEDEASFK  Phospho  (S) 
Protein ENL  1999,8607  -0,0505  144,82    32  LSFSDSESDNSADSSLPSR   
Protein ENL  2052,0026  0,0162  96,78  34  35  VEESGYAGFIMPIEVHFK   
Protein ENL  2079,827  0,0095  142,7    32  LSFSDSESDNSADSSLPSR  Phospho  (S) 
Protein ENL  2193,1178  0,0997  44,47  29  32  KGTYDKAYTDELVELHRR   
Protein ENL  2342,1671  -0,075  58,49  26  35  ETKLESTSPKGGPPPPPPPPPR  Phospho  (S) 
Protein ENL  2517,2475  -0,0521  149,14    36  VCFTYDLFLNLEGNPPVNHLR   
Protein ENL  2630,0297  -0,0277  59,27  29  30  SMVEDLQSEESDEDDSSSGEEAAGK   
Protein ENL  2645,3424  0,0813  156,72    33  KVCFTYDLFLNLEGNPPVNHLR   
Protein ENL  2666,309  0,0122  68,66  28  36  EPPYKVEESGYAGFIMPIEVHFK   
Protein ENL  3398,7193  0,0352  73,48  30  35  NKEEPRKVCFTYDLFLNLEGNPPVNHLR   
Protein ENL  3490,6488  0,0083  136,32    36  LSFSDSESDNSADSSLPSREPPPPQKPPPPNSK   
Protein ENL  3570,6151  -0,0261  66,74  30  36  LSFSDSESDNSADSSLPSREPPPPQKPPPPNSK  Phospho  (S) 
Protein ENL  3598,48  0,0309  225,02    34  SESAQSSPSNSSSSSDSSSDSDFEPSQNHSQGPLR 
Heat shock 70 kDa  800,414  0,0168  36,37    33  DNNLLGR    
 
protein 1 
Heat shock 70 kDa 
protein 1 
859,4512  0,0189  45,94    34  DISQNKR   
Heat shock 70 kDa 
protein 1 
1002,5345  -0,0224  73,08    33  LSKEEIER   
Heat shock 70 kDa 
protein 1 
1108,5665  0,0475  88,73    32  LLQDFFNGR   
Heat shock 70 kDa 
protein 1 
1136,5462  0,0006  75,48    33  YKAEDEVQR   
Heat shock 70 kDa 
protein 1 
1182,6397  -0,0304  44,02  29  33  FELSGIPPAPR   
Heat shock 70 kDa 
protein 1 
1196,6877  -0,0136  113,32    31  DAGVIAGLNVLR   
Heat shock 70 kDa 
protein 1 
1227,6207  -0,0057  65,12    34  VEIIANDQGNR   
Heat shock 70 kDa 
protein 1 
1260,6503  0,0403  63,54    33  LVNHFVEEFK   
Heat shock 70 kDa 
protein 1 
1314,5914  0,0118  79,46    33  FEELCSDLFR   
Heat shock 70 kDa 
protein 1 
1416,7514  0,0578  87    32  LVNHFVEEFKR   
Heat shock 70 kDa 
protein 1 
1464,8049  -0,0123  101,03    33  AQIHDLVLVGGSTR   
Heat shock 70 kDa 
protein 1 
1486,694  -0,0081  76,09    34  TTPSYVAFTDTER   
Heat shock 70 kDa 
protein 1 
1541,7296  0,0591  75,56    34  ARFEELCSDLFR   
Heat shock 70 kDa 
protein 1 
1657,8424  -0,0097  100,74    34  NQVALNPQNTVFDAK   
Heat shock 70 kDa 
protein 1 
1674,7234  0,0213  128,27    34  ATAGDTHLGGEDFDNR   
Heat shock 70 kDa 
protein 1 
1679,842  0,0457  82,08  33  34  HWPFQVINDGDKPK   
Heat shock 70 kDa 
protein 1 
1686,894  0,081  136,28    30  IINEPTAAAIAYGLDR   
Heat shock 70 kDa 
protein 1 
1813,9435  -0,043  110,5    35  NQVALNPQNTVFDAKR   
Heat shock 70 kDa 
protein 1 
1821,0108  -0,0053  94,69    32  LDKAQIHDLVLVGGSTR   
Heat shock 70 kDa 
protein 1 
2264,126  0,0896  132,08    33  AAAIGIDLGTTYSCVGVFQHGK   
Heat shock 70 kDa 
protein 1 
2785,3559  -0,1093  142,81    36  QTQIFTTYSDNQPGVLIQVYEGER    
 
Heat shock 70 kDa 
protein 1 
2980,4553  -0,0895  125,71    36  TLSSSTQASLEIDSLFEGIDFYTSITR   
Heat shock 70 kDa 
protein 1 
3000,4869  0,0422  160,55    35  EIAEAYLGYPVTNAVITVPAYFNDSQR   
Heat shock 70 kDa 
protein 1 
3054,4869  0,0899  147,92    35  ELEQVCNPIISGLYQGAGGPGPGGFGAQGPK   
Heat shock 70 kDa 
protein 1 
3259,6223  -0,0143  115,47    36  MKEIAEAYLGYPVTNAVITVPAYFNDSQR   
Heat shock 70 kDa 
protein 1 
3338,683  0,0623  186,14    34  RKELEQVCNPIISGLYQGAGGPGPGGFGAQGPK   
Heat shock cognate 71 
kDa protein 
860,4352  0,0016  43,45    33  DISENKR   
Heat shock cognate 71 
kDa protein 
1080,5604  -0,0393  73,58    33  LLQDFFNGK   
Heat shock cognate 71 
kDa protein 
1165,5727  0,0065  73,97    34  YKAEDEKQR   
Heat shock cognate 71 
kDa protein 
1227,6207  -0,0057  65,12    34  VEIIANDQGNR   
Heat shock cognate 71 
kDa protein 
1252,6088  0,0156  70,53    34  FEELNADLFR   
Heat shock cognate 71 
kDa protein 
1409,6609  0,05  54,83    34  RFDDAVVQSDMK   
Heat shock cognate 71 
kDa protein 
1479,747  0,0493  85,25    33  ARFEELNADLFR   
Heat shock cognate 71 
kDa protein 
1480,7998  0,053  60,76  26  30  SQIHDIVLVGGSTR   
Heat shock cognate 71 
kDa protein 
1486,694  -0,0081  76,09    34  TTPSYVAFTDTER   
Heat shock cognate 71 
kDa protein 
1652,8246  0,0584  61,28  29  33  HWPFMVVNDAGRPK   
Heat shock cognate 71 
kDa protein 
1658,8879  0,0065  51,93  30  34  IINEPTAAAIAYGLDK   
Heat shock cognate 71 
kDa protein 
1690,7183  0,0059  117,52    33  STAGDTHLGGEDFDNR   
Heat shock cognate 71 
kDa protein 
1744,8016  -0,0244  89,19    34  NQTAEKEEFEHQQK   
Heat shock cognate 71 
kDa protein 
1786,9828  -0,0829  113,07    35  IINEPTAAAIAYGLDKK   
Heat shock cognate 71 
kDa protein 
1980,9905  0,058  122,45    34  TVTNAVVTVPAYFNDSQR   
Heat shock cognate 71 
kDa protein 
2259,1383  0,0137  91,8  34  35  SINPDEAVAYGAAVQAAILSGDK   
Heat shock cognate 71 
kDa protein 
2262,1104  -0,0822  116,08  33  35  GPAVGIDLGTTYSCVGVFQHGK    
 
Heat shock cognate 71 
kDa protein 
2773,3195  -0,0373  155,25    36  QTQTFTTYSDNQPGVLIQVYEGER   
Heat shock cognate 71 
kDa protein 
2996,4502  -0,012  128,61    36  TLSSSTQASIEIDSLYEGIDFYTSITR   
Heat shock 70 kDa 
protein 1L 
800,414  0,0168  36,37    33  DNNLLGR   
Heat shock 70 kDa 
protein 1L 
859,4512  0,0189  45,94    34  DISQNKR   
Heat shock 70 kDa 
protein 1L 
1002,5345  -0,0224  73,08    33  LSKEEIER   
Heat shock 70 kDa 
protein 1L 
1136,5462  0,0006  75,48    33  YKAEDEVQR   
Heat shock 70 kDa 
protein 1L 
1182,6397  -0,0304  41,96  29  33  FDLTGIPPAPR   
Heat shock 70 kDa 
protein 1L 
1196,6877  -0,0136  113,32    31  DAGVIAGLNVLR   
Heat shock 70 kDa 
protein 1L 
1227,6207  -0,0057  65,12    34  VEIIANDQGNR   
Heat shock 70 kDa 
protein 1L 
1464,8413  -0,0487  101,03    33  AKIHDIVLVGGSTR   
Heat shock 70 kDa 
protein 1L 
1486,694  -0,0081  76,09    34  TTPSYVAFTDTER   
Heat shock 70 kDa 
protein 1L 
1658,8879  0,0065  51,93  30  34  IINEPTAAAIAYGLDK   
Heat shock 70 kDa 
protein 1L 
1674,7234  0,0213  128,27    34  ATAGDTHLGGEDFDNR   
Heat shock 70 kDa 
protein 1L 
2785,3559  -0,1093  142,81    36  QTQIFTTYSDNQPGVLIQVYEGER   
Heat shock 70 kDa 
protein 6 
800,414  0,0168  36,37    33  DNNLLGR   
Heat shock 70 kDa 
protein 6 
1080,5604  -0,0393  73,58    33  LLQDFFNGK   
Heat shock 70 kDa 
protein 6 
1182,6397  -0,0304  44,02  29  33  FELSGIPPAPR   
Heat shock 70 kDa 
protein 6 
1227,6207  -0,0057  65,12    34  VEILANDQGNR   
Heat shock 70 kDa 
protein 6 
1314,5914  0,0118  79,46    33  FEELCSDLFR   
Heat shock 70 kDa 
protein 6 
1486,694  -0,0081  76,09    34  TTPSYVAFTDTER   
Heat shock 70 kDa 
protein 6 
1541,7296  0,0591  75,56    34  ARFEELCSDLFR   
Heat shock 70 kDa 
protein 6 
1674,7234  0,0213  128,27    34  ATAGDTHLGGEDFDNR    
 
Heat shock 70 kDa 
protein 6 
1686,894  0,081  136,28    30  IINEPTAAAIAYGLDR   
Heat shock 70 kDa 
protein 6 
1716,8584  -0,0114  62,97  31  35  HAVITVPAYFNDSQR   
Heat shock 70 kDa 
protein 6 
2980,4553  -0,0895  40,51    36  TLSSSTQATLEIDSLFEGVDFYTSITR   
Tubulin alpha-1B chain  1022,4417  0,0103  53,1    31  EDAANNYAR   
Tubulin alpha-1B chain  1084,6128  -0,0189  57,97    33  EIIDLVLDR   
Tubulin alpha-1B chain  1409,7667  -0,005  46,11    33  QLFHPEQLITGK   
Tubulin alpha-1B chain  1486,8719  0,0056  127,37    30  LISQIVSSITASLR   
Tubulin alpha-1B chain  1700,8985  -0,0824  122,31    35  AVFVDLEPTVIDEVR   
Tubulin alpha-1B chain  1717,8747  0,0338  69,07    34  NLDIERPTYTNLNR   
Tubulin alpha-1B chain  1755,9559  -0,0277  80,63  30  34  IHFPLATYAPVISAEK   
Tubulin alpha-1B chain  1863,8971  -0,0398  91,42  34  35  AVCMLSNTTAIAEAWAR   
Tubulin alpha-1B chain  2006,8858  -0,0318  109,22    33  TIGGGDDSFNTFFSETGAGK   
Tubulin alpha-1B chain  2329,011  -0,0727  33,68  26  32  AFVHWYVGEGMEEGEFSEAR   
Tubulin alpha-1B chain  2408,2012  -0,0298  154,58    36  FDGALNVDLTEFQTNLVPYPR   
Tubulin alpha-1B chain  2414,1978  0,0363  79,65    35  QLFHPEQLITGKEDAANNYAR   
Tubulin alpha-1B chain  2749,284  0,1104  54,42  34  35  AYHEQLSVAEITNACFEPANQMVK   
Tubulin beta chain  1038,5862  0,003  49,63    31  YLTVAAVFR   
Tubulin beta chain  1076,525  -0,0283  42,35    32  IREEYPDR   
Tubulin beta chain  1129,588  -0,0212  96,81    34  FPGQLNADLR   
Tubulin beta chain  1300,6299  -0,0099  45,22  27  33  ISVYYNEATGGK   
Tubulin beta chain  1957,9745  -0,0487  175,3    35  GHYTEGAELVDSVLDVVR   
Tubulin beta chain  2086,0695  -0,0734  144,68    35  GHYTEGAELVDSVLDVVRK   
Tubulin beta chain  2707,331  0,0979  125,06  33  34  LTTPTYGDLNHLVSATMSGVTTCLR   
Tubulin beta chain  2797,3361  -0,0461  110,72    36  SGPFGQIFRPDNFVFGQSGAGNNWAK   
Tubulin beta chain  3101,4003  -0,0972  114,52    34  FWEVISDEHGIDPTGTYHGDSDLQLDR   
Tubulin alpha-1A chain  1022,4417  0,0103  53,1    31  EDAANNYAR   
Tubulin alpha-1A chain  1084,6128  -0,0189  57,97    33  EIIDLVLDR   
Tubulin alpha-1A chain  1409,7667  -0,005  46,11    33  QLFHPEQLITGK   
Tubulin alpha-1A chain  1456,8613  -0,0445  46,63    33  LIGQIVSSITASLR    
 
Tubulin alpha-1A chain  1700,8985  -0,0824  122,31    35  AVFVDLEPTVIDEVR   
Tubulin alpha-1A chain  1717,8747  0,0338  69,07    34  NLDIERPTYTNLNR   
Tubulin alpha-1A chain  1755,9559  -0,0277  80,63  30  34  IHFPLATYAPVISAEK   
Tubulin alpha-1A chain  1863,8971  -0,0398  91,42  34  35  AVCMLSNTTAIAEAWAR   
Tubulin alpha-1A chain  2006,8858  -0,0318  109,22    33  TIGGGDDSFNTFFSETGAGK   
Tubulin alpha-1A chain  2329,011  -0,0727  33,68  26  32  AFVHWYVGEGMEEGEFSEAR   
Tubulin alpha-1A chain  2408,2012  -0,0298  154,58    36  FDGALNVDLTEFQTNLVPYPR   
Tubulin alpha-1A chain  2414,1978  0,0363  79,65    35  QLFHPEQLITGKEDAANNYAR   
Tubulin alpha-1A chain  2749,284  0,1104  54,42  34  35  AYHEQLSVAEITNACFEPANQMVK   
Heat shock-related 70 
kDa protein 2 
1080,5604  -0,0393  73,58    33  LLQDFFNGK   
Heat shock-related 70 
kDa protein 2 
1182,6397  -0,0304  41,96  29  33  FDLTGIPPAPR   
Heat shock-related 70 
kDa protein 2 
1227,6207  -0,0057  65,12    34  VEIIANDQGNR   
Heat shock-related 70 
kDa protein 2 
1252,6088  0,0156  70,53    34  FEELNADLFR   
Heat shock-related 70 
kDa protein 2 
1479,747  0,0493  85,25    33  ARFEELNADLFR   
Heat shock-related 70 
kDa protein 2 
1486,694  -0,0081  76,09    34  TTPSYVAFTDTER   
Heat shock-related 70 
kDa protein 2 
1658,8879  0,0065  51,93  30  34  IINEPTAAAIAYGLDK   
Heat shock-related 70 
kDa protein 2 
1690,7183  0,0059  117,52    33  STAGDTHLGGEDFDNR   
Heat shock-related 70 
kDa protein 2 
1786,9828  -0,0829  113,07    35  IINEPTAAAIAYGLDKK   
Heat shock-related 70 
kDa protein 2 
3014,4539  -0,115  71,06  34  35  EIAEAYLGGKVHSAVITVPAYFNDSQR  Phospho  (S) 
Heat shock protein HSP 
90-beta 
828,5221  0,006  38,52    31  ALLFIPR   
Heat shock protein HSP 
90-beta 
900,5181  -0,0278  43,03    34  TKPIWTR   
Heat shock protein HSP 
90-beta 
950,457  -0,03  42,16    32  ADHGEPIGR   
Heat shock protein HSP 
90-beta 
1235,6299  0,0151  57,08    33  RAPFDLFENK   
Heat shock protein HSP 
90-beta 
1248,6098  -0,0366  63,04    33  EQVANSAFVER    
 
Heat shock protein HSP 
90-beta 
1310,5626  -0,0276  94,05    31  EDQTEYLEER   
Heat shock protein HSP 
90-beta 
1363,7248  -0,0132  39,51    34  RAPFDLFENKK   
Heat shock protein HSP 
90-beta 
1512,7784  -0,0072  73,2  32  34  GVVDSEDLPLNISR   
Heat shock protein HSP 
90-beta 
1526,7365  0,0552  47,38  32  34  SLTNDWEDHLAVK   
Heat shock protein HSP 
90-beta 
1781,9424  -0,0203  81,64  34  35  HLEINPDHPIVETLR   
Heat shock protein HSP 
90-beta 
1807,9509  0,0102  130,1    34  HSQFIGYPITLYLEK   
Heat shock protein HSP 
90-beta 
1846,7897  -0,0654  81,52    31  NPDDITQEEYGEFYK   
Heat shock protein HSP 
90-beta 
1910,0374  -0,0043  53,09  28  33  KHLEINPDHPIVETLR   
Heat shock protein HSP 
90-beta 
2014,0371  -0,0175  85,05    35  VILHLKEDQTEYLEER   
Heat shock protein HSP 
90-beta 
2175,9379  -0,0757  46,87  24  32  YHTSQSGDEMTSLSEYVSR   
Heat shock protein HSP 
90-beta 
2254,9516  -0,009  118,18    34  HNDDEQYAWESSAGGSFTVR   
Heat shock protein HSP 
90-beta 
2373,1385  -0,0052  102,9    36  VFIMDSCDELIPEYLNFIR   
Heat shock protein HSP 
90-beta 
2431,097  -0,0011  66,87  30  35  LVSSPCCIVTSTYGWTANMER   
Heat shock protein HSP 
90-beta 
3531,6376  -0,1257  112,46    35  LGLGIDEDEVAAEEPNAAVPDEIPPLEGDEDASR   
Heat shock protein HSP 
90-alpha 
814,5065  -0,0056  50,11    33  ALLFVPR   
Heat shock protein HSP 
90-alpha 
900,5181  -0,0278  43,03    34  TKPIWTR   
Heat shock protein HSP 
90-alpha 
1223,6186  -0,0052  34,47  29  34  HIYYITGETK   
Heat shock protein HSP 
90-alpha 
1263,636  0,0131  43,3  31  34  RAPFDLFENR   
Heat shock protein HSP 
90-alpha 
1310,5626  -0,0276  94,05    31  EDQTEYLEER   
Heat shock protein HSP 
90-alpha 
1512,7784  -0,0072  73,2  32  34  GVVDSEDLPLNISR   
Heat shock protein HSP 
90-alpha 
1526,7365  0,0552  47,38  32  34  SLTNDWEDHLAVK   
Heat shock protein HSP 
90-alpha 
1588,8685  0,0444  43,87  29  31  ELHINLIPNKQDR    
 
Heat shock protein HSP 
90-alpha 
1777,9403  -0,0783  120,26    35  HSQFIGYPITLFVEK   
Heat shock protein HSP 
90-alpha 
1785,9373  0,0232  93,5    34  HLEINPDHSIIETLR   
Heat shock protein HSP 
90-alpha 
1832,7741  -0,0693  80,59    31  NPDDITNEEYGEFYK   
Heat shock protein HSP 
90-alpha 
1914,0323  -0,0793  84,08    35  KHLEINPDHSIIETLR   
Heat shock protein HSP 
90-alpha 
2014,0371  -0,0175  85,05    35  VILHLKEDQTEYLEER   
Heat shock protein HSP 
90-alpha 
2063,084  -0,0498  56,96  27  35  HSQFIGYPITLFVEKER   
Heat shock protein HSP 
90-alpha 
2254,9516  -0,009  118,18    34  HNDDEQYAWESSAGGSFTVR   
Heat shock protein HSP 
90-alpha 
2414,165  0,0344  99,03    36  VFIMDNCEELIPEYLNFIR   
Heat shock protein HSP 
90-alpha 
2445,1127  0,0189  39,45  30  36  LVTSPCCIVTSTYGWTANMER   
Tubulin beta-2A chain  1076,525  -0,0283  42,35    32  IREEYPDR   
Tubulin beta-2A chain  1129,588  -0,0212  96,81    34  FPGQLNADLR   
Tubulin beta-2A chain  1957,9745  -0,0487  175,3    35  GHYTEGAELVDSVLDVVR   
Tubulin beta-2A chain  2086,0695  -0,0734  144,68    35  GHYTEGAELVDSVLDVVRK   
Tubulin beta-2A chain  2707,331  0,0979  125,06  33  34  LTTPTYGDLNHLVSATMSGVTTCLR   
Tubulin beta-2A chain  2797,3361  -0,0461  110,72    36  SGPFGQIFRPDNFVFGQSGAGNNWAK   
Tubulin beta-2A chain  3101,4003  -0,0413  59,01    35  FWEVISDEHGIDPTGSYHGDSDLQLER   
Tubulin beta-2C chain  1038,5862  0,003  49,63    31  YLTVAAVFR   
Tubulin beta-2C chain  1076,525  -0,0283  42,35    32  IREEYPDR   
Tubulin beta-2C chain  1129,588  -0,0212  96,81    34  FPGQLNADLR   
Tubulin beta-2C chain  1957,9745  -0,0487  175,3    35  GHYTEGAELVDSVLDVVR   
Tubulin beta-2C chain  2086,0695  -0,0734  144,68    35  GHYTEGAELVDSVLDVVRK   
Tubulin beta-2C chain  2707,331  0,0979  125,06  33  34  LTTPTYGDLNHLVSATMSGVTTCLR   
Tubulin beta-2C chain  2797,3361  -0,0461  110,72    36  SGPFGQIFRPDNFVFGQSGAGNNWAK   
Tubulin alpha-8 chain  1022,4417  0,0103  53,1    31  EDAANNYAR   
Tubulin alpha-8 chain  1409,7667  -0,005  46,11    33  QLFHPEQLITGK   
Tubulin alpha-8 chain  1486,8719  0,0056  127,37    30  LISQIVSSITASLR    
 
Tubulin alpha-8 chain  1717,8747  0,0338  69,07    34  NLDIERPTYTNLNR   
Tubulin alpha-8 chain  1863,8971  -0,0398  91,42  34  35  AVCMLSNTTAIAEAWAR   
Tubulin alpha-8 chain  2329,011  -0,0727  33,68  26  32  AFVHWYVGEGMEEGEFSEAR   
Tubulin alpha-8 chain  2408,2012  -0,0298  154,58    36  FDGALNVDLTEFQTNLVPYPR   
Tubulin alpha-8 chain  2414,1978  0,0363  79,65    35  QLFHPEQLITGKEDAANNYAR   
Tubulin alpha-3C/D 
chain 
1022,4417  0,0103  53,1    31  EDAANNYAR   
Tubulin alpha-3C/D 
chain 
1409,7667  -0,005  46,11    33  QLFHPEQLITGK   
Tubulin alpha-3C/D 
chain 
1456,8613  -0,0445  46,63    33  LIGQIVSSITASLR   
Tubulin alpha-3C/D 
chain 
1686,8829  0,0208  34,6    34  AVFVDLEPTVVDEVR   
Tubulin alpha-3C/D 
chain 
1717,8747  0,0338  69,07    34  NLDIERPTYTNLNR   
Tubulin alpha-3C/D 
chain 
1755,9559  -0,0277  80,63  30  34  IHFPLATYAPVISAEK   
Tubulin alpha-3C/D 
chain 
1863,8971  -0,0398  91,42  34  35  AVCMLSNTTAIAEAWAR   
Tubulin alpha-3C/D 
chain 
2006,8858  -0,0318  109,22    33  TIGGGDDSFNTFFSETGAGK   
Tubulin alpha-3C/D 
chain 
2329,011  -0,0727  33,68  26  32  AFVHWYVGEGMEEGEFSEAR   
Tubulin alpha-3C/D 
chain 
2408,2012  -0,0298  154,58    36  FDGALNVDLTEFQTNLVPYPR   
Tubulin alpha-3C/D 
chain 
2414,1978  0,0363  79,65    35  QLFHPEQLITGKEDAANNYAR   
Tubulin alpha-3C/D 
chain 
2749,284  0,1104  54,42  34  35  AYHEQLSVAEITNACFEPANQMVK   
Tubulin alpha-3E chain  1409,7667  -0,005  46,11    33  QLFHPEQLITGK   
Tubulin alpha-3E chain  1456,8613  -0,0445  46,63    33  LIGQIVSSITASLR   
Tubulin alpha-3E chain  1686,8829  0,0208  34,6    34  AVFVDLEPTVVDEVR   
Tubulin alpha-3E chain  1717,8747  0,0338  69,07    34  NLDIERPTYTNLNR   
Tubulin alpha-3E chain  1755,9559  -0,0277  80,63  30  34  IHFPLATYAPVISAEK   
Tubulin alpha-3E chain  1863,8971  -0,0398  91,42  34  35  AVCMLSNTTAIAEAWAR   
Tubulin alpha-3E chain  2006,8858  -0,0318  109,22    33  TIGGGDDSFNTFFSETGAGK   
Tubulin alpha-3E chain  2408,2012  -0,0298  154,58    36  FDGALNVDLTEFQTNLVPYPR    
 
Tubulin alpha-3E chain  2749,284  0,1104  54,42  34  35  AYHEQLSVAEITNACFEPANQMVK   
78 kDa glucose-
regulated protein 
996,5101  0,0069  48,01    32  ALSSQHQAR   
78 kDa glucose-
regulated protein 
1227,6207  -0,0057  65,12    34  VEIIANDQGNR   
78 kDa glucose-
regulated protein 
1429,6838  -0,0634  49,57    33  TWNDPSVQQDIK   
78 kDa glucose-
regulated protein 
1511,7442  -0,0037  46,83  29  34  AKFEELNMDLFR   
78 kDa glucose-
regulated protein 
1565,7726  -0,0396  58,3    34  ITPSYVAFTPEGER   
78 kDa glucose-
regulated protein 
1658,8879  0,0065  51,93  30  34  IINEPTAAAIAYGLDK   
78 kDa glucose-
regulated protein 
1814,989  -0,0754  97,63    35  IINEPTAAAIAYGLDKR   
78 kDa glucose-
regulated protein 
1886,9639  -0,0011  87,82  27  35  VTHAVVTVPAYFNDAQR   
78 kDa glucose-
regulated protein 
1973,9007  -0,0546  46,82  30  34  IEWLESHQDADIEDFK   
78 kDa glucose-
regulated protein 
2163,9848  -0,0482  114,71    34  IEIESFYEGEDFSETLTR   
78 kDa glucose-
regulated protein 
2174,9855  0,0091  120,11  33  35  LYGSAGPPPTGEEDTAEKDEL   
Tubulin beta-4 chain  1038,5862  0,003  49,63    31  YLTVAAVFR   
Tubulin beta-4 chain  1129,588  -0,0212  96,81    34  FPGQLNADLR   
Tubulin beta-4 chain  1941,9796  -0,0006  88,47    35  GHYTEGAELVDAVLDVVR   
Tubulin beta-4 chain  2707,331  0,0979  125,06  33  34  LTTPTYGDLNHLVSATMSGVTTCLR   
Tubulin beta-4 chain  2797,3361  -0,0461  110,72    36  SGPFGQIFRPDNFVFGQSGAGNNWAK   
Importin subunit alpha-2  824,4545  -0,0379  46,45    33  FVSFLGR   
Importin subunit alpha-2  1376,6871  -0,0552  56,37    33  NLTWTLSNLCR   
Importin subunit alpha-2  1548,9239  -0,0472  80,25    32  LLGASELPIVTPALR   
Importin subunit alpha-2  1875,8599  -0,0123  94,24    34  NVSSFPDDATSPLQENR   
Importin subunit alpha-2  1942,0887  0,0406  85,82  26  29  NPAPPIDAVEQILPTLVR   
Importin subunit alpha-2  1955,8262  -0,0021  35,43    33  NVSSFPDDATSPLQENR  Phospho  (S) 
Importin subunit alpha-2  2184,2266  0,043  109,38    28  NKNPAPPIDAVEQILPTLVR   
Putative heat shock 
protein HSP 90-beta- 
1235,6299  0,0151  57,08    33  RAPFDLFENK    
 
Putative heat shock 
protein HSP 90-beta- 
1248,6098  -0,0366  63,04    33  EQVANSAFVER   
Putative heat shock 
protein HSP 90-beta- 
1310,5626  -0,0276  94,05    31  EDQTEYLEER   
Putative heat shock 
protein HSP 90-beta- 
1363,7248  -0,0132  39,51    34  RAPFDLFENKK   
Putative heat shock 
protein HSP 90-beta- 
1807,9509  0,0102  130,1    34  HSQFIGYPITLYLEK   
Putative heat shock 
protein HSP 90-beta- 
2014,0371  -0,0175  85,05    35  VILHLKEDQTEYLEER   
Putative tubulin-like 
protein alpha-4B 
1409,7667  -0,005  46,11    33  QIFHPEQLITGK   
Putative tubulin-like 
protein alpha-4B 
1486,8719  0,0056  127,37    30  LISQIVSSITASLR   
Stress-70 protein, 
mitochondrial 
1289,6728  -0,0232  37,63  31  34  VQQTVQDLFGR   
Stress-70 protein, 
mitochondrial 
1360,7351  -0,0137  97,33    34  AQFEGIVTDLIR   
Stress-70 protein, 
mitochondrial 
1693,8424  -0,0323  75,21    35  NAVITVPAYFNDSQR   
Stress-70 protein, 
mitochondrial 
2054,9545  0,0044  102,07    35  STNGDTFLGGEDFDQALLR   
Tubulin beta-6 chain  1129,588  -0,0212  96,81    34  FPGQLNADLR   
Tubulin beta-6 chain  1941,9796  -0,0006  88,47    35  GHYTEGAELVDAVLDVVR   
DnaJ homolog 
subfamily A member 1 
1867,751  -0,0394  90,98    30  HYNGEAYEDDEHHPR   
DnaJ homolog 
subfamily A member 1 
2128,0913  0,0786  119,12    33  NVVHQLSVTLEDLYNGATR   
Putative heat shock 
protein HSP 90-beta 2 
900,5181  -0,0278  43,03    34  TKPIWTR   
Putative heat shock 
protein HSP 90-beta 2 
1807,9509  0,0102  130,1    34  HSQFLGYPITLYLEK   
Heat shock 70 kDa 
protein 4 OS=Homo 
sapiens GN=HSPA4 
PE=1 SV=4 
1417,6183  -0,0105  48,49  31  32  NAVEEYVYEMR  Oxidation (M) 
Heat shock 70 kDa 
protein 4 
1494,695  -0,0503  52,53    33  AGGIETIANEYSDR   
Heat shock 70 kDa 
protein 4 
1734,9192  -0,0841  77,88  31  35  EFSITDVVPYPISLR   
Heat shock 70 kDa 
protein 4 
2140,1164  -0,1049  62,83    35  TSTVDLPIENQLLWQIDR    
 
4F2 cell-surface antigen 
heavy chain 
1370,8286  0,0074  69,38    28  LLTSFLPAQLLR   
4F2 cell-surface antigen 
heavy chain 
1504,7522  -0,0355  53,03    34  GQSEDPGSLLSLFR   
4F2 cell-surface antigen 
heavy chain 
2291,1487  -0,1015  94,89  30  35  SLLHGDFHAFSAGPGLFSYIR   
Reticulocalbin-2  2213,96  -0,1103  100,12  29  31  VIDFDENTALDDAEEESFR   
Reticulocalbin-2  2640,2442  -0,1032  134,9    35  LSEEEILENPDLFLTSEATDYGR   
Putative tubulin beta 
chain-like protein 
ENSP00000290377 
1076,525  -0,0283  42,35    32  IREEYPDR   
Putative tubulin beta 
chain-like protein 
ENSP00000290377 
1129,588  -0,0212  96,81    34  FPGQLNADLR   
Tubulin beta-1 chain  1076,525  -0,0283  42,35    32  IREEYPDR   




1129,588  -0,0212  96,81    34  FPGQLNADLR   
Translocon-associated 
protein subunit delta 
1404,6561  0,0074  65,73  28  34  FFDEESYSLLR   
Translocon-associated 
protein subunit delta 
2165,1117  0,0094  104,54    35  NNEDISIIPPLFTVSVDHR   
DnaJ homolog 
subfamily A member 4 
2128,1164  -0,0549  101,92    35  NVVHQLSVTLEDLYNGVTK   
Heat shock protein 105 
kDa 
1417,6514  0,0383  51,42    34  NAVEEYVYEFR   
Heat shock protein 105 
kDa 
1605,7358  0,044  46,17    35  FICEQDHQNFLR   
Heat shock protein 105 
kDa 
1781,9927  0,0524  71,67    29  IEVPLYSLLEQTHLK   
Heat shock protein 75 
kDa, mitochondrial 
1512,7784  -0,0072  73,2  32  34  GVVDSEDIPLNLSR   
Casein kinase II subunit 
alpha 
1864,0418  -0,012  39,1  26  32  GGPNIITLADIVKDPVSR   
Casein kinase II subunit 
alpha 




1809,9876  0,0656  76,3  27  29  NAPAIIFIDELDAIAPK   
Casein kinase II subunit 
beta 
1083,5938  -0,0316  61,47    33  RPANQFVPR    
 
Casein kinase II subunit 
beta 
1389,5772  0,0111  57,75    32  YQQGDFGYCPR   
ATP synthase subunit 
alpha, mitochondrial 
2337,1601  -0,0262  101,12    36  EVAAFAQFGSDLDAATQQLLSR   




1862,9203  -0,0848  64,54  31  34  KIPNPDFFEDLEPFR   
D-3-phosphoglycerate 
dehydrogenase 
985,596  0,0094  55,45    31  DLPLLLFR   
Protein transport protein 
Sec16A 




1515,7147  -0,0105  83,33  30  34  FYGPEGPYGVFAGR   
Myosin-14  1957,9929  -0,0671  57,19    35  AELSSLQTARQEGEQRR   
Importin subunit alpha-3  2035,8858  0,0066  75,36  31  34  NVPQEESLEDSDVDADFK   
Squalene synthetase  2039,9324  -0,0845  74,94    33  LFSASEFEDPLVGEDTER   
Importin subunit alpha-8  1376,6871  -0,0552  56,37    33  NITWTLSNLCR   
Pyruvate carboxylase, 
mitochondrial 
1362,6667  -0,0546  73,56    33  IAEEFEVELER   
Tubulin alpha chain-like 
3 
1022,4417  0,0103  53,1    31  EDAANNYAR   
Elongation factor 1-
alpha 1 
1024,603  -0,0107  54,15    30  IGGIGTVPVGR   
Probable Xaa-Pro 
aminopeptidase 3 
814,5065  -0,0056  50,11    33  AILFVPR   
Protein AF-9  723,4028  0,0232  45,47    28  LELGHR   
Protein AF-9  771,3875  0,012  37,75    31  NKEEPR   








1793,8696  0,0633  41,22    34  HGAGAEISTVHPEQYAK   
45 kDa calcium-binding 
protein 
1319,563  -0,004  58,14    32  DLGGFDEDAEPR   
Protein spinster 
homolog 1 
1611,7376  -0,0111  57,18  32  34  SEEPEVPDQEGLQR    
 
STIP1 homology and U 
box-containing protein 1 




1174,6387  -0,0289  45,37  27  34  FLDFIGHILT   
Elongation factor 2  1443,7609  0,0522  45,85  28  32  EGIPALDNFLDKL   
Protein CASC5  1726,7788  -0,0365  39,93    33  ERTDRPNFELSQR  Phospho  (S) 
Leucine zipper protein 1  1002,5345  0,0171  44,51    33  ELKSEIER   
Proteasome subunit beta 
type- 
1305,7445  -0,018  44,17  31  32  FILNLPTFSVR   
Regulator of nonsense 
transcripts 2 
814,5065  -0,0295  38,7    33  ALFIVPR   
Tight junction-
associated protein 1 
1428,6732  -0,033  42,91  29  33  LEQEEPLTDAER   
POTE ankyrin domain 
family member E 
1514,7419  -0,0092  42,07  33  34  IWHHTFYNELR   
Actin, cytoplasmic 1  1514,7419  -0,0092  42,07  33  34  IWHHTFYNELR   
Beta-actin-like protein 3  1514,7419  -0,0092  42,07  33  34  IWHHTFYNELR   
Band 4.1-like protein  1377,7445  0,0389  36,81    31  NLPWLFTFNVK   
Probable ATP-
dependent RNA helicase 
DDX6 
1230,6972  -0,0175  40,48  25  33  SGAYLIPLLER   
DnaJ homolog 
subfamily C member 1 
1002,5094  0,0028  40,35    33  LGASEKNER   
Splicing factor 3B 
subunit 1 
914,5185  -0,0372  39,58    33  VGAAEIISR   
Adipocyte enhancer-
binding protein 1 
789,3868  0,0363  38,09    34  KEDSSPK   
Elongation factor 1-
gamma 
1706,8641  -0,03  38,03  27  35  VLSAPPHFHFGQTNR   
Keratin, type II 
cytoskeletal 1 
2382,9447  0,042  33,02  19  33  GGGGGGYGSGGSSYGSGGGSYGSGGGGGGGR   
Protein FAM184A  1002,4982  0,014  37,6    33  LSQLEEER   
Ataxin-2-like protein  2289,1713  -0,0431  36,93  31  36  TLSSPSNRPSGETSVPPPPAVGR   
DnaJ homolog 
subfamily B member 12 
1958,1214  -0,0902  36,64    34  ALRFLEKAQRLYPTPR   
Microtubule-associated 
protein 1A 
1118,5455  0,0315  35,48    34  DKDLEEKDK   
Serine/arginine 
repetitive matrix protein 









1366,6629  -0,0452  34,41  30  33  FQARDADIEFR   
Histone H1oo  941,5116  -0,0158  34,2    32  KMAPATAPR   
UPF0419 protein 
C12orf48 
1248,554  0,0614  34,17  25  34  GYAPPPSDPLR  Phospho  (S) 